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 Abkürzungsverzeichnis 
 
ADAP adhesion- and degranulation-promoting adapter protein  
APC Antigen-präsentierende Zelle  
ATP   adenosine triphosphate  
CD  cluster of differentiation  
CTL   cytotoxic T-lymphocyte  
CTLA-4  cytotoxic T-lymphocyte-associated antigen 4 (CD152)  
DAG   Diacylglycerol  
DC  Dendritische Zelle 
DNFB 2,4-Dinitro-1-Fluorbenzol  
ERK   Extracellular-signal regulated kinases  
iTreg induzierte regulatorische T-Zelle  
IL-#  Interleukin-#  
IP3  Inositol-1,4,5-Trisphosphat 
IFNγ Interferon gamma 
ITAM   immunoreceptor tyrosine-based activation motif  
IVIG  intravenöse Immunglobuline  
KO  knock-out  
LAT  linker for activation of T cells  
LFA-1 lymphocyte function-associated antigen (LFA)-1 
Lck   lymphocyte-specific protein tyrosine kinase (p56Lck)  
mTOR  mammalian Target of Rapamycin 
MAPK   mitogen-activated protein kinase  
MHC   major histocompatibility complex, 
Haupthistokompatibilitätskomplex  
NFAT   nuclear factor of activated T cells  
NF-κB nuclear factor-κB  
PCB Polychlorierte Biphenyle 
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PI3K   Phosphoinositol-3-Kinase  
PIP2   Phosphoinositol-4,5-Bisphosphat  
PIP3   Phosphoinositol-3,4,5-Trisphosphat 
PKB   protein kinase B (Akt)  
PLCγ   phospholipase C gamma  
pMHC  Peptid-MHC (-Komplex) 
PUFA   polyunsaturated fatty acid  
SDF-1 stromal cell-derived factor-1  
S1P1 Sphingosin-1-phosphat-Rezeptor-1  
SKAP55  Src kinase−associated phosphoprotein of 55 kDa 
SLP76 Src homology 2 (SH2) domain-containing leukocyte  
protein of 76 kDa  
STED  Stimulated-Emission Depletion 
STAT  signal-transducer-and-activator-of-transcription  
TCR   T-Zell-Rezeptor  
TNFα  Tumor-Nekrose-Faktor α 
TDI TGFβ  Toluen-2,4-diisocyanate 
TGFβ transforming growth factor beta  
Th  T-Helfer  
Treg   Regulatorische T-Zelle  
TIRF   total internal reflection fluorescence (Mikroskopie) 
ZAP70  zeta-associated protein of 70 kDa  
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 Zusammenfassung 
 
Der adaptive Charakter des T-Zell-Rezeptor-Reservoirs bildet den Schlüssel 
für die Entwicklung eines immunologischen Gedächtnisses. Auf 
Umwelteinflüsse gezielt reagieren zu können stellt einen evolutionär Aufwand 
dar, der sich für den Menschen lohnt. Gleichzeitig bringt dieses neue 
Verteidigungskonzept eine Reihe von Problemfeldern mit sich. Intrinsische 
und extrinsische Einflussfaktoren können dazu führen, dass sich das 
Immunsystem funktionell so verändert, dass es dem Wirtsorganismus selbst 
Schaden zufügt. Die Gewährleistung effizienter und gleichzeitig sicherer  
T-Zell-Aktivierung besitzt daher höchste Relevanz für den Organismus.  
 
Der Prozess der antigenspezifischen Aktivierung der T-Zelle wird im 
Zusammenspiel zwischen T-Zell-Rezeptor(TCR)- und costimulatorischen 
Signalen sowie unter Einbeziehung biophysikalischer Eigenschaften der 
Antigenpräsentation entscheidend moduliert. Die immunologische Synapse 
bildet dabei das morphologische Korrelat physiologischer T-Zell-Aktivierung 
an der Grenzfläche zwischen antigenpräsentierende Zelle und T-Zelle. Ein 
multimolekulares Netzwerk an Signalen von protrahierter Dauer und hoher 
Intensität innerhalb der Synapse kennzeichnet die Signalübermittlung 
während der T-Zell-Aktivierung. Um eine zentrale Akkumulation von TCR und 
phospho(p)-LAT bilden sich „signaling hotspots“ mit zusätzlicher Anreicherung 
von pCD3ζ, pZAP70, pSLP76 und pPLCγ1. Eines der frühesten Ereignisse der 
T-Zell-Aktivierung ist die Aktivierung der Src-Kinase Lck. Dabei sind es 
vorrangig Konformationsänderungen und nicht Phosphorylierungen, welche 
Lck auf den Angriff am TCR-CD3-Komplex vorbereiten. 
 
Die T-Zell-Migration durch den Organismus wird durch zeitlich und örtlich 
selektiv wirkende Signale gesteuert, um eine erfolgreiche Kontaktaufnahme 
mit antigenpräsentierenden Zellen und eine effiziente Immunantwort zu 
gewährleisten. Dazu gehört die Aktivierung von Integrinen wie LFA-1 beim 
Eintritt- und Austritt von T-Zellen aus Blut- und Lymphbahnen sowie die über 
Adaptermoleküle wie SLP76 vermittelte selektive Aktivierung von Integrinen 
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nach TCR- bzw. Chemokinrezeptor-Triggering. Gα-Proteine wie Gα12 und 
Gα13 spielen eine wichtige Rolle für Integrin-Signaling und korrekte T-Zell-
Positionierung im Lymphknoten. Integrin-Signal-regulierende Proteine wie 
ADAP und SWAP70 sind dabei notwendig für intakte Motilität und Migration.  
 
T-Zellen als Bestandteil des Organismus sind ständigem Kontakt mit der 
Umwelt ausgesetzt. Kovalente chemische Bindungen mit reaktiven 
Schadstoffen (elektrophile Xenobiotika) oder mit Medikamenten (β-Lactame) 
können das T-Zell-Signaling beeinflussen, myelotoxische Effekte die Reifung 
von Immunzellen stören. Nahrungsbestandteile wie langkettige Fettsäuren  
besitzen modulierenden Einfluss auf die T-Zell-Aktivierung und die 
Entwicklung allergischer Sensibilisierungen. Infektiöse Agenzien können das 
Immunsystem unterdrücken oder ungewöhnlich stark aktivieren (bakterielle 
Superantigene). Infektionen sind mögliche ungewollte Folge der Anwendung 
immunsuppressiver Medikamente (anti-TNFα). Genetische Defekte und 
Varianten (VHL-Gen) können zur Überforderung des Immunsystems und der 
Karzinom-Entwicklung führen. 
 
Immuntherapeutische Ansätze umfassen sowohl die Anwendung von  
löslichen Substanzen (small molecules, altered peptide ligands, Biologicals 
wie anti-TNFα und anti-CD28) als auch zelltherapeutische Ansätze. Die 
Generierung von regulatorischen T-Zellen (Tregs) bildet dabei einen 
Schwerpunkt. Die Induktion von Tregs durch Antigenpräsentation mittels 
naiver B-Zellen stellt einen Ansatz mit möglichen Vorteilen für die 
reproduzierbare Umsetzbarkeit dar. Eine veränderte Balance des 
PI3K/Akt/mTOR-Signalwegs durch Akt-spezifische Phosphatasen scheint der 
Bildung dieser induzierten Tregs  zugrunde zu liegen.  
 
Für die medizinische Anwendung der T-Zell-Modulation, sei es zur 
Behandlung von immunpathologischen Zuständen oder zu deren Vermeidung, 
ist es sowohl notwendig, die molekularen Grundlagen der T-Zell-Aktivierung 
besser zu verstehen als auch die Mechanismen von deren Modulation sowie 
die gegenwärtigen Prinzipien gezielter Beeinflussung zu kennen. Diesem Ziel  
widmet sich diese zusammenfassende Darstellung. 
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1. Einleitung  - Modulation der T-Zell-Aktivierung im Zentrum der 
adaptiven Immunantwort 
 
Das adaptive Immunsystem entstand vor circa 500 Millionen Jahren, als mit 
Entwicklung der Wirbeltiere, Vertebraten, und insbesondere der 
kiefertragenden Wirbeltiere (Kiefermäuler, Gnathostomata, jawed 
vertebrates) die ersten T-Zell-Rezeptoren auf der Oberfläche von 
Abwehrzellen entstanden (Forni 2013).  
Der adaptive Charakter des T- (und B-Zell)-Rezeptor-Reservoirs, d.h. die 
Möglichkeit der Anpassung an Umgebungsfaktoren und deren Nutzung 
innerhalb der Lebenszeit eines Organismus, bildet den Schlüssel für die 
Entwicklung eines immunologischen Gedächtnisses. Ein solches Gedächtnis 
verstärkt die Immunantwort beim erneuten Zusammentreffen mit einem 
„Aggressor“ (z.B. Bakterium, Virus) um Größenordnungen. Es bildet die 
Voraussetzung für den Erfolg jeder Vakzinierung und erweitert die 
Verteidigungsfähigkeiten des hinsichtlich der Antigenspezifität „unflexiblen“  
angeborenen (engl. innate) Immunsystems wesentlich. Auf Umwelteinflüsse 
gezielt reagieren zu können stellt einen evolutionären Aufwand dar, der sich 
in Organismen mit relativ langer Lebensspanne wie dem Menschen offenbar 
lohnt (Best 2013).   
Gleichzeitig bringt dieses neue, adaptive Verteidigungskonzept eine Reihe 
neuer Problemfelder mit sich. Umwelteinflüsse können dazu führen, dass sich 
das Immunsystem funktionell so verändert, dass es dem Wirtsorganismus 
selbst Schaden zufügt.  T-Zellen sowie die funktionellen Partner der T-Zell-
Rezeptoren, die MHC-(Major Histocompatibility Complex) Moleküle auf 
antigenpräsentierenden Zellen, sind nicht nur geeignet, die Antwort möglichst 
spezifisch gegen Infektionserreger zu lenken, sondern sie sind oft auch 
assoziiert mit immunologisch-vermittelten pathologischen Prozessen wie 
Neoplasien, Allergien und Autoimmunerkrankungen. Offenbar besteht eine 
evolutionäre Balance zwischen hohem Abwehrpotential und möglicher 
Selbstreaktivität, um die immunologische Reaktionsfähigkeit in notwendiger 
Stärke und Geschwindigkeit zu erhalten (Thomas 2010).  
Deshalb besitzt die Gewährleistung einer effizienten und gleichzeitig sicheren 
T-Zell-Aktivierung höchste Relevanz für den Organismus.  
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Intrinsische, körpereigene Mechanismen der Steuerung der T-Zell-Aktivierung 
gehen dabei weit über effiziente T-Zell-Reifung im Thymus hinaus. So ist der 
Prozess der antigenspezifischen Aktivierung der T-Zelle an der 
immunologischen Synapse im Zusammenspiel zwischen T-Zell-
Rezeptor(TCR)- und costimulatorischen Signalen sowie die resultierende 
Herausbildung eines Netzwerks intrazellulärer Signale ein komplexer und 
mannigfach modulierter Prozess (besprochen im Text anhand App. 04, 06, 
07).  
Intrinsisch gesteuert wird auch die T-Zell-Migration durch den Organismus. 
Ohne spezifische Signale, welche die Navigation innerhalb von 
Organkompartimenten sowie den Eintritt und das Verlassen von Blut- und 
Lymphgefäßen steuern, wäre eine rechtzeitige Kontaktaufnahme mit 
passenden antigenpräsentierenden Zellen und damit eine effiziente 
Immunantwort nicht möglich (App. 11, 9, 1, 10, 5). 
Extrinsischen Einflüssen sind T-Zellen durch ständigen Kontakt des 
Organismus mit der Umwelt ausgesetzt. Dazu gehören Kontakte mit 
chemisch-reaktiven Substanzen (Schadstoffe, Medikamente) sowie Kontakte 
zu infektiösen Agenzien. Daneben beeinflussen genetische Varianten die T-
Zell-Verteidigungsfunktionen des Individuums (siehe App. 15, 16, 20, 18, 17, 
19).                       
Gezielt versucht der Mensch das adaptive Immunsystem zu beeinflussen 
durch Applikation pharmakologisch aktiver Immunmodulatoren sowie durch 
die Anwendung manipulierter Immunzellen zur Steuerung von T-Zellen und 
der Immunantwort (App. 12, 13, 8, 3, 14, 2). 
Für die medizinische Anwendung der T-Zell-Modulation, sei es zur 
Behandlung immunpathologischer Zuständen oder zu deren Vermeidung, ist 
es zum einen notwendig, die molekularen Grundlagen der T-Zell-Aktivierung 
besser zu verstehen und zum anderen die Prinzipien experimenteller und 
klinischer Ansätze zu deren Modulation zu kennen und weiter zu entwickeln. 
Die vorliegende Arbeit fasst wichtige Elemente des gegenwärtigen 
Kenntnisstands zur T-Zell-Aktivierung und –Modulation mit Blick auf ihre 
potenzielle medizinische Relevanz zusammen und beschreibt die Resultate 
meiner Arbeit auf diesem Gebiet. 
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2. Die antigenspezifische T-Zell-Aktivierung erfolgt  
an der immunologischen Synapse 
 
Das Immunsystem des Menschen wird regelmäßig in ein angeborenes 
(innate) Immunsystem und ein adaptives Immunsystem unterteilt. Das 
angeborene Immunsystem umfasst neben den wichtigsten professionellen 
antigenpräsentierenden Zellen (APC), den Dendritischen Zellen (DC), vor 
allem Fresszellen wie Makrophagen und neutrophile Granulozyten, daneben 
Natürliche Killerzellen (NK-Zellen) und andere. Ihnen gemeinsam ist, dass sie 
Untypisches, potentiell Fremdes (Gefährliches) anhand bestimmter 
molekularer Muster (molecular pattern) erkennen. Auch Epithelzellen können 
solche Mustererkennungsrezeptoren (pattern recognition receptors, PRR) 
tragen und damit in bestimmtem Maße an der frühen Immunerkennung 
teilnehmen. Die Signalübertragung über die PRR, darunter toll-like 
Rezeptoren (TLR), führen zur Aktivierung z.B. der Makrophagen, fördern 
deren Fähigkeit, aufgenommene Partikel abzutöten und zu zerstören und 
induzieren gleichzeitig „Gefahren“-Signale (danger signals), die an das 
adaptive Immunsystem weitergeleitet werden und deren Aktivierung dienen. 
Insoweit bildet das Triggering des angeborenen Immunsystems die 
funktionale Grundlage für die anschließende Aktivierung des adaptiven 
Immunsystems (Kumar 2011, Jin 2012). 
 
Die zellulären Bestandteile des adaptiven Immunsystems sind vorrangig B- 
und T-Lymphozyten. B-Zellen sind für die Antikörperproduktion 
verantwortlich, sie verlangen in den meisten Fällen eine vorherige 
Lizensierung (Freischaltung) dieser Funktion durch CD4+ T-Zellen (T-Helfer-
Zellen). Diese bilden beim Menschen die Mehrzahl der T-Zellen. Daneben 
kommen CD8+ T-Zellen vor, die direkte zytotoxische Funktionen 
wahrnehmen. CD4+ T-Zellen werden dagegen überwiegend durch die 
Produktion und Sekretion von löslichen Botenstoffen, z.B. Zytokinen, 
wirksam. Auf dem Muster sezernierter Zytokine basiert schwerpunktmäßig 
die funktionelle Unterteilung der T-Zellen und zwar zunächst dichotomal in 
Th1 und Th2-Zellen (Mosmann 1986). Dieses Konzept von vorrangig IFNγ/ 
IL-12 (Th1) bzw. IL-4/IL-10 (Th2) produzierenden T-Zell-Subtypen wurde 
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inzwischen wesentlich erweitert. Man unterscheidet eine Reihe anderer, 
distinkter Subtypen, darunter proinflammatorische Th17 (IL-17-
produzierende)- und Th22-T-Zellen sowie Follikuläre Helferzellen (follicular 
helper T cells, wichtig für die Reifung antikörperproduzierender B-Zellen im 
Lymphknoten) sowie immunsupprimierende, regulatorische T-Zellen, Tregs. 
Die Balance dieser Subtypen im Verlauf einer Immunantwort ist von zentraler 
Bedeutung für den resultierenden biologischen Effekt der Immunantwort. 
Zunehmend wird erkannt, dass eine hohe funktionelle Plastizität zwischen 
einigen dieser Subtypen besteht und dass Übergänge auch noch in späten 
Entwicklungsstadien der Zellen auftreten können mit Konsequenzen für die 
anhaltende Immunantwort (Magombedze 2013, Basu 2013). 
 
Die antigenspezifische T-Zell-Aktivierung erfolgt an der immunologischen 
Synapse. Keine Struktur verdeutlicht die Kooperation von angeborenem und 
adaptivem Immunsystem so eindrucksvoll wie diese multimolekulare 
Organisationsplattform an der Interaktionsfläche zwischen APC (z.B. einer DC 
als Vertreter der angeborenen Immunität) und T-Zelle (als Repräsentant des 
adaptiven Immunsystems). Die Synapse bildet die molekulare Matrix, über 
welche die T-Zelle im antigenspezifischen Kontext Signale empfängt. Hier 
wird bildlich gesprochen „der Staffelstab“ der Immunantwort vom 
angeborenen an das adaptive Immunsystem übergeben (Reichardt 2010).  
Mittels ihrer MHC-II-Moleküle präsentiert die APC ein Antigenbruchstück (in 
aller Regel ein Peptid) der T-Zelle. Diese interagiert mittels ihres TCR-CD3-
Komplexes mit dem angebotenen Peptid-MHC (pMHC)-Liganden. Zusätzlich 
sichern Verbindungen zwischen Ankermolekülen wie dem Integrin LFA-1 
(lymphocyte function-associated antigen-1) und ICAM-1 (Intercellular 
Adhesion Molecule 1) sowie costimulatorische Moleküle wie CD28 auf T-Zell-
Seite mit z.B. B7.2 auf APC-Seite die Verbindung (Bromley 2001). 
Der Kontakt des T-Zell-Rezeptors mit einem passenden pMHC-Komplex löst 
eine Plethora an Signalprozessen in der T-Zelle aus. Diese können zur 
vollständigen Aktivierung der T-Zelle führen, ihre funktionelle Prägung und 
die Ausübung ihrer Effektorfunktionen einleiten. Es ist wichtig zu betonen, 
dass eine immunologische Synapse nur ausgebildet wird, sofern ein Antigen-
MHC-Komplex mit ausreichender Affinität zum T-Zell-Rezeptor präsentiert 
10 
 
wird. Unterhalb einer kritischen Schwelle kontaktieren sich die Zellen nur kurz 
ohne Einleitung einer T-Zell-Aktivierung. Ausreichend lange Kontakte mit 
ausreichend starken Signalen führen stattdessen zur Initiation der T-Zell-
Aktivierung (Gunzer 2001, Henrickson 2008).  
Erfolgreiches TCR-Triggering  führt zu einer Kaskade an Signalprozessen. 
Zunächst werden Src-Kinasen wie die Lymphozyten-spezifische Tyrosinkinase 
p56(Lck) aktiviert, und diese phosphorylieren die ζ-Kette des TCR-CD3-
Komplexes an ITAMS (immunoreceptor tyrosine-based activation motifs) (Lin 
2001). Anschließend wird die Tyrosinkinase ZAP70 (zeta-associated protein of 
70 kDa) zu den ITAMs rekrutiert und phosphoryliert ihrerseits Adapter wie 
LAT (linker for activation of T cells) und SLP76. Diese wiederum rekrutieren 
PLCγ1, einen Aktivator von Calciumströmen, und Vav1, einen Regulator der 
Aktin-Reorganisation. Dies führt u.a. zur Aktivierung von MAP–Kinasen und 
Transkriptionsfaktoren wie NFAT und NF-κB (Costello 1999, Smith-Garvin 
2009). Allerdings besteht sowohl in Art und Umfang der notwendigen 
Zellkontakte als auch in der Qualität der eingeleiteten Aktivierung große 
Plastizität (Reichardt 2007). Daher ist, aufgrund ihrer sprichwörtlich zentralen 
Rolle bei der T-Zell-Aktivierung (ohne Synapse keine antigen-spezifische T-
Zell-Aktivierung) die Entstehung, der molekularer Aufbau und das Signaling 
von Synapsen von großem Interesse (Dustin 2010, Xie 2013).  
 
Um das komplexe Signaling-Netzwerk in immunologischen Synapsen zu 
untersuchen, entwickelten wir ein Multi-Parameter-Fluoreszenz-
Mikroskopiesystem (Multi-Epitope Ligand Cartography, MELC) so weiter, dass 
es für die dreidimensionale Analyse der immunologischen APC-T-Synapse 
geeignet war (App. 04, Philipsen 2013).  
Wir charakterisierten die gleichzeitige räumliche Verteilung von 25 
molekularen Markern über 2 Stunden auf dem Niveau einzelner stabiler 
Synapsen, darunter phosphorylierte und nichtphosphorylierte Signalproteine 
(wie phospho(p)ZAP70, pSLP76, pCD3 und pLAT sowie Proteine, welches die 
Struktur der Synapse beeinflussen wie F-Aktin, Tubulin, CD45 und ICAM-1.  
 
Wir beobachteten die Bildung einer klassischen ringförmigen bull’s eye 
Synapse (Fooksman 2010, Reichardt 2007c) mit einem zentralen 
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supramolekularen Bereich (cSMAC, central supramolecular activation cluster), 
der vorrangig eine Akkumulation von pLAT und TCR aufwies. Ein weiterer, 
peripherer Bereich (pSMAC) in welchem sich ebenfalls Signalmoleküle 
ansammelten, wurde distal von einem strukturbildenden F-Aktin-Ring 
begrenzt. Wir sahen anhaltendes TCR-Signaling während der gesamten 
Beobachtungszeit von 2 Stunden. Dabei folgte einer Phase intensiven TCR-
Signalings unmittelbar nach dem Zellkontakt eine verstärkte Rekrutierung 
von Strukturproteinen gefolgt von einer anhaltenden Akkumulation von TCR 
und Signalproteinen (pLAT) im Zentrum der Synapse. Wir identifizierten 
diskrete Cluster (Signaling hotspots) im zentralen Synapsenbereich und 
fanden diese angereichert mit TCR, mit TCR-proximalen Signaling-Proteinen 
wie pLck und pZAP70 sowie Adapterproteinen wie pLAT und pSLP76.    
Unsere Studie war die erste, die gleichzeitig eine größere Anzahl an 
Signalmolekülen während des Aufbaus der stabilen immunologischen Synapse 
verfolgen konnte. Die Tatsache, dass an der Synapse über Stunden 
dynamische Rekrutierung von Struktur- und Signalmolekülen erfolgt, führte 
auch Beobachtungen zusammen, die eine vollständige Aktivierung von T-
Zellen erst nach einem Kontakt (oder einer sequentiellen Abfolge von 
Kontakten) über mehrere Stunden nahelegen (Iezzi 1998, Faroudi 2003).  
Weiter offen ist, wie genau sich Synapsen von T-Zellen verschiedener 
Subtypen unterscheiden. Erste Hinweise auf z.B. verstärkte Rekrutierung von 
IFNγ-Rezeptor in Th1-Zellen bzw. ausbleibende Rekrutierung von 
Proteinkinase C Theta (PKCθ) in Tregs existieren (Maldonado 2009, Sumoza-
Toledo 2006). Weiterhin gilt zu beachten, dass die Synapse nicht nur eine 
Struktur zum Austausch von Rezeptor-Liganden-Signalen sondern auch von 
Substrat ist. Die Untersuchung der Anordnung von membrannahen Vesikeln 
und deren intra- und interzellulären Transportwege sind neue, relevante 
Aspekt des Studiums der synaptischen Funktion (Soares 2013). Notwendig 
für solche Studien ist allerdings eine exzellente räumliche Zuordnung 
innerhalb der dreidimensionalen Synapsenstruktur. In der Zukunft werden 
geeignete technische Apparaturen, die eine verbesserte räumliche Anordnung 
von APC-T-Zell-Paaren ermöglichen, die Bildqualität verbessern (Biggs 2011). 
Hochauflösende Mikroskopie, die eine Betrachtung im Nanometer-Bereich 
erlaubt, wird weitere strukturelle Details zutage fördern und damit 
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mutmaßlich auch eine bessere Abschätzung funktioneller Zusammenhänge 
ermöglichen (Betzig 2006, Baddeley 2011).  
 
Eine wichtige Frage im Kontext der antigeninduzierten T-Zell-Aktivierung ist 
die nach den frühesten molekularen Ereignissen auf der T-Zell-Oberfläche. 
Wie beschrieben weiß man, dass Lck unmittelbar nach Beginn des TCR-
Triggerings Phosphorylierungen von ITAMS am TCR-CD3-Komplex vornimmt 
(Lin 2001). Allerdings ist Lck zu jeder Zeit bereits in großer Menge auf der 
Membranoberfläche von T-Zellen vorhanden. Wie wird Lck strukturell auf 
diesen „Angriff“ am TCR vorbereitet?  
 
In einem weiteren Projekt (App. 06, Stirnweiss 2013) gelang es uns, 
mittels unserer Multi-Epitop-Liganden-Cartographie, MELC, die räumliche und 
zeitliche Verteilung sowie den Phosphorylierungszustand verschiedener 
Kinasen, darunter Lck, gleichzeitig mit anderen Molekülen an der 
Membranoberfläche von (T-zell-ähnlichen) humanen Jurkat-Zellen zu messen. 
Durch vergleichende Betrachtung der Signalintensitäten der einzelnen 
Proteine auf Einzelzellebene war es uns möglich nachzuweisen, dass bei anti-
CD3-getriggerter Aktivierung zwar TCR-Signaling-abhängige Moleküle wie 
CD3ε und ζ eine deutliche Phosphorylierung erfuhren, dass auf den 
identischen Zellen jedoch keine oder kaum Veränderungen der Lck-
Phosphorylierung stattfanden. Dies war neben anderen Ergebnissen im Paper 
ein wichtiger Bestandteil der Beweisführung, dass es vorrangig 
Konformationsänderungen und nicht Phosphorylierungen waren, welche das 
Lck zum enzymatischen Angriff (Kinase-Aktivität) auf den TCR-Komplex 
vorbereitet. Diese Erkenntnis unterstrich frühere Beobachtungen (Nika 2010) 
und stellte ein zentrales Prinzip der T-Zell-Aktivierung in den Vordergrund 
(Paper wurde in Faculty of 1000, Immunology, gewählt).  
 
Der Typ der beteiligten APC prägt wie beschrieben maßgeblich das Resultat 
der T-Zell-Aktivierung. Dies hängt (bei angenommen identischem kognaten 
TCR-Liganden (dem passenden Peptid-MHC-Komplex) vor allem von Art und 
Menge an costimulatorischen Signalen ab, welche zusätzlich auf die T-Zelle 
einwirken. Darüber hinaus kann auch die Beschaffenheit der Zelloberfläche 
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einen Einfluss haben. Große sphärische Oberflächen wie die einer ruhenden, 
runden B-Zelle treten großflächig mit T-Zellen in Kontakt zur Bildung einer 
symmetrischen, stukturell reifen (bull’s eye) Synapse, während die eher 
kleinen, multimorphen Dendriten einer DC typischerweise nur punktuell 
(dafür oft multifokal) mit T-Zellen interagieren (Brossard 2005). Dass die 
Form der physikalischen Präsentation eines Stimulus eine Rolle bei der 
Signalinduktion spielt, konnten wir in einem anderen Zusammenhang zeigen. 
Erneut konnten wir mit Untersuchungen des T-Zell-Signalings durch 
multimolekulare Analyse auf Einzelzellebene beitragen (App. 07, Arndt 
2013). Bei der Analyse des Signalings nach T-Zell-Rezeptor-Stimulation 
humaner T-Zellen konnten wir charakteristische Unterschiede im 
Stimulationsmuster, hervorgerufen durch lösliche vs. (durch Anheftung an 
Microbeads) immobilisierte CD3-Antikörper, nachweisen. Wir fanden, dass 
lösliche Antikörper nur sehr  kurzzeitige, wenngleich starke Signale auslösten, 
während immobilisierte Antikörper eher ein protrahiertes Signalmuster in T-
Zellen erzeugten, was eher dem durch APC erzeugten Muster entsprach.  
Diese Ergebnisse weisen (im begrenzten Umfang eines in vitro-Experiments) 
auf die Abhängigkeit des erzeugten Signalmusters von der räumlichen 
Anordnung eines ansonsten identischen Stimulus hin (in dem Fall anti-CD3-
Antikörper). Sie verdeutlichen, dass die Anwendung immobilisierter 
Antikörper besser geeignet ist, die T-Zell-Aktivierung durch eine APC 
nachzustellen,  da die induzierten Signalmuster wesentlich ähnlicher als nach 
der Anwendung löslicher Antikörper war. Zusammengefasst sind die 
Ergebnisse Indiz dafür, dass die  biophysikalische Form, in welcher ein TCR-
Trigger-Signal auf T-Zellen einwirkt, für das induzierte Signalmuster in T-
Zellen wichtig ist. Auch das Konzept der Verbindung zwischen Signalstärke, 
Polarisation des Zytoskeletts und  Zellkontaktarchitektur  (eher rigide 
Synapse vs. eher fluide Kinapse) findet inzwischen breitere Anwendung 
(Dustin 2009, Moreau 2012). 
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3. T-Zell-Migration als conditio sine qua non  
der T-Zell-Aktivierung in vivo 
 
Bis zur Ausbildung einer funktionalen immunologischen Synapse zwischen 
APC und T-Zelle müssen die Partner im Verlauf der Immunantwort weite 
Wege zurücklegen. Komplexe Migrationsvorgänge sind notwendig, denn 
typischerweise residieren beide Zelltypen zunächst an entfernten Punkten des 
Organismus. Diese in vivo Migration von Lymphozyten und anderen 
Immunzellen ist ein streng regulierter Prozess mit großem Einfluss auf die 
Immunantwort.   
Die APC (z.B. eine Dendritische Zelle) nimmt das Antigen typischerweise im 
Gewebe der Haut, der Lunge, des Darms oder im Blutgefäßendothel auf und 
präsentiert Bruchstücke davon auf ihren MHC-Molekülen während die Zelle 
zum drainierenden Lymphknoten wandert. T-Zellen ruhen vorrangig in 
lymphatischen Organen, z.B. in der parakortikalen T-Zell-Zone des 
Lymphknotens. Residente und einwandernde DC präsentieren dort „ihre“ 
prozessierten Antigene im Rahmen multipler Zellkontakte an zahlreiche T-
Zellen. Im Parenchym wandern DCs vergleichsweise langsam (3 µm/min), 
kontaktieren jedoch mittels langer dendritischer Ausläufer innerhalb einer 
Stunde bis zu 5000 hochmotile T-Zellen, die sich mit der drei- bis vierfachen 
Geschwindigkeit bewegen (Miller 2004). Antigenspezifische Kontakte führen 
zu einer über Stunden anhaltenden Abfolge an Interaktionen mit wechselnder 
Beweglichkeit (phasenweise geringere Geschwindigkeiten teilweise bis hin zur 
Arretierung der T-Zellen) sowie veränderlichem Schwarmverhalten der T-
Zellen (Friedl 2002, Reichardt 2006, Reichardt 2010).  
 
Den unmittelbarsten Einblick in diese Abläufe einer Immunantwort und die 
dabei stattfindenden Zellkontakte gewinnt man durch moderne Methoden der 
Mikroskopie. Die Entwicklung hochsensitiver Bildgebungssysteme, welche 
bestimmte funktionelle Abläufe (wie z.B. Calcium-Signale) durch 
Reportersysteme visualisiert, die Beobachtung tief im lebenden Gewebe 
ermöglicht oder mit nanoskopischer Auflösung kleinste strukturelle Details 
erkennen lässt, hat in den letzten Jahren enorme Fortschritte gemacht 
(Reichardt 2009). 
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 Um das dreidimensionale Milieu des Körpergewebes, in welchem die 
spezifischen immunologischen Zellkontakte stattfinden, bestmöglich in vitro 
nachzubilden, haben wir und andere experimentelle Systeme entwickelt, in 
welchen sich bestimmte biophysikalische Eigenschaften der Zellbewegung 
sehr ähnlich zu denen in vivo beobachten lassen (Reichardt 2007b). 
Lebendzellbeobachtung in solchen Systemen erlaubte uns u.a. den Einfluss 
des Adaptermoleküls SLP76 auf die Chemokin-vermittelte Motilität humaner 
T-Zellen zu untersuchen. Es ist bekannt, dass als eine Konsequenz aus dem 
TCR-Triggering in der T-Zelle Integrine wie LFA-1 aktiviert werden. Integrine 
als Ankermoleküle auf  der T-Zelle sind (neben der Funktion für die Stabilität 
der Synapse) auch für T-Zell-Motilität und Adhäsion wichtig (Campbell 2003). 
Neben den TCR-Signalen werden Integrine auch durch das Triggering von 
Chemokinrezeptoren wie CXCR4 (durch Stromal cell-derived factor-1, 
CXCL12) aktiviert und in ihrer Affinität und Avidität reguliert (Kinashi 2005). 
Das Adaptermolekül SLP76 ist ein wichtiger Bestandteil membrannaher 
Molekülkomplexe, seine Anwesenheit ist notwendig für den Anstieg an 
intrazellulärem Calcium und die Aktivierung des intrazellulären 
Ras/Raf/MAPK/ERK-Signalwegs (Yablonski 1998). Gleichzeitig  sind 
Komponenten der SLP76-Signaling-Plattform an der Aktivierung von LFA-1 
nach TCR-Triggering beteiligt (Bezman 2008).  
Um den Einfluss von SLP76 nach Triggering von CXCR4 zu untersuchen, 
ermittelten wir (als ein Bestandteil des Papers) die basale und CXCR12-
induzierte laterale Motilität (auf Fc-ICAM-1-beschichteten Oberflächen) von 
SLP76+/+ und SLP76-/- T-Zellen. Wie fanden vergleichbare Werte, d.h. die 
Zellen bewegten sich unabhängig von der Anwesenheit von SLP76 
(wohingegen sie bei Fehlen des Adaptermoleküls Vav1 deutlich langsamer 
wurden) (App. 11, Horn 2009). Unsere Daten war im Kontext mit anderen 
Resultaten des Papers ein wichtiger Baustein für die Erkenntnis, dass eine 
differentielle Abhängigkeit von SLP76 im T-Zell-Signaling besteht und zwar 
dahingehend, dass SLP76 zwar für TCR-vermittelte Signale, nicht aber für das 
Chemokin-Rezeptor-Signaling (die CXCR4-Triggerung durch CXCL12) bei der 
Aktivierung des Integrin-Moleküls LFA-1 notwendig ist. Die komplexe 
Steuerung der Integrin-Affinität durch Chemokin-Rezeptor-Signale wurde 
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kürzlich erneut unterstrichen, als zwei räumlich getrennte, unabhängige 
(ADAP/SKAP55-)Molekülkomplexe in T-Zellen identifiziert wurden, die in 
Antwort auf CCR7-Triggering die LFA-1-Affinität regulieren (Kliche 2012). 
 
Ferner, Lebendzellmikroskopie unter Verwendung von Kollagen-beschichteten 
Oberflächen gestattete uns, die Feinstrukturen der Oberflächenbeschaffenheit 
von APC wie DC genau zu beobachten und charakteristische Eigenschaft wie 
Dendritenanzahl und -länge zu quantifizieren. In einer solchen Studie ging es 
um die Charakterisierung der Rolle von SWAP70 auf die Sphingosin-1-
Phosphat–induzierte Motilität von DC. SWAP70 ist ein Guanin-Nucleotid-
Exchange-Faktor (GEF), der Signale von Tyrosinkinase-Rezeptoren wie 
Phosphatidylinositoltrisphosphat weiterleitet und so die Zytoskelettarchitektur 
und Membranbeschaffenheit beeinflusst (Shinoara 2002). Sphingosin-1-
Phosphat ist ein bioaktives Lipid und ein Zellmembranbestandteil, der 
chemoattraktiv wirksam und am lymphozytären Egress aus Lymphknoten in 
vivo sowie an der Wanderung  reifer DC beteiligt ist (Rosen 2005, Czeloth 
2005).  
Wir beobachteten (als ein Teil der Studie) in Abwesenheit von SWAP70 bei DC 
morphologische Auffälligkeiten (App. 09, Ocaña-Morgner 2011). Dazu 
zählten eine reduzierte Anzahl von Dendriten, deren geringere Kontraktion 
sowie ein eher elongierter Zellkörper mit dezentralem, rostralen Kernbereich.  
Diese Beobachtung lieferte ein morphologisches Korrelat welches die 
verminderte Motilität in 3D-Umgebungen und die verminderte Anreicherung 
im Lymphknoten in Abwesenheit von SWAP70 (parallel bestimmt in der 
Studie) zu erklären halfen. Die Bedeutung von SWAP70 für die T-Zell-
Aktivierung wurde kürzlich erneut unterstrichen als bekannt wurde, dass ein 
SWAP70-intaktes Zytoskelett notwendig ist, einer u.a. durch Integrine 
(CD11b) vermittelten spontanen Reifung von DC entgegenzuwirken. Solche 
Reifungsprozesse fördern die Induktion von Immunprozessen beim DC-
Kontakt mit T-Zellen und modulieren so deren Aktivität (Ocaña-Morgner 
2013).    
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Zur Visualisierung der Zell-Zell-Distribution und -Kommunikation tief im 
lebenden Gewebe, im intakten Organ wie z.B. im Lymphknoten, ist vor allem 
die 2-Photon-Mikroskopie hervorragend geeignet. Diese Technik ermöglichte 
uns, in einer Reihe von Studien die in vivo Verteilung und Motilität von 
Lymphozyten an charakteristischen Strukturen des Lymphknotens der Maus 
zu untersuchen.  
 
So konnten wir u.a. nachweisen, dass sich in vivo in Lymphknoten von ADAP 
(adhesion- and degranulation-promoting adapter protein)-defizienten Mäusen 
B- und T-Lymphozyten an lymphatischen Gefäßen ansammelten (App. 01,  
Engelmann 2013). ADAP ist ein zytosolisches Adapterprotein, welches u.a. 
in T-Zellen und myeloiden Zellen exprimiert wird (Dluzniewska 2007). ADAP 
ist beteiligt an der TCR- und Chemokin-vermittelten Aktivierung der 
Integrine, sein Fehlen führt zu verminderter T-Zell-Adhäsion und 
verminderter Konjugat-Formation mit APC (Burbach 2008).  
Unsere Beobachtung war ein wichtiger Baustein im Paper und lieferte eine 
mögliche Erklärung für die parallel registrierte verminderte Induktion der 
Multiple-Sklerose-ähnlichen experimentellen autoimmunen Enzephalitis (EAE) 
bei Fehlen von ADAP. Unsere Daten demonstrierten, dass auch T-Zell-
unabhängig (die adoptiv transferierten T-Zellen waren ADAP-kompetent) bei 
Fehlen von ADAP eine migratorische Defizienz bestand und dass diese 
selektiv war: während das Homing in den Lymphknoten normal blieb, wurde 
der Egress aus dem Lymphknoten vermindert, es bestand ein Hindernis im 
Überwinden der endothelialen Barrieren von lymphatischen Gefäßen. Die 
molekulare Ursache für das beobachtete intranodale Trapping sind derzeit 
allerdings unklar. Eine Defizienz im S1P-System wurde ausgeschlossen, 
weiterhin möglich wäre eine verstärkte Interaktion mit ICAM-1 in vivo. 
Weitere Experimente dazu sind von den Initiatoren der Studie geplant. 
 
Die molekularen Grundlagen der integrinvermittelten T-Zell-Motilität waren 
der Fokus einer weiteren Studie, zu der wir durch Mikroskopie intakter 
Lymphknoten der Maus beitragen konnten. Bekanntermaßen vermitteln 
Integrine in vivo die Verankerung von T-Zellen im Gewebe und spielen eine 
zentrale Rolle beim Übertritt zwischen Blutgefäßen und z.B. lymphatischen 
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Organen (Hamann 1988, Berlin-Rufenach 1999). Entsprechend führen 
Störungen in der Aktivierung der Integrine zur Beeinträchtigung der 
Wanderwege von T-Zellen und damit zu Störungen der Immunantwort.  
Elementar für die Integrin-Aktivierung ist das Signaling über Guanin-
Nucleotid-bindende Gα-Proteine. Gegenstand der Studie war der Nachweis, 
dass die genetische Inaktivierung der G-Proteinuntereinheiten Gα12 und 
Gα13 zu einer erhöhten Aktivität von LFA-1 in CD4+ T-Zellen führt (App. 10, 
Herroeder 2009).  
Speziell untersuchten wir (als Teil des Papers) die in vivo Verteilung von 
Gα12, Gα13-doppeldefizienten CD4+ T-Zellen im Lymphknoten der Maus. Wir 
fanden eine verstärkte Präsenz dieser T-Zellen in vaskularisierten Bereichen 
der T-Zell-Zone. Diese Anreicherung war, wie im Paper weiter gezeigt wurde, 
mit einer erhöhten T-Zell-Proliferation und einer verstärkten Suszeptibilität 
gegenüber immunvermittelten Erkrankungen (darunter Diabetes) verknüpft. 
Die Daten legten nahe, dass lokale Signale, die über Gα12- und Gα13-
gekoppelte Rezeptoren vermittelt werden, eine Modulation der T-Zell–
Wanderung bewirken können. Die Modulation der Migration über Gα-
Rezeptoren ist auch Bestandteil der funktionellen Reifung von T-Zellen. Wie 
inzwischen gezeigt werden konnte, kommt es auf CD4+ T-Zellen im Verlauf 
ihrer Differenzierung zu einer selektiven Änderung des Gα-Repertoires, was 
eine spezifische Lokalisierung entsprechend ihres funktionalen Profils 
reflektiert  (Foley 2010). 
  
Einen neuartigen modulierenden Effekt durch Integrine auf T-Zell-Migration 
und –Funktion wiesen wir in einer weiteren, sehr umfangreichen Studie nach, 
welche sich mit dem Einfluss von LFA-1 auf die T-Zell-Migration beim Austritt 
aus dem Lymphknoten beschäftigte (App. 05, Reichardt 2013). 
Zwar war wie oben beschrieben bekannt, dass LFA-1 essentiell für den 
Übertritt aus dem Blutgefäß in den Lymphknoten ist. Unklar war jedoch, ob 
Integrine auch beim Verlassen des Lymphknotens über die Lymphbahnen 
eine Rolle spielen. Bekannt war lediglich, dass T-Zellen den Lymphknoten 
über subkapsuläre Sinus, T-Zell-Zonen-nahe corticale Sinus und die Medulla  
verlassen können (Grigorova 2009, Sinha 2009) und dass der Egress vom 
Zusammenspiel zwischen zurückhaltenden Signalen (Chemokin-Rezeptor 
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CCR7) und egressfördernden Signalen (Sphingosin-1-Phosphat-Rezeptor-1, 
S1P1) (Pham 2008) abhängt.  
Wir konnten mittels intravitaler Mikroskopie zeigen, dass auch LFA-1 eine 
Rolle bei der Entscheidung Egress vs. Retention im Lymphknoten spielt. Wir 
beobachteten ein differentielles Verhalten von LFA Wildtyp(WT)- und LFA-1-
KO-T-Zellen beim Kontaktieren von ICAM-1-exprimierenden lymphatischen 
Netzwerken. Während WT-T-Zellen eher ins Lymphknotenparenchym 
zurückkehrten, verließen LFA-1-KO-T-Zellen den Knoten rascher. Offenbar 
spielt LFA-1 als Adhäsionsrezeptor bei der Entscheidungsfindung eine Rolle. 
Es ist noch unklar, welche T-Zell-Funktionen dabei beeinflusst werden. Der 
Effekt könnte aber die Immunantwort verstärken, indem die Anzahl an T-
Zellen, welche im Verlauf einer Immunantwort aktiviert werden, erhöht wird. 
Dass der Kontakt zu lymphatischen Membranen zelluläre Aktivität 
beeinflussen kann wurde bereits früher für DC gezeigt (Podgrabinska 2009). 
Unsere Ergebnisse verdeutlichten ein neues mechanistisches Prinzip, über 
welches LFA-1 die T-Zell-Migration und damit die T-Zell-Aktivierung 
beeinflussen kann.   
  
Zusammengefasst unterstrichen unsere intravitalen und ex vivo Experimente 
mittels 2-Photon-Mikroskopie die Bedeutung eines intakten 
Migrationsverhalten von T-Zellen in vivo. Sie zeigen, dass die korrekte 
Wanderung durch lymphatisches Gewebe in wesentlicher Weise die 
Aktivierbarkeit und damit die Funktionsfähigkeit von T-Zellen bestimmt.  
 
Wie kann diese Erkenntnis genutzt werden? Die immuntherapeutische 
Beeinflussung der T-Zell-Wanderung steht erst am Anfang. Sie hat jedoch mit 
der medikamentösen Gabe von FTY720, Sphingolimod, eines S1P-Rezeptor-
Modulators, eine erste erfolgreiche Anwendung gefunden. FTY720 hemmt den 
Austritt von T-Zellen aus dem Lymphknoten und damit die T-Zell-vermittelte 
Inflammation. FTY720 wird bei der Prävention der Transplantatabstoßung und 
insbesondere bei der Behandlung bestimmter Formen der Multiplen Sklerose 
angewandt (Brinkmann 2001, Brinkmann 2009). 
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4. extrinsische Modulation der T-Zell-Aktivierung  
durch Umwelteinflüsse 
 
Die T-Zell-Aktivierung läuft auch bei Angriff identischer Mengen identischen 
Antigens nicht in zwei Individuen gleich ab. Neben genetischen 
Voraussetzungen modulieren zahlreiche Umwelteinflüsse die auf T-Zellen 
einwirkenden Signale und beeinflussen damit die gesamte Immunantwort. 
 
Das Immunsystem befindet sich in ständigem Austausch mit der Umwelt. 
Bereits intrauterin kommt es zum ersten Kontakt zwischen sich 
entwickelnden Bestandteilen des Immunsystems, darunter T-Zellen, mit von 
der Mutter aufgenommenen Substanzen wie Nahrungsbestandteilen (darunter 
komplexe Proteine aus Kuhmilch oder Fisch) oder Gräserpollen. 
Schwangerschaft und früheste Kindheit sind besonders sensible Phasen, in 
denen das Immunsystem geprägt wird (Prescott 2009). Das werdende Kind 
kann schon frühzeitig substanzspezifisch immunologische Toleranz oder 
allergische Sensibilisierungen entwickeln. Solchen Sensibilisierungen 
vorzubeugen bzw. sie frühzeitig zu entdecken ist von großer klinischer 
Bedeutung (Sausenthaler 2011, Leermakers 2013).  
Eine der Hauptquellen für die Auseinandersetzung mit der Umwelt ist die 
Nahrung. Die Hauptnahrung für Neugeborene ist die Muttermilch. Ein Ansatz 
zur Untersuchung von Umweltfaktoren und immunologischen Erkrankungen 
ist daher der Vergleich der Zusammensetzung der Muttermilch mit späteren 
klinischen und paraklinischen Zeichen der allergischen Sensibilisierung.  
Im Rahmen einer großen klinischen Studie zur Untersuchung der Entstehung 
allergische Sensibilisierungen bei Neugeborenen mit erhöhtem Allergierisiko 
(LARS, Leipziger Allergie-Risiko[kinder]-Studie) fanden wir eine Assoziation 
zwischen der Zusammensetzung der Muttermilch und der allergischen 
Sensibilisierung (App. 15, Reichardt 2004). Unter anderem fanden wir für 
Kinder mit vermindertem Geburtsgewicht eine Korrelation von hohen 
Spiegeln an Linolensäure (LA, 18:2n-6) mit hohem spezifischem IgE gegen 
Kuhmilch sowie von niedriger Docosapentaensäure (DPA, 22:5n-3) mit 
erhöhtem totalem Serum-IgE im Alter von 1 Jahr. Diese Daten stimmten 
überein mit der generellen Beobachtung, dass die langkettigen (mindestens 
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14 Kohlenstoffatome) n-6- (synonym Ω6-) Fettsäuren, insbesondere wie von 
uns gefunden LA, 18:2n-6, einen atopiefördernden Einfluss haben, während 
n3 (Ω3)-Fettsäuren eher schützen. Der Grund hierfür liegt darin, dass viele 
Vertreter der n6-Reihe, darunter Arachidonsäure (AA, 20:4n-6) und deren 
Metaboliten wie Leukotrien B4 proinflammatorische Eigenschaften haben 
(Ohtsuka 1997), während die n3-Reihe, z.B. Eicosapentaensäure (EPA, 
20:5n-3) und Docosahexaensäure (DHA, 22:6n-3), eher als anti-
inflammatorisch beschrieben werden. Insbesondere DPA, 22:5n-3, für 
welches wir niedrige Spiegel mit erhöhtem IgE verbunden sahen, ist als 
metabolischer Linker mit 20:5n-3 (EPA) und 22:6n-3 (DHA) verknüpft, und 
für diese beiden langkettigen Fettsäuren wurde anti-inflammatorische 
Kapazität beschrieben (Calder 1998). Für EPA wurde u.a. die Hemmung der 
T-Zell-Proliferation und der IL-2-Produktion sowie die Induktion von Apoptose 
in T-Zell-Blasten berichtet (Terada 2001). Inzwischen sind neuere Hinweise 
vorhanden die zeigen, dass n-3-Fettsäuren die proinflammatorische 
Entwicklung von Th17-T-Zellen unterdrücken bzw. die Entwicklung von 
regulatorischen T-Zellen fördern können (Han 2012, Monk 2013).  
Langkettige Fettsäuren sind integrale Bestandteile der Zellmembran und 
beeinflussen die laterale Motilität von Signalmolekülen durch Veränderung der 
Zusammensetzung von lipid rafts. Eine n-3/n-6-Imbalance verändert das 
Signaling, auch von T-Zellen, darunter die Produktion des Calcium-second 
messengers Diacylglycerol (DAG) sowie die Rekrutierung und Aktivierung von 
PKCθ, MAPK und anderen Signalmolekülen (Kim 2010). Erst kürzlich wurde 
eine Arbeit veröffentlicht, welche (ähnlich zu dem von uns untersuchten 
Synapsensystem, s. App. 04) die Synapsenbildung zwischen B- und T-Zellen 
in Anwesenheit von Fischöl (reich an n-3 Fettsäuren) mittels TIRF-
Mikroskopie (total internal reflection fluorescence) untersuchte (Rockett 
2013). Die Zugabe von Fischöl verminderte die Anreicherung von MHC II und 
das Rekruitment von PKCθ an der Synapse. Wenngleich es sich um eine 
artifizielle Stimulation und ein in vitro System handelt, ist es doch interessant 
festzuhalten, dass dies ähnliche Resultate sind, wie sie bei der direkten 
Betrachtung von Synapsen von Tregs beobachtet wurden (Sumoza-Toledo 
2006, Zanin-Zhorov 2010).  
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Unsere Daten aus der Muttermilchstudie ließen schlussfolgern, dass 
bestimmte Risikoneugeborene von einer frühzeitigen Supplementierung mit 
(n-3) langkettigen Fettsäuren profitieren könnten; ein Procedere, das damals 
nur für Neugeborene mit sehr niedrigem Geburtsgewicht empfohlen wurde 
(ESPGAN Committee 1990). In der Tat lassen inzwischen neuere Daten 
vermuten, dass die perinatale Supplementierung einen positiven Effekt auf 
die Atopievermeidung hat (Klemens 2011). Andere zusammenfassende 
Untersuchungen sehen hingegen keinen eindeutigen Zusammenhang (Sala-
Vila 2008, Greer 2008). Da die Datenlage international nicht einheitlich ist, 
werden Kohortenstudien ähnlich zu unserer auch aktuell noch mit 
vergleichbarer Zielstellung durchgeführt. Erst kürzlich zeigte eine solche 
Studie erneut Resultate, die unseren Daten entsprachen, diesmal in der 
Korrelation von Fettsäuren der Muttermilch  mit dem Risiko für allergisches 
Asthma (Soto-Ramirez 2012). Wahrscheinlich ist jedoch für eine 
aussagekräftige Risikoabschätzung aufgrund der multifaktoriellen Genese 
atopischer Erkrankungen eine deutlich umfangreichere Erhebung von 
klinischen und paraklinischen Parametern empfehlenswert (Szefler 2012). Die 
derzeitigen Empfehlungen zur Prävention von Allergie und Asthma beruhen 
weiterhin hauptsächlich auf dem ausschließlichen Stillen für 5 Monate bzw. 
der Gabe von stark hydrolysierter Formula-Milch (zur Vermeidung 
frühzeitigen Kontakts mit Allergenen) in dieser Zeit. Probiotika haben in 
bestimmten Konstellationen einen protektiven Effekt gezeigt. Noch offen ist 
der Effekt der Supplementierung mit Vitamin D und mit mikrobiellen 
Komponenten zur Steuerung intestinaler Inflammation (Lau 2013).  
 
Neben Nahrungsbestandteilen werden Schadstoffe der Außenluft (reaktive 
Stickstoff- und Sauerstoffverbindungen aus Abgasen) sowie 
Innenraumschadstoffe (biologische Fremdstoffe wie Schimmelpilze oder 
reaktive Chemikalien in Farbstoffen, Kleber, Lösemittel) als wichtige 
Allergieauslöser angesehen (D’Amato 2010, Jaakola 2013, Mendel 2007).  
 
Insbesondere die Beteiligung niedermolekularen Verbindungen (small 
molecules) wirft die Frage auf, ob und wie diese Substanzen gegenüber T-
Zellen immunologisch wirksam werden können. Die TCR-Reaktivität ist 
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bekanntlich auf Peptide, wesentlich größere Moleküle, beschränkt. Neben 
toxischen Effekten wären auch epigenetische Einflüsse möglich (Karmaus 
2013). Allerdings sind auch funktionelle Beeinflussungen des Signalings 
denkbar, z.B. von T-Zellen, wie nachfolgend gezeigt.  
 
Seinerzeit viel beachtet waren die Studien (insbesondere die Nature-
Publikation) von John Rhodes, welche einen wichtigen molekularen 
Mechanismus möglicher signalmodulierender Eigenschaften von Xenobiotika, 
chemisch reaktiven Fremdstoffen, beleuchteten  (Rhodes 1989, Rhodes 
1995). Er bewies die Fähigkeit von Xenobiotika aus der Gruppe der Aldehyde, 
Schiff-Basen mit Aminogruppen auf der Oberfläche von T-Zellen einzugehen. 
In Schiff-Basen (Imine) sind typischerweise Carbonylgruppen kleiner 
Moleküle (z.B. von Aldehyden) mit Aminogruppen (z.B. Lysyl-Reste von 
Aminosäuren) gekoppelt. Die so auf T-Zellen entstandenen Bindungen 
interferierten mit  Clofilium-sensitiven Natrium- und Kaliumkanälen und 
beeinflussten dadurch das costimulatorische Signaling. Zudem zeigten die 
Daten, dass solche Bindungen offenbar auch integraler Bestandteil der 
molekularen Interaktion zwischen APC und T-Zellen waren.  
Ausgehend von diesen Erkenntnissen führten wir eigene Untersuchungen zur 
Adduktbildung einer Reihe von umweltrelevanten Xenobiotika darunter von 
Aldehyden, Toluen-2,4-diisocyanat (TDI), 2,4-Dinitro-1-Fluorbenzol (DNFB) 
u.a. mit der ε-Aminogruppe von Modellpeptiden durch und quantifizierten die 
relative in vitro-Reaktivität der Xenobiotika (App. 16, Reichardt 2003). 
 
Wir konnten regelmäßige und stabile Adduktbildungen nachweisen und damit 
zeigen, dass die Formation einfacher chemischer Bindungen wie Schiff-Basen 
nicht auf Aldehyde beschränkt ist, sondern auch bei anderen Klassen an 
Xenobiotika beobachtet werden kann. Solche elektrophilen Reaktionen bilden 
die molekulare Basis für die in vivo-Immuntoxizität und Immunmodulation 
zahlreicher Xenobiotika und reaktiver Metaboliten (Pumford 1997). Neben 
Aminogruppen sind häufig Thiole bevorzugte Angriffspunkte reaktiver 
Xenobiotika. Im Rahmen von intrazellulären Redoxreaktionen sind solche 
Prozesse auch bei der Entstehung posttranslationaler Modifikationen beteiligt 
(Rudolph 2009).  
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Im Detail zeigten unsere Daten, dass niedrig-aktive Substanzen kaum 
Tendenz haben, Bindungen einzugehen. Dies war zu erwarten. Wir 
beobachteten aber gleichzeitig, dass die von uns untersuchten Xenobiotika 
mit der strukturell höchsten Reaktivität ebenfalls nur geringe 
Adduktbildungen mit dem Modellpeptid eingingen. Offenbar werden sie in 
einem wässrigen Umgebungsmilieu, wie es im Organismus vorliegt, durch 
sofortige Reaktion mit dem Umgebungswasser in ihrer Reaktionsfähigkeit 
gegenüber Proteinen beschränkt. In der Folge wurden von uns die stärksten 
Effekte im physiologischen Milieu für Xenobiotika mit mittlerer chemischer 
Reaktivität beobachtet. Solche Zusammenhänge können Konsequenzen für 
die Einschätzung der Toxizität einer Substanz in vivo haben (Rotroff 2010). 
Inzwischen können mittels modernster Verfahren (Ultra-performance LC, 
UPLC, gekoppelt mit Time-of-Flight-Massenspektrometrie, TOF-MS) auch 
Substanzen mit hoher Reaktivität und kurzer Lebensdauer erfasst werden, für 
die in vivo bei Entstehung in unmittelbarer Nähe zu Proteinen oder DNA 
ebenfalls Adduktbildungen zu erwarten sind (Rousu 2009).  
Die Bewertung gesundheitsschädlicher Arbeitsstoffe erfolgt in Deutschland 
maßgeblich durch die Ständige Senatskommission zur Prüfung 
gesundheitsschädlicher Arbeitsstoffe (MAK-Kommission) der Deutschen 
Forschungsgemeinschaft (DFG), und zwar hinsichtlich ihrer 
krebserzeugenden, keimzellmutagenen, sensibilisierenden, hautresorptiven 
und die Schwangerschaft beeinträchtigenden Eigenschaften. Entsprechend 
werden Grenzwerte wie maximale Arbeitsplatz-Konzentrationen (MAK-Werte) 
für flüchtige Chemikalien und Stäube, biologische Arbeitsstoff-Toleranzwerte 
(BAT-Werte), biologische Leitwerte (BLW) bzw. biologische Arbeitsstoff-
Referenzwerte (BAR) festgelegt und jährlich aktualisierte Übersichten 
herausgegeben (MAK Collection 2013). 
Immunmodulatorische Eigenschaften jenseits der Sensibilisierung werden 
nicht explizit berücksichtigt und die Klassifizierung orientiert sich an 
Einzelsubstanzen. Schwierig aber notwendig ist die Entwicklung geeigneter 
Systeme der experimentellen Testung bzw. der statistischen Erfassung 
komplexer klinischer und paraklinischer Daten, welche potentielle Effekte der 
Immunmodulation besser zu erkennen und zu beschreiben in der Lage sind 
(Rotroff 2010). 
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Die modulierenden Einflüsse von Xenobiotika auf Zellphysiologie und 
Immunantwort werden zunehmend besser verstanden. Eine wichtige Rolle 
spielen z.B. Xenobiotika-Rezeptoren wie der Aryl hydrocarbon Rezeptor (Ah 
Rezeptor), ein zytosolischer transkriptioneller Regulator, der seinen Namen 
aufgrund charakteristischer Interaktion mit aromatischen 
Kohlenwasserstoffen wie PCB (polychlorierten Biphenylen) und Dioxinen 
erhielt. Der Ah-Rezeptor ist in zahlreichen Immunzellen zu finden und besitzt 
u.a. modulierende Eigenschaften bei der T-Zell-Differenzierung (Hao 2013, 
Nakahama 2013).  
Die Beeinflussung der T-Zell-Costimulation durch Xenobiotika wurde 
inzwischen auch der klinischen Anwendung zugeführt. So wurde die oben 
beschriebene costimulatorische Wirkung von Schiff-Base-formenden 
Substanzen erfolgreich zur Erzielung eines Adjuvans-Effekts bei einer 
Influenza-Vakzine angewandt (Charo 2004).  
 
Fremdstoffe treten nicht immer nur zufällig bzw. ungewollt mit dem 
Organismus in Kontakt. Sie können auch durch den Arzt (iatrogen) gezielt 
zugeführt werden (als Medikamente). Teilweise geschieht dies mit dem 
expliziten Wunsch, das Immunsystem zu beeinflussen, teilweise auch mit 
anderer Zielstellung, in deren Rahmen sich die Beeinflussung des 
Immunsystems als Nebenwirkung ergibt.  
Schon länger bekannt ist z.B. die Tatsache, dass Antibiotika, darunter 
Macrolide, Tetracycline und β-Lactam-Antibiotika, nicht nur eine spezifische 
bakterientötende oder -hemmende Wirkung besitzen sondern auch 
immunmodulatorische Effekte aufweisen. Allerdings sind viele Details zur 
Beeinflussung der Signalkaskade erst in den letzten Jahren zutage getreten 
(Aminov 2013). Rapamaycin, ein mTOR (mammalian Target of Rapamycin) -
Inhibitor und ein potentes Immunsuppressivum, ist von seiner Struktur her 
ein Antibiotikum, ein Makrolid. Rapamycin und ein jüngeres Derivat der 
Gruppe, Everolimus, wird weitverbreitet bei Transplantationen von Herz-, 
Lunge, Leber und Niere eingesetzt (Gunk-Turner 2012). Mehr zur zentralen 
Rolle von mTOR für die Immunantwort und die Treg-Bildung weiter unten 
(App. 02, Etemire 2013).  
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Ein Beispiel für immunmodulierende Antibiotika aus der Gruppe der β-
Lactam-Antibiotika ist die Kombination aus Piperacillin und Tazobactam. 
Dieses Antibiotikum wird vorrangig bei respiratorischen Infektionen 
angewendet. Piperacillin ist ein Penicillin-Derivat mit erweitertem 
Wirkungsspektrum, Tazobactam hemmt die Penicillin-abbauende Wirkung 
(Penicillinase) von Bakterien und verstärkt dadurch die Wirkung des 
Medikaments.  
Wir beobachteten bei der klinischen Anwendung in einer Kinderklinik, dass 
überdurchschnittlich viele Patienten, die mit diesem Antibiotikum behandelt 
wurden, Fieber sowie Leukozytopenie und Thrombopenie entwickelten. Nach 
Absetzen des Medikaments sistierten diese Symptome (App. 20, Reichardt 
1999). Unmittelbare allergische Reaktionen (IgE- und IgG-vermittelt) gegen 
Medikamente, darunter Penicilline, sind seit langem bekannt und stellen die 
am häufigsten berichteten Antibiotikaallergien dar (Chang 2012). Darüber 
hinaus wurden zirkulierende  Benzylpenicillin-spezifische CD4+ T-Zellen 
nachgewiesen (Nhim 2013). Auch die kovalente Bindung an Albumin (ähnlich 
zu Xenobiotika) und die nachfolgende Beeinflussung der T-Zell-Funktion 
wurde für β-Lactam-Antibiotika vor kurzem gezeigt: Gene, die mit Th2- und 
Treg-Differenzierung verknüpft waren, wurden in T-Zellen nach Stimulation 
mit (dem β-Lactam-Antibiotikum) Cefuroxim herunterreguliert, während die 
Behandlung mit Ampicillin diese Gene aufregulierte (Mor 2013). Mithin 
können β-Lactame T-Zellen direkt immunmodulatorisch beeinflussen. 
Der von uns beobachteten Nebenwirkung lag aber offenbar ein 
immunsuppressiver Effekt zugrunde, der schon im Knochenmark ansetzt 
(bone marrow suppression). Wahrscheinliche Ursache ist ein durch Piperacillin 
ausgelöster Reifungsdefekt (Scheetz 2007). Dies war zuvor bereits für eine 
Reihe von ß-Lactam-Antibiotika beobachtet worden und erklärt die bei 
unseren Patienten aufgetretene Erniedrigung der granulozytären und 
thrombozytären Zellreihe. Eine Schwierigkeit im klinischen Alltag besteht 
darin, mögliches medikamentenassoziiertes Fieber (Drug-related fever) von 
einer durch die Grundkrankheit (bakterielle Infektion) hervorgerufenen 
inflammatorischen Reaktion abzugrenzen. Deshalb ist es wichtig, Kenntnis 
von den molekularen Mechanismen zu haben, über die bestimmte 
Medikamente immunmodulatorische Effekte ausüben können, um klinische 
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und paraklinische (Labor-)Konstellationen rasch zu erkennen und richtig 
einordnen zu können. Unsere Studie konnte möglicherweise zu erhöhter 
Achtsamkeit bei der Anwendung von Piperacillin/Tazobactam beitragen. 
Unsere Schlussfolgerung, bei prolongierter Therapiedauer regelmäßiges 
Immunmonitoring / Blutbildkontrollen durchzuführen, wurde erst kürzlich 
erneut unterstützt [und unser Paper zitiert] (Lee 2009).  
 
Die Anwendung von direkt immunmodulierenden Substanzen stellt den 
unmittelbarsten Eingriff in das Immunsystem dar. Sogenannte Biologicals 
(Biologics, Biopharmaka) sind bio- oder gentechnologisch hergestellte 
Proteine, die ganz oder teilweise körpereigenen Immunmediatoren 
entsprechen (z.B. Zytokine, -Rezeptoren, Antagonisten) bzw. diese gezielt 
blockieren sollen. Eine ganze Reihe solcher Substanzen ist den letzten Jahren 
entwickelt und z.T. mit großem Erfolg angewendet worden. Insbesondere 
monoklonale Anti-TNFα-Antikörper (darunter Infliximab) hat bei 
Rheumatoidarthritis und chronisch-entzündlichen Darmerkrankungen das 
Therapiespektrum wesentlich erweitert (Tambralli 2013, Costa 2013). 
Mechanistisch führt die Blockade des TNFα einerseits zu einer Verminderung 
der (intrazellulären) Abwehrleistung (von Makrophagen), andererseits wurde 
auf Jurkat-(T)-Zellen anti-inflammatorisches Signaling nach Kopplung von 
anti-TNFα an transmembranöses TNFα beobachtet, das zur Induktion von 
TGFβ und IL-10 führte (Mitoma 2005). In vivo wurde u.a. bei chronisch-
entzündlichen Darmerkrankungen eine Suppression der inflammatorischen 
Zytokinproduktion sowie eine Induktion von Apoptose in T-Zellen der Lamina 
propria des Darmes  beobachtet (Di Sabatino 2004, Dahlén 2013).   
Allerdings ist zu beachten, dass immunsupprimierende Medikamente auch 
stets die Hauptaufgabe des Immunsystems, die Bekämpfung von Infektionen, 
erschweren. Infektionen unter anti-TNFα verlaufen z.T. schwer und gehören 
zu den gefürchtetsten Nebenwirkungen der Therapie (Keystone 2011). Bei 
einem 11-jährigen Patienten der Kinderklinik mit Morbus Crohn sahen wir 3 
Tage nach Beginn einer Infliximab-Therapie eine massive Verschlechterung 
mit kardialer Dekompensation (App. 18, Reichardt 2002b). Es ergab sich, 
dass ein bis dahin klinisch nicht manifester intramyokardialer Abszess mit 
Absiedelung von S. aureus durch die immunsuppressive Therapie aktiviert 
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worden war und die Aortenklappe zerstörte. Die Infektion wurde antibiotisch 
rasch kontrolliert, die Aortenklappe musste aber operativ ersetzt werden. 
Solche und ähnliche Fälle machen deutlich, dass bei der Anwendung von anti-
TNFα begleitende Infektionen weitgehend auszuschließen sind. Als eine 
Konsequenz wird inzwischen vor Therapiebeginn die routinemäßige Testung 
auf latente Tuberkulose empfohlen (Diel 2009).  
 
Infektionen gehören zu den häufigsten Ereignissen, mit denen sich das 
Immunsystem auseinandersetzen muss, nicht selten mit hoher klinischer 
Relevanz. Nicht umsonst ist das Immunsystem evolutionär auf das 
Bekämpfen von Mikroorganismen ausgerichtet worden. Bakterien, Viren, Pilze 
und Protozoen verursachen akute Infektionen, denen das Immunsystem im 
Normalfall innerhalb von Stunden oder Tagen Herr wird. Allerdings versuchen 
viele Mikroorganismen mittels einer Unzahl an Strategien, der Zerstörung 
durch das Immunsystem zu entkommen und das Immunsystem 
herunterzuregulieren (immune evasion). Dies kann zu chronischen 
Infektionen führen.  
Bekannte Beispiele sind chronische Infektionen durch Viren. Das HI-Virus 
befällt neben Endothelzellen, Makrophagen und DC nicht zuletzt auch CD4+ 
T-Zellen, deren Zahl im Verlauf der Erkrankung abnimmt. Unglücklicherweise 
sind Memory CD4+ T-Zellen als Hauptorganisatoren der Erkrankungsabwehr 
auch die Hauptbetroffenen der Infektion, weshalb eine vollständige 
Eradikation durch das Immunsystem so schwierig ist (Zhang 2013). Ein 
weiteres, in vieler Hinsicht prototypisches Beispiel für ein 
immunsupprimierendes Virus ist das Masern-Virus. Es infiziert DC und 
(wahrscheinlich über deren Kontakt) T-Zellen. In T-Zellen stören virale 
Glycoproteine die F-Aktin-Umlagerung und damit Signalprozesse. Die Folge 
ist eine Depletion der T-Zellen und eine klinisch relevante Immunsuppression 
(Avota 2010). Aus dem Spektrum bakterieller Infektionen mit Chronizität ist 
vor allem die Tuberkulose zu nennen. Sie gehört zu den häufigsten 
Infektionen weltweit und die Anzahl beobachteter Tuberkulose-Fälle bei 
Personen mit Risikofaktoren (darunter Patienten unter anti-TNFα-Therapie!) 
steigt in Deutschland (Diel 2009). Hinsichtlich einer zugrundeliegenden 
Immunmodulation wurde als direkter T-Zell-assoziierter Mechanismus die 
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präferentielle Induktion von regulatorischen T-Zellen nach Kontakt mit M. 
tuberculosis beobachtet, was die Ausbreitung der Infektion und deren 
Chronizität unterstützen soll (Larson 2013). 
Neben immunsupprimierenden Effekten durch Infektionen kommt es teilweise 
auch zu einer sehr starken Aktivierung des Immunsystems mit z.T. fatalen 
Folgen. Dazu zählen u.a. allergische bzw. Überempfindlichkeitsreaktionen, bei 
denen (T-Zell-lizensiert) inadäquate Mengen an IgE- und IgG-Antikörpern von 
B-Zellen gebildet werden. Einen Sonderfall, der explizit T-Zellen betrifft,  
stellen sogenannte Superantigene dar. Diese Antigene (oft toxinähnliche 
Proteine bakteriellen oder viralen Ursprungs) sind in der Lage, TCR-
unabhängig große Anteile der T-Zellen eines Organismus zu aktivieren. Die 
molekulare Grundlage dieser Eigenschaft besteht typischerweise darin, dass 
sie am MHC-Molekül einerseits und an der TCR-Seitenkette (z.B. β-Kette) 
andererseits binden können (Marrack 1990, Li 1999). Erkrankungen, die 
durch solche Superantigene ausgelöst werden, sind z.B. das Toxic-Shock-
Syndrom sowie das mukokutane Lymphknotensyndrom oder auch Kawasaki-
Syndrom (die Kawasaki-Erkrankung, engl. Kawasaki disease, KD).  
KD ist eine akute systemische Vaskulitis des Kindesalters mutmaßlich 
infektiösen Ursprungs  (Jamieson 2013). Zahlreiche Hinweise bestehen für die 
Beteiligung von Superantigenen, es ist jedoch nicht geklärt, ob diese 
überwiegend streptokokken- oder staphylokokkenassoziiert sind oder viralen 
Ursprungs. Die Krankheit führt infolge der (unbestrittenen) T-Zell-Aktivierung 
sowie systemischer Zytokinausschüttung (u.a. IL-1, IL-2, IL-6, TNFα, IFNγ) 
zu schweren generalisierten Symptomen (Lin 1993). KD kann unbehandelt in 
bis zu 25% zu koronaren Anomalien führen und ist eine der führenden 
Ursachen erworbener Herzerkrankungen im Kindesalter (Kato 1996, Jamieson 
2013). Komplikationsrate und Folgen der Erkrankung können deutlich 
gemindert werden, wenn rasch hochdosierte intravenöse Immunglobuline 
(IVIG) verabreicht werden, mutmaßlich vor allem aufgrund einer toxin-
neutralisierenden Wirkung (Durongpitsikul 1995).  
Deshalb ist die frühzeitige Erkennung der Superantigenbeteiligung besonders 
wichtig. Um dies zu erreichen, untersuchten wir in einer klinischen Studie die 
TCR-Vβ-Ketten-Verteilung bei Kindern mit akutem fieberhaftem Infekt (App.  
17, Reichardt 2002). Wir fanden bei Kindern, die im Verlauf die klinischen 
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Kriterien des KD erfüllten, einen höheren Prozentsatz an Vβ2 TCR als bei 
Patienten mit anderen Ursachen fieberhafter Erkrankungen bzw. ohne das 
klinische Bild von KD. Unsere Beobachtung zeigte eine Möglichkeit einer 
frühzeitigen Diagnose und damit gezielter Therapie von KD auf. Die 
Korrelation zwischen Vβ2 und KD ist von anhaltendem Interesse und wurde 
erst kürzlich erneut bestätigt (Natividad 2013). Therapeutisch begegnet man 
der proinflammatorischen T-Zell-Expansion, die mittlerweile als Th17/Treg–
Dysbalance angesehen wird, jetzt neben der Anwendung von IVIG auch 
erfolgreich mit anti-TNFα (Mori 2012). Allerdings ist auch aktuell weder eine 
einheitliche infektiöse Ursache gefunden noch besteht eine einheitliche 
Meinung zur zwangsläufigen Beteiligung von Superantigenen in Patienten mit 
dem klinischem Bild von KD (Pinna 2008). Möglicherweise spielen individuelle 
genetische Faktoren eine entscheidende Rolle und können die uneinheitlichen 
klinischen Verläufe bei KD erklären helfen (Onuchi 2012).  
 
Genetische Faktoren spielen neben den genannten Umwelt- und iatrogenen 
Einflüssen generell eine große Rolle bei der Modulation der T-Zell-Aktivierung 
bzw. der Immunantwort. Bekannt (aber glücklicherweise sehr selten) sind 
z.B. Defekte in der genetischen Information für die ζ-Kette des TCR-CD3-
Komplexes oder der signal-transducer-and-activator-of-transcription (STAT)-
Familie, die zu schweren kombinierten Immundefekten (SCID) führen können 
(Hernandez-Trujillo 2013). Wesentlich häufiger als diese T-Zell-
Immundefekte sind dagegen Allergien und Autoimmunerkrankungen, für die 
ebenfalls genetische Risikofaktoren ermittelt wurden. Da viele dieser 
Erkrankungen wie z.B. Multiple Sklerose polygenetisch bedingt sind und 
multifaktorielle Auslöser besitzen, geschieht dies heutzutage nicht selten mit 
Hilfe systembiologischer Ansätze (Stranger 2012, Liu 2012, Baranzini 2013). 
Die rasche Entdeckung schwerer Defekte kann dazu beitragen, Therapien 
rasch einzuleiten und so die Prognose zu verbessern. Dazu gehören bei 
schwersten Immundefekten Knochenmarktransplantationen oder Gen-
therapien insbesondere bei monogenetischen Erkrankungen (Kelly 2013).  
Eine in immunologischer Hinsicht besonders interessante monogenetische 
Erkrankung, das von-Hippel-Lindau-Syndrom oder die retino-cerebelläre 
Angiomatose, beruht auf Punktmutationen im von-Hippel-Lindau-Gen (VHL) 
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(Neumann 1991). Dieses Tumor-Suppressor-Gen kodiert ein Protein mit 
Ubiquitin-Ligase-E3-Aktivität, das am Abbau des Hypoxie-induzierbaren 
Faktors (HIF) beteiligt ist (Hsu 2012). HIF spielt eine zentrale Rolle beim 
Signaling in Antwort auf den im Milieu verfügbaren Sauerstoff (oxygen 
sensing). Permanent hohe Aktivität von HIF im Kolon wird in Verbindung mit 
der Entwicklung von chronisch-entzündlichen Darmerkrankungen gebracht  
(Sha 2008). Die Inaktivierung des VHL-Gens kann zur verstärkten Expression 
des vaskulären endothelialen Wachstumsfaktors VEGF1 in DC führen. Auch 
oxidativer Stress, wie er u.a. in der Folge einer Tumorentwicklung entsteht, 
lässt VEGF1 ansteigen. VEGF1-high DC können immunsuppressive 
Eigenschaften entwickeln und die Proliferation von T-Zellen inhibieren 
(Kusmartsev 2008). Diese Zusammenhänge weisen auf eine mögliche 
Verbindung hin zwischen Oxygen-sensing, Immunsuppression und der 
Entwicklung von Karzinomen (als ultimative Form des Versagens des 
Immunsystems und der Immunüberwachung). Im Zentrum dieser 
Verbindung steht in diesem Beispiel  das VHL-Gen.  
Als Folge von sporadischen und hereditären Mutationen im HVL-Gen sind vor 
allem Nierenzellkarzinome bekannt. Aber auch Phäochromozytome und 
(multilokuläre) Paragangliome (alles Tumoren der chromaffinen Zellen der 
Nebenniere) sind damit assoziiert (Bausch 2013). Bei einem 9 Jahre alten 
Patienten einer Kinderklinik mit extraadrenalem Phäochromozytom fand sich 
nur 7 Monate nach Entfernung des ersten Tumors erneut ein Paragangliom, 
kontralateral gelegen. Da multifokale Paragangliome typisch für Syndrome 
wie die von-Hippel-Lindau-Erkrankung sind, leiteten wir umgehend die 
Untersuchung des  VHL-Gens ein (App. 19, Reichardt 2002c). Statt einer 
der bis dato bekannten Mutationen ergab die Sequenzierung eine neue 
Punktmutation  im VHL-Gen  an Position 406 (VHL nt. 406 T→G). Der Patient 
wurde an dem histologisch gutartigen Tumor erfolgreich operiert und in ein 
Screening-Programm für VHL-Patienten übernommen.  
Solche Anstrengungen, die Diagnose auf molekularer Ebene zu sichern, sind 
aus mehreren Gründen wichtig. Zum einen sicherte der Nachweis die 
Diagnose für den betreffenden Patienten. Die molekulare Zuordnung hatte 
zudem Konsequenzen hinsichtlich der Risikostratifizierung, hinsichtlich  
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Häufigkeit und Umfang des Follow-Up-Screenings sowie der Einbeziehung 
weiterer Familienmitglieder in das Screening. 
Aus Sicht auf das adaptive Immunsystem noch interessanter ist ein erst 
kürzlich veröffentlichter Ansatz zum VHL-Gen: Patienten mit 
metastasierendem Nierenzellkarzinom wurden mit einer neuartigen 
Peptidvakzine behandelt. Das Besondere bestand darin, dass das verwendete 
Peptid auf Sequenzen des mutierten VHL-Gens beruhte. Ziel war es also, eine 
Immunreaktion gegen diese VHL-Peptide und damit gezielt gegen das 
Karzinom, in dem das VHL-Gen mutiert vorlag, zu induzieren (Rahma 2010). 
In jener Studie entwickelten vier der fünf so behandelten Patienten eine 
spezifische Immunreaktion (gemessen an der IFNγ-Produktion zytotoxischer 
T-Zellen) gegen das VHL-Peptid. Es ist vorstellbar, dass weiterentwickelte 
Verfahren dieser Immuntherapie zur Induktion von tumorspezifischen T-
Zellen auch für unseren Patienten mit Paragangliom (die sich in bis zu 40% 
metastasierend entwickeln können) eines Tages nutzbar sein werden. 
Angiogenese-blockierende Medikamente werden bereits heute in der Therapie 
des metastasierenden Nierenkarzinoms eingesetzt und haben dessen 
Therapie revolutioniert (Richard  2013).  
Das Beispiel unterstreicht gleichzeitig die Bedeutung eines weitläufigen Feldes 
der derzeitigen klinischen Immunologie: der gezielten Immuntherapie zur 
Verbesserung der Immunantwort gegen Tumoren.     
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 5. Gezielte Modulation der T-Zell-Aktivierung durch Immuntherapie 
 
Die T-Zell-Aktivierung erfordert einen passenden (kognaten) pMHC-
Interaktionspartner. Aufgrund der exquisiten Spezifität dieser Interaktion 
hielt man die pMHC-TCR-Bindung lange Zeit für eine „all or none“ Interaktion 
(Schlüssel-Schloss-Prinzip), d.h. entweder wird eine Aktivierung ausgelöst 
oder nicht. Dies ist aber nicht korrekt. Vielmehr gibt es eine Vielzahl von 
Abstufungen in der Aktivierung, ausgelöst durch in ihrer Struktur ähnliche 
(aber nicht identische) Peptide (Evavold 1991).  
Die Synthese gezielt abgewandelter Peptidliganden (altered peptide ligands, 
APL) und ihre experimentelle Anwendung zur TCR-Stimulation erbrachte 
wichtige Erkenntnisse zu strukturellen Voraussetzungen und Hierarchie der 
Effektorfunktionen bei aberranter T-Zell-Stimulation (Kilgore 2003). So 
können bestimmte Peptide (partial agonists) selektiv Zellfunktionen wie 
Zytotoxizität auslösen aber keine Proliferation. Andere APL wirken als 
Antagonisten d.h. sie hemmen dominant die Stimulation durch kognate 
Peptidliganden (unterdrücken z.B. die Produktion von IFNγ). Wir konnten 
zeigen (App. 12, Jones 2008), dass ein antagonistischer Effekt an eine 
hohe TCR-Dichte gebunden ist. Offenbar benötigen Antagonisten eine 
kritische Menge an TCR damit ihr dominant negatives Signaling, welches sie 
in T-Zellen auslösen, wirksam wird. Antagonistische Peptide wurden in vivo 
als Varianten viraler zytotoxischer Peptide gefunden, welche die T-Zell-
Antwort unterdrückten (im Sinne einer „immune evasion“-Strategie) und zur 
Persistenz von Infektionen beitragen können (Bertoletti 1994). Gleichzeitig 
erschienen solche Antagonisten als ideale Werkzeuge, um gezielt 
antigenspezifische Immunmodulation vorzunehmen (Vukmanović 2005). Die 
Hoffnung auf eine breite klinische Anwendung von APL hat sich bislang aber 
nicht erfüllt. In der klinischen Erprobung befinden sich derzeit (Treg-
induzierende) APL u.a. im Tiermodell der Arthritis (Dominguez 2011).  
 
Einer der weltweit meistbeachteten Fehlschläge der Immuntherapie fußt auf 
dem CD28-Superagonisten TGN1412. Dieses Molekül vermittelt ein so starkes 
Signal an CD28, dass die ansonsten essentielle Stimulation des TCR-CD3-
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Komplexes nicht notwendig zur T-Zell-Aktivierung ist (Tacke 1997). In 
zahlreichen in vitro- und Tierversuchen hatte sich dabei geringe Toxizität und 
die präferentielle Induktion regulatorischer T-Zellen ergeben, weshalb das 
Molekül als erfolgversprechende immunmodulierende Substanz galt. Leider 
endete die Erstanwendung unglücklich; alle Probanden erkrankten schwer 
infolge eines ausgelösten Zytokinsturms (Suntharalingam 2006).  
Auf der Suche nach einer Erklärung konnten wir zeigen, dass das durch 
TGN1412 induzierte Signalmuster sich von dem durch konventionellen CD28-
Antikörper deutlich unterschied (App. 13, Waibler 2008). Speziell konnten 
wir (als ein Teil der Studie) mittels Lebendzell-Fluoreszenzmikroskopie 
zeigen, dass TGN1412 einen verzögerten aber extrem lang anhaltenden 
Calciumstrom in die Zelle initiiert. Dieses veränderte Signaling war in 
humanen CD4+ T-Zellen (naive und Memory-T-Zellen) zu beobachten aber 
nicht in T-Zellen von Cynomolgus-Affen (wie sie auch in vorangehenden 
Tierversuchen vor der klinischen Anwendung verwendet worden waren). Der 
verstärkte Calcium-Einstrom war auch notwendige Voraussetzung für die 
ferner nachgewiesene Aktivierung von Src- und Phospho-Inositol-3(PI3)-
Kinasen sowie für die Produktion von IFNγ und IL-2. Unsere Daten lieferten 
einen wesentlichen molekularen Mechanismus für die unerwartet starke 
Immunantwort bei den Probanden. Der unterschiedlichen Reaktion auf den 
CD28-Superagonisten in Cynomolgus-Affe bzw. Mensch zugrundeliegend ist 
wahrscheinlich die selektive Expression inhibitorischer Siglec-Rezeptoren, die 
beim evolutionären Übergang vom Affen zum Menschen verlorenging 
(Nguyen 2006). Insgesamt hat das Drama um TGN1412 mehr zum 
Verständnis und zum Fortschritt der Immuntherapie beigetragen (und 
wichtige Veränderungen in den Regeln zur experimentellen Durchführung 
bewirkt) als viele Ansätze, die erfolgreicher verliefen (Hünig 2012). Allerdings 
unterstreichen die gemachten Erfahrungen die bestehenden komplexen 
Herausforderungen bei der Anwendung löslicher, synthetischer Moleküle.  
 
Zelltherapeutische Ansätze repräsentieren einen noch komplexeren Ansatz 
und ein umfangreiches Feld der Immuntherapie, auf welchem große 
Anstrengungen unternommen werden um v.a. Autoimmunerkrankungen und 
Krebs zu behandeln. Insbesondere regulatorische T-Zellen, Tregs, sind in 
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Forschung und experimenteller Therapie von großem Interesse. Tregs können 
einerseits bereits im Thymus entstehen (natürliche Tregs) und andererseits 
auch in der Peripherie induziert werden (u.a. in Anwesenheit von TGFβ). Sie 
unterdrücken andere T-Zellen durch direkten Zellkontakt oder über lösliche 
Mediatoren (z.B. IL-10). Thymische Tregs zeigen stabile Expression des 
Transkriptionsfaktors Foxp3, der als Masterregulator für Tregs angesehen 
wird, während peripher induzierte Tregs diesen häufig nicht oder nicht stabil 
exprimieren (Josefowicz 2012).  
In jüngster Zeit wurde deutlich, dass Tregs eine besondere Plastizität 
besitzen und im Verlauf der Immunantwort teilweise (wieder) klassische 
Effektorfunktionen annehmen können (Kleinewietfeld 2013). Entsprechend 
relevant sind Studien über die Unterschiede in der Signaltransduktion  
zwischen konventionellen T-Effektorzellen (Tcon) und Treg. Wir waren an 
einer derartigen Studie beteiligt (App. 08, Schmidt 2011), zu der wir mit 
Calcium-Imaging beitragen konnten. Im Paper konnte gezeigt werden, dass 
humane Treg (CD4+ CD25hi Foxp3+) bei Kokultur mit Tcon rasch Calcium-
Ströme in Tcon unterdrückten und nachfolgend die Aktivierung der 
Transkriptionsfaktoren NFAT1 und NF-kB blockierten. Die Suppression 
erfolgte unterhalb des TCR-proximalen Signalingmoleküls PLCγ1, da dessen 
Aktivität unbeeinträchtigt blieb. Der exakte Angriffspunkt für die 
Unterdrückung des Calciumstroms blieb ungeklärt. Spekuliert werden kann 
über mögliche Modifikationen in der Interaktion von IP3, das als second 
messenger für Calciumsignale fungiert,  mit seinem Rezeptor (IP3-Rezeptor). 
Unsere Daten offenbarten einen bis dato unbekannten, rasch einsetzenden 
intrazellulären signalmodulierenden Effekt der Treg-Suppression bei direktem 
Zellkontakt.  
Wie aber wird der calcium-modulierende Effekt auf der T-Zelle überhaupt 
ausgelöst? Es gibt Hinweise, dass dafür der initiale sterische Kontakt zu 
bestimmten Oberflächenmolekülen auf Tregs verantwortlich ist, da eine 
intakte Membranbeschaffenheit für den suppressorischen Effekt bei 
ansonsten avitalen, Formaldehyd-fixierten Tregs notwendig war (Hagness 
2012). Eine Reihe von selektiv bzw. bevorzugt auf natürlichen oder 
induzierten Tregs exprimierten regulatorischen Molekülankern ist 
beschrieben, darunter CTLA-4, OX40, Neuropilin und andere (Yadav 2013). 
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Allerdings war in der Studie von Hagness et. al. keiner der bekannten 
Inhibitoren zu ermitteln. Insgesamt muss angenommen werden, dass 
mehrere, voneinander unabhängige Mechanismen existieren, über welche 
(Foxp3+) Tregs ihre suppressive Aktivität in vivo ausüben (Shevach 2009). 
Eine differentielle Aktivierung (Phosphorylierung) von wenigen Kinasen (11 
von 185 mittels Phosphoproteomics untersuchten Kinasen in eine Studie, 
König 2012) wurde als ein Korrelat für Besonderheiten im Signaling von Tregs 
im Vergleich zu konventionellen CD4+ T-Zellen ermittelt. Zu den differentiell 
erhöht gefundenen Kinasen zählten u.a. STK10 und STK4, was als Hinweis 
auf eine differenzielle Regulation LFA-vermittelter T-Zell-Adhäsion 
interpretiert wurde. Verminderte Aktivität zeigte AURKB, ein downstream 
target von AKT, welches involviert ist in die Kontrolle des Zellzyklus durch 
mTOR (König 2012).  
 
Tregs sind auch an der physiologischen Aufrechterhaltung der perinatalen 
Toleranz beteiligt, die das Abstoßen des immunologisch teilweise fremden 
Embryos verhindert. Dies geschieht möglicherweise vor allem durch lokale, 
im Bereich des Uterus präsente Tregs (Ernerudh 2011). Offenbar sind Tregs 
dabei auch in einer sehr frühen Phase der Schwangerschaft, bei der 
Implantation der Blastozyste, von Bedeutung. Wir konnten mittels intravitaler 
2-Photon-Mikroskopie zeigen (App. 03, Teles 2013), dass Tregs 
zyklusabhängig am Uterus gefunden werden. Ihre Zahl ist dynamischen 
Schwankungen unterworfen, die an hormonelle Regelkreise (insbesondere 
Estrogen-abhängig) gekoppelt sind. Die Anreicherung der Tregs ist dabei 
(ähnlich zum Lymphknoten) chemotaktisch über den (T-Zell-) 
Chemokinrezeptor CCR7 gesteuert. Solche Erkenntnisse können helfen, die 
immunologische Toleranz während der Schwangerschaft besser zu verstehen. 
Die physiologische Reduzierung der Anzahl gewebsspezifischer, 
inflammatorisch reaktiver T-Zellen am Uterus während der Schwangerschaft 
kann auch als Modell organbezogener Immuntoleranz verstanden werden und 
insofern generelle Hinweise zum Verständnis von T-Zell-
Toleranzmechanismen liefern  (Erlebacher 2013).  
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Zahlreiche Bestrebungen zielen darauf ab, die Bildung von Tregs zu fördern 
und klinisch nutzbar zu machen. Dies geschieht entweder durch Applikation 
Treg-fördernder Stimuli in vivo oder durch die ex vivo-Generierung, -
Expansion und –genetische oder funktionelle Modulation von T-Zellen 
und/oder APC (Tang 2013, McMurchy 2013). Ebenfalls große Anstrengungen 
werden unternommen, ex vivo immunogene oder tolerogene DC zu 
generieren, um so gezielt inflammatorische Effektor-T-Zellen zu induzieren 
(z.B. in der Tumortherapie) bzw. um regulatorische T-Zellen zu erzeugen 
(z.B. bei Autoimmunerkrankungen, Kalantari 2011). Allerdings ist die Kultur 
von DC mit einer Reihe von Schwierigkeiten verbunden: Die Generierung aus 
Vorläuferzellen ist zeitaufwändig und die Erzielung des gewünschten 
Aktivierungszustands (immunogen vs. tolerogen) ist schwierig in dieser 
häufig heterogenen Zellpopulation (Gunzer 2011).   
Die Verwendung von B-Zellen als APC würde eine Reihe von Vorteilen mit sich 
bringen. B-Zellen bilden eine im Vergleich zu DC homogene Zellgruppe, sie 
sind in großer Zahl aus peripherem Blut zu gewinnen. Zudem ist ihre in vitro-
Kultur vergleichsweise einfach und kostengünstig. In der Tat wurden B-Zellen 
bereits in zelltherapeutischen Ansätzen als APC eingesetzt, allerdings vor 
allem unter maximaler Stimulation (mittels CD40-Aktiverung), damit sie als 
bestmögliche (starke) APC wirken (Kondo 2009).  
Um die Aktivierung von T-Zellen durch naive B-Zellen genauer zu studieren, 
kultivierten wir naive B-Zellen, welche ein TCR-kognates Peptid MHC-
restringiert präsentierten (hier ein Ovalbumin-Fragment), mit CD4+ T-Zellen. 
Wir fanden einen aberranten Phänotyp und immunregulatorische 
Eigenschaften bei den entstehenden T-Zellen und wiesen deren in vivo-
Relevanz im (tierexperimentellen) Ansatz nach (App. 14, Reichardt 2007). 
Wir beobachteten, dass es bei dem B-T-Kontakt zur Ausbildung einer reifen, 
strukturell vollständig ausgebildeten immunologischen Synapse kam. Dies 
war überraschend, da naive B-Zellen in vivo keine wesentliche Rolle bei der 
Initiierung der T-Zell–Antwort spielen (Epstein 1995). Zwar lagern sich 
lösliche Antigene (z.B. nach Immunisierung) auch auf B-Zellen an 
(Byersdorfer 2004), und B-Zellen können in bestimmten Situationen zur T-
Zell-Aktivierung in vivo beitragen (Crawford 2006). Ferner sind B-Zellen in 
Abwesenheit anderer APC durchaus in der Lage, CD4+ T-Zellen effizient zu 
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stimulieren (Rodriguez-Pinto 2005). Allerdings resultiert die Antigen-
präsentation durch B-Zellen vielfach nicht in T-Effektoren sondern in T-Zell-
Toleranz (Raimondi 2006, Frommer 2008). Offenbar bestehen 
Besonderheiten in der T-Zell-Aktivierung durch B-Zellen im Vergleich zu DC.  
In der Tat wiesen die von uns untersuchten B-Zell-induzierten T-Zellen (TofB) 
verglichen mit konventionellen (DC-induzierten) Effektor-T-Zellen einen 
aberranten Phänotyp und funktionelle Besonderheiten auf. Sie zeigten 72 h 
nach Aktivierung eine hohe Expression von L-Selectin, CD62L, was untypisch 
für aktivierte Zellen war. Ferner waren die TofB in der Lage, in vitro und in 
vivo im Tiermodell eine (ektope Herz-)Transplantatabstoßung zu verhindern 
(während konventionelle T-Zellen dies nicht taten). Die TofB agierten dabei 
über direkten Zellkontakt, waren aber Foxp3 negativ. Insofern unterschieden 
sie sich von bekannten Subtypen regulatorischer Zellen (Yadav 2013). 
Unsere B-Zell-generierten Tregs bildeten daher eine neue Art induzierter 
Tregs, die aufgrund ihres Ursprungs eine Reihe von Vorteilen für die 
therapeutische Anwendung mit sich brachten. Tatsächlich waren B-Zellen 
bereits genutzt worden, um Mäuse gegen Epitope mit pathophysiologischer 
Relevanz zu tolerisieren (Lei 2005). Inzwischen werden B-Zellen auch direkt 
als APC zur Erzeugung von Tregs in vitro und in vivo verwendet (Sun 2012). 
Allerdings wurde in diesem Ansatz die immunsuppressorische Wirkung durch 
Kopplung des Antigens an Choleratoxin B (was die Expression von TGFβ und 
IL-10 in den B-Zellen induzierte) noch verstärkt.  
Tatsächlich  gibt es neben der toleranzinduzierenden Wirkung von B-Zellen 
als APC zahlreiche Hinweise auf indirekte, auf löslichen Faktoren (z.B. IL-10) 
beruhenden immunsuppressorischen Effekten von B-Zellen (die in diesem 
Zusammenhang dann auch häufig als regulatorische B-Zellen oder BiRegs 
bezeichnet werden) bei der Regulation von Autoimmunerkrankungen und der 
Antwort auf Infektionen (Mauri 2010). 
Zusammengefasst hob unsere Arbeit zu B-Zell-induzierten Tregs eine Reihe 
von Besonderheiten beim Priming von CD4-Zellen durch naive B-Zellen 
hervor und unterstrich damit Eigenschaften von B-Zellen für die 
Immunantwort, die über die Antikörperproduktion hinausgehen (Lund 2010).  
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Die intrazellulären Signalwege, die mit diesem unerwarteten Phänotyp bei B-
Zell-induzierten Tregs verknüpft waren, blieben zunächst unbekannt. Die 
molekularen Grundlagen zu erhellen gelang uns in einer weiteren Studie 
(App. 02, Etemire 2013).  
Wir fanden Hinweise auf eine transiente Erniedrigung des PI3K/Akt/mTOR-
Signalwegs in den regulatorischen T-Zellen. PI3-Kinasen (PI3K) (der Klasse 
IA bzw. IB) werden durch Signale vom TCR und Zytokin-Rezeptoren bzw. 
Chemokinrezeptoren aktiviert (Han 2012). Die PI3K phosphoryliert dann 
Phosphoinositol-4,5-bisphospat (PIP2) zu PIP3  an der inneren Zellmembran 
und leitet so eine Signalkaskade ein, welche die Aktivierung der Proteinkinase 
B (PKB oder auch Akt genannt) einschließt. Akt wird sowohl an Thr308 als 
auch (zur vollen Aktivierung) an S473 phosphoryliert (Fayard 2010). Aktives 
Akt phosphoryliert dann Substrate (v.a. Transkriptionsfaktoren der FOXO-
Familie), fördert deren nukleäre Exclusion und beeinflusst so die Transkription 
zahlreicher immunologisch wichtiger Gene darunter IL-2 (Hay 2011). 
Gleichzeitig aktiviert Akt den mTOR-Komplex1 (mTORC1). mTOR ist eine 
Serin/Threonin-Kinase, die in Abhängigkeit vom Energiestatus der Zelle 
(Insulin, Glucose, ATP, Sauerstoff) in elementare Zellfunktionen wie 
Wachstum, Proliferation, Überleben und Transkription eingreift. Dabei spielt 
mTOR auch eine Schlüsselrolle bei Proliferation und Differenzierung von T-
Zellen (Chi 2012). Phosphatasen wie PHLPP regulieren den PI3K/Akt-
Signalweg negativ indem sie Akt dephosphorylieren (Gao 2005). 
Konkret untersuchten wir die Signalmuster bei iTreg-Bildung nach Stimulation 
mit naiven B-Zellen bzw. mittels unreifer DC im Vergleich mit Effektor-T-
Zellen nach Kontakt zu reifen (vollständig costimulierenden) DC. Wir fanden 
in den so induzierten Tregs (CD4+CD25+Foxp3-) zu frühen Zeitpunkten 
Signalmuster, die ähnlich zu denen in konventionellen Effektor-T-Zellen 
waren. Interessanterweise gehörte dazu eine initial effektive Aktivierung der 
Metalloprotease ADAM-17, die für das  Abwerfen (Shedding) des CD62L 
verantwortlich war. Fehlende Downregulation des CD62L war die 
augenfälligste phänotypische Besonderheit der B-Zell-induzierten Tregs 
(TofB, App. 14, Reichardt 2007) gewesen. Wir sahen nun, dass es nach einer 
Phase effektiv downregulierten CD62L (bis 24 h nach Stimulationsbeginn) in 
den Tregs (nicht aber in konventionellen Effektor-T-Zellen) zu einer 
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Reexpression von CD62L kam, die zu der (ähnlich wie in naiven T-Zellen) 
früher von uns beobachteten hohen Expression zum Zeitpunkt 72 h führte. 
Parallel dazu beobachteten wir zum Zeitpunkt 24 h eine wesentlich niedrigere 
Phosphorylierungsrate von Akt-S473 in den Tregs. Dies ließ auf eine 
erniedrigte Aktivität des PI3K/Akt-Signalwegs zu diesem Zeitpunkt schließen.  
Weiterführend fanden wir als Ursache für die transiente phospho-Akt-
Erniedrigung eine (nur in den Tregs stattfindende) Induktion von PHLPP1, 
einer Akt-spezifischen Phosphatase. Die iTregs wiesen regulatorische 
Kapazität in vitro und in vivo auf, die durch zusätzliche Applikation von 
costimulatorischen Signalen (CD28-Triggering im in vitro-System) 
aufgehoben wurde.  
Unsere Daten zeigten, dass ähnlich zur Induktion von klassischen Foxp3+ 
Tregs auch für (durch schwache APC wie naive B-Zellen und unreife DC) 
induzierte Tregs die Intensität der PI3-Kinase-/Akt-Achse wichtig ist. Zudem 
legen unsere Ergebnisse nahe, dass für die Entwicklung von naiven T-Zellen 
zu Treg bzw. Effektor-Zellen ein kinetisches Fenster innerhalb der ersten 24 h 
besteht.  
Insgesamt existieren inzwischen zahlreiche Hinweise, dass die Intensität des 
PI3K-mTOR-Signalings eine zentrale Rolle bei der T-Zell-Differenzierung in 
verschiedene Subtypen, darunter Tregs, spielt (Miskov-Zivanov 2013). Die 
genaue Rolle von PI3K-Signalen bei der Induktion von Treg ist jedoch nicht 
klar. Es gibt Berichte, dass PI3K-Aktivierung die Treg-Entwicklung sowohl 
hemmen (Littmann 2010) als auch fördern kann (Soond 2012). Unsere Daten 
könnten helfen, diese Diskrepanz zu erklären, indem sie nahelegen, dass 
PI3K-vermittelte Signale notwendig sind, dass es aber insbesondere 
erniedrigte Signalintensität ist, welche die Treg-Induktion begünstigt. In der 
Tat wurde verminderte Akt-S473-Phosphorylierung in Foxp3+ Tregs auch von 
anderen Arbeitsgruppe beobachtet (Crellin 2007, Oyang 2012). Mittlerweile 
hat sich die therapeutische Beeinflussung der PI3K/Akt-Signalings zu einem 
sehr umfangreichen immuntherapeutischen Feld bei der Bekämpfung von 
Neoplasien und Autoimmunerkrankungen entwickelt (Foster 2012).  
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6. Ausblick 
 
So wie sich die Immunologie in den letzten Jahren rasant entwickelt hat sind 
auch zukünftig wesentliche Fortschritte im Verständnis und in der gezielten 
Anwendung der Immunmodulation zu erwarten. Die Modulation der T-Zell-
Aktivierung wird dabei aller Voraussicht nach weiterhin einen elementaren 
Pfeiler moderner Immuntherapie bilden.  
 
Grundlegendes Prinzip der sich abzeichnenden interventionellen 
Entwicklungen  ist oft die direkte Modulation des an der T-Zelle eingehenden 
Musters aus TCR- und costimulatorischen Signalen. Eine etablierte Strategie 
ist dabei die direkte, antikörpervermittelte Blockade  der costimulatorischen 
Rezeptoren CD28 sowie von deren Gegenspielern CTLA-4 (cytotoxic T-
lymphocyte antigen-4) und PD-1 (programmed death-1) (Bour-Jordan 2011, 
Iannone 2012). Die wie beschrieben für die Treg-Entwicklung zentrale Achse 
PI3K/Akt/mTOR wird zum Gegenstand immuntherapeutischer Intervention 
unter Verwendung von komplett neuen Klassen an mTOR-Inhibitoren (Bruno 
2008, Benjamin 2011).   
 
Zelltherapeutische Ansätze werden dabei neben löslichen 
immunmodulierenden Faktoren (small molecule-drugs und biologicals) 
wahrscheinlich immer wichtiger (Fischbach 2013). Ein Schwerpunkt wird 
weiterhin die Induktion und gezielte Verwendung von regulatorischen T-
Zellen sein (Daniel 2011). Moderne Methoden werden die Erzeugung, 
Identifizierung und Gewinnung von T-Zellen mit gewünschter Avidität und 
Spezifität erleichtern (Weissbrich 2013, Stärck 2013). Andere Ansätze 
trachten danach, den elementarsten Vorteil aber auch gleichzeitig die 
umfassendste Limitation des adaptiven Immunsystems, die Antigenspezifität, 
zu überwinden und antigen-unspezifische immunmodulierende Maßnahmen 
einzusetzen (Monjazeb 2013). Solche Arbeiten bilden bereits eine Brücke zur 
Anwendung von Komponenten des angeborenen, per se antigen-
unspezifischen Immunsystems (van den Boorn 2013).  
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Eine vollständig neue Ebene der Modulation des Immunsystems wurde erst in 
den letzten Jahren deutlich: das Mikrobiom. Der menschliche Organismus teilt 
sich seinen „individuellen Lebensraum“, seinen Körper, mit tausenden 
weiteren Arten an lebenden Organismen. Unsere Körperzellen sehen sich 
einer mehr als zehnfachen Menge co-existierender Zellen gegenüber, von 
Bakterien, Viren, Einzellern und möglichweise anderen Lebensformen. Viele 
von ihnen sind für unsere Gesundheit unentbehrlich, andere eher abträglich. 
Die Balance innerhalb dieses gemeinsamen Superorganismus beeinflusst 
unsere physischen und psychischen Regelkreise und Organfunktionen, 
darunter unser Immunsystem, offenbar in weit stärkerem Maße als bisher 
angenommen. Als ein konkretes Beispiel seien mikrobielle Stoffwechsel-
produkte wie kurzkettige Fettsäuren genannt, welche die Homöostase 
intestinaler regulatorischer T-Zellen beeinflussen können (Smith 2013). Wie 
robust diese Aussagen tatsächlich sind, wird sich erst in Zukunft erweisen. 
Allerdings wird die Modulation der T-Zell-Aktivität über das Mikrobiom mit 
Sicherheit zu einem weiteren hochspannendes Feld der Immunbiologie 
darunter der T-Zell-Immunologie (Brerer 2011, Strober 2013).  
 
Bildgebende Verfahren zum molekulare Studium des T-Zell-Signalings und 
der Synapse werden zunehmend auch die in vivo-Situation der T-Zell-
Aktivierung besser erfassen können. Derzeit können intravital nur grobe 
Umrisse der Synapse sowie die räumliche Verteilung einiger weniger Proteine 
dargestellt werden (Barcia 2006, Azar 2010). Eine genauere Darstellung 
intakter Synapsen wird mit hochauflösender Mikroskopie, nanoskopischen 
Verfahren, wie z.B. STED (Stimulated-Emission Depletion) (Willig 2006) oder 
der Lokalisationsmikroskopie möglich sein (Cremer 2011). Die Verknüpfung 
dieser hochauflösenden Verfahren mit Intravitalmikroskopie befindet sich 
jedoch noch in ihren Anfängen (Eggeling 2009, Andresen 2012, Huber 2012).  
Es kann erwartet werden, dass die Analyse von molekularen 
Wechselwirkungen (auch innerhalb der immunologischen Synapse) durch 
hochauflösende Darstellung bis hinunter zur Betrachtung von Einzelmolekülen 
im lebenden Organismus neue und faszinierende Einblicke in die 
Mechanismen der T-Zell-Aktivierung ermöglichen und neue Wege zu deren 
Modulation aufzeigen wird.   
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T Cell–Independent Modulation of Experimental
Autoimmune Encephalomyelitis in ADAP-Deficient Mice
Swen Engelmann,*,1 Mauro Togni,*,1 Anja Thielitz,† Peter Reichardt,* Stefanie Kliche,*
Dirk Reinhold,* Burkhart Schraven,*,‡ and Annegret Reinhold*
The adhesion- and degranulation-promoting adaptor protein (ADAP), expressed in T cells, myeloid cells, and platelets, is known to
regulate receptor-mediated inside-out signaling leading to integrin activation and adhesion. In this study, we demonstrate that, upon
induction of active experimental autoimmune encephalomyelitis (EAE) by immunization with the myelin oligodendrocyte glyco-
protein35–55 peptide, ADAP-deficient mice developed a significantly milder clinical course of EAE and showed markedly less
inflammatory infiltrates in the CNS than wild-type mice. Moreover, ADAP-deficient recipients failed to induce EAE after adoptive
transfer of myelin oligodendrocyte glycoprotein–specific TCR-transgenic T cells (2D2 T cells). In addition, ex vivo fully activated
2D2 T cells induced significantly less severe EAE in ADAP-deficient recipients. The ameliorated disease in the absence of ADAP
was not due to expansion or deletion of a particular T cell subset but rather because of a strong reduction of all inflammatory
leukocyte populations invading the CNS. Monitoring the adoptively transferred 2D2 T cells over time demonstrated that they
accumulated within the lymph nodes of ADAP-deficient hosts. Importantly, transfer of complete wild-type bone marrow or even
bone marrow of 2D2 TCR–transgenic mice was unable to reconstitute EAE in the ADAP-deficient animals, indicating that the
milder EAE was dependent on (a) radio-resistant nonhematopoietic cell population(s). Two-photon microscopy of lymph node
explants revealed that adoptively transferred lymphocytes accumulated at lymphatic vessels in the lymph nodes of ADAP-deficient
mice. Thus, our data identify a T cell–independent mechanism of EAE modulation in ADAP-deficient mice. The Journal of
Immunology, 2013, 191: 000–000.
A
daptor proteins play crucial roles in organizing mo-
lecular signaling complexes called signalosomes. They
are subdivided in transmembrane adapter proteins and
cytosolic adaptor proteins (1). The cytosolic adapter protein,
adhesion- and degranulation-promoting adapter protein (ADAP), was
originally identiﬁed on the basis of its association with SLP-76
(SLP-76–associated protein of 130 kDa also known as SLAP-130)
(2) and with the Src family kinase Fyn (Fyn-binding protein called
Fyb) (3). ADAP is expressed in T cells, NK cells, and myeloid
cells but not in mature B cells (4). ADAP possesses a number of
protein–protein interaction domains. These include a proline-rich
region, tyrosine-based signaling motifs, two helical SH3 domains,
two putative nuclear localization sites, and an Ena-Vasp homology
(EVH1) domain binding site (5).
It is well established that ADAP couples TCR and chemokine
receptor stimulation to the activation of integrins via a process
called inside-out signaling. ADAP-deﬁcient T cells display altered
TCR-mediated adhesion, diminished LFA-1 activation (6, 7), and
impaired conjugate formation with APCs (8). In addition to its
role in TCR-mediated adhesion and T cell interaction with APCs,
ADAP is also involved in chemokine receptor CCR7-mediated
LFA-1 afﬁnity/avidity regulation, adhesion, homing, as well as
T cell motility within in the lymph nodes (9).
ADAP is also required for NF-kB activation in T cells (10). In
this study, ADAP is critical for the assembly of the Carma1-Bcl10-
Malt1-complex (11). Furthermore, ADAP associates with the adap-
tor molecule Nck (12). It has been shown that the functional coop-
eration between ADAP and Nck stabilizes the interaction of SLP-76
and the Wiskott–Aldrich syndrome protein (13). Thus, ADAP is also
involved in the regulation of actin cytoskeleton rearrangement after
TCR stimulation.
Recent work has established that ADAP may also play a role in
outside-in signaling from integrins in T cells. Following LFA-1
stimulation of T cells, the ADAP-dependent formation of a ring-
shaped actin reorganization called actin cloud was discovered
(14). This LFA-1–mediated costimulation enhances IL-2 produc-
tion, F-actin clustering, T cell polarization, and T cell motility (15).
Besides its regulation of outside-in signaling in T cells, ADAP is
also required for optimal CD11c integrin–mediated outside-in sig-
naling in dendritic cells (DCs) (16).
ADAP-deﬁcient mice have been studied in a limited number
of disease models. In transplantation models, ADAP-deﬁcient
mice showed prolonged heart graft survival and ameliorated rejec-
tion of intestinal allografts (17, 18). In contrast, ADAP-deﬁcient
TCR-transgenic mice revealed an increased incidence of autoim-
mune diabetes (19). In platelets, loss of ADAP results in impaired
aIIbb3 integrin activation, leading to increased rebleeding of ADAP-
deﬁcient mice from tail wounds (20) and to instable thrombus
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formation after carotid artery injury in vivo (21). Recently, it was
shown that loss of ADAP attenuated neutrophil recruitment in an
ischemia–reperfusion-induced acute kidney injury model (22).
Experimental autoimmune encephalomyelitis (EAE) is a proin-
ﬂammatory autoimmune disorder that targets the CNS and serves
as an animal model for the human disease multiple sclerosis (MS).
EAE can be induced in C57BL/6 mice by immunization with
the encephalitogenic peptide myelin oligodendrocyte glycoprotein
(MOG)35–55. Historically, the disease is considered to be mediated
by Thl cells because the adoptive transfer of activated brain-
speciﬁc CD4+ cells is sufﬁcient to induce EAE in recipient ani-
mals. Recent evidence suggests that a proinﬂammatory cascade of
Th17 cells, IL-6 and TGF-b1, in the CNS plays a critical role in
the pathogenesis of EAE and MS (23, 24). The role of B cells and
myelin-speciﬁc Abs is still controversial, because depending on
the model, the presence of B cells is necessary or dispensable for
the development of the disease (25, 26). However, it is clear that
B cells are important in the relapsing phase by their production of
the anti-inﬂammatory cytokine IL-10 (27).
During the past few years, an important immunological role of
APCs, especially DCs and CNS-resident microglia, is emerging.
In the normal CNS, microglia cells express low levels of MHC
molecules. During EAE, the expression of costimulatory and MHC
molecules on microglia increases, and this may play an important
role in the reactivation of T cells that inﬁltrate the CNS (28). Bone
marrow (BM)–derived DCs are the most potent APC population at
priming naive T cells in secondary lymphoid organs. Indeed, it
was shown that peripherally derived inﬁltrating DCs rather than
radio-resistant CNS-resident microglia cells are involved in the
pathogenesis of EAE (29).
In this paper, we report that ADAP-deﬁcient mice undergo
milder EAE. This is shown for active EAE as well as in a passive
transfer EAE model. We further demonstrate that the ameliorated
course of disease in the absence of ADAP is not primarily because
of an intrinsic activation defect of T cells. Radiation-induced BM
chimeras surprisingly reveal that the attenuated course of EAE is
dependent on a radio-resistant nonhematopoietic compartment. We
provide evidence that in ADAP-deﬁcient hosts adoptively trans-
ferred T cells accumulate at LYVE-1+ lymphatic vessels in the
lymph nodes. Thus, it appears that trapping of T cells in the lymph
nodes results in reduced inﬁltration of inﬂammatory cells into the
CNS and consequently in strongly attenuated EAE.
Materials and Methods
Mice
ADAP-deﬁcient mice (7) were backcrossed to C57BL/6JBom for at least
10 generations. Lck-deﬁcient mice were provided by Dr. T. Mak (Uni-
versity of Toronto, Toronto, ON, Canada) (30). MOG35–55-speciﬁc TCR trans-
genic mice (2D2 mice) were provided by Dr. V. Kuchroo (Harvard Medical
School, Boston, MA) (31). Congenic C57/BL6-Ly 5.1 mice (B6.SJL) were
purchased from Charles River Laboratories. The mice were bred and
maintained under speciﬁc pathogen-free conditions in the central animal
facility of the medical faculty of the University of Magdeburg. In all
experiments, 8- to 12-wk-old littermate mice were used. All procedures
were conducted according to protocols approved by the local authorities.
EAE induction
Induction of EAE was performed as described earlier (32). Brieﬂy, active
EAE was induced by immunization with 200 mg MOG p35–55 emulsiﬁed
in CFA (Sigma-Aldrich) containing 800 mg heat-killed Mycobacterium
tuberculosis (Difco Laboratories). The emulsion was administered s.c. as
four 50-ml injections into the ﬂanks of each leg. In addition, 200 ng per-
tussis toxin (List Biological Laboratories) dissolved in 200 ml PBS was
injected i.p. on days 0 and 2 after immunization. Mice were monitored
daily for clinical signs of EAE and graded on a scale of increasing severity
from 0 to 5 as described earlier (33). Daily clinical scores were calculated
as the average of all individual disease scores of each group, including
mice not developing clinical signs of EAE.
For the adoptive transfer experiments, splenic T cells were isolated using
a Pan T cell isolation kit and AutoMACS (Miltenyi Biotec). The indicated
number of puriﬁed T cells in 100 ml PBS was injected into the tail vein.
One week later, EAE was induced by immunization with MOG in CFA.
Passive induction of EAE by adoptive transfer of polarized MOG-speciﬁc
Th1 cells was performed as described by Yang et al. (34). Brieﬂy, splenocytes
from 2D2 mice were cultured and stimulated with MOG35–55 (20 mg/ml) in
the presence of 5 mg/ml IL-2/IL-7 (Miltenyi Biotec) for 2 d. At the end of
this incubation period, cells were expanded with IL-2 and IL-7 for another
4 d. Subsequently, cells were reactivated for 24 h with plate-bound anti-CD3
and anti-CD28 (1 mg/ml) in the presence of IL-12 (20 ng/ml; R & D Sys-
tems) and IL-18 (20 ng/ml; Biozol). Activated T cells were collected and
washed, and 2–5 3 106 cells were transferred i.p. into recipient mice.
Ab-mediated depletion of host T cells was performed using anti-Thy1.2
Ab. Recipient mice were repeatedly injected i.p. with 500 mg anti-Thy1.2
mAb (clone 30H12; BioXCell) 2 d before transfer and on days 2, 6, and 10
after adoptive transfer of activated 2D2 T cells. Blood samples were taken
on days 0, 2, 6, and 10 to control depletion of host T cells.
Immunohistological analysis
Mice were killed and cardially perfused with NaCl. Spinal cords were
removed and ﬁxed in 4% formaldehyde. Parafﬁn-embedded spinal cord
longitudinal sections were stained with H&E for visualization of inﬂam-
matory inﬁltrates and evaluated in a blinded manner for the amount of
inﬂammation as described previously (35).
ELISA
For the determination of speciﬁc anti-MOG Abs, plates were coated with
MOG35–55 (10 mg/ml) in bicarbonate buffer overnight at 37˚C. After blocking
with 1% BSA, the plates were incubated with serial dilutions of mouse serum
overnight at 4˚C. Speciﬁc binding was detected using alkaline phosphatase–
labeled goat anti-mouse IgG (subclasses 1+2a+2b+3, Fcg-fragment speciﬁc;
Dianova, Hamburg, Germany).
Cytokine concentration
Levels of cytokines in plasma were determined using the Th1/Th2/Th17
cytometric bead array kit (BD Biosciences).
Isolation of leukocytes from spinal cord
Mice were killed with CO2 and cardially perfused through the left ventricle
using NaCl. Spinal cords were extruded by ﬂushing the vertebral canal
with PBS. CNS tissue was cut into pieces and treated with collagenase (2.5
mg/ml; Roche Diagnostics) and DNAse I (1 mg/ml; Sigma-Aldrich) for 45
min at 37˚C. Tissue was ground through a cell strainer (70 mm), washed,
resuspended in 37% Percoll, and layered onto 70% Percoll. After centri-
fugation (2000 rpm, 25 min), cells were removed from the interphase,
washed, and stained for FACS analysis.
Flow cytometry
Flow cytometric analysis was performed on BD LSRFortessa using BD
FACSDiva software (BD Biosciences). The following Abs were used for
staining: anti-CD3, anti-CD4, anti-CD8, anti-Va3.2, anti-CD11b, anti-
CD11c, anti CD45, anti-CD45.1 and anti-CD45.2, anti-podoplanin (Gp38),
and anti-CD31 (all BD Biosciences).
For staining of stromal cells, pooled lymph nodes were cut into pieces
and digested with collagenase IV (ﬁnal concentration, 4 mg/ml; Invitrogen)
and DNAse (ﬁnal concentration, 100 mg/ml; Sigma-Aldrich) for 25 min
at 37˚C. Cells were stained for podoplanin (Gp38) and CD31. For ﬂow
cytometric analysis, the CD45-negative cells were gated and analyzed for
the expression of podoplanin, CD31, and ADAP. The polyclonal sheep
anti-ADAP antiserum and the respective preimmune serum were provided
by G. Koretzky (University of Pennsylvania, Philadelphia, PA) and were
used for intracellular staining as described previously (4). The monoclonal
anti-Fyb Ab was purchased from BD Biosciences.
Radiation-induced BM chimeric mice
BM donor mice were killed using CO2, and BM cells were isolated by
ﬂushing femur and tibia bones with RPMI 1640 medium. BM cells were
washed and resuspended in PBS. Anesthetized congenic recipient mice
were lethally irradiated with 1200 rad using a BioBeam 8000 (STS
Steuerungstechnik and Strahlenschutz), and 8 3 106 BM cells were ad-
ministered by retro-orbital injection. Recipient mice were maintained on
antibiotic-containing water (2 mg/ml neomycin sulfate; Sigma-Aldrich) for
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1 wk after transplantation. Engraftment took place over 6–8 wk of re-
covery. Successful reconstitution was checked by ﬂow cytometry using
congenic markers CD45.1 and CD45.2.
Microglia function
Primary microglia cultures were prepared fromwild-type and ADAP-deﬁcient
1- to 3-d-old pups. The cerebral cortices and meninges were removed, and the
brains of up to 10 mice were pooled. A single-cell suspension was generated
by several rounds of enzymatic and mechanical digestion with the neural
dissociation kit (Miltenyi Biotec). Subsequently, microglia cells were isolated
using CD11b microbeads (Miltenyi Biotec) as described in the manufactures
protocol (purity . 90%). Cells (5 3 104) were cultured in 96-well plates in
DMEM (Life Technologies) supplemented with 10% FCS (Life Technolo-
gies), 1% gentamicin, 1% penicillin/streptomycin, and 0.5% glutamine. After
resting for 24 h, microglia cells were stimulated with LPS from Salmonella
minnesota (1 mg/ml; Sigma-Aldrich). Following stimulation for 24 h, super-
natants were removed and stored for NO and cytokine measurement at
220˚C. Concentration of TNF-a was determined using Mouse CBA Kit
(BD Biosciences). NO production was quantiﬁed using Griess Reagent
System (Promega) following the manufacturer’s protocol.
Two-photon microscopy of inguinal lymph node explants
Splenic T cells and B cells from congenic B6.SJL mice were isolated by
magnetic depletion (Miltenyi Biotec). Puriﬁed B cells were labeled with
CFSE (5 mM), and puriﬁed T cells were labeled with Cell Tracker Orange
(5 mM; both Molecular Probes). Approximately 10 3 106 cells (ratio 1:1)
were administered i.v. by retro-orbital injection into each recipient mouse.
Lymphatic vessels were visualized by Paciﬁc Blue–labeled anti–LYVE-1
Ab (10 mg in 30 ml PBS) applied s.c. into the right ﬂank 24 h before im-
aging. The left lymph node was left unstained and was used as control for
FACS analysis. The inguinal lymph nodes of wild-type and ADAP-deﬁcient
recipients were imaged 48 h after adoptive transfer. Two-photon micros-
copy of explanted lymph nodes was performed as reported previously (36).
The inguinal lymph node was surgically removed, immediately immersed in
PBS, and placed with the medullary (hilar side) or the follicular (convex)
side up, respectively, onto a glass slide. Imaging was performed at a 50 and
150 mm depth. Microscopy was performed using a ZeissLSM710 (Carl
Zeiss, Jena, Germany) equipped with a MaiTai DeepSee Femtosecond-
Laser (Spectra-Physics, Darmstadt, Germany) tuned to 850 nm on an
AxioExaminer upright stage with a 320, numerical aperture 1.0 (Carl
Zeiss) water dipping lens. Image detection was done with three non-
descanned detectors, typically equipped with emission detection ﬁlters of
565–610 nm (red), 500–500 nm (green), and ShortPass485 nm (blue).
Individual red, green, blue, z-stacks of 606 3 606 mm images were
recorded and tiled to combine up to 6 3 4 of such ﬁelds. Rendering of
images was performed using Volocity software (version 4.3; Improvision,
Waltham, MA). The number of LYVE-1–associated T cells and B cells was
quantiﬁed in at least 20 deﬁned areas of two-photon microscopic images.
Statistical analysis
Results are expressed as mean 6 SEM. Student unpaired t test was used to
assess the statistical signiﬁcance of the differences. Statistical comparison
of EAE disease severity between different two groups of animals was
accomplished by performing nonparametric Wilcoxon matched pairs test
using GraphPad Prism software (37). p , 0.05 was considered signiﬁcant.
Results
ADAP-deﬁcient mice developed milder EAE
EAE (the mouse model of MS) can be induced in C57BL/6 mice
by s.c. immunization with MOG35–55 peptide in mycobacteria-
containing CFA. To assess the consequences of ADAP deﬁciency
in this disease model, we induced EAE in ADAP-deﬁcient mice
and wild-type mice. Fig. 1A shows that ADAP-deﬁcient mice un-
dergo a signiﬁcantly milder disease compared with wild-type mice.
FIGURE 1. Milder EAE in ADAP-deﬁcient mice. (A) EAE was induced following immunization with MOG35–55 peptide in CFA. The clinical score of
EAE was assessed for 35 d after immunization (mean 6 SD; n = 5; p , 0.05 wild-type [WT] versus ADAP). (B) Representative histology of spinal cord
longitudinal sections. Inﬂammatory inﬁltration was visualized by H&E staining. The arrowhead shows a typical heavy inﬂammatory cellular inﬁltration in
WT animals. Original magniﬁcation 3200. (C) Histopathological analysis was performed, and meningeal, parenchymal, and total numbers of inﬂammatory foci
were determined. Data represent mean number of inﬂammatory foci + SEM (n = 5; p, 0.05). (D) Serum levels of anti-MOG35–55 speciﬁc IgG Abs were measured
by ELISA (n = 8; p, 0.01). (E) WT T cells and ADAP-deﬁcient T cells were adoptively transferred into Lck-deﬁcient recipients. One week later, EAE was induced
by immunization with MOG35–55 peptide in CFA, and the animals were scored for clinical signs of disease (mean 6 SD of at least ﬁve animals per group).
The Journal of Immunology 3
The milder clinical score of ADAP-deﬁcient mice was further re-
ﬂected by signiﬁcantly reduced numbers of inﬂammatory foci in the
spinal cord (Fig. 1B, 1C) where total inﬂammatory foci as well
those in the meninges and the parenchyma were reduced. In addi-
tion, the levels of MOG-speciﬁc IgG Abs in the serum were sig-
niﬁcantly lower in ADAP-deﬁcient-mice compared with wild-type
mice (Fig. 1D). Taken together, these results suggest that loss of
ADAP leads to a strongly attenuated clinical course of EAE, which
is accompanied by lower inﬂammatory inﬁltrates in the CNS and
reduced concentrations of anti-MOG Abs in the serum.
It has been reported previously that ADAP-deﬁcient T cells show
defective proliferation, IL-2 production, as well as impaired TCR-
mediated LFA-1 clustering and adhesion (6, 7). To assess whether
the observed amelioration of EAE in the absence of ADAP was
due to impaired function of the ADAP-deﬁcient T cell, we per-
formed an adoptive transfer experiment in which wild-type T cells
or ADAP-deﬁcient T cells were transferred into Lck-deﬁcient ani-
mals, which completely lack mature T cells. After 7 d, EAE was
induced by immunization with MOG35–55 peptide. The onset of
EAE was delayed, although not statistically signiﬁcant, when
ADAP-deﬁcient T cells were adoptively transferred into the Lck-
deﬁcient hosts compared with transferred wild-type T cells (Fig.
1E). This is possibly due to the well established defect in inside-
out signaling of ADAP-deﬁcient T cells (6, 7). However, both
wild-type and ADAP-deﬁcient T cells produced the same clinical
score of disease at later time points of disease. These data indicate
1) that ADAP-deﬁcient T cells are principally capable to induce
EAE in T cell–deﬁcient hosts and 2) that non-T cell–speciﬁc
functions of ADAP are likely responsible for the blunted course
of EAE in the absence of ADAP.
FIGURE 2. Reduced EAE severity in ADAP-deﬁcient mice after adoptive transfer of 2D2-transgenic T cells. (A) Wild-type (WT) and ADAP-deﬁcient
mice were adoptively transferred with MOG-speciﬁc transgenic T cells (2D2). One week later, EAE was induced by immunization with MOG35–55 peptide
in CFA. The severity of EAE is presented as clinical score (mean6 SD; n = 5; p, 0.05 WT + 2D2 T cells versus ADAP + 2D2 T cells). (B) Splenic T cells
of 2D2 mice were stimulated in vitro with MOG35–55 in the presence of IL-2 and IL-7 and were reactivated with plate-bound anti-CD3 and anti-CD28 in the
presence of IL-12 and IL-18. Fully activated transgenic *2D2 T cells were adoptively transferred into WT or ADAP-deﬁcient recipients, and EAE course
was monitored. Data are shown as mean 6 SD of one representative experiment (n = 13 for WT and n = 10 for ADAP, respectively; p , 0.05 WT + *2D2
T cells versus ADAP + *2D2 T cells). (C) Representative images show longitudinal sections of spinal cords of ADAP-deﬁcient and WT recipients
adoptively transferred with *2D2 T cells (H&E staining, original magniﬁcation 3200). (D) Histopathological analysis was performed, and meningeal,
parenchymal, and total numbers of inﬂammatory foci were determined. Data represent mean number of inﬂammatory foci + SEM (n = 5; *p, 0.05; **p,
0.01). (E) Mice adoptively transferred with *2D2 T cells were killed at day 14, and plasma concentrations of IL-17A, IFN-g, and TNF-a were measured by
cytometric bead array (n = 9, mean + SEM; *p , 0.05).
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2D2 TCR–transgenic T cells do not reconstitute EAE in
ADAP-deﬁcient mice
To further substantiate this assumption we performed an additional
adoptive transfer experiment where we transferred 2D2 TCR–
transgenic T cells (the 2D2 T cells express a TCR that speciﬁcally
recognizes the MOG33–55 peptide) into either wild-type or ADAP-
deﬁcient recipient mice. Subsequently, we induced EAE in the two
cohorts by immunization with MOG35–55 peptide. As shown in Fig.
2A, even under these experimental conditions, ADAP-deﬁcient
mice display a signiﬁcantly milder disease score compared with
wild-type mice, thus corroborating that T cell–extrinsic functions
of ADAP are responsible for the ameliorated disease in ADAP-
deﬁcient animals.
The blunted course of EAE even after transfer of MOG-speciﬁc
2D2 cells could be due to an impaired priming phase of the T cell
response or due to an altered effector phase (or both). To distinguish
between these possibilities, we by-passed the induction phase of the
immune response in the peripheral lymphoid organs by transferring
ex vivo–activated and polarized 2D2-transgenic T cells. To this end
primary non-activated 2D2 TCR transgenic T cells were isolated
and ex vivo activated for 2 rounds using MOG35–55 peptide fol-
lowed by one round of in vitro stimulation using anti-CD3/anti-
CD28 Abs. This procedure resulted in the generation of fully ac-
tivated *2D2 T cells. The *2D2 T cells were then transferred into
either wild-type or ADAP-deﬁcient hosts and the clinical score of
the diseased animals was monitored over time. This experiment
showed that even the ex vivo–activated *2D2 T cells induced
signiﬁcantly less severe EAE in ADAP-deﬁcient recipients com-
pared with wild-type recipients (Fig. 2B). Histological analysis of
the spinal cords conﬁrmed the clinical data by showing less cellular
inﬁltration and signiﬁcantly reduced numbers of meningeal, pa-
renchymal, and total inﬂammatory foci in the ADAP-deﬁcient
recipients (Fig. 2C, 2D). Similarly, plasma concentration of the
proinﬂammatory cytokine IFN-g that plays a major pathophysio-
logical role in EAE was signiﬁcantly lower in ADAP-deﬁcient
mice. In contrast, no differences in the serum levels of IL-17A
and TNF-a were observed between the two cohorts (Fig. 2E).
To exclude the possibility that endogenous ADAP-deﬁcient
T cells contribute to the milder EAE in ADAP-deﬁcient mice,
we performed Ab-mediated depletion of host T cells. Therefore,
recipient mice were repeatedly injected with an anti-Thy1.2 Ab
2 d before adoptive transfer and on days 2, 6, and 10 after transfer.
This Ab-mediated depletion of host T cells does not alter EAE
severity in ADAP-deﬁcient and wild-type recipient mice after
adoptive transfer of fully activated 2D2-transgenic T cells (Fig. 3).
In summary, the data shown in Figs. 2 and 3 clearly demonstrate
that T cell–extrinsic functions of ADAP impair the inﬂammatory
response in the ADAP-deﬁcient animals.
ADAP-deﬁcient mice showed reduced leukocyte inﬁltration in
the spinal cord
We next attempted to characterize the immune cell populations
that inﬁltrate the CNS during EAE in ADAP-deﬁcient animals
following transfer of *2D2 TCR–transgenic cells. Therefore, we
FIGURE 3. Reduced EAE severity in ADAP-deﬁ-
cient mice after adoptive transfer of 2D2-transgenic
T cells and depletion of host T cells. (A) To deplete
host T cells, recipient mice were repeatedly injected
i.p. with 500 mg anti-Thy1.2 mAb 2 d before adoptive
transfer and on days 2, 6, and 10 after transfer. Starting
on day 5, the disease progression was monitored daily.
Data are shown as mean 6 SD of one representative
out of two independent experiment (n = 6 mice/group;
p , 0.05 wild-type [WT] + *2D2 T cells + anti-Thy1.2
versus ADAP + *2D2 T cells + anti-Thy1.2). (B) FACS
plots demonstrate the depletion of endogenous T cells
in peripheral blood taken on day 6 after transfer.
FIGURE 4. Less inﬂammatory cells in the spinal
cord in ADAP-deﬁcient mice. EAE was induced by
adoptive transfer of fully activated MOG-speciﬁc *2D2-
transgenic T cells. At day 14 after transfer, leukocytes
were isolated from the spinal cord by Percoll gradient.
(A) Cells were stained with Abs to CD45 and CD11b
and analyzed by ﬂow cytometry: R2, CNS-resident
microglia; R4, invading macrophages and granulocytes;
and R6, invading lymphocytes. (B) Absolute cell numbers
of these CNS subpopulations are depicted. Transgenic
*2D2 T cells were identiﬁed by the presence of the
Va3.2 TCR a-chain within the lymphocyte population.
DCs were identiﬁed by CD11c+ staining. Data show
one representative out of ﬁve independent experiments
(mean + SEM, n = 6). *p , 0.05, **p , 0.01.
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isolated the leukocytes from the spinal cord at the clinical peak
of disease and assessed their phenotypes by ﬂow cytometry. Ex-
pression of CD45 was used to distinguish CNS-resident microglia
(CD45 low) from invading leukocytes (CD45 high, R2; Fig. 4A).
The CNS invading cell populations were further distinguished by
the presence (macrophages and granulocytes) or absence (lympho-
cytes) of CD11b. This analysis revealed that ADAP-deﬁcient mice
showed consistently fewer invading leukocytes than their wild-type
counterparts (regions R4 and R6; Fig. 4A). A deeper analysis of the
leukocytes showed that signiﬁcantly less lymphocytes, including
TCR-transgenic Va3.2 T cells, macrophages and DCs invaded the
CNS of ADAP-deﬁcient mice. In contrast, no difference in the
number of resident microglia was observed (Fig. 4B). Further sub-
typing of the inﬁltrating CD4+ T cells showed similar frequencies of
FoxP3 regulatory T cells, IL-17+ Th17 cells, IFN-g+ Th1 cells and
IL-10–producing cells (data not shown). Thus, loss of ADAP leads
to a globally impaired inﬁltration of leukocytes into the CNS
without affecting a particular T cell or leukocyte subpopulation.
*2D2 T cells accumulate in the lymph nodes in ADAP-deﬁcient
mice
After induction of passive EAE, activated encephalitogenic T cells
home through the secondary lymphoid organs before they enter the
CNS (38). To localize the ex vivo–activated inﬂammatory *2D2
cells over time, we isolated lymph nodes, spleen, blood, and spinal
cord at days 7, 10, and 14 after adoptive transfer and quantiﬁed the
transgenic T cells within the individual organs by ﬂow cytometry.
This approach revealed no signiﬁcant differences between wild-
type and ADAP-deﬁcient recipients in the absolute number of
*2D2 T cells in the spleen and the percentage of *2D2 T cells in
the blood (Fig. 5A). However, at the same time, we recovered
signiﬁcantly more *2D2 T cells from the lymph nodes and sig-
niﬁcantly less *2D2 T cells from the spinal cord of ADAP-deﬁcient
recipients. This indicates that in the absence of ADAP the ac-
tivated *2D2-transgenic T cells are retained within the peripheral
lymph nodes.
Next, we investigated whether the accumulation of T cells within
the lymph nodes was a speciﬁc property of the ex vivo–activated
*2D2 T cells. Therefore, we repeated the adoptive transfer experi-
ments this time using nonactivated 2D2 T cells (Fig. 5B). Also under
these experimental conditions, we found an increased percentage of
nonactivated 2D2 T cells in the lymph nodes of ADAP-deﬁcient
recipients. At the same time, similar numbers of nonactivated 2D2
T cells were recovered from the blood and the spleen of both
ADAP-deﬁcient and wild-type mice. Collectively, these results
demonstrate that in ADAP-deﬁcient recipients, T cells accumulate
in the peripheral lymph nodes independent of their activation state.
Nonhematopoietic radio-resistant cells partially mediate the
milder course of EAE in ADAP-deﬁcient mice
To dissect whether the accumulation of T cells in the lymph nodes of
ADAP-deﬁcient mice was mediated by cells of the hematopoietic
system or by nonhematopoietic cells (e.g., stromal cells of the
lymph node), we generated radiation BM chimeras and recon-
stituted the hematopoiesis of ADAP-deﬁcient recipients with wild-
type BM. To track the reconstituted cells, we used the B6.SJL
congenic mouse strain carrying the CD45.1 (Ly-5.1) allele. Eight
weeks after reconstitution, EAE was induced by immunization with
MOG35–55 peptide in CFA. As shown in Fig. 6A, even after transfer
of whole B6.SJL BM into ADAP-deﬁcient recipients, the severity
of EAE was much lower in ADAP-deﬁcient recipients compared
with wild-type recipients. To conﬁrm this result using a different
experimental setup, we reconstituted both wild-type and ADAP-
deﬁcient recipients with complete BM of 2D2 TCR–transgenic
mice. After reconstitution, EAE was induced by two injections of
pertussis toxin. As shown in Fig. 6B, wild-type recipients devel-
oped severe disease whereas ADAP-deﬁcient recipients did not.
These data show that the attenuated EAE in ADAP-deﬁcient mice
is mediated via a radio-resistant nonhematopoietic mechanism.
Microglia is the CNS-resident radio-resistant macrophage, critical
for the development of EAE by the release of cytokines as well as
reactive oxygen species (39). To assess whether ADAP deﬁciency
might result in diminished function of radio-resistant microglia
cells, we investigated functional activity of wild-type and ADAP-
deﬁcient primary microglia. For this purpose, NO production and
FIGURE 5. Accumulation of adoptively transferred T cells in the lymph
nodes of ADAP-deﬁcient mice. (A) Wild-type (WT) and ADAP-deﬁcient
recipients were adoptively transferred with fully activated *2D2-transgenic
T cells. At days 7, 10, and 14 after transfer, the number of activated *2D2
T cells (gated on CD4+Va3.2+) in spleen, lymph nodes, spinal cord, and
blood was analyzed (mean6 SEM, n = 6; *p, 0.05; **p, 0.01). (B) WT
and ADAP-deﬁcient recipients were adoptively transferred with nonacti-
vated transgenic 2D2 T cells. At days 3 and 6 after transfer, the recovery of
transgenic T cells (gated on CD4+Va3.2+) in the lymphoid organs was
determined by ﬂow cytometry (mean + SEM, n = 3; *p , 0.05).
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cytokine secretion after LPS stimulation were measured. Compari-
son of wild-type and ADAP-deﬁcient microglia revealed similar
amounts of NO and TNF-a in response to LPS stimulation (Sup-
plemental Fig. 1). Therefore, we can exclude the possibility that
hypofunctional radio-resistant microglia cells contribute to the
milder EAE in ADAP-deﬁcient mice.
Next, we asked the question whether non–BM-derived radio-
resistant lymph node stromal cells would express ADAP. Stromal
cells of the lymph nodes can be divided into two categories: fol-
licular DCs are prominent stromal cell constituents of the B cell
follicles, and ﬁbroblastic reticular cells associate with the T cells
areas. Marginal reticular cells are also known as sinus-lining cells.
The other nonhematopoietic cells in the lymph node include blood
endothelial cells and lymphatic endothelial cells (40). To distinguish
these different subsets within the CD45-negative cell population
of the lymph nodes, we performed FACS analysis of collagenase-
digested lymph nodes and stained the cells for CD31 and podo-
planin (Gp38). All four subsets were subsequently analyzed by ﬂow
cytometry for their expression of ADAP using a polyclonal anti-
ADAP antiserum (4). This approach revealed that none of the stromal
cell populations expresses ADAP (Fig. 7A). The same result was
achieved when we used a monoclonal anti-ADAP Ab (data not
shown). These results indicate that ADAP is not expressed in
lymph node stromal cells and thus exclude the possibility that
impaired stromal cell functions ameliorate the clinical course of
EAE in ADAP-deﬁcient animals.
Adoptively transferred lymphocyte accumulate on LYVE-1+
structures in the lymph node
To further elucidate the reason for the accumulation of T cells
within the lymph nodes of ADAP-deﬁcient animals, we applied
two-photon microscopy and studied the localization of adoptively
transferred and differentially labeled T and B cells within the in-
guinal lymph nodes. To identify the lymphatic vessels an anti–
LYVE-1 Ab was applied s.c. in the ﬂank and the tail base 24 h
before imaging. Fig. 7B depicts that inguinal lymph nodes were
structurally normal and that the transferred T cells and B cells
properly homed to the T cell zone and to the B cell follicles, re-
spectively. Further analysis of the images and quantiﬁcation of the
numbers of T cells and B cells associated with LYVE-1+ lym-
phatic vessels revealed signiﬁcantly higher numbers of adoptively
transferred T and B lymphocytes on LYVE-1+ lymphatic vessels
in ADAP-deﬁcient recipients compared with wild-type recipients
(Fig. 7B). In contrast, there was no such increase in T and B cell
areas (data not shown). These results demonstrate that the adop-
tively transferred lymphocytes localize within the lymph nodes
of ADAP-deﬁcient mice at lymphatic vessels. Thus, it appears that
ADAP-deﬁcient hosts undergo a much milder EAE course because
the encephalitogenic T cells are retained at LYVE-1+ lymphatic
vessels within the lymph nodes.
Discussion
To determine the role of the cytosolic ADAP in an autoimmune
mouse model we induced EAE in wild-type and ADAP-deﬁcient
mice by immunization with MOG35–55 peptide. This approach
revealed that the loss of ADAP strongly attenuates the clinical
course of EAE. In line with the lower EAE score, we observed
reduced inﬂammatory inﬁltrates in the spinal cord of ADAP-
deﬁcient mice and lower levels of MOG-speciﬁc Abs in the serum.
It is well established that loss of ADAP impairs the function of
T cells (6, 7). Therefore, we expected that the ameliorated EAE
in ADAP-deﬁcient animals is to a large extent because of an al-
tered T cell function. Surprisingly, however, when transferred into
a T cell–deﬁcient background (Lck2/2 hosts), ADAP-deﬁcient
T cells displayed a similar capability of inducing EAE as wild-
type T cells. Thus, it appears that despite altered inside-out sig-
naling capability and impaired NF-kB activation (which might be
responsible for the delayed onset of disease that we observed in
our experiment), ADAP-deﬁcient T cells are capable of exerting
similar effector functions as wild-type T cells, at least in the EAE
model.
To gain further insights into the mechanisms underlying the
blunted EAE in the ADAP-deﬁcient mice, we applied a passive
transfer EAE model using ADAP-proﬁcient transgenic T cells
expressing the MOG35–55-speciﬁc TCR 2D2. Unexpectedly,
adoptive transfer of either nonprimed 2D2 T cells or even ex vivo–
activated *2D2 T cells also failed to induce EAE in ADAP-
deﬁcient recipients. This ﬁnding strongly suggests that the ame-
liorated clinical course of EAE in the ADAP-deﬁcient hosts is
indeed not mediated by functionally altered T cells but rather via
a T cell–independent mechanism. Moreover, it shows that the
described immunological dysfunction of ADAP-deﬁcient mice
(e.g., with regard to vesicular stomatis virus infection or trans-
plantation models) very likely has a much more complex cellular
basis as thought previously (6, 17, 18).
During induction of EAE, activated encephalitogenic T cells are
the ﬁrst immune cells that enter the CNS (38). In this study, they
induce an inﬂammatory response that, among other pathophysio-
FIGURE 6. Milder EAE in mice with ADAP deﬁciency in the radio-resistant nonhematopoietic compartment. (A) Radiation BM chimeras were gen-
erated by reconstitution of ADAP-deﬁcient mice and wild-type (WT) mice with congenic WT BM (B6.SLJ). Eight weeks after successful reconstitution,
EAE was induced by immunization with MOG35–55 in CFA. Data represent one of two independent experiments (n = 8 for WT recipients and n = 7 for
ADAP recipients; mean EAE score6 SD; p, 0.05; B6.SJL..WT versus B6.SJL.. ADAP). The representative FACS plot shows ablation of CD45.2
cells in chimeras reconstituted with B6.SJL (CD45.1) BM. (B) Lethally irradiated ADAP-deﬁcient mice and WT mice were reconstituted with 2D2 BM
cells. After reconstitution, EAE was induced by two doses of pertussis toxin on days 0 and 2. Results of one representative out of two independent
experiments are shown as mean EAE score 6 SD (n = 6; p , 0.05; 2D2 . . WT versus 2D2 . . ADAP).
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logical consequences, leads to recruitment of additional inﬂam-
matory cells such as macrophages, B cells, and DCs. Flow cyto-
metric analysis of the cellular populations in the inﬂamed CNS
showed a strong reduction of invading T cells in the absence of
ADAP. Importantly, however, the percentages of CNS-inﬁltrating
Tregs, Th1, and Th17 cells were found to be equal in wild-type
versus ADAP-deﬁcient hosts, indicating that the ameliorated dis-
ease in the absence of ADAP is not due to expansion or deletion of
a particular T cell subset.
However, analysis of the CNS-invading cell populations revealed
that loss of ADAP affected all leukocyte populations (T cells,
macrophages, and DCs) that invade the CNS. On the basis of the
above thoughts that activated T cells recruit inﬂammatory immune
cells to the CNS, we hypothesized that the globally reduced in-
ﬂammatory response within the CNS was primarily because of the
reduced recruitment of encephalitogenic T cells into the brain. In
line with this idea, a FACS-based analysis of hematopoietic tissues
clearly revealed that in ADAP-deﬁcient hosts the transferred T cells
do not reach the CNS because they accumulate within the lymph
nodes. It is tempting to assume that as a consequence other in-
ﬂammatory cells that normally drive the clinical course of EAE do
not become activated as well, thereby causing the generally reduced
EAE response in ADAP-deﬁcient mice.
It is well known that ADAP is not only expressed in T cells but
also in a variety of other hematopoietic cells (DC, mast cells, and
platelets) that have been shown to inﬂuence the course of EAE.
Thus, it was necessary to investigate whether an impaired function
of one of these cell populations might be responsible for the blunted
inﬂammatory response and the accumulation of T cells in the
lymph nodes of ADAP-deﬁcient animals. However, to our great
surprise, analysis of BM chimeras revealed that neither transfer of
complete wild-type BM nor of BM of 2D2 TCR–transgenic mice
reconstituted the clinical course of EAE in the ADAP-deﬁcient
recipients. This ﬁnding strongly suggests that not impaired func-
tions of hematopoietic cells but rather altered functions of (a)
nonhematopoietic cell population(s) prevent(s) the induction of
FIGURE 7. Association of adoptively transferred lymphocytes with LYVE-1+ structure in the lymph nodes of ADAP-deﬁcient mice. (A) Lymph nodes
were digested with collagenase and stromal cell subsets were identiﬁed by FACS analysis. The CD45-negative cells were gated, and staining with
podoplanin and CD31 identiﬁed the stromal cell subset in the four quadrants. Histograms show staining for ADAP in these four quadrants. Dot plot and
histograms of one representative FACS analysis are shown. The control for intracellular ADAP staining was performed on CD45+ lymph node cells from
wild-type (WT) and ADAP-deﬁcient mice (right panel). (B) Inguinal lymph nodes of WT and ADAP-deﬁcient recipients were imaged 48 h after adoptive
transfer of WT CFSE-labeled B cells and Cell Tracker Orange–labeled T cells using two-photon laser scanning microscopy (original magniﬁcation 3200).
Lymphatic vessels were visualized by Paciﬁc blue–labeled anti–LYVE-1 Ab applied s.c. 24 h before imaging. The ﬁgure shows representative images from
the follicular side of WTand ADAP-deﬁcient inguinal lymph nodes at 150-mm depths. The counting grids were used for quantitative analysis. (C) LYVE-1–
associated T cells and B cells were counted. The graphic plots represent the cell number (mean + SEM; **p , 0.01) from 20 counting grids. Results show
one representative out of three independent experiments. BEC, Blood endothelial cell; DN, double-negative cell; FDC, follicular DC; FRC, ﬁbroblastic
reticular cell; LEC, lymphatic endothelial cell; MRC, marginal reticular cell.
8 EAE IN ADAP-DEFICIENT MICE
EAE in the absence of ADAP. However, ﬂow cytometry analysis
of isolated wild-type lymph nodes as well as analysis of publicly
available mRNA expression data (previously assembled by the
Immunological Genome Project Consortium, www.immgen.org)
(41) did not provide evidence for expression of ADAP in stromal
cell populations. Hence, we conclude that loss of ADAP in lymph
node stromal cells also does not account for blunted course of
EAE in ADAP-deﬁcient mice.
We are aware of the possibility that the persistence of ADAP-
deﬁcient radio-sensitive cells caused by incomplete BM ablation
could exert an inhibitory effect on encephalitogenic cells. In ad-
dition, ADAP-deﬁcient radio-resistant BM-derived APCs might
be responsible for attenuated EAE severity. Langerhans cells of
host origin remain for months in lethally irradiated mice that had
received BM transplants (42). Microglia cells (which express
ADAP) might inhibit the development and maintenance of in-
ﬂammation in the CNS (39). However, we believe it unlikely that
altered functions of microglia in the absence of ADAP are re-
sponsible for the ameliorated recruitment of inﬂammatory T cells
for the following reasons. First, it has been reported that in the
normal CNS microglia express low levels of MHC molecules and
thus are poor activators of naive T cells (43). Second, using BM
chimeras, it has been shown that inﬁltrating hematopoietic DCs
rather than radio-resistent CNS-resident microglia cells are sufﬁ-
cient to induce EAE (29). Third, it was reported that eradicating
part of the myeloid compartment or blocking speciﬁc signaling
capacity of DCs/APCs (in the periphery as well as in the CNS)
reduces the severity of EAE (44–46). Fourth, intracerebral appli-
cation of MOG-loaded DCs results in exacerbation of EAE (47).
Finally, our own data show that TNF-a secretion and NO pro-
duction after LPS stimulation was similar in wild-type and ADAP-
deﬁcient microglia cells. These data suggest that DCs rather than
microglia cells are involved in the onset of EAE.
Insights into the mechanism that leads to the accumulation of
T cells in the ADAP-deﬁcient hosts were provided by two-photon
microscopy of ADAP-deﬁcient lymph nodes following adoptive
transfer of ﬂuorescence-labeled T cells. This analysis showed that
in ADAP-deﬁcient hosts the wild-type T cells (as well as trans-
ferred wild-type B cells, which both properly homed to the lymph
nodes) accumulated at LYVE-1+ lymphatic vessels within the lymph
nodes. We interpreted this observation in the way that in the ab-
sence of ADAP T cells can enter the lymph nodes but are unable
to egress the lymph node.
What could be the mechanism(s) that lead(s) to the trapping of
T cells in lymph nodes in the absence of ADAP?Most obviously an
alteration of the sphingosine 1-phosphate system could account for
such a phenotype. However, ex vivo analysis of 2D2 T cells re-
covered from the lymph nodes of wild-type or ADAP-deﬁcient
recipients did not show differences in the expression of the sphin-
gosine 1-phosphate receptor 1 (S. Engelmann and A. Reinhold, un-
published observations). Moreover, it seems unlikely that the serum
levels of sphingosine 1-phosphate (S1P) themselves are affected by
the loss of ADAP because blood-borne S1P is primarily produced
by erythrocytes and vascular endothelial cells, which do not ex-
press ADAP (48). In addition, replacement of the ADAP-deﬁcient
hematopoietic system by the wild-type hematopoietic system did
not rescue the clinical course of EAE in the ADAP-deﬁcient ani-
mals. Hence, an alteration of the S1P system as the reason for the
lymph node trapping of the T cells in the ADAP-deﬁcient animals
seems unlikely.
It is known that ADAP is expressed in platelets that have been
suggested to be involved in the blood-lymphatic vascular separa-
tion during embryonic development (49). Although ADAP-deﬁcient
platelets have an altered function and ADAP-deﬁcient mice show
prolonged bleeding after injury (20), we so far do not have con-
vincing evidence that the blood and the lymphatic vessels are not
properly separated from each other in the ADAP-deﬁcient ani-
mals. However, we cannot rule out the possibility that very minor
alterations in the separation process between blood and lymphatic
vessels account for the observed phenotype. Further studies are
required to evaluate this possibility.
Finally, it could be that via direct or indirect mechanisms loss of
ADAP leads to an enhanced expression of ICAM-1, the ligand for
the T cell integrin LFA-1 on lymphatic endothelial cells. This might
induce a stronger adhesion of the T cells to the lymphatic endo-
thelial cells, thereby preventing their egress from the lymph node.
Indeed, we recently observed that the interaction between LFA-1
expressed by lymph node T cells and ICAM-1 expressed by lym-
phatic vessels determines the egress rate of T cells from the lymph
nodes (50). We are currently setting up the experimental systems to
evaluate this possibility.
In summary, we demonstrate that loss of ADAP promotes resis-
tance of EAE in mice, likely by trapping encephalitogenic T cells
in the peripheral lymph nodes on LYVE-1+ lymphatic structures.
Further studies using lineage-speciﬁc ADAP-deﬁcient mice are
needed to precisely dissect which nonhematopoietic cell population
is responsible for the observed phenotype and also to identify the
functional role of ADAP in, for example, microglia. Neverthe-
less, our data show that altered immune functions in ADAP-
deﬁcient mice have a complex cellular basis that goes beyond
impaired functions of the T cells and likely also involves non-
hematopoietic cells.
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Abstract
Regulatory T-cells (Tregs) are central for immune homeostasis and divided in thymus-derived natural Tregs and peripherally
induced iTreg. However, while phenotype and function of iTregs are well known, a remarkable lack exists in knowledge about
signaling mechanisms leading to their generation from naı¨ve precursors in peripheral tissues. Using antigen specific naı¨ve T-
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with weak antigen presenting cells (APC). We show that early signaling pathways such as ADAM-17-activation appeared
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after 24 h while Teff permanently downmodulated it. Furthermore, between 24 and 72 hours iTreg presented with
significantly lower phosphorylation levels of Akt-S473 suggesting lower activity of the PI3K/Akt-axis. This was associated
with a higher expression of the Akt hydrophobic motif-specific phosphatase PHLPP1 in iTreg. Importantly, the lack of
costimulatory signals via CD28 from weak APC was central for the development of regulatory function in iTreg but not for
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Introduction
Following T-cell receptor (TCR) triggering, naı¨ve T-cells have
multiple possibilities into which type of effector phenotype they
develop [1]. Current concepts describe the effector lineages, Th1,
Th2, Th17, TFH and Treg and variations of these, where the status
of ‘‘lineage’’ is still debated [2]. For these T-cell types master
regulators have been identified driving the expression of lineage-
identifying functions [3]. Meanwhile evidence is accumulating that
T-cells can express more than one ‘‘master regulator’’ and thereby
acquiring new functions even after initial differentiation [4]. Tregs
are a special lineage as they downregulate the activity of all other
lines [5] and are divided into naturally occurring nTreg generated
from T-cell precursors in the thymus and induced iTreg, which
form in the periphery by conversion of effector T-cells or by
appropriate de novo activation of naı¨ve T-cells [6]. Tregs can also be
viewed based on their expression of the specific transcription factor
FoxP3 as either FoxP3+ or FoxP32 Tregs [7,8].
Master regulators and functional capacities of established T-cell
lineages are well understood [9] and very recently also the
differences in signaling of established Treg in response to TCR
triggers have being elucidated in great detail [10]. However, much
less is known about initial signaling events that lead to the
generation of defined cell lineages. This is despite the fact that
differentiation starts from a specific TCR trigger on naı¨ve T-cells
as common signal and only differs in ‘‘environmental conditions’’
such as the type of cytokines present or the APC present during
triggering. Thus, next to TCR signaling the impact of environ-
mental factors should trigger additional distinct events that can
modulate the overall outcome of the effector function. In a way
analogous to the identification of master regulators in stably
established lineages [11] it should therefore be possible to identify
the earliest signaling events differing in TCR-triggered T-cells on
their way to specific lineages by investigating signaling pathways
downstream of the TCR under distinct inducing conditions.
Environmental conditions transforming naı¨ve T-cells into specific
lineages in vitro are well known. Next to TCR-triggering they
require specific lineage inducing cytokines [11]. In vitro conditions
for iTreg induction typically involve TGFb [12,13] and iTregs can
be induced in vivo from naı¨ve T-cells by targeting cognate antigens
to immature dendritic cells (DC) [14,15].
We previously demonstrated the induction of CD4+ CD25+
Foxp3- Treg cells from TCR-transgenic T-cells in vitro without
lineage-modifying cytokines using TCR-triggers by weak antigen
presenting cells (i.e. non-professional APCs with low levels of
costimulation such as naı¨ve B-cells [16]). This approach allowed
the transformation of naı¨ve T-cells within 3 days of co-culture into
FoxP32 iTregs that potently inhibited transplanted heart rejection
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in vivo. In contrast, when using mature DC as APC the cells
developed into Th2-type effector cells (Teff) [16,17]. In this model
iTregs demonstrated proliferation and expression of the activation
markers CD25/CD69, yet in contrast to Teff retained high surface
levels of CD62-L [16]. Since these distinct phenotypes developed
from a population of naı¨ve T-cells within 72 hours of co-
incubation, we reasoned that this model would allow studying the
immediate signaling events leading to the generation of either Teff
or iTreg.
We report here that naı¨ve T-cells on their way to iTregs display
remarkably similar signaling mechanisms compared to T-cells on
their way to Teffs. However, after an initial CD62-L loss similarly
to Teff, iTreg start re-expressing CD62-L 24 hours after onset of
TCR-triggering. Low co-stimulatory levels from weak APC
resulted in defective activation of the phosphatidyl-inositol-3-
kinase (PI3K) pathway inducing a transiently lower activity of Akt
accompanied with increased expression of the Akt-hydrophobic
motif-specific phosphatase PHLPP1 in iTregs. The regulatory
phenotype could be overridden by external CD28 stimulation.
Importantly, later PI3K signaling in iTreg reached again effectivity
levels of Teff. Thus, transiently reduced PI3K activity in the first 24
hours of TCR triggering appears to be decisive in the lineage
decision of iTregs in this model.
Results
Transient Downregulation of CD62-L is Mediated by
TACE
iTregs generated by antigen specific activation of naı¨ve T-cells
through naı¨ve B-cells (TofB) were identified by high expression of
CD62-L despite proliferation and expression of the activation
markers CD25 and CD69 [16]. This was in contrast to Teffs
generated from activating naı¨ve T-cells by DC (TofDC) that
showed permanent downregulation of CD62-L and effector
functions of conventionally activated T-cells [16]. This system
provided a model for investigating the molecular mechanisms
driving T-cell differentiation from naı¨ve T-cells as common
starting point.
To clarify when loss of CD62-L on T-cells started relative to the
onset of APC contact we observed the levels of surface CD62-L on
T-cells following co-incubation with naı¨ve B-cells or DC.
Interestingly, under both conditions we observed initial CD62-L
shedding that was more extensive in TofDC at 6 hours after
contact formation but reached almost the same level in TofDC
and TofB after 12 hours (Figure 1A). However starting at 24 hours
after contact formation, TofB re-expressed CD62-L, and at 72
hours the number of CD62-L expressing cells was undistinguish-
able from naı¨ve T-cells cultured alone. In contrast, CD62-L in
TofDC was lost from most T-cells at 12–72 hours of observation
(Figure 1A). It is pertinent to note that based on gating strategy
and morphological analysis, we can exclude differential apoptosis
kinetics as driving this difference in CD62-L kinetics (data not
shown). Thus, CD62-L shows distinct kinetics in T-cells develop-
ing into iTreg or Teff cells.
CD62-L shedding marks T-cell activation and is mediated by
the matrix metalloprotease TACE on the cell surface [18]. To
clarify if TACE was involved in early CD62-L loss here, we
blocked TACE with the specific inhibitor TAPI-2. Indeed TAPI-2
significantly reduced CD62-L shedding in TofB and TofDC at 6
and 24 hours of co-incubation but importantly not at 72 hours
(Figure 1B–C).
TACE activity is linked to TCR triggering by the signaling
effector MEK, which in turn activates the kinase Erk. Erk
phosphorylates the inactive endoplasmatic TACE leading to its
extracellular expression [19,20]. To test, whether Erk was also
involved in CD62-L shedding here we inhibited MEK using
PD184352. Confirming an important role of TACE in the early
but not late loss of CD62-L we observed that MEK-inhibition
induced a significant block of CD62-L shedding during the
‘‘shedding phases’’ at 6 and 24 hours of T-APC co-incubation
(Figure 1 D–E). Taken together, CD62-L shedding in the first 6–
24 hours of T-cell activation is a TACE mediated pERK driven
event requiring antigen specific activation but being independent
of the APC strength.
Sustained Downregulation of CD62-L Mediated by PI3K
and mTOR
The observation that TACE drives only the initial regulation of
CD62-L required to identify pathways responsible for the long-
term regulation of CD62-L in TofB and TofDC. The PI3K/
mTOR pathway is involved in regulating CD62-L following TCR
triggering by sequestration of the transcription factor Foxo1 from
the nucleus. This leads to decreased expression of the transcription
factor KLF2 which binds the promoter of CD62-L [10,21,22].
Having seen the different long-term expression of CD62-L in TofB
and TofDC we hypothesized that differences in PI3K/mTOR
signaling might provide a mechanism for this dichotomy. We thus
investigated the involvement of both pathways on protein and
mRNA levels of CD62-L and KLF-2.
The addition of the PI3K inhibitor Ly294002 (10 mM) to both
co-culture systems had no effect on early CD62-L regulation.
However, at 24 hours CD62-L surface expression was significantly
increased in TofB and TofDC. Importantly, at 72 hours, PI3K
inhibition significantly increased CD62-L in TofDC but not in
TofB (Figure 2 A–B). The addition of the mTOR inhibitor
Rapamycin (100 nM) partially mirrored the effects of PI3K
inhibition in TofDC, but not in TofB. We saw no significant effect
of Rapamycin on CD62-L surface expression at any time in TofB
while in TofDC the inhibitor significantly increased the expression
at 24 and 72 hours, albeit to a lower extent as the PI3K-inhibitor
(Figure 2 C–D). The effects of Rapamycin and LY2924002 were
titratable but both inhibitors showed toxic effects when used at
supra-effective doses during long-term exposure (Figure S1A and
Figure S1B).
Re-expression of CD62-L is dependent on protein neo synthesis
[22]. Consequently we measured significantly higher levels of
mRNA for both, CD62-L (Figure 2E) and KLF-2 (Figure 2F) in
TofB as opposed to TofDC by qPCR. Already detectable as a
trend at 24 hours, it was more pronounced at 72 hours. The
inhibition of PI3K (Figure 2G) or mTOR (Figure 2H) also led to a
pronounced increase of mRNA for CD62-L and KLF-2 in both
TofB and TofDC at 24 hours after initiation of activation.
Collectively this suggests that the induction of TofB and TofDC
is similar at the level of initial CD62-L shedding but shows
differences with respect to PI3K/mTOR signaling culminating in
high versus low levels of CD62-L at later time points.
T-cells Triggered by iDC Replicate CD62-L Expression and
Regulatory Behavior of TofB
While naı¨ve B-cells are able to activate naı¨ve T-cells in culture,
it is unlikely that this happens in lymph nodes in vivo. Here, B-cells
are localized in follicles and the majority of naı¨ve T-cells localize in
T-cell zones enriched in DC [23]. While DC are the most efficient
APC under inflammatory conditions, their lack leads to autoim-
munity rather than immune suppression [24]. Thus, without
inflammation DC serve as gate keepers of self tolerance [14,25].
Here DC reside in a resting or immature state in the middle of T-
Signalling in Developing Tregs
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cell zones maintaining self tolerance by the generation of iTregs
[26] in vivo. Thus, immature DC (iDC) should be a more
physiological weak APC to investigate the plasticity of T-cell
responses in our model.
Therefore we generated iDC by culturing non-adherent bone
marrow cells in the presence of GM-CSF alone as described [27].
iDC in comparison to DC expressed comparable levels of MHC II
but far lower levels of CD11c and the co-stimulatory molecules
CD80 and CD86 (Figure S2).
Next we measured CD62-L expression in T-cells primed by
iDC (TofiDC). Remarkably we found a transient downregulation
and re-expression of CD62-L in TofiDC in a fashion almost
identical to that seen with TofB. Furthermore, TofiDC always
showed a higher expression of CD62-L as compared to TofDC
(Figure 3A–B). Thus it was important to test whether TofiDC
would also functionally equal TofB. We therefore decided to test,
whether TofiDC were functionally Tregs. In vitro inhibitory tests
indeed confirmed that TofiDC possessed regulatory activity of the
same potency as TofB (Figure 3C–D). In addition, the character-
ization of TofiDC showed them to be Foxp3 negative just as TofB
(data not shown).
The analysis of the PI3K/mTOR pathway had suggested that
an incomplete triggering of this mechanism mediated the inability
to permanently downregulate CD62-L in TofB and TofDC. We
therefore asked, whether the blockade of this pathway would also
functionally change the activity of TofDC. Thus we generated
TofDC in the presence of Ly294002 and Rapamycin. When tested
in in vitro inhibitory assays, indeed PI3K inhibited cells
(TofDC+Ly) presented with a regulatory capacity equal to TofiDC
and TofB (Figure 3 C–D). Interestingly, the blockade of mTOR
Figure 1. Downregulation of CD62-L is mediated by TACE. Naı¨ve antigen specific T-cells were either left untreated (T naı¨ve) or stimulated with
either naı¨ve B-cells (TofB) or activated dendritic cells (TofDC), both loaded with a cognate peptide of chicken ovalbumin, for different periods of time
and in the absence or presence of inhibitors. Subsequently the number of cells expressing CD62-L was measured by flow cytometry. (A) one
representative Kinetic of CD62-L expression on naı¨ve and differentially activated T-cells over a 72 hour incubation time (representative experiment of
5) (B) Kinetics of CD62-L expression in the presence of the TACE sheddase inhibitor, TAPI-2. (C) The inhibition of TACE shows a significant interference
with CD62-L shedding up to 24 hours after the initiation of T-cell priming. (D) Kinetics of CD62-L expression in the presence of the MEK-inhibitor
PD184352 (E) Inhibition of MEK blocks CD62-L shedding in the first 24 hours of T-cell activation while the long term regulation of CD62-L expression is
independent of MEK-TACE driven regulation. (C) and (E) show mean values+SEM of three independent experiments.
doi:10.1371/journal.pone.0068378.g001
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could not significantly induce a regulatory phenotype in TofDC
(Figure 3C–D) despite its pronounced effect on CD62-L expres-
sion. Thus, incomplete PI3K- but not mTOR-activation was
responsible for the induction of iTregs in this system.
Sub-optimal Co-stimulation Induces Regulatory Function
but does not Influence CD62-L
Naı¨ve B-cells and iDC both lack costimulatory molecules,
especially CD80 and CD86 (Figure S2 and [16]). These molecules
Figure 2. Sustained downregulation of CD62-L is mediated by PI3K and mTOR signaling. For FACS analysis, cells were treated and
analyzed as described in Figure 1, while for qPCR analysis T-cells were recovered/enriched from co-cultures by MACS depletion. (A) Kinetics of CD62-L
expression in the presence of the PI3K inhibitor, LY294002. (B) LY294002 has no effect on CD62-L loss in the first 6 hours after onset of T-cell
activation but induces significant upregulation of CD62-L at later time points. (C) Kinetics of CD62-L expression in the presence of the mTOR inhibitor,
Rapamycin. (D) Rapamycin has no effect on CD62-L loss in the first 6 hours after onset of T-cell activation but induces upregulation of CD62-L at later
time points. (E) qPCR analysis of CD62-L mRNA expression level in TofB and TofDC at 24 and 72 hours. (F) qPCR analysis of KLF2 mRNA expression
levels in TofB and TofDC at 24 and 72 hours. (G) qPCR analysis of CD62-L mRNA induction in both TofB and TofDC by Rapamycin and a detectable yet
non-significant induction of KLF2 mRNA. (H) qPCR analysis of CD62-L and KLF2 mRNA induction in TofB and TofDC in the presence or absence of
Ly294002. Data in B and D-H are means+SEM of 3–5 independent experiments.
doi:10.1371/journal.pone.0068378.g002
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Figure 3. T-cells triggered by immature DC replicate CD62-L expression signature and regulatory behavior of TofB. Naı¨ve antigen
specific T-cells were treated as described in Figure 1 except for priming with immature DC (TofiDC), which was additionally run in a separate culture.
For in vitro inhibitory assays, naı¨ve T-cells were stained with CFSE and incubated alone or in the presence of mature dendritic cells loaded with
cognate peptide. To the same type of culture we also added various types of CFSE-negative activated T-cells for modulation of T-cell proliferation.
The proliferation of the naı¨ve T-cells was measured by CFSE-dilution after 72 hours of co-incubation (A) Kinetics of CD62-L dynamics in TofiDC with
respect to the TofB and TofDC (B) CD62-L levels in naive T-cells primed with iDC, B-cells or mature DC. (C) Regulatory capacity of the various activated
T-cells (representative experiment). (D) Statistical analysis shows that TofB, TofDCLy and TofiDC induce significant inhibition of naive T-cell
proliferation relative to TofDC while TofDCRapa induce no significant inhibition. Data are means+SEM of 4–5 experiments.
doi:10.1371/journal.pone.0068378.g003
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are triggers for CD28 on T-cells which in turn is a prominent
activator of the PI3K pathway [28]. The lack of costimulation
might thus underly the inability of naı¨ve B-cells or iDC to induce
effector T-cells.
To study this we generated TofB, TofDC and TofiDC in the
absence or presence of artificial CD28-signals provided by soluble
antibodies. In an in vitro test for T-cell activation we observed that
TofB and TofiDC generated in the presence of CD28 antibodies
showed significantly less inhibition of T-cell proliferation as
compared to TofB or TofiDC generated without additional co-
stimulation (Figure 4 A–B). TofDC generated with additional
CD28 triggering had the same effect on T-cell proliferation as the
regular TofDC indicating the level of stimulation in DC could not
be further augmented by the addition of CD28. However, opposed
to the fundamental change in functional activity induced by CD28
co-ligation we only observed a mild effect of this treatment on
CD62-L loss at 6 hours in TofB while at later time points CD62-L
expression returned to its high levels seen before with naı¨ve B-cells
or iDC (Figure 4 C).
Together these results suggest that defective CD28 co-stimula-
tion plays a key role in the induction of regulatory function in
naı¨ve T-cells but has no discernible influence on CD62-L
dynamics.
Defective Akt Signaling Following T-cell Triggering by
Weak APCs
Analysis so far had suggested suboptimal PI3K/mTOR
signaling as basis for the induction of iTregs by weak APC.
However, TofB and TofiDC were viable proliferating cells
expressing levels of CD25 equivalent to TofDC (not shown).
Proliferation of T-cells requires nutrient production. This is
dependent on a functional PI3K/mTOR pathway and mediated
by the downstream effector Akt [22]. Thus the question was how a
low activity of the PI3K/mTOR pathway would be consistent
with active cell proliferation.
Therefore we tested the activity of Akt via the phosphorylation
status of its activation loop at Thr308 and the hydrophobic motif
at Ser473. Differences at the phosphorylation of Ser473 can be
found in Tregs [10,29]. As expected, in all three T-cell types total
levels of Akt were mostly unchanged over the observation period
of 72 hours (Figure 5A and Figure S3). However, also Thr308-
phosphorylation was always identical in all cells (Figure 5B and
Figure S3). But we did detect defective phosphorylation of Ser473
in TofB and TofiDC compared to TofDC starting at 6 hours after
contact initiation and being highly significant at 24 hours
(Figure 5C/D). Both, the number pAkt Ser473-expressing cells
as well as their amount of pAkt Ser473 (by MFI) were lower in
TofB/TofiDC as compared to TofDC (Figure 5D). However, at
72 hours the reduced phosphorylation of Ser473 was mostly lost
again (Figure 5C and Figure S3B). Thus during generation, TofB
and TofiDC have a phase of reduced Akt-Ser473 phosphorylation
that is gradually abrogated again.
What mechanism could drive this phospho-site specific defect in
TofB and TofiDC? We measured the phosphatase PHLPP1 which
can induce regulatory properties in T-cells and is associated with
the defective phosphorylation of pAkt Ser473 [12]. Indeed,
PHLPP1 mRNA was significantly increased in TofB and TofiDC
as compared to TofDC. This was highly significant at 6 hours and
still maintained as a trend at 24 and 72 hours (Figure 5E). These
levels of PHLPP1 fit with the temporal downregulation of pAkt
Ser473. Collectively these data show that during the generation of
iTregs by weak APC there was an initial phase of weak PI3K/
mTOR induction leading to transiently defective Akt activity and
the re-expression of CD62-L coincided with this period of weak
Akt activity.
Discussion
By virtue of their unique activity as suppressors of all other T-
cell types Tregs occupy a special niche in adaptive immunity. There
are several studies exploring their biology ranging from their
development/induction to the mechanisms of action [30,31].
However, despite the extensive knowledge we have about these
issues of Treg biology there is a remarkable dearth of information
regarding early signaling events driving the induction of iTregs
from naı¨ve CD4 T-cells despite the central role of this mechanism
in adaptive immunity.
To bridge this gap, we present in this report a kinetic study
examining early signaling events that lead to the production of
CD4+ CD25+ Foxp3- iTregs from naı¨ve CD4 T-cells. Thereby we
took advantage of our previously reported model of naı¨ve CD4 T-
cell co-culture with naı¨ve B-cells as APC [16]. In addition, we
incorporated a well-known second type of weak APC in our
system, immature DC, which also provides a physiologically
relevant means of T-cell activation in vivo. Furthermore we
performed experiments on 2 different strains of mice, with both
showing similar results and trends thus negating the possibility of
our observations been a strain specific effect.
We were surprised to find that the induction of Tregs in this
model was achieved via triggering of remarkably similar pathways
as that of Teffs. We only found a transiently reduced activity of the
PI3K/Akt pathway between 6–24 hours post-activation as a
characteristic sign for the induction of a Treg phenotype. This was
accomplished by the transient induction of PHLPP1, an Akt
hydrophobic motif-specific phosphatase, selectively in Tregs. It is
very interesting to see that a recent report found very similar
defects in signaling (namely low Akt473 phosphorylation) in fully
established FoxP3-expressing Tregs [10]. Thus, the signaling
defect seen in Tregs might also be the same initial defect that leads
to Treg induction from naı¨ve T-cells.
The role of the PI3K pathway in Treg development is presently
controversial as there are reports that PI3K activation inhibits Treg
development [32] while others claim the opposite [33]. Our data
indicate that PI3K activation is necessary for and compatible with
iTreg development but only when being attenuated at the
beginning of the T-cell stimulation. In our model, this is achieved
by weak APCs such as naı¨ve B-cells and immature DC via their
characteristically low co-stimulatory input derived from sub-
optimal surface levels of co-stimulatory molecules. Interestingly,
while not a downstream effector molecule of the TCR complex,
CD28 co-stimulation is known to be vitally involved in producing
robust PI3K activation [34,35]. Adding CD28 to the weak APC-
T-cell co-culture led to the restoration of the effector phenotype
and abrogation of regulatory function. This shows that a low
degree of CD28 signaling at the onset of TCR triggering can lead
to a signal sufficiently high to drive T-cell activation and
differentiation but favoring the development of a regulatory
phenotype, a conclusion also reached by others [36]. As PI3K
activity reached levels similar to those in Teffs at timepoints later
than 24 hours, early signaling events up to 24 hours after the initial
TCR trigger appear to occur in a window of sensitivity in a T-cell,
where the activity of the PI3K pathway is decisive in determining
the later effector phenotype.
A characteristic peculiarity of iTreg in our model was the high
expression of CD62-L despite effective activation and proliferation
of the cells. We found that CD62-L in iTreg followed a pattern of
initial TACE-mediated loss, as in Teff. Then, however, the cellular
Signalling in Developing Tregs
PLOS ONE | www.plosone.org 6 July 2013 | Volume 8 | Issue 7 | e68378
Figure 4. Sub-optimal co-stimulation drives acquisition of regulatory function but exerts negligible influence on CD62-L dynamics.
Co-stimulation was augmented by the addition of CD28 antibodies to cultures during the generation of TofB, TofiDC or TofDC for their use in
downstream studies. The obtained activated cells were then tested for their inhibitory capacity against naı¨ve T-cells. (A) Representative FACS analysis
of in vitro proliferation assays of CFSE stained naı¨ve T-cells in the presence of various activated T-cells showing that the addition of CD28 antibodies
during the generation of TofB and TofiDC strongly reduces their regulatory capacity. (B) Statistical analysis of the effect of increased co-stimulation on
the regulatory capacity of TofB and TofiDC. (C) CD62-L expression levels in T-cells generated with or without additional CD28 antibodies. Data are
means+SEM of 3–4 experiments.
doi:10.1371/journal.pone.0068378.g004
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development deviated and iTreg re-expressed CD62-L while Teff
maintained low levels of the molecule. Again we observed that
CD62-L re-expression coincided with the timing of defective
PI3K/Akt activity. Attenuation of PI3K signaling during Treg
differentiation/development has been put forward by Okkenhaug
and coworkers as allowing for the nuclear return and subsequent
binding of the transcription factor Foxo on the promoter region of
the Foxp3 locus in the nucleus [33]. We extend this position by
suggesting that Foxo on return possibly also binds onto the
promoter for KLF2 thereby leading to increased CD62-L
transcription and its re-expression in the iTreg but not the Teff in
our model. The latter showed consistently high PI3K activity. It
was possible that CD62L was additionally modulated by the
selective presence of microRNAs as recently reported [37].
However, we could not confirm a role for the miRNA let7-b in
inducing CD62-L re-expression as we found it to be equally
downregulated in both TofB and TofDC (unpublished data). Also
of interest was the observation that both Tregs in our model were
Foxp32. While we previously showed that the TofB developed
independent of IL-10 presence in B cells, the Roncarolo group
have shown that immature DCs produce Foxp32 CD25low Tr1
Figure 5. Phospho-site specific defective Akt signaling observed following T-cell triggering by weak APCs. Cells were treated as
described in Figure 3 including priming with immature DC (TofiDC) and intracellular FACS staining of total Akt and phopho-forms was performed at
indicated time points. For qPCR analysis, T cells were recovered/enriched from co-cultures by MACS depletion. (A) Time course of the number of cells
expressing total Akt. (B) Time course of the number of cells expressing pAkt Thr308. (C) Time course of the number of cells expressing pAkt Ser473.
(D) One representative FACS blot showing reduced pAkt Ser473 activation in TofB and TofiDC at 24 hours. Numbers in quadrants denominate the
percentage of cells. The dashed region indicates the pSer473 positive fraction analyzed for its MFI value (fat number on the right of the dashed
region). (E) qPCR readout of PHLPP1 levels in TofB and TofiDC compared to TofDC. Data are means+SEM of 3–4 experiments. Data in D are
representative of 4 independent experiments.
doi:10.1371/journal.pone.0068378.g005
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like Tregs under allogeneic sub-optimal T cell activation conditions
under the influence of IL-10 [38].
Having observed the re-expression of CD62-L on the iTregs in
our model we asked whether the re-expression of CD62-L was
always associated with the acquisition of regulatory function. This
question is pertinent as there are several studies linking the CD62-
L transcription factor Foxo with Treg induction [39–42] or
function [10]. However, CD62-L aside its requirement for homing
to lymph nodes has also been related with the acquisition and
maintenance of memory in central memory T-cells [43,44] as well
as with the development of effector function such as lytic activity in
human tumor-infiltrating T lymphocytes [45]. Our data indeed
showed independence of the development of lymphatic homing
capacity and regulatory activity since Ly294002-treated Teff with
high CD62-L did show regulatory properties when tested
functionally while Rapamycin-treated TofDC with high CD62-L
showed no inhibitory function. Furthermore, our data also show
that increased co-stimulation via CD28 has no discernible effect
on CD62-L regulation while at same time inducing a complete loss
of regulatory function.
Together these data suggest a compartmentalization in the
signaling pathways controlling the acquisition of regulatory activity
and homing. Obviously, only PI3K but not mTOR inhibition is
able to upregulate CD62-L together with the acquisition of a
regulatory phenotype in naı¨ve T-cells. This unexpected finding is
interesting given that administration of the mTOR-inhibiting drug
Rapamycin is an established means of inducing Treg expansion
from CD4+ CD25+ cells [46]. Furthermore, Rapamycin was
reported to induce Tregs from naı¨ve T-cells [47]. In said study
however, naı¨ve CD4+ T-cells were co-cultured with B-cells as APC
in the presence of Rapamycin. Based on similarities with our
study, it is tempting to speculate that the resultant regulatory
behavior might have been conferred by the presence of the B-cell,
as in our system. However, even in the absence of B-cells, naı¨ve T-
cells triggered with CD3 antibodies in the presence of Rapamycin
or Ly294002 do acquire a Treg phenotype [48]. This disparity in
results might be indicative that antigen specific activation by weak
APC can trigger more delicate pathways of T-cell activation as
opposed to the very strong stimulus coming from polyclonal CD3
crosslinking. The nature of these triggers has, however, remains
elusive so far.
In summary, we present data showing that remarkably similar
signaling pathways drive the generation of iTregs and Teff from
naı¨ve T-cells and iTreg inducing signaling features are again very
similar to those active in established Treg [10]. The key difference
between the induction of a Treg and a Teff phenotype appears to be
signaling thresholds combined with carefully timed signal intensity
modulation in the PI3K/Akt pathway. At the same time separate
mechanisms exist, that control the expression of specific homing
markers. A better understanding of these mechanisms might help
to provide means for a selective generation and tissue specific
recruitment of T-cell effector phenotypes in the future.
Materials and Methods
Ethics
All cells used in this study were isolated from organs of mice.
Before organ harvest the mice were sacrificed painlessly by deep
narcosis followed by cervical dislocation according to institutional
guidelines and no invasive procedures were carried out using live
animals. According to the German Tierschutzgesetz (TSchG) the
use of animal tissue following painless sacrifice and without any
further treatment of live animals is not considered an animal
experiment and therefore does not require ethical approval.
However, the animal welfare officer of both institutions, where
the experiments were performed, was informed and had to collect
information on the number of animals used for tissue donation. This
information was forwarded to the local authorities (Landesverwal-
tungsamt Sachsen-Anhalt and LANUV, Nordrhein Westfalen).
Mice
DO11.10 [49] and OT-II mice [50] with transgenic TCRs
recognising a peptide of chicken-ovalbumin (pOVA AA323–339)
were used for T-Cells while B-cells and bone marrow DCs (DCs)
were obtained from C57BL/6 and BALB/c mice. Animals were
housed and bred in an animal facility of the Otto-von Guericke
University and the University Duisburg-Essen, Germany, under
SPF-conditions and treated according to institutional guidelines.
Cell Preparation
Naive CD4+ T-cells from spleens of DO11.10 or OT-II mice,
splenic B-cells BALB/c or C57BL/6 and mature bone marrow
derived DC were all generated as previously described [16] while
immature DC (iDC) were generated using the same technique as
DC but with absence of IL-4 as described [51]. All cells were
cultured at 37uC with 5% CO2.
T-cell Activation Assays
Naı¨ve T-cells were co-cultured with OVA-peptide loaded LPS
stimulated DC, iDC or naive B-cells at a ratio of 10:1/10:1 or 1:1,
respectively. The cell culture medium was RPMI-based and
supplemented with 10% fetal calf serum (Gibco, Los Angeles,
USA). After 72 hours co-cultures underwent immunomagnetic
depletion of non-CD4 cells using the MACS system as described
[16]. B-cell (TofB), iDC (TofiDC) or DC (TofDC)–primed T-cells
(with or without pharmacological modulators) were extensively
washed with PBS after immunomagnetic recovery to deplete any
inhibitors and assayed to test their inhibitory capacity on naı¨ve T-
cells primed with pOVA loaded DCs (10:1) at a ratio of 1:1 (T
primed: T naı¨ve). To measure T-cell proliferation, naı¨ve DO11.10
or OT-II T-cells were stained with 5,6-carboxyfluorescein-
diacetate-succinimidyl-ester (CFSE, 0.5 mM; Molecular Probes,
Leiden, Netherlands). Readouts for proliferation or activation
markers were taken at indicated timepoints. T-cell activation was
modulated pharmacologically using TAPI-2 (Calbiochem, Darm-
stadt, Germany, 100 mM), Ly294002 (Promega, Mannheim,
Germany, 10 mM), PD184352 (Selleck Chemicals, Munich,
Germany, 2 mM) [22] and Rapamycin (Calbiochem, 100 nM)
[52]. Anti-CD28 (Beckton Dickinson, Heidelberg, Germany)
mediated co-stimulation was provided at 10 mg/ml.
Flow Cytometry
For surface staining, all antibodies were purchased from BD
except for CD11c (Caltag, Burlingame, USA), MHCII
(eBioscience, Frankfurt, Germany) and CD80/86 (Abcam, Cam-
bridge, UK). For intracellular staining, FITC conjugated pan Akt,
pAkt Thr308 and pAkt Ser473 with isotype controls were from
Cell Signalling Technology (Frankfurt, Germany) and used with
the BD cytoperm/cytofix with GolgiPlug kit. Events were acquired
on a BD FACSCaliburTM and LSRFortessaTM.
Real-Time PCR
T-cells co-incubated with B-cells, iDC or DC were recovered
via the MACS system to an average purity of 88%. Total RNA
was isolated and cDNA synthesized using the RNeasy kit and the
Quantitect Reverse-Transcriptase-kit (Qiagen, Cologne, Ger-
many). Primers were reagent kits from Qiagen. Real-time PCR
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was performed on either the Qiagen RotorGene or ABI prism
7000, using the QuantiTect SYBR Green PCR Kit (Qiagen) or
the Maxima SYBR Green/ROX qPCR Master Mix (26) kit
(Fermentas, St. Leon-Rot, Germany) in duplicates. Ct values were
averaged and normalized against Ct values of b-Actin. Results
were derived using the comparative Ct method (DDCt).
Statistical Analysis
Statistical significance was evaluated with student’s t-test using
GraphPad Prizm 5 (GraphPad Software, San Diego, CA, USA). P-
values ,0.05 were considered significant. Data were expressed as
means +/2 SEMwith 3 ormore independent experiments performed.
Supporting Information
Figure S1 Effect of inhibitor Titration on CD62-L levels.
Naı¨ve antigen specific T-cells were stimulated with either naı¨ve B-
cells (TofB) or activated dendritic cells (TofDC), both loaded with
a cognate peptide of chicken ovalbumin, for different periods of
time and in the absence or presence of inhibitors. Subsequently,
CD62-L expression levels on T cells were measured by flow cyto-
metry. (A) One representative FACS blot showing the dose
dependent regulation of CD62-L in T cells by the PI3K inhibitor
LY294002. (B) One representative FACS blot showing the dose
dependent regulation of CD62-L in T cells by the mTOR inhibitor
Rapamycin. Data are representative of 3 independent experiments.
(PDF)
Figure S2 Characterization of Immature DCs against
mature DCs. Immature DC were characterized with respect to
expression levels of relevant lineage and stimulatory marker
molecules.(A) Representative FACS histogram showing expression
levels of the indicated surface molecules. Dashed lines represent
isotypes and solid lines indicate expression level of quantified
molecules (B) Comparison of % surface expression of MHC II,
CD11c, CD80 and CD86 between both cell phenotypes. (C) On a
per cell basis, DC express more CD11c than immature DC while
both cells possess equal amounts of MHC II. (D) On a per cell
basis, DC express more co-stimulatory molecules than immature
DC. Data are means+SEM of 2 experiments.
(TIF)
Figure S3 Akt signaling profile at 6 and 72 hours. Cells
were treated as described in Figure 5. (A) Representative FACS
blots showing Akt/pAkt levels in TofB, TofiDC and TofDC at 6 h
(B) Representative FACS blots showing Akt/pAkt levels in TofB,
TofiDC and TofDC at 72 hours.
(TIF)
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Implantation of the fertilized egg into the maternal uterus depends on the fine balance
between inflammatory and anti-inflammatory processes. Whilst regulatory T cells (Tregs)
are reportedly involved in protection of allogeneic fetuses against rejection by the maternal
immune system, their role for pregnancy to establish, e.g., blastocyst implantation, is not
clear. By using 2-photon imaging we show that Foxp3+ cells accumulated in the mouse
uterus during the receptive phase of the estrus cycle. Seminal fluid further fostered Treg
expansion. Depletion of Tregs in two Foxp3.DTR-based models prior to pairing drastically
impaired implantation and resulted in infiltration of activated T effector cells as well as in
uterine inflammation and fibrosis in both allogeneic and syngeneic mating combinations.
Genetic deletion of the homing receptor CCR7 interfered with accumulation of Tregs in
the uterus and implantation indicating that homing of Tregs to the uterus was mediated
by CCR7. Our results demonstrate that Tregs play a critical role in embryo implantation by
preventing the development of a hostile uterine microenvironment.
Keywords: regulatoryT cells, implantation, pregnancy, fibrosis, inflammation
INTRODUCTION
Normal pregnancy is a physiological state during which dis-
tinct processes take place at different stages. Pregnancy begins
with the fertilization of the ovum, followed by implantation of
the blastocyst in the maternal uterus. To implant, the blastocyst
needs to adhere to the endometrium so that it can be pro-
vided with oxygen and nutrients. For these changes to occur
tissue remodeling and inflammatory processes in the uterus are
required. It has been observed that ablation of immunoregula-
tory molecules such as transforming growth factor beta (TGF-β)
or heme oxygenase-1 (Hmox1) negatively interferes with implan-
tation (McLennan and Koishi, 2004; Zenclussen et al., 2011).
Thus, a balance between pro- and anti-inflammatory mole-
cules is assumed to support successful implantation. Cells of
the innate immune system present in the uterus are known to
be critical for implantation. For example, uterine natural killer
cells (uNK cells) produce IFN-γ, which contributes to the ini-
tiation of vascular modification and decidual integrity (Ashkar
et al., 2000). Macrophages present in the uterus secrete IL-1,
which is reportedly involved in implantation (Houser et al.,
2011). Ablation of uterine dendritic cells (DC) causes implan-
tation failure due to perturbed angiogenesis (Plaks et al., 2008)
while the absence of uterine mast cells (MCs) leads to defec-
tive implantation and spiral artery remodeling (Woidacki et al.,
2013).
Once implantation is established, a period of maintenance
follows, during which the maternal immune system actively
tolerates the foreign paternal antigens expressed by the fetus
(Tafuri et al., 1995) while being fully active against potential infec-
tions. Maternal CD4+CD25+ regulatory T cells (Tregs) have been
reported to contribute to the maintenance of tolerance during
pregnancyby suppressingmaternal alloreactive immune responses
against paternal structures in fetal cells (Zenclussen et al., 2005;
Shima et al., 2010; Rowe et al., 2012; Samstein et al., 2012). It
has been speculated the Tregs also participate at initial stages of
pregnancy, e.g., implantation (Zenclussen et al., 2005; Schumacher
et al., 2007), at which inflammatory processes and innate cell pop-
ulations play an important role. However, conclusive experimental
proof that Tregs are important for implantation was missing.
The present study addresses this question and by using specific
models shows that Foxp3+ Tregs are needed for successful implan-
tation because they prevent the development of a hostile uterine
microenvironment. In their absence, inflammation and fibrosis
occur, both negatively interfering with embryo implantation.
MATERIALS AND METHODS
STUDY APPROVAL
All studies were conducted according to governmental and
institutional regulations (AZ 42502-2-868, Magdeburg; AZ 35-
9185.81/G-98/08, Heidelberg; AO 10/2010, Oeiras).
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MICE AND TREG DEPLETION
Foxp3DTR (Kim et al., 2007) and Foxp3GFP knock-in mice
(Fontenot et al., 2005) were kindly provided by Alexander
Rudensky (Washington, DC, USA) and Jocelyne Demengeot
(Oeiras, Portugal) and bred in our facilities. CCR7−/− mice
were purchased from Jackson Laboratories; C57BL/6 and BALB/c
(intact, vasectomized, and seminal vesicle-deficient) mice from
Charles River, Germany. BAC transgenic Foxp3.LuciDTR-4 mice
(Suffner et al., 2010) were generated and maintained at the DKFZ,
Heidelberg. Mated females were checked daily for vaginal plugs;
its appearance indicates day 0 of pregnancy. Females were mated
and checked daily for vaginal plugs, its appearance indicates day
0.5 of pregnancy. Vaginal lavage was performed with 20µL of
0.9% sodium chloride. Cycle stage was defined after observation
of the cellular components under light microscopy (Axiovert C,
Carl Zeiss, Germany; magnification ×200), and was confirmed
by hematoxylin/Eosin. Treg depletion in Foxp3DTR mice was per-
formed by i.p. application of 15 ng/g body weight diphtheria toxin
(DT) every fourth day. In Foxp3Luci.DTR mice, DT was applied
daily beginning at day −2. Control mice received PBS or DT.
Implantations sites at day 5 of pregnancy were identified after
i.v. injection of 0.5% Chicago Blue dye.
2-PHOTON IN VIVO MICROSCOPY
Imagining of uterine Foxp3GFP cells during the estrus cycle was
performed as follows. Animals were anesthetized by i.p. injection
of ketamine and xylazine, 120 or 16µg/g of mouse weight, respec-
tively, and kept on a heating pad at 37°C. One of the uterine horns
was carefully exposed and 0.1M caffeine (Sigma-Aldrich, USA)
was applied to decrease uterine contractions. For maternal blood
visualization, animals were intravenously injected with 100µl of
Rhodamine B isothiocyanate-Dextran (RhoB-Dex) 70,000KDa
(Sigma-Aldrich, Inc.,USA) before acquiring images in amultipho-
ton laser scanningmicroscope (MPLSM).Weused aPrairieUltima
2-photonmicroscope (Prairie Technologies, Inc.). Themicroscope
was equipped with a Chameleon Ti:Sapphire laser (Coherent, Inc.,
USA), four top PMTs for simultaneous up to four channel acquisi-
tions and a 20×water immersion objective (Olympus, Inc., USA).
The laser was tuned to 880 nm to allow for concomitant exci-
tation of RhoB-Dex and GFP+-Treg. The wavelength emission
for RhoB-Dex and GFP is 590 and 509 nm, respectively. Sequen-
tial images were acquired for observation of Treg in the uterus.
For analysis of uterine Treg images, we have developed our own
software algorithms based on endogenous tissue markers infor-
mation (e.g., location of blood vessels) from consecutive z-stacks
acquisitions for stabilization of Treg movies. Once the images
were stabilized, we used Imaris software (Bitplane AG, Inc.) for
reconstruction of three-dimensionalmodels in order to determine
distribution in the uterus. For more detail, please see Zenclussen
et al. (2013).
FLOW CYTOMETRY
The following fluorescence-conjugated antibodies were purchased
from BD Biosciences or eBioscience: CD4 (RM-4 or RM4-5),
CD8 (53-6.7), Foxp3 (FJK-16s or NRRF-30), Ki67 (B56), CD44
(IM7), CD62L (Mel-14). Samples were processed as described
(Zenclussen et al., 2005; Woidacki et al., 2013), measured in a
FACSCalibur or FACSCanto II (BDBiosciences) and analyzedwith
CellQuest Pro software (BD Biosciences).
HISTOLOGY AND IMMUNOFLUORESCENCE
Analysis of uterine tissuewas performed after stainingwithHema-
toxylin/Eosin. The slides were dewaxed and left in Hematoxylin
(Fluka Biochemika, Germany) for 1–2min followed by rinse with
tap water and a further incubation in Eosin (Fluka Biochemika,
Germany) for 1–2min and finally dehydrated to xylol and cov-
ered. Fibrosis extent was evaluated by Masson’s trichrome and
Picrosirius red stainings. For the first, the dewaxed slides were
left in picrosirius red stain solution (Sigma) for 1 h and rinsed
in 10 dips of water before being dehydrated to xylol and cov-
ered. For Masson’s trichrome staining it was proceed as follows:
after dewaxing, the slides were placed in Bouin’s solution (Sigma)
overnight (ON) for mordating and washed in running tap water
before staining for 5min in working Weigert’s iron Hematoxylin
solution (Sigma). After washing in running tap water, the samples
were stained in Biebrich Scarlet-acid Fuchsin (Sigma) for 5min
and rinsed in distilled water. The slides were placed in Phospho-
molybdic/Phosphotungstic acid solution (Sigma) for 10min and
the solutionwas discarded and substituted by aniline blue solution
for five more min. Finally, the slides were placed in 1% acetic acid
solution for 3min and dehydrated to xylol before being covered.
Connective tissue growth factor (CtGF) in uterine tissue was
studied by immunofluorescence. For this, tissue sections were
dewaxed and blocked for 30min with 3% bovine serum albu-
min (BSA) in PBS at room temperature (RT). The slides were then
washed in PBS and incubated with anti-CTGF primary antibody
(Abcam ab6992) in 2% BSA at a dilution of 1:200 ON at 4°C. After
furtherwashing the slideswith PBS theywere incubatedwithAlexa
Fluor 488 goat anti-Rabbit IgG secondary antibody (Abcam) at a
dilution of 1:200 for 45min at RT. Sections were washed and the
slides were covered with Dapi Vecta Shield mounting medium.
IN VITRO PROLIFERATION
MACS-sorted Treg or effector T cells were stained with carboxy-
fluorescein diacetate succinimidyl ester (CFSE, Molecular Probes,
Leiden, Netherlands), cultured with rmIL-2 (R & D systems) and
treated with freshly prepared seminal vesicle fluid (SVF) from
BALB/c males. Anti-TGF-β1mAb was kindly provided by Hideo
Yagita (Juntendo University, Tokyo, Japan).
QUANTITATIVE REAL TIME PCR
mRNA was isolated using Trizol® and cDNA synthesis was done
using reverse transcriptase (Invitrogen,Karlsruhe,Germany). Real
time PCR was performed with the help of an iCycler (BIORAD,
Munich, Germany) using SYBR Green (Applied Biosystems, Ger-
many). Initial denaturation was done at 95°C for 5min followed
by a denaturation step of 40 cycles of 45 s at 95°C. Annealing step
followed at 59°C for 30 s 72°C for 30 s extension. The amount of
cDNA was standardized with the reference gene β-actin. Primers
are available upon request.
STATISTICAL ANALYSIS
Statistical analyses were performed with Prism software (Graph-
Pad). Normality in the distribution of the data was analyzed by
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the D’Agostino and Pearson omnibus normality test. Differences
in the percentage of CD4+Foxp3GFP+, CD8+ KI67+, CD44+, and
CD62L+ cells between groupswere analyzed byMann–Whitney-U
test. The in vitro experiments using cells cultured with SVF were
analyzed by two-way ANOVA test. Implantation numbers were
measured at day 5,data are expressed asmedians of%of implanted
females and analyzed by Fisher’s exact test. Levels of molecules
measured by qPCR [IL-15, CCR5, CCL19, CXCL3, IL-1b, gp130,
TNF-α, RORγτ, CCL5, CtGF, CXCL9, urokinase-type plasmino-
gen activator (uPA), prostaglandin F receptor (Ptgfr), IL-9, Gal-1,
leukemia inhibitory factor (LIF), p. 53] were analyzed by Mann–
Whitney-U test. Number of animals used for each experiment is
included in the Figure legends.
RESULTS
UTERINE Foxp3+ TREGS ACCUMULATE DURING THE FERTILE PHASE OF
THE CYCLE AT THE ANTIMESOMETRIAL REGION
First, we determined the frequencies of CD4+Foxp3+ Tregs in
samples from Foxp3gfp female animals at each stage of the estrus
cycle (diestrus, proestrus, estrus, metestrus, Figure 1A) by flow
cytometry (Figure 1B). We observed substantial fluctuation in
Treg frequency in the vaginal lavage, with Tregs peaking at the
receptive phase, namely estrus, and decreasing toward metestrus.
In vivo 2-photon microscopy in Foxp3gfp animals impressively
demonstrated a clustering of Tregs in uterine tissue during estrus
(Figure 1C; Movie S1 in Supplementary Material) that was not
observed during the other phases of the estrus cycle, e.g., diestrus
FIGURE 1 |Tregs fluctuate during estrus cycle peaking at estrus,
time point of sexual receptivity. Determination of the estrus cycle in
non-pregnant females according to cell types in vaginal smears (A).
Percentage of CD4+Foxp3GFP+ cells of female Foxp3GFP mice (n=5/cycle
stage) was analyzed in vaginal lavage (B). Data are expressed as single
dot plots with medians and were analyzed by Mann–Whitney-U test
(*P ≤0.05). Snap shots of two-photon microscopy videos of Foxp3GFP
positive cells in uterus performed at different phases of the cycle (C)
estrus phase; (D) diestrus phase; (E) metestrus phase; (F) proestrus
phase.
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[Figure 1D; metestrus (Figure 1E) or proestrus (Figure 1F);
Movies S2–S4 in Supplementary Material]. In agreement with
these findings, previous work has suggested oscillations in uterine
Foxp3 mRNA expression levels during the estrus cycle (Kallikour-
dis and Betz, 2007; Guerin et al., 2011). According to the 2-photon
studies, Tregs seem to accumulate preferentially in the perivascu-
lar space close to small blood vessels at the antimesometrial region
during estrus (Movie S1 in Supplementary Material).
SEMINAL FLUID FOSTERS THE EXPANSION OF UTERINE Foxp3+ TREGS
Next, we paired females with seminal vesicle-deficient, vasec-
tomized, or intact allogeneic males. When compared to virgin
mice, an expansion of Tregs was observed in the uterine drain-
ing lymph nodes from females paired with intact or vasectomized
males, whereas no expansion was found in females mated with
seminal vesicle-deficient males (Figure 2A). Hence, seminal fluid
has a proliferative effect on Tregs in vivo. These results could be
reproduced in vitro with CSFE-labeled CD4+CD25+ Tregs iso-
lated bymagnetic cell sorting,which were stimulated to proliferate
by addition of seminal fluid and this was partially inhibited by
addition of anti-TGF β (Figure 2B), whereas conventional T cells
were not affected (Figure 2C). Thus, the accumulation of Tregs at
sexual receptivity is followed by an expansion triggered by seminal
fluid, most likely by TGF-β contained herein.
FIGURE 2 |Tregs expand in vivo and in vitro in presence of seminal
fluid. Percentage of CD4+Foxp3+ cells in the uterine draining lymph
nodes of CBA/J females mated with seminal vesicle-deficient,
vasectomized, or intact BALB/c males was analyzed at day of conception
(day 0.5) and compared to virgin CBA/J females (n=4–7) (A). Statistical
analysis were performed by Mann–Whitney-U test (**P ≤0.01). (B)
Tregs were isolated from non-pregnant CBA/J females by magnetic cell
sorting, stained with CFSE and cultured with seminal vesicle fluid (SVF)
from BALB/c males. TGF-β1 was blocked with anti- TGF-β1 antibody, and
proliferation of Treg determined after 24 h by using FACScan Calibur. Data
are representative of four experiments and expressed as mean with
SEM. Analysis was performed by two-way ANOVA test (**P ≤0.01). (C)
Conventional T effector cells were isolated from non-pregnant CBA/J
females by magnetic cell sorting, stained with CFSE and cultured with
seminal vesicle fluid (SVF) from BALB/c males. TGF-β1 was blocked with
anti- TGF-β1 antibody, and proliferation of Treg determined after 24 h by
using FACScan Calibur. Data are representative of four experiments and
expressed as mean with SEM. Analysis was performed by two-way
ANOVA test and no statistically significant differences were found
among the groups.
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DEPLETION OF Foxp3+ TREGS PRIOR TO MATING RESULTED IN UTERINE
INFLAMMATION AND FIBROSIS THAT IMPAIRED IMPLANTATION
As Treg accumulation at receptivity suggested a role for embryo
implantation, we investigated the effect of CD4+Foxp3+ Treg
depletion on implantation by using two distinct strains of
Foxp3.DTR mice, namely Foxp3DTR knock-in mice (Fontenot
et al., 2005), and BAC-transgenic Foxp3.LuciDTR-4 mice (Suffner
et al., 2010). Upon application of DT, at least 90%of CD4+Foxp3+
Tregs were specifically depleted in both strains. Thus, for
Treg depletion Foxp3.DTR mice are superior to the frequently
used anti-CD25 antibodies, which deplete only about 70% of
CD4+Foxp3+ Treg, owing to limited expression of CD25 on
Foxp3+ T cells (Shima et al., 2010). Moreover, Foxp3 represents a
highly selective marker for Tregs, whereas CD25 is also expressed
on a fraction of other leukocytes (Shima et al., 2010). Treg deple-
tion was performed during various time intervals before mating,
namely from day 9 to 5 of pregnancy, and from day 2 to 5. To con-
firm the occurrence of implantations at day 5, Chicago Blue was
utilized (Figure 3A) Treg depletion beginning at day 9 in Foxp3DTR
mice provoked a failure of the embryos to implant, whereas
PBS- and DT-treated control mice displayed normal implanta-
tion (Figures 3B,C). When Foxp3.LuciDTR mice were used, syn-
geneic matings were included in order to elucidate whether the
mechanisms leading to implantation failure were dependent on
potentially present paternal alloantigens (Figure 3C). Treg abla-
tion from day 2 to 5 resulted in severely impaired implantation not
only in biologically relevant allogeneic pregnancies but also in syn-
geneic matings (Figure 3C). We speculated that at this early time
point Tregs may counteract pro-inflammatory events occurring
during implantation. Without Tregs, inflammation may be too
strong and hinder the nidation of the embryo. Indeed,we observed
that Treg depletion resulted in accumulation of CD8+ T cells in the
uterus (Figure 3D) and the presence of activated T cells in lymph
nodes draining the uterus, as indicated by the increased expression
of KI67, CD44, and down-regulation of CD62L in CD4+Foxp3−
effector cells (Figures 3E–G). Additionally, the uterine tissue was
inflamed and thickened after DT treatment. mRNA expression of
the inflammatory mediators IL-15, CCR5, CCL19, and CXCL3,
all inflammatory was upregulated (Figures 4A–D). Levels of IL-
1β, gp130, TNF-α, ROR-gamma-t, or CCL5 were not significantly
modified (Figures 5A–E). We also observed the appearance of
fibrosis in the uterus of mice depleted of Treg as indicated by ele-
vated levels of CtGF andCXCL9mRNA(Figures 6A,B), important
regulators of fibrosis (Gressner andGressner, 2008; Zeremski et al.,
2011). Fibrosiswas further confirmedhistologically inmice devoid
of Tregs bymeans of Hematoxylin-Eosin (Figure 6Cii), Picrosirius
(Figure 6Civ), and the Masson’s trichrome staining (Figure 6Cv)
as well as by means of CtGF immunofluorescence (Figure 6Cviii)
as compared to DT-treated control mice (Figures 6Ci,iii,v,vii).
The levels of uPA, known to positively influence tissue remodel-
ing and whose absence leads to infertility (Carmeliet et al., 1994),
were downregulated and almost undetectable in the absence of
Tregs (Figure 6D). It is of interest that Ptgfr was also upregulated
(Figure 6E) as prostaglandin is routinely given to provoke ther-
apeutic abortions (Wagner et al., 2011). No changes were found
in the levels of the immunosuppressive factors IL-9 and Gal-1
(Figures 7A,B). LIF and p53, known to define fertility (Hu et al.,
2007),were also notmodified after Treg depletion (Figures 7C,D).
Inflammation and fibrosis were only investigated in syngeneic
matings in order to investigate the effects of Treg depletion inde-
pendent of allogenicity. Together, the data indicate that depletion
of Tregs prior tomating leads to a hostile uterine environment that
is characterized by the occurrence of inflammation and fibrosis,
thereby interfering with implantation.
CCR7 MEDIATED THE HOMING OF TREG TO THE UTERUS AND ITS
GENETIC ABLATION IMPAIRED IMPLANTATION
The chemokine receptor CCR7 has been identified as a hom-
ing receptor on Tregs required for migration to lymph nodes
and spleen (Worbs and Förster, 2007). In order to explore a
role for CCR7 in Treg homing into the uterus and for embryo
implantation, we employed CCR7-deficient mice. The number
of CD4+Foxp3+ Treg in the uterus was drastically reduced in
CCR7−/− mice (Table 1), whereas the frequency of conventional
CD4+Foxp3− T cells was only partially reduced (data not shown).
Consistent with the absence of uterine Treg, CCR7 deficiency
resulted in implantation failure (Table 1). Supporting our find-
ings on the importance of CCR7 on Treg for implantation, Guerin
et al. (2011) reported the presence of CCL19, the ligand for CCR7,
in glandular and luminal uterine epithelial cells, however a role
for this chemokine for the recruitment of Treg into the uterus was
not investigated. We show here that CCR7 mediates the homing
of Treg to the uterus and that its absence hampers implantation.
DISCUSSION
The presence of Foxp3+ Tregs in uterus during early pregnancy
has already been reported (Schumacher et al., 2007; Thuere et al.,
2007). Here, by employing flow cytometry, we confirm that these
cells are present in the uterus in the non-pregnant state and that
they further fluctuate during the different phases of the estrous
cycle. It seems that this fluctuation occurs in response to hor-
mones, as has been proposed after observing variations in the
Foxp3 mRNA levels (Kallikourdis and Betz, 2007; Guerin et al.,
2011). In vivo 2-photon microscopy in Foxp3gfp animals impres-
sively confirmed oscillations in the frequency of Treg in the uterus
and further revealed a clustering of Tregs in uterine tissue during
the receptive phase of the cycle, the estrus. This may be interpreted
as an accumulation of these cells at the future implantation niches
and preparation of the uterus for implantation.
We further observed that Foxp3+ Tregs expanded immediately
after copulation at day 0 of pregnancy. The expansion occurred
after mating females with intact or vasectomized males but not
after mating with males lacking seminal vesicles, suggesting that
components of the seminal fluid are active in expanding Tregs
which is in accordance with other reports (Robertson et al., 2009;
Guerin et al., 2011). Treg expansion by seminal fluid could be con-
firmed by in vitro experiments that further indicated TGF-β as
a possible modulator of Treg expansion. Hence, Treg presence at
the moment of pairing and their further expansion by paternal
components implies a role for embryo implantation.
To investigate the potential role of CD4+Foxp3+ Tregs we
employed two distinct strains of Foxp3.DTR mice for Treg
depletion, namely Foxp3DTR knock-in mice and BAC-transgenic
Foxp3.LuciDTR-4 mice. We observed that depletion of Tregs
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FIGURE 3 | Embryo implantation is impaired afterTreg depletion. Foxp3+
Treg were depleted in Foxp3DTR mice by application of DT every fourth day,
starting 9 days before mating (day 9) with BALB/c males. Control groups
received PBS. (A) shows a representative picture of a uterus stained at day 5
post conception with Chicago Blue dye application. The arrow indicates a
representative implantation site. The percentage of females presenting
implantations was analyzed on day 5 after mating [(B), n= 5–12]. Foxp3+ Treg
were depleted in Foxp3.LuciDTR-4 mice by daily application of DT, starting on
day 2 with allogeneic (CBAJ) or syngeneic (C57/BL6) males. Control groups
were wt C57/BL6 females treated with DT. Implantation numbers were
measured at day 5 [(C), n=15–21]. For (B,C), data are expressed as medians
of % of implanted females and analyzed by Fisher’s exact test (#P <0.1,
*P <0.05). Not all plugged animals became pregnant. In samples from
animals shown in Figure 3B, the percentage of CD8+ cells was analyzed in
the uterus by flow cytometry (D), and the percentage of KI67+, CD44+, and
CD62L+ (E–G) determined in uterine draining lymph nodes (n=5/group).
Data are expressed as medians and were analyzed by Mann–Whitney-U test
(*P <0.05; **P <0.01).
prior to mating resulted in a dramatic impairment of implan-
tation. In line with this, it was recently reported that dimin-
ished endometrial Foxp3 mRNA was associated with infertility
in women (Jasper et al., 2006). We speculated that at this early
time point Tregs may counteract pro-inflammatory events occur-
ring during implantation and facilitate a uterine environment that
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FIGURE 4 | Depletion of Tregs creates an inflammatory uterine milieu. In
samples from Foxp3.LuciDTR-4 or wild type animals treated with DT by daily
application starting on day 2 and further mated syngeneically, inflammation
markers were measured (n=4–6/group) in uterine tissue by qPCR. Levels of
IL-15 (A), CCR5 (B), CCL19 (C), and CXCL3 (D) were significantly elevated in
mice depleted of Tregs as compared to DT-treated controls. Data are
expressed as single dots with medians and were analyzed by
Mann–Whitney-U test (#P <0.1, P <0.05; **P <0.01).
supports implantation. Without Tregs, inflammation may be too
strong and may favor a hostile uterine microenvironment that
would hinder nidation of the embryo. Indeed, we observed a
strong upregulation of the pro-inflammatory mediators IL-15,
CCR5 CCL19 and CXCL3. We also found augmented levels of
CD8+ cells and activated CD4+ cells in uterus. These findings are
supported by studies showing that Treg depletion in Foxp3.DTR
mice leads to T cell activation and pro-inflammatory modulation
of the microenvironment of sites where Tregs accumulate, such as
tumors (Li et al., 2010). Besides inflammation and accumulation
of effector cells, we observed swollen uteruses that were devoid of
implantations. The development of uterine fibrosis was indicated
by the upregulation of CtGF and CXCL9. uPA, a positive regulator
of tissue remodeling in the uterus was almost undetectable in the
absence of Treg, which is in line with impaired infertility of uPA
deficient animals (Carmeliet et al., 1994). Our data reveals that
the lack of Tregs results in uterine conditions that are hostile for
the embryo to implant. The levels of the known fertility factors
LIF and p53 (Hu et al., 2007) were not modified in the absence
of Treg.
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FIGURE 5 | Depletion of Tregs does not provoke changes in the levels of
IL-1b, gp130,TNF-α, ROR-γτ, or CCL5. In samples from Foxp3.LuciDTR-4 or
wild type animals treated with DT by daily application starting on day 2 and
further mated allogeneically, inflammation markers were measured
(n= 4–6/group) in uterine tissue by qPCR. Levels of IL-1b (A), gp130 (B), TNF-α
(C), RORγτ (D), and CCL5 (E) mRNA were comparable in mice depleted of
Tregs and DT-treated controls. Data are expressed as single dot plots with
medians and were analyzed by Mann–Whitney-U test. No statistically
significant differences were observed between both groups in any of the
molecules.
We conclude that Treg are pivotal for implantation as they
control the uterine microenvironment needed for the blasto-
cyst to attach and grow in the uterus. Many of the effects
seen here after Treg depletion are reminiscent of clinical para-
meters associated with infertility. Pathologies like endometri-
tis, endometriosis, inflammatory pelvic diseases, and fallopian
tube blockage associated with inflammatory processes cause
the metamorphosis of reproductive tract tissues and vaginal
fluid and are often a cause of infertility by hindering nida-
tion (Shah et al., 2005; He et al., 2010; Braundmeier et al.,
2012). Likewise, it is known that, e.g., pelvic inflammation, uter-
ine swelling, and intraluminal occluding fibrosis of the oviduct
after infections with Chlamydia sp. are associated with infer-
tility (Weiss et al., 2009; Wiesenfeld et al., 2012). Thus, it
seems that the specific depletion of Treg mimics alterations
induced by pathogens that lead to infertility, specifically an
inflammatory milieu and fibrosis, thereby hindering successful
implantation.
The targets for regulation by uterine Tregs are not clear,
but as T cell-deficient mice such as RAG mutant mice lack
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FIGURE 6 |Treg depletion leads to uterine fibrosis. In samples from
Foxp3.LuciDTR-4 or wild type animals treated with DT by daily application
starting on day 2 and further mated syngeneically, fibrosis markers were
measured (n=4–6/group) in uterine tissue by qPCR. Levels of CtGF (A) and
CXCL9 (B) were significantly elevated in mice depleted of Tregs as compared
to DT-treated controls. Data are expressed as single dots with medians and
were analyzed by Mann–Whitney-U test (#P <0.1, **P <0.01). Additionally,
staining with Hematoxylin/Eosin revealed fibrosis areas with disorganized
collagen fibers in animals without Tregs compared to wild type controls (C ii
vs. i). Pricosirius red staining revealed a higher amount of green/blue-stained
thin collagen fibers that confirms fibrosis in mice devoid of Tregs vs. controls
(C iv vs. iii). Further, Masson’s staining manifested larger areas of collagen
fibers in blue/violet in DT-treated Foxp3.Luci.DTR animals compared to
DT-treated controls (C vi vs. v). Finally in (C vii, viii), immunofluorescence
staining for CtGF confirmed accumulation of CtGF positive cells in mice
depleted in Tregs as compared to the controls. All pictures were taken with a
10× objective. Analysis of uPA mRNA revealed that animals depleted in Tregs
presented very low, almost undetectable levels of this molecule as compared
to DT-treated controls (D). Treg depletion further provoked an augmentation of
prostaglandin 1A mRNA (E).
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FIGURE 7 |Treg depletion does not provoke changes in IL-9, Gal-1, LIF,
or p53. In samples from Foxp3.LuciDTR-4 or wild type animals treated with
DT by daily application starting on day 2 and further mated allogeneically,
inflammation markers were measured (n=4–6/group) in uterine tissue by
qPCR. Levels of IL-9 (A), Gal-1 (B), LIF (C), and p53 (D) mRNA were
comparable in mice depleted of Tregs and DT-treated controls. Data are
expressed as single dot plots with medians and were analyzed by
Mann–Whitney-U test. No statistically significant differences were
observed between both groups in any of the molecules.
both Tregs and effector T cells, but present normal implanta-
tion rates, it seems reasonable to assume that effector T cells
are major targets and that uterine Tregs serve to control exces-
sive production of inflammatory cytokines.We also demonstrated
that homing of Tregs to the uterus depends on CCR7 and that
CCR7 deficiency resulted in implantation failure. In support
of this finding, Guerin et al. (2011) described the presence of
CCL19, the ligand for CCR7, in glandular and luminal uterine
epithelial cells.
Table 1 | Consequences of CCR7 deficiency in number of uterineTregs
and implantation rate.
% of uterine Foxp3+
cells within CD4 cells
Implantation rate
Wild type controls (n=5) 11.97 (4.48–21.1) 100%
CCR7−/− animals (n=5) 0 (0–0.01) 55%
Statistical significance <0.05 <0.05
In another study it was reported that Treg depletion with
anti-CD25 antibody at day 2.5 post conception would hinder
implantation only in allogeneic but not syngeneic mating com-
binations (Shima et al., 2010). At first sight this appears to be at
disagreement with our findings that Treg depletion in Foxp3.DTR
mice causes implantation failure also in syngeneic matings. How-
ever, in view of the fact that Foxp3.DTR allow more efficient and
more specific depletion of Tregs the above authors themselves have
suggested the use of Foxp3.DTRmice for respective studies, as has
been done here (Shima et al., 2010).
Once pregnancy is established, the embryo expressing pater-
nal antigens needs to be protected against the maternal immune
system. In several reports Tregs have been shown to be impor-
tant for this process (Zenclussen et al., 2005; Schumacher et al.,
2007; Samstein et al., 2012). Using the same Foxp3.DTR knock-in
mice employed here, Samstein et al. (2012) have shown that the de
novo conversion of Treg in the periphery contributes to embryo
protection. However, as only 10% of all embryos are rejected in
the absence of Foxp3+ Tregs their protective role for maintaining
the integrity of the fetus appears to be limited as compared to the
strong effect of Treg on implantation observed here. Additional
and multiple mechanisms must exist to ensure maternal toler-
ance toward the fetus. Several distinct tolerance mechanisms have
been reported, such as awareness of maternal T cells for paternal
alloantigens and acquisition of a transient state of tolerance during
pregnancy (Tafuri et al., 1995), ignorance of fetus-specific T cells,
epigenetic silencing in decidual tissue of chemokines that attract
T cells (Nancy et al., 2012), and others.
In view of the importance of pregnancy for survival of a
species; its first phase, namely embryo implantation, must be
tightly controlled. Our data reveal the importance of Treg for this
process, likely by suppressing excessive inflammation in the uterine
microenvironment. The results are relevant for human pregnan-
cies, especially when designing protocols for improving fertility.
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Movie S1 | Estrus: 3D reconstruction of live 2-photon-microscopy of uterus
from a representative Foxp3gfp animal during the estrus phase oft he estrus
cycle.The green cells are Tregs clustered at the mesometrial region. Animals
were anesthetized by i.p. injection of ketamine and xylazine, 120 or 16µg/g of
mouse weight, respectively, and kept on a heating pad at 37°C. One of the
uterine horns was carefully exposed and 0.1M caffeine (Sigma-Aldrich, USA)
was applied to decrease uterine contractions. For maternal blood visualization,
animals were intravenously injected with 100µl of Rhodamine B isothiocyanate-
Dextran (RhoB-Dex) 70,000KDa (Sigma-Aldrich, Inc., USA) before acquiring
images in a multiphoton laser scanning microscope (MPLSM).We used a Prairie
Ultima 2-photon microscope (Prairie Technologies, Inc.). The microscope was
equipped with a ChameleonTi:Sapphire laser (Coherent, Inc., USA), four top
PMTs for simultaneous up to four channel acquisitions and a 20× water immer
sion objective (Olympus, Inc., USA). The laser was tuned to 880 nm to allow for
concomitant excitation of RhoB-Dex and GFP+-Treg. The wavelength emission
for RhoB-Dex and GFP is 590 and 509 nm, respectively. Sequential images were
acquired for observation of Treg in the uterus. For analysis of uterine Treg
images, we have developed our own software algorithms based on endogenous
tissue markers information (e.g., location of blood vessels) from consecutive
z-stacks acquisitions for stabilization of Treg movies. Once the images were
stabilized, we used Imaris software (Bitplane AG, Inc.) for reconstruction of
three-dimensional models in order to determine distribution in the uterus.
Movie S2 | Diestrus: depicts a 3D reconstruction of representative live
2-photon-microscopy of uterus from a Foxp3gfp animal at diestrus. Green
Tregs are scarce. Animals were anesthetized by i.p. injection of ketamine and
xylazine, 120 or 16µg/g of mouse weight, respectively, and kept on a heating
pad at 37°C. One of the uterine horns was carefully exposed and 0.1M caffeine
(Sigma-Aldrich, USA) was applied to decrease uterine contractions. For maternal
blood visualization, animals were intravenously injected with 100µl of
Rhodamine B isothiocyanate-Dextran (RhoB-Dex) 70,000KDa (Sigma-Aldrich,
Inc., USA) before acquiring images in a multiphoton laser scanning microscope
(MPLSM).We used a Prairie Ultima 2-photon microscope (Prairie Technologies,
Inc.). The microscope was equipped with a ChameleonTi:Sapphire laser
(Coherent, Inc., USA), four top PMTs for simultaneous up to four channel
acquisitions and a 20× water immersion objective (Olympus, Inc., USA). The
laser was tuned to 880 nm to allow for concomitant excitation of RhoB-Dex and
GFP+-Treg. The wavelength emission for RhoB-Dex and GFP is 590 and 509 nm,
respectively. Sequential images were acquired for observation of Treg in the
uterus. For analysis of uterine Treg images, we have developed our own
software algorithms based on endogenous tissue markers information (e.g.,
location of blood vessels) from consecutive z-stacks acquisitions for stabilization
of Treg movies. Once the images were stabilized, we used Imaris software
(Bitplane AG, Inc.) for reconstruction of three-dimensional models in order to
determine distribution in the uterus.
Movie S3 | Metestrus: shows a video from a 3D reconstruction of live
2-photon microscopy showing almost undetectable greenTregs within the
uterus. Animals were anesthetized by i.p. injection of ketamine and xylazine,
120 or 16µg/g of mouse weight, respectively, and kept on a heating pad at
37°C. One of the uterine horns was carefully exposed and 0.1M caffeine
(Sigma-Aldrich, USA) was applied to decrease uterine contractions. For maternal
blood visualization, animals were intravenously injected with 100µl of
Rhodamine B isothiocyanate-Dextran (RhoB-Dex) 70,000KDa (Sigma-Aldrich,
Inc., USA) before acquiring images in a multiphoton laser scanning microscope
(MPLSM).We used a Prairie Ultima 2-photon microscope (Prairie Technologies,
Inc.). The microscope was equipped with a ChameleonTi:Sapphire laser
(Coherent, Inc., USA), four top PMTs for simultaneous up to four channel
acquisitions and a 20× water immersion objective (Olympus, Inc., USA). The
laser was tuned to 880 nm to allow for concomitant excitation of RhoB-Dex and
GFP+-Treg. The wavelength emission for RhoB-Dex and GFP is 590 and 509 nm,
respectively. Sequential images were acquired for observation of Treg in the
uterus. For analysis of uterine Treg images, we have developed our own
software algorithms based on endogenous tissue markers information (e.g.,
location of blood vessels) from consecutive z-stacks acquisitions for stabilization
of Treg movies. Once the images were stabilized, we used Imaris software
(Bitplane AG, Inc.) for reconstruction of three-dimensional models in order to
determine distribution in the uterus.
Movie S4 | Proestrus: distribution of green Foxp3gfp+ cells (Tregs) inside the
uterus during proestrus. Animals were anesthetized by i.p. injection of
ketamine and xylazine, 120 or 16µg/g of mouse weight, respectively, and kept
on a heating pad at 37°C. One of the uterine horns was carefully exposed and
0.1M caffeine (Sigma-Aldrich, USA) was applied to decrease uterine
contractions. For maternal blood visualization, animals were intravenously
injected with 100µl of Rhodamine B isothiocyanate-Dextran (RhoB-Dex)
70,000KDa (Sigma-Aldrich, Inc., USA) before acquiring images in a multiphoton
laser scanning microscope (MPLSM).We used a Prairie Ultima 2-photon
microscope (Prairie Technologies, Inc.). The microscope was equipped with a
ChameleonTi:Sapphire laser (Coherent, Inc., USA), four top PMTs for
simultaneous up to four channel acquisitions and a 20× water immersion
objective (Olympus, Inc., USA). The laser was tuned to 880 nm to allow for
concomitant excitation of RhoB-Dex and GFP+-Treg. The wavelength emission
for RhoB-Dex and GFP is 590 and 509 nm, respectively. Sequential images were
acquired for observation of Treg in the uterus. For analysis of uterine Treg
images, we have developed our own software algorithms based on endogenous
tissue markers information (e.g., location of blood vessels) from consecutive
z-stacks acquisitions for stabilization of Treg movies. Once the images were
stabilized, we used Imaris software (Bitplane AG, Inc.) for reconstruction of
three-dimensional models in order to determine distribution in the uterus.
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Multimolecular Analysis of Stable
Immunological Synapses Reveals Sustained
Recruitment and Sequential Assembly of
Signaling Clusters*□S
Lars Philipsen‡, Thomas Engels‡, Kerstin Schilling§, Slavyana Gurbiel‡,
Klaus-Dieter Fischer¶, Kerry Tedford§, Burkhart Schraven‡¶¶, Matthias Gunzer‡¶¶,
and Peter Reichardt‡¶¶**
The formation of the immunological synapse between T
cells and antigen-presenting cells (APC) begins within
minutes of contact and can take hours for full T-cell ac-
tivation. Although early phases of the synapse have been
extensively studied for a select number of proteins, later
phases have not yet been examined in detail. We studied
the signaling network in stable synapses by measuring
the simultaneous localization of 25 signaling and struc-
tural molecules over 2 h at the level of individual synapses
using multi-epitope ligand cartography (MELC). Signaling
proteins including phospho(p)ZAP70, pSLP76, pCD3, and
pLAT, along with proteins that influence synapse struc-
ture such as F-actin, tubulin, CD45, and ICAM-1, were
localized in images of synapses and revealed the multi-
dimensional construction of a mature synapse. The con-
struction of the stable synapse included intense early TCR
signaling, a phase of recruitment of structural proteins,
and a sustained increase in signaling molecules and co-
localization of TCR and pLAT signaling clusters in the
center of the synapse. Consolidation of TCR and associ-
ated proteins resulted in formation of a small number of
discrete synaptic microclusters. Development of syn-
apses and cSMAC composition was greatly affected by
the absence of Vav1, with an associated loss in PLC1
recruitment, pSLP76, and increased CXCR4. Together,
these data demonstrate the use of multi-epitope ligand
cartography to quantitatively analyze synapse formation
and reveal successive recruitment of structural and sig-
naling proteins and sustained phosphorylation at the ma-
ture synapse. Molecular & Cellular Proteomics 12:
10.1074/mcp.M112.025205, 2551–2567, 2013.
Adaptive immune responses are initiated by the meeting of
a T cell and an antigen-presenting cell (APC)1 bearing pep-
tide-MHC (pMHC) complexes that are a specific fit for the
T-cell receptor (TCR) on the T-cell surface. Within seconds,
TCR signaling starts with a sequence of phosphorylation and
de-phosphorylation events of membrane-proximal and -distal
TCR-signaling molecules and their spatial reorganization into
protein multiclusters (1). Together with the rearrangement of
structural molecules at the cell–cell interface, these signals
lead to the formation of a supramolecular structure termed the
immunological synapse (1–3). The synapse can differ sub-
stantially in size and composition, but comprises several com-
mon structural motifs (4–6). In the classical synapse, these
structural motifs are organized in domains that form a target
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1 The abbreviations used are: APC, Antigen-presenting cell; 3D,
Three-dimensional; AA, Amino acid; BIRT377, (R)-5-(4-bromophenyl)-
3-(3,5-dichlorophenyl)-1,5-dimethylimidazolidine-2,4-dione. A small
molecule and integrin antagonist, BT B cell-T cell; Ca, Calcium; CMP,
Combinatorial molecular phenotype, syn. combinatorial molecular
pattern; cSMAC, Central supramolecular activation cluster; CXCR4,
C-X-C chemokine receptor type 4; ERK, Extracellular signal-related
kinase; FCS, Fetal calf serum; IS, Immunological Synapse; KO,
Knock-out; LAT, Linker for the Activation of T cells; LCK, Lympho-
cyte-Specific Protein Tyrosine Kinase; MAPK, Mitogen-activated pro-
tein kinase; MELC. Multi-Epitope Ligand Cartography; MFI, Median
fluorescence intensity; NA, Numerical aperture; NFAT, Nuclear factor
of activated T cells; NF-B, Nuclear Factor kappa B; PBS, Phosphate-
buffered saline; pOVA, Peptide [of the AA sequence 323–339] of the
Ovalbumin protein, cognate ligand for OT-II TCR transgene CD4 T
cells; pPLC1, Phospho-Protein kinase C 1; pSMAC, Peripheral
supramolecular activation cluster; pTyr, Phospho-Tyrosine; pZAP70,
Phospho-Zeta-chain-associated protein kinase [with molecular
weight of 70 kDa]; RhoGEF, Rho guanine nucleotide exchange factor;
RPMI, A cell culture medium first developed at Roswell Park Memorial
Institute; SH2, Src homology-2 domain ; SLP76, SH2-containing leu-
kocyte protein [with molecular weight of 76 kDa]; TCR, T cell receptor;
WT, Wildtype.
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pattern. Two signaling areas form the middle of the synapse:
the bullseye in the center is the central supramolecular acti-
vation cluster (cSMAC), dominated by TCR and associated
signaling molecules, and the ring around it is called the pe-
ripheral (p)SMAC, dominated by the presence of stabilizing
integrins (1, 6). The outermost ring, the distal (d)SMAC, is
composed of F-actin important for structural integrity of the
synapse. The purpose of the synapse, and its dynamic pre-
cursor the kinapse, is to translate information obtained from
the APC on amount and quality of peptide and presence of
coreceptors into T-cell actions such as proliferation or secre-
tion (1).
TCR triggering activates a cascade of signaling events.
First, Src kinases such as LCK are activated and phosphory-
late the TCR-complexed CD3 chain on intracellular tyrosine-
based activation motifs (ITAMs). Next, ZAP70 is recruited to
ITAMs and phosphorylates adaptors such as LAT and SLP76.
These in turn recruit PLC1, an activator of calcium flux, and
Vav1, a regulator of actin reorganization, leading to activation
of MAPKs and transcription factors such as NFAT and NF-kB
(7, 8). The early TCR signaling leading to calcium flux takes
place in seconds, followed by the appearance of the synapse
within minutes. Recruitment and assembly of preformed com-
plexes of signaling proteins facilitate structural formation of
synapse and TCR signal amplification (9–11). For example,
TCR and LAT are found in separate protein islands in the
membrane, or in subsynaptic vesicles, and are brought to-
gether at the membrane to initiate signaling in microclusters
(12–15). Microclusters are small aggregates of signaling pro-
teins, adaptors, and TCR that change location in the synapse
over time. Microclusters originate in the dSMAC and migrate
in an actin-dependent manner through the pSMAC toward the
center of the cSMAC (16, 17).
Current views on the formation and functions of the cSMAC
are evolving with ongoing research. Because the cSMAC
contains an accumulation of TCR, it was originally posited to
serve as a platform for TCR signaling (2, 3). However, further
investigations revealed that the centrally located TCR are not
signaling-active and are down-regulated for recycling or deg-
radation (17–20). The cSMAC is not uniform in composition
but contains at least two different zones: a central zone where
TCR signaling terminates, encompassed by a zone enriched
with actively-signaling TCR, F-actin and associated corecep-
tors and kinases (9–12, 16, 21). It was proposed that the
cSMAC modulates receptor degradation and signaling by
regulating association of TCR with phospho-tyrosine proteins
(22, 23).
Multi-epitope ligand cartography (MELC) is a microscopy-
based technology that was developed to study the simulta-
neous locations of dozens of proteins in a single sample of
fixed cells or tissue (24). The MELC system consists of a
microscope, a CCD camera and a robotic transfer device
enabling an automated sequence of delivering washing fluid
and staining solution to the sample—all controlled by a com-
puter. To perform MELC, the sample is stained with a fluo-
rescent reagent, imaged, photo-bleached to completely re-
move fluorescence, washed, and then stained again with a
subsequent fluorescent reagent until all detection reagents
have been applied in sequence. The image data can be ana-
lyzed directly as raw fluorescence intensity or converted to
binary data for each pixel confirming presence or absence of
fluorescence for each protein. This resulting mathematical
data can then be used to analyze colocalizations of all the
proteins studied in the sample at a network-level scale
(24–27).
We report here the results of using MELC technology to
study the co-localizations of 25 molecules (24 proteins and
DNA) in T cell–APC conjugates that were imaged at different
time points to monitor synapse formation. To investigate the
roles of these molecules in synapse formation for longer than
the few minutes it takes to form the outlines of the cSMAC,
cells were imaged over 2 h. MELC revealed a layered con-
struction of the synapse with sequential recruitment of struc-
tural proteins and signaling molecules and a consolidation of
LAT and TCR complexes that ultimately formed the mature
synapse at late time points (60 min). Synapses contained a
limited number of microclusters consisting of TCR associated
with phosphorylated CD3 and signaling proteins in the
cSMAC. Furthermore, MELC was used to analyze synapse
formation in T cells from Vav1 knockout mice, and identified
key differences in synapse signaling in the mutant T cells. Our
results show that MELC technology is valuable in analyzing
the large-scale translocation of many proteins in individual T
cell–APC contacts simultaneously and thus can deliver new
insights into the function and dynamics of formation of the
immunological synapse.
EXPERIMENTAL PROCEDURES
Mice—OT-II mice carrying a transgenic TCR recognizing peptide of
chicken ovalbumin (AA 323–339) peptide, pOVA, in the context of I-Ab
have been described (28) and were used as a source of T cells.
C57Bl/6 (H-2b) mice (from Harlan Germany) were used as a B cell
source. Vav1/ mice (29) were provided by Dr. Klaus-Dieter Fischer,
University of Magdeburg, Germany. Animals were housed under spe-
cific pathogen-free conditions and treated according to institutional
guidelines. All animal experiments were approved by the animal pro-
tection committee of the local authorities.
Cell Preparation, Pair Formation—Cell preparation and induction of
B cell-T cell (BT) pair formation were performed as previously de-
scribed (5). In brief, naïve CD4 T cells from spleens of OT-II mice
were enriched to over 90% purity (as assessed by expression of V2
TCR transgene) by negative isolation via immunomagnetic depletion
(Miltenyi, Bergisch Gladbach, Germany). Naïve splenic B cells from
C57Bl/6 mice were obtained by the same procedure with purities
between 90 and 95%. For T cell activation, B cells were loaded with
100 g/ml pOVA for 24 h and washed. Freshly isolated T cells were
then mixed in a 1:1 ratio with B cells and co-incubated in an RPMI-
based, FCS-supplemented media (Invitrogen, Los Angeles, CA). To
synchronize pair formation, cells were centrifuged shortly at 260  g
and incubated at 37 °C, 5% CO2. Cells were used for subsequent
analysis at indicated time points.
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Slide Preparation for MELC—T and B cell mixtures were fixed with
2% paraformaldehyde for 15 min and adhered to poly-L-Lysine-
coated glass slides. Two to three different cell-coated areas per slide
(reflecting different time points of pair formation or different biological
samples, e.g. KO versus WT) were created by applying single droplets
of cell suspension. Slides were stored in PBS at 4 °C until imaged by
MELC.
MELC—
Antibody Library—We established a MELC library of 24 fluores-
cence tags (plus propidium iodide) as listed in Table I. We performed
a stepwise selection process to judge specificity and usability of each
antibody in our system. In brief, we first chose antibody products and
clones based on evidence of previous successful and specific usage,
ideally by multiple methods, as documented in peer-reviewed litera-
ture (see Table I). We then tested the performance of their directly
immunofluorescent dye-coupled derivatives in our system by assess-
ing the spatial distribution of the resulting signals (T cell-/B cell-
specific, synaptic enrichment) as well as the signal quality (signal-to-
noise ratio; details in Table I and supplemental Fig. S3). Most of the
antibodies tested performed well in our system. However, several
molecules of interest to the study of immune synapses (such as
LFA-1) could not be included in the library as the signals delivered by
the antibodies were not reliable, too weak or too unspecific in our
system. Such, in the case of CD11a (LFA-1), the antibody did not
deliver a T-cell specific pattern or synaptic enrichment in our hands.
This was possibly due to effects of fixation and/or permeabilization in
our protocol, which for technical reasons had to be identical for all
markers. Wherever possible such molecules were replaced with
stains for surrogate markers, e.g. the stain for LFA-1 was replaced by
a stain for its main ligand ICAM-1, CD54. The appropriate working
dilutions, incubation times and positions within the MELC run were
worked-out in a series of pilot experiments based on previous con-
ditions found to be generally suitable to MELC (24) and adapted to our
system. During build-up of the MELC library, MELC runs were per-
formed with varying and cumulative numbers and positions of the
individual markers to ensure consistency of fluorescence signals in
our system.
Image Recording by Toponome Imaging Cycler (TIC)—The sample
was placed on the stage of an inverted wide-field fluorescence mi-
croscope (Leica DM IRE2; 63  oil lens NA 1.40). For each of the two
or three conditions defined by application of individual droplets of cell
solution, one or two suitable fields of view were defined manually, and
the corresponding XYZ-positions and a transmitted light reference
image was acquired. A fully automated cyclic robotic process started
with the incubation of the first fluorescently labeled antibody. After a
washing step, the fluorescence signals and a corresponding phase
contrast image were acquired by a cooled charge-coupled device
camera (Apogee KX4; Apogee Instruments, Roseville, CA, USA). We
performed z-stacks to investigate the three-dimensional (3D) struc-
ture of the synapse (32 z-planes with a distance of 300 nm and 2
binning resulting in three-dimensional image stacks of 1024  1024 
32 voxels, with a corresponding object space of 292  292  9.3
m3; final voxel size 286  286  300 nm3). To eliminate specific
signal from a given tag before the addition of the next tag, a bleaching
step was performed. A following image of postbleaching fluorescence
signals was recorded before the subsequent incubation-imaging-
bleaching-cycle started. These cycles were processed until all tags
were applied to the sample.
Image Analysis—The fluorescence and post-bleaching fluores-
cence images produced by each tag were automatically aligned
voxel-wise using the corresponding phase contrast images reaching
an alignment accuracy of 1 pixel in all dimensions. Fluorescence
images were corrected for illumination faults using flat-field correc-
tion. Post-bleaching images were subtracted from the following fluo-
rescence tag images. Finally, cases of section artifacts were excluded
as invalid by a mask-setting process.
3D Reconstruction and Visualization—To improve the resolution of
the 3D image stacks of wide field fluorescent images, we performed
a deconvolution/deblurring using the XCOSM software package (an
interface to Computational Optical Sectioning Microscopy algorithms
for removing out-of focus light in 3D image volumes, Washington
University St. Louis, MO, USA; www.essrl.wustl.edu/preza/xcosm/).
Volocity software was used for rendering and visualization (Version
4.0.1, Perkin Elmer, Improvision). Definition of synapse in 3D space:
We visualized the synapse with multicolor overlays using the de-
blurred fluorescence images of the CD3, CD45R, F-actin and pLAT
markers and recorded the positions (x,y,z) of the cSMAC, the diam-
eters of the synapse and the angles of the virtual plane through the
synapse in relation to the xy-plane and the xz-planes for each indi-
vidual synapse. Regions of interest, ROIs, were calculated for the
SMAC and derived p- and cSMAC in relation to these coordinates as
depicted in supplemental Fig. S4. Compartments for B cell, T cell and
the distal pole (uropod) of the T cell in the BT pair were manually
defined for each synapse.
CMP Analysis—The preprocessed image data were subjected to
binarization as described previously (24). Briefly, the thresholds au-
tomatically generated by the system were validated and adjusted
manually for each fluorescence signal. The expression of an epitope
was set to the value of “0” for a signal below the threshold and to “1”
for a signal above the threshold in projection to a pixel. CMP matrices
were generated by superimposing binarized images where each pixel
in the visual field was coded with a 1/0 code of n epitope expression.
Specific combinations of a selection of markers, termed CMP motifs,
were also analyzed. These CMP motifs were defined using a 1/0/*
code to signify if the signal was present (1), absent (0), or undeter-
mined (*). We calculated the relative frequency of CMPs or CMP
motifs either by dividing the number of positive pixels for the individ-
ual molecule by the total pixels within the ROI (subcompartment, e.g.
cSMAC) analyzed (the resulting motif was then called a “base motif”)
or by the total number of valid pixels within the BT pair analyzed.
Flow Cytometry—Antibodies against surface markers (CD4, CD19)
were from BD Pharmingen, San Jose´, CA, USA and antibodies for
intracellular staining of total tyrosine-phosphorylated signaling mole-
cules (anti-pTyr-Alexa488, clone PY20) were from Biolegend, San
Diego, CA, USA. The integrin inhibitor BIRT377 was a kind gift from
Terence Kelly (Boehringer Ingelheim). Staining procedure was per-
formed using the BD Fix&Perm Kit as indicated by manufacturer. Flow
cytometry was performed at a BD Fortessa. BT pair formation was
quantified as the percentage of all live CD4 T cells in contact with B
cells (CD19). Median fluorescence intensity (MFI) of signaling proteins
was calculated and the signal from the identically labeled isotype
control subtracted.
Western Blot—For analysis of pERK in cell pairs: co-incubation of
T and B cells was stopped at 30 min. To some samples, anti-CD3
(2C11, 5 g/ml) was added to boost signal. Cells were lysed as
described previously (30) to obtain cytoplasmic extracts. Protein ly-
sate (20 g) was separated on a 10% SDS-PAGE and transferred to
PVDF membranes. Proteins were detected with primary antibodies to
phospho-ERK1/2 (S202/Y204, Cell Signaling) and beta-actin (Sigma),
followed by HRP-coupled anti-rabbit and anti-rat secondary antibod-
ies (BD Pharmingen) respectively, and analyzed with the Rotilumin
detection system (Roth, Karlsruhe, Germany).
For ERK, Vav1, and SLP76 expression in WT and Vav1/ OT-II T
cells, purified T cells were activated by CD3-crosslinking and ana-
lyzed using anti-p-ERK (E4), ERK1 (K23) (both from Santa Cruz, Santa
Cruz, CA, USA), Anti-Vav, sheep anti-human SLP76 (all from Upstate,
Lake Placid, NY, USA), and purified mouse anti-SLP (pY128) (BD
Pharmingen). Total ERK and beta-actin served as loading controls.
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Statistical Analysis—Student’s t test or a nonparametrical test
where indicated in the results section were applied to assess statis-
tical significance. Significance levels and symbols employed were
p  0.05 (*), p  0.01 (**); and p  0.001(***). Statistical analysis and
plotting was done with GraphPad Prism 5.01 (Graphpad Software, La
Jolla, CA, USA) or MATLAB (The Mathworks Inc., Natick, MA, USA).
RESULTS
Establishment of the MELC System to Study the Immuno-
logical Synapse—The MELC system displays the location of
many proteins simultaneously in fixed cells. This large-scale
mapping of proteins makes it possible to do statistical anal-
ysis of protein co-localizations in subdomains of a cell. Here
we used MELC to study the formation of the immunological
synapse over a 2 h time course by following 25 molecules (24
proteins and DNA) in BT pairs. Murine OT-II TCR transgenic
CD4 naïve T cells (28) were stimulated with naïve primary B
lymphocytes from C57/Bl6 mice as APC. B cells were loaded
with saturating concentrations (100 g/ml,  105 nM) of a full
agonist peptide (pOVA, AA 323–339, the cognate ligand to the
OT-II TCR) (5). T cells and B cells were co-incubated, centri-
fuged to initiate conjugate formation, plated, and then fixed
and permeabilized at various time points. The MELC system
was programmed to subject the T cell–B cell pairs to 25
rounds of an automated sequence of staining and image
collection, followed by bleaching of the fluorescence. The
resulting microscopic images were then processed with algo-
rithms to compensate for systemic artifacts such as lateral
shift or residual, nonspecific fluorescence signals (24).
A representative field of view for BT pairs with stainings for
5 proteins (CD3, CD45R, pLCK, pLAT, pSLP76) is shown in
Fig. 1A, with insets of magnifications of 4 selected pairs
(labeled I-IV). Serial stainings of a BT pair show the cumulative
appearance of fluorescence with pseudocolor applied to each
stain to distinguish between the molecules (Fig. 1B). To con-
firm that the signaling protein localizations studied were spe-
cific to the APC - T cell synapse, we used T cell–T cell pairs as
controls (Fig. 1C). In the upper block showing BT pairs and the
lower block showing T cell–T cell pairs, F-actin, tubulin and
DNA were similarly stained in both B cells and T cells. T cell
marker CD3, total (t)-LCK, and CD45 stained T cells only
whereas CD45R stained specifically B cells. Importantly,
punctate staining of pLAT, pLCK, pSLP76, and pZAP70 was
specific to the interface of the BT pairs. Further confirmation
of the restriction of signaling to specific antigen-loaded BT
pairs was provided by Western blot of activated ERK MAPK
and by FACS analysis of phospho-tyrosine (supplemental Fig.
S1A and S1B). The final library of antibodies and stains to
target 25 molecules simultaneously is shown in Table I. A
complete sequence of all 25 individual fluorescence signals
within one representative BT pair is shown in supplemental
Fig. S2.
We first compared the cell-type specificities and strengths
of the 25 signals generated with the panel of antibodies and
stains. We recorded the fluorescence signal intensities for
each reagent stain at 30 min after conjugation in B cells alone,
T cells alone, and T cell–B cell pairs. The resulting numerical
values of signal intensity were displayed graphically (Fig. 1D,
supplemental Fig. S3). The cell-type and BT-pair-specific ex-
pression pattern was statistically distinct for the majority of
molecules and cellular entities. Several markers such as the
co-stimulatory protein CD86, the integrin-ligand CD54, the
chemokine receptor CXCR4 and phosphorylated signaling
molecules such as pPLC1 were represented by very weak or
undefined signals when referenced to the total cell bodies.
However, enrichment of these markers at the cell-cell inter-
face forming the APC–T-cell synapse could be clearly visual-
ized. Thus, measurements within the synaptic subregion of
the cell pairs (as employed in Figs. 2ff) resulted in statistically
distinct and specific patterns for all 25 molecules used in the
study (supplemental Fig. S2). Together, these data demon-
strate the imaging acquisition of signals from 25 molecules
involved in TCR signaling simultaneously at the level of indi-
vidual BT pairs.
Sustained Antigen-specific TCR Signaling During a Two-
hour Process of Physical Maturation of the Synapses—TCR
activation triggers an immediate burst of signaling in TCR
microclusters and subsequent organization of SMACs into
central and peripheral zones within minutes. Subsequently,
productive signaling through the T-cell synapse can last for
hours. To determine the optimal time window for synapse
formation, we evaluated pair formation and associated syn-
aptic signaling in BT pairs in our system.
To more specifically allocate the signals detected in the BT
pairs, we defined synaptic subregion based on the well-es-
tablished division into central and peripheral signaling clusters
(Fig. 2A–2C). The p- and cSMAC borders are generally de-
fined by the presence of specific molecules such as LFA-1 or
TCR respectively (2, 31, 32), but we chose instead to use
spatial orientation and the location of pLAT to define these
domains in the x-, y- and z-planes. pLAT was chosen as a
marker for the center of the synapse and to define the ideal
z-plane because pLAT was consistently found at the BT in-
terface from 5 min after pair formation to the last time point
and was typically found at the center of the synapse in a small
number of discrete points. The F-actin ring around the syn-
apse in the dSMAC was used to define the outer border of the
pSMAC. We then developed an algorithm to use these F-actin
and pLAT coordinates to calculate the position and alignment
of the synapse in the x, y and z axes. The areas encircled by
the actin ring ranged in diameter between 4 and 5 m, and we
defined the inner third of the areas as the cSMAC (Fig. 2A–C,
Fig. S4).
Using this spatial synaptic definition we followed the kinet-
ics of localization of key synaptic molecules within the
pSMAC and cSMAC, respectively, in MELC. We observed
(supplemental Fig. S1C) a gradual accumulation of F-actin in
the peripheral subregion of the synapse with a peak at 60 min
followed by a plateau. Similarly, CD3, an integral component
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FIG. 1. Establishment of the MELC system. Sequential imaging of 25 molecules in synapse formation during in vitro activation of naïve
CD4 T-cells (OT-II) with specific antigen (100 g/ml pOVA peptide)-loaded primary B cells as APC. A, Representative field of view in MELC
imaging. Overlay image of the field of view acquired in individual fluorescence channels generated from 5 channels: CD3: red; CD45R: green;
pLCK: pink; pLAT: cyan; pSLP76: yellow; PI (propidium iodide, nuclear marker): purple. Magnified insets (I-IV) demonstrate typical T-cell-B cell
(BT) pairs. Scale bar in insets: 10 m. B, Magnified, cumulative, multicolor overlay image of selected individual signals in one specific BT-cell
pair with a characteristic synapse. For visual clarity, the CD45 signal is only depicted in the first and in the last two images. Scale bar: 10 m.
C, Phospho-signaling proteins at the synapse are limited to antigen-specific BT pairs. Upper panels: BT pair displaying a characteristic
synapse. Top Row: F-actin, tubulin, PI, phase contrast image of cell pair. Middle row: CD3, tLCK, CD45, CD45R, to show T or B cells. Bottom
row: synapse-localized pLAT, pLCK, pSLP76 and pZAP70 signals. Lower block: Absence of signals in T-cell-T-cell pairs. Scale bar: 10 m.
D, Comparison of levels of fluorescence obtained from all 25 markers in BT pairs (BT), single B (sB) and single T-cells (sT). Intensity of raw
fluorescent signals at the 30 min time point is shown was converted to a color scale to visually illustrate cell type-specific expression.
Statistically significant expression (p  0.05 or lower) is indicated by bars. Note that the raw intensity approach here fails to resolve small
differences in expression for several markers demonstrating medium to very low intensity (CD86, CD54, CD3[Y1]). This formed the basis for
the subsequent use of BT (synaptic) subregions and a pixel-based analysis (Figs 2ff). Analysis was performed in 32 BT pairs, 40 single B cells
and 40 single T-cells in four independent experiments.
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TABLE I
List of 25 molecules and epitopes detected by 24 specific antibodies (plus propidium iodide) used in MELC analysis. Specificity and Quality Control Criteria:
Methods/Lit: Key publications are listed where the actual product or the exact clone was employed by the methods indicated. Reports on the biology of the target protein with only
indirect, not clone-specific evidence for antibody specificity were termed accordingly (Biology). More details can be found on the manufacturer’s website. IB, Immunoblot; FC, Flow
Cytometry; IHC, Immunohistochemistry; Biol., Biology.
Distribution: Predominant spatial distribution of the molecule based on the mean fluorescence intensity in the respective compartment: T cell (if single T sT  single B sB; t test,
see all individual graphs and statistics in Fig. S3); B cell (if sT  sB); T and B (if sT not  sB and sT not  sB); Synapse (if Synapse cS, central Synapse, cSMAC  sT and sT 
sB).
S/N Ratio: Signal-to-Noise Ratio: Mean (mean fluorescence intensity in the respective compartment); S.D. (standard deviation); p, p value in the G test likelihood ratio to differ from
an arbitrary threshold of 1.5.
Molecule Phospho site Clone Fluorophore Source Cat. no Methods/Lit Distribution S/N Ratio (mean, S.D., p)
IA-IE (I-A/I-E) 2G9 FITC BD Pharmingen 553623 IF55, IB56 B cell 6,4360 1,2158 0,000
CD80 16-10A1 Alexa488 Biolegend 104716 IB57, IHC58 Synapse 1,6733 0,0961 0,001
CD86 GL-1 Alexa488 Biolegend 105018 IB59, IHC58 Synapse 2,7400 1,0622 0,000
CD54 (ICAM-1) YN1/1.7.4 FITC Biolegend 116112 IHC60, IB61 Synapse 3,3510 0,8439 0,000
CD45R RA3–6B2 Alexa488 BD Pharmingen 557669 FC62, IF63 B cell 7,0420 1,9092 0,000
CD45 30-F11 FITC BD Pharmingen 553080 FC, IF64, FC, IB65 T cell 4,5800 0,8806 0,000
F-actin C4 Alexa488 BD Pharmingen 558623 IF, IB66, WB67 Synapse 5,9470 0,6657 0,000
-Tubulin TU-01 FITC Acris BM753 IB68, IB, IF69 Synapse 2,8340 0,3413 0,000
CD184 (CXCR4) 2B11 FITC BD Pharmingen 551967 FC70 IB, IF, FC71 Synapse 1,6210 0,1753 0,015
CD4 RM4-5 Alexa488 BD Pharmingen 557667 IP72 FC73 T cell 3,6280 0,4174 0,000
CD3	 17A2 Alexa488 Biolegend 100210 IB, IHC74, IF75 T cell 6,3510 1,3455 0,000
pCD3 Y5 ITAM 5, pY142 K25-407.69 Alexa488 BD Pharmingen 558486 FC76 IB77 T cell 2,8600 0,4193 0,000
pCD3 Y1 ITAM 1 EM-26 Alexa488 SYBILLAa IB78, IB79 Synapse 1,5650 0,0545 0,008
tLCK MOL-171 Alexa488 BD Pharmingen 558504 IB80, IB81 T cell 3,5660 0,3203 0,000
pLCK p505 4 Alexa488 BD Pharmingen 557879 Biol.82, FC76 Synapse 1,8610 0,2861 0,000
pLAT p171 158–1169 Alexa488 BD Pharmingen 558519 Biol.83 Synapse 2,9040 0,8116 0,000
tPLC1 10 Alexa488 BD Pharmingen 558566 Biol.84 T cell 2,2600 0,1511 0,000
pPLC1 pY783 27 Alexa488 BD Pharmingen 557884 Biol.85 FC86 Synapse 1,8160 0,2890 0,000
tSLP76 H3 Alexa488 BD Pharmingen 560056 IB87, IB88 T cell 2,3830 0,2939 0,000
pSLP76 pY128 J141 Alexa488 BD Pharmingen 558439 IB 89, IF90 Synapse 3,3450 0,6042 0,000
pZap70/Syk pY319/pY352 Syk 17A Alexa488 BD Pharmingen 557818 Biol.91, Biol.92 Synapse 1,7820 0,2446 0,000
tERK1/2 G263-7 Alexa488 BD Pharmingen 612592 IB, FC93, FC76 T and B 5,3420 0,5224 0,000
pERK1/2 pT202/pY204 20A Alexa488 BD Pharmingen 612594 Biol.94, FC95 T cell 2,5110 0,3598 0,000
p-p38 pT180/pY182 36 Alexa488 BD Pharmingen 612594 Biol.96, FC97 T cell 1,5533 0,0306 0,001
PI (propidium iodide,
nuclear marker)
Sigma P4170 Nucleus 2,7450 0,4333 0,000
a The pCD3Y1 antibody was generously provided by Dr. J. Lindquist and the SYBILLA (Systems Biology of T-cell activation in Health and Disease) consortium.
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of the TCR-CD3 complex, continuously accumulated and
reached high levels at 120 min for most of the synapses in the
population. As CD3 accumulation in the cSMAC is consid-
ered to represent structural maturation of the synapse, we
concluded that the physical maturation of the synapse in our
system was completed after 120 min. In addition, we ob-
served pLAT to be consistently enriched at the cSMAC
throughout the entire observation period, which suggested
ongoing signaling activity. Likewise, using conventional flow
cytometry measuring signals of an anti-phospho-tyrosine
monoclonal antibody (PY20) we observed high signaling ac-
tivity in APC-T cells pairs exceeding the levels found in single
T cells at early (5 min) and late (120 min) time points (supple-
mental Fig. S1D). Of note, onset of pair formation was imme-
diate after the synchronized APC-T-cell contact. Most BT
pairs had formed already after 5 min and were strictly depen-
dent on the presence of specific antigen and integrity of
integrins (supplemental Fig. S1E).
Based on these kinetic evaluations, we decided to use
MELC to study T-cell signaling events at various time points
FIG. 2. Sustained antigen-specific TCR signaling during a two-hour process of forming physically mature immunological synapses.
A, Graphical illustration of the spatial definition of the synapse. The synaptic area peripherally bordered by an F-actin perimeter was divided
into thirds centered on pLAT as marker for cSMAC (cS) and flanked by pSMAC (pS). Adjacent to the synapse was the B cell (B) and T-cell (T)
body defined as further compartments used in the subsequent analysis. B, Representative micrograph of a BT pair with the cSMAC (red) and
pSMAC (yellow). Scalebar: 10 m. C, Defining synaptic position in x,y direction and optimal z-plane (z) for analysis from the 3D image stack.
MATLAB tool developed by us (for more details see supplemental Fig. S4 and Methods Section) D, Signal enrichment at the synapse. Relative
signal intensity for all markers studied within the four compartments, T-cell body, B cell body and the synaptic subregions cSMAC (cS) and
pSMAC (pS), over time. Fluorescent signal intensities of markers in each compartment were normalized to the mean intensity of signal over
all four subregions at each time point. The color scale represents the intensity of each marker (1 	 mean intensity over all four subregions).
E, Density map of signals in the cSMAC (cS) subregion only. The sequence of markers is identical to Fig. 2D. Data represent the mean of 130
synapses analyzed in four (at 5 min, three) independent experiments per time point.
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up till 2 h (at 5, 10, 30, 60, and 120 min). For each time point,
we calculated the intensities of the stains in the four compart-
ments T-cell body (T), B cell body (B), pSMAC (pS), and
cSMAC(cS) relative to the total intensity of the stain in the
entire BT pair. We chose this form of graphical display to
better visualize the enrichment over time of structural and
signaling molecules at the synaptic interface of the BT pair.
The relative intensities are depicted graphically with a color
scale (Fig. 2D). The majority of signaling proteins and phos-
phorylated signaling proteins relocated to the synapse within
5 min and remained there for the entire observation period.
The values for the cSMAC alone from each time point were
aligned for a direct comparison, and showed a rapid and
sustained influx of signaling proteins to the synapse (Fig. 2E).
The two most enriched proteins at the cSMAC were pLAT
and pSLP76, followed by many other signaling proteins such
as t- and pLCK, t- and pPLC1, tSLP76, and moderate levels
of pERK1/2. The TCR, represented by CD3, CD3, and its
co-receptor CD4, also enriched at the synapse (Fig. 2D, 2E).
Additionally, the intensities of structural/adhesive proteins
were enhanced. For example, we observed a strong increase
in F-actin in the pSMAC and a more moderate increase in
tubulin, predominantly in the cSMAC, reflecting the reorgani-
zation of the cytoskeleton during synapse formation (5, 33,
34). There was a corresponding synaptic enrichment in the
chemokine receptor CXCR4 which contributes to LFA-1 acti-
vation and thus mediates signal amplification at the synapse
(35, 36), and a slow increase in CD54 (ICAM-1), the main
ligand for the LFA-1 integrin—the prototypic marker for the
pSMAC. Enrichment of B cell-specific proteins also took
place at the synapse. We saw increased fluorescent signals at
the synapse of MHC II (the ligand for the TCR), CD86 (a ligand
for T-cell co-stimulation marker CD28), and CD45R (B220, a
marker for the B cell membrane). In addition to the clear trend
of gradual synaptic enrichment of different proteins, some of
which peaked at 60 min whereas others peaked at 120 min,
one important observation was the rapid high signaling activ-
ity by 5 min. In fact, several phosphorylated signaling pro-
teins, notably pLAT, pSLP76, and pZAP70, were already de-
clining toward 10 min (only the decline for pZAP70 in the
cSMAC reached statistical significance, p  0.05, see sup-
plemental Table S2). It is possible that this decline represents
a property of the experimental system, where the T and B
cells are mixed by centrifugation to trigger conjugation. The
force with which the cells are brought together might initiate a
burst of TCR signaling (37, 38), followed by a lull as the T-cell
deformation is corrected and the T cell begins to adhere
normally to the APC. Because the APC are homogenously
coated with the TCR-specific peptide, the T cells can then
immediately and synchronously begin again to signal to the
formation of the synapse. A period of re-orientation and re-
setting of the synapse before proper formation of a cSMAC
was described before (39). Indeed, the subsequent rise of
synaptic enrichment at 30 min and later is paralleled by an
increase in CD3 accumulation in the cSMAC (Fig. S1C). Thus,
a constant stream of synaptic signaling accompanies the
proper physical maturation of the synapse, which, in our
system, following a brief stage of SMAC resetting, starts at 10
min and is completed by 120 min of BT pair formation.
Distinct Phases of Molecular Recruitment and Colocaliza-
tion Define Kinetic Changes in the Signaling Signature of the
Synapse and Reveal a Delayed “Signaling Maturation”—Given
the known centripetal movement of TCR microclusters
through the pSMAC to the cSMAC (12, 40), we sought to
analyze the location frequencies of our set of TCR signaling
proteins in these individual compartments. As TCR signaling
efficiency relies on coordinated spatial arrangement of a net-
work of molecules we also aimed at looking into specific
colocalizations of signaling proteins in the stable synapse.
As the fluorescent signals obtained for phosphorylated sig-
naling proteins at the synapse were relatively low (Fig. 1D) we
applied a threshold algorithm that transformed the 16-bit
intensity signal into binary information for each protein at a
pixel: either present (1) or absent (0) (supplemental Fig. S2).
This approach also facilitated collection of signals of phos-
pho-proteins from small subregions of the cells that measured
only a few pixels in diameter. The amount of pixels positive for
each signal within a subregion was then recorded and com-
pared with the total number of pixels in this subregion to
obtain the relative frequency of each protein in a given com-
partment of the synapse.
Using this approach, we analyzed the location of individual
signaling proteins in the subcompartments of the immune
synapse with MELC. Characteristic changes are illustrated as
an archetypal graphical display of synapse formation in Fig.
3A (complete list in supplemental Table S1). The analysis
revealed several layers in the synaptic buildup based on the
consecutive recruitment of groups of proteins.
First, the kinetics of signaling in the synapse showed the
previously mentioned high signaling levels at 5 min and sub-
sequent decline at 10 min likely reflecting a period of resetting
following the forced onset of pair formation. The decline of
active signaling molecules toward 10 min in the cSMAC was
significant for pZAP70 but pSLP76, pLAT, pLCK, pCD3[Y5]
and pCD3 [Y1] also showed a decline (supplemental Table
S1). In contrast, other molecules like F-actin showed no de-
crease but rather increased toward 10 min.
Second, between 10 and 30 min key components of TCR
signaling including pZAP70, pSLP76, and pPLC1 increased
strongly and remained high from then on. These dynamic
changes likely reflected consistent TCR signaling via the now
evolving structurally stable synapse following the resetting
and reorientation phase.
Third, between 30 and 60 min, the data showed a rise in the
recruitment of molecules supportive for TCR signaling such as
tERK in the cSMAC and the chemokine receptor CXCR4 in the
pSMAC. This suggested an increased build-up of the physical
structure and binding strength of the T-cell–B-cell pair during
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FIG. 3. Distinct phases of molecular recruitment and co-localization in pSMAC and cSMAC during buildup of the mature synapse.
A, Sequential molecular assembly of the synapse with phases of earls TCR signaling, structural enforcement and delayed accumulation of
signaling molecules. Data obtained in MELC. Characteristic changes in positioning and amount of molecules are indicated by symbols. A
complete list of numerical data is given in supplemental Table S1. B, Localization of selected signaling molecules pLAT, pCD3[Y5], pZAP70,
and pSLP76 in synaptic subcompartments during stepwise formation of the stable synapse between 10 and 120 min. Graphical Tables
illustrate the relative frequencies of pixels positive for the indicated proteins over time in the cSMAC and pSMAC subcompartment A
color-coded scale in shades of orange enables a visual scan of data to detect trends: Color shades and numbers in the orange-colored boxes
represent relative frequencies of a protein (0.0, minimum, yellow; 1.0, maximum, orange) relative to minimum and maximum frequencies (%
of positive pixels in compartment) of that protein (white boxes, Rel. Freq.: Min, Max). Green squares identify protein represented by row.
Visualized is an continuous increase of signaling molecules in the cSMAC toward 60 to 120 min (identical trend in pSMAC). Statistical
significance is shown using bars (thin line, p  0.05; thick line, p  0.01). C, Co-localization of signaling molecules confined to synaptic areas
positive for pLAT- and CD3. Graphical Tables illustrate CMPs and their relative frequencies over time using the orange color-coded scale. The
increase in signaling molecules in cSMAC appears more pronounced (16-fold for areas with co-localizing pLAT, CD3, pZAP70, and pSLP76)
than for single molecules alone. Bars indicate statistical significances (thin line: 0.05; thick line: p  0.01). D, Opposed kinetics of co-localization
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this period. Supporting this, we previously described an in-
crease in binding forces between T cell–APC conjugates after
30 min (41). In addition, the presence of the CD45 phospha-
tase and its splicing form CD45R in the pSMAC decreased
between 30 and 60 min of synapse formation. These changes
all suggested a critical phase of molecular recruitment favor-
ing binding and prolonged TCR signaling.
Finally, between 60 and 120 min, we observed a continuous
rise of active signaling molecules such as pCD3 and pZAP70
in the cSMAC and recruitment of tPLC1 toward the center
and of F-actin toward the periphery of the synapse. These
events occurred at timepoints accompanying the final struc-
tural maturation of the synaptic population studied (Fig. 2) and
indicated a delayed TCR signal amplification and change in
TCR signaling signature.
Next, to analyze the kinetics and distribution of TCR signal-
ing in more depth, we focused on selected signaling proteins
and their colocalizations during the period of the proper for-
mation of the stable synapse in our system, i.e. between 10
and 120 min. We initially analyzed the presence of pLAT,
pCD3[Y5], pZAP70, and pSLP76, in cSMAC and pSMAC,
respectively (Fig 3B). We found that all three molecules dis-
played a gradual increase of the frequencies of these individ-
ual molecules in both cSMAC and pSMAC (between 1.4-fold,
pSLP76 in cSMAC; and 3.5-fold, pZAP70 in cSMAC). Highest
levels were reached at 60 and 120 min, respectively, suggest-
ing ongoing recruitment of signaling molecules at delayed
time points.
We next wanted to analyze the frequencies of co-localiza-
tions of these synaptic molecules (Fig. 3C). We tested the
frequencies of co-localization of pZAP70 and pSLP76 in syn-
aptic areas that were also positive for pLAT and CD3
(pCD3[Y5]). The use of binarized imaging data resulting from
the thresholding of fluorescent signals was not only useful in
evaluating low-intensity signals of individual markers, but
could also be used to generate and quantify CMP motifs (25,
42, 43), patterns of localizations of several markers within one
spot (pixel). Although it is conceptually easier to think of a
CMP motif as a protein complex, MELC analysis does not
provide data on actual binding between proteins—only on
shared locations. Using such colocalization CMPs for analy-
sis, the accumulation of signaling molecules in the cSMAC
over time became more obvious. For example, the frequency
of pixels positive for pLAT, pCD3[Y5], and pZAP70 increased
9.5-fold (from 2.5% to 23.8%) and the frequency of colocal-
izations of pLAT, pCD3[Y5], pZAP70, and pSLP76 increased
16.2-fold (from 1.0% to 16.2%) (Fig. 3C).
Finally, we studied the frequency of synaptic areas distinc-
tively characterized by the presence or absence of pLAT and
pCD3, respectively (Fig. 3D). pLAT is considered to mainly
correspond to membrane domains or vesicles, and CD3 pri-
marily localizes with TCR in domains separate from those
containing pLAT (12). During the course of synapse formation,
we found that the frequencies of CMPs containing pLAT but
not pCD3 peaked very early in the pSMAC (at 10 min) and at
30 min in the cSMAC and then strongly decreased over time
(in the pSMAC by approximately two-thirds, from 71.2% to
25.9%). In contrast, (TCR)-areas containing pCD3 but not
pLAT showed an increase in both pSMAC and cSMAC peak-
ing at 120 min (in the cSMAC from 8.2% to 20.3%). Both
pCD3pLAT- areas and pCD3pLAT areas (Fig. 3C)
were found at higher frequencies in the cSMAC than in the
pSMAC (20.3 versus 11.9%, and 59.8 versus 34.2%, respec-
tively). However, the area of the pSMAC was 8 times that of
the cSMAC according to our definition of the cSMAC as 1/3 of
the radius of the pSMAC. The continuous increase of CD3
was consistent with the CD3 enrichment observed earlier
and paralleled the general recruitment toward the synapse
(supplemental Fig. S1C). Our observation of an increase of
pLAT clusters (Fig. 3B), and increase of pLATpCD3 (Fig.
3C) yet decrease of pLATpCD3- (Fig. 3D) suggests that the
TCR and pLAT clusters became confluent over time in both
pSMAC and cSMAC. Indeed, the merging of LAT with TCR/
CD3 clusters during T-cell activation has been described to
start within minutes after onset of synapse formation (14).
Here we observe this process on a multiprotein level for
longer time periods, up to 120 min.
In summary, these findings suggest that sustained TCR
signaling within the synapse is accompanied by a gradual
accumulation of distinct clusters of signaling molecules and a
delayed change in signaling that we would call synaptic “sig-
naling maturation.”
Molecular Composition of Microclusters at the Center of the
Synapse—TCR signaling in T cells on planar lipid bilayers
takes place in numerous microclusters that take between 70
and 140 nm (14) and vary from 10 to close to a 100 TCR
molecules per cluster while in transit to the cSMAC (44).
Studies of T cell–APC conjugates immobilized in an upright
position on grids showed that larger microclusters measuring
about 1.5 m2 form in these synapses and coalesce in the
center by 60 min (45). To study the distribution of microclus-
ters in late-stage synapses in the BT pairs, we applied three-
dimensional graphical rendering to selected synapses. TCR
signaling proteins at the interface of the cell pairs were local-
of signaling molecules in synaptic subcompartments with distinctive presence or absence of pLAT and CD3[Y5]. Green and red color code
for the presence or absence of the protein markers indicated. pLAT cluster (in absence of CD3) peak early in pSMAC (10 min) and then
disappear. In contrast, signaling-associated pLAT cluster (pLAT, CD3-, ZAP70, SLP76) and CD3-cluster increase toward 60 to 120 min
in the cSMAC (identical trend in pSMAC). Bars indicate statistical significances (thin line: 0.05; thick line: p  0.01). E, shows two of the
characteristic CMP motifs illustrated (and highlighted by frame) in D as box plots. Bars indicate statistical significances (thin: 0.05; thick: p 
0.01). pLAT and CD3 were used as base motifs to define the subregion for analysis in C and D, respectively. CMP analysis of 130 synapses.
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ized predominantly in several microclusters 2–3 pixels (600–
900 nm) in diameter. These microclusters surrounded the
center of the synapse and contained activated signaling mol-
ecules including pSLP76, pLAT, and pLCK (Fig. 4A, 4B). We
used CMP analysis to contrast the molecular composition of
signaling clusters containing pSLP76 areas versus pSLP76
areas (Fig. 4C). pSLP76 was chosen from among the signaling
molecules as its staining showed a high signal-to-noise ratio
and clearly revealed the location and shape of the signaling
clusters. CMP analysis showed that pSLP76 was strongly and
significantly colocalized with pLCK, pLAT, pCD3, pZAP70,
and pPLC1. In contrast, CD4, CD86, CD45, and total signal-
ing proteins such as tPLC1 showed little or no tendency to
accumulate in these clusters. Also notable, F-actin was found
more frequently outside these clusters than in them (Fig. 4C).
Thus, signaling in the synapse is concentrated in a few mi-
croclusters of active TCR signaling (including pSLP76, pLAT,
pLCK, pCD3, pZAP70, and PLC1) whereas the surrounding
area is dominated by molecules more important for the integ-
rity of structure (F-actin) and signal termination (such as
CD45) (Fig. 4D).
Altered Molecular Composition of Synapses in T Cells from
Vav1/ Mice—An important application of MELC technology
to the study of the synapse would be to use it to characterize
signaling defects in T cells from mutant mice such as Vav1
knockout mice (Vav1/). Vav1 is required for T-cell devel-
opment and activation by mediating signals leading to cal-
cium fluxing, MAPK activation and actin polymerization (46).
Vav1 can act as a scaffold protein through its many protein
interaction domains and as an enzyme that activates Rho
GTPases (47). Studies on mutants of Vav1 lacking GEF
activity have shown that Vav1 acts through recruitment of
signaling proteins to activate PLC1 (47) and regulate cal-
cium signaling. Vav1 is also recruited to and stabilizes
SLP76 microclusters (48), (49). To investigate the molecular
composition of synapses in the absence of Vav1, we
applied a MELC analysis to T-cell synapses from Vav1-
mutant mice.
FIG. 4. Molecular composition of microclusters at the synapse. A, Localization of pSLP76 clusters around the center of the synapse.
Micrographs of a representative BT-cell pair (first panel) show the cumulative overlay of images of structural molecules (F-actin, CD45, CD45R)
with signaling molecules (pSLP76, pLAT, pLCK, tLCK) in the indicated colors (next 5 panels). B, En face view of a representative synapse at
a B cell-T-cell pair. Original image stained for the same proteins as in (A) (left image) and 2 axial en face views (middle and right image) through
the synapse showing all molecules (middle image) or signaling molecules only (right image). Note the presence of discrete microclusters around
the cSMAC. Scale bar: 10 m. C, Molecular composition of pSLP76 clusters in the synapse at 60 min. CMP analysis shows percentage of
pixels positive for the given protein colocalizing with pSLP76 (pSLP76) compared with the percentage of pixels in areas (pixels) that do not
contain pSLP76 (pSLP76). These values are compared in the ratio column (pSLP76/pSLP76). Highest ratios are colored (red: ratio4;
orange: ratio2.) Significant p values are colored (green: p  0.05; blue: p  0.01). D, Graphical illustration of the composition of SLP76
clusters in the cSMAC and the surrounding area, respectively. Red bars point to the projected locations of the molecules listed. Potential
functions of the respective clusters are indicated (signaling versus structure/signaling termination).
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We first quantified the overall capacity of Vav1/ T cells to
stably bind to APC and to form synapses. The numbers of
conjugates formed was strongly reduced in BT pairs with T
cells from Vav1/ mice (from 31.1 
 4.9% for WT to 11.2 

.2% for Vav1/) (Fig. 5A, 5B). Similar data were obtained by
flow cytometry (supplemental Fig. S5A). The overall signaling
in Vav1/ T cells was defective as shown conventionally by
Western blot demonstrating greatly reduced activation of
pERK in total cell extracts (supplemental Fig. S5B), however
tSLP76 expression was normal in these cells (supplemental
Fig. S5C). ERK and SLP76 were chosen because Vav1 is
known to induce ERK activation (46) and to influence stability
of the SLP76 complex (49). CMP analysis of individual syn-
apses formed by Vav1/ T cells revealed significant shifts in
groups of proteins when compared with synapses by WT T
cells (supplemental Table S2). First, in WT synapses (supple-
mental Table S2, Part A) TCR-associated molecules CD4,
pCD3, and pCD3 were much more likely to be found in WT
synapses than in Vav1/ synapses. Second, structural and
costimulatory proteins CD80/86, CXCR4 and F-actin were all
present at lower frequencies in WT synapses than in Vav1/
synapses. These differences are more obvious when directly
looking at the CMP motifs found be higher in Vav1/ syn-
apses (Table S2, Part B). Third, several signaling molecules
were mislocalized in Vav1/ synapses. For example, CD45
was found enriched in Vav1/ synapses suggesting failure in
synaptic exclusion. Most notably, total PLC1 was greatly
reduced in Vav1/ synapses and consequently also
pPLC1. Given the importance of Vav1 to SLP76 microclus-
ters (49), we expected to find reductions in tSLP76 at the
synapse but tSLP76 was unexpectedly less enriched in WT
synapses. However, motifs containing pSLP76 were clearly
expressed at lower frequencies in Vav1/ synapses again
suggesting inadequate signaling in Vav1/ synapses. In con-
trast, no or only minor differences were found in localization of
LCK, pLAT, pZAP70, CD54, p38 and ERK, indicating that
FIG. 5. Synapse formation and signaling is impaired in the absence of Vav1. A, Representative field of view WT versus Vav1/
T-cell–B-cell pairs. Selected synaptic pairs indicated by rectangles: green: used for analysis; red: excluded from analysis because of
interference by neighboring cells. Left: WT T-cells. Right: Vav1/ T-cells. Note that very few pairs are formed with Vav1/ T-cells. Scale bar:
50 m. B, Quantification of pair formation. Mean 
 S.E. from two independent experiments each with more than 50 WT and 50 KO T-cells
analyzed. C, Significant differences in molecular composition of WT versus Vav1/ synapses. Micrographs displaying signals of specific
molecule/co-localization motif (red) and synapse areas (SMAC or cSMAC, yellow) in synapses of two characteristic T-cell-B cell pairs. Box plots
and statistical significance of relative frequencies of the indicated molecules in the cSMAC. Whiskers show 5–95% confidence interval. Scale
bar: 10 m. D, Graphical illustration of the principal differences in composition between WT and Vav1/ synapses based on data obtained
from MELC CMP analysis.
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localization of these proteins does not primarily depend on
Vav1. Images of selected CMP motifs and quantitative com-
parisons of their occurrence in WT and Vav1/ synapses are
shown in Fig. 5C. A graphical summary of the signaling profile
in the Vav1/ T cells illustrates these alterations in signaling
clusters, showing the impaired recruitment of tPLC1,
pPLC1 and pSLP76 (Fig. 5D). These data confirm that Vav1
regulates PLC1 localization, either directly or indirectly
through protein complex formation, SLP76 activation, and
reveal a novel defect in CXCR4 localization. These results
represent the first large-scale imaging data on Vav1/ T-cell
synapses and validate the use of MELC to detect and quantify
molecular signaling defects at the level of the individual
synapses.
DISCUSSION
Current imaging technologies directed at the study of the
synapse are limited in the number of proteins that can be
tracked simultaneously. MELC technology has been used to
map multiple proteins in the same sample of fixed cells or
tissues. In this report, we used MELC for the first time to study
25 molecules at the immune synapse over an extended period
of time. We evaluated individual reagent stains over five time
points and performed quantitative analysis of co-localizations
of proteins and the relationships between different classes of
proteins at the synapse. We used the resulting data to char-
acterize the layered construction of the synapse, the compo-
sition of late-stage microclusters, and the structure of Vav1
mutant synapses.
Signaling at the synapse takes place in microclusters of
proteins containing TCR, phosphorylated TCR-proximal sig-
naling proteins including pLCK and pZAP70 and adapter pro-
teins including pLAT and pSLP76. Studies on live T cells
immobilized on lipid planar bilayers demonstrated that micro-
clusters originate in the dSMAC and migrate in an actin-de-
pendent manner to the center of the cSMAC (12, 40). We
analyzed images of signaling changes over 2 h at the synapse
of fixed cell pairs to identify trends in synapse formation. We
used primary mouse naïve T cells and naïve B cells, a homog-
enous APC population that display lower levels of co-stimu-
latory and danger signals than macrophages and dendritic
cells. With these cells, central localization of TCR clusters
took between 30 and 60 min, and TCR signaling, as measured
by the appearance of phosphorylated proteins, peaked at
60–120 min, consistent with previous observations (3, 17, 19).
While individual signaling molecules have been followed at
the synapse for over an hour (50), MELC enabled us to
analyze network-scale numbers of signaling proteins in this
time period.
Results from MELC revealed that the construction of the
synapse occurred in overlapping layers of proteins classes.
Based on recruitment of F-actin toward the periphery and of
CD3 toward the center of the synapse we observed the struc-
tural maturation in our synaptic population to be complete
after 120 min. Already at 5 min, we observed high levels of
phosphorylated molecules suggesting a rapid burst of signal-
ing from the sudden contact of T cell and B cells after cen-
trifugation, along with an appearance of pLAT and pZAP70,
but little F-actin or SLP76. This initial jolt of signaling tapered
off by 10 min, probably as T cells re-oriented to build a stable
synapse. The proper buildup of the mature synapse including
formation of a cSMAC (central CD3 accumulation) then
started at 10 min when intense TCR signaling (re-) started and
continued throughout. This was supported by processes of
consolidation and structural reinforcement that ranged from
30 to 60 min. At this time, costimulatory proteins like CD86
and CXCR4 began to appear and nonactivated signaling pro-
teins such as tERK were recruited. These events indicated a
period of structural enforcement and increased binding
strength of the cell-cell contact. In accordance with this, we
have previously observed a rise in binding forces between
APC-T-cell pairs after 30 min of APC-T-cell contact (41).
Furthermore, CD45R and CD45 were reduced in the synapse
area likely resulting in a release of TCR signaling from phos-
phatase inhibition, further indicating that a platform for sig-
naling was being assembled. A last, protracted stage of
strong TCR signaling accumulation and coalescence was ap-
parent at the timepoints 60 min and 120 min. The overall
levels of signaling molecules present in pSMAC and cSMAC
further increased compared with earlier timepoints. Signals by
pLAT in the pSMAC peaked at 60 min, although signaling
continued to rise in the central synapse area toward 120 min.
Thus, synapses were built in stages with a structural platform
that accompanied a gradual increase in signaling by pCD3,
pZAP70, pLAT, pSLP76 over the entire 2 h and a prolonged
and gradual shift from pSMAC to cSMAC signaling.
To parse the numerical data derived from our MELC anal-
ysis of synapses, we compared CMPs containing pLAT
and/or TCR (CD3) over the time course of the study. pLAT
was chosen as a marker of membrane domains that are
initially distinct from TCR membrane domains. It has recently
been shown that LAT is recruited to the membrane in sub-
synaptic vesicles where it becomes phosphorylated at SLP76
microclusters, and that when LAT domains couple to TCR
domains they become microclusters (12, 15). LAT and TCR
are also located in separate protein islands that concatenate
on activation (14). Analysis of CMP featuring pLAT alone
versus CMP with TCR alone revealed that they exhibited
dynamics consistent with the merging of LAT and TCR into
clusters. As the CMP containing pLAT alone without TCR
declined in the pSMAC, they increased in the cSMAC together
with CMP containing both pLAT and TCR, suggestive of a
merging of two different clusters to make a functional signal-
ing TCR microcluster (14). In addition, the high frequency of
colocalized signaling mediators at delayed time points under-
lines the potential importance of these late stages of synapse
formation for T-cell activation. Indeed, the time point of 120
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min coincides with the minimum time needed for a B-cell–T-
cell contact to ensure full T-cell activation (3).
We found that signaling within the synapse culminated in a
small number of large microclusters at the border between the
pSMAC and cSMAC. Within these microclusters the proteins
most specifically co-localized were active pSLP76 (used to
define the clusters), pLAT, pLCK, pZAP70, and pCD3. This
cluster composition corresponds to that described for proper
microclusters (signalosomes consisting of CD3, pZAP70,
pSLP76, pLAT, pPLC1, and others) and their surrounding
area (consisting of CD3, pERK, CD45, and others) as previ-
ously reported (40). Surprisingly, F-actin was negatively as-
sociated with these microclusters. It is possible that these
microclusters (rendered at 60 min onset of pair formation)
represent late-stage signaling in a mature, fully developed
synapse. The large size of the microclusters, the small number
of them, the location and the negative association with F-actin
are all consistent with the possibility that these microclusters
have coalesced, moved toward the center of the synapse and
are detaching from actin, but can nonetheless still actively
signal.
MELC was also used to analyze synapse formation in Vav1
mutant T cells. We observed that loss of Vav1 resulted in an
approximate two-thirds decrease in the number of synapses
formed, which represents a challenge in conventional bio-
chemical analysis of signaling in synapses. However, MELC
assessment of mass protein localization at single T-cell level
could still point to defects in Vav1 KO T cells that might lead
to insights into development of mutant cells. Given that Vav1
is mutated in the T-cell germline of the mice used here, we
reasoned that it is possible that any signaling-active T-cells
were selected during development for the ability to overcome
the loss of Vav1, possibly by having greater levels of proteins
that would make TCR signaling easier (51) and that MELC
might be helpful in detecting them. For example, our CMP
array showed that CXCR4 is significantly increased in the
synapses of Vav1 T cells. CXCR4 is associated with TCR,
recruited to synapses and signals through ZAP70 (52). It is
possible that increased levels of CXCR4 at the synapse gen-
erate enough additional signaling through ZAP70 to partially
compensate for lower levels of TCR and higher levels of
CD45, leading to signaling-active Vav1 KO T cells. However,
the severe decrease in PLC1 recruitment to the synapse we
observed would hinder normal TCR signaling to calcium-de-
pendent targets such as NF-kB or NFAT. In contrast, we
observed normal localization and activation of the critical
adaptor LAT, indicating that some of the main TCR signaling
events can still occur without Vav1.
In the future, MELC results can be expanded by using new
techniques such as using grids to hold conjugate pairs in
place to enable clear imaging of the interface planes (45), or
using super-resolution imaging technologies (53, 54) to im-
prove resolution to low nm scales. We demonstrated here the
use of MELC as a tool to analyze the architecture of the
synapse over 2 h, the composition of microclusters, and the
synapse composition following loss of a key TCR signaling
protein, Vav1. This report highlights the advantages of using
MELC to perform network-scale studies to shed light on the
complex functions of the immune synapse.
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Lymphocytes use the integrin leukocyte function-
associated antigen-1 (LFA-1) to cross the vasculature into
lymph nodes (LNs), but it has been uncertain whether
their migration within LN is also LFA-1 dependent. We
show that LFA-1 mediates prolonged LN residence as
LFA-1
 / CD4 T cells have significantly decreased dwell
times compared with LFA-1þ /þ Tcells, a distinction lost in
hosts lacking the major LFA-1 ligand ICAM-1. Intra-vital
two-photon microscopy revealed that LFA-1þ /þ and
LFA-1
 / T cells reacted differently when probing the
ICAM-1-expressing lymphatic network. While LFA-1þ /þ
T cells returned to the LN parenchyma with greater
frequency, LFA-1 / T cells egressed promptly. This
difference in exit behaviour was a feature of egress
through all assessed lymphatic exit sites. We show that
use of LFA-1 as an adhesion receptor amplifies the number
of T cells returning to the LN parenchyma that can lead to
increased effectiveness of T-cell response to antigen. Thus,
we identify a novel function for LFA-1 in guiding T cells at
the critical point of LN egress when they either exit or
return into the LN for further interactions.
The EMBO Journal (2013) 32, 829–843. doi:10.1038/
emboj.2013.33; Published online 26 February 2013
Subject Categories: signal transduction; immunology
Keywords: LFA-1; lymphatics; lymph node; migration;
T cells
Introduction
The integrin leukocyte function-associated antigen-1 (LFA-1;
aLb2; CD11a/CD18) contributes to lymphocyte adhesion and
migration in two major ways. It orchestrates adhesive inter-
actions between T and B lymphocytes and their antigen-
presenting cells (APC) thereby lowering the threshold for
stimulation during immune responses (Grakoui et al, 1999;
Carrasco et al, 2004). LFA-1 is also vital for the continual
migration of lymphocytes across high endothelial venules
(HEVs) into lymph nodes (LNs) and into other tissues during
an infection (Hamann et al, 1988; Berlin-Rufenach et al,
1999). Entering an LN is a multistep process that includes
signalling into lymphocytes by endothelial-tethered
chemokines (von Andrian and Mempel, 2003; Bajenoff
et al, 2007; Evans et al, 2009; Girard et al, 2012). This
initiates the process of LFA-1 activation, firm binding of
lymphocytes and their subsequent migration across the
vasculature into the LN parenchyma. An unresolved
question is whether LFA-1 exclusively mediates immigration
into the LN or, in the absence of antigen, also has a role in
leukocyte trafficking within the node itself. In favour of
integrin-independent migration are studies with ‘integrin
nude’ dendritic cells (DCs) that migrate normally in vivo
(Lammermann et al, 2008). In contrast, CD18 / T cells
move in the T zone of the LN with 15% lower velocity than
WT T cells (Woolf et al, 2007).
T lymphocytes continually leave the circulation and spend
6–12 h within an LN where they may encounter APC in
keeping with their role in immune surveillance (Smith and
Ford, 1983; Tomura et al, 2008). The LN is a lymphocyte-
filled structure consisting of dense T and B cell-dominated
areas, each with a network of potentially antigen-loaded
conduits and presenting cells along which the lymphocytes
migrate (Gretz et al, 2000; Sixt et al, 2005; Bajenoff et al,
2006). T cells exit the LN via the lymphatic vessel (LV)
network composed of the subcapsular sinus that connects
with the T zone adjacent cortical sinuses and the
macrophage-rich medulla. Recent reports show that T cells
can exit into the LVs from all these locations within the node
(Grigorova et al, 2009; Sinha et al, 2009). Their departure
from the LN depends on competition between the CCL19/
CCL21 chemokine receptor CCR7 that delivers a retention
signal and the sphingosine 1-phosphate receptor-1 (S1P1)
that increases in expression over time that the Tcells spend in
the LN (Lo et al, 2005; Pham et al, 2008). Interaction of S1P1
with its ligand sphingosine 1-phosphate (S1P) on the
lymphatic endothelium is considered to constitute a
directional signal for T-cell egress (Grigorova et al, 2009).
As a final step, the lymphocytes are transported by the
lymphatic drainage into blood via the thoracic duct
(Gowans, 1957).
We show by adoptive transfer and intra-vital two-photon
microscopy that LFA-1 / T cells pass through the LN more
rapidly than LFA-1þ /þ T cells and that LFA-1 is not essential
for T-cell egress. In contrast, LFA-1-expressing T cells are
restrained on the lymphatic vasculature and re-visit the
LN parenchyma with greater frequency rather than exiting
immediately. This leads to a more effective priming
of adoptively transferred T cells in WT LNs, compared with
ICAM-1 / LNs. Thus, we identify LFA-1 as a critical
adhesion factor influencing the fate of T cells at the point
of LN exiting.
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Results
Transit of LFA-1 / and LFA-1þ /þ T lymphocytes
through the inguinal LN
To assess whether the major subset of recirculating CD4 T
cells use LFA-1 as they travel through a LN, we compared the
intra-nodal behaviour of LFA-1 / and LFA-1þ /þ T cells.
The two CD4 T-cell populations expressed comparable pro-
portions of CD44lo and CD62Lhigh markers typical of recircu-
lating naı¨ve cells that have not been exposed to antigen
(WT, 68.5±3.66%; KO, 75.63±3.02% (mean±s.e.m.),
n¼ 6 mice, P¼ 0.163), with the remainder representing a
more mature CD44high and CD62Llo-int CD4 T-cell phenotype
(Supplementary Figure 1A). Thus, lack of LFA-1 did not affect
T-cell maturation in terms of proportions of naı¨ve and non-
naı¨ve CD4 T cells.
Following differential labelling using either fluorescent green
CSFE or orange SNARF-1 dyes, we injected purified CD4 Tcells
in equivalent numbers into the tail vein of host WT mice as
previously described (Berlin-Rufenach et al, 1999). The
adoptively transferred CD4 T cells revealed a uniform
phenotype of CD44lo and CD62Lint, typical of intra-nodal
naı¨ve T cells (WT, 93.2±0.92%; KO, 95.2±0.95%
(mean±s.e.m.), n¼ 4 mice/group, P¼ 0.335) (Supple-
mentary Figure 1B; Klinger et al, 2009). Pre-sorting CD4 and
CD44lo T cells yielded a similar result (data not shown).
At 6 h when both entry into and egress from the inguinal
LN was occurring, the ratio of LFA-1þ /þ over LFA-1 / CD4
T cells was B7:1 (WT/KO, 6.8±1.5) (mean±s.d.)
(Figure 1A; Smith and Ford, 1983; Tomura et al, 2008).
To focus exclusively on the behaviour of T cells already in
the LN, we blocked further entry at 6 h using a combination
of MEL-14 and PS2/3 mAbs specific for L-selectin and a4
integrin, adhesion receptors that have critical roles in
lymphocyte LN entry along with LFA-1. In control
contemporaneous experiments, we showed that the mAb-
blocking regime equivalently prevented entry of LFA-1þ /þ
and LFA-1 / T cells into the inguinal LN (WT block—
98.9±0.4%, KO block—99.4±0.3% (mean±s.e.m.), n¼ 3
mice per group) (Supplementary Figure 1C). Following
this blockade, the WT/KO ratio was altered 4–6 h later to
B16:1 (10 h: WT/KO, 15.7±5.0; 12 h: WT/KO, 17.5±4.5)
(mean±s.d.) (Figure 1A). It was important to establish that
the adoptively transferred LFA-1þ /þ and LFA-1 / T cells
were equally viable between 6 and 10 h (Annexin V staining,
data not shown). Thus, the 2.3-fold increase in WT/KO ratio
suggested that LFA-1 / T cells passed through the LN at a
faster rate than LFA-1þ /þ T cells.
To further confirm that it was absence of LFA-1 itself that
was responsible for the altered LN trafficking, we decreased
the advantage of LFA-1þ /þ over LFA-1 / CD4 T cells by
transferring both T-cell types into host mice deficient in the
most widespread LFA-1 ligand, ICAM-1 (Figure 1B). In this
situation, the initial ratio of LFA-1þ /þ to LFA-1 / T cells
was similar to the WT hosts as LFA-1þ /þ T cells can make
use of a second LFA-1 ligand, ICAM-2, to cross the HEV
(Boscacci et al, 2010). Following mAb blockade at 6 h of
further T-cell LN entry into ICAM-1 / host mice, the WT/
KO ratio did not however significantly change at 10 h (6 h:
WT/KO, 5.4±1.2; 10 h: WT/KO, 3.5±0.2 (mean±s.d.))
unlike the situation in the WT host (Figure 1B). This provided
more evidence that it was lack of LFA-1 and not some other
developmental feature of LFA-1 / T cells that was respon-
sible for the accelerated journey of the Tcells through the LN.
We next asked whether T-cell access to the different
compartments of the LN was LFA-1 dependent and would
provide an explanation for the more rapid LN journey
of LFA-1 / T cells. Adoptively transferred LFA-1þ /þ and
LFA-1 / CD4 T cells were both observed to be widespread
in the T-cell parenchymal areas at 6 h after T-cell transfer,
ranging from the peripheral areas bordering the B-cell
follicles (inset 1) to the dense T-cell zone (inset 2)
(Figure 1C). An average of 95.7±16.6 LFA-1þ /þ and
LFA-1 / 16.7±2.8 T cells was counted in LN sections of
the T-cell zone (mean±s.e.m. of individual LN tissue slices
from 7 host mice) giving a ratio of 7/1, which is identical to
the ratio obtained by flow cytometry of whole LNs.
Although lack of LFA-1 expression did not prevent T cells
from accessing the T-cell zone, it might influence the
characteristics of their migration. Investigating the motility
of the two types of cells using intra-vital two-photon micro-
scopy within the T zone, we found that LFA-1þ /þ Tcells were
11% faster than LFA-1 / T cells (WT, 12.30±0.49 mm/min
versus KO, 10.82±0.44 mm/min (mean±s.e.m), Po0.02)
(Figure 1D). There was no significant difference in their
migration in ICAM-1 / hosts (WT, 9.84±0.55 mm/min
versus KO, 8.62±0.41 mm/min, P¼ 0.08) (Figure 1D).
This further confirmed that the effect on migration was
LFA-1 regulated by binding of LFA-1 to ICAM-1.
In summary, LFA-1 / CD4 T cells had a shorter dwell
time in the LN than LFA-1þ /þ T cells implying that the latter
cells were being restrained through interaction via LFA-1. The
fact that LFA-1þ /þ T cells had slightly increased speed
compared with LFA-1 / T cells in the T zone did not
obviously account for their apparently longer time in the
LN. Importantly, the difference in travel time was abolished
when LFA-1þ /þ T cells were adoptively transferred into
ICAM-1 / hosts where they behaved like LFA-1 / Tcells.
Accumulation of LFA-1þ /þ T cells compared with
LFA-1 / T cells at LYVE-1-expressing LVs
A possible explanation for the difference between LFA-1þ /þ
and LFA-1 / T cells in the timing of LN residence might
depend on a differential ability to leave the LN via the
draining lymphatic vasculature. To directly test this possibi-
lity, we investigated T-cell associations with the LV by intra-
vital two-photon imaging of the inguinal LN from its hilar
side towards the follicular side up to a depth of B150mm.
It was possible to compare areas of the T zone that were LV
free as well as distinct LV-containing areas. Within the latter,
we observed centrally located, T zone-adjacent LV areas
(central, cLV) where the network of LV was tubular in
shape and without any macrophage association and more
peripherally located LV areas (peripheral, pLV) towards the
medullary region, where the tubular LV became increasingly
lined with macrophages (Miller et al, 2002; Matheu et al,
2011) (Figure 2A; Supplementary Figure S2A).
The overall density of adoptively transferred T cells in these
two areas was similar (cLV, 26.8±6.4 total Tcells/field of view;
pLV, 29.0±12.9 total T cells/field of view). However, the
important finding was that the ratio of LFA-1þ /þ /LFA-1 /
T cells in both of the LV-dominated regions was enhanced by
B50% compared with the proper T zone (ratio in T zone set at
1:0 for comparison purposes) (Figure 2B). This greater
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LV-associated accumulation of LFA-1þ /þ Tcells was lost when
ICAM-1 / mice were used as hosts further confirming a key
role for LFA-1 in this skewed distribution (Figure 2C).
Collectively, the analysis of T-cell distribution within the
LN revealed that LFA-1þ /þ T cells were more extensively
represented than LFA-1 / T cells in the regions where
LV pre-dominated. As this effect was dependent on ICAM-1,
LFA-1 appeared to affect the behaviour of T cells at the LV via
ICAM-1 interactions.
Expression of ICAM-1 by LVs
An important issue was whether LYVE-1þ LV directly
expressed the most widespread LFA-1 interaction partner,
ICAM-1, under non-inflammatory conditions. A broad pattern of
ICAM-1 staining was observed on LN tissue sections with
labelling of macrophages, DCs, fibroblastic cells, and endothelial
cells as previously described (Katakai et al, 2004; Westermann
et al, 2005; Woolf et al, 2007). We also observed significant
ICAM-1þ staining that colocalised with LYVE-1þ LV in both
the central (inset 1) and peripheral (inset 2) regions of the LN
(Figure 3A). To quantify the coincidence in expression of LYVE-1
and ICAM-1 on the LVs, we randomly selected LVand performed
pixel-by-pixel comparison of LYVE-1 and ICAM-1 staining
(Figure 3B). The overlap in staining indicated substantial
co-expression (central LV: 72.93±1.75%; peripheral LV:
80.26±3.0%; isotype control: 1.2±0.4% (mean±s.d.)).
Figure 1 Comparison of non-stimulated LFA-1þ /þ and LFA-1 / CD4 T-lymphocyte behaviour in the inguinal LN. (A) The numbers of CD4 T
cells in host mice expressed as a ratio of LFA-1þ /þ (WT) to LFA-1 / (KO) over time; CFSE and SNARF-1-labelled CD4 Tcells (5106 per cell
type) were adoptively transferred into WT host mice and the T cells present in the LN at 6, 10 and 12h were quantified; further entry was
blocked from 6h onwards with anti-L-selectin and a4 mAbs; each data point representsX7 mice. (B) Experimental set-up as in (A), but with
ICAM-1 / mice used as adoptive transfer hosts. The ratio of WT/KO CD4 Tcells at 6 and 10 h is shown; n¼ 9 mice per time point. (C) Tiled
image showing immunostained CD3þ T-cell area (green) and B220þ B-cell follicles (red). Insets show the distribution at 6 h following transfer
of LFA-1þ /þ Tcells (WT, red), LFA-1 / Tcells (KO, green) and collagen IV (blue) at the T-/B-cell boundary (inset 1) and the deep T-cell zone
(inset 2). The images are representative of six tissue slices from three mice. (D) Motility of LFA-1 / and LFA-1þ /þ CD4 cells in T-cell zone in
WT and ICAM-1 / host mice in the T zone at 150mm depth; velocity data from intra-vital two-photon imaging combined from three
experiments with 4100 cells analysed per host mouse strain.
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These findings established that the LV of unimmunised
mice expresses the LFA-1 ligand ICAM-1 in situ, thus provid-
ing interaction opportunities for LFA-1-expressing T cells.
LFA-1þ /þ and LFA-1 / T cells differ in terms of ICAM-
1-dependent migration to chemokine CCL21 and S1P
As critical interplay between receptors CCR7 and S1P1 gov-
erns T-cell exit into the LV (Lo et al, 2005; Pham et al, 2008;
Grigorova et al, 2009), a difference in migratory response to
the key mediators CCL21 and S1P might explain the
behaviour of LFA-1 / compared with LFA-1þ /þ T cells.
Western blotting indicated that their receptors S1P1 and
CCR7 were equally expressed in terms of total receptor
amounts by the two T cell types (Figure 4A) and CCR7 was
detected equivalently at membrane level as determined by
FACS analysis (WT, 4745±2285 versus KO, 4482±2264
Figure 2 Distribution of LFA-1þ /þ and LFA-1 / Tcells in T zone and peripheral regions of the LN. (A) Tiled image of an explanted inguinal
LN showing three distinct zones used for quantification of the LFA-1þ /þ /LFA-1 / T cell (WT/KO) ratio; scale bar¼ 100mm. Insets for each
zone as typically quantified for analysis are shown: the T-cell zone (T zone,4150mm depth); central zone (cLV) at 80–150mm depth showing
LYVE-1þ lymphatic vessels (blue); peripheral medullary region (pLV) at 50–80 mm depth showing LYVE-1þ LV (blue)±associated auto-
fluorescent macrophages (white). (B) Increased prevalence of LFA-1þ /þ over LFA-1 / T cells in the central and peripheral LV-associated
regions over the T zone (set at an index ratio of 1.0) in WT host mice; data are averaged from four experiments with a total of 4600 T cells
analysed. (C) Lack of increased prevalence of LFA-1þ /þ over LFA-1 / Tcells in central and peripheral type LV-associated regions over T zone
in host ICAM-1 / mice; data are averaged from three experiments with 4500 T cells analysed.
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(mean fluorescence intensity±s.d.)) (Figure 4B). We next
tested the T cells for their ability to undergo migration to S1P
and CCL21 using a transwell chemotaxis assay under ICAM-
1-independent (Figure 4C) or ICAM-1-dependent conditions
(Supplementary Figure 3). Under these circumstances,
LFA-1 / as well as LFA-1þ /þ T cells responded positively
to the mediators and in a similar fashion whether or not
ICAM-1 was present. Finally, we measured the response to
S1P and CCL21 in a shear flow assay where engaging im-
mobilised ICAM-1 and stimulants was necessary for adhesion
and migration. Under these conditions only LFA-1þ /þ Tcells,
but not LFA-1 / T cells, were able to attach and migrate
to both S1P and CCL21 (Figure 4D).
Although these in vitro experiments showed LFA-1 / and
LFA-1þ /þ Tcells to be migrating similarly in response to S1P,
a question was whether the motility difference observed
in vivo was dependent upon responsiveness toward S1P
within the node. However, treatment of mice with FTY720,
the general downregulator of S1P receptor that causes block-
ade of T-cell egress from the pLN, did not alter the velocity
differential between LFA-1þ /þ and LFA-1 / CD4 T-cell
motility within the LN (Supplementary Figure 4).
These experiments showed that signalling through CCR7
and S1P1 on the CD4 T cells was not altered by LFA-1
deficiency. Additionally, both mediators had the ability
to activate LFA-1 adhesion/migration under shear flow
conditions. This differential adhesion to ICAM-1 could also
be a factor determining T-cell behaviour in vivo and, when
happening at ICAM-1-expressing LV, might be expected
to influence their egress.
Figure 3 Co-expression of ICAM-1 and LYVE-1 on the lymphatic vasculature. (A) Immunohistochemical images of an unstimulated inguinal
pLN tissue section comparing LYVE-1 (green) LV with ICAM-1 (red) and merged (yellow) staining; scale bar¼ 50mm. Shown enlarged below:
inset 1 indicates a T zone-associated LV and inset 2, a peripheral LV region; scale bars 10 and 20 mm, respectively. (B) Pixel-by-pixel
determination of the overlap in staining between LYVE-1 and ICAM-1 on LV; data were generated from tissue sections of seven LNs. An isotype
control mAb for ICAM-1 was also compared with LYVE-1 mAb and showed no staining or overlap; tissue sections from three LNs.
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LFA-1þ /þ and LFA-1 / T-cell associations with central
LVs adjacent to the T zone
We next studied the motile behaviour of T cells in regions
with LYVE-1þ LVs. In general, the T cells within the para-
cortical region were observed to migrate with higher motility
than the Tcells at the periphery of the T zone (Supplementary
Video 1). The spread of high MW FITC dextran indicated that
the flow of lymphatic fluid throughout the network was intact
during the investigation (Supplementary Figure S2B; Gretz
et al, 2000). This was further corroborated by observing
persistent lymphatic flow during the whole imaging period
as detected in an efferent vessel over 2 h (Supplementary
Video 2).
The LVs in the paracortical area were characteristically
tubular shaped and devoid of associated macrophages
(Figure 5A). The velocity of the T cells associated
with these LVs resembled their average speed in the T zone
with LFA-1þ /þ T cells migrating faster than the LFA-1 /
T cells (WT, 12.47±0.53 mm/min versus KO, 8.54±0.55 mm/
min) (Figure 5B). Towards the periphery of the T zone, the
tubular LVs gradually became sparsely associated with
auto-fluorescing macrophages (white) (Supplementary
Figure 5). The speed of the more peripheral LFA-1þ /þ
T cells also decreased to the extent that they now migrated
more slowly than the LFA-1 / T cells (WT, 4.45±
0.43 mm/min versus KO, 6.48±0.41 mm/min).
In spite of these differences in speed between LFA-1þ /þ and
LFA-1 / T cells in the T zone regions, similar propor-
tions contacted and probed the LV membranes (WT,
65.79±5.22% versus KO, 65.23±8.47% (mean±s.e.m))
(Figure 5C). However, the outcome of this contact was
substantially different when the two types of T cells were
compared in that a higher proportion of LFA-1 / than
LFA-1þ /þ T cells crossed into the LV sinuses (WT,
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Figure 4 Responses of LFA-1þ /þ and LFA-1 / CD4 Tcells to S1P and CCL21. (A) Western blotting analysis of CCR7 and S1P1 (EDG-1) levels
in CD4 Tcells with a-tubulin serving as a sample loading control; data are typical for n¼ 2 experiments. (B) Flow cytometry analysis indicating
the proportions of LFA-1þ /þ and LFA-1 / CD4 lymphocytes in LN and splenocyte sample and the proportion of each that expressed CCR7;
typical result of n¼ 2. (C) Transwell assay on uncoated filters showing the percentage of total input T cells that responded to 25 nM S1P and
6 mM CCL21 in the lower chamber; data averaged from n¼ 6 assays. (D) Shear flow assay showing proportion of total T cells in contact with
ICAM-1 that adhered and migrated under flow conditions of 1 dyne cm2 in response to S1P and CCR7 as above; n¼ 90–120 T cells were
analysed per condition; n¼ 3 experiments.
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11.62±3.34% versus KO, 29.73±4.70% (mean±s.e.m))
(Figure 5D; Supplementary Video 3). Correspondingly, higher
numbers of LFA-1þ /þ than LFA-1 / T cells returned to the
T-cell parenchyma after making LV contact (WT,
88.37±3.34% versus KO, 70.25±4.71% (mean±s.e.m))
(Figure 5E).
A question was whether the 2.3-fold decrease in LN dwell
time of LFA-1 / compared with LFA-1þ /þ T cells
(Figure 1A) could be accounted for by the use of LFA-1 to
reverse migrate back into the LN. To investigate this issue, the
comparative proportion of LFA-1þ /þ or LFA-1 / T cells
leaving the LN at 6 h was determined by calculating the
percentage of each T-cell type in contact with LV that
subsequently exited over 30min following adoptive transfer
(WT—11.62 0.65¼ 7.55%; KO—29.73 0.65¼19.32%).
Over this time period 2.6-fold more LFA-1 / than
LFA-1þ /þ T cells left the LN indicating that their distinctive
behaviour at the point of LV contact could account for the
effect of LFA-1 on T-cell LN dwell time. This is a rough
estimate as it is unknown whether the rate of reverse migra-
tion versus exiting is the same at all time points and at all LV
contacts within the LN.
In summary, LFA-1 / T cells were able to cross into the
LV and did so with almost three times the frequency of
LFA-1þ /þ T cells which preferentially reverse migrated back
to the node parenchyma following LV contact.
LFA-1þ /þ and LFA-1 / T-cell interactions with
the distal LV network vessels in the medulla region
of the LN
The final option for exit from the LN is in the medulla
although many fewer T cells exited in this region compared
with the more centrally located LVs. Immunohistochemical
staining showed the medullary LVs to have the appearance
of an open meshwork of interconnecting LYVE-1þ
sinuses (green) intimately associated with numerous
MOMA-1þ (CD169, sialoadhesin) macrophages (blue) some
of which also expressed LYVE-1 (Gordon et al, 2010;
Figure 6A, inset). Both LVs and associated macrophages
expressed ICAM-1 (Supplementary Figure 6).
Furthermore, because of the dominance of the meshwork-
like LV network in this region it was easier to observe the
shape of the T cells, but more difficult to identify individual
LV and T-cell entry and exit events. T cells extensively probed
the interconnected LV structures by crawling over and adher-
ing to them. LFA-1þ /þ T cells migrated at an average lower
velocity than the LFA-1 / T cells (WT, 3.83±0.37 mm/min
versus KO, 5.93±0.40 mm/min, Po0.001 (mean±s.e.m))
(Figure 6B and C; Supplementary Video 4). LFA-1þ /þ
T cells frequently appeared elongated, whereas many of the
LFA-1 / T cells maintained a rounder morphology.
Measurement of the cells’ longest versus shortest dimensions
indicated that 38.5% of LFA-1þ /þ T cells had axis ratios of
Figure 5 Association of LFA-1þ /þ and LFA-1 / Tcells with the lymphatic vessels in the central LV region. (A) Intra-vital microscope image
of LFA-1 / and LFA-1þ /þ CD4 cells interacting with cortical LV located at 80–150 mm depth from the hilar region where LV (LYVE-1þ , blue)
appears tubular and macrophage free; scale bar¼ 50mm. (B) Quantification data for T-cell velocity in areas with x–y axis length of 250mm
encompassing tubular cLV; a total of 4150 cells were analysed (WT, 94 cells; KO, 67 cells) combined from 3 experiments. (C) Frequency of
probing on outer LV walls by both T-cell types. (D) Proportion of T cells that crossed into the LV following probing of LV walls. (E) Proportion
of T cells that returned to T-cell parenchyma following probing behaviour; (C–E) data combined from n¼ 5 experiments with 4400 T cells
analysed; T-cell probing and crossing in LV was recorded during an observation time of 30min.
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41.5 compared with only 7.7% LFA-1 / T cells
(Figure 6D). This difference in morphology suggested
that the elongated LFA-1þ /þ T cells, unlike the LFA-1 /
Tcells, were attached and adhesive. Swapping the fluorescent
dyes between LFA-1þ /þ and LFA-1 / T cells yielded the
same result (Supplementary Figure 7).
Figure 6 Association of LFA-1þ /þ and LFA-1 / T cells with the LV network in the medulla. (A) LYVE-1þ LV and MOMA-1/CD169þ
macrophages in the medulla area. Tissue section of inguinal LN was stained for LYVE-1 (green) and MOMA-1/CD169 (blue) and analysed by
confocal microscopy, scale bar¼ 30 mm; inset shows detail of close association of LVand macrophages; image typical of sections from n¼ 3 LN.
(B) Migratory behaviour of LFA-1þ /þ (WT, green tracks) and LFA-1 / (KO, red tracks) CD4 T cells on the LYVE-1 network of vessels (blue)
viewed from the hilar region at 50 mm depth, scale bar¼ 50 mm. (C) Quantification of velocity is shown for both LFA-1þ /þ and LFA-1 / cells;
data combined from two characteristic experiments each with 450 T cells analysed/group. (D) Axis ratio of LFA-1þ /þ and LFA-1 / T-cell
shape; quantification of the relative proportion of each cell type with a length/width ratio ofo1.5 compared with proportion that were41.5;
data combined from three experiments with a total of 4100 T cells/type analysed are shown. (E) T cells in contact with LYVE-1þ LV in the
medulla (blue); kinetics of LFA-1þ /þ and LFA-1 / T-cell migration across the LV of the medulla into the efferent lymphatic drainage; paths
taken by the T cells over 6min are indicated (WT: green; KO: red), scale bar¼ 50mm; upper right panel: proportion of each T-cell
type disappearing into lymphatic drainage and lower right panel: duration of presence or dwell time of each T-cell type during the observation
period; data represent the mean±s.e.m. of two characteristic experiments (45 WT and 25 KO T cells analysed) each observed over a
10-min period.
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Supporting their adhesive appearance, LFA-1þ /þ T cells
displayed a more sessile behaviour, while LFA-1 / moved
more rapidly over the LV network and disappeared faster
from the imaging field. Over a 10-min period, 68% LFA-1 /
T cells left the tissue compared with 31% of the LFA-1þ /þ
T cells which continued their probing interactions on the LV
network (Figure 6E). Correspondingly, the LFA-1 / T cells
disappeared quickly with an average lymphatic contact time
of 5.7±0.67min, whereas the LFA-1þ /þ T cells took
8.24±0.33min to cross the LVs (Figure 6E).
In summary in the medulla the LFA-1þ /þ T cells migrated
more slowly than LFA-1 / T cells which correlated with
greater adhesive contact with the LV network of cells.
In contrast, LFA-1 / T cells were observed to be less
adherent and more motile, with the consequence that they
exited more rapidly than the LFA-1þ /þ T cells after they had
engaged the LV membrane.
An assessment of directionality of T-cell migration
at the lymphatic vasculature and its functional
implications
As a further measure of the effect of LFA-1 on exiting
behaviour, we measured the T-cell migratory angle in
association with the LVs in the central paracortical region
(Figure 7A). As the LVs were frequently branched and
curvaceous, we defined a default exit angle for each
individual imaging field according to its planar orientation
to the LVand quantified the path length travelled by the Tcell
within a range of 901 around the specified exit angle. LFA-1 /
T cells followed a more direct trajectory compared with
LFA-1þ /þ T cells (Figure 7B). This suggested that LFA-1 inter-
actions were dictating the deviation from the most straightfor-
ward exit route. The difference disappeared in ICAM-1 /
hosts further confirming the role of LFA-1 in the migration
pattern at the point of making the exit decision (Figure 7C).
Figure 7 Measurement of directionality of T-cell migration at LV exit structures. (A) Migratory behaviour of LFA-1þ /þ and LFA-1 / T cells
showing their individual tracks adjacent to LYVE-1þ lymphatic vasculature (blue); exit angle as defined for this field of view indicated by
arrow (white); scale bar¼ 50mm. (B) Quantification of all cumulative path length and orientation data: proportion of LFA-1þ /þ and LFA-1 /
T cells in WT hosts migrating in exit direction (within a 90o angle around defined exit angle). (C) As (B) but in ICAM-1 / hosts.
(D) A comparison of T cells migrating directly on the LV versus T cells within this area without LV contact during the time of analysis. Data
represent the mean of n¼ 3 experiments with 4150 cells total analysed in each experimental group during an observation time of 30min.
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To test whether the direction of migration was influenced
by the LV directly or alternatively by closely associated cells
in the immediate microenvironment, we looked at direction-
ality of T cells both on and off the LV. LFA-1þ /þ T cells
displayed a more random directionality compared with
LFA-1 / T cells when in direct contact with LV, whereas
their migratory behaviour did not differ when not in contact
(Figure 7D). Thus, the more random migration of LFA-1þ /þ
T cells at the point of LV exit is dictated by direct contact
with LV.
A role for ICAM-1-expressing LV in increased immune
responsiveness
It was important to clarify whether prolonged T-cell contact
with ICAM-1-expressing LVs might be an epi-phenomenon
without biological significance or would directly affect T-cell
function. A reasonable hypothesis was that such contact
aiding reverse migration back into the LN would allow
T cells further opportunities to encounter any antigen-laden
APC thus enhancing an immune response. To discriminate
between the use of LFA-1/ICAM-1 for optimal antigen pre-
sentation and LV egress behaviour, we adoptively transferred
equal numbers of WT DCs pre-incubated or not with ovalbu-
min peptide (pOVA) into the footpads of ICAM-1 / and WT
hosts as previously described (Mempel et al, 2004;
Lammermann et al, 2008). CFSE-labelled OVA-TCR
transgenic OT-2 CD4 T cells were injected i.v. 16 h later.
Previous studies have shown overlapping roles for ICAM-1
and ICAM-2 in LN homing, suggesting that OT-2 T cells
would not be significantly delayed in entry into the LN of
ICAM-1 / host mice (Lehmann et al, 2003; Boscacci et al,
2010) and we observed this to be the case (WT, 3315±843
versus KO, 2270±551 homing OT-2 T cells; n¼ 3
experiments). In this context, the OT-2 T cells should have
an equivalent opportunity for stimulation in each host. When
proliferation of the T cells isolated from ipsilateral LNs was
assessed at 72 h, proliferation in the nodes of ICAM-1 /
hosts was significantly reduced compared with WT hosts
(Figure 8A and B). There was also a trend for ongoing
proliferation in the contralateral LN of the WT host, suggest-
ing that stimulated T cells had already left the directly
stimulated LN. These experiments indicate that LFA-1 con-
tributes to an immune response not only via the well-
described interaction between T cells and DCs but also at
the level of the LVs.
Discussion
It is well established that T-cell migration across the high
endothelial vasculature into LN relies on the integrin LFA-1
(Hamann et al, 1988; Berlin-Rufenach et al, 1999). In this
study, we have asked whether LFA-1 plays any role within the
LN during the trafficking of T cells that continually circulate
between blood and the LNs. We found that LFA-1 / CD4 T
cells spend less time in the LN than LFA-1þ /þ lymphocytes
yet show similar behaviour in ICAM-1 / host mice. Intra-
vital microscopy revealed that after probing the surface of
LVs, LFA-1þ /þ Tcells more frequently returned back into the
LN, whereas LFA-1 / Tcells had a greater tendency to exit.
Thus, T cells did not require LFA-1 to exit, but rather LFA-1-
mediated adhesion to the LV contributed to reverse migration
back into the LN parenchyma.
We first verified that the reduced dwell time of LFA-1 /
Tcells in the LN was not accounted for by lack of niche access
nor speed of migration within the T zone. In fact, LFA-1 /
T cells migrated somewhat more slowly than LFA-1þ /þ
T cells, a deficit also observed in CD18 / T cells (Woolf
et al, 2007). This difference was lost in host mice lacking the
LFA-1 ligand ICAM-1. Comparison of the migration in
different areas of the LN revealed a gradual decrease in
T cell speed from central T zone to the peripheral and
medullary regions, that predominantly affected LFA-1þ /þ
T cells. The slower speed in the medulla has previously also
been noted by others (Wei et al, 2005; Sanna et al, 2006;
Nombela-Arrieta et al, 2007; Grigorova et al, 2009, 2010).
The speed of T-cell migration may be influenced by locally
regulated LFA-1 activation and deactivation brought about
through contacts in the densely cellular LN microenviron-
ment where ICAM-1 varies. A feature of DC migration, for
example, is chemokine-induced adhesion to ICAM-1-expres-
sing stromal cells (Schumann et al, 2010). However, the use of
knock-in T cells expressing LFA-1 in a primed intermediate
affinity conformation suggests that regulated LFA-1 activity is
not involved in motility within the LN parenchyma (Park
et al, 2010). It is currently difficult to reconcile these
conflicting data.
However, the varying speeds of migration within the
T zone do not provide an explanation for a faster exit rate
of LFA / T cells from the LN. A clue to this different
behaviour was the finding that LFA-1þ /þ CD4 T cells had
increased presence over LFA-1 / cells in regions of the LN
where LVs were most concentrated. A key finding was that
the LFA-1þ /þ Tcells reverse migrated back into the LN more
frequently than LFA-1 / T cells after probing the LV walls.
An observation was that the paths of the LFA-1 / Tcells on
the LV were straighter than those of the LFA-1þ /þ T cells
which displayed more random trajectories correlating with
frequency of in migration back into the node parenchyma. As
this LFA-1-mediated activity took place on the LVwalls, it was
relevant to demonstrate that the ligand ICAM-1 was ex-
pressed by the non-stimulated LV for which there has pre-
viously been both positive and negative evidence (Johnson
et al, 2006; Link et al, 2007). In addition, the differences in
the T-cell trajectories disappeared in ICAM-1 / host mice.
The arrival of T cells at the point of egress occurs stochas-
tically as a balance of responsiveness to retaining factors such
as CCL21 and factors influencing egress such as S1P. Our
study indicates that adhesion through LFA-1 is another factor
determining egress potential. In in vitro chemotaxis assays,
the state of LFA-1 expression had no impact on the response
to CCL21 and S1P whether the assays were ICAM-1 depen-
dent or independent. In seeming conflict is our data indicat-
ing that the LFA-1/ICAM-1 interaction dictates how T cells
migrate on the LV. The requirement for shear flow conditions
to activate LFA-1 on recirculating primary T cells has been
reported by Woolf et al (2007) and we show that LFA-1þ /þ
CD4 T cells, but not LFA-1 / T cells, adhered and migrated
under shear flow conditions on ICAM-1 in response to both
immobilised S1P and CCL21. The LVs display fluid flow, but
the parenchyma of the LN is considered to be shear free at
least in terms of fluid. We show that Tcells are adhering in an
LFA-1-dependent way on the LV but not in the adjacent areas.
One explanation is that the expression or organisation of
ICAM-1 on LV surface activates LFA-1. Alternatively, T cells
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interacting with HEV bear filipodia expressing LFA-1 that
extend into the HEV from the leading edge (Shulman et al,
2009; Heasman et al, 2010). This might provide another
possible means of LFA-1 activation if a similar process
occurs when T cells interact with LVs.
These data are consistent with reports that the interaction
of S1P1 with its ligand S1P causes integrin activation
(Paik et al, 2001; Ledgerwood et al, 2008) and that
S1P1 / T cells are deficient in firm adhesion to LN HEVs
under flow conditions, an LN entry step that is integrin
mediated (Halin et al, 2005). In terms of distribution, S1P is
LV associated as well as being present in lymph and therefore
in position to influence LFA-1 activity on the T cells
(Pham et al, 2008; Grigorova et al, 2009). Although the
initial lymphatics express CCL21 (Tal et al, 2011), it is not
yet established whether chemokines within the LN are LV
tethered (Randolph et al, 2005). Thus, it is tempting to
speculate that local concentration of LV-associated S1P
might be responsible for stimulating the random migratory
trajectory of LFA-1þ /þ T cells at the LV membrane via its
LFA-1 activating function.
Our study provides evidence that LFA-1-mediated migra-
tion on the LV contributes to the balance of factors determin-
ing whether or not a T cell will leave the LN. A key issue is
what T-cell functions might be influenced by this behaviour.
Contact of DCs with LVs can suppress their activation,
suggesting a role for lymphatic membranes in influencing
the state of leukocyte activation (Podgrabinska et al, 2009).
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Figure 8 Response of OT-2 transgenic T cells in WT and ICAM-1 host mice. (A) The proportion of proliferating CFSE-labelled OT-2 T cells
exposed to WT dendritic cells pre-incubated or not with pOVA in either WT or ICAM-1 / host mice; dendritic cells were injected into hind
foot pad and both ipsilateral (IPSI) and contralateral (CONTRA) lymph nodes were examined at 72 h following i.v. injection of OT-2 CD4 Tcells;
(B) combined data from n¼ 3 experiments showing the extent of proliferation in both ipsilateral and contralateral nodes as in (A).
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However, revisiting of the T zone parenchyma gives T cells
further opportunity to scan for antigen-loaded presenting
cells and to subsequently become activated. This might be
a particularly decisive mechanism for effective immune
activation when the numbers of cognate APC in an LN or
the amount of presented antigen on their surface are low.
We provide evidence that such a mechanism does indeed
function in vivo. Stimulation of OT-2 transgenic T cells by
ovalbumin-laden ICAM-1-expressing DCs in a WT host was
30% more efficient compared with the same situation in
an ICAM-1 / host. Collectively, these data show that
intranodal T-cell activation is not only dependent on the
LFA-1-ICAM-1 axis during T-cell/APC interaction, but also
during migration on and contact formation with LVs.
Our data add to previous reports that T cells engage in one
or more rounds of shuttling between T zone parenchyma and
the LV prior to finally exiting (Grigorova et al, 2009, 2010).
LFA-1-mediated adhesion contributes to this reverse
migration back into the node parenchyma. We propose that
this behaviour increases the probability on a per T-cell basis
of encountering APC-associated antigen. In contrast,
according to the concept of immune surveillance, T cells
enhance their opportunities of encountering foreign antigen
by recirculating around the body and entering into and
exiting from many LNs. However, this LFA-1-mediated
shuttling of T cells may make an additional contribution to
immune surveillance at the level of the individual LN.
In terms of LN entry across the HEV, LFA-1 supplies
adhesive support for the T cells enabling them to withstand
the force of blood flow and to migrate across the HEV into the
node. Conversely, at the point of leaving the LN, LFA-1-
mediated T cell contacts with LV membranes represent a
critical contribution in shaping whether or not T cells exit.
Thus, LFA-1 contributes to the functions that T cells perform
both at the beginning and end of their LN journey.
Materials and methods
Mice
LFA-1 / mice were bred on the C57BL/6JCrl to backcross gen-
eration 12 (Berlin-Rufenach et al, 1999). ICAM-1 / mice (C57BL/
6J) were obtained from Drs Britta Engelhardt and Urban Deutsch
(Theodor Kocher Institute, Bern, Switzerland) with the permission
of Dr Arthur Beaudet (Baylor College, Houston, TX, USA) (Bullard
et al, 2007). Sex-matched 5- to 12-week-old mice were used in the
experiments. Mice transgenic for 3A9 TCR specific for I-Ak/HEL46-71
were on a B10.BR background (Jackson Laboratory, Bar Harbor,
ME, USA) and bred at LRI (Ho et al, 1994). All animal experiments
were approved by the Landesverwaltungsamt Sachsen-Anhalt
(file number: 203.h-42502-2-874 Uni MD) and the United
Kingdom Home Office.
Purification of CD4þ T lymphocytes
CD4 splenic and LN T cells were enriched by negative isolation via
immunomagnetic depletion using a mouse CD4þ T cell Isolation
kit (MACS Miltenyi Biotech) with purity of 495% as assessed
by flow cytometry. In some experiments, naı¨ve CD4 T cells were
isolated by FACS through gating on the CD4 T cells and sorting the
CD44lo cell population.
Flow cytometry
Leukocytes (5105) were incubated on ice in 50 ml of PBS/0.1%
BSA containing the following directly conjugated mAbs at optimal
dilution: CD4-APC or -FITC (RM4-5, eBioscience or BD
Biosciences); CD44-FITC or -BrilliantViolet421 (IM7, PharMingen
or Biolegend); CD62L-APC-eFluor780 (MEL-14, eBioscience);
CD69-PE (eBioscience). In some experiments, intact LNs were
cultured under appropriate conditions, then fluorochrome-labelled
CD4 T cells were tested for state of apoptosis using biotinylated
Annexin V (Invitrogen) detected with Streptavidin-Pacific Blue.
Immunoblotting
Cell lysates, prepared as previously described (Svensson et al,
2009), were separated using pre-cast 3–8% SDS–PAGE gels
(Invitrogen) and transferred onto PVDF membrane (Immobilon-P,
Millipore). Blots were probed with rabbit anti-S1P1 (EDG-1, H-60,
Santa Cruz), rat CCR7 mAb (4B12, eBioscience) and mouse anti-a-
tubulin mAb (Sigma Aldrich Ltd), followed by secondary Abs: goat
anti-rabbit Ig-HRP, rabbit anti-rat Ig-HRP, and sheep anti-mouse
Ig-HRP (all Dako Ltd) and ECL detection reagents (GE Healthcare).
Chemotaxis
Splenocytes were washed twice in 0.1% fatty acid-free BSA (Sigma
Aldrich Ltd) and incubated for 1 h at 371C prior to incubation at
1106 cells/100 ml in 5mm pore Transwell insert wells (Corning)
that were either uncoated or coated overnight with mouse ICAM-1-
Fc at 1 mg/ml. The lower wells contained either 600 ml RPMI-1640/
0.1% fatty acid-free BSA, medium plus 25 nM S1P (Biomol/Enzo
Life Sciences) or 6mM CXCL21 (PeproTech EC Ltd) with dose level
determined by titration. After incubation at 371C for 2.5 h on
uncoated filters or the shorter time of 1.5 h on ICAM-1-coated
wells (to detect rapid migration), the chambers were rested on ice
for 20min, inserts discarded and the migrated cells recovered
using ice-cold 5mM EDTA/PBS. CD4 T cells were identified by
flow cytometry and enumerated with the aid of counting beads
(CountBright absolute counting beads, Invitrogen).
Shear flow assay
ibiTreat m-slide VI flow chambers (Ibidi) were coated overnight with
protein A (0.5mg/ml, Sigma-Aldrich Ltd), then incubated with 2%
fatty acid-free BSA for 30min at RT followed by mouse ICAM-1Fc
(1mg/ml), S1P (1mM), or CCL21 (6mM). Purified CD4 T cells
(5105 cells/ml) were allowed to attach for 15min at 371C in
20mM HEPES pH 7 in HBSS, then flow conditions of 1 dyn cm2
were implemented using an automated syringe pump (KDS model
200; Linton Instrumentation) as previously reported (Evans et al,
2011). The adhesion/migration characteristics of T cells were
recorded using a 20 lens on a Nikon Diaphot 300 microscope, a
Sony XCD-X700 camera and AQM2001 Kinetic Acquisition Manager
software (Kinetic Imaging Ltd, Bromborough, UK). Images were
taken every 2 s for 3min.
Immunofluorescence: in vitro and in vivo labelling
For immunohistology, snap-frozen inguinal LNs were cut in 10mm
sections, fixed in 4% paraformaldehyde, blocked in 1% BSA and
10% rabbit serum and stained for 1 h at RTwith various mAbs and
pAbs: FITC-CD3, PE-B220 (eBioscience); ICAM-1-Biotin (YN1/1.7.4,
eBioscience). Biotinylated primary mAbs were detected using
Streptavidin-AlexaFluor555 (Invitrogen). LYVE-1 (clone 223322,
R&D Systems, Europe) was directly labelled with AlexaFluor488,
AlexaFluor546 or Pacific Blue (Molecular Probes) and MOMA-1
(CD169, Bachem or Acris) was directly labelled with
AlexaFluor680 or Pacific blue. Sections were assessed using LSM
510 and 710 confocal microscopes using 20 /0.8 Plan-Apochromat
and 40 /1.3 Plan-NEOFLUAR DIC oil objectives and capturing
images using, respectively, LSM 510 software and Software Zen
2009 (Zeiss).
Pixel-by-pixel determination of overlap between ICAM-1
and LYVE-1 staining was analysed using ImageJ software. Each
fluorescence channel was treated separately by giving a value of 1.0
to each pixel to indicate positive staining and then the two values
derived from ICAM-1 and LYVE-1 staining were multiplied. Staining
of LYVE-1 was set at 100% to obtain percentages for co-staining
with ICAM-1.
Adoptive transfer of T cells for homing and intra-vital studies
For adoptive transfer studies, CD4 T cells from LFA-1 / and LFA-
1þ /þ control C57BL/6JCrl mice at 5106 cells/ml in 5% FCS/RPMI
were labelled as described (Berlin-Rufenach et al, 1999). Briefly,
T cells were incubated with either 0.5mM CFSE or 5mM SNARF-1
(all Molecular Probes) according to manufacturer’s protocol at 371C
for 45min. The differentially labelled T-cell preparations were
mixed at 5106 cells each to achieve a 1:1 ratio of LFA-1þ /þ and
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LFA-1 / cells for i.v. injection into recipient mice. For
quantification of the entry ratio, a correction factor was applied to
the subsequent data if the injected lymphocyte ratio was not 1:1.
To block further lymphocyte entry, 100 mg each of purified rat
mAbs MEL 14 (L-selectin, CD62L) and PS2/3 (a4, CD47d) per
mouse were injected i.v. at 6 h post T-cell transfer. To test the
efficiency of this blockade while simultaneously mimicking the
LN trafficking experiments, endotoxin-free L-selectin mAb MEL-14
and a4 integrin mAb PS2/3 or PBS as a control were injected 30min
prior to the fluorochrome-labelled T cells (5106 per cell type),
then LN T-cell numbers were assessed 4 h later (see text). PS2/3 was
prepared by the CRUK Monoclonal Antibody Service; MEL-14 was a
kind gift of Dr Alf Hamann, Charite Universitaetsmedizin Berlin,
Germany and purchased from eBioscience.
For two-photon imaging, T cells were stained with 5mm CFSE,
5 mM Cell Tracker Orange (CTO) or 5mM Cell Tracker Blue (CTB) (all
from Molecular Probes) according to manufacturer’s protocols and
as previously described (Reichardt et al, 2007b). Colours were
routinely swapped between experiments. For in vivo labelling of
LV, anti-mouse LYVE-1 labelled with Alexa 546 or Pacific Blue at
5–10 mg in 30ml PBS was injected s.c. in the mouse flank 24h before
imaging. To visualise dynamics of lymph flow, FITC dextran
(2MDa, Sigma-Aldrich Ltd) was applied s.c. into the right footpad
at 2 h and 30min before imaging.
Two-photon microscopy
Fluorescently labelled, purified CD4 Tcells (1:1 ratio, 5106 per cell
type) were injected i.v. into the tail vein of 5- to 6-week-old C57BL/
6 mice at 6 h before imaging as previously described (Gunzer et al,
2004; Reichardt et al, 2007a, b). For some experiments, the KO:WT
ratio was increased up to 5:1 cells to compensate for the deficiency
of LN entry of LFA-1 / T cells. The ratio or time of natural
homing, without the use of blocking antibodies, in the time
window chosen had no effect on viability or motility behaviour of
the T cells imaged.
For intra-vital microscopy, anaesthesia of mice was initiated with
i.p. application of 30mg/kg ketamine (Inresa, Freiburg, Germany)
plus 3mg/kg xylazine (Bayer Health Care, Leverkusen, Germany)
followed by intra-tracheal intubation and ventilation with oxygen-
isoflurane (Deltaselect, Pfullingen, Germany). The inguinal LN was
exposed by surgically removing surrounding tissue carefully sparing
blood and lymph vessels. Quality of regional perfusion and oxyge-
nation under anaesthesia was monitored oxymetrically (O2C, LEA,
Giessen, Germany), and temperature maintained at 371C. For
ex vivo imaging of explanted LN, organs were kept in PBS and
imaged immediately after being explanted. Single scan fields of
typically 303 303mm were imaged, which in some experiments
were tiled to combine up to 3636 3636mm combined fields.
Two-photon microscopy was performed using a ZeissLSM710
microscope (Carl Zeiss, Jena, Germany) equipped with a MaiTai
DeepSee Femtosecond-Laser (Spectra-Physics, Darmstadt,
Germany) typically tuned to 800 nm on an AxioExaminer upright
stage with a 20 , NA 1.0 (Zeiss) water dipping lens. Image
detection was done with three non-descanned (NDD) detectors
typically equipped with emission detection filters of 565–610nm
(red), 500–500 (green), and ShortPass485 (blue). Individual RGB
z-stacks of max 606 606 mm images were recorded in single plane
or multiple z-planes as indicated, for time-lapse sequences typically
every 4–20 s and lasting typically 15–30min. Image rendering was
performed using Volocity 4.3 (Improvision, Waltham, MA, USA).
Cell tracking was done using the ImageJ Plugin ManualTracker and
the computer-assisted manual tracking software CellTracker as
described before (Reichardt et al, 2007b).
CellTracker software was also used for computing path length
within exit angles. For each path of movement of individual cells as
recorded by the software between two observation points, a direc-
tional xy angle was automatically assigned. This allowed quantifi-
cation of the summary path lengths in each directional angle for
each T-cell population. When comparing with the exit angle defined
for the field of view based on its positioning in the LN, the
percentage of path length in exit direction (exit angle ±901) could
be quantified and allowed a measure of the propensity to exit for
this cell type. Data were plotted with Prism 4 (GraphPad Software,
San Diego, CA, USA).
Adoptive transfer of dendritic and T cells for testing immune
responsiveness
DCs were prepared as previously reported (Gunzer et al, 2000;
Reichardt et al, 2007a). Briefly, bone marrow-derived cells (BMDCs)
were differentiated in RPMI-based media with IL-4 and GM-CSF for
7 days and treated with 20 ng/ml LPS (E. coli 0111, B4; Sigma,
Deisenhofen, Germany) on day 7. On day 8, OVA peptide (pOVA, AS
323-339 from chicken ovalbumin, Peptide Core facility, HZI,
Braunschweig, Germany) was added at 20 ng/ml to the culture.
After 4 h of co-incubation with pOVA, non-adherent DC was
harvested, extensively washed to remove excess peptide and
injected (0.5106 in 20ml PBS) into the right hind footpad of age-
matched C57/BL6 WT or ICAM-1 / hosts as in Mempel et al
(2004) and Lammermann et al (2008). As a control, DC from the
same culture (but not peptide loaded) was injected into the right
hind footpad of WT hosts. After 16 h, CD4 T cells from OVA TCR-
transgenic OT-2 mice (Barnden et al, 1998) were obtained by
negative isolation. All OT-2 cells were stained with 10 mM CFSE as
described (Reichardt et al, 2007a) and 5106 cells were injected
retro-orbitally into each host. Seventy-two hours later ipsilateral
and contralateral popliteal nodes were prepared separately and the
contained leukocytes were labelled with fluorochrome-conjugated
antibodies against CD4 and analysed for proliferation by CFSE
dilution using flow cytometry on a MCAS-Quant system (Miltenyi,
Bergisch-Gladbach, Germany).
Statistical analysis
The statistical package within GraphPad Prism 4 was used for
analysing data. Student’s t-test or a non-parametric test (Mann–
Whitney) or Fisher’s Exact Test (for analysis of a contingency table)
was applied to assess statistical significance. Significance levels
employed are indicated in Results; *P-value o0.05; **P-value
o0.01; ***P-value o0.001 were considered as significant.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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T Cell Activation Results in Conformational
Changes in the Src Family Kinase Lck to Induce
Its Activation
Anja Stirnweiss,1* Roland Hartig,1 Steffi Gieseler,1† Jonathan A. Lindquist,1
Peter Reichardt,1 Lars Philipsen,1 Luca Simeoni,1 Mateusz Poltorak,1 Camilla Merten,1
Werner Zuschratter,2 Yury Prokazov,2 Wolfgang Paster,3‡ Hannes Stockinger,3
Thomas Harder,1 Matthias Gunzer,1§ Burkhart Schraven1,4∥
The lymphocyte-specific Src family protein tyrosine kinase p56Lck (Lck) is essential for T cell development
and activation and, hence, for adaptive immune responses. The mechanism by which Lck activity is
directed toward specific substrates in response to T cell receptor (TCR) activation remains elusive. We
used fluorescence lifetime imaging microscopy to assess the activation-dependent spatiotemporal changes
in the conformation of Lck in live human T cells. Kinetic analysis of the fluorescence lifetime of Lck bio-
sensors enabled the direct visualization of the dynamic local opening of 20% of the total amount of Lck
proteins after activation of T cells with antibody against CD3 or by superantigen-loaded antigen-presenting
cells. Parallel biochemical analysis of TCR complexes revealed that the conformational changes in Lck
correlated with the induction of Lck enzymatic activity. These data show the dynamic, local activation
through conformational change of Lck at sites of TCR engagement.
INTRODUCTION
Src family tyrosine kinases (SFKs) trigger numerous cellular processes,
including proliferation, differentiation, adhesion, and migration. The
SFK family member p56Lck (referred to as Lck) critically induces T cell
responses after activation of cell surface receptors. Lck-deficient periph-
eral T cells cannot be activated through the T cell receptor (TCR). Con-
sequently, T cell development is severely impaired in the absence of Lck
(1). Phosphorylation of immunoreceptor tyrosine-based activation motifs
(ITAMs) within the TCR-associated CD3 and z chains by Lck is one of
the earliest detectable events after TCR stimulation, and it initiates multi-
ple signaling cascades that culminate in T cell activation and proliferation
(2); however, despite years of research, the molecular events preceding
ITAM phosphorylation are poorly understood. Changes in the accessibility
of ITAM-containing substrates and in the catalytic activity of Lck have
been proposed to contribute to the initiation of signaling after TCR
stimulation.
The activity of SFKs is tightly controlled by structural dynamics that
are highly conserved between members and across species (3). Accord-
ingly, the activity of Lck is controlled by conformational changes that
arise from phosphorylation and dephosphorylation of two critical tyrosine
residues, Tyr394 and Tyr505 (4). When phosphorylated by the C-terminal
Src kinase (Csk), the C-terminal tyrosine residue Tyr505 inhibits Lck ac-
tivity (5, 6). Phosphorylation of the inhibitory tyrosine induces an intra-
molecular association with the Src homology 2 (SH2) domain, causing
the kinase to adopt a closed, “inactive” conformation (3, 7), which is sta-
bilized by an additional interaction between the SH3 domain and a polypro-
line helix within the linker region (7, 8). The plasma membrane–localized
tyrosine phosphatase CD45 counteracts Csk by dephosphorylating Tyr505,
thereby generating a pool of Lck in an open, “primed” conformation (9, 10).
Ligand binding to the SH2 and SH3 domains of Lck may additionally con-
tribute to its activation (11–13). Activation of Lck is thought to depend on
the autophosphorylation of Tyr394 within the activation loop of the kinase
domain (14). Only Lck molecules phosphorylated on Tyr394 show enhanced
enzymatic activity and facilitate substrate phosphorylation (15, 16).
Nika et al. demonstrated that in resting T lymphocytes, as well as in
nonstimulated Jurkat cells (a human CD4+ leukemic T cell line), a substan-
tial amount of Lck exists in a constitutively active (Tyr394-phosphorylated)
form (17). The authors described four pools of Lck in resting T cells:
(i) closed, inactive Lck (Tyr505-phosphorylated); (ii) primed (nonphos-
phorylated); (iii) active Lck (Tyr394-phosphorylated); and (iv) active,
doubly phosphorylated (DPho) Lck (phosphorylated on both Tyr394
and Tyr505). In Jurkat cells, each pool constitutes about 25% of the total
amount of Lck, whereas in resting human T cells, about 50% of the total
Lck protein is primed (17). Nika et al. did not observe changes in the
enzymatic activity of Lck upon stimulation of the TCR. The authors con-
cluded that the Lck-dependent tyrosine phosphorylation of ITAMs does
not result from TCR-mediated de novo activation of Lck, but rather
from other mechanisms, such as the relocalization of active Lck within
the cell or from ligand-mediated conformational changes within the TCR
(18, 19).
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To assess the potential role of the conformational dynamics of Lck in
T cell activation, Paster et al. constructed a biosensor consisting of the
complete Lck backbone flanked by enhanced cyan fluorescent protein
(ECFP) and enhanced yellow fluorescent protein (EYFP) (20), which
act respectively as donor and acceptor fluorophores for Förster resonance
energy transfer (FRET). When the Lck biosensor molecule is in the active,
open conformation, FRET is low, whereas a closed enzyme (inactive,
Tyr505-phosphorylated) produces a strong FRET signal. With this Lck bio-
sensor, the authors measured FRET with intensity-based detection tech-
niques and observed no substantial changes in the FRET efficiency of
the biosensor upon TCR-mediated activation of Jurkat cells (20, 21).
We investigated the conformational dynamics of Lck in response to TCR
activation with an alternative technique to monitor FRET. FRET affects the
mean lifetime for which the donor fluorophore molecules remain in the
excited state before they relax back to the ground state and release a pho-
ton. Through the use of fluorescence lifetime imaging microscopy (FLIM)
(22, 23), we recorded, at microscopic resolution, donor fluorescence decay ki-
netics, which enabled the measurement of FRET independently of fluorophore
concentrations. We used a new time domain FLIM strategy to follow the con-
formational dynamics of the Lck biosensor of Paster et al. The greatly im-
proved signal-to-noise ratio obtained with our strategy enabled us to directly
measure and visualize the conformational opening of Lck upon TCR activa-
tion in live T cells. Moreover, in vitro kinase assays revealed that the open-
ing of Lck correlated with the enhanced enzymatic activity of the kinase.
RESULTS
A fluorescence-based Lck biosensor rescues signaling
in Lck-deficient Jurkat cells
To identify changes in the conformational states of Lck in live cells, we
used a unimolecular biosensor consisting of the complete Lck backbone
flanked by ECFP and EYFP, which acted as donor and acceptor fluoro-
phores, respectively (CLckY-1; Fig. 1A) (20). To assess the function of the
biosensor, we expressed it in the Lck-deficient Jurkat cell line JCam1.6, which
is unresponsive to TCR-mediated signals (24). Expression of CLckY-1 in
JCam1.6 cells reconstituted global tyrosine phosphorylation (Fig. 1B) and
Ca2+ flux in response to soluble stimulation with a monoclonal antibody
against CD3 (aCD3) similar to that in Jurkat cells that express wild-type
Lck (Fig. 1, C and D).
Spectral measurements reveal the FRET behavior
of the CLckY-1 biosensor
To distinguish the true FRET events of the biosensor from other ex-
cited state reactions, we recorded intensity spectra with a time-resolved,
Fig. 1. Functional characterization of the Lck biosensor CLckY-1. (A)
Schematic illustration of the Lck biosensor (CLckY-1) and the control
constructs used in this study. UD, unique domain; 21 aa, linker of 21
amino acid residues. (B) Wild-type (WT) Jurkat cells (JE6.1) or Lck-
deficient JCam1.6 cells transfected with either control plasmid or
plasmid encoding WT Lck or the CLckY-1 biosensor were stimulated
with antibody against CD3 (aCD3). At the indicated times, cells were
harvested and lysates were analyzed by Western blotting for total
tyrosine phosphorylation with the antibody 4G10. A typical result from one of three independent experiments is shown. (C and D) JCam1.6 cells
transfected as described in (B) were loaded with the Ca2+-sensitive dye Indo-1 AM. Ca2+mobilization of cells after treatment with aCD3 or ionomycin
(Ionom) was measured either (C) by confocal microscopic analysis of individual cells, which showed that only transfected cells responded to an-
tibody stimulation, or (D) by bulk analysis by flow cytometry measured at a flow rate of 300 cells s−1. Representative results out of three (for confocal
analysis) or five (for flow cytometric analysis) independent experiments are shown.
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microspectroscopic delay line (DL) detector. To generate a FRET-positive
control, we transfected cells with a plasmid encoding a plasma membrane–
anchored fusion protein in which the donor and acceptor fluorophores were
separated by 21 amino acid residues (ECYFP; Fig. 1A). Because of the
close proximity of the fluorophores, ECYFP reports on the maximal possi-
ble FRET signal. We also used a variant of CLckY-1 in which Tyr394 was
mutated to phenylalanine (CLckY-1–Y394F; Fig. 1A). This Y394F muta-
tion induces formation of the closed conformation of Lck (20); hence,
the FRET of CLckY-1–Y394F reports on a fraction of the Lck biosensor
that is in the constitutively closed conformation, which is expected to be
greater than that of CLckY-1. As a FRET-negative control, we generated
CLckY-1–Y505F, in which the C-terminal negative regulatory residue Tyr505
was mutated to phenylalanine (Fig. 1A). This mutation prevents the intra-
molecular interaction between the C terminus and the SH2 domain of
Lck, thus generating a constitutively open conformation that exhibits a
low FRET efficiency (20).
At an excitation wavelength of 420 nm, which excites the donor
ECFP only, the intensity spectra of all constructs showed a first peak
at 475 nm (Fig. 2A). This peak represents the characteristic emission
spectrum of the donor (ECFP). A prominent second peak at 525 nm
indicates the FRET-induced fluorescence of the acceptor (EYFP) and
marks the FRET signal of the positive control (ECYFP). The peak at
525 nm was also observed in the biosensor molecules (Fig. 2A). As
expected, the peak intensity was highest in the spectrum of the Lck
Y394F biosensor, lower in the wild-type Lck biosensor (CLckY-1),
and undetectable in cells with the FRET-negative control (CLckY-1–
Y505F), consistent with the constitutively open conformation of this
mutant Lck.
To differentiate between inter- and intramolecular FRET, we compared
the fluorescence spectra of JCam1.6 cells expressing the CLckY-1 bio-
sensor with those of cells expressing a version that contained only ECFP
(donor-tagged Lck, CLck-1; Fig. 1A) and cells that coexpressed donor-
only (CLck-1) and acceptor-only (LckY-1) tagged biosensors (Fig. 1A).
A FRET-specific peak at 525 nm was not detectable in cells expressing
CLck-1 alone or in those coexpressing CLck-1 and LckY-1 (Fig. 2B). Hence,
the FRET signals measured in cells expressing Lck biosensor variants
were caused by intramolecular energy transfer and correlated with the con-
formational states of the Lck biosensors.
FLIM discriminates between the individual kinetic
components of ECFP fluorescence
For unknown molecular reasons, not all ECFP molecules mediate FRET
(25). Thus, a subfraction of the ECFP molecules that undergo a change
in FRET may escape detection against a background of fluorescence
signal from molecules that do not undergo FRET. To tackle these inher-
ent problems of the low signal-to-noise ratio in FRET measurements,
Fig. 2. Microspectroscopic characterization of CLckY-1 and different control
constructs. (A and B) Spectral emissions along a wavelength range of 460 to
650 nm were resolved and collected by the DL detector after excitation at
420 nm. Represented are the relative fluorescence intensities against the
emission wavelength of five independent measurements for JCam1.6 cells
transfected with the appropriate plasmids encoding (A) ECYFP, CLckY-1,
CLckY-1–Y394F, or CLckY-1–Y505F or (B) CLckY-1, CLck-1, or CLck-1 and
LckY-1. (C) DAS spectra of the measurements shown in (A) and (B) of ECFP
subpopulations that were identified by a three-exponential fit of the experimen-
tal data with individual characteristic lifetimes of t1 (3.2 ns), t2 (1.4 ns), and t3
(0.8 ns), respectively. Diagrammed are the changes in the pre-exponential
factors of the three lifetimes as a function of the wavelengths for ECYFP, the
Lck-biosensor CLckY-1, CLckY-1–Y394, and CLckY-1–Y505F. Negative pre-
exponential factors result from FRET between the donor and acceptor.
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we made use of detailed characterizations of the decay kinetics of ECFP
fluorescence. Our work and that of others showed that in an ECFP-EYFP
FRET pair, the mean decay of ECFP fluorescence, described by the
mean lifetime tmean, can be fitted with three exponential decay com-
ponents. These kinetic components are defined by three individual
decay lifetimes: t1, t2, and t3, which characterize individual subpopu-
lations of fluorophore pairs that can be individually selected for FRET
measurements (26–31). We applied a Levenberg-Marquardt nonlinear,
least-squares algorithm to dissect the decay kinetics of ECFP fluores-
cence in the Lck biosensor into individual lifetimes. A three-exponential
fit resulted in a precise (c2 < 1.3) description of the experimental data and
revealed three individual t values of ECFP within the biosensor of 3.2 ns
(t1), 1.4 ns (t2), and 0.8 ns (t3), respectively. The fractional distribu-
tions of the individual lifetimes were calculated as 40% (t1), 35% (t2),
and 25% (t3).
Analysis of decay-associated spectra identifies the ECFP
subpopulation of the Lck biosensor involved in FRET
Plotting the pre-exponential factors of the individual lifetimes against the
emission wavelength yielded the decay-associated spectra (DAS) (Fig.
2C), which were used to identify those ECFP molecules engaged in FRET.
When the component undergoes FRET, the pre-exponential factor of an in-
dividual lifetime acquires a more negative value relative to the baseline at
the emission wavelength of the acceptor. At the acceptor emission maxi-
mum of 525 nm, only t3 acquired negative values in Jurkat cells expressing
ECYFP, CLckY-1, or CLckY-1–Y394F (Fig. 2C). Comparing the FRET sig-
nals of these constructs led to the following arrangement of FRET signals:
ECYFP > CLckY-1–Y394F > CLckY-1. No negative value for t3 was found
in cells expressing the constitutively open CLckY-1–Y505F, which indicated
that among the three components contributing to the mean fluorescence decay
of ECFP, only t3was affected by FRET. In addition, t3 contributed to 25% of
Fig. 3. Conformational changes in the Lck biosensor in response to stim-
ulation of cells with anti-CD3 antibody. (A to C) Live JCam1.6 cells that had
been transfected with plasmid encoding the biosensor (CLckY-1) or with a
control plasmid lacking the FRET acceptor EYFP (CLck-1) were analyzed
with the QA detector. After excitation at 420 nm, the spectral emissions of
the FRET donor ECFP were detected at 465 to 485 nm. Data from at least
three independent experiments were analyzed, and representative results
are shown in (A) and (B). (A and B) ECFP intensity images captured by the
QA detector are represented in the upper panels. (A to C) Pseudocolored
images for the pre-exponential factors of t3 and tmean revealed the location
of FRET events within the cells. Purple to blue pixels correspond to closed
Lck molecules (high FRET), whereas yellow to red pixels indicate mole-
cules with low FRET because of an open conformation of the Lck biosensor.
(A) JCam1.6 cells transfected with plasmids encoding CLckY-1 or CLck-1
before and 7 min after stimulation with aCD3. (B) JCam1.6 cells transfected
with plasmid encoding CLckY-1 were pretreated for 30 min with 10 mM PP2
or 10 mM PP3. Nonstimulated cells and cells stimulated with aCD3 for 7 min
are depicted. (C) Time-resolved analysis of changes in the pre-exponential
factor of t3 at the plasma membrane of JCam1.6 cells transfected with plas-
mid encoding CLckY-1 (n = 10 cells, from n = 3 independent experiments;
data are means ± SD). The measured area in the lower micrograph is high-
lighted in red.
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the total mean lifetime and therefore may
remain undetected when conventional meth-
ods of FRET detection, such as intensity-
based measurements or mean lifetime FLIM
measurements, are applied.
The biosensor reports on the
conformational dynamics of Lck
at sites of TCR activation in
Jurkat cells
Next, we investigated whether Lck under-
went conformational change upon T cell
activation. We expressed the biosensor or
the donor-only tagged variants in JCam1.6
cells and measured the fluorescence lifetimes
with the position-sensitive photomultiplier
(QA detector) (32) to resolve the spatial dis-
tribution, as well as the three individual life-
times of the biosensor (fig. S1). Both CLck-1
and CLckY-1 localized to two major areas,
the plasma membrane and a cytoplasmic
compartment that partially overlap with ear-
ly endosomes but not with the endoplasmic
reticulum or the Golgi apparatus (Fig. 3A
and figs. S2 and S3). Similar subcellular dis-
tributions of Lck have been reported previ-
ously (33–35).
FLIM analysis focusing on t3 within the
CLckY-1 biosensor detected a constitutive-
ly open Lck population (low FRET) at the
plasma membrane of Jurkat cells and in
the cytoplasmic compartment (Fig. 3A, right
panels, middle row). Upon treatment with
PP2, an inhibitor of SFKs, but not with the
inactive analogPP3, these openCLckY-1mol-
ecules became undetectable, and the biosen-
sor assumed the closed conformation (Fig.
3B, middle panels). These data indicate that
the open Lck molecules in unstimulated
Jurkat cells were constitutively active, which
confirmed previous data (17).
We then investigated whether Lck under-
went conformational changes upon T cell
activation. Stimulation with aCD3 induced
a detectable decrease in the pre-exponential
factors of t3 at the plasma membrane and in
the cytoplasmic compartment of cells with
the CLckY-1 biosensor (Fig. 3A, middle right
panels), but not in cells with the ECFP-only
variant CLck-1 (Fig. 3A, middle left panels).
Opening of the biosensor at the plasma
membrane was observed to last for at least
20 min (Figs. 3C and 4A). Again, the de-
crease in FRET upon T cell activation was
completely lost when the cells were pretreated
with PP2 (Fig. 3B, lower panels). Together,
the behavior of t3 in aCD3-stimulated Jurkat
cells showed that T cell activation induced
an opening of the biosensor. This finding
suggested that Lck became activated by a
0.0 min 0.5 min 1.0 min 1.5 min 2.0 min 2.5 min 3.0 min 3.5 min 4.0 min
4.5 min 5.0 min 5.5 min 6.0 min 6.5 min 7.0 min 7.5 min 8.0 min 8.5 min
13.5 min 14.0 min 14.5 min 15.0 min 15.5 min 16.0 min 16.5 min 17.0 min 17.5 min
9.0 min 9.5 min 10.0 min 10.5 min 11.0 min
18.0 min 18.5 min 19.0 min 19.5 min 20.0 min
11.5 min 12.0 min 12.5 min 13.0 min
1 min 2 min 3 min 4 min 5 min 6 min 7 min 8 min 9 min
10 min
18 min
11 min 12 min 13 min 14 min 15 min 16 min 17 min
0.0 min 0.5 min 1.0 min 1.5 min 2.0 min 2.5 min 3.0 min 3.5 min 4.0 min
4.5 min 5.0 min
αCD3
5.5 min 6.0 min 6.5 min 7.0 min 7.5 min 8.0 min 8.5 min
9.0 min 9.5 min 10.0 min 10.5 min 11.0 min 11.5 min 12.0 min 12.5 min 13.0 min
13.5 min 14.0 min 14.5 min 15.0 min 15.5 min 16.0 min 16.5 min 17.0 min 17.5 min
0.0 min 4.0 min 8.0 min 12.0 min 16.0 min 20.0 min
αCD3
αCD3
Fig. 4. Changes in the conformation of the Lck biosensor are mediated by stimulation through aCD3. (A toC)
Pseudocolored FLIM images measured with the QA detector represent the pre-exponential factors of t3 in
(A) JCam1.6 cells, (B) human T cells, and (C) Zap70-deficient P116 cells expressing CLckY-1. (D) In Jurkat
cells stimulated with SEE-loaded Raji B cells (APCs), the Lck biosensor adopts an open conformation at
the site of contact between the Jurkat cell and the APC. The transmitted light images show CLckY-1–
expressing Jcam1.6 cells before and after contact with SEE-loaded Raji B cells. Representative images
of cells are shown from 30 (A), 10 (B), 12 (C), and 10 (D) measurements from three independent experi-
ments each. Scale bars, 10 mm.
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conformational change immediately after stimulation of cells with aCD3.
The constitutively open Lck molecules in unstimulated cells and the activation-
induced decrease in FRET could only be observed by combining FLIM
measurements with an analysis of the pre-exponential factors of t3, the
characteristic lifetime of the subpopulation of the donor molecules
involved in the FRET process. We did not detect alterations in the mean
lifetime of the FRET signal in stimulated cells that had the CLckY-1 bio-
sensor (Fig. 3A, lower panels). This observation corroborates the data of
Paster et al. (20).
We then analyzed the tracks of TCR-mediated conformational changes in
the Lck biosensor as visualized by FLIM over time after TCR stimulation
(Fig. 4). Activation-induced opening of the Lck biosensor was observed in
JCam1.6 cells (Fig. 4A) and in primary human T lymphocytes (Fig. 4B). The
opening of the biosensor was already detectable just 1 min after application of the
aCD3 antibody. Similarly, rapid opening of the biosensor was also observed in
the z chain–associated protein kinase of 70 kD (Zap70)–deficient Jurkat variant
P116 cells, which rules out the possibility that TCR-mediated opening of the
biosensor in transfected JCam1.6 and primary T cells was a result of the
binding of the SH2 domain of Lck to phosphorylated Zap70 (Fig. 4C).
To determine the relative fraction of the open biosensor molecules in
unstimulated and activated T cells, we split the data stream into 2-min time
windows. Photons collected during the first 2 min were defined as the base-
line value. With this approach, we found that 16% of the biosensor mole-
cules involved in FRET showed an open conformation before stimulation.
After 5 min, the cell was stimulated with aCD3 antibody. Continuously
recorded FLIM data were analyzed at the time points 0 to 2, 7 to 9, 13 to
15, and 18 to 20 min (Table 1), and the fractional intensities were
calculated. This calculation showed that TCR stimulation induced a con-
tinuous decrease in the FRET signal
(equivalent to opening of the Lck mole-
cule) of an additional 20% of the biosensor
molecules undergoing FRET at the plasma
membrane (Table 1).
To visualize the conformational changes
in the biosensor under more physiological
conditions, we monitored the spatiotemporal
changes in Lck conformation in a T cell ac-
tivation model system in which the TCR was
triggered by contact with antigen-presenting
cells (APCs). We incubated superantigen
(SEE)–loaded Raji B cells with Jurkat cells
expressing the biosensor. Changes in FRET
signals reported the rapid accumulation of
the open, activated conformation of the Lck
biosensor at the contact zone between both
cell types (Fig. 4D). No changes in biosensor
FRET occurred in conjugates of T cells with
nonpulsed APCs (fig. S4), indicating that
opening of the biosensor required engage-
ment of the TCR.
The enzymatic activity of Lck is
enhanced upon T cell activation
A fraction of Lck molecules underwent con-
formational changes upon T cell activation,
in apparent disagreement with Nika et al.,
who proposed that activation of T cells is
not accompanied by increased pools of acti-
vated Lck. Consistent with this proposal, we
observed that Lck in total cell lysates ob-
tained from aCD3-stimulated primary human
T cells showed no substantial increase in
the Lck-activating Tyr394 phosphorylation
(Fig. 5A). We obtained similar results when
we examined the phosphorylation status of
Lck by automated multidimensional fluo-
rescence microscopy [multi-epitope ligand
Table 1. Changes in Tmean and the pre-exponential factors of t3 of a
JCam1.6 cell expressing the biosensor after TCR stimulation. The
time range of 0 to 2 min was used as the reference point. n.d., not
detectable.
Time points
(min)
tmean (ns) Change of
tmean (%)
Change of fractional
distribution of t3 (%)
0–2 2.82 — —
7–9 2.82 n.d. 16
13–15 2.83 n.d. 20
18–20 2.84 n.d. 35
Fig. 5. Global analysis of Lck phosphorylation after T cell activation. (A) Lysates of unstimulated, con-
trol Jurkat cells (ctr.) and cells stimulated for the indicated times with aCD3-coated microbeads were
subjected to immunoprecipitations. The Lck immunoprecipitates were analyzed in a dual fluorescence
Western blot (right panel) with aLck (blue) and antibodies against Src family kinases containing
pTyr416, which label the corresponding pTyr394 of Lck (yellow). The ratios of signals from tyrosine-
phosphorylated Lck and total Lck protein were calculated from four independent experiments and
are shown in the bar graph on the left as means ± SD. (B and C) MELK analysis: quantification of
changes in signal intensities of the displayed signaling molecules after stimulation of Jurkat JE6.1 cells
with aCD3 for 5 min. (B) Ratio of the signals of the indicated proteins between aCD3-stimulated and
unstimulated Jurkat cells (mean ± SD). (C) Relative changes in the fluorescence signal ratios between
stimulated and nonstimulated cells (mean ± 95% confidence interval). Data are combined from six
independent experiments in which a total of 448 cells were analyzed.
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cartography (MELK)], which enables simultaneous imaging of several sig-
naling molecules within the same cell (Fig. 5, B and C). However, when
we subjected Lck immunoprecipitated from resting or aCD3-stimulated hu-
man T lymphocytes or Jurkat cells to a classical in vitro kinase assay with
radiolabeled adenosine 5′-triphosphate (ATP), we observed a 20% increase in
Lck activity in four independent experiments with each cell type after 30 and
120 s of stimulation (Fig. 6). The increase in Lck phosphorylation was not a
consequence of coimmunoprecipitation of Lck with Csk (fig. S5) and corre-
lated well with our FLIM data, which showed that 20% of the biosensor mol-
ecules locally adopt an open active conformation at sites of TCR activation.
DISCUSSION
One of the first biochemical events after stimulation of the TCR is the phos-
phorylation of ITAMs within the TCR by the SFK Lck; however, very little
is known about the regulation of Lck activity after T cell activation. With a
FRET-based Lck biosensor and a new FLIM-based strategy, we assessed
the intracellular conformation of Lck in unstimulated and TCR-stimulated
Jurkat cells and primary human T lymphocytes. In unstimulated Jurkat
cells, a fraction of the biosensor (and hence of Lck) was found in a consti-
tutively open conformation. These open Lck molecules rapidly assumed a
closed conformation when cells were treated with the SFK-specific in-
hibitor PP2. This suggests that the open fraction of Lck represents con-
stitutively active Lck molecules, corroborating the data of Nika et al., who
identified constitutively active forms of Lck in resting T cells (17). Mech-
anistically, PP2 induced a reduction in the extent of Tyr394 phosphorylation,
which most likely was mediated by the transmembrane phosphatase CD45.
Our FLIM measurements provide a direct demonstration of conformational
changes in an SFK in live cells as a result of a change in its phosphorylation
status. TCR activation induced the rapid opening of the Lck biosensor in T
cells, including the Zap70-deficient P116
Jurkat variant cell line. This suggests that the
binding of Lck to tyrosine-phosphorylated
Zap70 through its SH2 domain (36) is not
required for the conformational opening of
Lck at sites of TCR activation.
Our FLIM and biochemical measure-
ments conflict with reports that suggest that
Lck changes neither its conformation nor
its enzymatic activity upon T cell activation.
Paster et al. did not detect changes in FRET
efficiency, as a measure of conformational
changes, with an Lck biosensor similar to
the one that we used here (20). We attribute
this discrepancy to the FRET detection tech-
nique that was used by Paster et al., namely,
a fluorescence intensity–based method that
monitors the integral of the mean fluores-
cence. Indeed, if considering the mean life-
times of donor fluorescence, our results
fit with those of Paster et al. This finding
shows an advantage of our method, which
focuses on the analysis of the subpopula-
tion of donor molecules that is engaged
in FRET. Antibody-based approaches led
Nika et al. to propose that T cell activation
does not increase the enzymatic activity of
Lck (17). Similarly, we did not detect sub-
stantial alterations in Lck activity when we
assessed its phosphorylation status in unstim-
ulated and stimulated T cells in experiments
with phosphorylation-specific antibodies.
However, when we subjected Lck immuno-
precipitates from primary T cells to in vitro
kinase assays, we reproducibly found an
~20% increase in the amount of autophos-
phorylated Lck, which correlated with our
biosensor data. We attribute the apparent
discrepancy between the antibody-based
approaches and the in vitro kinase assays
to the higher sensitivity of the radioactive
assays.
Wewould like to emphasize that our data
do not exclude the possibility that, in addi-
tion to activation of Lck, additional changes
Fig. 6. Activation of Lck in primary human T cells and Jurkat E6.1 cells upon stimulation with aCD3. (A and B)
Primary human T cells and (C and D) Jurkat cells were either left unstimulated as controls (ctr.) or stimulated
with aCD3 for the indicated times. After lysis in buffer containing NP-40 and lauryl maltoside (LM), a fraction
of the detergent lysate was subjected to SDS-PAGE andWestern blotting analysis with the anti-pTyr antibody
4G10 (left panels of A and C). The remaining lysate was subjected to immunoprecipitation with antibody
against Lck. Of the immunoprecipitated samples, 50% were subjected to SDS-PAGE and Western blotting
analysis with anti-Lck antibody [right lower panels of (A) and (C)], whereas the remaining 50% were
subjected to a classical in vitro kinase assay with radiolabeled 32g-ATP. After washing, the in vitro–labeled
immunoprecipitates were subjected to SDS-PAGE, which was followed by autoradiography [right upper
panels of (A) and (C)]. Data shown are a representative blot and autoradiogram from four independent
experiments. (B and D) Densitometric analysis of autoradiographs of in vitro–labeled Lck immunoprecipitates
obtained from unstimulated or aCD3-stimulated (B) primary human T cells or (D) Jurkat cells. The graphs
show the means ± SD for the four independent experiments and indicate an increased autophosphorylation
activity of Lck at 30 and 120 s after TCR activation of both cell types.
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in the subcellular localization of Lck or enhanced substrate accessibility
(for example, conformational changes in the TCR) contribute to ITAM
phosphorylation after ligand binding. However, our data showed that a
fraction of Lck adopted an open conformation and enhanced its activity
after T cell activation and thus suggest that the highly conserved intra-
molecular regulatory mechanism of SFKs has evolved to fine-tune their
activity at defined sites within T cells.
MATERIALS AND METHODS
Antibodies, cell culture, and transfection
The following antibodies were used in this study: horseradish peroxidase–
conjugated mouse anti-phosphotyrosine (4G10, Millipore); mouse anti-Lck
(clone 28), mouse anti-Csk, Alexa Fluor 488–conjugated mouse anti-Lck
(clone 28), and Alexa Fluor 488–conjugated mouse anti-pCD3z (pY142,
K25-407.69) (all from BD Transduction Laboratories); mouse anti-Lck
(3A5, Santa Cruz Biotechnology Inc.); rabbit anti-Lck (Upstate); and rab-
bit anti–Src-pY416, rabbit anti-pLck (pY505), Alexa Fluor 488–conjugated
mouse anti-pERK1/2 (E10), and Alexa Fluor 555–conjugated goat anti-
rabbit Fab2 (all from Cell Signaling Technology). Secondary antibodies
used for dual fluorescence analysis of Western blots were goat anti-rabbit
IRDye 680LT and goat anti-rabbit IRDye 800CW and were obtained from
LI-COR. The Jurkat cell line E6.1, the Lck-deficient variant cell line
JCam1.6 (24, 37), the Zap70-deficient variant Jurkat cell line P116, and
the Raji B cell lymphoma cell line were obtained from the American Type
Culture Collection. Cell lines were maintained in RPMI 1640 medium sup-
plemented with 10% fetal calf serum (FCS; PANBiotech), stable L-glutamine,
penicillin (50 U/ml), and streptomycin (50 mg/ml) (Biochrom) in humidi-
fied 5% CO2 at 37°C. Primary human T cells were isolated from healthy
donors with the Pan T Cell Isolation Kit II and autoMACS (Miltenyi Biotec).
The mouse anti-human CD3 monoclonal antibodies UCHT1 (eBioscience),
C305 [immunoglobulin M (IgM), provided by A. Weiss, University of Cal-
ifornia San Francisco (UCSF)], and MEM92 (IgM, provided by V. Horejsi,
Prague) were used to activate primary human T cells or Jurkat cells. JCam1.6
cells and P116 cells were transfected by electroporation as previously de-
scribed (38). Briefly, 1.5 × 107 cells were transfected with 20 mg of the in-
dividual Lck-encoding plasmids or the FRET-positive control (20) and were
analyzed 24 hours after transfection.
Fluorescence lifetime imaging microscopy
Reconstituted JCam1.6 cells (1 × 106/ml), in 1 ml of Krebs-Ringer solu-
tion [10 mM Hepes (pH 7.0), 140 mM NaCl, 4 mM KCl, 1 mM MgCl2,
10 mM glucose, 1 mM CaCl2], were plated on poly-L-lysine–coated glass-
bottom culture disks (MatTek) for 10 min. The cells either were stimulated
with soluble monoclonal antibody against human CD3e (UCHT1, 5 mg/ml)
for the indicated times or were mixed at a 1:1 ratio with Raji B cells that
had been pulsed with SEE. Emission spectra (460 to 650 nm) and fluo-
rescence lifetimes of the three pre-exponential factors of ECYFP and the
different Lck constructs were determined with a microscopy system that
enables time- and space-correlated single-photon counting. The imaging
setup consisted of a frequency-doubled femtosecond laser (excitation wave-
length, 420 nm), an inverted microscope, and two sensitive detectors: a mi-
crospectroscopic DL detector and a position-sensitive photomultiplier (QA
imaging detector) (28, 31, 39, 40). The DL detector was used to statistically
analyze a very small area of the sample (with a diameter of 5 to 10 mm) and
to resolve spectrally the corresponding fluorescence decays. Measurements
with the QA imaging detector setup were performed to analyze the spatial
distribution of the biosensors, as well as changes in their individual fluores-
cence lifetimes.
Analysis of FLIM data
In a multiexponential fluorescence system (for example, the ECFP-EYFP
FRET pair), the intensity of the fluorescence signal decays as a sum of in-
dividual single lifetimes I(t) is given by
IðtÞ ¼ ∑iaiexp − t=ti
where ti represents the individual decay times, and the pre-exponential
factors ai are the amplitudes of the components (indexed by i), for example,
subpopulations of the fluorophore that are involved or not involved in
FRET. The values of ai and ti can be used to calculate the fractional dis-
tributions fi of each of the decay times (41). Thus, the value of fi represents
the fractional intensities of the individual subpopulations of a mixture of
fluorophores, for example, subpopulations of proteins that do or do not un-
dergo FRET, such as ECFP.
fi ¼ ðaitiÞ=ð∑iaitiÞ
The values of fi and ai can be used to determine the mean fluorescence
lifetime of each biosensor (41). To analyze the fluorescence decay I(t), the
data measured with both detectors were modeled by the convolution product
of a multiexponential theoretical model with the instrument response
function (IRF):
IðtÞ ¼ IRFðtÞ ⊗ ∑iai exp − t=ti
where IRF is the measurement of the pulsed laser excitation obtained by
acquiring the reflection of the laser beam. The data were analyzed by a
Levenberg-Marquardt nonlinear, least-squares algorithm with the MATLAB
software package, version R12.
Data acquired by the spectral (DL) detector were fitted with linked life-
times along the wavelength band (460 to 650 nm). In this case, the intensity
decay of the fluorescence signal can be described as (41)
Iðl, tÞ ¼ ∑iaiðlÞ exp − t=ti
The wavelength-dependent pre-exponential factors ai(l) of the individ-
ual lifetimes ti were plotted along different wavelengths, which resulted in
generation of the DAS.
These spectra
IiðlÞ ¼ aiðlÞtiIðlÞ ½∑iaiðlÞti%
−1
represent the emission spectra of the individual components charac-
terized by the individual lifetime ti (41). The comparison of the DAS
of the individual lifetimes enables the identification of the fluorescent
species (the donor and acceptor molecules) that are involved, or not, in
FRET, as explained below:
Because FRET is a bimolecular process, the exited state population of
the system can be described after excitation of the donor with a d-shaped
laser pulse:
dDðtÞ=dt ¼ −ðkd þ ktÞDðtÞ ð1Þ
and
dAðtÞ=dt ¼ DðtÞkt − AðtÞka ð2Þ
where D(t) is the concentration of the donor molecules in the exited state,
A(t) is the concentration of the exited acceptor molecules, kd is the rate
constant of relaxation of the donor molecules in the absence of the acceptor,
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ka is the acceptor de-excitation rate constant, and kt is the rate constant of
resonance energy transfer. The differential equations 1 and 2 describe the
fluorescence decays of the donor and acceptor molecules and can be
solved as follows (42):
DðtÞ ¼ D0 exp − ðkd þ ktÞt
AðtÞ ¼ −D0kt=ðkd þ kt − kaÞexp − ðkd þ ktÞt þ
D0 kt=ðkd þ kt − kaÞ exp − kat
D0 represents the exited state population of the donor at time t = 0. The
negative term in the function of the acceptor A(t) reflects a rise component
in the decay of the acceptor because of energy transfer (42, 43) and results
in a longer lifetime of the acceptor compared to its native lifetime. This
can be detected as a negative term in the DAS in the wavelength range of
the native acceptor emission wavelength (41). Therefore, negative terms in
the DAS plot of the individual lifetimes of a multiexponential system (for
example, a FRET pair consisting of fluorescent proteins) identify the sub-
population of molecules involved in the FRET process. Data collected by
the QA detector were analyzed as previously described (28, 31). To visu-
alize the spatial distribution of different exited states (high or low FRET
signals) of the fluorophores inside a cell, the pre-exponential factors of the
lifetime t3, which characterizes the subpopulation of the donor molecules
involved in the FRET process, were plotted as previously described (32).
The resulting pseudocolor-coded maps show the distribution of the con-
formational changes of the biosensor.
Analysis of intracellular Ca2+ flux
JCam1.6 cells (0.3 × 106/ml) transfected with either plasmid encoding
the Lck biosensor or the empty plasmid were loaded with Indo-1 AM
(5 mg/ml) (Molecular Probes) for 45 min at 37°C in RPMI 1640 with-
out phenol red (Invitrogen). After washing, cells were rested for 45 min at
37°C. Stimulation was initiated by adding 10 ml of C305 monoclonal an-
tibody hybridoma supernatant per milliliter of cell suspension. Changes
in intracellular Ca2+ were monitored with either a flow cytometer LSR
I analyzer (BD Biosciences) or a confocal microscope Leica SP2 (Leica
Microsystems Heidelberg). Cells were illuminated with the 364-nm line of
an argon UV laser (for the confocal microscope) or the 325-nm laser line
of a helium-cadmium laser (for the LSR flow cytometer). In both experi-
mental settings, fluorescence emissions at 390 to 420 nm and 500 to
520 nm were detected simultaneously, and changes in the ratio of the two
emission intensities were analyzed with ImageJ (confocal) or FlowJo
(LSR) software, respectively. To demonstrate successful loading with
the dye, we induced maximal Ca2+ release by adding calcium ionophore
ionomycin (10 mg/ml) (Sigma-Aldrich).
Immunoprecipitations and in vitro kinase assays
To immunoprecipitate Lck (as shown in Fig. 5A), we left 5 × 106 Jurkat
cells untreated or activated them with microbeads coated with anti-CD3
antibody. SuperAvidin-coated polystyrene microspheres (diameter, 10.14
mm; density, 1.6 × 107/ml; Bangs Laboratories Inc.) were incubated with
the biotinylated aCD3e monoclonal antibody UCHT1 (10 mg/ml) in
phosphate-buffered saline (PBS) for 30 min at 37°C. aCD3-coated mi-
crobeads were washed twice with PBS and resuspended in RPMI 1640.
Stimulation of Jurkat cells (at a cell-to-bead ratio of 2:1) was synchronized
by centrifugation at 100g for 10 s. After the indicated times, cells were
washed and lysed in buffer containing 1% LM (an N-dodecyl b-maltoside),
1% NP-40, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 10 mM
NaF, 10 mM EDTA, 50 mM tris-HCl (pH 7.5), and 150 mM NaCl. Deter-
gent cell lysates were incubated overnight at 4°C with the anti-Lck
monoclonal antibody 3A5 coupled to protein A–agarose (Santa Cruz Bio-
technology Inc.). Samples were separated by 10% SDS–polyacrylamide gel
electrophoresis (SDS-PAGE) and blotted onto nitrocellulose. For dual-color
analysis, membranes were first incubated with rabbit antibody against pSrc-
pY416, which corresponds to pY394 of Lck, and goat anti-rabbit IRDye
680LT, stripped for 20 min (in Restore PLUS Western Blot Stripping
Buffer, Thermo Scientific) and then incubated with secondary antibody
to exclude remaining anti–Src-pY416 binding. Membranes were subse-
quently incubated with rabbit antibody against Lck and goat anti-rabbit
IRDye 800CW. Signal intensities were determined by scanning the mem-
branes with an Odyssey infrared imager (LI-COR) and analyzing the data
with the Odyssey application software. For in vitro kinase assays, freshly
prepared human T lymphocytes (5 × 107 cells per sample) or Jurkat cells
(2 × 107 cells per sample) were stimulated for 30 or 120 s with a 1:100 (v/v)
dilution of ascites fluid of the aCD3 monoclonal antibody MEM92 (IgM,
provided by V. Horejsi, Prague). In some experiments, the aCD3e mono-
clonal antibody UCHT1 (10 mg/ml) was used to stimulate cells, yielding
identical results. After stimulation, cells were lysed in lysis buffer supple-
mented with 1% NP-40 and 1% LM as detergents. Detergent lysates were
subjected to immunoprecipitation with aLck antibody with 2 mg of polyclo-
nal rabbit antibody (Upstate) used for each immunoprecipitation. After
washing, the immunoprecipitates were split; 50% of the immunoprecipitates
were used for Western blotting analysis, with the aLck antibody as a con-
trol, whereas the remaining 50% of the samples were resuspended in kinase
buffer [20 mM tris-HCl (pH 7.5), 10 mM MnCl2, 100 mM ATP, 10 mCi of
32g-ATP (PerkinElmer; 3000 Ci/mmol)] and subjected to an in vitro ki-
nase assay for 20 min at 30°C. After the kinase reaction was complete,
the radiolabeled immunoprecipitates were washed four times in washing
buffer [20 mM tris-HCl (pH 7.5), 20 mM EDTA, 150 mM NaCl2] and
subsequently subjected to SDS-PAGE and autoradiography.
Automated multidimensional fluorescence
microscopy (MELK)
Jurkat cells (1 × 106/ml) were placed onto poly-L-lysine–coated cover slides
and stimulated with the aCD3e monoclonal antibody UCHT1 (5 mg/ml)
or RPMI without FCS (as a negative control) at 37°C. After 5 min, the
slides were transferred into ice-cold PBS to stop the stimulation. Cells
were fixed with 2% paraformaldehyde (PFA; Santa Cruz Biotechnology
Inc.) and permeabilized with 0.2% Triton X-100. After labeling and im-
aging of the first antibody set, the dye (Alexa Fluor 488) was bleached,
and samples were then incubated with the next antibody. The appropriate
working dilutions, incubation times, and positions within the MELK run
were validated systematically with conditions suitable to MELK (44).
Images were recorded with a toponome imaging cycler (TIC). The sam-
ple was placed on the stage of an inverted, wide-field fluorescence mi-
croscope (Leica DM IRE2, 63× oil lens with 1.40 numerical aperture).
For each of the two conditions defined by application of individual drop-
lets of cell solution, a suitable field of view was defined manually, and
the corresponding XYZ positions and a transmitted light reference image
were stored by the TIC Control software. A fully automated cyclic ro-
botic process started with the incubation of the first fluorescent antibody
(or tag). After a washing step, the fluorescence signals and a correspond-
ing phase-contrast image were acquired by a cooled charge-coupled device
camera (Apogee KX4, Apogee Instruments, 1× binning results in images
of 2048 × 2048 pixels; final pixel size, 143 × 143 nm2). To eliminate the
specific signal of a given tag before the addition of the next, we performed
a bleaching step. A post-bleaching fluorescence signal was recorded be-
fore the next incubation-imaging-bleaching cycle started with the next tag.
These cycles were processed until all of the tags were applied to the sample.
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The fluorescence and post-bleaching fluorescence images produced by each
tag were automatically aligned pixel-wise with the corresponding
phase-contrast images, reaching an alignment accuracy of 1 pixel. Fluores-
cence images were corrected for illumination faults with flat-field correc-
tion. Post-bleaching images were subtracted from the subsequent
fluorescence tag images. Finally, cases of section artifacts were excluded
as invalid by a mask-setting process. Regions of interest for T cells analyzed
were defined manually, and the background-subtracted intensities for the
individual tags were recorded.
Confocal imaging
Lck-deficient JCam1.6 cells expressing a biosensor were plated on poly-L-
lysine–covered slides at room temperature for 5 min and immediately
fixed for 10 min in PBS (pH 7.4) containing 1.5% PFA and 0.025% glu-
taraldehyde. Cells were permeabilized in PBS containing 0.2% Triton
X-100 for 10 min, rinsed twice with PBS, and blocked with 1% bovine
serum albumin in PBS (pH 7.4) for 10 min. Cells were incubated with
primary antibodies including anti-Jurkat TCR monoclonal antibody
C305 (IgM, provided by A. Weiss, UCSF) and antibodies against
EEA1, Rab11, and Rab5 (all from BD Bioscience) for 1 hour, and cells
were subsequently washed and blocked as described earlier. Specimens
were then treated with a secondary antibody (DyLight 549, Dianova) for
1 hour. After washing three times with PBS, specimens were washed once
in PBS (pH 8.9) and subsequently embedded. The specimens were ana-
lyzed with a confocal microscope (Leica SP2, Leica Microsystems
Heidelberg). Sequential images were acquired in the corresponding
wavelength channels to avoid bleed-through processes and were later
merged with ImageJ software. For membrane staining, CellTracker
(CM-Dil, Molecular Probes) was added to the plated cells, incubated
for 5 to 10 min, washed with PBS, and fixed and scanned with a con-
focal microscope as described earlier.
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/6/263/ra13/DC1
Fig. S1. Two versus three lifetimes are needed to describe the fluorescence decay of an
ECFP-EYFP FRET pair.
Fig. S2. Localization of the biosensor CLckY-1 at the plasma membrane.
Fig. S3. Localization of the biosensor in transfected Lck-deficient JCam1.6 cells.
Fig. S4. Conjugate formation between transfected JCam1.6 cells expressing CLckY-1 and
mock-treated Raji B cells as measured with the QA detector in the FLIM setup.
Fig. S5. Lck does not coimmunoprecipitate with Csk.
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Signaling through the TCR is crucial for the generation of different cellular responses including
proliferation, differentiation, and apoptosis. A growing body of evidence indicates that
differences in the magnitude and the duration of the signal are critical determinants in eliciting
cellular responses. Here, we have analyzed signaling dynamics induced upon TCR ligation in
primary human T cells. We used CD3 antibodies either cross-linked in solution (sAbs) or
immobilized on microbeads (iAbs), two widely employed methods to stimulate T cells in vitro.
We show that classical sAbs stimulation induces a transient and abortive response, whereas iAbs
induce sustained TCR-mediated signaling, resulting in productive T-cell responses previously
observed only in antigen-specific murine systems. In summary, our analysis documents TCR
signaling kinetics and suggests that iAbs are better suited for studying TCR-mediated signaling as
they mimic antigen specific systems.
© 2012 Elsevier B.V. All rights reserved.
Keywords:
T-cell activation
Signaling signature
Antibody stimulation
Physiological stimuli
Erk dynamics
TCR-mediated signaling
1. Introduction
Triggering of the T cell receptor (TCR) by pathogens
activates an intricate network of signaling cascades that are
both temporally and spatially regulated. These signaling
events will lead to transcriptional activation, proliferation,
and differentiation of T cells that will ultimately culminate in
an immune response. Defects in signal transduction may lead
to either T-cell hyperresponsiveness or impaired T-cell activa-
tion, which results in autoimmunity or immunodeficiency,
respectively. Thus, the study of how TCR signaling is initiated,
propagated, and translated into a cellular response is important
for the understanding not only of physiological processes, but
also of the molecular mechanisms underlying human diseases.
To reproduce in vitro the signaling events occurring
during physiological T-cell activation, immunologists need
to pay particular attention in the choice of an appropriate
stimulus. In vivo, T cells are activated upon contact with APCs
expressing the agonistic peptide in the context of MHC-
molecules. Therefore, the ideal method to activate T cells
in vitro e.g. for biochemical analyses should mimic these
conditions. Antigen-based systems, however, can only be used
for the in vitro stimulation of monoclonal T-cell populations
expressing a specific TCR, usually expressed on transgenic T
cells, and are thus limited to mouse models.
Methods such as artificial antigen-presenting systems
employing both cell-based and acellular technologies have
been developed and are now being used to different extents
in immunotherapy (Kim et al., 2004). However, to assess
biochemical events during T-cell activation, soluble polyclonal
stimuli such as agonistic antibodies against the TCR/CD3
complex, the co-receptors and/or the co-stimulatory mole-
cules (i.e. CD4, CD28) are still largely used. For more than
30 years, this method has been extensively employed and
indeed, has provided significant insight into the molecular
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events occurring during T-cell activation. However, stimula-
tions with soluble ligands have clear limitations, as they fail to
reproduce the extra dimension of a cell–cell contact and, more
importantly, they do not induce T-cell responses (Berg et al.,
1998; Wang et al., 2008). Thus, it is questionable whether TCR
signaling induced upon stimulation with soluble Abs mirrors
the physiologic signaling cascade leading to productive T-cell
responses. Moreover, it appears somehow surprising that,
despite the availability of tools that trigger T-cell activation,
mimic APCs, and induce proliferation, the analyses of intracel-
lular signaling pathways are stillmainly performed by applying
soluble ligands.
Alternative method of T-cell stimulation is based on
microbeads coated with the same antibodies against TCR
complex is an efficient tool that can be used to expand T cells
ex vivo especially for immunotherapeutic applications (Levine
et al., 1997; Garlie et al., 1999; Trickett and Kwan, 2003). It is
generally believed that sAbs and iAbs have different functional
properties. However, a comprehensive functional and bio-
chemical characterization of the twowidely employedmethods
to stimulate human T cells in vitro has not yet been performed.
Additionally, it has also not yet been analyzed which of the
two stimuli more closely mimics physiological stimulation
and hence is more suitable for signaling studies. Therefore, we
performed a systematic analysis of the signaling signatures
induced by Abs against the TCR complex either cross-linked in
solution (sAbs) or immobilized on microbeads (iAbs). Our
analysis documents signaling kinetics and functional responses
of iAbs and shows that they are better suited than sAbs for
studying TCR-mediated signaling.
2. Materials and methods
2.1. Human ethics
Approval for these studies involving the analysis of
TCR-mediated signaling in human T cells was obtained from
the Ethics Committee of the Medical Faculty at the Otto-von-
Guericke University, Magdeburg, Germany with the permis-
sion number [107/09]. Informed consent was obtained in
writing in accordance with the Declaration of Helsinki.
2.2. Cell puriﬁcation
Peripheral blood mononuclear cells were isolated by Ficoll
gradient (Biochrom) centrifugation of heparinized blood
collected from healthy volunteers. Total population of human
T cells or CD4+ naïve andmemory subpopulationswere further
purified by non-T cell depletion using specific T cell isolation
kits (Miltenyi Biotec). The purity of T cells, determined by flow
cytometry, was usually more than 96%.
OT-II TCR transgenic or wild type mouse T cells were
isolated using a Pan T-cell Isolation Kit and AutoMacsmagnetic
separation system (Miltenyi Biotec). APCs were prepared as
follows: T and NK cells were stained using FITC-labeled CD3,
CD4, CD8, and NK1.1 mAbs (BD Biosciences). After staining, T
and NK cells were depleted using anti-FITC microbeads on an
AutoMacs magnetic separation system. The remaining splenic
cell suspension was used as APCs.
2.3. T-cell stimulation
After isolation, human T cells were cultured overnight in
RPMI 1640 medium containing 10% FCS (PAN Biotech) and
2 μg/ml Ciprobay (Bayer Schering Pharma). Successively, T
cells were stimulated with either soluble or immobilized
mAbs as follows. For soluble Ab stimulation, 2×106 cells
were loaded with 10 μg/ml biotinylated anti-human CD3
(clone UCHT1, eBioscience) alone or in combination with
10 μg/ml biotinylated anti-human CD28 (clone CD28.2,
eBioscience), and 10 μg/ml biotinylated anti-human CD4
(clone OKT4, eBioscience) mAbs as indicated in 100 μl RPMI
1640 and for 15 min on ice. After washing, receptors were
cross-linked by adding 25 μg/ml NeutrAvidin™ (Pierce). For
microbead stimulation, SuperAvidin™-coated polystyrene
microspheres (Ø~10 μm, Bangs Laboratories) were coated
with biotinylated CD3 alone or in combination with CD28
and CD4 mAbs as indicated (10 μg/ml each) for 30 min at
37 °C in PBS. Antibody-coated microbeads were washed
twice with PBS, resuspended in RPMI 1640 and incubated
with T cells in a 1:1 ratio. Stimulation of T cells was facilitated
and synchronized by centrifugating samples for about 10 s at
1000 rpm. Biotinylated IgG2a and IgG1 mouse immunoglob-
ulins (eBioscience) were used as a control. Stimulation with
plate-bound antibodies was performed as follows. 10 μg/ml
of CD3 and 10 μg/ml CD28 Abs were coated on U-bottomed
96-well plates for 2 h at 37 °C. After washing, 1×106 cells
were added to the plates, rapidly centrifuged at 1000 rpm
and incubated at 37 °C for the indicated time points.
Mouse T cells were stimulated with either soluble or
immobilized βTCR×CD28 mAbs and processed as described
above. For stimulations, 10 μg/ml of soluble or immobilized
βTCR (clone H57-597, BD Biosciences) and CD28 (clone 37.51,
BD Biosciences) mAbs were used. OT-II TCR transgenic T cells
(1×106) were stimulated with (2×106) APCs that were either
left unloaded or loaded with 5 μg/ml of OVA323–339 for the
indicated period of time.
2.4. Western blotting
T cells were lysed in buffer containing 1% lauryl maltoside
(N-dodecyl β-maltoside), 1% NP-40, 1 mM Na3VO4, 1 mM
PMSF, 10 mM NaF, 10 mM EDTA, 50 mM Tris pH 7.5, and
150 mM NaCl. Post-nuclear lysates were separated by
SDS-PAGE and transferred onto nitrocellulose membranes.
Membraneswere probedwith the indicated primary antibodies
and the appropriate HRP-conjugated secondary antibodies
(Dianova) and developed using the ECL detection system
(Amersham Pharmacia). The following antibodies were used
for Western blotting in this study: anti-phospho(p)-T202/Y204
Erk1/2, anti-pY171LAT, anti-pY783PLC-γ1, anti-pS338-c-Raf,
anti-pS217/221MEK1/2 (all from Cell Signaling Technology),
and anti-β-actin (clone AC-15) (Sigma-Aldrich). For quantifi-
cations of theWestern blots, the intensity of the detected bands
was acquired using theKodak Image Station 2000R and analysis
was performed using 1D ImageQuant software (Kodak).
2.5. In vitro assays
Proliferation experimentswere carried out in 96-well plates
(Costar). T cells were labeled with 2.5 μM CFSE (Molecular
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Probes) for 10 min at 37 °C. After washing, 2×105 cells were
seeded in a total volume of 200 μl to each well and cultured
in RPMI (supplemented with 10% FCS and antibiotics). Human
T cells were either left unstimulated or were stimulated
with soluble or immobilized CD3 alone, CD3×CD28, and
CD3×CD28×CD4 mAbs as indicated above (see T-cell stimu-
lation). Mouse T cells were either left unstimulated or
stimulated with 10 μg/ml of soluble or immobilized βTCR
(clone H57-597, BD Biosciences) and CD28 (clone 37.51,
BD Biosciences) mAbs. T cells were cultured for 72 h at 37 °C,
5% CO2. Proliferation was assessed by CFSE dilution using a
FACS-Calibur and the CellQuest software (BD Biosciences) or
BD LSRFortessa, FACSDiva Software 6.1.3 (BD Biosciences), and
FlowJo 7.6.5 (Tree Star, Inc.).
To measure proliferation of lymph node cells isolated
from OT-II transgenic mice 1×105 cells/well were cultured
for 2 days in RPMI 1640 medium (supplemented with 10%
FCS, antibiotics, 2-ME) in U-bottom 96-well plates (Costar) in
the presence of 2×105 T cell-depleted irradiated splenocytes
from wild-type mice loaded with increasing amount of
OVA323–339 peptide. Cells were pulsed with 1 μCi [
3H]-thy-
midine per well during the last 8 h and harvested using a
PHD cell harvester (Inotech AG, Basel, Switzerland). Thymidine
incorporation was measured by liquid scintillation counting.
To determine T-cell activation, human T cells were
stimulated as described above. After 24 h, T cells were stained
with either FITC- or PE-labeled mAbs against CD25 and CD69
(BD Biosciences), respectively. Cell associated fluorescencewas
analyzed by flow cytometry.
To quantify cell survival under different stimulation
conditions, human T cells were stimulated with either soluble
or immobilized mAbs as described above, and resuspended in
RPMI supplementedwith 10% FCS at a density of 1×106 cells/ml
in a 24-well tissue culture plate. Cells were harvested after 24 h
and the percentage of cells undergoing apoptosis were mea-
sured by flow cytometry using FITC-annexin V and propidium
iodide (PI) (rh annexin V/FITC kit; Bender MedSystems)
according to manufacturer's instructions.
To measure the antibody binding capacity, 1×106
microbeads were coated with either CD3 alone or in combina-
tionwith CD28 andCD4mAbs as described above. Subsequently,
microbeads were washed and stained with FITC-conjugated
anti-mouse antibody (Jackson ImmunoResearch Laboratories).
Beads associated fluorescencewas analyzed by flow cytometry.
2.6. T cell/microbead binding
Primary human T cells were mixed with the CD3×CD28
coated microbeads in a 1:1 ratio, rapidly centrifuged at
1000 rpm and incubated at 37 °C for the indicated time
points in a 3 ml round-bottom tube. Subsequently, the
samples were gently resuspended in 500 μl PBS and analyzed
on a FACS Calibur. Microbeads coated with IgG2a and IgG1
were used as a control. T cell/microbead conjugates were also
counted by using a hemocytometer. Single-cell imaging was
done on a Leica microscope equipped with a 20× imaging
system from Visitron Systems Imaging GmbH.
2.7. Florescence microscopy
Cell stimulation was performed as indicated above.
Subsequently, cells were transferred to PLL-coated cover
slides and allowed to settle down for 10 min at 4 °C before
fixation with 2% para-formaldehyde. The samples were
permeabilized with 0.2% TritonX100 for 10 min and blocked
with 1% BSA for 30 min. Cell conjugates were stained with
propidium iodide (SigmaAldrich) and anti-pY142CD3ζ-Alexa488
antibody (BD Pharmigen), and placed on the stage of an inverted
wide-field fluorescencemicroscope (Leica DM IRE2; 63× oil lens
NA 1.40). The fluorescent signals and the corresponding phase
contrast imagewere acquired by a cooled charge-coupled device
camera (Apogee KX4; Apogee Instruments, Roseville, CA, 2×
binning). Fluorescence images were corrected for illumination
faults using flat-field correction.
3. Results
3.1. iAbs induce activation and proliferation, whereas, sAbs
result in T-cell unresponsiveness
It is generally accepted that soluble antibodies cannot
induce productive T-cell responses. Indeed, we and others
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Fig. 1. Analysis of the functional effects of sAbs and iAbs. Purified human T cells were treated as indicated. (a) 24 h after stimulation, the activation of T cells was
analyzed by staining with CD25 and CD69 and flow cytometry. (b) T cells were labeled with CFSE and stimulated as indicated. Proliferation was assessed after
72 h by analyzing CFSE content on a FACS Calibur. (c) T cells were stimulated as indicated for 24 h. Cell survival was assessed by FITC-annexin V and PI staining.
One representative experiment of at least three independent experiments is shown. Numbers in c indicate the proportion of cells in each quadrant.
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have demonstrated that OT-I transgenic T cells and cytotoxic
T-lymphocyte clones are not activated and do not differentiate
upon stimulation with antibodies cross-linked in suspension
(Berg et al., 1998;Wang et al., 2008). Here, we have stimulated
primary human T cells with either sAbs or iAbs and analyzed
their functional responses. Fig. 1 shows that treatment of T cells
with iAbs led to an expression of CD25 and CD69 and to a
proliferative response. Conversely, treatment with sAbs (CD3
alone or in combination with CD28) failed to induce T-cell
activation as indicated by the absence of CD69 and CD25
expression (Fig. 1a). In agreement with these data, prolifera-
tion assays revealed that T cells stimulated with sAbs (CD3
alone or in combination with CD28 and CD4) also did not
proliferate (Fig. 1b).
To exclude the possibility that the lack of proliferation
depends on the particular clone of antibody used for stimula-
tion, we repeated the experiments depicted in Fig. 1 using two
other CD3 mAbs of different Ig classes (OKT3 and MEM92).
Moreover, we also tested different concentrations of soluble
anti-CD3 (UCHT-1) (ranging from 0.1 μg/ml to 10 μg/ml)
together with various concentrations of anti-CD28 (ranging
from 0.1 μg/ml to 10 μg/ml) in different ratios in the presence
or absence of anti-CD4. Under all conditions tested, human
T cells did not proliferate in response to stimulation with
cross-linked soluble Abs (Fig. 1b, Supplementary Fig. 1, and
data not shown).
Finally, similar to human T cells, also the stimulation of
mouse T cells with TCRβ×CD28 mAbs immobilized on
microbeads resulted in proliferation, whereas, stimulation
with the same antibodies cross-linked in suspension did not
induce productive T-cell response (Supplementary Fig. 2).
Similar stimulation conditions also failed to induce prolifer-
ation in OT-I transgenic T cells (Wang et al., 2008).
We have previously shown that cross-linked soluble
CD3×CD8 antibodies induce apoptosis rather than prolifer-
ation in OT-I TCR transgenic CD8+mouse T cells (Wang et al.,
2008). To analyze whether stimulation of human T cells with
sAbs may also induce apoptosis, peripheral T cells were
stimulated overnight and assayed for annexin V expres-
sion. Fig. 1c shows that, in contrast to mouse, stimulation of
human T cells with sAbs did not induce apoptosis. Thus, despite
the fact that sAbs are commonly used to activate proximal and
distal TCR-mediated signaling pathways, they are unable to
induce productive T-cell activation and proliferation.
3.2. iAbs efﬁciently stimulate T cells
To date, little is known about the signaling properties
of mAbs coated to microbeads. We initially established
a protocol to efficiently stimulate T cells with iAbs. For
stimulation, we employed 10 μm microbeads that were
coated with SuperAvidin. This gives the possibility to bind
any biotin-labeled antibody or recombinant protein on the
surface of the microbeads. For this investigation, we used
biotinylated CD3ε and CD28 mAbs unless indicated other-
wise. Microbeads were coated with 10 μg/ml biotinylated
CD3 and CD28 mAbs. Microbeads loaded with non-relevant
antibodies of the same isotype were used as control. To
induce rapid and synchronous cell contact with the beads, we
performed a brief centrifugation (5 s at 1000 rpm) in a small
volume (100 μl). Aliquots of the samples were taken at
regular time intervals and analyzed on a FACS Calibur. Fig. 2a
shows that T cells and microbeads have clearly different
physical parameters and can be easily visualized in FSC/SSC dot
plots. The data also demonstrate that a significant number of
cells associated with microbeads coated with CD3×CD28 Abs
and appeared as a new population indicated in the gate RTc+m
(Fig. 2b). Conversely, in the control samples the emergence of a
new population in the RTc+m gate is not detected (Fig. 2b,
upper panels), thus indicating that microbeads loaded with
isotype controls do not bind to T cells. Successively, to quantify
T cell-microbead association, we calculated the ratio Ra of the
number of T cell/microbead conjugates (events in the RTc+m
gate) to the total number of T cells (events in the RTc gate). We
found that a high fraction of the cells was in contact with
microbeads already after 5 min incubation, with Ra approxi-
mately 0.2 (Fig. 2c). After 15 min incubation, the proportion
of T cells in contact withmicrobeads increased up to 50% (Ra=
0.5). Afterwards, the Ra slightly decreased and stabilized at
values close to 0.3. A similar association rate between Jurkat T
cells and CD3-coated micrometric particles has been recently
described (Carpentier et al., 2009). To further address this issue
and to checkwhethermechanical stress during flow cytometry
measurements resulted in the disruption of T cell/bead
conjugates, we performed additional analyses. We initially
assessed cell/bead conjugates using light microscopy (Fig. 2d).
We found that a high number of T cells rapidly established
contact with iAbs. We next quantified cell/bead conjugates by
manual counting in a hemocytometer. The data depicted in
Fig. 2e show that around 50–70% of the cells conjugate with
beads. As the proportion of T cell/microbead conjugates was
slightly higher than this presented in Fig. 2c, this suggests that
some contacts with beads were lost during flow cytometry.
Collectively, these data demonstrate that a very high number of
iAbs interact with T cells, thus ensuring a focal stimulation.
Additionally, we have analyzed formation of signaling
microclusters in the T cell/bead contact zone by fluorescence
microscopy. As shown in Supplementary Fig. 3, both physio-
logical and iAbs stimulation induce the formation of signaling
microclusters.
We next quantified the effectiveness of the stimulation by
analyzing the proportion of cells displaying phosphorylated
Erk1/2. The data presented in Fig. 2f confirmed that the cell/
bead contact indeed resulted in T-cell stimulation as the
proportions of T cells in contactwith beads and those displaying
intracellular phospho-Erk1/2 were similar. Similar proportions
of activated T cells were also obtained upon stimulation with
sAbs (Fig. 2g). Thus, the efficiency of iAbs and sAbs in
stimulating T cells appears to be comparable.
Next, we have measured fluorescence of beads loaded
with either CD3 alone or CD3×CD28 and CD3×CD4×CD28
to analyze binding capacity of microbeads. We have observed
a consistent increase in the fluorescence of beads loaded with
single vs. beads loaded with multiple mAbs. These data
indicate that the coatingwith CD3 andCD3×CD28mAbs are not
sufficient to saturate the microbeads (Supplementary Fig. 4).
3.3. Sustained versus transient activation kinetics in
TCR-mediated signaling induced by iAbs and sAbs, respectively
As sAbs and iAbs induce markedly different cellular
outcomes, we next performed a comparative analysis of
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their signaling signatures in primary human T cells. We found
that the magnitude and the duration of the signal induced
by iAbs were strikingly different to those induced by sAbs
(Fig. 3). Indeed, stimulation with sAbs (CD3 alone or in
combination with CD28 or CD4) resulted in strong and
transient activation of molecules involved in TCR-mediated
proximal signaling, such as LAT and PLCγ1, whereas iAbs
stimulation led to weaker but sustained phosphorylation
(Fig. 3a). As an example of downstream pathway activated
via the TCR, we investigated the phosphorylation levels of
molecules in the Ras-Erk signaling cascade. Despite the fact
that the magnitude of the phosphorylation of c-Raf, MEK1/2,
and Erk1/2 appeared to be comparable in both types of
stimulation, their activation was sustained upon iAbs treat-
ment (Fig. 3a). Similar activation kinetics were also observed
when purified mouse splenic T cells were stimulated with
b c 
e d 
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Fig. 2. Analyses of the T cell/microbead binding. (a) T cells and microbeads alone were analyzed by side scattering versus forward scattering dot plots.
(b) Subsequently, T cells and microbeads loaded either with isotype controls (isotypes, upper panels) or CD3×CD28 mAbs (iAbs, lower panels) were brought into
contact for the indicated time periods. T cell/microbead conjugates (RTc+m) are clearly distinct from free T cells (RTc) and microbeads (Rm). (c) Statistical
analysis of the ratio (Ra) between the numbers of T cell/microbead conjugates (events in the RTc+m gate) to the total number of unconjugated T cells (events in
the RTc gate) is presented. (d) Transmission light images of T cells incubated with microbeads loaded either with isotype controls (isotypes, upper panels) or
CD3xCD28 mAbs (iAbs, lower panels) are shown. (e) T cell/microbead conjugates were diluted and manually counted in a hemocytometer. The graph shows
statistical analysis of the ratio (Ra) between the numbers of T cell/microbead conjugates to the total number of T cells from three independent experiments.
Human T cells were purified and stimulated with beads loaded either with CD3xCD28 mAbs (iAbs) or isotype control (isotypes) for the indicated time points.
(f) The level of pErk1/2 as marker of activation was measured by intracellular staining. Data represent the mean proportions of pErk1/2 positive cells±SEM of 3
independent experiments. (g) Human T cells were purified and either left unstimulated (medium) or were treated with CD3×CD28mAbs cross-linked in solution
(sAbs) for 2 min. The graph shows the mean proportions of pErk1/2 positive cells±SEM from 3 independent experiments.
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TCRβ×CD28 Abs immobilized on microbeads or cross-linked
in solution (Supplementary Fig. 5), suggesting that TCR-
mediated signaling induced by antibodies immobilized on
beads is not dependent on the antibody clones used for
stimulation.
Next, we compared activation kinetics of purified naïve
and memory CD4+ T cells upon stimulation with sAbs and
iAbs. Similar to unfractionated T cells, both CD4+ T-cell
subsets displayed a transient activation upon sAbs stimula-
tion, but sustained signaling upon treatment with iAbs
(Supplementary Fig. 6). Thus, it appears that the signaling
signatures of sAbs and iAbs are independent of the differen-
tiation status of the cells.
Finally, we analyzed the signaling signatures induced by
plate-bound antibodies, which also induce T-cell activation
and proliferation. As shown in Supplementary Fig. 7, we
found that plate-bound Abs have signaling kinetics similar to
iAbs.
In summary, we show that stimulation with sAbs vs. iAbs
induces different activation kinetics of both TCR proximal
and distal signaling molecules. We believe that the duration
of the signal may be the determinant factor for the generation
of cellular responses.
3.4. Signaling dynamics induced by iAbs are similar to those
induced by stimulation with APC
We next analyzed the signaling kinetics induced by
physiological stimuli. We used CD4+ T cells isolated from
OT-II transgenic mice that were stimulated with APCs alone
as control or with APCs loaded with the OVA323–339 peptide.
Stimulation with OVA-loaded APC proved to be effective
method to generate productive response of OT-II transgenic T
cells in the dose dependent manner (Fig. 4a). Fig. 4b shows
that stimulation with peptide loaded APCs, but not with
control APCs, induces sustained phosphorylation of LAT,
PLCγ1, and Erk1/2 in OT-II transgenic T cells. These data
further corroborate our previous observations showing that
the stimulation of CD8+ T cells from OT-I transgenic mice
with physiological ligands also induced sustained phosphor-
ylation of signaling molecules such as Erk1/2 and PLCγ-1
(Wang et al., 2008). It is important to note that, iAbs elicit
effects that are comparable to those obtained with a
physiological stimulation (Fig. 4 and (Wang et al., 2008)).
Collectively, these data show that stimulation of human
T cells with immobilized Abs induces activation kinetics
similar to those induced by physiological ligands in mouse
TCR transgenic systems and that sustained activation of
TCR signaling correlates with proliferation. In conclusion, it
appears that iAbs mimic more closely physiological stimula-
tion than sAbs and hence are better suited to study signaling
correlating with productive T-cell responses.
4. Discussion
Current stimulation protocols to study T-cell signaling are
mainly based on agonistic antibodies cross-linked in solution.
This method has several advantages such as low costs, easy
handling, high reproducibility, effective activation of sig-
naling molecules, polyclonal activity and, most of all, it is
well-characterized. However, despite its routine use to study
signaling during T-cell activation, it is known that sAbs
induce only a transient activation signal that results in an
abortive response. Moreover, soluble antibodies do not repro-
duce the cell–cell contact induced by an APC and therefore fail
to mimic at least one crucial event occurring during T-cell
activation.
Here, we have analyzed whether Abs immobilized on
microbeads, which mimic APCs and induce proliferation,
represent an alternative and more suitable method to sAbs
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Fig. 3. sAbs induce transient, whereas, iAbs induce sustained signaling. (a,b) Purified human T cells were treated with either soluble (sAbs) or immobilized (iAbs)
mAbs as indicated. Samples were analyzed by Western blotting using the indicated Abs. For each condition one representative immunoblot of at least 4
independent experiments is shown.
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for the stimulation of T cells for signaling studies. We further
compared the kinetics of central signaling events induced by
Abs immobilized on microbeads to those generated by Abs
cross-linked in solution. We document profound signaling
differences between these methods of stimulation.
One of the most important findings is that the sustained
activation induced by iAbs recapitulated signaling events
observed in antigen-specific systems. In fact, we show that
T cells stimulated with APCs loaded with the OVA-peptide
display similar activation kinetics as T cells stimulated with
beads. Moreover, we have previously shown that H-2Kb
molecules loaded with the SIINFEKL peptide triggered
prolonged activation of ZAP-70, LAT, PLCγ-1, and Erk1/2 and
also induced proliferation in OT-I transgenic T cells (Wang et
al., 2008).
In addition to the immobilization on beads, Abs can also
be bound to cell culture plates. Similarly to iAbs, also plate-
bound antibodies induce functional responses. Previous
studies have shown that plate-bound, but not soluble CD3
Abs induce sustained TCR-mediated tyrosine phosphorylation
and MAPK activation in murine CTL clones (Berg et al., 1998;
Puente et al., 2000, 2006). However, the relevance of these
studies is limited. They utilize CD8+ T-cell clones, which were
expanded in the presence of IL-2 and were stimulated with
CD3 Abs alone in the absence of co-stimulation. Therefore, it
is questionable whether these data also apply to primary
human T cells. Conversely, in our studies we have provided an
extensive biochemical characterization of signaling networks
upon stimulation with either sAbs or iAbs in total human
peripheral T cells as well as in naïve and memory CD4+ T cells.
To our knowledge similar studies describing the signaling
properties of Abs immobilized either on beads or cell culture
plates have not been performed. Despite the fact that both iAbs
and plate-bound antibodies induce functional responses and
likely similar signaling kinetics, antibodies immobilized on
microbeads allow an easier handling of the samples during
stimulation compared to plate-bound antibodies. Therefore,
webelieve that iAbs are a validmethodof stimulation that allows
easy and large scale biochemical analyses of TCR-mediated
signaling events.
The availability of a method that mimics antigen-specific
systems is of particular importance to study primary human
T cells, which cannot be stimulated on a large scale by antigen-
specific systems. Data from primary human T cells are still
scarce andmost of our knowledge on signaling in humanT cells
is based upon data obtained from the analysis of lymphoid cell
lines that were stimulated with cross-linked soluble mAbs.
Experiments employing primary human cells stimulated with
more physiological systems are not only necessary to study the
basis of T-cell function, but are also essential to understand the
molecular mechanisms of human diseases such as autoimmu-
nity and cancerogenesis.
In summary, our studies clearly show that iAbs are a valid
alternative to sAbs for stimulation of T cells for signaling
analysis. First, iAbs are easy and ready-to-use. Second, iAbs
mimic signaling kinetics described in antigen-specific systems.
Third, iAbs trigger signaling pathways correlating with T-cell
activation and proliferation.
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Human Regulatory T Cells Rapidly Suppress
T Cell Receptor–Induced Ca2+, NF-kB, and NFAT
Signaling in Conventional T Cells
Angelika Schmidt,1* Nina Oberle,1* Eva-Maria Weiß,1 Diana Vobis,1
Stefan Frischbutter,2 Ria Baumgrass,2 Christine S. Falk,3 Mathias Haag,4
Britta Brügger,4 Hongying Lin,5 Georg W. Mayr,5 Peter Reichardt,6 Matthias Gunzer,6
Elisabeth Suri-Payer,1 Peter H. Krammer1†
CD4+CD25hiFoxp3+ regulatory T cells (Tregs) are critical mediators of self-tolerance, which is crucial for
the prevention of autoimmune disease, but Tregs can also inhibit antitumor immunity. Tregs inhibit the
proliferation of CD4+CD25− conventional T cells (Tcons), as well as the ability of these cells to produce
effector cytokines; however, the molecular mechanism of suppression remains unclear. Here, we
showed that human Tregs rapidly suppressed the release of calcium ions (Ca
2+) from intracellular stores
in response to T cell receptor (TCR) activation in Tcons. The inhibition of Ca
2+ signaling resulted in
decreased dephosphorylation, and thus decreased activation, of the transcription factor nuclear fac-
tor of activated T cells 1 (NFAT1) and reduced the activation of nuclear factor kB (NF-kB). In contrast,
Ca2+-independent events in Tcons, such as TCR-proximal signaling and activation of the transcription
factor activator protein 1 (AP-1), were not affected during coculture with Tregs. Despite suppressing intra-
cellular Ca2+mobilization, coculture with Tregs did not block the generation of inositol 1,4,5-trisphosphate in
TCR-stimulated Tcons. The Treg-induced suppression of the activity of NFAT and NF-kB and of the expres-
sion of the gene encoding the cytokine interleukin-2 was reversed in Tcons by increasing the concentration
of intracellular Ca2+. Our results elucidate a previously unrecognized and rapid mechanism of Treg-mediated
suppression. This increased understanding of Treg functionmay be exploited to generate possible therapies
for the treatment of autoimmune diseases and cancer.
INTRODUCTION
CD4+ regulatory T cells (Tregs), which are characterized by high abun-
dance of the surface marker CD25 and by the presence of the transcription
factor Foxp3, play a pivotal role in the immune system and are involved in
the prevention of autoimmune diseases and allergies (1). In addition to the
beneficial functions of Tregs in graft-versus-host disease (GVHD) and in
the prevention of organ pathology after infection, Tregs also lead to the un-
wanted dampening of immune responses, for example, in cancer (2). Tregs
directly inhibit the proliferation of responder CD4+CD25− conventional T
cells (Tcons) and the production of effector cytokines by these cells (3).
Some mechanisms of Treg-mediated suppression have been described thus
far (4, 5). For example, adenosine 3,5-monophosphate (cAMP) inhibits
the production of the cytokine interleukin-2 (IL-2) by murine Tcons. This study
implied that cAMP was transferred from Tregs to Tcons to induce expression of
the gene encoding the transcriptional repressor inducible cAMP early
repressor (ICER), which in turn represses expression of the Il2 gene encoding
the cytokine IL-2 in Tcons (6). Various factors, such as location, inflammatory
milieu, antigen load, cell number, and activation status of the responder
cells, influence the mechanism of Treg-mediated immune regulation in vivo
(4). Furthermore, species differences regarding Treg function have been
found. For example, the immunosuppressive cytokine IL-35 is produced
by murine Tregs but is not constitutively produced by human Tregs (7, 8).
Therefore, we sought to clarify the inhibitory mechanism(s) in vitro and
investigated the direct suppression of primary human Tcons by Tregs.
We hypothesized that Tregs might disrupt a key component of T cell
receptor (TCR) signaling and that such disruption could perturb the func-
tion of Tcons. Thus far, the influence of Tregs on signaling events in sup-
pressed Tcons has not been investigated extensively. Stimulation of the
TCR initially leads to the activation of the Src family kinase leukocyte-
specific protein tyrosine kinase (Lck), which phosphorylates tyrosine res-
idues in CD3, z chainassociated protein kinase of 70 kD (ZAP-70), and
other substrates. This initiates signaling cascades that lead to the activation
of transcription factors crucial for the expression of genes involved in T
cell activation and proliferation. Central transcription factors that induce
the expression of genes encoding cytokines are nuclear factor kB (NF-kB),
nuclear factor of activated T cells (NFAT), and activator protein 1 (AP-1) (9).
The AP-1 pathway depends on the activation of mitogen-activated protein
kinases (MAPKs), such as extracellular signalregulated kinase (ERK),
c-Jun N-terminal kinase (JNK), and p38, which promote the synthesis, phos-
phorylation, and activation of the Fos and Jun proteins that together comprise
the AP-1 transcription factor (10). Activation of both NF-kB and NFAT
requires the activity of phospholipase Cg1 (PLC-g1), which generates the
second messengers diacylglycerol (DAG) and inositol 1,4,5-trisphosphate
(IP3). DAG leads to activation of protein kinase C q (PKCq), which, in
turn, activates the inhibitor of kB (IkB) kinase (IKK) complex, resulting
in the phosphorylation and degradation of IkBa and the translocation of
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the NF-kB p50:p65 heterodimer to the nucleus (11). IP3 induces an in-
crease in the concentration of cytoplasmic calcium (Ca2+) and activation
of the Ca2+-dependent phosphatase calcineurin, which results in the rapid
dephosphorylation and activation of NFAT, which is followed by its trans-
location to the nucleus (12). Ca2+ is critically involved not only in the acti-
vation of NFAT but also in the activation of NF-kB, because Ca2+ channel
blockers, as well as other agents that prevent Ca2+ influx, inhibit the acti-
vation of NF-kB (13, 14). Indeed, Ca2+may lead to the activation of NF-kB
signaling by inducing the degradation of IkBa (15, 16). A previous study
showed that murine Tcons deficient in both NFAT1 and NFAT4 are less
susceptible to Treg-mediated suppression than are their wild-type counter-
parts (17); however, TCR signaling and the subsequent activation of the
transcription factors NFAT, NF-kB, and AP-1 in suppressed Tcons have not
been analyzed so far.
We previously showed that suppression of the expression of cytokine-
encoding genes by human Tregs is a rapid process (18). Here, we describe
that this suppressive effect was persistent in Tcons even after the removal of
Tregs from the coculture. To analyze this rapid suppression in more detail,
we compared TCR signaling in suppressed and nonsuppressed Tcons by
focusing on the signaling events immediately after TCR stimulation. We
found that TCR-proximal signals as well as activation of PLC-g1 were not
altered in suppressed Tcons, whereas Ca
2+, NF-kB, and NFAT signaling
pathways were strongly inhibited. An increase in intracellular Ca2+ con-
centrations in Tcons abrogated the Treg-mediated suppression of NFAT and
NF-kB activation as well as of the expression of IL2. These results suggest
that suppression of Ca2+ signals appears to be a crucial event in the Treg-
mediated suppression of Tcons.
RESULTS
Suppression of Tcons is sustained upon
removal of Tregs
To study Treg-mediated suppression of Tcons in detail, we analyzed primary
human responder Tcons from cocultures with Tregs (suppressed Tcons) and,
as a control, responder Tcons from cocultures with Tcons (control Tcons)
(Fig. 1A). The frequent human leukocyte antigen (HLA) serotype HLA-
A2, which belongs to the major histocompatibility complex (MHC) class
I proteins, was used as a cell surface marker to differentiate between the
two populations of cells in the coculture. By the use of HLA-A2disparate
cells from HLA-A2disparate donors in the coculture, we were able to
reisolate pure populations of responder Tcons after coculture and, thus,
to compare signaling in suppressed Tcons and control Tcons. All experi-
ments were set up as described (Fig. 1A) with pre-activated Tregs, unless
stated otherwise, and were controlled by determining the extent of inhibi-
tion of expression of IL2 and IFNg [which encodes the proinflammatory
cytokine interferon-g (IFN-g)] through measurement of the amounts of
their mRNAs in suppressed Tcons and comparing them to those of control
Tcons. As shown previously (18), we detected the inhibition of IL2 and
IFNg expression within 3 hours of TCR stimulation in suppressed Tcons
(Fig. 1A). Within that time frame, either pre-activated or resting Tregs
suppress cytokine mRNA production to a similar extent (18).
We were interested in how rapidly Tregs could exert suppression and
whether Tcons remained suppressed after removal of the Tregs. Therefore,
we used another coculture system (Fig. 1B), in which we cocultured Tcons
with pre-activated Tregs (or with Tcons as control) for 10, 30, 45, and 60 min
without TCR stimulation and tested whether this short coculture period
was sufficient to suppress the Tcons. After the coculture period, Tcons were
isolated on the basis of their distinct HLA-A2 and were stimulated sepa-
rately, without Tregs, for 3 hours through the TCR to induce the expression
of cytokine-encoding genes. We observed that IL2 and IFNg expression in
suppressed Tcons was inhibited compared to that in control Tcons after a
coculture period of 30 to 45 min (Fig. 1B). Suppression of cytokine se-
cretion by Tconswas retained upon removal of the Tregs, whereas inhibition
of proliferation was not sustained (fig. S1). Even when the TCR stimulus
was provided 24 hours after a short coculture period, the abundances of
IL2 and IFNg mRNAs were still reduced in suppressed Tcons compared to
those in control Tcons (Fig. 1C). These results implied that Tregs altered the
TCR signaling machinery of Tcons within 30 to 45 min of cell contact,
which subsequently led to long-lasting suppression of cytokine gene ex-
pression in Tcons even in the absence of Tregs.
To analyze the suppression of cytokine gene expression in a more
physiological setting, we performed cocultures in the presence of antigen-
presenting cells (APCs). Costimulation with APCs and polyclonally stimu-
lating antibody against CD3 (which mimics antigenic TCR stimulation)
resulted in the production of lower amounts of cytokines than occurred
in cells stimulated through cross-linked antibodies against CD3 and against
the costimulatory receptor CD28; however, the extent of suppression of IL2
mRNA generation was similar (fig. S2). Thus, the rapid Treg-mediated sup-
pression of cytokine-encoding gene expression in Tcons also occurred in the
presence of APCs, which may be similar to the in vivo situation.
CTLA-4 is not involved in the rapid suppression of
cytokine gene expression in Tcons
The presence of the inhibitory receptor cytotoxic T lymphocyte antigen 4
(CTLA-4) on the surface of murine Tregs contributes to the suppression of
Tcons by decreasing the abundance of the costimulatory B7 molecules on
APCs, thereby limiting the stimulatory capacity of the APCs (1921). Mice
with Tregs deficient in CTLA-4 suffer from autoimmune disease (19), sug-
gesting that CTLA-4 is a key component of Treg-mediated suppression. Be-
cause Tregs can suppress Tcons directly, we asked whether CTLA-4 was also
important for Tcon suppression in the absence of APCs and in the context
of human cells, because CTLA-4 on Tregsmay bind to B7molecules that may
be expressed on the surface of Tcons. First, we analyzed the kinetics of B7 ex-
pression onTcons because it was reported that stimulation of the TCR formore
than 24 hours can lead to the appearance of CD80 (B7.1) and CD86 (B7.2)
on the surface of T cells (22). However, we could not detect CD80 before
24 hours of TCR stimulation, and we could not detect CD86 at any time
point (fig. S3A). Thus, the involvement ofCTLA-4 in the direct suppression
of cytokine gene expression in Tcons through these ligands was unlikely.
We could also exclude a role for unknown CTLA-4 receptors (23) in
the rapid suppression of cytokine gene expression because we detected no
difference in the suppression of IL2 and IFNg expression (as determined
by measurement of mRNA abundance) in cocultures treated with a block-
ing antibody against CTLA-4 compared to that in cocultures incubated
with isotype control antibodies (fig. S3B). In addition, in the presence
of APCs, blocking CTLA-4 did not affect the rapid suppression of cyto-
kine gene expression (fig. S3B). However, in proliferation assays contain-
ing APCs, suppression of proliferation was partly abrogated by blocking
CTLA-4 (fig. S3C), as was shown similarly by others (21). Thus, we con-
cluded that CTLA-4 was not involved in the Treg-mediated rapid suppres-
sion of cytokine-encoding gene expression in human Tcons in the presence
or absence of APCs. Because the rapid suppression of cytokine gene ex-
pression occurred to similar extents in the presence and absence of APCs
(figs. S2 and S3), this suggested that the suppression of cytokine gene
expression occurred through an APC-independent mechanism.
TCR-proximal signaling is not altered in suppressed Tcons
The observed rapid suppression of cytokine gene expression prompted us
to investigate whether Tregs inhibited the activation of Tcons at the level of
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Fig. 1. Suppression of Tcons
persists after the removal of
Tregs. Quantitative reverse
transcription–polymerase
chain reaction (qRT-PCR)
analysis of the abundances
of IL2 and IFNg mRNAs in
HLA-A2− Tcons. (A) HLA-A2
−
Tcons were cocultured with
pre-activatedHLA-A2+Tregs
(supTcon) or with HLA-A2
+
Tcons as a control (cTcon) at
a 1:1 ratio and stimulated
with cross-linked antibodies
against CD3 and CD28
for 3 hours. HLA-A2− Tcons
were then isolated and the
abundances of IL2 and
IFNg mRNAs were ana-
lyzed. Results are presented
as the fold change in the
abundance of the indicated
mRNA in stimulated sup-
pressed Tcons or stimulated
control Tcons compared to
that in unstimulated Tcons,
which was set to 1. Data
are means ± SD of dupli-
cate samples of a single
donor and are representa-
tive of >20 donors. The per-
centages of reduction in
the abundances of IL2 and
IFNg mRNAs in the sup-
pressed Tcons compared to
those in control Tcons are
indicated in gray (% Sup-
pression). (B) Cells were
cocultured as described
for (A) (coculture stimula-
tion, left bars) or were co-
cultured for 10 to 60 min
before undergoing stimula-
tion of isolated responder
Tcons (“pre-cocultured”). For
the pre-cocultures, HLA-A2−
Tcons were left unstimu-
lated in the presence of
pre-activated Tregs or Tcons,
as a control, at a 1:1 ratio.
HLA-A2− Tcons were then
isolated and stimulated
alone as described in (A),
and the abundances of
mRNAs for the indicated
cytokines were measured.
Shown are the percent-
ages of suppression as described for (A). n.s., not significant. (C) Co-
cultures were established as described in (B), with the exception that
after a pre-coculture period of 60 min, HLA-A2− Tcons were isolated and
rested for 24 hours before they were stimulated. Data are the means ±
SEM from four (B) or three (C) donors. Statistical significance of suppres-
sion was calculated with the Student’s one-sample t test.
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the TCR. If this were true, it would result in the immediate blockage of
signaling pathways that lead to TCR-induced expression of cytokine-
encoding genes. To explore whether Treg-mediated suppression occurred
at the TCR itself or at a TCR-proximal level, we set up cocultures as out-
lined earlier (Fig. 1A) and determined the extent of phosphorylation of
CD3e and ZAP-70. We found that the rapid tyrosine phosphorylation
of CD3e after TCR stimulation in control Tcons was not decreased in sup-
pressed Tcons (fig. S4A). Similarly, we detected the rapid phosphoryl-
ation of ZAP-70 in both control Tcons and suppressed Tcons (fig. S4B).
We then tested whether Treg-mediated suppression affected the activa-
tion of PLC-g1 downstream of ZAP-70, which represents the branching
point at which the NF-kB and NFAT signaling pathways diverge. Flow
cytometric and Western blotting analyses revealed that the extent of
PLC-g1 phosphorylation was similar in control Tcons and suppressed Tcons
5 min after TCR stimulation (fig. S4C). To further analyze PLC-g activity,
we determined the amounts of DAG by lipid mass spectrometry, and we
found no difference in the amounts of DAG between control Tcons and
suppressed Tcons (fig. S4D). Our results showed that the TCR-proximal
signaling machinery was not affected during the rapid Treg-mediated sup-
pression of Tcons. Thus, we further investigated signaling events down-
stream of PLC-g1.
NF-kB signaling is impaired in suppressed Tcons
To study the involvement of PKCq in Treg-mediated suppression, we set
up cocultures as described earlier (Fig. 1A) and performed Western blot-
ting analysis with phosphospecific antibodies. We detected no difference
between control Tcons and suppressed Tcons in terms of the phosphoryl-
ation of PKCq 5 and 25 min after TCR stimulation (Fig. 2A). PKCq ac-
tivates the IKK complex, which consists of IKKa, IKKb, and IKKg (11).
Despite the phosphorylation of PLC-g1 and PKCq being unaffected in sup-
pressed Tcons, we found that IKK phosphorylation was markedly inhibited
in suppressed Tcons compared to that in control Tcons (Fig. 2B), which also
occurred in the presence of APCs (fig. S2). Because the IKK complex di-
rectly affects the phosphorylation and subsequent degradation of IkBa (24),
we were interested in determining whether the phosphorylation of IkBa
was also diminished in these cells. Indeed, we found that the phosphoryl-
ation of IkBa was strongly inhibited in suppressed Tcons compared to that
in control Tcons within 5 min of TCR stimulation (Fig. 2C).
In T cells, the classical NF-kB pathway depends mainly on the NF-kB
heterodimer p50:p65, which translocates to the nucleus upon degradation
of IkBa. Similarly to IKK and IkBa, the phosphorylation of p65 was al-
most completely blocked in suppressed Tcons 30 min after TCR stimula-
tion, and it remained blocked until 2.5 hours after stimulation (Fig. 2D).
Furthermore, we performed gene array analysis and compared the mRNA
expression profiles of suppressed Tcons and control Tcons 3 hours after
TCR stimulation. The expression of several NF-kB target genes (25),
including CCL22, ICAM1, IL2, IL8, TNF, and TNFAIP3, was inhibited
specifically in suppressed Tcons (Fig. 2E), confirming our Western blotting
analysis that NF-kB signaling was impaired in these cells. Because Tregs
need to be activated through the TCR to be suppressive (26, 27), we pre-
activated Tregs before their coculture with Tcons. However, to exclude any
effects of the antibody against CD3 that was used for the pre-activation of
the Tregs, we covalently coupled this antibody to plates that were used for
the pre-activation of Tregs or, as a control, of Tcons. To minimize the pro-
duction of the transcription factor Foxp3 in activated human Tcons, which
may result in suppressive function (28, 29), we also shortened the time for
the pre-activation of Tregs and Tcons. In addition, we used Tregs that had not
been pre-activated in our assays of cytokine mRNA suppression, because
stimulation in coculture for several hours might have been sufficient for
the Tregs to acquire suppressive function. With these controls, we only ob-
served the suppression of NF-kB target genes and of IkBa phosphoryl-
ation in responder Tcons when they were cocultured with Tregs (fig. S5A).
Thus, Tregs specifically and rapidly blocked the NF-kB pathway in sup-
pressed Tcons.
Dephosphorylation of NFAT1 is inhibited in
suppressed Tcons
In T cells, transcription of many activation-associated genes is dependent
not only on NF-kB but also on the binding of the cooperative NFAT-Fos-Jun
complex to DNA response elements, which results in T cell proliferation
and the expression of cytokine-encoding genes. Therefore, we hypothesized
that the transcription factors NFATand AP-1 were additional possible targets
in the Treg-mediated suppression of Tcons. The NFAT family consists of five
transcription factors, four of which (NFAT1 to NFAT4) are Ca2+-dependent
(30). In resting T cells, NFAT1 is the predominant isoform (31). TCR stimula-
tion induces the activation of calcineurin, which dephosphorylates NFAT and
thereby unmasks its nuclear localization sequence. This enables NFAT to
translocate to the nucleus and induce the expression of cytokine-encoding
genes in synergy with AP-1 and NF-kB (32).
We established cocultures and investigated the activation status of
NFAT1 by Western blotting analysis by comparing the extent of NFAT1
dephosphorylation in control and suppressed Tcons. We observed a marked
inhibition of NFAT1 dephosphorylation in suppressed Tcons after 5 min of
TCR stimulation (Fig. 3A). We could not detect NFAT2 in human T cells
after short-term stimulation. In addition, gene array analyses revealed sig-
nificant inhibition of the expression of NFAT-dependent genes (33), such
as EGR2, IL2RA, CTLA4, IL3, IL4, and COX2, in suppressed Tcons com-
pared to that in control Tcons (Fig. 3B). As described earlier for NF-kB,
only Tregs pre-activated with covalently plate-bound antibody against
CD3, but not Tcons pre-activated in the same manner, suppressed NFAT1
dephosphorylation and the expression of NFAT target genes in responder
Tcons (fig. S5B). Together, these findings showed that Tregs potently and
rapidly suppressed TCR-induced NFAT1 activation in Tcons.
AP-1 signaling is not involved in Treg-mediated
suppression of cytokine gene expression
Because Treg-mediated suppression of NF-kB and NFAT signaling pathways
occurred downstream of TCR-proximal signaling events, the question re-
mained whether Tregs acted through a general blockage of all transcription
factors relevant for T cell activation, including AP-1. AP-1 is controlled
mainly by phosphorylation of ERK, p38, and JNK and the subsequent ac-
tivation of Fos and Jun (34). We found that ERK was activated similarly in
control Tcons and suppressed Tcons after short-term TCR stimulation as as-
sessed by Luminex analysis (Fig. 4A). Correspondingly, we observed no
suppression of the phosphorylation of ERK in suppressed Tcons compared to
that in control Tcons, as assessed by flow cytometry (fig. S6A). We moni-
tored the activation status of p38 by Western blotting analysis with phospho-
specific antibodies. We did not observe suppression of p38 phosphorylation
in suppressed Tcons (Fig. 4B), which was confirmed by flow cytometric anal-
ysis (fig. S6B).
To test events further downstream in the AP-1 pathway, we investigated
the phosphorylation of the transcription factor c-Jun, but we did not observe
any inhibition of the phosphorylation of c-Jun in suppressed Tcons compared
to that in control Tcons up to 60 min after TCR stimulation (Fig. 4C). These
data are supported by analysis of the expression of representative AP-1 tar-
get genes (35), including MMP9, MMP13, EGFR, FGF7, VEGF, CD69,
and FYN, which were not significantly changed in suppressed Tcons com-
pared to that in control Tcons (Fig. 4D). Thus, in contrast to their potent
inhibition of NF-kB and NFAT signaling pathways in Tcons, Tregs did not
influence the early activation of AP-1 in Tcons.
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Ca2+ signaling is abrogated in suppressed Tcons
Whereas NF-kB and NFAT signaling pathways rely on Ca2+ signals,
AP-1 activation is largely Ca2+-independent. The Ca2+- and calmodulin-
dependent phosphatase calcineurin dephosphorylates numerous sites in
NFAT, which enables the nuclear translocation of NFATand its subsequent
binding to DNA target sequences. Furthermore, Ca2+ is involved in the
activation of NF-kB, for example, by enhancing the degradation of IkBa
(15, 16). Because we observed the suppression of NF-kB and NFAT1
signaling, but not of TCR-proximal events orAP-1 signaling,we speculated
that the inhibition of Ca2+ signaling might be the cause of Treg-mediated
suppression of Tcons. TCR-induced IP3 stimulates the release of Ca
2+ from
intracellular stores into the cytoplasm (36). Depletion of Ca2+ stores is sensed
by stromal interactionmolecule 1 (STIM1),which resides in the endoplasmic
reticulummembrane and contributes to the openingofCa2+ releaseactivated
Ca2+ (CRAC) channels and the influx of Ca2+ from the extracellular space.
To measure Ca2+ signals, we loaded responder Tconswith the Ca
2+-sensitive
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Fig. 2. NF-kB signaling is inhibited in suppressed Tcons. (A to C) Western
blotting analysis of the phosphorylation of (A) PKCq (pT538), (B) IKKa
(pS180) and IKKb (pS181), and (C) IkBa (pS32) in HLA-A2− Tcons. Cocultures
were established as described for Fig. 1A, and cells were stimulated for the
indicated times. Suppressed Tcons or control Tcons were analyzed with
phosphospecific antibodies (upper images in each panel). Blots were then
incubated with antibodies against the indicated total proteins and with anti-
body against tubulin, which served as a loading control. Blots are from one
experiment representative of 4 (A), 3 (B), or >12 (C) donors. The right panel
in (C) shows the mean percentage suppression of IkBa phosphorylation ±
SEM from 19 (5 min) or 12 (25 min) donors. Statistical significance of sup-
pression was calculated with the Student’s one-sample t test. (D) Western
blotting analysis of the amount of phosphorylated p65 (p-p65). Sup-
pressed Tcons (red) or control Tcons (black) were analyzed with fluores-
cently labeled antibodies against p-p65 (pS536) and b-actin. One
representative experiment from five different donors is shown. (E) NF-kB
target genes obtained from gene array data. The gene expression patterns
of control and suppressed Tcons were compared after 3 hours of TCR stim-
ulation. D signifies genes whose expression was significantly decreased in
suppressed Tcons compared to that in control Tcons. The array was per-
formed with two different donors, and one donor is shown. T, threonine;
S, serine.
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ratiometric dye Indo-1 AM. To further distinguish responder Tcons from co-
culturedTregs (orTcons in control assays),we labeled each cell populationwith
different PKH dyes for general cell membrane labeling (Fig. 5A). Hence, we
were able to specifically measure changes in Ca2+ concentrations only in re-
sponder Tcons even if they were conjugated with Tregs or, as a control, with
Tcons. To enable the formation of cell pairs, we established cocultures at least
30minbeforeTCR-induced triggering ofCa2+ signals. In our flowcytometric
analysis, by gating on Tcons that were not conjugated during the time of mea-
surement, we observed an immediate increase in Ca2+ concentrations in the
cytosol after TCR stimulation in control Tcons, and a partial inhibition of Ca
2+
flux in suppressed Tcons (Fig. 5A, Q4 gate, lower left). By gating on PKH26
and PKH67 double-positive cell conjugates (Fig. 5A, Q2 gate), we detected
an almost complete block of Ca2+ influx in suppressed Tcons (Fig. 5A, lower
right). This result implied that, upon cell contact, Tregs entirely abrogatedCa
2+
signals in Tcons. The partial inhibition of Ca
2+ signals in the nonconjugated
cell population might be ascribed to suppressed cells within the population
that had contact with Tregs before the flow cytometric measurement.
Our analyses of cytokine gene expression and protein phosphorylation
required the coculture of responder Tcons with Tregs (or Tcons, as a control)
from different (HLA-A2disparate) donors. Because of the staining
protocol used for Ca2+ analyses, we were also able to analyze the suppres-
sion of Ca2+ signals in responder Tcons upon coculture with Tregs isolated
from the same donor (autologous). We also observed suppression of Ca2+
signals when autologous Tregs were used (fig. S7A), and, thus, we can ex-
clude the possibility that suppression is an artifact that resulted fromcoculture
with T cells from a different donor. Because we observed suppression of
NFAT1 and NF-kB signaling as well as IL2 expression after a 30- to 45-min
coculture period with Tregs before TCR stimulation (Fig. 1), we tested whether
suppression of Ca2+ signaling also required similar conditions. Indeed, we
found that for suppression of Ca2+ influx, it was necessary to coculture Tregs
and Tcons for at least 30 min before TCR stimulation (fig. S7B); however,
maximal conjugate formation was already reached after about 10 min of
coculture (fig. S7C). Almost no conjugates formed between Tcons and con-
trol Tcons (fig. S7C). Because conjugates were strongly enriched in the pop-
ulation representing cell pairs according to their size (fig. S7D), they are
unlikely to result from the transfer of PKH dyes from one cell to another.
We next tested whether the depletion of intracellular Ca2+ stores was
blocked by Tregs or if suppression occurred later, at the level of influx of
Ca2+ through the plasma membrane. To this end, cocultures were es-
tablished and pre-cocultured as described earlier to enable formation of
cell pairs. After this pre-coculture, cocultures were washed and resus-
pended in Ca2+-free buffer to permit measurement of intracellular depletion
of Ca2+ stores by flow cytometric analysis. We found that Tregs suppressed
Ca2+ store depletion in Tcons during TCR stimulation in Ca
2+-free buffer
(Fig. 5B). Unfortunately, because of the low number of conjugates formed
in Ca2+-free buffer, we could not analyze conjugates thoroughly with re-
spect to Ca2+ store depletion. Because Ca2+ store depletion in T cells is
mainly triggered through the binding of IP3 to IP3 receptors (IP3Rs), we
investigated whether the amounts of IP3 in suppressed Tcons were reduced
compared to those in control Tcons because of either decreased IP3 gen-
eration or altered inositol phosphate metabolism. Consistent with earlier
analysis of PLC-g1 phosphorylation and DAG generation, we detected no
difference in the amount of IP3 in responder Tcons cocultured with Tregs
and that of responder Tcons cocultured with Tcons (Fig. 5C). Similarly,
A B NFAT target genes
p-NFAT1
Tubulin
c  
Tcon
5 25            (min)0
sup 
Tcon
c  
Tcon
sup 
Tcon
c  
Tcon
NFAT1
Ratio NFAT1/p-NFAT10.09       2.97       1.37        0.67      0.38
% Suppression54                         43
Gene symbol
Fold 
change Change
IL3 –59.7 D
IL4 –14.9 D
IL5 –9.2 D
IL2RA –8 D
IL13 –3.7 D
EGR2 –2.5 D
FASLG –2.5 D
CTLA4 –2.5 D
COX2 –1.2 D
CD5 –1.2 MD
NFAT1 suppression
0
15
30
45
5 25 (min)
%
 S
up
pr
es
sio
n
*
P < 0.001
*
P = 0.001
Fig. 3. NFAT1 dephosphorylation is inhibited in suppressed Tcons. (A) Western blotting analysis
of NFAT1 dephosphorylation in HLA-A2− Tcons. Cocultures were established as described for
Fig. 1A and cells were stimulated for the indicated times. Suppressed Tcons and control Tcons
were then analyzed for the presence of phosphorylated and total NFAT1 proteins. The upper
bands represent phosphorylated NFAT1 (p-NFAT1), whereas the lower bands represent de-
phosphorylated NFAT1. Blots were then incubated with antibody against tubulin as a loading
control. Data are from one donor representative of 11 (5 min) or 10 (25 min) donors. Lower graph shows the percentage suppression of NFAT1
dephosphorylation as determined by densitometric analysis of Western blots as shown in the upper panels. Data are the means ± SEM of 11
(5 min) or 10 (25 min) donors. Statistical significance of suppression was determined by Student’s one-sample t test. (B) NFAT target genes
obtained from gene array analysis as described for Fig. 2E. D, genes whose expression in suppressed Tcons was significantly decreased com-
pared to that in control Tcons; MD, marginal decrease.
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stimulation-induced quantities of IP4 species were not reduced in sup-
pressed Tcons, further implying that IP3 metabolism was unchanged
(Fig. 5C).
cAMP has been described as a suppressive molecule involved in the
Treg-mediated inhibition of murine T cells (6) and the suppression of Ca
2+
signals in mast cells (37). However, we observed that the rapid suppression
of Ca2+ signaling in Tcons was independent of cAMP, because a cAMP an-
tagonist was unable to prevent suppression of Ca2+ influx in suppressed
Tcons (fig. S8). Because Ca
2+ signals were measured immediately after
TCR stimulation, this time frame was likely too short to activate the sup-
pressive potential of Tregs; thus, Tregs likely have to be pre-activated. To
exclude potential effects of the antibody against CD3 that was used for
pre-activation, we pre-activated Tregs or control Tcons with covalently plate-
bound antibody against CD3. Tregs that were pre-activated in this way sup-
pressed Ca2+ signals in responder Tcons, whereas pre-activated Tcons did not
(fig. S9A). However, the suppressive capacity of Tregs was increased after
pre-activation with soluble antibody against CD3. In addition, Tregs pre-
activated with covalently plate-bound antibody against CD3 formed sub-
stantially more conjugates with responder Tcons than did Tcons that were
pre-activated in the same way (fig. S9B).
Suppression of Ca2+ signaling causes the inhibition of
NFAT and NF-kB signaling in Tcons
Wehypothesized that suppression ofCa2+ signalsmight lead to inhibition of
the activation of NFAT and NF-kB. To test the Ca2+ dependency of NFAT
andNF-kBactivation in our experimental system,we stimulatedTcons through
the TCR in the presence of the Ca2+ chelator EGTA and investigated the
phosphorylation status of various signalingmolecules.As expected,we found
that NFAT dephosphorylation was completely inhibited in the presence of
EGTA, whereas the phosphorylation states of the TCR-proximal molecules
ZAP-70 and PLC-g1 were not affected (fig. S10). Phosphorylation of IkBa
and IKK was also entirely inhibited in the presence of EGTA, whereas the
phosphorylation of PKCq was unchanged (fig. S10), supporting the notion
that the suppressionofCa2+ signals caused the inhibition ofNFATandNF-kB
activation in Tcons that are suppressed by Tregs.
To further support this idea, we investigated whether artificial deple-
tion of Ca2+ stores in responder Tcons could abrogate the suppression of
Ca2+, NFAT, and NF-kB signaling. To this end, we performed experiments
with the specific Ca2+ storedepleting agent thapsigargin. Alternatively,
we used the Ca2+ ionophore ionomycin in concentrations (≤0.5 mM) that
are described to selectively release Ca2+ from intracellular stores without
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Fig. 4. AP-1 signaling is not involved in Treg-mediated suppression of Tcons.
(A) Luminex analysis of the phosphorylation of ERK1 and ERK2 (ERK1/2)
in HLA-A2− Tcons after TCR activation. Cocultures were established as
described for Fig. 1A, and cells were stimulated for the indicated times.
Suppressed Tcons and control Tcons were analyzed for the extent of phos-
phorylation of ERK1/2 (pT185/pY187). Values were normalized to account for
the amounts of total protein. Data are expressed as the fold change in the
abundances of the indicated phosphorylated protein compared to those in
unstimulated control Tcons, which were set at 1. Analyses were performed
in duplicate, and mean fold change ± SD is shown. Data are from one
donor representative of three different donors. (B) Western blotting analysis
of the presence of p-p38 (pT180/pY182) in suppressed Tcons and control
Tcons. Blots were analyzed with antibody against p-p38 and then incubated
with antibodies against total p38 and tubulin. Data are from one experiment
that is representative of five experiments. (C) Analysis of the phosphoryl-
ation of c-Jun (pS63) as described for (A). Data are from one donor and are
representative of five donors. (D) Analysis of the expression of AP-1 target
genes obtained from gene array assays as described for Fig. 2E. NC,
genes whose expression in suppressed Tcons was not significantly different
from that in control Tcons; Y, tyrosine.
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Fig. 5. Ca2+ signaling is
abrogated in suppressed
Tcons independently of
IP3. (A) Tcons were la-
beled with Indo-1 AM
and PKH67 and cocul-
turedwith PKH26-labeled,
pre-activated allogeneic
Tregs (supTcon) or with allo-
geneic Tcons (cTcon) for at
least 30 min. Cells were
analyzed by flow cytom-
etry and gated on Indo-
loaded responder Tcons,
as shown in the dot plots,
and cells were then moni-
tored for Ca2+ signaling as
shown in the bottom pan-
els depicting Ca2+ traces.
After 1 min to establish a
baseline, cross-linked anti-
bodies against CD3 and
CD28 were added to the
cells (arrow) to stimulate
Ca2+ signaling. The lower
left panel shows Ca2+ in-
flux in unconjugated Tcons
(stained only with PKH67,
from the Q4 gate in the
upper dot plot), where-
as the lower right panel
shows Ca2+ influx in con-
jugated Tcons (PKH67-
and PKH26-positive cells,
from the Q2 gate in the
upper dot plot). Data are
from one donor and are
representative of 20 do-
nors. (B) Cells were la-
beled and cocultured as
described for (A). Co-
cultured cells were then
washed, resuspended in
Ca2+-free PBS, and ana-
lyzed for Ca2+ signaling.
After 1 min, cross-linked
antibodies against CD3
and CD28 were added
to the cells (arrow), and
then medium was added
to provide a final extra-
cellular concentration of
Ca2+ of 0.75 mM (arrow-
head). Ca2+ influx in un-
conjugated Tcons (from the
Q4 gate) is shown. Data
are fromonedonor representativeof seven independentdonors. (C)Responder
Tcons were labeled with [
3H]inositol, cocultured with either unlabeled Tcons
(cTcon) or unlabeled Tregs (supTcon), and thenwere stimulated for 5min or were
left unstimulated. Inositol phosphates were extracted from the cells and fractio-
natedbyHPLC, and the counts perminute (cpm) valuesweremeasured. Data
are from one donor and are representative of five donors. OD, optical density.
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increasing the Ca2+ permeability of the plasma membrane (38, 39). Al-
though suppression of Ca2+ store depletion was not complete in suppressed
Tcons when Ca
2+ amounts were compared to those in control Tcons (Fig.
5B), it was completely abrogated by addition of the Ca2+ storedepleting
agent thapsigargin, further underlining that the observed partial reduction in
Ca2+ signals was a result of suppression of Ca2+ store depletion (Fig. 6A).
We also examined whether not only the suppression of Ca2+ store depletion
(Fig. 6A) but also the suppression of Ca2+ signals in Ca2+-containing me-
dium was abrogated in the presence of thapsigargin. For this purpose, we
added thapsigargin at the peak of Ca2+ influx when suppression already
occurs, and indeed, we found that the addition of thapsigargin immediately
resulted in an increase in intracellular Ca2+ concentrations in both sup-
pressed and control Tcons, leading to nearly complete abrogation of sup-
pression (Fig. 6, B and C).
To further examine whether suppression of Ca2+ signals caused inhi-
bition of NFAT and NF-kB activation, we examined the phosphorylation
of signaling molecules and the abundance of cytokine mRNAs in sup-
pressed and control Tcons upon addition of thapsigargin and ionomycin,
respectively. To treat only Tcons and not Tregswith thapsigargin or ionomycin,
we set up cocultures similar to those described earlier (Fig. 1B): Tcons and
Tregs were preincubated and then separated, after which responder Tcons
were stimulated through the TCR in the absence or presence of thapsigargin
or ionomycin (Fig. 6D). We found that suppression of NFAT1 activation
was partially abrogated in the presence of thapsigargin and completely ab-
rogated in the presence of ionomycin (Fig. 6D). In addition, suppression
of the phosphorylation of IkBa was abrogated with both substances (Fig.
6D). Accordingly, suppression of IL2 mRNA generation was reversed
upon treatment with ionomycin (Fig. 6D). Thus, inhibition of Ca2+ signals
largely contributed to Treg-mediated suppression of NFAT and NF-kB
signaling and, consequently, of cytokine gene expression. In conclusion,
our results demonstrate that pre-activated Tregs need a short period (30 to
45 min) of coculture with Tcons to actively alter and suppress the signaling
machinery of Tcons. Suppressed Tcons are unable to activate Ca
2+, NF-kB, or
NFAT1 signaling pathways upon subsequent stimulation of their TCRs, which
consequently prevents the expression of cytokine-encoding genes.
DISCUSSION
Tregs play an important role in the immune system because they can sup-
press different immune cells, including autoreactive T cells, and thereby
prevent autoimmunity (1). Many groups have investigated the features of
Tregs, but few data exist from studies of Treg-mediated suppression mecha-
nisms and signaling events in suppressedT cells.Most of the previous studies
were conducted with mouse T cells; however, suppression mechanisms in
mice and humans can differ (4). Therefore, research on the function of hu-
man Tregs is crucial, especially with regard to their clinical application.
We previously showed that inhibition of the expression of cytokine-
encoding genes occurs rapidly in Tcons upon coculture with Tregs (18). In
the current study, we demonstrated that suppression of the expression of
cytokine-encoding genes persisted in Tcons even if the Tregs were removed
before the Tcons were stimulated through the TCR. To be suppressed, Tcons
had to have cell-cell contact with pre-activated Tregs for only 30 to 45 min.
This suggests that Tregs, despite being present in lower numbers than those
of Tcons in vivo, might have the capacity to suppress several Tcons in a
sequential fashion.
In vivo, several immunosuppressive cytokines, such as transforming
growth factorb (TGF-b) and IL-10, are important for the prevention of
inflammation of the colon and of experimental autoimmune encephalo-
myelitis (which is a mouse model similar to human multiple sclerosis),
but they seem to be unnecessary for the prevention of other disorders,
for example, autoimmune gastritis (4042). Because various factors might
contribute to T cell suppression in different microenvironments in vivo, it
might be easier to clarify the inhibitory mechanisms in vitro. Therefore,
many groups have investigated the direct suppression of Tcons by Tregs and
have revealed a contact-dependent inhibitory mechanism that is indepen-
dent of soluble cytokines (43, 44). To date, several putative surface markers
for Tregs have been described (45). For example, CTLA-4 is predominantly
found on the surface of Tregs as well as on activated T cells, and CTLA-4
influences Treg-mediated suppression in mice by limiting the stimulatory
capacity of APCs (1921). Our blocking experiments excluded a role for
CTLA-4 in the rapid suppression of cytokine gene expression in human
Tcons in the presence or absence of APCs, although CTLA-4 was involved
in suppression of the proliferation of human Tcons in the presence of APCs.
The receptor on Tcons that is recognized by Tregs remains elusive; however,
our results indicate that triggering of this unknown receptor must lead to a
suppressive signal within about 30 min.
We compared TCR signaling in control and suppressed Tcons and in-
vestigated the main signaling pathways that lead to the transcription of
cytokine-encoding genes, namely, the AP-1, NF-kB, and NFAT pathways.
We found no indication that the TCR itself or its associated proximal
signaling molecules were involved in the suppression mechanism, because
there was no change in the extent of phosphorylation of CD3e, ZAP-70,
or PLC-g1 between control Tcons and suppressed Tcons, neither was there
any difference in the generation of DAG and IP3. Accordingly, we found
no evidence of suppression of the AP-1 pathway by Tregs, as determined
by analysis of the phosphorylation of ERK, p38, and c-Jun, as well as of
the expression of AP-1 target genes in suppressed Tcons compared to con-
trol Tcons. However, we found that the NFAT1 and NF-kB pathways in
suppressed Tcons were rapidly and markedly inhibited directly after TCR
stimulation. We also detected the immediate suppression of Ca2+ release
from intracellular stores in suppressed Tcons, which caused the reduced ac-
tivation of NFAT and NF-kB and, consequently, the suppression of NFAT-
and NF-kBdependent expression of IL2.
As suggested by others (46), different mechanisms of suppression
might be used by Tregs depending on, for example, the site of inflamma-
tion, the effector cell types, and the time point of suppression. In addition
to suppression of the priming and proliferation of Tcons through the inhi-
bition of APCs by Tregs, direct suppression of CD8
+ T cell effector func-
tion independently of repressed proliferation has been described (47),
underscoring the in vivo relevance of direct suppression of T cells by Tregs.
Our data suggest that at least two different mechanisms of suppression of
human Tcons might operate. First, rapid suppression of Ca
2+, NFAT, and
NF-kB signaling might result in inhibition of cytokine production, which
is maintained upon removal of Tregs and seems to be independent of
CTLA-4 and APCs. Second, suppression of the proliferation of human
Tcons might require prolonged contact with Tregs and may be independent
of Ca2+ signaling and the suppression of cytokine production. Consistent
with this, mice with CD4+ T cells that are doubly deficient in STIM1 and
STIM2 display enhanced T cell proliferation compared to that of wild-
type cells despite the lack of store-operated Ca2+ influx (48). In addition,
a marked decrease in Treg numbers contributes to lymphoproliferation in
these mice. However, alternative modes of Ca2+ entry might compensate
for the absence of STIM, for example, Cav calcium channels might oper-
ate when their inhibition by STIM1 is lacking (49, 50).
Furthermore, NFAT might play multiple roles during the course of sup-
pression. We showed that the suppression of NFAT signaling occurred
within minutes of TCR stimulation, which, consequently, led to reduced
NFAT-dependent gene expression. Nevertheless, NFAT may also actively
contribute to the suppression of gene expression at later time points. In
assays in which long-term suppression was assessed, such as by measuring
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Fig. 6. Forced depletion of intracellular Ca2+ stores abrogates Treg-mediated inhibi-
tion of Ca2+, NFAT, and NF-kB signals in Tcons. (A to C) Cells were labeled and co-
culturedasdescribed for Fig. 5. (A)Analysis inCa2+-freePBS.Thearrow indicates the
addition of cross-linked antibodies against CD3 and CD28 in the absence or pres-
enceof thapsigargin (TG,1mM).Thearrowheadsat the topof thegraph indicate theadditionofmedium toobtainanextracellularCa2+concentrationof 0.5mM. (B
and C) The arrow indicates the addition of cross-linked antibodies against CD3 and CD28. Dashed arrow indicates the addition of (B) 100 nM or (C) 1 mM
thapsigargin. Ca2+ influx in conjugated Tcons is shown. Data are from a single donor representative of four (A) or three (B and C) donors. (D) HLA-A2
− Tconswere
cocultured with HLA-A2+ Tcons (cTcon) or pre-activated HLA-A2
+ Tregs (supTcon) for 60min, and then cell populations within the cocultures were separated on the
basis of HLA-A2 expression.Middle panel showsWestern blotting analysis of HLA-A2− Tcons stimulatedwith cross-linked antibodies against CD3 andCD28 in
the absenceor presenceof ionomycin (500 nM) or thapsigargin (50 nM) for 5min. Lower panel showsanalysis of theabundanceof IL2mRNA inHLA-A2−Tcons
after 2 hours of stimulation with cross-linked antibodies against CD3 and CD28 in the absence or presence of ionomycin (100 and 500 nM). Relative mRNA
amountswerenormalized to thoseofGAPDHmRNA.Results arepresentedas the foldchange in theabundanceof IL2mRNAcompared to that in unstimulated
Tcons, which was set to 1. Data are the means ± SD of the analysis of duplicate samples from one donor by qRT-PCR and are representative of three donors.
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proliferation or IL-2 production 18 hours after TCR stimulation, a study
showed that murine Tcons doubly deficient in NFAT1 and NFAT4 are less
susceptible to Treg-mediated suppression than are wild-type Tcons (17).
NFAT might form inhibitory complexes on the promoters of cytokine-
encoding genes in conjunction with transcriptional repressors, as has been
proposed for ICER-NFAT complexes (51) and in particular for NFAT2
(52). The amounts of ICER protein and mRNA are increased in sup-
pressed mouse Tcons after 17 to 20 hours of stimulation compared to those
in control Tcons, which correlates with an increase in the amount of cAMP
in suppressed Tcons (6, 53). In suppression assays with B7-deficient re-
sponder T cells, ICER fails to accumulate, but residual suppression is still
detectable (53). This argues for additional suppressive mechanisms other
than those mediated by CTLA-4, cAMP, and ICER. We did not detect
accumulation of ICER mRNA or of mRNAs for other anergy-related
genes in suppressed human Tcons up to 5 hours after TCR stimulation,
whereas we found that the expression of cytokine-encoding genes was re-
pressed earlier (18). Also, the passive diffusion of large amounts of cAMP
through gap junctions from Tregs to Tcons, as has been proposed (6), seems
unlikely within the short time period that we investigated.
The exact signaling events leading to the inhibition of Ca2+ release and
NFAT1 and NF-kB activation in suppressed Tcons remain to be determined.
We did not find any involvement of TCR-proximal signaling molecules,
including PLC-g1, which is crucial for Ca2+ influx and PKCq activation.
A report by Gri and colleagues showed the Treg-mediated suppression
of Ca2+ signals in murine mast cells in a PLC-g2independent fashion
(37). However, suppression of Ca2+ signals in mast cells does not involve
the suppression of depletion of Ca2+ stores, but rather involves a cAMP-
dependent suppression of Ca2+ influx through the plasma membrane. We
now describe a cAMP-independent, rapid suppression of Ca2+ store deple-
tion in human T cells, which occurred downstream of PLC-g1. Ca2+ store
depletion was suppressed without alterations in PLC-g1 activity. Because
the amounts of IP3 in suppressed Tcons were unaltered compared to those
in control Tcons, it appears that IP3 metabolism was unchanged. The exact
mechanism through which Tregs inhibit store depletion therefore remains
elusive. It might involve currently unknown modifications of the IP3R that
could hinder its interaction with IP3. Future studies will be needed to ad-
dress these questions and to decipher the mechanism by which Tregs inhibit
Ca2+ signals in Tcons. We propose that the suppression of Ca
2+ signals leads
to the suppression of both NFAT1 and NF-kB signaling because treatment
of Tcons with ionomycin or thapsigargin relieved the suppression of NFAT1
and NF-kB activation. Suppression of IL2 expression was completely ab-
rogated upon treatment with ionomycin. This implies that inhibition of Ca2+
release is sufficient for the suppression of IL2 expression.
In conclusion, we have elucidated the initial molecular processes that
occur in primary human CD4+CD25− Tcons upon suppression by CD4
+CD25+
Tregs. Our data reveal that Tregs mediate an immediate block of NF-kB and
NFAT signaling in Tcons through the inhibition of Ca
2+ signals, which then
leads to the suppression of cytokine gene expression. In cancer, suppres-
sion of effector T cells is deleterious, and breaking this suppressive state is
highly desirable, whereas in autoimmunity, the suppression of autoreactive
T cells is warranted. Thus, an understanding of the molecules and sig-
naling pathways in Tcons that are affected upon suppression by Tregs is cru-
cial for their future therapeutic manipulation.
MATERIALS AND METHODS
Preparation of Tregs and Tcons
Human peripheral blood leukocytes were purified from buffy coats by
Biocoll (Biochrom) gradient centrifugation followed by adherence to
plastic to deplete monocytes. Blood from HLA-A2+ donors was used to
isolate Tregs and Tcons, and blood from HLA-A2
− donors was used to iso-
late responder Tcons. We first isolated CD25
high cells with CD25-specific
magnetic-activated cell sorting (MACS) beads (2 ml per 107 cells, Miltenyi).
CD4+CD25− Tcons were isolated from the CD25
− fraction with the CD4
Isolation Kit II and were additionally depleted from the CD25+ cells with
CD25-specific MACS beads (6 ml per 107 cells). For some experiments,
CD4+CD25high Tregs were sorted on a FACS (fluorescence-activated cell
sorting) Diva flow cytometer. Tconswere rested overnight in X-VIVO 15 me-
dium (Lonza) supplemented with 1% GlutaMAX. Tregs were pre-activated
overnight with antibody against CD3 (1 mg/ml) in X-VIVO 15 medium
containing 1% GlutaMAX and IL-2 (50 U/ml), if not stated otherwise.
Coculture assays
HLA-A2+ Tregs (using a pool of cells from several donors when we needed
to obtain sufficient cell numbers) and HLA-A2+ Tconswere incubated with
fluorescein isothiocyanate (FITC)conjugated antibody against HLA-A2
and FITC-specific microbeads (Miltenyi), whereas HLA-A2− Tcons were
left untreated. Cocultures of HLA-A2− Tcons and either HLA-A2
+ Tregs or
HLA-A2+ Tcons as a control were set up in a 1:1 ratio. Cells were cultured
for 30 to 60 min and then stimulated with soluble antibody against CD3
(0.2 mg/ml), antibody against CD28 (2 mg/ml), and goat antibody against
mouse antibody as a cross-linker (2 mg/ml) for the indicated time periods
at 37°C. Stimulation was then stopped, and the differing cell populations
were separated on the basis of HLA-A2 expression by passing the cells over
an LS column (Miltenyi) on ice. HLA-A2− Tcons (flowthrough from the
column, >98% pure) were used for subsequent Western blotting, Luminex,
and mRNA analyses. The suppressive capacity of Tregs was controlled in
every assay by analyzing the abundances of IL2 and IFNg mRNAs in
the HLA-A2− Tcons after 2 to 3 hours of coculture with the Tregs. In some
experiments, cell populations within cocultures were separated by MACS
technology before stimulation of responder Tcons, which had been washed
twice with X-VIVO medium to remove MACS buffer before stimulation. In
some experiments, ionomycin (0.1 to 0.5 mM) or thapsigargin (0.05 to
1 mM) was added in addition to the stimulating antibodies.
RNA preparation and quantitative reverse
transcription–polymerase chain reaction assays
Total RNAwas isolatedwith theRNAqueousMicroKit (Ambion), and com-
plementaryDNA(cDNA)was preparedwith oligo(dT)16primers (Invitrogen).
We quantified mRNAs by detection of incorporated SYBR Green with the
ABI Prism 5700 sequence detector system (Applied Biosystems). The rel-
ative abundance of a given mRNAwas determined by normalization to that
ofGAPDHmRNA, and the results are presented as the fold difference com-
pared to the abundance of mRNA in unstimulated Tcons, which was set to 1.
Primer sequences are listed in the Supplementary Methods.
Gene array analysis
HLA-A2+ Tregs and HLA-A2
+ Tconswere incubated with FITC-conjugated
antibodyagainstHLA-A2andFITC-specificmicrobeads.HLA-A2−Tconswere
left unstimulated or were stimulated with antibody against CD3 (0.2 mg/ml)
andantibodyagainstCD28 (0.5mg/ml) for 3hours in thepresenceofHLA-A2+
Tregs or HLA-A2
+ Tcons at a 1:1 ratio. After the stimulation period, cocul-
tures were separated, RNAwas isolated as described earlier, and gene array
analysis (Affymetrix whole genome U133A 2.0.CHIP) was performed.
Western blotting analysis
Cocultures were established as described earlier, and cells were incubated
for 30 to 60 min before stimulation. After separation of the individual pop-
ulations in the coculture, responder Tcons were washed in tris-buffered
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saline (TBS) and lysed in Beadlyte Cell Signaling Universal Lysis Buffer
(Upstate) supplemented with complete protease inhibitors (Roche Applied
Science) and PhosSTOP (Roche Applied Science). Proteins were dena-
tured in SDS sample buffer, resolved by 8 to 12% SDSpolyacrylamide
gel electrophoresis (SDS-PAGE), and transferred to Hybond nitrocellulose
membranes (Amersham). After the membranes were blocked with 5%
nonfat dry milk in TBS containing 0.1% (w/v) Tween 20 (TBST) and in-
cubated with primary and horseradish peroxidase (HRP)conjugated sec-
ondary antibodies, protein bands were developed with Immobilon Western
Chemiluminescent HRP substrate (Millipore) in a Vilber Lourmat chemi-
luminescence acquisition system, and bands were quantified with Bio-1D
software (Vilber Lourmat). For the detection of phosphorylated p65 by
Western blotting analysis with fluorescently labeled secondary antibodies,
cells were lysed by sonication for 1.5 min in sample buffer, Western blot-
ting was performed as described earlier, and blots were scanned with the
LI-COR Odyssey infrared imaging system.
Measurement of Ca2+ flux
T cells were incubated with the dyes PKH26 or PKH67 (1:200 in diluent
C, 200 ml/106 cells, Sigma) for 5 min at 20°C, and the reaction was
stopped with fetal bovine serum (FBS, Gibco). Cells were washed three
times with X-VIVO 15 medium and left in X-VIVO 15 for 2 hours at 37°C.
Responder Tcons were then labeled with Indo-1 AM (1 mM, Invitrogen)
for 30 min at 37°C, washed, and resuspended in X-VIVO 15 medium. In
some experiments, responder Tcons were incubated with the cAMP an-
tagonist Rp-cAMPS (1 mM, Calbiochem) for 30 min at 37°C in X-VIVO
15 medium after incubation with PKH and Indo-1 and subsequently
washed twice with medium before cocultures were established. Tregs or
Tcons were cocultured in X-VIVO 15 medium supplemented with 0.5 mM
CaCl2 in a 1:1 ratio with allogeneic responder Tcons at 5 × 10
6 cells/ml for
at least 30 min (if not stated otherwise) at 37°C to enable cell pairs to form.
Ca2+ influx in X-VIVO 15 medium supplemented with 0.5 mM Ca2+
(final concentration, 2 mM) was induced after 1 min of measurement
of basal Ca2+ flux by the addition of antibody against CD3 (0.2 mg/ml),
antibody against CD28 (2 mg/ml), and cross-linking antibodies (2 mg/ml).
In some experiments, thapsigargin was added. Measurements were per-
formed on a FACS Diva or LSRII flow cytometer (BD Biosciences). For
measurements of Ca2+ store depletion and Ca2+ influx through Ca2+ chan-
nels in the plasma membrane, cocultures were incubated for at least 30 min
inX-VIVO15mediumat 37°C to enable conjugate formation and then cells
were washed twice with Ca2+-free, phosphate-buffered saline (PBS) and
immediatelymeasured inPBS.After 1min,Ca2+ store depletionwas induced
by the addition of antibodies against CD3 and CD28 and cross-linking anti-
bodies, as described earlier, in PBS, and after further measurement, extra-
cellular Ca2+ was added in X-VIVO 15 medium to a final concentration of
0.75 mM. Data were analyzed with the kinetics tool of FlowJo software and
exported to PowerPoint to adjust baselines (Indo-1 ratio before stimulation) to
equal levels for responder Tcons of one donor within one experiment. As an
alternative to staining with PKH, responder Tcons were distinguished from
allogeneic Tcons or Tregs by staining for surface HLA-A2, and Ca
2+measure-
ments were performed as described above.
Inositol phosphate analysis
Responder Tcons were labeled with myo-[
3H]inositol (10 mCi/ml; Perkin
Elmer) in inositol-free RPMI medium (Biomol) containing 10% dialyzed
FBS (Sigma) for 48 to 50 hours. Tcons were then washed and resuspended
in X-VIVO 15 medium for 12 hours. Cocultures were established with
unlabeled Tregs or Tcons in a 1:1 ratio; the cells were incubated for 60 min
at 37°C and then stimulated as described earlier. After stimulation, co-
cultures were washed with cold PBS, lysed in 10% trichloroacetic acid
(TCA) supplemented with EDTA and sodium fluoride, and subjected
to two rounds of freezing and thawing, and then the TCAwas removed by
diethyl ether extraction. The pH of the sample was adjusted to ~6, and
sampleswere partially lyophilized, frozen, and shipped on dry ice. Inositol
phosphate extracts were subjected to metal-dye detection high-performance
liquid chromatography (MDD-HPLC), which was performed on a MiniQ
PC 3.2/3 column (Pharmacia Biotech) with a Kontron system (BioTEK),
as described previously (54), with slight modifications (see the Supplemen-
tary Methods). The radioactivity of [3H]-labeled inositol phosphate isomers
synthesized frommyo-[3H]inositol in the collected fractions was determined
by liquid scintillation counting (Flo-Scint IV, Packard). The suppression of
cytokine mRNA expression was controlled in parallel experiments with
an aliquot of cells cultured under the same conditions, but with nonradio-
active inositol. Before the analysis of mRNAs in responder Tcons, cell pop-
ulations within the coculture were separated as described above.
Antibodies and reagents
Antibody against CD3 (OKT3) and antibody against CD28 (15E8) were
purified from hybridoma supernatants. The cross-linking goat antibody
against mouse antibody was obtained from Southern Biotechnology. Anti-
bodies for the flow cytometric analysis of human HLA-A2, CD80, CD86,
CTLA-4, PLC-g1 (pY783), p38 (pT180/pY182), and ERK1/2 (pT202/pY204)
and the corresponding isotype control antibodies were purchased from BD
Biosciences. Antibodies for the detection by Western blotting of IkBa
(pS32), IKKa (pS180)/b(pS181), ZAP-70 (pY319)/Syk (pY352), p65 (pS536),
and p38a were from Cell Signaling Technology; antibodies against ZAP-70,
NFAT1, IkBa (c-21), PLC-g1, and actin were from Santa Cruz Bio-
technology; antibodies against PLC-g1 (pY783) and PKCq (pT538) were
from BD Biosciences; antibody against tubulin was obtained from Sigma;
and antibody against p38 (pT180/pY182) was from Promega. The HRP-
conjugated antibodies against mouse immunoglobulin G (IgG), IgG1, IgG2a,
IgG2b, or rabbit IgG were purchased from Santa Cruz Biotechnology.
Alexa Fluor 680conjugated antibody against rabbit IgG, Indo-1 AM, and
thapsigargin were obtained from Invitrogen. PKH dyes, EGTA, and ionomycin
were purchased from Sigma.
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/4/204/ra90/DC1
Methods
Fig. S1. Suppression of cytokine secretion is retained after removal of Tregs.
Fig. S2. Treg-mediated rapid suppression of IL2 expression in Tcons also occurs in the
presence of APCs.
Fig. S3. CTLA-4 is not involved in the suppression of cytokine gene expression.
Fig. S4. Proximal TCR signaling is not altered in suppressed Tcons.
Fig. S5. Suppression of NFAT and NF-kB activation is independent of the antibody used
to activate Tregs.
Fig. S6. Phosphorylation of ERK and p38 is not affected in suppressed Tcons.
Fig. S7. The block in Ca2+ influx in Tcons is not caused by allogeneic responses and requires
30 min of previous coculture with Tregs.
Fig. S8. Suppression of Ca2+ signaling is independent of cAMP.
Fig. S9. Tregs, but not Tcons, pre-activated with covalently plate-bound antibody against CD3
suppress Ca2+ signaling in responder Tcons.
Fig. S10. NFAT and NF-kB activation in Tcons is Ca
2+-dependent.
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Sphingosine 1-Phosphate–Induced Motility and Endocytosis
of Dendritic Cells Is Regulated by SWAP-70 through RhoA
Carlos Ocan˜a-Morgner,* Peter Reichardt,† Michae¨l Chopin,* Sarah Braungart,*
Christine Wahren,* Matthias Gunzer,† and Rolf Jessberger*
The phospholipid mediator sphingosine 1-phosphate (S1P) enhances motility and endocytosis of mature dendritic cells (DCs). We
show that in vitro migration of Swap-702/2 bone marrow-derived DCs (BMDCs) in response to S1P and S1P-induced upregulation
of endocytosis are significantly reduced. S1P-stimulated movement of Swap-702/2 BMDCs, specifically retraction of their trailing
edge, in a collagen three-dimensional environment is impaired. These in vitro observations correlate with delayed entry into
lymphatic vessels and migration to lymph nodes of skin DCs in Swap-702/2 mice. Expression of S1P receptors (S1P1–3) by wild-
type and Swap-702/2 BMDCs is similar, but Swap-702/2 BMDCs fail to activate RhoA and to localize Rac1 and RhoA into areas of
actin polymerization after S1P stimulus. The Rho-activating G protein Gai interacts with SWAP-70, which also supports the
localization of Ga13 to membrane rafts in BMDCs. LPS-matured Swap-70
2/2 BMDCs contain significantly more active RhoA
than wild-type DCs. Preinhibition of Rho activation restored migration to S1P, S1P-induced upregulation of endocytosis in mature
Swap-702/2 BMDCs, and localization of Ga13 to membrane rafts. These data demonstrate SWAP-70 as a novel regulator of S1P
signaling necessary for DC motility and endocytosis. The Journal of Immunology, 2011, 186: 5345–5355.
U
ptake of Ag by dendritic cells (DCs) and their subsequent
maturation and movements to lymphoid tissue to present
to and activate T lymphocytes are key to initiate an
adaptive immune response (1). Elucidating the mechanisms that
regulate DC motility and Ag uptake is important also to design
vaccination strategies and treatment of infections.
Sphingosine 1-phosphate (S1P) acts as a chemoattractant in the
blood and lymph at concentrations in the hundred-nanomolar range
(2). S1P promotes lymphocyte egress from lymphoid organs (3)
and, as revealed through studies using S1P agonists and S1P re-
ceptor knockout mice, regulates migration of mature DCs from
skin or lung to draining lymph nodes in vivo (4–8). S1P signals
through G protein-coupled receptors (GPCRs) named S1P1–5.
These receptors execute different cellular functions through cou-
pling to distinct heterotrimeric G proteins (ai, aq, or a12/13),
resulting in activation of the small Rho GTPase family members
Rac, RhoA, and/or Cdc42. Diversity in the expression of S1P
receptors and in the response to S1P is seen among several cell
types. The regulation of cell motility is a main function of these
receptors (9, 10). In mature DCs, motility toward S1P is modu-
lated by S1P1 and S1P3 (4, 5, 8, 11, 12). The in vitro observation
that S1P induces upregulation of endocytosis in matured DCs
suggests that S1P may promote the rapid removal of bacteria at
sites of infection (11). S1P1 activates Rac1 after coupling GaI,
whereas S1P3 activates Rac1 and RhoA after association with Gai
and Ga12/13, respectively (10). The importance of S1P to control
motility and endocytosis of mature DCs has clearly been dem-
onstrated, but regulatory mechanisms that govern the S1P sig-
naling pathways in DCs remain to be fully understood.
SWAP-70 is expressed in DCs and localizes to DCmembranes at
sites of cell–cell contact and of micropinosomes (13). Function-
ally, SWAP-70 supports surface localization of peptide-loaded
MHC class II (MHC-II) on DCs (14). Maturation of DCs trig-
gers massive cytoskeletal rearrangements mainly controlled by
activation of Rho GTPases (15, 16), which also regulate DC mi-
gration (16–20). SWAP-70 loosely resembles proteins of the Dbl
family of guanine nucleotide exchange factors for Rho GTPases,
and it binds to F-actin and Rac (21, 22). We demonstrated that
SWAP-70 preferentially interacts with active RhoA (RhoA-GTP)
and Rac1 (Rac1-GTP) in lysates of stimulated DCs. Unlike naive
wild-type (wt) bone marrow-derived DCs (BMDCs), naive Swap-
702/2 DCs show constitutively active RhoA (14). On LPS stim-
ulation, further Rho activation fails in Swap-702/2 DCs. Con-
sidering the function of SWAP-70 to regulate Rho GTPases, we
hypothesized that SWAP-70 affects S1P receptor signaling re-
quired for migration of DCs.
In this study, we aimed at testing this hypothesis. We demon-
strate the requirement for SWAP-70 in RhoA-dependent, S1P-
dependent motility and endocytosis of DCs. Swap-702/2 BMDCs
show deficient upregulation of motility and endocytosis in re-
sponse to S1P. Migration to S1P is restored by re-expression of
SWAP-70 in Swap-702/2 BMDCs. Analysis of Rho GTPase ac-
tivation in mature Swap-702/2 BMDCs revealed that Swap-702/2
BMDCs fail to activate RhoA after an S1P stimulus. In BMDCs
lysates, SWAP-70 was shown to interact with the proteins Gai.
Swap-70
2/2 BMDCs also fail to localize the signaling protein
Ga13 required for RhoA activation to membrane rafts. These
results thus highlight a novel pathway of S1P-induced DC func-
tions.
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Materials and Methods
Animals
Swap-70
2/2 and the isogenic wt 129vEMS mice were described before
(14) and maintained at the Experimental Center of the Medizinisch-
Theoretisches Zentrum of the Medical Faculty at the Dresden University
of Technology according to approved animal welfare guidelines.
BMDC cultures
Primary cultures of immature DCs from Swap-702/2 and wt 129vEMS
mice were obtained by differentiation of bone marrow-derived precursors
as described previously (14). At days 10–11, 1 mg/ml LPS (Sigma-Aldrich;
Salmonella enterica) was added overnight. For most of the experiments,
CD11c+ BMDCs were then purified from cultures using anti-CD11c Abs
bound to magnetic beads (Miltenyi Biotec). For activation of Rho GTPa-
ses, BMDCs were activated with LPS and then starved from GM-CSF for 4
h before S1P stimulus.
Real time-PCR
Total BMDC RNA was prepared using the TRIzol method (Invitrogen)
according to the manufacturer’s instructions. RNAwas reverse transcribed
(SuperScript reverse transcriptase; Invitrogen). Expression of S1P1, S1P2,
S1P3, and GAPDH was analyzed using a Rotor-Gene RG3000 (Qiagen)
and the DNA Master Plus SYBR Green Kit (Roche). The relative gene
expression was calculated by dividing by the expression of GAPDH. Sam-
ples were amplified in duplicate. S1P1, S1P2, and S1P3 primers used were
previously described (23): S1P1 forward, 59-GTGTAGACCCAGAGTC-
CTGCG-39; S1P1 reverse, 59-AGCTTTTCCTTGGCTGGAGAG-39; S1P2
forward, 59-GGCCTAGCCAGTGCTCAGC-39; S1P2 reverse, 59-CCTTG-
GTGTAATTGTAGTGTTCCAGA-39; S1P3 forward, 59-GGAGCCCCTA-
GACGGGAGT-39; S1P3 reverse, 59-CCGACTGCGGGAAGAGTGT-39.
PCR product sizes were as follows: S1P1, 88 bp; S1P2, 118 bp; S1P3, 104
bp.
Flow cytometry
LPS-stimulated BMDCs were used to detect the expression of receptors
S1P1 and S1P3 on the surface of the cells using an LSRII flow cytometer
and FACSDiva software (BD Biosciences). Polyclonal Abs against S1P1
and S1P3 were used at a concentration of 4 mg/ml (Cayman Chemical).
FITC-labeled goat anti-rabbit IgG (SouthernBiotech) was used as sec-
ondary Ab at a dilution of 1:250.
In vitro migration assay
Chemotaxis in response to chemoattractants was analyzed by measuring the
number of cells migrating through a polycarbonate filter (8-mm pore size) in
24-well Transwell chambers (Costar). The upper chamber included 1–3 3
105 BMDCs in 100 ml chemotaxis medium (DMEM medium with 0.1%
BSA and 10 mM HEPES), and the lower chamber contained 600 ml of the
same medium with or without chemoattractants. After incubation for 3 h at
37˚C, cells that migrated to the bottom chamber were stained with
eFluor450 anti-CD11c (eBioscience) and analyzed for 1 min using LSRII
flow cytometer and FACSDiva software (BD Biosciences). Numbers of
CD11c+ cells obtained in the lower chambers were divided by the number
of CD11c+ cells in the input samples and represented as percentage of
input. In some experiments, cells were treated with 1 mg/ml exoenzyme C3
(cell-permeable form; Cytoskeleton) for 4 h before the migration assays.
C3 was added or not to the upper chamber together with the cells.
DC retroviral infection
BMDCs were transfected by retroviral infection as described previously
(14). Retrovirus was produced by transfecting Phoenix Eco 293T pack-
aging cell line with SWAP-70–IRES–GFP or IRES-GFP. BMDCs were
infected with retroviral supernatant at day 6. The plate was centrifuged at
1200 rpm at 24˚C for 90 min and left overnight at 37˚C. Virus was re-
moved and DCs were reinfected with new retroviral supernatant. After 48
h of the second infection, CD11c+ DCs were purified from cultures using
anti-CD11c Abs bound to magnetic beads (Miltenyi Biotec) and activated
overnight with LPS (1 mg/ml).
Time-lapse series of motile DC under an S1P concentration
gradient
BMDCs were applied on a m-slide for chemotaxis assay (ibidi) according
to manufacturer’s instructions. A total of 150 nM S1P was applied to create
a concentration gradient. Time-lapse series of moving DCs were recorded
every 2 min for 5 h on a Nikon live imaging station (Nikon) equipped with
a 203 phase-contrast objective, automated X-Y-Z-stage, a climate chamber,
and camera. Migration speed and directionality were analyzed with the
Chemotaxis and Migration tool plug-in (ibidi) for ImageJ.
In vitro three-dimensional live cell imaging of DC morphology
Purified LPS-matured CD11c+ BMDCs (3 3 105/ml) were kept in RPMI
media (phenol red free; Invitrogen) containing 10% FCS and added to self-
constructed imaging chambers with the glass bottom coated with a colla-
gen mixture described previously for use in three-dimensional (3D) col-
lagen matrices (24). Stimulation occurred with 100 nM S1P (Sigma).
Imaging was performed on a CellR imaging workstation (Olympus, Ham-
burg, Germany) using an upright microscope stage (BX61) with a 603
(NA 0.9) water-coupled lens. Using an automated X-Y-Z-stage, we chose
between 5 and 10 optical fields in each culture. Frame dimensions were
68 3 68 mm total. Images were taken every 20 s for up to 4 h with the
transmitted light channel recorded. Images were processed with Virtualdub
1.8.6 and ImageJ 1.34s. For a total of 40 wt and Swap702/2 cells, mean
dendrite length and number were quantified by measuring apparent den-
drites at 5 consecutive time points with 240-sec interval for each cell.
Ear skin explant culture
Ears from wt or Swap702/2 animals were split into dorsal and ventral
halves, and the cartilage-free half was cultured with medium in 24-well
tissue culture plates for 24 or 48 h. Mechanical splitting of the ears is
enough to trigger maturation of skin DCs (25). After incubation, ear halves
were washed three times in PBS, fixed with methanol for 5 min, and in-
cubated with PBS + 1% BSA before use for fluorescent labeling.
Confocal microscopy
For F-actin and Rho GTPases staining, LPS-matured BMDCs were left to
adhere for 3 h on glass slides; then 50 nM S1P was added to the cells and left
for 30 min. Cells were fixed with 3.7% paraformaldehyde in PBS for 10 min
at room temperature. Cells were then blocked with 3% BSA in PBS and
permeabilized with 1% Triton X-100 (Sigma) in PBS. Rac1 and RhoA
staining was done with mAbs (Cytoskeleton) followed by Alexa Fluor 594-
labeled Ab against mouse IgG (Invitrogen). Alexa Fluor 488-labeled
phalloidin (Invitrogen) was used to visualize F-actin. Slides were mounted
in Fluoromont-G (SouthernBiotech) and viewed using the Zeiss LSM 510
confocal microscopy system (Carl Zeiss). Imaging was performed using
a 403/1.3 differential interference contrast oil objective. Lasers of 488 and
561 nm were used for excitation of FITC and Alexa Fluor 594 respectively.
Emissions wavelengths were separated by band passes 505–550 and .575
nm, respectively. Confocal sections of 1 mm/cell were taken. Colocaliza-
tion of F-actin and Rho GTPases was quantified according to Ocan˜a-
Morgner et al. (14). Forty cells were analyzed via ImageJ using the
colocalization plug-in (ratio: 30%; threshold for each channel: 50). Nuclei
were visualized with DAPI staining and an area around the cytoplasm of
each cell in the colocalization image was analyzed for gray values repre-
senting the level of colocalization of two proteins (values close to the
maximum of 256 represent strong colocalization). Profiles for each cell
with a mean gray value per square micrometer were obtained, and the
average of these mean values was plotted for Rac1–F-actin and RhoA–F-
actin colocalization. Ears explant staining was done with goat polyclonal
anti–LYVE-1 Abs (R&D Systems), FITC-labeled anti-murine Langerin/
CD207 (Dendritics), FITC-labeled anti-CD86 (BD Biosciences), and Alexa
594-labeled anti-goat Abs (Invitrogen). The ear halves were mounted in
Fluoromont-G (SouthernBiotech) and viewed using the Zeiss LSM 510
confocal microscopy system (Carl Zeiss). Imaging was performed using
a 253/0.8 differential interference contrast objective. Lasers of 488 and
561 nm were used for excitation of FITC and Alexa Fluor 594, respec-
tively. Emissions wavelengths were separated by band passes 505–550
and .575 nm, respectively. Images were acquired using LSM 5Pas soft-
ware (Carl Zeiss), analyzed by ImageJ (National Institutes of Health), and
transferred to Photoshop 7.0 (Adobe Systems) to produce the final figures.
Skin FITC painting
Migration of skin DCs in foot pads was induced in vivo by applying 20 ml of
8 mg/ml FITC dissolved in a 50:50 (v/v) mixture of acetone and dibu-
tylphthalate. After several time points, draining popliteal lymph node cell
suspensions were analyzed for CD11c+FITC+ DCs by flow cytometry.
Nondraining popliteal lymph nodes were used as control.
Endocytosis assay
LPS-mature BMDCs were incubated in DMEMwith 0.5% BSA and 10 mM
HEPES for 3 h at 37˚C, then FITC-dextran (1 mg/ml) and S1P (100 nM)
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were added together and left incubating for 5 min. Endocytosis was
stopped by placing the cells on ice. DCs were then washed three times with
cold PBS containing 0.1% NaN3. Mean fluorescence intensity of FITC-
dextran+ cells was analyzed by flow cytometer. Incubation of DCs with
FITC-dextran and S1P at 4˚C was used as negative control. In some ex-
periments, cells were treated with 1 mg/ml exoenzyme C3 (cell-permeable
form; Cytoskeleton) for 4 h before the migration assays. C3 was added or
not to the lower chamber together with the chemoattractant.
Rho GTPases activity
The activities of Rho GTPases were analyzed using rhotekin-Rho– or PAK-
rac/cdc42–binding domain agarose. Beads were subjected to SDS-PAGE
andWestern blotting with Abs against Rac1/2 (23A8; Upstate Biotechnology)
and RhoA (119; Santa Cruz Biotechnology). Activity of Rho GTPases was
quantified by densitometric analysis using ImageQuant software (Molec-
ular Dynamics).
Puriﬁcation of detergent-resistant membrane rafts
Membrane rafts were prepared by cell lysis of BMDCs followed by
OptiPrep (Progen Biotechnik) gradient fractionation using ultracentrifu-
gation as previously described (26). Five hundred-microliter fractions were
collected from the top of the gradient. Protein concentration of each
fraction was assayed by protein assay kit (Bio-Rad) based on the Bradford
dye procedure. Fractions were analyzed individually by SDS-PAGE and
Western blotting. Anti-caveolin 1 (Santa Cruz Biotechnology) and anti-
transferrin receptor (Abcam) were used for positive and negative control of
membrane rafts, respectively. Anti-Ga12, anti-Ga13, and anti-GaI (all from
Santa Cruz Biotechnology) were also used.
Immunoprecipitation
LPS-treated wt BMDCswere stimulated with 50 nM S1P for 30 min. A total
of 23 107 DCs were incubated on ice for 10 min in hypertonic buffer (250
mM sucrose, 10 mM Na-HEPES pH 7.2, 2 mM MgCl2, 10 mM NaF) that
was freshly supplemented with a protease inhibitor mixture. Cells were
lysed twice in a nitrogen cavitation apparatus at 1000 pounds per square
inch for 7 min each. The soluble cell lysates were mixed with 1 mg
polyclonal anti–SWAP-70. Cell lysates were rocked overnight at 4˚C.
Protein G Sepharose beads were added and rocked for 1 h. The beads were
washed three times with the hypertonic buffer and the precipitates ana-
lyzed by SDS-PAGE, followed by immunoblotting using anti–SWAP-70 or
anti-Rho GTPase Abs.
Statistical analysis
For direct comparison of the activity of wt and Swap702/2 cells, statistical
significance was determined with the Mann–Whitney U test for two-tailed
data. The p values ,0.05 were considered highly significant.
Results
Swap-702/2 BMDCs are impaired in S1P-induced motility
In mature DCs, motility is enhanced by S1P signaling mainly
through S1P1 and S1P3 (8, 11, 12). Transwell chemotaxis assays
showed that Swap-702/2 BMDCs are significantly reduced in
their S1P-induced motility at every effective S1P concentration
tested as compared with wt (Fig. 1A). This difference was ob-
served for both BMDCs (Fig. 1A) and spleen-derived DCs (data
not shown). Motility of immature DCs was not different from that
seen without S1P and was similar in wt and Swap-702/2 BMDCs
(data not shown). Motility tests using other chemoattractants, that
is, CCL19 or CCL21, showed no difference in the response of
Swap-702/2 or wt BMDCs (Fig. 1A), indicating specificity of
SWAP-70 for S1P signaling. To confirm the SWAP-70 depen-
dency of the S1P-mediated chemotactic response phenotype, we
introduced a SWAP-70–IRES–GFP retroviral expression con-
struct (14) into SWAP-70–deficient BMDCs. Expression of
SWAP-70 in Swap-702/2 BMDCs restored their S1P response to
levels comparable with wt cells (Fig. 1B). In wt BMDCs, ex-
pression of SWAP-70, as well as infection by the empty control
vector itself, stimulated their migration when compared with
mock-treated control cells. Transduction of DCs with retroviral
vectors leads to some activation (27), which may be reflected in
the improved capacity to migrate to S1P in wt BMDCs. Thus,
activation is not sufficient to rescue the migration deficiency in
Swap-702/2 BMDCs.
The speed of motility was also reduced in response to an S1P
concentration gradient as seen by analysis of time-lapse movies of
Swap-702/2 and wt BMDCs on two-dimensional (2D) surfaces
(Fig. 1C, Supplementary Videos 1, 2). There was no difference
between wt and Swap-702/2 BMDCs in response to CCL19 or
CCL21 in these assays (not shown). Directionality toward S1P,
however, was not affected in Swap-702/2 BMDCs (Fig. 1C).
Analysis of individual cells in response to an S1P concentration
gradient on 2D surfaces showed no significant difference in
morphology (data not shown). The morphology of cells in re-
sponse to S1P in a 3D environment was investigated next. In this
study, motility is driven by cytoskeleton dynamics, that is, flow of
actin polymerization at the cell front and actomyosin contractions
of the trailing edge to propel the nucleus through narrow spaces
(17). A deficiency in DCs to properly move through 3D envi-
ronments, which to some extent reflect the interstitial space in the
skin, was previously reported to result in deficient migration to
lymph nodes (17, 18). Morphological analyses of wt cells showed
a round cell body with the nucleus mostly close to the body center.
Their dendrites were usually not very long and they spread around
the entire cell body (circular dendrites) most of the time (Fig. 1D,
Supplemental Video 3). Swap-702/2 BMDCs, in contrast, showed
a more elongated morphology; the cell body was more stretched
out and the nucleus often lagging behind. In addition, the den-
drites of Swap-702/2 BMDCs were significantly longer when
compared with wt BMDCs, whereas there was no difference in
number of dendrites (Fig. 1D, Supplemental Video 4).
Delayed entry into lymphatic vessels and migration to lymph
nodes of Swap-702/2 DCs
Recent studies indicate that S1P does not regulate migration of DCs
from the periphery to lymph nodes under steady-state conditions
(11, 28). However, this situation may change under local or sys-
temic inflammatory conditions (8). In addition, S1P regulation of
migration of DCs in vivo is indicated by studies with S1P agonists
and S1P receptor knockout mice where S1P controls migration of
mature DCs from skin, lung, or lamina propria to draining lymph
nodes (4–8). The morphology of Swap-702/2 BMDCs on 3D
collagen matrix indicated a defect in dragging the nucleus through
small pores. This deficiency may reflect impaired migration of
skin Swap-702/2 DCs through interstitial space likely resulting in
impaired entry into lymphatic vessels in the skin (17). To test this,
we studied entry of DCs into lymphatic vessels by analyzing the
migration of DCs in the skin of ear explants. Mechanical splitting
of ears into halves followed by incubation in medium at 37˚C
triggered activation of DCs and their migration into lymphatic
vessels, which were visualized by LYVE-1 staining (5). CD86 and
Langerin were used as markers for skin DCs (5). We did not use
MHC-II as a marker because of the MHC-II phenotype in Swap-
70
2/2 BMDCs previously described (14). Vessel morphology and
intervessel distance were the same in wt and Swap-702/2 ears.
CD86+- and Langerin+- Swap-702/2 DCs showed significantly
delayed entry into lymphatic vessels as compared with wt (Fig.
2A). Thus, Swap-702/2 DCs were impaired in their entry into skin
lymphatic vessels in vivo. We also observed that Langerin+ DCs
generally entered lymphatic vessels later than the majority of
CD86+ cells. This probably is due to the fact that Langerin+ DCs,
which are mostly epidermal, are known to enter lymphatic nodes
after dermal DCs (25, 29, 30). Entry of DCs into lymphatic vessels
also depends on adhesion molecules on DCs that interact with
ligands on lymphatic endothelial cells (31, 32). Lymphatic entry
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defect in the skin may reflect an impairment of Swap-702/2 DCs
to transmigrate through lymphatic endothelial cells. To address
this, we tested the chemotactic response of wt and Swap-702/2
BMDCs to CCL19 in a modified Transwell system where the
porous membranes were coated with the C3H/HeJ mouse endo-
thelial line SVEC4-10 that is reported as lymphatic endothelial
cells (33). Although the transmigration through the endothelial
cells greatly improved the chemotactic response to CCL19 of wt
cells, the magnitude of the Swap-702/2 BMDCs response was
significantly lower (Supplemental Fig. 1A). We observed the same
deficiency to transmigrate in Swap-702/2 BMDCs when S1P was
used as chemoattractant (Supplemental Fig. 1B). SWAP-70–de-
ficient B cells have impaired entry to lymph nodes from the blood
(34). During this process, Swap702/2 B cells aberrantly regulated
integrin-mediated adhesion to blood endothelial cells (34). To
address the role of integrins in the transmigration defect of Swap-
702/2 BMDCs, we performed the same experiments as in Sup-
plemental Fig. 1A in the presence of different concentrations of
either EDTA or a blocking Ab against integrin b2, which has been
reported to regulate transmigration of DCs (31, 32). Although
EDTA and the anti-b2 Ab had an immediate negative effect on wt
BMDCs, it took concentrations of up to 10003 (EDTA) or 5003
(anti-b2) higher to have an effect on Swap-70
2/2 BMDCs (Sup-
plemental Fig. 1C). A blocking Ab against VCAM did not have an
effect on either wt or Swap-702/2 DCs. These results indicate
defective integrin signaling in Swap-702/2 BMDCs, and future
studies will be done to characterize the integrin-mediated adhe-
sion to lymphatic endothelial cells in Swap-702/2 BMDCs.
Skin-resident DCs require S1P1 for efficient migration into the
draining lymph node (8). We analyzed in vivo migration of DCs by
FITC painting of foot pads of Swap-702/2 and wt mice followed by
analysis of FITC+CD11c+ cells in the draining lymph nodes after
24, 48, and 72 h. Although we observed a decrease in the per-
centage of FITC+CD11c+ cells in the draining lymph nodes of wt
animals as time increases after painting, the percentage of cells in
Swap-702/2 animals actually increased to reach similar levels as
wt DCs at 24 h (Fig. 2B). The failure to migrate early to lymph
nodes in Swap-702/2mice was not due to reduced numbers of DCs
in the skin of the animals, because microscopic analysis and cell
isolation procedures did not reveal a difference between wt and
Swap-70
2/2 mice in the number of skin DCs (Supplemental Fig.
1D, left panel, and data not shown). As already suggested by data
shown in Fig. 2A, these results indicate delayed migration of skin-
resident DCs to draining lymph nodes in Swap-702/2 mice. The
assays used in this set of experiments represent inflammatory
conditions (35), but under steady-state, Swap-702/2 animals also
show significantly decreased percentage and total numbers of DCs
in lymph nodes (Supplemental Fig. 1D, right panels); MHC-II2
cells, considered quiescent resident cells (24), are not changed.
This indicates a mechanism, controlled by SWAP-70, that is shared
for migration of DCs under steady-state and inflammatory con-
ditions, and shall be the subject of further studies.
FIGURE 1. Impaired motility response to S1P by Swap-702/2 BMDCs. A, In vitro migration assays of LPS-activated Swap-702/2 and wt BMDCs in
response to S1P (top left panel), CCL19 (top right panel), or CCL21 (bottom left panel). Migration is calculated as percentage of input after 3-h exposure to
different concentrations of the chemoattractants in a Transwell system. Data are representative of at least 10 independent experiments. B, In vitro migration
assays of LPS-activated Swap-702/2 and wt BMDCs in response to S1P after retroviral infection used for the expression of SWAP-70. Mock treatment and
empty retroviral vector were used as control. Migration is calculated as percentage of input after 3-h exposure to 50 nM S1P in a Transwell system. C,
Quantification of time series after live cell imaging in response to an S1P gradient using ibidi m-slide shows velocity (mm/sec) and directionality. Images
were taken every 2 min for up to 5 h. Videos were analyzed with the Chemotaxis and Migration tool plug-in (ibidi) for ImageJ. D, In vitro 3D live cell
imaging of DC morphology. LPS-matured and MACS-purified CD11c+ BMDCs (3 3 105/ml) were added to self-constructed imaging chambers with the
glass bottom coated with a collagen mixture. Stimulation occurred with 100 nM S1P. Images were taken every 20 s for up to 4 h. Swap-702/2 BMDCs show
a more elongated body shape with the nucleus dragging behind (arrows) and long dendrites (arrowheads). Dendrite length (left panel) and number (right
panel) were determined for a total of 40 wt and Swap702/2 cells. Data are representative of at least three independent experiments.
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Expression of S1P receptors is unaltered in Swap-702/2
BMDCs
Using real-time PCR, we analyzed the expression of mRNA of the
S1P receptors known to control DC motility and endocytosis in
response to S1P, that is, S1P1 and S1P3 (11, 12), and of S1P2.
mRNA levels of these three receptors were not significantly dif-
ferent in Swap-702/2 or wt BMDCs at several time points after
incubation with LPS (Table I). In agreement with previous reports,
we observed upregulation of mRNA levels S1P1 and S1P3 and
downregulation of S1P2 (4, 8, 11). At the protein level, deter-
mination of expression of the receptors S1P1 and S1P3 by flow
cytometry on the surface of LPS-stimulated Swap-702/2 or wt
BMDCs did not show significant differences (Fig. 3). These
results indicated that SWAP-70 might control signaling in re-
sponse to S1P after binding to the receptors in mature DCs rather
than receptor expression.
Defective S1P-induced endocytosis of Swap-702/2 BMDCs
In vitro, S1P enhances endocytosis in LPS-mature BMDCs, but not
in immature BMDCs, through S1P3 signaling (11, 36). This would
constitute a mechanism thought to promote the rapid removal of
pathogens at sites of infection (11, 36). To test this, we studied the
effect of S1P on the endocytosis of LPS-matured BMDCs. After 5
min of exposure to S1P, endocytosis of FITC-dextran particles was
significantly increased in wt BMDCs. In contrast, Swap-702/2
BMDCs failed entirely to enhance endocytosis of FITC-dextran
(Fig. 4). Endocytosis is affected by the endosome transport inside
cells that is mainly controlled by activation of RhoB (37, 38). We
previously reported reduced expression of total RhoB during
stimulus with LPS of Swap-702/2 BMDCs (14). However, the
level of active RhoB-GTP remained the same in Swap-702/2
BMDCs after LPS addition (14). We excluded that the defect in
S1P-induced endocytosis is due to failure to activate RhoB in
FIGURE 2. Delayed entry of Swap-702/2 DCs to lymphatic vessels and migration to lymph nodes. A, Confocal microscopy analysis of localization of
CD86+ and Langerin+ cells outside or inside LYVE1+ lymphatic vessels of ear explants after 24- or 48-h incubation at 37˚C. CD86+ and Langerin+ cells
were counted in each picture of ears, and the number of cells outside LYVE1+ lymphatic vessels were plotted against the number of cells inside. Scale bars,
100 mm. B, FITC painting of foot pads. Swap-702/2 and wt animals were painting in one foot pad with 8 mg/ml FITC dissolved in a 50:50 (v/v) mixture of
acetone and dibutylphthalate. After 24 h, draining popliteal lymph nodes were isolated and analyzed for CD11c+FITC+ DCs by flow cytometry. Popliteal
lymph nodes from nonpainted foot pads were used as control. Data are representative of at least three independent experiments.
Table I. mRNA expression pattern of S1P1, S1P2, and S1P3 in inactivated (LPS
2) and activated (LPS+)
DCs
BMDCs S1P1 (Mean 6 SEM) S1P2 (Mean 6 SEM) S1P3 (Mean 6 SEM)
wt
LPS2 0.0009 6 0.0001 0.0015 6 0.0001 0.0001 6 9.76E-05
LPS+ 0.0025 6 0.0003 0.0008 6 0.0002 0.0046 6 0.0003
SWAP-70
2/2
LPS2 0.0009 6 0.0001 0.0014 6 0.0002 0.0002 6 0.0001
LPS+ 0.0021 6 0.0003 0.0007 6 0.0002 0.0039 6 0.0006
Real-time quantitative PCR analysis of wt and SWAP-702/2 BMDCs was performed as described in Materials and
Methods. The amount of product for each PCR was normalized to GAPDH (mean 6 SEM of a representative experiment).
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Swap-70
2/2 BMDCs because we do not observe any difference in
the activation of RhoB after S1P stimulus in LPS-treated wt and
Swap-702/2 BMDCs (data not shown). Furthermore, we did not
find differences in endocytosis of immature wt and Swap-702/2
BMDCs (data not shown). These and the earlier data demonstrate
an impaired S1P response in LPS-mature Swap-702/2 BMDCs
that results in a failure to activate important functions, that is,
motility and endocytosis.
SWAP-70 interacts with GaI in BMDC extracts, and
Swap-702/2 BMDCs fail to localize Ga13 in membrane rafts
Previously, we reported interaction of SWAP-70 with the active
forms of Rac1 and RhoA in BMDC lysates (14). This interaction
may account for the proper activation and localization of these
Rho GTPases after S1P stimulus. Failure of S1P signaling in
Swap-702/2 DCs may also suggest interaction of SWAP-70 with
other members upstream of Rho GTPases, for example, S1P
receptors, G proteins, or both. We tested whether SWAP-70 in-
teracts with S1P receptors and Ga proteins. We performed im-
munoprecipitation assays of cells after S1P stimulus. Lysates were
obtained after incubation of cells with hypertonic buffer followed
by lysis with nitrogen cavitation to preserve receptors complex
that may form at the membrane, which otherwise would be dis-
rupted in lysates prepared with detergents. We found that in wt
BMDCs lysates, SWAP-70 interacts strongly with GaI and, to
a lesser level, with Ga13 (Fig. 5A). We did not detect interaction
with S1P3 (Fig. 5A) or S1P1 (data not shown). To test whether this
interaction depends on intact membrane fragments where the
proteins may associate, but not necessarily directly interact, we
performed immunoprecipitation in detergent-containing lysis
buffers. We observed interaction of SWAP-70 with GaI, but not
with Ga13, when the detergent NP-40 was used (Supplemental
Fig. 2). However, this interaction disappeared when octyl gluco-
side was used, a detergent known to dissociate membranes and
their associated proteins (39) (Supplemental Fig. 2). Together,
these results show direct or membrane domain-mediated inter-
actions of SWAP-70 with GaI proteins.
S1P GPCRs and their signaling components, for example, Ga
proteins, can be compartmentalized in membrane rafts and cav-
eolae to initiate receptor-specific signal transduction (see Refs. 40,
41 for review). We analyzed the membrane localization of Ga
proteins that are responsible for Rho GTPases activation after S1P
stimulus (10). Fig. 5B shows that, in both immature wt BMDCs
and Swap-702/2 BMDCs, GaI and Ga13 localized in membrane
rafts/caveolae, which were identified by the use of caveolin 1.
However, after LPS stimulus, Ga13 disappeared from the mem-
brane rafts/caveolae fractions of Swap-702/2 BMDCs, whereas it
largely remained in the corresponding wt fractions. The same
relocalization events happened in BMDCs stimulated by LPS and
S1P. In wt BMDCs, a relatively large portion of Ga13 localized to
membrane rafts/caveolae (gradient fraction no. 2) compared with
the portion of Ga13 appearing in the heavy fractions (no. 5, 6). In
addition, the Rac activator Gai was lost from raft fractions in wt
and Swap-702/2 BMDCs on LPS or LPS/S1P stimulation (Fig.
5B). Our initial data on failure of MHC-II localization into lipid
FIGURE 3. Expression of receptors S1P1 and S1P3 on the surface of LPS-stimulated wt (top panels) and Swap-70
2/2 BMDCs (lower panels). Secondary
Ab anti-rabbit IgG was used as control. Data are representative of at least three independent experiments.
FIGURE 4. Deficient S1P-induced endocytosis of Swap-702/2 BMDCs.
After serum starvation, LPS-matured BMDCs were incubated with 1 mg/
ml FITC-dextran in the presence or absence of 100 nM S1P for 5 min at
37˚C. After incubation, cells were analyzed by flow cytometry to de-
termine the FITC mean fluorescence intensity (MFI). Incubation at 4˚C
was used as negative control. Data are representative of at least three in-
dependent experiments.
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rafts (14) were reproduced using additional markers such as
caveolin 1 (Fig. 5B). Unlike in wt BMDCs, lipid raft formation is
inefficient in Swap-702/2 BMDCs, as is formation of caveolin-
positive membrane fractions. Thus, SWAP-70 is involved in con-
trol of formation of membrane domains like lipid rafts.
Swap-702/2 BMDCs fail to activate RhoA and to localize Rac1
and RhoA to areas of F-actin on S1P treatment
DC motility is enhanced by stimulation of S1P1 and S1P3 (5, 8, 11,
12), whereas endocytosis is mainly mediated through S1P3 sig-
naling (11). Previously, it was demonstrated that migration of
mature DCs toward S1P depends on cytoskeleton-associated ac-
tivation of Rho GTPases Rac1 and RhoA (4). S1P1 activates Rac1,
whereas S1P3 activates Rac1 and RhoA (10). Thus, we studied the
activation of Rac1 and RhoA in LPS-matured BMDCs after ad-
dition of S1P. Swap-702/2 BMDCs failed to activate RhoA and
rather did not maintain its basal activation level (Fig. 6A). In
contrast, activated Rac1 in Swap-702/2 BMDCs was not signifi-
cantly different from wt BMDCs (Fig. 6B).
The role of RhoA activation in the chemotactic response to
S1P of mature DCs was assayed using the exoenzyme C3
ADP-ribosyltransferase from Clostridium botulinum, which ADP-
ribosylates and thus inactivates RhoA, but not Rac1 or Cdc42 (42).
Although Swap-702/2 BMDCs were low in migration anyway,
inactivation of RhoA during the transwell chemotaxis assays
strongly inhibited migration to S1P of wt BMDCs (data not shown),
indicating that RhoA plays an active role during migration to S1P
in DCs in agreement with previous studies (4). In contrast, mi-
gration to CCL19 and CCL21 was not affected (data not shown),
agreeing with previous data where RhoA inactivation with exo-
enzyme C3 did not inhibit CCR7-mediated migration of human
DCs (43).
Rho GTPases colocalize with centers of actin polymerization as
cells migrate in response to extracellular stimuli (44). Rho GTPases
localize to F-actin structures that control migration in cells (45,
46). Colocalization analysis by confocal microscopy of Rac1 in F-
actin areas in wt BMDCs on stimulation with S1P shows signifi-
cantly more localization of the two proteins in the same areas (Fig.
6C), as shown by the levels of gray values representative of
colocalization (Fig. 6D, 6E). There was a modest, albeit signifi-
cant, increase in the level of localization of RhoA in F-actin areas
in wt BMDCs after S1P stimulus (Fig. 6C–E). Swap-702/2
BMDCs fail to increase the level of localization of either Rac1 or
RhoA with F-actin areas (Fig. 6C–E). In addition, the level of
localization between RhoA and F-actin is significantly greater in
Swap-702/2 BMDCs than in their wt counterparts before S1P
stimulus (Fig. 6D, 6E). This agrees with the higher content of
active RhoA, that is, RhoA-GTP, in unstimulated Swap-702/2
BMDCs (Fig. 6A). Taken together, these results show that Swap-
702/2 BMDCs are impaired in their ability to properly activate
and localize Rac1 and RhoA after S1P stimulus.
Preinhibition of RhoA restores S1P-induced motility,
endocytosis, and localization of Ga13 in membrane rafts in
Swap-702/2 BMDCs
In nonactivated, immature Swap-702/2 BMDCs, RhoA is con-
stitutively active, and this activation can be inhibited by pre-
treatment of the cells with exoenzyme C3 (14). In this study, we
observed that in LPS-matured Swap-702/2 BMDCs, RhoA was
also significantly more active than in wt BMDCs (Fig. 6A). We
FIGURE 5. SWAP-70 interacts with GaI in BMDC extracts and Swap-70
2/2 BMDCs fail to localize Ga13 in membrane rafts. A, Swap-70
+/+ BMDCs
lysates were immunoprecipitated with polyclonal anti–SWAP-70. Complexes were analyzed by Western blotting with anti–SWAP-70, anti-S1P3, anti-GaI,
and anti-Ga13. B, Lysates of immature (LPS
2), LPS-matured (LPS+), or LPS-S1P–matured (LSP+S1P+) BMDCs were subjected to OptiPrep gradient
ultracentrifugation system. After centrifugation, six fractions were collected from the top of the tube, resolved by SDS-PAGE, and analyzed by Western
blotting. Membranes were probed with polyclonal Ab against caveolin 1 for localization of membrane rafts and polyclonal Ab against transferring receptor
as negative control.
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preincubated LPS-matured BMDCs with exoenzyme C3 before
performing S1P chemotaxis transwell and endocytosis assays. The
cells were washed thoroughly before performance of the assays.
Restoration of Rho GTPase activity is known to occur within 3 h
after removal of the drug (42). Such treatment restored Swap-702/2
BMDC migration to S1P to levels close to wt cells (Fig. 7A). The
same treatment inhibited to some degree migration of wt cells as
well, indicating that there was some remaining inhibitory effect of
the exoenzyme (Fig. 7A). Preinhibition of RhoA also restored the
capacity of Swap-702/2 BMDCs to upregulate endocytosis after
S1P triggering (Fig. 7B). In contrast, wt cells lost the ability to
upregulate endocytosis, suggesting that RhoA activation was re-
quired for upregulation of S1P-mediated endocytosis (Fig. 7B).
Moreover, localization of Ga13 in membrane rafts in Swap-70
2/2
DCs was seen at the same level as in wt BMDCs when RhoAwas
preinhibited (Fig. 7C). Inactivation of RhoA by exoenzyme C3
before and during S1P stimulus in Swap-702/2 and wt BMDCs
was tested by using pull-down assays with rhotekin-Rho–binding
domain agarose (Supplemental Fig. 3). These results indicated that
SWAP-70 ensures regulated and timely activation of RhoA in
mature DCs, thereby allowing proper S1P signaling.
Discussion
S1P signaling through its receptors constitutes an important
mechanism to enhance motility and endocytosis of mature DCs (4,
5, 8, 11, 12). In this article, we identify SWAP-70 as a new factor
controlling S1P signaling in mature DCs. Swap-702/2 BMDCs
showed deficient upregulation of motility and endocytosis in re-
sponse to S1P. Migration to S1P was restored by re-expression of
SWAP-70 in Swap-702/2 BMDCs. Morphological analysis in
a 3D collagen matrix under S1P stimulus showed a deficiency of
Swap-702/2 BMDCs to migrate through small pores. Reduced
motility to S1P of Swap-702/2 BMDCs in 2D and 3D environ-
ments correlated with delayed entry into lymphatic vessels and
migration to lymph nodes of skin Swap-702/2 DCs. Migration of
mature DCs to S1P depends on the simultaneous activity of the
GTPases Rac1 and RhoA (4), and our study shows that inhibition
of RhoA activation abolished the upregulation of endocytosis in
wt BMDCs. However, the analysis of Rho GTPase activation in
mature Swap-702/2 BMDCs demonstrated that they contained
a significantly greater level of active RhoA, and that they failed to
upregulate active RhoA after an S1P stimulus. In this study, we
found for the first time, to our knowledge, an interaction of
SWAP-70 with the S1P signaling proteins GaI. These interactions
may be direct, but as a membrane-solubilizing detergent dis-
sociates them, the interaction may depend on the membrane; thus,
SWAP-70 may colocalize with the G proteins in a membrane
signaling cluster. This hypothesis fits to the observation that Swap-
702/2 BMDCs failed to localize the signaling proteins Ga13 re-
quired for RhoA activation to membrane rafts/caveolae. Together,
FIGURE 6. Swap-702/2 BMDCs fail to activate RhoA and to localize Rac1 and RhoA to areas of F-actin on S1P treatment. A and B, Activation of Rho
GTPases in LPS-activated BMDCs after S1P stimulus was analyzed using (A) rhotekin-Rho–binding domain or (B) PAK-Rac/Cdc42–binding domain
agarose beads. Beads were then subjected to SDS-PAGE and Western blotting. Activity of Rho GTPases was quantified by densitometric analysis and
expressed as ratio of activated to total Rho GTPases. C–E, Localization of RhoA and Rac1 into F-actin areas in wt and Swap-702/2 BMDCs. C,
Colocalization images show gray spots representing localization of the two proteins in F-actin areas. An area around the cytoplasm (yellow line) was drawn
for quantification of gray values. Scale bars, 10 mm. D, Histograms show the distribution of gray values per square micrometer for the colocalization images
used in C. E, Average of the mean gray values per square micrometer obtained from all of the histograms (40 for each staining) analyzed for RhoA (upper
panel) and Rac1 (lower panel). Data are representative of at least 2 independent experiments, each with 40 cells measured.
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these results indicate that a failure in RhoA activation by S1P
accounts for the impaired upregulation of motility and endocytosis
of Swap-702/2 BMDCs.
In vitro transwell assays showed that Swap-702/2 BMDCs
migrate poorly to S1P. Video microscopic analyses of Swap-702/2
BMDCs revealed a significant decrease in migratory speed, but
not in directionality, when compared with wt BMDCs in response
to S1P. This indicates two different mechanisms controlling speed
and directionality toward S1P, and that SWAP-70 regulates the
former. In addition, this indicates that functional S1P receptors are
expressed and locate on the surface of Swap-702/2 BMDCs, in
agreement with their wt-like expression levels of S1PR mRNA
and proteins. Interestingly, wt and Swap-702/2 BMDCs showed
no difference in in vitro migration to CCL19 and CCL21. S1P and
chemokines signal through GPCRs, which activate Rho GTPases
necessary for the cytoskeletal rearrangements involved in migra-
tion of cells (10, 47). In DCs, signaling through CCR7 also acti-
vates RhoA, but this modulates only the migratory speed and not
CCR7-dependent chemotaxis (43). We confirmed that inhibition
of RhoA activation with exoenzyme C3 does not block CCR7-
chemotaxis of BMDCs. In addition, Swap-702/2 BMDCs show no
difference in migratory speed in response to CCL19 (data not
shown) and behave like wt in transwell assays. Consistent with the
previous notion (4) that RhoA activation by S1P or by chemokines
are independent processes, we conclude that SWAP-70 plays a
particular role in RhoA-dependent S1P signaling necessary for DC
motility. We found that skin-derived DCs in ears of Swap-702/2
mice migrate poorly into dermal lymphatic vessels. Swap-702/2
BMDCs showed impaired transmigration through endothelial
lymphatic cells in vitro in response to CCL19, which may account
for the defect in entering to lymphatic vessels. However, this
phenotype may also be caused by failure to activate RhoA and to
localize Rac1 and RhoA to centers of actin polymerization after
S1P stimulus because S1P1 controls migration of skin-derived
DCs to draining lymph nodes (8). Therefore, SWAP-70 may con-
trol S1P-dependent signaling and transmigration in skin-derived
DCs, two processes that regulate DC migration to lymph nodes
(8, 31, 32), an aspect that will be the subject of future studies.
Our previous studies showed interaction of RhoA and SWAP-70
in BMDC lysates, and that RhoA is already activated before arrival
of an LPS stimulus in Swap-702/2 BMDCs, which suggests the
control of RhoA activation by SWAP-70 (14). The abrogation of
the preactivated state of RhoA in Swap-702/2 BMDCs by treat-
ment with exoenzyme C3 before, but not during, a LPS stimulus
restored upregulation of MHC-II on the surface of Swap-702/2
BMDCs (14). In this study, we detected a significant difference in
the activation state of RhoA in LPS-matured wt and Swap-702/2
BMDCs before appearance of the S1P stimulus. Similar to the
upregulation of MHC-II in Swap-702/2 BMDCs (14), treatment
with the exoenzyme C3 before, but not during, the S1P stimulus
restored migration to S1P and S1P-induced upregulation of en-
docytosis in Swap-702/2 BMDCs. Pretreatment with C3 also re-
stored proper caveolin and G protein distribution to raft fractions.
MHC-II is redistributed to the raft fraction only if the cells were
not activated with LPS as described before (14). This indicates
that SWAP-70 allows regulated and timely activation of RhoA,
and thereby supports a proper response to S1P. SWAP-70 thus
constitutes a novel element controlling S1P signaling in DCs.
Morphological analysis of BMDCs moving through pores in
a 3D environment in response to S1P showed that wt cells have
a rounded body shape and short dendrites that usually point to the
direction of cell movement. In contrast, Swap-702/2 BMDCs
showed an elongated morphology and long dendrites that pointed
to different directions at the same time. The nucleus was often
lagging behind the cell body. The analysis of Swap-702/2 BMDCs
without S1P stimulus showed no morphological difference when
FIGURE 7. Preinhibition of RhoA activation
increases the S1P-induced motility, endocytosis, and
localization of Ga13 in membrane rafts in Swap-70
2/2
BMDCs. A, LPS-activated Swap-702/2 and wt BMDCs
were treated with exoenzyme C3 before or during
in vitro migration in response to S1P. Migration is
calculated as percentage of input after 3-h exposure to
50 nM S1P in a transwell system. B, LPS-activated
Swap-702/2 and wt BMDCs were treated with 1 mg/
ml exoenzyme C3 for 4 h before in vitro endocytosis
in the presence or not of 100 nM S1P. Cells were
analyzed by flow cytometry to determine the FITC
mean fluorescence intensity (MFI). C, LPS-activated
Swap-70
2/2 and wt BMDCs were treated or not with
exoenzyme C3 for 4 h before S1P stimulus. Lysates of
DCs were subjected to OptiPrep gradient ultracentri-
fugation system and analyzed as in Fig. 5B. Data are
representative of at least three independent experi-
ments.
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compared with wt cells (data not shown). DC movement in 3D
environments is regulated by dynamic actin polymerization at the
cell front and actomyosin contractions of the trailing edge to push
the nucleus through narrow spaces (17). Swap-702/2 BMDCs
required more time to move through the pores of the collagen
matrix, and as a result, their dendrites are longer and the nucle-
us was often dragged behind. As a consequence, Swap-702/2
BMDCs may fail to retract the trailing edge on time. These
observations are in agreement with the failure of Swap-702/2
BMDCs to activate RhoA on S1P stimulation, because this Rho
GTPase is required for the contraction of the trailing edge of
mature DCs moving in collagen matrix (17).
The inhibition of Rac1 through activation of RhoA impairs
migration toward S1P in cells expressing only the S1P2 receptor
(48, 49). We deem it unlikely that the deficiency of Swap-702/2
BMDCs to migrate toward S1P results from deficient S1P sig-
naling through S1P2, because activation of Rac1 on S1P treatment
is not significantly different between Swap-702/2 and wt BMDCs.
However, localization of Rac1 to areas of actin polymerization
after S1P stimulus is impaired in Swap-702/2 BMDCs. This
failure may negatively affect S1P1 signaling. In studies done with
different cell lines, it has been concluded that S1P1 only activates
Rac1 by Gai association, whereas S1P3 activates both Rac1 and
RhoA by coupling to Gai and Ga12/13, respectively (10). In
BMDCs lysates, SWAP-70 interacts with Rac1, RhoA (14), and
GaI (this study). It is plausible to hypothesize that SWAP-70 acts
at the level of interaction of G proteins with Rho GTPases during
S1P signaling and, therefore, that its absence causes poor S1P-
induced migration and endocytosis. At which level SWAP-70
regulates other G protein-dependent responses, for example, to
chemokines, will be further studied. Both Ga12 and Ga13 localize
to plasma membrane (50), and their compartmentalization into
membrane rafts/caveolae can provide rapid and strong activation
signaling (51, 52). In both immature wt and Swap-702/2 BMDCs,
a fraction Ga13, as well as the Rac1 activator GaI, localized into
membrane rafts/caveolae. After LPS and S1P stimulus, Ga13 is
absent from membrane rafts/caveolae in Swap-702/2 BMDCs.
Failure to localize Ga13 to membrane rafts/caveolae may lead to
poor activation of RhoA in LPS-matured Swap-702/2 BMDCs
after S1P stimulus. In agreement with this, it has been demonstrated
that membrane localization of Ga13 is necessary to recruit p115-
RhoGEF to the membrane for subsequent RhoA activation (53, 54).
GaI was observed to disappear from membrane rafts/caveolae in
lysates from both wt and Swap-702/2 BMDCs after stimulation
with LPS and S1P. This observation is reminiscent of the situation
in smooth muscle cells where GaI and Gaq redistribute to the cy-
tosol after an agonist stimulus (55). This also suggests a mechanism
of Rac1 activation different from that of RhoA.
Collectively, our results suggest that SWAP-70 contributes to
proper, timely, and stable activation of RhoA in S1P signaling
affecting motility and endocytosis in DCs. In addition, given that
SWAP-70 interacts with GaI and Ga13, and that initial signaling
through Ga13 proteins may be negatively affected by a failure to
localize in membrane rafts/caveolae, SWAP-70 is of considerable
biological significance in S1P-induced functions of mature DCs.
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SUMMARY
Integrin-mediatedadhesionplaysacentral role inTcell
trafficking and activation. Genetic inactivation of the
guanine nucleotide-binding (G) protein a-subunits
Ga12 and Ga13 resulted in an increased activity of
integrin leukocyte-function-antigen-1 in murine CD4+
T cells. The interaction with allogeneic dendritic cells
was enhanced, leading to an abnormal proliferative
response in vitro. In vivo, T cell-specific inactivation
of Ga12 and Ga13 caused lymphadenopathy due to
increased lymphnodeentryandenhancedTcell prolif-
eration, and the susceptibility toward T cell-mediated
diseases was enhanced. Mechanistically, we show
that in the absence of Ga12 and Ga13 the activity of
the small GTPases Rac1 and Rap1 was increased,
whereas signaling of the small GTPase RhoA was
strongly reduced. Our data indicate that locally
produced mediators signal through Ga12- and Ga13-
coupled receptors to negatively regulate cell polariza-
tion and adhesiveness, thereby fine-tuning T cell
trafficking, proliferation, and susceptibility toward
T cell-mediated diseases.
INTRODUCTION
Integrin-mediated adhesion plays a central role in T cell functions.
The integrin leukocyte-function-antigen-1 (LFA-1), for example, is
crucial for the formationof the immunological synapse, the interface
between antigen-loaded mature dendritic cells and naive T cells.
LFA-1 also mediates firm adhesion to high endothelial venules,
thereby allowing naive T cells to enter secondary lymphatic organs.
In addition, LFA-1 has been implicated in the control of lymphocyte
differentiation and proliferation, as well as in the regulation of T cell
effector functions (Mor et al., 2007; Smith et al., 2007).
Given this multitude of LFA-1 functions, a precise under-
standing of the spatial and temporal control of the interaction
between LFA-1 and its cellular counter-receptors, the intercel-
lular adhesion molecules (ICAMs), is of great importance. In
naive T cells, LFA-1 is tethered to components of the actin cyto-
skeleton and thereby held in the inactive state with the result that
naive T cells are rounded and only mildly adhesive (Shimaoka
et al., 2002; van Kooyk et al., 1999). Activation of LFA-1 occurs
in response to a variety of extracellular signals, for example
stimulation of cytokine receptors, the TCR-CD3 complex, or
G protein-coupled receptors (GPCRs) (Kinashi, 2005). Best
studied among the latter are the chemokine receptors, which
have been shown to positively regulate LFA-1 through heterotri-
meric G proteins of the Gi family (Laudanna and Alon, 2006; Lau-
danna et al., 2002). The intracellular signaling cascades medi-
ating the effects of chemokines on integrin activation have
been shown to involve several monomeric GTPases such as
Rap1, Rac1, or RhoA (Mor et al., 2007). However, chemokine
receptors are probably not the only GPCRs contributing to the
regulation of integrin activity; T cells also express a variety of
other GPCRs, such as lysophospholipid or prostanoid receptors,
many of which have been implicated in the regulation of adhe-
siveness as well (Chun and Rosen, 2006; Matsuoka and Naru-
miya, 2007). In contrast to chemokine GPCRs, these receptors
couple not only to Gi but also to other G protein families such
as G12 (Riobo and Manning, 2005), but the role of this G protein
family in the regulation of T cell in vivo functions has not been
investigated so far.
The two members of the G12 family, G12 and G13, are ubiqui-
tously expressed and interact upon receptor-mediated activa-
tion with certain Rho guanine nucleotide exchange factors (Rho-
GEFs) (Fukuhara et al., 2001), which in turn mediate activation of
the small GTPase RhoA. Because of the embryonic lethality of
mice lacking the a-subunits of G12 and G13 (Ga12 and Ga13)
(Gu et al., 2002; Offermanns et al., 1997), and because of the
lack of specific inhibitors of these proteins, the relevance of
this family in the adult organism has long been elusive. The
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recent generation of tissue-specific Ga12,Ga13 double-deficient
mice revealed important functions in platelets and B cells (Moers
et al., 2003; Rieken et al., 2006a; Rieken et al., 2006b); the in vivo
role of Ga12 andGa13 in peripheral T cells, however, has not been
addressed up to now. With the help of the Cre-loxP system, we
generated T cell-specific Ga12,Ga13 double-deficient mice and
show here that these proteins negatively regulate the activation
state of integrin LFA-1, thereby modulating T cell trafficking and
proliferation, as well as responses to foreign and self antigen.
RESULTS
Lymphadenopathy in T Cell-Specific Ga12,Ga13
Double-Deficient Mice
T cell-specific Ga12,Ga13 double-deficient mice were generated
by intercrossing animals in which the gene coding for Ga13,
Gna13, was flanked by loxP sites (Gna13fl/fl) with the T cell-
specific Lck-Cre line (LckCre+/) and constitutively Ga12-defi-
cient (Gna12/) mice (Gu et al., 2002; Hennet et al., 1995;Moers
et al., 2003). As controls we used LckCre/Gna13fl/flGna12+/
littermates throughout the study. Immunoblots showed that
Ga13 immunoreactivity was strongly reduced and that Ga12
was absent in extracts of isolated CD90.2+ (Thy1.2) T cells
(Figure 1A). T cell-specific Ga12,Ga13 double-deficient mice
were born at expected frequencies and were viable and fertile,
but showed an increased size and weight of axillary, cervical,
and inguinal lymph nodes (Figure 1B). Mesenteric lymph nodes
were enlarged as well, whereas Peyer’s patches appeared
normal (data not shown). The increased lymph node weight cor-
responded to increased cell numbers (Figure 1C), and flow cyto-
metric analysis of lymphocyte subpopulations revealed that this
was predominantly a result of an expansion of the CD4+ T cell
population (Figure 1D). The general organization into B cell folli-
cles and T cell areas was not disturbed (Figure 1E). The relative
numbers of CD4+ regulatory T cells and CD4+ memory-effector
T cells within lymph nodes were not altered (data not shown).
In addition to lymphadenopathy, T cell-specific Ga12,Ga13
double-deficient mice showed an increased thymic weight and
cell number, with a proportionate increase in all subpopulations
(Table S1 available online). There were no substantial differences
with respect to the expression of TCRb chain, CD33, CD69, or
CD5 in the different thymic subpopulations (data not shown).
The splenic weight and splenocyte numbers were increased,
although not significantly (p = 0.08 and 0.27, respectively). The
CD4+ T cell population in the blood was increased (Table S1).
Taken together, these results show that genetic inactivation of
Ga12 and Ga13 in T cells resulted in an increased cell number
especially of CD4+ T cells in lymph nodes, blood, and the
Figure 1. Lymphadenopathy in T-Ga12,Ga13 DKOs
(A) CD90.2+ T cells were isolated from lymph nodes of controls (LckCre/Gna13fl/flGna12+/) and T-Ga12,Ga13 DKOs (LckCre
+/Gna13fl/flGna12/) and sub-
jected to immunoblotting with antibodies directed against Ga13, Ga12 and a-tubulin as loading control.
(B) Weight of peripheral lymph nodes (n = 8).
(C) Leukocyte numbers per node (n = 8).
(D) Absolute numbers of CD45R/B220+ B cells as well as CD4+ and CD8+ T cells per node (n = 10).
(E) Immunohistochemical staining of T cells and B cells in inguinal lymph nodes with antibodies against CD90.2 and CD45R/B220.
(F) Percentage of BrdU-positive T cells in lymph nodes 4 hr after intraperitoneal injection of BrdU as determined by intracellular flow cytometry (n = 6).
(G) In vitro proliferation of 23 105CD4+ T cells after 72 hr of culture with 53 104CD11c+ allo-DCs, after TCR crosslinking with immobilized CD3-CD28 antibodies,
or after stimulation with staphylococcal enterotoxin B (10 ng/ml) (n = 6–10).
(H) The concentration of secreted cytokines was determined in the supernatant of cocultures between CD4+ T cell and allo-DC after 72 hr (n = 8).
White bars represent the control; black bars represent the T-Ga12,Ga13 DKO. Data are displayed as mean ± SEM. *p < 0.05; ***p < 0.0005.
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thymus, suggesting that these G proteins have regulatory func-
tions in CD4+ T cell proliferation, apoptosis, or trafficking.
Proliferation Is Enhanced in Ga12,Ga13Double-Deficient
CD4+ T Cells
To study the causes of lymphadenopathy in T cell-specific
Ga12,Ga13 double-deficient mice, we investigated apoptosis
and proliferation. Apoptosis, here determined as the percentage
of Annexin V-positive T cells in freshly isolated lymph nodes, did
not differ between the genotypes (data not shown). To assess
basal T cell proliferation in lymph nodes, we determined the
percentage of 5-bromo-2-deoxyuridine (BrdU) incorporating
T cells 4 hr after intraperitoneal injection of BrdU. We found that
lymph nodes from mutant mice contained more BrdU-positive
CD4+ T cells than those from control animals, whereas the
proportion of BrdU-positive CD8+ T cells was not increased
(Figure1F).Wenextdetermined in vitroproliferationbymeasuring
the incorporation of [3H]-thymidine into CD4+ T cells after 72 hr of
culture.Although therewasnodifference in theproliferationof un-
stimulatedCD4+ T cells,mutant cells showed an increased prolif-
eration in response to allogeneic splenic CD11c+ dendritic cells
(allo-DCs) (Figure 1G). In contrast, the proliferative response
induced by CD3-CD28 crosslinking, staphylococcal enterotoxin
B, or phorbol-12-myristate-13-acetate (PMA) did not differ
between the genotypes (Figure 1G and data not shown).
To test whether increased proliferation in response to allo-DCs
was accompanied by altered cytokine production, we deter-
mined cytokine amounts in the supernatant of cocultures
between CD4+ T cell and allo-DCs by ELISA. The production of
interleukin (IL)-2 was increased in mutant cells, whereas the
production of tumor necrosis factor-a (TNFa) or interferon-g
(IFNg) remained unchanged (Figure 1H). Taken together, these
results indicate that Ga12 and Ga13 negatively regulate CD4
+
T cell proliferation in response to allogeneic dendritic cells.
Ga12,Ga13 Double-Deficient CD4
+ T Cells Show
Enhanced Interaction with Dendritic Cells
Because theG12 family is known to contribute to the regulation of
cellular adhesiveness, we investigated whether the enhanced
proliferation in response to allo-DCs was due to abnormal cell-
cell interactions in mutant cells. Flow cytometric analysis of
conjugate formation between fluorescently labeled CD4+
T cells and allo-DCs revealed an increased interaction if the
CD4+ T cells were Ga12,Ga13 deficient (Figure 2A). We next
investigated the interaction between purified CD4+ T cells and
fluorescently labeled allo-DCs by live-cell imaging (Figure 2B
and Movies S1 and S2). In mutant CD4+ T cells, the proportion
of cells with stable DC interactions (‘‘stable’’ here defined as
an interaction that lasted throughout a 10 min movie) was
increased (Figure 2C andMovies S1 and S2), as well as the inter-
action between CD4+ T cells themselves (Figure 2D). These data
suggest an important role of Ga12 and Ga13 in the regulation of
cellular interactions between CD4+ T cells and allo-DCs.
LFA-1 Activity Is Increased in Ga12,Ga13
Double-Deficient CD4+ T Cells
To further investigate LFA-1 activity in mutant cells, we
compared adhesiveness of control and Ga12,Ga13 double-
deficient CD4+ T cells on ICAM-1- and VCAM-1 (vascular cell
adhesion molecule-1)-coated plastic (Figure 3A). On ICAM-1,
mutant cells showed a higher basal adhesion than control cells,
whereas there was no difference with respect to basal adhesion
on VCAM-1. Mutant cells also showed increased ICAM-1 adhe-
siveness after integrin activation by chemokines or Mg2+ and
EGTA, whereas no differences were found in response to PMA
or TCR crosslinking (data not shown). On VCAM-1, none of these
integrin activators resulted in a substantial difference between
the genotypes (Figure 3A and data not shown).
LFA-1 activation has been shown to involve two modalities,
increased affinity and enhanced integrin clustering (Hogg et al.,
2002; Laudanna et al., 2002). To assess LFA-1 affinity, we deter-
mined binding of soluble ICAM-1 to CD4+ T cells in a flow cyto-
metric assay and found that in mutant T cells, the proportion of
cells that bound ICAM-1 was increased both under basal condi-
tions and after stimulation with Mg2+ and EGTA, which are
known to increase LFA-1 affinity (Figure 3B). We next investi-
gated LFA-1 clustering by immunofluorescent staining of the
Figure 2. Cell-Cell Interactions of Ga12,Ga13 double-deficient CD4
+
T Cells
(A) Flow cytometric analysis of dimer formation between CD4-PE-labeled
T cells and CD11c-FITC-labeled allo-DCs (n = 8).
(B) Live-cell imaging of isolated CD4+ T cells and CFSE-labeled allo-DCs.
Time-lapse movies of 10 min duration were recorded and exemplary micro-
graphs are depicted (magnification 403). The microphotographs taken at
0 min are overlaid with the GFP fluorescence image for identification of
CFSE-labeled DCs (marked by white arrows).
(C and D) Statistical evaluation of stable interactions between CD4+ T cells and
DCs (C) or between CD4+ T cells (D).
White bars represent the control; black bars represent the T-Ga12,Ga13 DKO.
Data are displayed as mean ± SEM. *p < 0.05.
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LFA-1 b-chain CD18 and found that the proportion of cells with
clusters was increased inmutant CD4+ T cells under basal condi-
tions and, less prominently, after chemokine stimulation (Figures
3C and 3D). However, because LFA-1 clustering was shown to
follow ligand binding (Kim et al., 2004), these findings might
represent a direct consequence of increased affinity. To exclude
that the observed differences were due to an increased surface
expression of LFA-1, we analyzed expression of the a- and b-
chains of LFA-1 by flow cytometry, but found no abnormalities
(data not shown). In order to test whether increased LFA-1
activity in Ga12,Ga13 double-deficient CD4
+ T cells altered integ-
rin outside-in signaling, we studied phosphorylation of extracel-
lular signal-regulated kinase (ERK) in response to Mn2+ and in-
tegrin crosslinking, but failed to detect differences between the
genotypes. Also, ERK phosphorylation in response to TCR
crosslinking or PMA was not altered (Figure S1).
To test whether increased interactions between mutant T cells
and allo-DCs were indeed due to increased LFA-1 activity, we
performed live-cell imaging in the presence of blocking anti-
bodies directed against LFA-1. Whereas LFA-1 antibodies had
only a minor effect on control CD4+ T cells, they normalized
enhanced interactions of Ga12,Ga13 double-deficient CD4
+
T cells. In contrast, a4b1 antibodies had no effect on either
control or mutant cells (Figure 3E). To further test whether
increased LFA-1 activity also contributed to enhanced prolifera-
tion of Ga12,Ga13 double-deficient CD4
+ T cells, we performed
in vitro proliferation assays with allo-DCs in the presence of
blocking antibodies directed against LFA-1. This treatment
reduced proliferation in mutant cells to the degree found in
control cells (Figure 3F), suggesting that deregulation of LFA-1
activity importantly contributes to hyperproliferation of mutant
T cells. Taken together, these findings indicate that inactivation
of Ga12 and Ga13 results in CD4
+ T cells in an increased affinity
and avidity of LFA-1, which in turn leads to an increased interac-
tion with antigen-presenting cells.
Polarization and Migration in the Absence of Ga12
and Ga13
In addition to increased LFA-1 avidity and affinity, morpholog-
ical changes such as increased spreading might contribute to
increased adhesiveness in the absence of Ga12 and Ga13. To
investigate cell shape in vitro, we performed phalloidin stain-
ings of polymerized actin in ICAM-1 adherent CD4+ T cells.
We found that the proportion of cells with firmly attached rear
end and elongated tail was substantially increased in mutant
cells (Figures 4A and 4B), as was the percentage of polarized
cells (Figure 4C). To correlate these morphological changes
with potential changes in migratory behavior, we performed
time-lapse video microscopy of CD4+ T cells on ICAM-1-
coated plastic. The distance traveled by individual CD4+
T cells was decreased in the absence of Ga12,Ga13
(Figure 4D and Movies S3 and S4), whereas the proportion of
motile cells did not differ between the genotypes (Figure 4E).
We next investigated whether increased adhesiveness and
polarization would affect transmigration through transwell
inserts coated with ICAM-1 or bEND.3 endothelial cells. Under
basal conditions, mutant cells showed reduced transmigration
both through ICAM-1 and endothelial cells, although migration
in response to chemokines CCL19 and CCL21 was not
impaired (Figure 4F).
Figure 3. LFA-1 Activity in Ga12,Ga13
double-deficient CD4+ T Cells
(A) Adhesionof lymphnodeCD4+ T cells to ICAM-1-
or VCAM-1-coated plastic. The percentage of
adherent CD4+ T cells was determined by flow
cytometry after 30 min of incubation under basal
conditions as well as after stimulation with chemo-
kines CCL19 and 21 (CCL19+21) or Mg2++EGTA.
Data are expressed as percent of input (n = 8).
(B) Flow cytometric analysis of basal and
Mg2++EGTA-induced binding of fluorescently
labeled soluble ICAM-1 to CD4+ T cells (n = 6).
(C and D) Basal and CCL19+21-induced LFA-1
clustering in CD4+ T cells was determined by immu-
nofluorescent staining with an CD18 antibody.
(C) shows exemplary photomicrographs of CD18-
stained cells (magnification 633). (D) shows statis-
tical evaluation of the percentage of cells showing
CD18 clusters (n = 3).
(E) Effect of blocking antibodies directed against
LFA-1,a4b1, or isotype control onT cell-DC interac-
tions in live-cell imaging (n = 3).
(F) Effect of blocking antibodies directed against
LFA-1 on CD4+ T cell proliferation in response to
DCs (n = 6).
White bars represent the control; black bars repre-
sent the T-Ga12,Ga13 DKO. Data are displayed as
mean ± SEM. *p < 0.05.
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Enhanced Lymph Node Entry of Deficient CD4+ T Cells
In addition to increased proliferation, LFA-1 hyperactivity in the
absence of Ga12 and Ga13 might affect T cell trafficking into
lymph nodes, thereby contributing to lymphadenopathy. To
study whether increased adhesiveness to ICAM-1 altered
T cell trafficking in vivo, we performed adoptive transfer experi-
ments with fluorescently labeled purified CD4+ T cells from
control and mutant mice. Twenty-four hours after injection,
significantly more mutant than control cells were found in
cervical lymph nodes of the respective host (Figure 5A). Because
this might be a result of altered entry and/or exit, we repeated
these experiments at 2 hr after transfer and found that even at
this time point, mutant CD4+ T cells were overrepresented
(Figure 5B). Also the entry of deficient CD4+ T cells into the
spleen was increased at two hours after transfer, whereas
numbers of mutant cells in the blood were reduced (Figure 5B).
Intravenous injection of LFA-1 antibodies into hosts 30 min prior
to adoptive transfer normalized the increased entry of Ga12,Ga13
double-deficient CD4+ T cells (Figure 5C), suggesting that
increased LFA-1 activity, but not disinhibition of other integrins
such as a4b1, underlies enhanced entry.
To investigate in vivo whether increased adhesiveness of
Ga12,Ga13 double-deficient CD4
+ T cells leads to a logjam of
cells within the lymphatic vessels or to the opposite, a more effi-
cient transendothelial migration, we performed two-photon
intravital microscopy of inguinal lymph nodes 2 hr after adoptive
transfer (Figures 5D and 5E). We determined the numbers of
control and Ga12,Ga13 double-deficient CD4
+ T cells in (1)
a vessel-rich zone, comprising mostly medulla, containing
higher-order venules and high endothelial venules (HEV), and
in (2) the T cell zone itself. Two hours after transfer, neither
control nor mutant CD4+ T cells were detected directly attached
to HEV endothelium; all cells had transmigrated through the
venule wall. Within the lymphatic tissue, the majority of cells
had already proceeded to dense lymphatic tissues, i.e., to the
proper T cell zones. A minority of CD4+ T cells was found in
the vessel rich zone, where Ga12,Ga13 double-deficient cells
were overrepresented (Figure 5E). These findings indicate that
enhanced transendothelial migration without persistent attach-
ment to HEV is the main factor underlying the observed domi-
nance of Ga12,Ga13 double-deficient CD4
+ T cells in the lymph
node 2 hr after adoptive transfer.
To also address the question of potentially impaired lymph
node egress, we studied transwell migration of Ga12,Ga13
double-deficient CD4+ T cells in response to the GPCR agonist
sphingosine 1-phosphate (S1P), which has been shown to regu-
late egress from lymph node or thymus through the S1P1
receptor (Matloubian et al., 2004). However, neither with ICAM-
1-coated nor with uncoated transwell inserts did we observe
differences between the genotypes with respect to S1P-induced
migration (Figure 5F and data not shown), and such a finding is in
line with the assumption that S1P1 is a predominantly Gi-coupled
receptor (Chun and Rosen, 2006). To address the possibility of
an egress impairment independent of S1P, we analyzed the
percentage of dye-positive cells 24 hr after adoptive transfer in
the cisterna chyli, which collects efferent lymph from the lower
body. Also in cisterna chili lymph,mutant CD4+ T cells were over-
represented, suggesting that the passage time through lymph
nodes was not altered (Figure 5G). In summary, these results
show that increased LFA-1-mediated adhesion in Ga12,Ga13
double-deficient CD4+ T cells does not only result in an
enhanced interaction with allo-DCs but also facilitates entry
into lymph nodes.
Signaling Pathways Involved in Ga12,Ga13-Mediated
Regulation of LFA-1
We next attempted to elucidate the molecular mechanisms
underlying increased integrin activation and polarization in
Ga12,Ga13 double-deficient CD4
+ T cells. Small GTPases such
as Rap1, RhoA, and Rac1 are known to regulate integrin activity
Figure 4. Migratory Behavior of Mutant
CD4+ T Cells
(A) Exemplary photomicrographs taken from phal-
loidin-stained CD4+ T cells that have adhered for
20 min to ICAM-1-coated plastic in the absence
(basal) or presence of CCL19+21 (magnification
633).
(B) Statistical analysis of the percentage of cells
with attached, elongated rear (n = 3).
(C) Percentage of CD4+ T cells with a polarized
phenotype (showing one or more F-actin positive
pseudopods) (n = 3).
(D) The distance traveled by CCL19+21-stimu-
lated CD4+ T cells was determined on ICAM-1-
coated plastic in time-lapse microscopy.
(E) Percentage of motile CD4+ T cells (i.e., traveling
more than one body length per 10 min) (n = 3).
(F) Percentage of CD4+ T cells that have migrated
through ICAM-1-coated transwells inserts (left) or
inserts covered with a confluent monolayer of
bEND.3 endothelial cells (right) during 3 hr of incu-
bation without agonist in the lower chamber
(basal) or in response to CCL19+21 (n = 5).
White bars represent the control; black bars repre-
sent the T-Ga12,Ga13 DKO. Data are displayed as
mean ± SEM. *p < 0.05; **p < 0.005.
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and cell polarization in response to chemokines (Iden and
Collard, 2008; Laudanna and Alon, 2006; Mor et al., 2007); we
therefore studied the activation state of these signaling mole-
cules in the absence of Ga12 and Ga13 (Figure 6). Both in control
and Ga12,Ga13 double-deficient cells, active Rap1 was barely
detectable in the basal state, but strongly increased 20 and
60 s after application of CCL19 and CCL21, and this increase
was even more prominent in Ga12,Ga13 double-deficient cells
(Figure 6A).
Although the potential interactions between the G12 family and
Rap1 still need to be elucidated, the small GTPase RhoA is
a well-known effector of G12 and G13. We studied RhoA activa-
tion in response to stimulation of known G12,G13-coupled recep-
tors such as the TXA2 receptor TP (Matsuoka and Narumiya,
2007) or LPA receptors (Chun and Rosen, 2006) and found that
the TP agonist U46619, as well as LPA, induced a robust RhoA
activation in control CD4+ T cells, but not in Ga12,Ga13 double-
deficient CD4+ T cells (Figure 6B). Interestingly, also basal
RhoA activity was reduced in Ga12,Ga13 double-deficient cells.
Given that RhoA has been shown to negatively regulate Rac1
(Iden and Collard, 2008), we next studied basal and chemo-
kine-induced Rac1 activation. We found that Rac1 activation
was generally enhanced in mutant cells, most prominently at
60 s after stimulation, but also under basal conditions
(Figure 6C). The G12,G13-mediated signaling pathway obviously
exerts an inhibitory effect on chemokine-induced Rac1 activa-
tion, and two different scenarios might underlie this finding:
(1) CCR7 directly activates G12 and G13 in parallel with its main
effector pathway Gi, or (2) the CCR7-Gi-Rac1 signaling cascade
is modulated by other receptors than CCR7. To address the first
possibility, we investigated whether CCL19 and CCL21 were
able to induce RhoA activation in T cells and whether this de-
pended on Gi and/or on G12 and G13 (Figure 6D). We found
that CCL19+21 induced a mild RhoA activation in control
T cells, but the response was weaker and slower than that
induced by the TXA2 analog U46619. Pretreatment with
pertussis toxin, which ADP-ribosylatesGi and thereby uncouples
it from receptors, did not affect U46619-induced RhoA activation
but abrogated chemokine-induced RhoA activation. In
Ga12,Ga13 double-deficient T cells, U46619-induced RhoA acti-
vation was clearly reduced, whereas RhoA activation in
response to CCL19+21 was not changed compared to control
cells (Figure 6D). These findings indicate that the mild RhoA acti-
vation observed after CCR7 stimulation is rather mediated
through G proteins of the Gi family than the G12 family.
To investigate the potential involvement of other GPCRs in this
context, we tested whether concomitant activation of the
G12,G13-RhoA pathway, for example in response to U46619,
was able to quench chemokine-induced Rac1 activation in
wild-type cells. We found that coapplication of U46619 with che-
mokines induced a strong RhoA activation within 20 s (Figure 6E)
and that Rac1 activation was concomitantly reduced (Figure 6F).
Of note, the quenching effect of U46619 on chemokine-induced
Rac1 activation was abrogated in Ga12,Ga13 double-deficient
Figure 5. Lymph Node Homing In Vivo
(A–C) Differentially labeled CD4+ T cells from control and mutant mice were mixed in a 1:1 ratio and injected intravenously into wild-type recipients (5 3 106 per
mouse). After 24 (A) or 2 (B) hr, the proportion of labeled CD4+ T cells was determined by flow cytometry (data are corrected for actual input ratio as determined by
FACS). At 2 hr, spleen and blood were also investigated (n = 6–8). (C) shows the adoptive transfer into wild-type recipients pretreated with blocking LFA-1 anti-
bodies or isotype control (n = 4).
(D and E) Intravital two-photonmicroscopy was used for analyzing the distribution of control versus Ga12,Ga13 double-deficient CD4
+ T cells in the inguinal lymph
node 2 hr after adoptive transfer. (D) shows examples for the different areas studied (control cells in red,mutant cells in blue). (E) shows the statistical evaluation of
the percentage Ga12,Ga13 double-deficient CD4
+ T cells found in the two respective image zones and in FACS analysis of the transferred population (n = 3).
(F) Migration of control and mutant CD4+ T cells through uncoated transwell inserts in response to S1P.
(G) Proportion of dye-positive cells in cisterna chyli aspirates 24 hr after adoptive transfer.
White bars represent the control; black bars represent the T-Ga12,Ga13 DKO. Data are displayed as mean ± SEM. *p < 0.05.
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Figure 6. Signaling Pathways Involved in Ga12,Ga13-Mediated Regulation of Adhesiveness and Polarization
(A) Basal and CCL19+21-inducedRap1 activation in control andGa12,Ga13 double-deficient T cells. The left panel shows exemplary immunoblots. The right panel
shows the statistical evaluation of the densitometric quantification (n = 5).
(B) Amounts of active, GTP-bound RhoA under basal conditions and 1 min after stimulation with the TXA2 analog U46619 or lysophosphatidic acid (LPA)
(n = 6–10).
(C) Basal and CCL19+21-induced Rac1 activation in CD4+ T cells (n = 6–10).
(D) Comparison of relative RhoA activation in response to U46619 and CCL19+21 in control T cells, pertussis toxin (PTX)-pretreated T cells, and Ga12,Ga13
double-deficient T cells (n = 3).
(E and F) Effect of U46619 on CCL19+21-induced activation of RhoA (E) and Rac1 (F) (n = 4–6).
(G) Effect of U46619 on conjugate formation between control or mutant CD4+ T cells and allo-DCs as determined by flow cytometry (n = 5).
(H) Effect of U46619 on allo-CD11c+-induced proliferation in control CD4+ T cells, as well as CD4+ T cells deficient for Ga12,Ga13 (Gna12
/,Gna13/), Lsc
(Arhgef1/), or LARG (Arhgef12/) (n = 3–5).
(I) Effect of LPA and S1P on allo-CD11c+-induced proliferation in control and Ga12,Ga13 double-deficient CD4
+ T cells (n = 3–5).
White bars represent the control; black bars represent the T-Ga12,Ga13 DKO. s, seconds. Data are displayed as mean ± SEM. *p < 0.05.
Immunity
G Proteins of the G12 Family and T Cell Functions
Immunity 30, 1–13, April 17, 2009 ª2009 Elsevier Inc. 7
Please cite this article in press as: Herroeder et al., Guanine Nucleotide-Binding Proteins of the G12 Family Shape Immune Functions by Controlling
CD4+ T Cell Adhesiveness and Motility, Immunity (2009), doi:10.1016/j.immuni.2009.02.010
cells (Figure 6F), in which RhoA activation was strongly reduced
(Figure 6E).
We next asked whether U46619-induced activation of the
G12,G13-RhoA-signaling cascade would also affect cell-cell inter-
actions and, secondary to that, proliferation. We found that
U46619 reduced dimer formation between control CD4+ T cells
and allo-DCs, whereas it moderately increased conjugate forma-
tion in Ga12,Ga13 double-deficient CD4
+ T cells (Figure 6G).
Furthermore, U46619 reduced in vitro proliferation of control
CD4+ T cells, and this effect was impaired in mutant cells
(Figure 6H). We next investigated the potential involvement of the
G12,G13-regulated RhoGEF proteins Lsc-p115RhoGEF (Lsc) and
leukemia-associated RhoGEF (LARG) in this process and found
that U46619-induced suppression of proliferation was reduced
in Lsc-deficient cells as well (Figure 6H). Also, inactivation of
LARG led to some reduction, although a less prominent one, sug-
gesting that both LARG and Lsc contribute to the effects of
Ga12,Ga13 on adhesiveness and proliferation, with a predominant
role of Lsc (Figure 6H). Interestingly, lysophospholipids LPA and
S1P also were able to reduce proliferation in response to allo-
DCs in a Ga12,Ga13-dependent manner (Figure 6I). Of note, the
inhibitory effects of U46619, LPA, and S1P on proliferation are
mild compared to the effect of LFA-blocking antibodies, showing
that the G12,G13-mediated signaling pathway only exerts a modu-
lating role. Taken together, these results suggest thatGPCRssuch
as the TXA2 receptor, but also LPA and S1P receptor subtypes,
negatively regulate cell adhesion and polarization through
G12,G13-mediated activation of RhoA, which in turn modulates
chemokine-induced activation of Rac1, and, directly or indirectly,
Rap1 (FigureS2).Wehypothesize that TXA2 or LPA regulate adhe-
sivenessofCD4+Tcells inanauto-orparacrinemanner; insupport
of this hypothesis, we found that gentlewashing of cells enhanced
ICAM-1 adhesion, but not VCAM-1 adhesion (Figure S3).
Immune Functions In Vivo
Increased CD4+ T cell proliferation and trafficking might alter
responses to exogenous or endogenous antigens, resulting in
abnormal immune responses or autoimmune disease. Neither
routine histological analysis of internal organs nor staining for
IgG deposition in the kidney of aged mice revealed signs of
spontaneous autoimmune disease (data not shown), which led
us to challenge T cell-specific Ga12,Ga13 double-deficient mice
in two models of T cell-mediated pathology: contact hypersensi-
tivity to dinitrofluorobenzene (DNFB) as a model for responses to
foreign antigen (Kurimoto and Streilein, 1993) and low-dose
streptozotocin-induced diabetes mellitus as a model of autoim-
mune disease (Like and Rossini, 1976).
During the sensitization phase of contact hypersensitivity, the
hapten DNFB is applied to the abdominal skin from where it is
transported to draining lymph nodes and presented by dendritic
cells. The resulting activation of naive T cells and generation of
effector cells leads during the elicitation phase (rechallenge
with DNFB in the ear of the skin) to leukocyte recruitment to
the ear, resulting in a Th1-cell-dependent local inflammation
with consecutive swelling (Kurimoto and Streilein, 1993). We
found that T cell-specific Ga12,Ga13 double-deficient mice
showed increased ear swelling at 24, 48, and 72 hr after sensiti-
zation and challenge (Figure 7A), and histological analyses of ear
Figure 7. Immune Responses in T-Ga12/13 DKOs
(A–C) Delayed type hypersensitivity. (A) shows an increase in ear thickness after sensitization and challenge with DNFB (n = 10). (B) and (C) show flow cytometric
analysis of BrdU-positive CD4+ T cells (B) and of CD4+,CD44+,CD62L effector and memory T cells (C) in cervical lymph nodes 72 hr after challenge (n = 6).
(D–F) MLD-STZ-induced diabetes mellitus. (D) shows urine glucose amounts at different time points after disease induction (n = 10). (E) shows flow cytometric
analysis of BrdU-positive CD4+ T cells in peripancreatic lymph nodes before onset of symptoms (days 5–6) and in the late phase of disease (day 14) (n = 4).
(F) shows flow cytometric analysis of pancreatic infiltrates at days 5–6 and day 14 (n = 4–6). White bars represent the control; black bars represent the
T-Ga12,Ga13 DKO. Data are displayed as mean ± SEM. *p < 0.05.
Immunity
G Proteins of the G12 Family and T Cell Functions
8 Immunity 30, 1–13, April 17, 2009 ª2009 Elsevier Inc.
Please cite this article in press as: Herroeder et al., Guanine Nucleotide-Binding Proteins of the G12 Family Shape Immune Functions by Controlling
CD4+ T Cell Adhesiveness and Motility, Immunity (2009), doi:10.1016/j.immuni.2009.02.010
sections taken at 72 hr showed an increased leukocytic infiltra-
tion (data not shown). Basal ear thickness and histology did
not differ between the genotypes (data not shown). CD4+
T cells in cervical lymph nodes from mutant mice showed
a higher proliferation rate than those of control mice (Figure 7B),
and the proportion of T memory and effector cells was increased
(Figure 7C).
In the second in vivo model, type I diabetes mellitus is induced
by intraperitoneal administration of multiple low doses of strep-
tozotocin (MLD-STZ), and the pathogenesis of this disease has
been shown to involve an autoimmune-mediated destruction
of pancreatic b-cells (Like and Rossini, 1976). We determined
urine glucose levels every 72–96 hr starting from the seventh
day after diabetes induction and found that in deficient mice dia-
betes development was both accelerated and aggravated
(Figure 7D). Because this might be due to an increased prolifer-
ative response to an altered cytokine profile, or to increased
entry into inflamed tissues, we investigated proliferation, cyto-
kine production and number of infiltrating leukocytes before
onset of symptoms (days 5–6) and at the height of disease
(day 14). We found that peripancreatic lymph nodes were clearly
enlarged already at day 5–6 (total cell number control mice: 9.8 ±
3.4 3 106, mutant mice: 25.9 ± 5.8 3 106); the CD4+ T cells
showed enhanced proliferation (Figure 7E) without substantial
changes in the production of IFNg, TNFa, or IL-4 (data not
shown). The numbers of pancreas-infiltrating CD4+ T cells,
CD8+ T cells, or CD11b+ macrophages did not differ between
the genotypes at days 5–6; at day 14, however, T cell-specific
Ga12,Ga13 double-deficient mice showed increased numbers
of pancreas-infiltrating CD4+ T cells (Figure 7F and data not
shown). Taken together, these findings show that the enhanced
proliferative responses in T cell-specific Ga12,Ga13 double-defi-
cient mice are associated with an increased susceptibility and
severity of T cell-mediated diseases.
DISCUSSION
Whereas Gi-coupled chemokine receptors have in many studies
been shown to importantly contribute to T cell trafficking or
formation of the immunological synapse (Kinashi, 2005; Lau-
danna et al., 2002), the role of the G12 family in peripheral
T cells is poorly understood. We report here that Ga12,Ga13
double-deficient CD4+ T cells show an enhanced interaction
with allo-DCs, thereby leading to abnormal proliferative
responses in vitro. Together with an increased lymph node entry,
this enhancement of proliferation most likely underlies the
increased lymph node size observed in T cell-specific
Ga12,Ga13 double-deficient mice in vivo. Our in vitro studies
suggest an increased activity of integrin LFA-1 as an underlying
mechanism, and this notion is strongly supported by the finding
that blocking antibodies directed against LFA-1 normalized
T-DC interactions and in vitro proliferation and increased lymph
node entry of Ga12,Ga13 double-deficient T cells. Also the fact
that hyperproliferation is only observed in response to adhe-
sion-dependent stimulation by DCs, but not in response to direct
stimulation of the T cell receptor (TCR), PMA, or superantigens,
points to the important role of LFA-1 in this context.
The increased adhesiveness observed in the absence of Ga12
and Ga13, however, is moderate compared to that observed in
a mouse line carrying a hyperactive LFA-1 mutant (ItgalD/D) con-
taining a five amino acid deletion in the membrane-proximal
region of LFA-1 (Semmrich et al., 2005). ItgalD/D lymphocytes
share with Ga12,Ga13 double-deficient cells in vitro phenotypes
such as increased ICAM-1 adhesion, impaired transmigration,
and tail retraction, but they differ considerably with respect to
their in vivo phenotype. In vivo, ItgalD/D mice resemble LFA-1-
deficient animals, with reduced lymph node and thymus sizes
and impaired proliferative responses (Berlin-Rufenach et al.,
1999; Schmits et al., 1996). These paradoxical findings are
most likely due to the constitutive active nature of the ItgalD/D
mutant, and this nature leads to irrevocable attachment to
HEV or DCs and thereby prevents normal transmigration or acti-
vation. In Ga12,Ga13 double-deficient T cells, in contrast, nega-
tive regulation of LFA-1 through other mechanisms such as
cbl-b (Zhang et al., 2003) or RhoH (Cherry et al., 2004) is still
functional, leading to the observed moderate changes in traf-
ficking and proliferation.
Our in vitro studies suggest that the inactivation of Ga12 and
Ga13 results in an altered activation state of three small GTPases
involved in the regulation of polarization and integrin-mediated
adhesion: RhoA, Rac1, and Rap1. RhoA has been shown to
regulate integrin activity in T cells both positively (Constantin
et al., 2000; Giagulli et al., 2004) and negatively (Rodriguez-Fer-
nandez et al., 2001; Smith et al., 2003); in addition, it has been
involved in polarization (Iden and Collard, 2008; Mor et al.,
2007). RhoA is probably the most important effector of Ga12
and Ga13, but it should be kept in mind that RhoA can also be
activated by a variety of other signaling pathways such as integ-
rins, receptor tyrosine kinases, plexins, or Gq and Gi family
G proteins. RhoA activation in response to stimulation of
G12,G13-coupled receptors is mediated by three specific
RhoGEF proteins, Lsc, LARG, and PDZ-RhoGEF (Fukuhara
et al., 2001), and our data indicate that Lsc, and to a lesser extent
also LARG, mediate the inhibitory effects of Ga12 and Ga13 on
adhesion and proliferation. In line with these findings, Lsc-defi-
cient mice share some phenotypical aspects with T cell-specific
Ga12,Ga13 double-deficient mice, for example increased lymph
node size and in vitro proliferation (Girkontaite et al., 2001) or
impaired rear detachment from ICAM-1 (Rubtsov et al., 2005).
An increased polarization was also observed in Ga12,Ga13
double-deficient B cells (Rieken et al., 2006b) or in neutrophils
expressing dominant-negative forms of Ga12 and Ga13 (Xu
et al., 2003). Xu et al. (2003) suggested that chemoattractant
receptors might activate Gi- and G12,G13-mediated signaling
pathways in neutrophils in parallel, whereas our data suggest
that G12,G13-mediated quenching of chemokine-induced Rac1
activity involves receptors other than CCR7, for example, TP.
RhoA is known to antagonistically regulate Rac1, a small
GTPase involved in the regulation of cellular morphology, polar-
ization, and integrin signaling (Iden and Collard, 2008; Mor et al.,
2007). We found that both basal and chemokine-induced Rac1
activation is increased in the absence of Ga12 andGa13, possibly
contributing to enhanced polarization and integrin-mediated
adhesion of Ga12,Ga13 double-deficient T cells (D’Souza-
Schorey et al., 1998; Garcia-Bernal et al., 2005). We furthermore
show that chemokine-induced Rac1 activation in control CD4+
T cells is dampened by concomitant simulation of the G12,G13-
RhoA pathway through the TP agonist U46619. Interestingly,
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U46619 alone induces Rac1 activation through G proteins of the
Gq family (Gratacap et al., 2001); it seems, however, that during
combined application of U46619 and CCL19+21, the G12,G13-
RhoA mediated inhibition of Rac1 outweighs Gq-induced Rac1
activation. Importantly, stimulation of the G12,G13-RhoA
signaling cascade by U46619 does not only impede
CCL19+21-induced Rac1 activation but also impacts on adhe-
siveness and, consecutively, on proliferation: U46619 is able to
reduce conjugate formation between wild-type CD4+ T cells
and allo-DCs, resulting in reduced proliferation in vitro. Of note,
the Ga12,Ga13-mediated modulation of adhesiveness and prolif-
eration was not restricted to U46619, but was also observed in
response to LPA and, to a lesser extent, S1P. We therefore
hypothesize that local mediators such as S1P, LPA, and TXA2
are released from lymphocytes or bystanding cells andmodulate
cell polarization and integrin-mediated adhesion in an auto- or
paracrine manner. Lysophospholipids and TXA2 are released
from blood cells, macrophages, and dendritic cells (Chun and
Rosen, 2006; Kabashima et al., 2003) and are therefore likely
to contribute to the regulation of cell-cell interactions during
lymph node entry or antigen presentation. Genetic inactivation
of the TXA2 receptor TP, for example, resulted in age-dependent
lymphadenopathy and enhanced immune responses to foreign
antigens (Kabashima et al., 2003). In line with an important role
of Ga12 and Ga13 in the negative regulation of adhesiveness
through auto- and paracrine factors, we found that gentle
washing significantly increased ICAM-1 adhesiveness in control
but not in Ga12,Ga13 double-deficient T cells.
The third GTPase that shows altered activation in the absence
of Ga12 and Ga13 is Rap1, which has been shown to increase
integrin-mediated adhesion (Katagiri et al., 2000; Sebzda et al.,
2002), for example in response to chemokine receptor activation
(Shimonaka et al., 2003). Whether increased chemokine-
induced Rap1 activation in the absence of Ga12 and Ga13 is
causally related to increased Rac1 and impaired RhoA activation
is currently unclear. Crosstalk between Rac1 and Rap1 has been
implicated in the regulation of cell migration, for example by
localizing GEFs for Rap1 and Rac1 to the ruffling membrane
(Arthur et al., 2004; Caloca et al., 2004), but the effects of
Ga12,Ga13 on Rap1 and Rac1 might also be independent.
A fourth GTPase involved in the regulation of LFA-1 activity in
lymphocytes is RhoH (Cherry et al., 2004). In contrast to other
small GTPases, RhoH is GTPase deficient and therefore does
not undergo the normal activation-inactivation cycle; instead, it
was suggested to be regulated on the transcriptional level (Li
et al., 2002). We investigated RhoH expression by RT-PCR but
did not find altered expression in the absence of Ga12 and
Ga13 (data not shown), suggesting that altered RhoH expres-
sion does not contribute to the phenotype of T cell-specific
Ga12,Ga13 double-deficient mice.
Interestingly, whereas LFA-1 activity is clearly enhanced in
Ga12,Ga13 double-deficient CD4
+ T cells, the activation state of
integrin a4b1 is not altered, suggesting that these integrins are
differentially regulated. A differential regulation of a4b1 and
LFA-1 by small GTPases has been described in a rat monocytic
cell line (Honing et al., 2004) and in human T cells (Ghandour
et al., 2007); the underlyingmechanisms, however, are unknown.
It is also currently unclear why Ga12,Ga13 deficiency seems to
affect CD4+ T cells more prominently than CD8+ T cells. Differ-
ences in the expression of G12 family G proteins or of G12,G13-
coupled receptors might explain these findings, but neither in
literature (Chun and Rosen, 2006; Kabashima et al., 2003) nor
in our own experiments did we find evidence for such differ-
ences. It might be speculated that not yet characterized
G12,G13-coupled receptors with cell type-specific expression
are involved in the negative regulation of integrin activity.
The in vivo relevance of the G12,G13-mediated negative regu-
lation of LFA-1 is clearly documented by the finding that T cell-
specific Ga12,Ga13 double-deficient mice show an increased
susceptibility toward endogenous and exogenous antigens, re-
sulting in increased severity of autoimmune diabetes and cuta-
neous hypersensitivity. Interestingly, except for the increased
lymph node size, we did not detect signs of spontaneous auto-
immune disease in T cell-specific Ga12,Ga13 double-deficient
mice, suggesting that the regulatory effect of Ga12 and Ga13 is
especially important under pathological conditions.
Taken together, our data show that heterotrimeric G proteins
of the G12 family negatively regulate the activation state of integ-
rin LFA-1, thereby fine-tuning T cell trafficking, proliferation, and
susceptibility toward immune disease. We show that a variety of
receptor systems such as lysophospholipid or prostanoid recep-
tors converge on Ga12 and Ga13 to modulate activation of RhoA,
Rac1, Rap1, and ultimately LFA-1, and it is well possible that
other, yet unknown mediators contribute to this process. There-
fore, a cell-type-specific manipulation of Ga12 and Ga13 or of
downstream RhoGEF proteins might in the future prove useful
tomodulate T cell trafficking or the strength of the immunological
synapse.
EXPERIMENTAL PROCEDURES
Animals and Cells
Mice were housed under specific pathogen-free conditions, and their genetic
background was predominantly C57BL6/N (fifth generation backcross).
Genotyping was performed as described previously (Moers et al., 2003). For
generation of conditional LARG-deficient mice, please see Supplemental
Experimental Procedures. Untouched lymph node CD4+ T cells and splenic
CD11c+ dendritic cells were isolated with the mouse CD4+ T cell isolation kit
or mouse CD11c-Microbeads, respectively (Miltenyi, Bergisch-Gladbach,
Germany). All animal experiments have been approved by local authorities.
Chemicals and Antibodies
U46619 was from Cayman (Ann Arbor, MI, USA); LPA and S1P were from Bio-
mol (Hamburg, Germany), chemokines from PeproTech (London, UK); and
STZ, DNFB, staphylococcal enterotoxin B, and a-tubulin antibodies were
from Sigma-Aldrich (St. Louis, MO, USA). Endotoxin-free antibodies against
LFA-1, VLA4, or isotype control were from the Cancer Research UK Mono-
clonal Antibody Unit, London. Antibodies against Ga13, Ga12, and LARG
were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). All other anti-
bodies were from BD Biosciences (San Jose, CA, USA).
Flow Cytometry
All flow cytometric analyses were performed with a FACSCalibur flow cytom-
eter and CellQuestPro Software (BD Biosciences). Apoptosis and proliferation
were determined with the Annexin-V-FITC apoptosis kit and the FITC-BrdU
flow kit, respectively; intracellular cytokine production was determined with
the mouse intracellular cytokine staining kit (all BD Biosciences). For the
flow cytometric analysis of conjugate formation, 1 3 105 PE-labeled CD4+
T cells and 1 3 105 FITC-labeled CD11c+ DCs were mixed, centrifuged for
1 min at 50 3 g, and incubated for 20 min. After gentle resuspension, the
proportion of CFSE-PE double-positive events was determined.
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Live-Cell Imaging
For live-cell imaging, 105 unstained purified CD4+ T cells from control or
mutant mice were mixed with 2 3104 CFSE-labeled CD11c+ DCs in a droplet
of 20 ml RPMI1640, 10 mM HEPES, and 10% FCS and allowed to attach to
CELL STAR plastic dishes (Greiner Bio-One GmbH, Essen, Germany) for 20
min at 37C and 5% CO2. In some cases, 10 mg/ml LFA-1 antibodies, 10 mg/
ml a4b1 antibodies, or 10 mg/ml isotype control were added to the mixture.
Cell interactions were recorded for 10 min with a Leica DM IRE2 inverted fluo-
rescence microscope and Leica FW4000 software at 37C and 5% CO2 (1
frame per 10 s). For statistical analysis, cell interactions were classified by
an investigator blinded to genotype; an interaction was classified as stable if
it lasted throughout a 10 min movie. In some cases, plates were coated with
ICAM-1 (for coating, see Adhesion Assays) and the distance traveled by indi-
vidual T cells was determined with the ImageJ program (NIH, Bethesda, MD,
USA).
Adhesion Assays
Adhesion assays were carried out in 48-well plastic dishes as described previ-
ously (Rieken et al., 2006a), with minor modifications: for ICAM-1 coating,
wells were coated with 50 mg/ml goat-anti-human-IgG-Fc antibody (Jackson
ImmunoResearch, West Grove, PA, USA) at 4C overnight, washed twice
with PBS, and incubated with 2.5 mg/ml mouse ICAM-1-Fc (R&D Systems,
Minneapolis, USA) in PBS for 2 hr. For VCAM-1 coating, wells were incubated
for 1 hr at 37C with 3 mg/ml hVCAM-1 (R&D Systems) in carbonate buffer. In
some cases, chemokines CCL19 and 21 were added at final concentrations of
100 ng/ml during ICAM-1 and hVCAM-1 coating. Afterward, all wells were
blocked with 0.5% bovine serum albumine (BSA) in PBS for 30 min before
use. The volume per well was 100 ml in each step. For the adhesion assay,
5 3 105 lymph node cells were incubated in 100 ml RPMI1640 containing
10 mM HEPES and 0.5% FCS for 30 min at 37C and 5% CO2; in some cases,
CCL19 and CCL21 (100 ng/ml final), Mg2+ (10 mM) and EGTA (1 mM), CD3-
CD28 antibodies (5 mg/ml each), or PMA (5 ng/ml) were added. After discarding
nonadherent cells, the plate was gently washed in PBS and adherent cells
were subsequently detached in RPMI1640, 5 mM EDTA for 20 min on ice.
Numbers of adherent CD4+ T cells were determined after antibody staining
by flow cytometry, and data are displayed as the proportion of adherent cells
relative to cell input into the adhesion assay.
Soluble ICAM-1 Binding
Binding of ICAM-1 (10 mg/ml, R&D Systems) to CD4+ T cells in the absence or
presence of 10mMMg2+ and 1mMEGTAwas determined as described previ-
ously (Sebzda et al., 2002). In brief, freshly isolated lymph node cells (1 3 105
cells/ml) were resuspended in HEPES buffer (20 mM HEPES, 140 mM NaCl,
and 2 g/l glucose) with 0.1% BSA at a concentration of 2 3 106 cells/ml.
Lymphocyte aliquots of 50 ml (1 3 105 cells) were added to 96-well plates
with or without 10 mM Mg2+ and 1 mM EGTA. Soluble murine ICAM-1Fc
(10 mg/ml, R&D Systems) was added to the cells. After 30 min incubation at
37C, cells were washed twice in ice-cold PBS with 0.1% BSA and incubated
with Fc-specific FITC-conjugated goat anti-human IgG (1:200; Jackson Immu-
noresearch, West Grove, PA, USA) and PerCP-conjugated anti-mouse CD4
antibody for 10 min on ice. We washed cells twice in PBS with 0.1% BSA to
remove excess unbound antibodies and detected fluorescence by flow
cytometry.
Migration Assays
For chemotaxis assays, lymph node cells were preincubated in RPMI1640 +
10 mM HEPES + 0.1% BSA for 30 min at 37C and 5% CO2 and then allowed
to migrate through 5 mm pore size transwell inserts (Corning, Acton, MA, USA)
at a density of 23 106 splenocytes/100 ml per well. The transwell inserts were
uncoated, ICAM-1-coated (as described for Adhesion Assays), or seeded with
3 3 104 bEND.3 endothelial cells (from ATCC [Montesano et al., 1990]) 24 hr
before the experiment. The lower wells contained either 600 ml RPMI1640 +
10 mM HEPES + 0.1% BSA alone or medium plus 100 ng/ml CCL19+21, or
1–100 nM S1P. After 3 hr of incubation at 37C and 5% CO2, transwell plates
were kept on ice for 20 min and centrifuged at 180 3 g for 3 min, inserts were
discarded, and cells were stained for CD4+ T cells and counted by flow cytom-
etry. Cell numbers were expressed as a proportion of input. All experiments
were done in triplicates.
Adoptive Transfer Experiments
Fluorescent labeling of cells with the Cell Trace CFSE Cell Proliferation Kit
(50 nM CFSE final), CellTracker CM-DiI (5 mM final), or SNARF (500 nM final)
(all Invitrogen, Karlsruhe, Germany) was performed according to the manu-
facturer’s instructions. For adoptive transfer experiments, isolated CD4+
T cells from mutant and control animals were labeled with CFSE and DiI, or
SNARF, mixed in a 1:1 ratio, and injected intravenously (5 3 106 cells per
mouse). In some cases, recipients were pretreated with 100 mg LFA-1 anti-
bodies or isotype control. After 2 or 24 hr, the proportion of CFSE- and DiI-
positive cells in cervical lymph nodes was analyzed by flow cytometry; in
some cases we also analyzed cisterna chyli punctate. All data were corrected
for the actual input ratio as determined by FACS.
RhoA, Rac1, and Rap1 Activation Assays
Amounts of GTP-bound RhoA or Rac1 were determined with RhoA or Rac1
G-LISA activation kits (Cytoskeleton, Denver, CO, USA), and Rap1 was de-
tected with the EZ-Detect Rap1 activation kit (Pierce, Rockford, USA). For
each measurement, 2 3 106 (RhoA) or 5 3 106 (Rac1, Rap1) T cells were
used; in some cases, cells were pretreated with PTX 100 ng/ml. Agonist
concentrations were 1 mM for U46618 and 100 ng/ml for chemokines.
Intravital Two-Photon Microscopy
Three-dimensional two-photon microscopy was performedwith aMaiTai laser
(Spectra-Physics, Darmstadt, Germany) running at 800 nm, amultibeam scan-
head (LaVision Biotech, Bielefeld, Germany), and an Olympus BX51WI micro-
scopic stage equipped with a XLUMPL 320, NA 0.95 water dipping lens.
Image detection was done with a cooled CCD-camera (Imager Intense, LaVi-
sion, Goettingen, Germany). RGB Z stacks of 300 3 300 mm images were re-
corded in typically 15 steps of 3 mm. Frames taken at two to three positions
within each of the two imaging areas (vessel-rich zone [medulla, paracortex]
and T cell zone) were analyzed (Sanna et al., 2006). Rendering of video
sequences was performed with Volocity 4.3 (Improvision, Waltham, MA,
USA). Cell tracking was done with computer-assisted manual tracking with
CellTracker. Data were plotted with Prism 4 (GraphPad Software, San Diego,
CA, USA). Swapping of dyes resulted in the same findings. For details, see
Supplemental Experimental Procedures.
Animal Models
Delayed type hypersensitivity and MLD-STZ diabetes mellitus were induced in
female (DTH) or male (MLD-STZ) mice aged 8–16 weeks as described previ-
ously (Kurimoto and Streilein, 1993; Like and Rossini, 1976). Urine glucose
levels were determined with the glucose hexokinase method (Randox Labora-
tories, UK). For the flow cytometric quantification of pancreatic leukocyte
infiltration, the peripancreatic lymph nodes were carefully removed; then pan-
creata were minced and digested for 10–15 min at 37C under vigorous
shaking in Krebs-Ringer solution containing 0.5 mg/ml Collagenase P (Roche
Diagnostics, Mannheim, Germany). Leukocytes were then purified via Percoll
and Lympholyte M gradients (Cedarlane, Burlington, Canada) according to the
manufacturer’s instructions and analyzed by flow cytometry.
In Vitro Proliferation Assays, Immunoblotting,
and Immunohistochemistry
In vitro proliferation assays, immunoblotting, and immunohistochemistry were
performed as described previously (Rieken et al., 2006a; Rieken et al., 2006b).
For details, see Supplemental Experimental Procedures.
Statistics
Data are displayed as mean ± SEM. Comparisons between two groups were
performed with unpaired t test. n indicates the number of animals per experi-
mental group.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, one
table, three figures, and four movies and can be found with this article online
at http://www.cell.com/immunity/supplemental/S1074-7613(09)00183-6.
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Src Homology 2-Domain Containing Leukocyte-Specific
Phosphoprotein of 76 kDa Is Mandatory for TCR-Mediated
Inside-Out Signaling, but Dispensable for CXCR4-Mediated
LFA-1 Activation, Adhesion, and Migration of T Cells1
Jessica Horn,2* Xiaoqian Wang,2* Peter Reichardt,* Theresia E. Stradal,† Nicole Warnecke,*
Luca Simeoni,* Matthias Gunzer,* Deborah Yablonski,‡ Burkhart Schraven,3*
and Stefanie Kliche3*
Engagement of the TCR or of chemokine receptors such as CXCR4 induces adhesion and migration of T cells via so-called
inside-out signaling pathways. The molecular processes underlying inside-out signaling events are as yet not completely
understood. In this study, we show that TCR- and CXCR4-mediated activation of integrins critically depends on the mem-
brane recruitment of the adhesion- and degranulation-promoting adapter protein (ADAP)/Src kinase-associated phospho-
protein of 55 kDa (SKAP55)/Rap1-interacting adapter protein (RIAM)/Rap1 module. We further demonstrate that the Src
homology 2 domain containing leukocyte-specific phosphoprotein of 76 kDa (SLP76) is crucial for TCR-mediated inside-out
signaling and T cell/APC interaction. Besides facilitating membrane recruitment of ADAP, SKAP55, and RIAM, SLP76
regulates TCR-mediated inside-out signaling by controlling the activation of Rap1 as well as Rac-mediated actin polymer-
ization. Surprisingly, however, SLP76 is not mandatory for CXCR4-mediated inside-out signaling. Indeed, both CXCR4-
induced T cell adhesion and migration are not affected by loss of SLP76. Moreover, after CXCR4 stimulation, the ADAP/
SKAP55/RIAM/Rap1 module is recruited to the plasma membrane independently of SLP76. Collectively, our data indicate
a differential requirement for SLP76 in TCR- vs CXCR4-mediated inside-out signaling pathways regulating T cell adhesion
and migration. The Journal of Immunology, 2009, 183: 5756 –5767.
S timulation of T cells through the TCR activates a wholeplethora of signaling pathways that collectively controlactivation, proliferation, and differentiation of T cells.
One immediate consequence of TCR engagement is the forma-
tion of a multicomponent signaling complex close to the plasma
membrane consisting of the Src homology 2-domain containing
leukocyte-specific phosphoprotein of 76 kDa (SLP76),4 the
small adapter protein Gads, and the transmembrane adapter pro-
tein linker for activation of T cells (LAT) (1). In response to
TCR engagement, LAT becomes phosphorylated on several ty-
rosine residues by the protein tyrosine kinase ZAP70 (1). This
phosphorylation leads to recruitment of Gads. Through its con-
stitutive association with Gads, SLP76 is also recruited to phos-
phorylated LAT (2). In the following, several other effector
molecules assemble with the LAT/Gads/SLP76-signaling plat-
form. These include phospholipase C1 (PLC1), the nucleo-
tide exchange factor Vav1, and the Tec family kinase IL-2-
inducible T cell kinase (Itk) (1). Together these molecules
coordinate TCR-mediated rises in intracellular calcium, up-reg-
ulation of CD69, and the activation of the Ras/ERK1/2 signal-
ing pathway (1, 3).
The importance of SLP76 for TCR-mediated signaling events
has been demonstrated in SLP76-deficient mice as well as in the
SLP76-deficient Jurkat T cell line J14. Thus, loss of SLP76 in mice
leads to a complete block at the double-negative 3 stage of thymic
development and results in an almost complete loss of mature T
cells (1). Moreover, loss of SLP76 in Jurkat T cells induces a
complete failure of the TCR to induce rises in intracellular cal-
cium, activation of the Ras/Raf/MAPK/ERK1/2 pathway, and up-
regulation of CD69 expression (3).
Besides inducing the above-mentioned signaling events, TCR
stimulation also leads to T cell adhesion, a process that is critical for
the interaction between T cells and APCs. In T cells, the 2 integrin
LFA-1 (L2) mediates adhesive events with APCs through binding
to its ligand ICAM-1. LFA-1/ICAM-1 interactions are critical for T
cell activation because they stabilize the interaction of T cells with
APCs and the formation of the immunological synapse (IS) (4, 5).
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Resting T cells are not adhesive because LFA-1 is presented in a
closed, inactive conformation. Upon triggering of the TCR or of
chemokine receptors (see below), a conformational change is
induced within LFA-1 that augments its affinity for ICAM-1. In
addition, clustering of LFA-1 molecules on the surface of T cells
enhances avidity for ICAM-1 binding. The molecular events lead-
ing to integrin activation have collectively been termed inside-out
signaling (6).
Gain-of-function and loss-of-function studies have demon-
strated that additional signaling proteins are involved in TCR-me-
diated integrin activation. These include talin (6, 7), the Wiskott-
Aldrich syndrome-Verprolin-homologous protein WAVE2 (8, 9),
Rap1 (6, 10, 11), and its downstream targets regulator of adhesion
and cell polarization enriched in lymphoid tissues or Rap1-inter-
acting adapter protein (RIAM) (12–14), adhesion- and degranula-
tion-promoting adapter protein (ADAP) (15, 16), and Src kinase-
associated phosphoprotein of 55 kDa (SKAP55) (17, 18).
Moreover, components of the LAT/Gads/SLP76 signaling plat-
form are also critically involved in TCR-mediated activation of
LFA-1. These include PLC1, Vav1, Itk, and ADAP (13, 19, 20).
How exactly these molecules orchestrate TCR-mediated activation
of integrins is not completely understood. However, we have re-
cently shown that the formation of a signaling module consisting
of ADAP/SKAP55 complex together with RIAM is required for
plasma membrane targeting of Rap1 in response to TCR stimula-
tion, and therefore for TCR-mediated activation of integrins (17,
21). In line with these data is the observation that ADAP- and
SKAP55-deficient mouse T cells show a severe defect in integrin
activation in response to TCR-mediated stimuli (15, 16, 18).
Currently, it is proposed that following T cell activation, ty-
rosine-phosphorylated ADAP binds to the Src homology 2 domain
of SLP76, thereby leading to membrane recruitment of the ADAP/
SKAP55/RIAM module and integrin activation. In line with this
idea is the observation that disruption of the interaction between
SLP76 and Gads blocks TCR-mediated adhesion to ICAM-1 (22).
Furthermore, it was shown that mutation of those tyrosine residues
within ADAP, which are believed to mediate the interaction be-
tween ADAP and SLP76, blocks TCR-mediated activation of
LFA-1 (23). Thus, it appears as if SLP76 would also play a major
role during TCR-mediated activation of integrins by facilitation
membrane targeting of the ADAP/SKAP55/RIAM module. However,
to date, an inducible interaction between endogenously expressed
ADAP/SKAP55/RIAM module and SLP76 in response to TCR en-
gagement has not been demonstrated biochemically. Hence, the mo-
lecular signaling events underlying the function of SLP76 for TCR-
mediated integrin activation are not completely elucidated.
Importantly, integrins not only become activated after stimu-
lation of the TCR, but also after triggering of chemokine re-
ceptors, such as CXCR4. Signaling via CXCR4 is induced by
stromal cell-derived factor-1 (or CXCL12) and induces affin-
ity and avidity regulation of LFA-1 (6). This process is impor-
tant for firm T cell adhesion, T cell polarization, chemokinesis,
and chemotaxis (24). Molecules involved in CXCR4-mediated
integrin activation and/or chemotaxis are talin (25), Rap1 (6,
26, 27), and its downstream targets regulator of adhesion and
cell polarization enriched in lymphoid tissues and MstI (28 –
30), Itk (20), Vav1 (20, 31, 32), Rac (31), and members of the
Wiskott-Aldrich syndrome protein family (33, 34). Moreover,
we and others have shown that overexpression of ADAP en-
hances chemotaxis of T cells in response to CXCL12 (35, 36).
These findings suggest an important role of ADAP for CXCR4-
induced migration of T cells. However, the molecular basis of
how ADAP is integrated into CXCR4 signaling is to date un-
clear. Based on its central role in TCR-mediated signaling pro-
cesses, SLP76 would be an attractive candidate that could fa-
cilitate membrane targeting of ADAP after CXCR4 stimulation.
Indeed, it was shown recently that SLP76 regulates CXCR4-
induced Ca2 flux and ERK1/2 phosphorylation (31). Con-
versely, we had demonstrated that disruption of the SLP76/
Gads association, albeit impairing TCR-mediated signaling
processes, does not affect CXCR4-induced Ca2 flux and che-
motaxis (22). Thus, it is unclear whether SLP76 is also
important for CXCR4-mediated activation of integrins and
chemotaxis.
In this study, we have addressed critical questions regarding the
function of SLP76 during TCR vs CXCR4-mediated signaling. We
show that SLP76 is indeed a critical regulator of TCR-mediated
inside-out signaling events in T cells, and we demonstrate that
SLP76 is mandatory for induction of TCR-mediated adhesion, af-
finity/avidity regulation of LFA-1, and the interaction between T
cells and B cells. Furthermore, we show that SLP76 is required for
TCR-induced Rap1 activation, Rac-mediated actin dynamics, and
recruitment of both talin and the ADAP/SKAP55/RIAM/Rap1
module to the plasma membrane and to the IS. Surprisingly, how-
ever, SLP76 is not mandatory for CXCR4-mediated activation of
LFA-1. In addition, SLP76 is dispensable for adhesion and migra-
tion of T cells in response to CXCL12. Finally, we demonstrate
that the ADAP/SKAP55/RIAM/Rap1 module is crucial for T cell
adhesion and migration in response to CXCR4 triggering, but is
recruited to the plasma membrane independently of SLP76. Our
findings show that SLP76 acts as a key player during TCR-medi-
ated inside-out signaling, whereas the adapter protein appears to be
dispensable for chemokine-dependent processes that regulate ad-
hesion and migration of T cells.
Materials and Methods
Reagents and Abs
All tissue culture reagents were from Biochrom, and all chemicals were
from Roth, unless mentioned otherwise. Staphylococcal enterotoxin B, D,
and E were purchased from Toxin Technology, respectively. Indo-1 AM,
Blue-7-amino-4-chloromethylcoumarin, DDAO-SE, and Alexa Fluor 633-
phalloidin were bought from Molecular Probes. FITC or tetramethylrho-
damine isothiocyanate (TRITC) phalloidin was from Sigma-Aldrich. PMA
was purchased from Calbiochem. Glutathione-Sepharose beads were
bought from Pharmacia. Protein A- and protein G-agarose beads were from
Santa Cruz Biotechnology. The chemokine CXCL12 was bought from
Tebu-bio, and the human Fc-tagged ICAM-1 was from R&D Systems. The
anti-RIAM rat mAbs were raised against the bacterially expressed GST-
tagged fragment of RIAM (1–420 aa), as previously described (37). Su-
pernatants of secreting hybridomas were screened by Western blotting,
immunofluorescence, and intracellular flow cytometry (FACS), and among
the various clones tested, the mAb RIAM15B7E8 was selected. The mouse
anti-CD3 mAb C305 (IgM) (38), OKT3 (ATCC), biotinylated UCHT-1
(NatuTec), or MEM92 (provided by V. Horejsi, Academy of Sciences of
the Czech Republic, Czech Republic) was used for TCR stimulation of
Jurkat T cells or human T cells. For protein surface expression analysis
by FACS, the following mAbs were used: CD18 (MEM48), CD29
(MEM101A; both provided by V. Horejsi), CD184 (CXCR4; clone
12G5; BD Biosciences), MHC class I (clone W6/32; ATCC), KIM127
(provided by N. Hogg, Cancer Research U.K. London Research Insti-
tute, London, U.K.), APC-conjugated anti-CD69 (BD Bioscience), or
FITC-conjugated MEM48 (Immunotools). The anti-SLP76 and anti-
preimmune sheep serum (39), anti-SKAP55 rabbit serum (40), or anti-
Gads rabbit serum (Upstate Biotechnology) was used for immunopre-
cipitation studies. The following Abs were used for immunoblot
analysis and/or immunofluorescence in this study: anti-SKAP55 rat
mAb (SK13B6) (17), anti-GST rat mAb (provided by C. Erk, Helm-
holtz-Zentrum fu¨r Infektionsforschung, Braunschweig, Germany), anti-
-actin mAb (Sigma-Aldrich), anti-phospho-ERK1/2 (T202, Y204) rabbit
serum and anti-Vav rabbit serum (both from Cell Signaling Technol-
ogy), anti-SLP76 mAb (Santa Cruz Biotechnology), anti-LAT mAb
(BD Biosciences), anti-ADAP sheep serum (41), anti-phospho-SLP76
mAb (pY145; BD Biosiences), anti-phospho-LAT (pY171) rabbit se-
rum and anti-phospho-ZAP70 (pY319) rabbit serum (both from Cell
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Signaling Technology), anti-Rap1 rabbit serum (Santa Cruz Biotech-
nology), anti-Rap1 mAb and anti-Rac mAb (both from BD Biosciences), and
anti-talin mAb (clone 8D4; Sigma-Aldrich). The following Abs were used for
phospho-epitope staining by FACS: anti-phospho-ZAP70 (pY319)-Alexa
Fluor 647, anti-phospho-PLC1 (pY783)-Alexa Fluor 647 (both from BD
Biosciences), and anti-phospho-ERK1/2 (pT202, pY204; clone E10; Cell Sig-
naling Technology). Streptavidin, HRP-labeled secondary Abs, and FITC-,
Cy3-, APC-, and Cy5-conjugated secondary Abs were purchased from
Dianova.
RNA interference (RNAi) of SLP76, ADAP, SKAP55, or RIAM
and cDNA constructs
For small hairpin RNA (shRNA) of SLP76, the following oligonucleotides,
shC (CCAAGTAATGTAGGATCAA; Renilla) and shSLP76 (CGAAGA
GAGGAGGAGCATC; shSLP76), were cloned into pSuper (provided by
T. Seufferlein (Universita¨tsklinik und Poliklinik fu¨r Innere Medizin I,
Halle, Germany) and pCMS3-EGFP vector (provided by D. Billadeau
(Mayo Clinic, Rochester, MN). For shRNA of ADAP and RIAM, the pre-
viously published oligonucleotides were cloned into the pCMS3 vector (12,
42). The pCMS3-EGFF construct for silencing of SKAP55 has been de-
scribed (17). The pGEX PAK-PBD was provided by T. Seufferlein. The
pGEX RalGDS-RBD was provided by J. Bos (University Medical Center,
Utrecht, The Netherlands), and the pmCherry-C1 vector was purchased from
BD Clontech.
Cell culture and transfection
Jurkat T cells (ATCC), B cells (Raji; ATCC), and SLP76-deficient/recon-
stituted Jurkat T cells (J14, J14-76-11, and J14-76-18) (3) were maintained
in RPMI 1640 medium supplemented with 10% FBS (PAN) and stable
L-glutamine at 37°C with 5% CO2. Jurkat T cells (2  107) were trans-
fected by electroporation, as previously described (17). Transfection with
the pCMS3-EGFP vector into Jurkat T cells consistently yielded in an
average of 80% GFP-expressing cell population. Primary human T cells
were prepared from healthy donors by standard separation methods using
AutoMACS (Miltenyi Biotec) maintained in RPMI 1640 medium contain-
ing 10% FBS, stable L-glutamine, and 1000 U/ml penicillin/streptomycin.
Approval for these studies was obtained from the Ethics Committee of the
Medical Faculty at the Otto-von-Guericke University. Informed consent was
obtained in accordance with the Declaration of Helsinki. For electroporation of
small interfering RNA (siRNA), human peripheral T cells (8  106) were
washed in PBS containing Ca2/Mg2 and resuspended in 200 l of Opti-
MEM (Invitrogen). siRNA smart pool against SLP76, ADAP (Dharmacon
smart pools for SLP76 or ADAP), control siRNA (siCONTROL nontargeting
smart pool from Dharmacon), Vav1.3 (31), siRNA for SLP76, or control
siRNA Renilla (see above; all purchased from Invitrogen) was added, and after
3 min cells were transfected by electroporation (square-wave pulse, 1000 V,
0.5 ms, 2 pulses (pulse interval 5 s); Bio-Rad X-cell). The cells were then
added to prewarmed cell culture medium, as described above, and cultured for
72 h before use. The knockdown efficiency of SLP76, ADAP, SKAP55,
RIAM, or Vav1 was evaluated either by Western blotting or on a single-cell
basis by intracellular flow cytometry.
Immunoprecipitation, Western blot analysis, isolation of
cytosolic and plasma membrane fractions, and GTPase assays
Cell lysis and immunoprecipitation were performed, as previously described
(17, 21). Equivalent amounts of protein (determined by Bradford assay (Roth))
were used in precipitation studies (500 g of total protein from either Jurkat T
cells or human primary T cells). Cell lysates (50 g of total protein) or immune
complexes were separated by SDS-PAGE and transferred to nitrocellulose.
Western blots were conducted with the indicated Abs and developed with the
appropriate HRP-conjugated secondary Abs and the Luminol detection system
(Roth). Isolation of cytosolic and plasma membrane fractions has been de-
scribed previously (17). GTPase activity of Rap1 or Rac activity was assessed,
as previously described (17). Briefly, Jurkat T cells were either left un-
treated or stimulated for various time points with anti-CD3 mAb C305
or CXCL12 (100 ng/ml) and lysed. An aliquot of the lysate (10%) was
used as loading control. Activated GTPases were precipitated using
either glutathione-Sepharose conjugated with the GST-RalGDS fusion
protein for Rap1 (RBD) or glutathione-Sepharose coupled with the GST
fusion protein of the p21-binding domain of Pak (PBD) for Rac. Bound
GTPases were quantified by Western blotting.
Flow cytometry, calcium release, and CD69 up-regulation
To analyze the cell surface expression of 1 or 2 integrin, CXCR4, TCR,
and MHCI, cells were stained with the indicated Abs in combination with
APC-conjugated goat anti-mouse IgG and analyzed using a FACSCalibur
flow cytometer and CellQuestPro software (BD Biosciences). Soluble Fc-
ICAM-1 binding of T cells after various stimuli was assessed, as previously
described (43). Briefly, T cells suspended in binding puffer (HBSS con-
taining 2% FBS) were either left untreated or stimulated with anti-CD3
mAb, CXCL12, or Mg2/EDTA for 5 min in the presence of 20 g/ml
human rFc-ICAM-1, and bound Fc-ICAM-1 was detected by flow cytom-
etry. Intracellular staining by flow cytometry for SLP76, ADAP, SKAP55,
or RIAM was performed, as previously described (44). The specificity of
the staining for each serum or mAb was assessed using either SLP76-
deficient/reconstituted Jurkat T cells or after loss of ADAP, SKAP55, or
RIAM expression by vector-based shRNA in Jurkat T cells (please see
supplemental Fig. 1).5 To assess the F-actin content, T cells (1  105) were
left untreated or stimulated with anti-CD3 mAbs or CXCL12, and reactions
were stopped by adding PBS containing 4% paraformaldehyde (PFA), 2
g/ml FITC- or Alexa Fluor 633-phalloidin, and 0.2% Triton X-100. After
15 min, cells were washed with 1% PFA in PBS and analyzed by flow
cytometry. Measurement of TCR-induced calcium release and CD69 up-
regulation have been previously described (17). Analysis of protein phos-
phorylation with phospho-specific Abs by flow cytometry was performed,
as described (45).
Conjugate formation, adhesion, migration, and motility assays
Conjugate assays were performed, as described (21). Briefly, superantigen
(SA) mixture of staphylococcal enterotoxin B-, D-, and E-pulsed and
DDAO-SE-labeled Raji B cells were incubated with an equal number of
Jurkat T cells or CFSE-loaded human T cells for 30 min at 37°C. Non-
specific aggregates were disrupted; cells were fixed with 1% PFA, and then
analyzed by flow cytometry. The percentage of conjugates was defined as
the number of double-positive events in the upper right quadrant. Adhesion
assays were performed, as previously described (17). Briefly, Jurkat T cells
or peripheral human T cells were stimulated with OKT3, PMA, or MnCl2
for 30 min at 37°C before adhesion on Fc-ICAM-1-coated dishes. The
bound total or GFP-expressing cell fraction was determined by counting
four independent fields by microscopy using an ocular counting reticule.
To assess CXCR4-mediated adhesion, peripheral human T cells were in-
cubated for 10 min at 37°C on Fc-ICAM-1-coated dishes coimmobilized
with or without CXCL12; subsequently, nonbound cells were removed by
washing with HBSS and bound cells were counted, as described above.
Chemotaxis assays were performed, as previously described, using Tran-
swells (Costar) coated with fibronectin (35). After 2 h, the number of
migrated cells into the lower chamber was counted and the percentage of
GFP-expressing Jurkat T cells was determined by flow cytometry. For live
cell imaging of either random or CXCL12-induced motility of T cells on
Fc-ICAM-1, self-constructed imaging chambers (46) were coated with Fc-
ICAM-1 in PBS at 4°C overnight. Immediately before imaging, cells were
left untreated or stimulated with CXCL12 (100 ng/ml), and imaging was
performed on a CellR imaging workstation (Olympus) using an upright
microscope stage (BX61) with a 20 lens. Using an automated X-Y-Z
stage, at least two optical fields were chosen for each culture condition.
Images were taken every 15–60 s for 2 h. At least 30 cells per observation
field were analyzed. Tracking analysis of migrating cells to determine the
velocity was done by computer-assisted cell tracking using the Software
CellTracker (46).
Immunofluorescence microscopy
For B cell/T cell conjugates, SA- and Blue-7-amino-4-chloromethylcou-
marin-loaded Raji B cells were incubated for 30 min at 37°C with human
T cells on poly(L-lysine)-coated coverslips and fixed with 3.5% PFA in
PBS for 10 min. Cells were permeabilized with 0.1% Triton X-100 in PBS,
blocked with 5% horse serum in PBS, and incubated with the indicated Abs
or phalloidin. Coverslips were mounted in Mowiol 488 and imaged with a
LEICA TCS SP2 laser-scanning confocal system (Leica Microsystems)
using a plan apochromatic oil emerging 63 objective (NA 1.4). Figure
constructions of images were performed in COREL Photopaint. For quan-
tification of recruitment of proteins and F-actin at the contact zone or at the
uropod, line scans (1 m) were obtained. Fluorescence intensity was plot-
ted as function of distance along this line, and the integrated areas under the
curves representing the fluorescence intensity were calculated as ratio be-
tween the immunological synapse vs the uropod. Thirty conjugates were
analyzed per experiment. To assess TCR-induced clustering of LFA-1,
Jurkat T cells were incubated with biotinylated anti-UCHT-1 in the pres-
ence of streptavidin at 4°C. After washing, the cells were stimulated at
37°C for 30 min on poly(L-lysine)-coated slides, fixed with 3.5% PFA in
PBS, and then blocked with 5% horse serum in PBS. The cells were stained
5 The online version of this article contains supplemental material.
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with FITC-conjugated anti-MEM48 and imaged, as described above. For
each experiment, a minimum of at least 40 cells with LFA-1 polarized to
one side of the cell was regarded as polarized, whereas those cells showing
equal distribution of LFA-1 were considered not to be polarized. The per-
centage of polarized cells in each field was determined.
Results
Loss of SLP-76 impairs TCR-mediated activation of LFA-1 and
T cell-APC conjugation
By using a small peptide that disrupts the constitutive interaction
between SLP76 and Gads, we recently provided evidence that
formation of the LAT/Gads/SLP76 signaling platform at the
plasma membrane is required for TCR-mediated integrin activa-
tion (22). However, we formally could not exclude the possibility
that the functional effects exerted by the Gads-binding fragment
were not due to targeting the SLP76/Gads complex, but rather to
disruption of a distinct signaling pathway that regulates intergrin
activation in response to TCR stimulation. To assess this point
more specifically, we reduced the expression of SLP76 in primary
human T cells by RNAi. As shown in Fig. 1, A and B, SLP76
siRNA treatment lowered the expression levels of endogenous
SLP76 up to 80%, whereas the expression levels of ADAP,
SKAP55, and RIAM remained unaffected.
FIGURE 1. SLP76 is crucial for TCR-induced adhesion to ICAM-1 and conjugate formation. A, Purified human T cells were transfected with control
siRNA (siC) or the indicated concentrations of siRNAs against SLP76 (siSLP76). After 72 h, whole-cell extracts were analyzed by Western blotting with
the indicated Abs. B, In parallel, cells transfected with 50 nM siC or siSLP76 were analyzed by flow cytometry for the intracellular expression of SLP76,
ADAP, SKAP55, and RIAM (black line). The preimmune sheep serum and the anti-GST mAb were used as isotype controls (dashed line). C, Human T
cells transfected as described in A were left untreated or stimulated with anti-CD3 mAbs (TCR) for the indicated period of time. Lysates were analyzed
by Western blotting using the indicated Abs. Moreover, the same transfectants were cultured on plate-bound anti-CD3 mAbs (TCR) or in the presence of
PMA for 18 h, stained with anti-CD69 mAbs, and analyzed by flow cytometry. Data are representative of three individual experiments. Note that
the total expression of LAT, ZAP70, PLC1, or ERK1/2 was not affected (data not shown). D, Human T cells transfected as described above were
left untreated or stimulated with anti-CD3 mAb (TCR), PMA, or MnCl2 for 30 min, and subsequently analyzed for their ability to adhere to
Fc-ICAM-1. Suppression of SLP76 expression for each experiment was assessed by flow cytometry, and the percentage of SLP76-expressing cells
was calculated. Data represent the mean and SE of three independently performed experiments. E, In parallel, transfectants were analyzed for the
surface expression of CD18 or the TCR (black line), and control IgG were used as isotype controls (dashed line). One representative experiment
of three is shown. F, Equal numbers of the same cells as described in A were stained with CFSE and incubated for 30 min without SA (SA) or
with SA-pulsed (SA) DDAO-SE-labeled B cells. The percentage of conjugate formation was assessed by flow cytometry. Data represent the mean
and SE of three independently performed experiments. Representative histograms of SA-pulsed DDAO-SE B cells conjugated with CFSE-stained
T cells in the presence or absence of SLP76 are shown.
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Previously, it had been reported that SLP76 is required for
phosphorylation of PLC1, activation of ERK1/2, as well as for
expression of CD69 upon TCR stimulation. To first address
whether loss of SLP76 interferes with these SLP76-mediated
functions also in primary human T cells, we analyzed the ability
of SLP76-deficient human T cells to activate PLC1 and
ERK1/2 in response to TCR stimulation by Western blotting
and to up-regulate CD69 expression by flow cytometry. As
shown in Fig. 1C, loss of SLP76 strongly attenuated TCR-me-
diated phosphorylation of PLC1 at Y783, activation of
ERK1/2, and up-regulation of CD69. As expected, more prox-
imal signaling events such as the phosphorylation of ZAP70 at
Y319 or tyrosine phosphorylation of LAT (either global or at
Y171) were not affected in the absence of SLP76 (Fig. 1C). Note
that similar data were obtained, when we suppressed the expres-
sion of SLP76 by shRNA in Jurkat T cells (supplemental Fig. 2).
Thus, with regard to well-established SLP76-regulated signaling
processes, SLP76-deficient primary human T cells behave like
their corresponding Jurkat T cell counterparts (3).
Using the siRNA approach, we next analyzed the capability of
T cells to adhere to ICAM-1-coated dishes in response to various
stimuli. As shown in Fig. 1D and supplemental Fig. 3A, control
transfected human T cells and Jurkat T cells readily adhered to
ICAM-1 upon TCR or PMA treatment. In contrast, loss of SLP76
substantially attenuated both PMA- and TCR-induced adhesion to
ICAM-1 (left panel), whereas the cells showed no defect in their
adhesiveness in response to Mn2 (middle panel). The defect in
TCR- or PMA-induced adhesion to ICAM-1 was not due to an
altered expression of the 2 integrin (or the TCR) as determined by
flow cytometry (Fig. 1E and supplemental Fig. 3B).
Because the interaction of LFA-1 with ICAM-1 is important
for the establishment and maintenance of T cell/APC interac-
tions (5), we next analyzed whether SLP76 is required for con-
jugate formation between human T cells and SA-loaded B cells.
Fig. 1F shows that in contrast to control transfected T cells, loss
of SLP76 substantially blunted conjugate formation. Similarly,
SLP76low Jurkat T cells failed to interact with SA-loaded B
cells (supplemental Fig. 3C). Collectively, the experiments
shown in Fig. 1 indicate that SLP76 is mandatory for both TCR-
mediated adhesion to ICAM-1 and conjugate formation.
Loss of SLP76 attenuates TCR-mediated affinity/avidity
regulation of LFA-1
TCR-mediated inside-out signaling alters both LFA-1 affinity
(conformation) and avidity (clustering) (6). To determine the role
of SLP76 for LFA-1 affinity modulation, we assessed the ability of
soluble Fc-ICAM-1 to bind to SLP76-proficient and SLP76-defi-
cient T cells after TCR stimulation by means of flow cytometry.
Fig. 2A shows that knockdown of SLP76 in human T cells abro-
gates binding of soluble Fc-ICAM-1 after TCR stimulation (for
Jurkat T cells, please see supplemental Fig. 3D). In contrast, both
transfectants were able to bind similar amounts of Fc-ICAM-1
after treatment with Mg2/EDTA, which directly induces the high-
affinity conformation of LFA-1.
Next, we investigated avidity regulation of LFA-1 by analyz-
ing clustering of CD18 (the 2 chain of LFA-1) to the IS in
response to TCR stimulation. Fig. 2B shows that localization of
CD18 to the IS occurred readily in SLP76-expressing T cells
after incubation with SA-pulsed B cells, whereas it was se-
verely impaired in SLP76low T cells. In line with these data,
SLP76low Jurkat T cells also displayed no typical clustering of
CD18 upon cross-linking of the TCR (supplemental Fig. 3E).
Taken together, SLP76 is required for both affinity and avidity
regulation of LFA-1 after stimulation of the TCR.
TCR-mediated activation of Rac and actin dynamics require
SLP76
Reorganization of the actin cytoskeleton is required for TCR-me-
diated integrin activation and conjugate formation (33, 34), and the
small GTPase Rac is a major regulator regulating this process. In
T cells, activation of Rac is mediated via the nucleotide exchange
factor Vav1, which is recruited to and activated by SLP76 upon T
cell activation (32). Therefore, it seemed likely that loss of SLP76
also leads to alterations in actin dynamics upon TCR stimulation.
As depicted in Fig. 3, this is indeed the case. TCR-mediated ac-
tivation of Rac (Fig. 3A), formation of F-actin (Fig. 3B), as well as
accumulation of F-actin at the IS (Fig. 3C, upper right panel) are
severely impaired in SLP76-deficient T cells. Note that similar
data were obtained when the F-actin content after TCR triggering
was assessed in SLP76low Jurkat T cells (data not shown). Hence,
loss of SLP76 induces a failure to activate Rac and a defect in
F-actin remodeling upon TCR stimulation.
Because the scaffolding protein talin links newly synthesized
F-actin branches to LFA-1 and, hence, stabilizes the position of
LFA-1 in the IS (7, 47), we also investigated whether SLP76 is
required for targeting of talin to the IS after TCR stimulation.
FIGURE 2. TCR-induced affinity/avidity regulation of LFA-1 depends on
SLP76. A, Human T cells were transfected with either 50 nM control siRNA
(siC) or siRNAs against SLP76 (siSLP76). After 72 h, cells were analyzed for
their ability to bind soluble Fc-ICAM-1 in response to anti-CD3 mAb (TCR)
or Mg2/EDTA stimulation for 5 min. Suppression of SLP76 expression was
evaluated by flow cytometry. One representative experiment of three is shown.
B, Human T cells transfected as described in A were allowed to form conju-
gates with SA-pulsed B cells for 30 min. Fixed cells were stained for the 2
subunit of LFA-1 (green) to determine IS localization of LFA-1. Fluorescence
intensity of LFA-1 at the contact zone or the uropod was quantified and cal-
culated as ratio of intensity at the IS vs the uropod. Knockdown efficiency of
SLP76 expression was assessed by flow cytometry. Data present the average
of three independently performed experiments.
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Fig. 3C (lower right panel) shows that SLP76low T cells also
fail to target talin to the IS upon incubation with SA-pulsed B
cells. Thus, SLP76 appears to also regulate LFA-1-dependent
adhesion processes in activated T cells through its ability to
recruit talin to the IS.
Activation of Rap1 and localization of the SKAP55/RIAM
module to the IS depend on SLP76
Both the activation and the transport of Rap1 to the plasma mem-
brane are known to regulate LFA-1 activation (6, 17, 48). There-
fore, we next investigated whether loss of SLP76 affects TCR-
mediated activation of Rap1. Fig. 4A demonstrates that control
transfected cells exhibited strong activation of Rap1 within 2–10
min after TCR stimulation, whereas in SLP76low Jurkat T cells,
TCR-induced Rap1 was strongly suppressed. These results dem-
onstrate that SLP76 is critically involved in Rap1 activation in
response to TCR triggering.
We have recently shown that formation and membrane re-
cruitment of a signaling module consisting of the cytosolic
adapter proteins ADAP and SKAP55 and the Rap1 effector mol-
ecule RIAM (ADAP/SKAP55/RIAM module) regulate TCR-
mediated LFA-1 activation through recruitment of Rap1 to the
plasma membrane (17, 21). Moreover, an inducible association
between SLP76 and ADAP following TCR stimulation had
been suggested in several previous studies, but the question of
whether SLP76 links the TCR via the ADAP/SKAP55/RIAM
module to integrin activation has to date not been addressed
directly. To clarify this point, we immunoprecipitated SLP76
from resting or TCR-stimulated T cells and subsequently ana-
lyzed the precipitates for coprecipitation of ADAP, SKAP55,
RIAM, and Rap1 by means of Western blotting. Fig. 4B depicts
that SLP76 inducibly associates with both the ADAP/SKAP55/
RIAM complex and Rap1 upon TCR stimulation of Jurkat T
cells (Fig. 4B, left panel) as well as of primary T cells (Fig. 4B,
right panel). Analysis of SKAP55 immunoprecipitates that
were prepared from either SLP76-proficient or SLP76-deficient
T cells further revealed that Rap1 only associates with the
ADAP/SKPAP55//RIAM module if SLP76 is present (Fig. 4C).
Because only active Rap1 can interact with RIAM (12), this
finding is most likely due to the attenuated activation of Rap1
in the absence of SLP76 (see Fig. 4A).
The immunoprecipitation data shown in Fig. 4, B and C, were
further substantiated by cellular subfractionation experiments that
showed that TCR-mediated plasma membrane recruitment of
ADAP, SKAP55, RIAM, and Rap1 (Fig. 4D) and, consequently,
targeting of SKAP55, RIAM, and Rap1 to the IS (Fig. 4E) were
strongly impaired in SLP76low T cells. In summary, the data
shown in Fig. 4 indicate that SLP76 is required for both activation
and plasma membrane/IS targeting through the ADAP/SKAP55/
RIAM/Rap1 module of Rap1 after TCR triggering.
SLP76 is dispensable for CXCR4-mediated adhesion to ICAM-1
and affinity regulation of LFA-1
Similar to the TCR, triggering of the chemokine receptor CXCR4
leads to activation of LFA-1 and T cell adhesion to ICAM-1 (6).
Above we have shown that SLP76 is mandatory for TCR-mediated
integrin activation (Figs. 1 and 2). Therefore, we were interested to
investigate whether SLP76 is also required for CXCR4-mediated
adhesion. To assess this point, we down-regulated SLP76 expression
by siRNA and subsequently analyzed the capability of SLP76low T
cells to adhere to ICAM-1 in response to CXCL12 in an adhesion
assay. Surprisingly, these experiments revealed that SLP76low T cells
were as capable to adhere to Fc-ICAM-1 in response to CXCL12 as
their SLP76high counterparts (Fig. 5A). Similarly, neither the binding
of soluble Fc-ICAM-1 (Fig. 5B) nor of the conformation-sensitive
anti-LFA-1 mAb KIM127 (data not shown) was altered in SLP76low
T cells. Hence, we conclude that, in contrast to TCR stimulation, the
presence of SLP76 is dispensable for T cell adhesion and affinity
regulation in response to CXCL12 stimulation.
FIGURE 3. TCR-mediated actin remodeling, Rac activation, and recruit-
ment of talin to the IS require the presence of SLP76. A, Jurkat T cells were
transfected with either control vector (shC) or SLP76-suppression vector
(shSLP76). After 48 h, cells were either left untreated or stimulated with anti-
CD3 mAbs (TCR) for the indicated periods of time. GTP-loaded Rac was
precipitated using the GST-PBD fusion protein. Precipitates and aliquots of
whole-cell extracts were analyzed using the indicated Abs by means of West-
ern blotting. One representative experiment of two is shown. B, Purified hu-
man T cells were transfected with either control siRNA (siC) or siRNA against
SLP76 (siSLP76). After 72 h, cells were left untreated or stimulated with
anti-CD3 mAbs (TCR) for 5 min and stained with FITC-coupled phalloidin.
Reduction of SLP76 expression in human T cells was assessed by flow cy-
tometry. Data are representative of three individual experiments. C, Human T
cells transfected as described above were allowed to form conjugates with
SA-loaded B cells for 30 min. Cells were fixed, permeabilized, and stained
with TRITC-phalloidin (red) or talin (green). Fluorescence intensity of F-actin
and talin at IS or uropod was quantified and calculated as ratio of intensity for
the individual molecules at the IS vs the uropod. The knockdown efficiency of
SLP76 was evaluated by flow cytometry. Data present the average results of
three independent experiments.
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SLP76 is dispensable for CXCR4-mediated Rac activation, actin
dynamics, and migration
Similar to TCR stimulation, remodeling of the actin cytoskeleton
through Rac is crucial for inducing T cell adhesion, polarization,
and chemotaxis following CXCR4 stimulation (33). Our above
findings led us to ask whether the presence of SLP76 might be
dispensable for Rac activation in response to CXCL12 triggering.
As shown in Fig. 6A, SLP76low Jurkat T cells indeed display no
obvious defect in CXCL12-mediated activation of Rac. Moreover,
both SLP76high and SLP76low T cells revealed comparable levels
of F-actin formation in response to CXCL12 (Fig. 6B). These data
strongly suggest that SLP76 is indeed dispensable for signaling
events that are critically involved in CXCR4-mediated activation
of Rac and actin polymerization.
To prove whether expression of SLP76 is required for CXCR4-
induced T cell chemokinesis, we determined the lateral locomotion of
T cells by live cell imaging on Fc-ICAM-1-coated coverslips. As
shown in Fig. 6C, both SLP76high and SLP76low T cells showed com-
parable basal and CXCL12-induced velocities. In contrast, and in line
with previously published data (31), Vav1-deficient T cells displayed
FIGURE 4. The inducible interaction between ADAP and SLP-76 is mandatory for the recruitment of SKAP55, RIAM, and Rap1 to the plasma membrane.
A, Jurkat T cells were transfected with either control vector (shC) or SLP76-suppression vector (shSLP76). After 48 h, cells were either left untreated or stimulated
with anti-CD3 mAbs (TCR) for the indicated periods of time. GTP-loaded Rap1 was precipitated using the GST-RalGDS-RBD fusion protein. Precipitates and
aliquots of whole-cell extracts were analyzed with the indicated Abs by Western blotting. One representative experiment of three is shown. B, Jurkat T cells or
human T cells (hT-cells) were left untreated or stimulated with anti-CD3 mAbs (). Immunoprecipitations were performed using anti-SLP76 or preimmune sheep
serum (anti-PIS), and precipitates were analyzed by Western blotting with the indicated Abs. One representative experiment of two is shown. C, Jurkat T cells were
transfected as described in A. SKAP55 was immunoprecipitated from untreated or stimulated cells, and proteins interacting with SKAP55 were detected by Western
blotting using the indicated Abs. Data are representative for two individual experiments. D, Jurkat T cells were transfected as described in A, and plasma membrane
or cytosolic fractions were prepared from untreated () or TCR-stimulated cells (). The individual fractions were analyzed by Western blotting using the
indicated Abs. Fractionation efficiency was assessed by Western blotting using anti-LAT (plasma membrane) or anti-ERK1/2 (cytosol) Abs, respectively. One
representative experiment of two is shown. E, Human T cells transfected with control siRNA (siC) or siRNA against SLP76 (siSLP76) were allowed to form
conjugates with SA-loaded B cells for 30 min. Fixed and permeabilized cells were stained with mAbs to SKAP55, RIAM, or Rap1 (green) and TRITC-phalloidin
(red). Fluorescence intensity of SKAP55, RIAM, or Rap1 at IS or uropod was quantified and calculated as ratio of intensity for the individual protein at the IS vs the uropod.
Loss of SLP76 expression for each experiment was analyzed by flow cytometry. Data present the average results of three independently performed experiments.
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a strongly reduced motility upon CXCR4 triggering (Fig. 6C). It is
also important to note that nearly all SPL76low T cells displayed a
polarized phenotype upon chemokine stimulation, whereas the ma-
jority of Vav1-depleted T cells remained a round, nonpolarized shape
(Fig. 6C). Fig. 6D further demonstrates that the absence of SLP76
does not alter CXCR4-induced chemotaxis of human primary T cells
in response to a CXCL12 gradient in vitro. In summary, it appears as
if SLP76 is not mandatory for migratory steps triggered by CXCL12.
The ADAP/SKAP55/RIAM module is recruited to the plasma
membrane independently of SLP76
Upon T cell activation, the Gads/SLP76 complex is recruited to
phosphorylated LAT, thereby coupling the TCR to the intracellular
signaling machinery (2, 49). Given the above data, we next inves-
tigated whether the LAT/Gads/SLP76 signaling platform would be
assembled after CXCR4 stimulation. To test this, we stimulated hu-
man T cells for various periods of time with CXCL12 and subse-
quently analyzed global tyrosine phosphorylation of LAT by Western
blotting. In contrast to TCR stimulation, phosphorylation of LAT was
only very weakly induced upon CXCR4 triggering (Fig. 7A). Similar
results were obtained when the phosphorylation status of LAT at Y171
(which is important for Gads binding) was assessed (Fig. 7A). These
data suggested that the Gads/SLP76 complex might not associate with
LAT following CXCR4 triggering. To investigate this point in more
detail, we immunoprecipitated the Gads/SLP76 complex from un-
treated, TCR-stimulated, or CXCR4-triggered T cells. Fig. 7B shows
that an inducible interaction among Gads/SLP76, LAT, and Vav1 was
readily detectable after TCR stimulation. In contrast, neither LAT nor
Vav1 was found to be associated with the Gads/SLP76 complex in
FIGURE 5. SLP76 is dispensable for CXCL12-mediated adhesion to
ICAM-1, affinity maturation of LFA-1. A, Human T cells were trans-
fected with control siRNA (siC) or siRNAs against SLP76 (siSLP76).
Cells were left untreated or stimulated with immobilized CXCL12 (10
min) or anti-CD3 mAbs (TCR) for 30 min. Subsequently, cells were
analyzed for their ability to adhere to Fc-ICAM-1. Suppression of
SLP76 expression was assessed by flow cytometry, and the percentage
of SLP76-expressing cells was calculated. Data represent the mean and
SE of three independently performed experiments. B, Human T cells
transfected as described in A were analyzed for their ability to bind
soluble Fc-ICAM-1 upon anti-CD3 (TCR), CXCL12, or Mg2/EGTA
(positive control) treatment for 5 min. Suppression of SLP76 expression
was evaluated by flow cytometry. One individual experiment of three is
shown.
FIGURE 6. The presence of SLP76 is not required for Rac activation, actin polymerization, motility, and chemotaxis in response to CXCL12. A, Jurkat
T cells were transfected with either control vector (shC) or SLP76-suppression vector (shSLP76). After 48 h, cells were either left untreated, or stimulated
with CXCL12 or anti-CD3 mAbs (TCR) for the indicated time points. Activated Rac was precipitated using the GST-PBD fusion protein. Precipitates and
aliquots of whole-cell extracts were analyzed by Western blotting using the indicated Abs. One representative experiment of three is shown. B, Human T
cells were transfected with control siRNA (siC) or siRNA against SLP76 (siSLP76). After 72 h, cells were left untreated, stimulated with anti-CD3 mAbs
(TCR, for 5 min) or CXCL12 for 1 min, and stained with FITC-coupled phalloidin. Reduction of SLP76 expression in human T cells was assessed by flow
cytometry. Data are representative of three independent experiments. C, Human T cells were transfected with control siRNA (siC), siRNA against SLP76
(siSLP76), or siRNA against Vav1 (siVav1). After 72 h, motility of T cells in the absence or presence of CXCL12 was determined on Fc-ICAM-1-coated
coverslips, as described in Materials and Methods. In parallel, transfectants were stimulated on Fc-ICAM-1-coated coverslips with CXCL12 for 30 min.
Cells were fixed, permeabilized, and stained with TRITC-phalloidin. Whole-cell extracts were analyzed by Western blotting for the expression of SLP76,
Vav1, and -actin. One individual experiment of three is shown. D, Chemotaxis of human T cells transfected as described in A was addressed using a
Transwell assay, as described in Materials and Methods. After 2 h, the number of migrated cells into the lower chamber was counted. Suppression of SLP76
expression was assessed by flow cytometry, and the percentage of SLP76-expressing cells was calculated. Data represent the mean and SE of three
independently performed experiments.
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response to CXCL12 stimulation (Fig. 7B). These experiments indi-
cate that the LAT/Gads/SLP76 signaling platform is not assembled in
response to CXCL12 in T cells.
Above we have shown that the ADAP/SKAP55/RIAM module
inducibly interacts with SLP76 upon TCR-mediated T cell activa-
tion, and that SLP76 is mandatory for membrane targeting of the
ADAP/SKAP55/RIAM module and for activation of Rap1 (Fig.
4). In marked contrast, CXCL12 stimulation of T cells did not lead
to an inducible interaction between the LAT/Gads/SLP76 complex
and the ADAP/SKAP55/RIAM module (Fig. 7B). However, the
ADAP/SKAP55/RIAM module (and also Rap1) was properly re-
cruited to the plasma membrane in response to CXCR4 stimulation
in both SLP76-proficient and -deficient T cells (Fig. 7, C and D).
Moreover, SLP76low Jurkat T cells displayed no obvious defect in
CXCL12-mediated activation of Rap1 (Fig. 7E). These data sug-
gest that SLP76 is not required for CXCR4-mediated Rap1 acti-
vation and plasma membrane targeting of ADAP, SKAP55,
RIAM, and Rap1.
To exclude the possibility that ADAP and SKAP55 them-
selves are dispensable for CXCR4-regulated adhesion and mi-
gration, we down-regulated ADAP expression in human T cells
by siRNA and subsequently assessed both the adhesiveness and
migratory capacity of these cells in response to CXCL12. Fig.
7F shows that loss of ADAP strongly attenuated CXCR4-in-
duced adhesion and chemotaxis in human T cells. Similar data
were obtained when we assessed CXCR4-induced migration of
ADAPlow Jurkat T cells or of T cells obtained from ADAP-
deficient mice (data not shown). In summary, our data show that
in contrast to TCR stimulation, SLP76 is not involved in mem-
brane recruitment of the ADAP/SKAP55/RIAM module, the
activation of Rac or Rap1, and the induction of adhesion or
migration in response to CXCR4 stimulation.
Discussion
Together with the transmembrane adapter protein LAT, the cyto-
solic adapter protein SLP76 facilitates the formation of a signaling
platform (LAT/Gads/SLP76) following TCR stimulation that leads to
the activation of multiple intracellular signaling pathways (49). Our
previous data suggested that the signaling pathways controlled by the
Gads/SLP76 complex also include those regulating adhesion pro-
cesses (22). In this study, we confirm this hypothesis by showing that
suppression of SLP76 expression by RNAi in human T cells or the
FIGURE 7. The SLP76/Gads complex is not associated with LAT or transported to the plasma membrane upon CXC12 stimulation. A, Human T cells were
either left untreated, or stimulated with anti-CD3 mAbs (TCR) or CXCL12 for the indicated periods of time. Lysates were analyzed by Western blotting using
the indicated Abs. B, The cell extracts as described in A were used for immunoprecipitation using anti-Gads Ab. Precipitates were analyzed by Western blotting
using the indicated Abs. C, Plasma membrane or cytosolic fractions were prepared from untreated () or CXCR4-stimulated human T cells (). The individual
fractions were analyzed by Western blotting using the indicated Abs. Fractionation efficiency was assessed by Western blotting using anti-LAT (plasma membrane)
or anti-ERK1/2 (cytosol) Abs, respectively. One representative experiment of two is shown. D, Jurkat T cells were transfected with either control vector (shC) or
SLP76-suppression vector (shSLP76). After 48 h, plasma membrane or cytosolic fractions were prepared from untreated () or CXCR4-stimulated cells (). The
individual fractions were analyzed by Western blotting using the indicated Abs. Fractionation efficiency was assessed by Western blotting using anti-LAT (plasma
membrane) or anti-ERK1/2 (cytosol) Abs, respectively. One representative experiment of two is shown. E, Jurkat T cells were transfected with either control vector
(shC) or SLP76-suppression vector (shSLP76). After 48 h, cells were either left untreated, or stimulated with CXCL12 or anti-CD3 mAbs (TCR) for the indicated
time points. GTP-loaded Rap1 was precipitated using the GST-RalGDS-RBD fusion protein. Precipitates and aliquots of whole-cell extracts were analyzed by
Western blotting using the indicated Abs. One representative experiment of three is shown. F, Human T cells were transfected with control siRNA (siC) or siRNA
against ADAP (siADAP). After 72 h, transfectants were left untreated or stimulated with CXCL12 (for 10 min) or MnCl2 (for 30 min) and subsequently analyzed
for their ability to adhere to Fc-ICAM-1. Chemotaxis of the same cells was analyzed using a Transwell assay, as described in Materials and Methods. After 2 h,
the number of migrated cells into the lower chamber was determined. Suppression of ADAP and SKAP55 expression was determined by flow cytometry, and the
percentage of ADAP/SKAP55-expressing cells was calculated. Note that loss of ADAP abrogates SKAP55 expression (17). Data represent the mean and SE of
three independently performed experiments.
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Jurkat T cell line abrogates TCR-mediated conjugate formation, ad-
hesion to ICAM-1, and affinity/avidity maturation of LFA-1. Consis-
tent with previously published data (50, 51), we also found that loss
of SLP76 attenuates adhesion to fibronectin (the ligand of 1 inte-
grins; VLA-4) in response to TCR stimulation (J. Horn and S. Kliche,
unpublished data). Thus, SLP76 regulates TCR-induced inside-out
signaling, leading to the activation of 1 and 2 integrins.
Reorganization of the actin cytoskeleton is critically involved in
TCR-mediated integrin activation (33, 34). Moreover, it has previ-
ously been demonstrated that overexpression of SLP76 enhances F-
actin formation in response to TCR stimulation (52). In addition to
these overexpression data, we show in this study that loss of SLP76
attenuates TCR-mediated polymerization of F-actin. Together these
findings suggest that SLP76 is one of the (if not the) central molecule
that links the TCR to remodeling of the actin cytoskeleton.
The defect in actin dynamics most likely results from an ab-
rogated activation of the small GTPase Rac. Activation of Rac
depends on membrane recruitment and activation of the GEF
Vav1 and the Tec kinase Itk (20, 32). Both Vav1 and Itk asso-
ciate with SLP76 upon TCR stimulation, and both molecules
are required for F-actin formation at the IS, activation of Rac,
clustering of LFA-1, adhesion to ICAM-1, and conjugate for-
mation (20, 32). In this scenario, the role of Vav1 is to generate
sufficient pools of activated Rac to promote F-actin polymer-
ization through activation of proteins of the Wiskott-Aldrich
syndrome protein/Wiskott-Aldrich syndrome-Verprolin-homo-
logues protein family (33, 34). Our data showing attenuated
actin reorganization in SLP76low cells are in line with a model
in which loss of SLP76 blocks activation of Rac (and conse-
quently signaling events downstream of Rac) by impairing the
functions of Vav1 and Itk.
We are, however, aware that another group recently reported
that TCR-mediated actin remodeling is not attenuated in the
SLP76-deficient Jurkat T cell line J14 (53). In addition, no de-
fect in Rac activation upon TCR stimulation was observed in
this Jurkat variant (54). The reasons for these discrepant find-
ings in SLP76-deficient Jurkat T cells vs SLP76low human T
cells are unclear at present. A possible explanation may come
from compensatory mechanisms that developed in line J14 to
escape the selection pressure that cannot develop in short-term
manipulated T cells.
Besides the reorganization of the actin cytoskeleton, one critical
regulator of TCR-mediated conjugate formation and inside-out sig-
naling is the small GTPase Rap1 (6). Several studies have reported
that Rap1 activation critically depends on the expression of PLC1
(13, 26, 55). PLC1 signaling to Rap1 occurs via the nucleotide ex-
change factor calcium and diacylglycerol-regulated guanine nucleo-
tide exchange factor I that is activated by the second messengers cal-
cium and diacylglycerol (which both are generated following
phosphatidylinositol 4,5-bisphosphate hydrolysis by PLC1). Thus, a
defect in PLC1 activation in SLP76-suppressed T cells (see Fig. 1C
and supplemental Fig. 2, C and D) and consequently a failure to ac-
tivate CalDAG-GEFI might be largely responsible for the attenuated
activation of Rap1 after TCR triggering in the absence of SLP76.
However, additional mechanisms controlled by SLP76 may also con-
tribute to the block in Rap1 activation. For example, SLP76 is man-
datory for activation and membrane targeting of protein kinase C,
which has recently been identified to control TCR-induced Rap1 ac-
tivity by phosphorylation of Rap1-GEF2 (56, 57). Hence, loss of
SLP76 might affect several signaling pathways that are critical for
TCR-induced activation of Rap1.
We had previously shown that the ADAP/SKAP55/RIAM com-
plex is required for plasma membrane targeting of Rap1. More-
over, we had demonstrated that this event is crucial for inside-out
signaling and for the activation of integrins in response to TCR
stimulation. However, loss of ADAP and/or SKAP55 selectively
abrogated plasma membrane recruitment of Rap1, although TCR-
mediated activation of Rap1 was not affected (17, 21). In contrast,
the data presented in this study show that SLP76 is mandatory for
both membrane targeting and activation of Rap1 after TCR trig-
gering. The former event most likely involves the ADAP/SKAP55/
RIAM module, whereas the activation of Rap1 might be regulated
through the PLC1- or the protein kinase C-signaling pathways
that were discussed above. Hence, our data support a model in
which plasma membrane targeting and activation of Rap1 are two
interrelated, but distinctly controlled signaling events that are or-
ganized at the level of SLP76.
The activation of Rap1 and Rac as well as changes in F-actin
dynamics are also mandatory for affinity modulation of LFA-1,
T cell adhesion, and migration in response to CXCR4 stimula-
tion (6, 58). Given the central role of SLP76 in TCR-mediated
signaling, it was totally unexpected for us to find that loss of
SLP76 did not affect these events after CXCR4 stimulation and
that the SLP76/Gads complex was not recruited to LAT in re-
sponse to CXCR4 stimulation. The latter observation is proba-
bly due to the fact that the tyrosine residue within LAT that is
responsible for recruiting the Gads/SLP76 complex (Y171) is
not phosphorylated in response to CXCL12 triggering.
Our data also showed that SLP76 is not involved in the recruitment
(and consequently the activation) of downstream effector molecules
(e.g., Vav1) that are important for mediating adhesion and migration
processes of T cells in response to CXCL12 triggering (58). Indeed,
whereas Vav1-deficient T cells failed to polarize in response to
CXCL12 stimulation, SLP76low T cells showed no defect in this pro-
cess. Moreover, CXCL12-induced lateral migration velocity and che-
motaxis were unaffected in SLP76low T cells. Hence, it appears as if
SLP76 is dispensable for both adhesive and migratory processes in
response to CXCL12 stimulation.
In line with the functional data, we found that membrane re-
cruitment of the ADAP/SKAP55/RIAM module that is critical for
CXCR4-mediated adhesion and migration of T cells was not af-
fected by loss of SLP76. Although this finding strongly supports
our above discussed hypothesis that membrane targeting of Rap1
and activation of this GTPase are distinct processes that are indi-
vidually regulated by different signaling receptors, it opens the
question as to which signaling molecule provides the molecular
link between CXCR4 and the ADAP/SKAP55/RIAM module.
In this regard, it has recently been shown that the cytosolic
adapter protein Shc is phosphorylated upon CXCR4 stimula-
tion and assembles into a complex that includes Lck, ZAP70,
Vav1, and LAT (59). Moreover, Shc-deficient Jurkat T cells
show an attenuated migratory capacity and impaired F-actin
dynamics upon CXCR4 stimulation, and mutation of critical
tyrosine residues of Shc (YY238/240 or Y317) results in defective
phosphorylation of Vav1 and Itk (59). Thus, Shc might be an
attractive candidate to connect CXCR4 with the Vav1-Itk-de-
pendent pathway of F-actin polymerization and T cell migration
(59). It will be important to assess the role of Shc in CXCR4-
induced inside-out signaling, adhesion, and Rap1 activation in
future studies. Similarly, it needs to be analyzed whether, and if
so how, LAT is involved in this process. Experiments are cur-
rently set up in our laboratory to assess these points. Neverthe-
less, our data collectively and surprisingly indicate that, in con-
trast to TCR signaling, SLP76 is not a key component
connecting the chemokine receptor CXCR4 with the activation
of integrins and the induction of T cell adhesion and migration.
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Current models of T cell activation focus on the kinetics of TCR-ligand interactions as the central parameter governing T cell
responsiveness. However, these kinetic parameters do not adequately predict all T cell behavior, particularly the response to
antagonist ligands. Recent studies have demonstrated that TCR number is a critical parameter influencing the responses of CD4
T cells to weak agonist ligands, and receptor density represents an important means of regulating tissue responsiveness in other
receptor ligand systems. To systematically address the impact of TCR expression on CD8 T cell responses, mAbs to the TCR
-chain and T cells expressing two TCR species were used as two different methods to manipulate the number of available TCRs
on P14 and OT-I transgenic T cells. Both methods of TCR reduction demonstrated that the efficacy of antagonist peptides was
significantly reduced on T cells bearing low numbers of available receptors. In addition, the ability of weak agonists to induce
proliferation was critically dependent on the availability of high numbers of TCRs. Therefore, in this report we show that TCR
density is a major determinant of CD8 T cell reactivity to weak agonist and antagonist ligands but not agonist ligands. The
Journal of Immunology, 2008, 181: 1760–1766.
H istorically, the activation of T lymphocytes through theTCR has been considered remarkably Ag specific. How-ever, more recent studies have identified variants of im-
munogenic peptides capable of dissociating the proliferative and
effector functions of Ag-specific T cells (1–3). These observations
have provided the rationale for a number of studies investigating
the ability of peptides containing amino acid substitutions at TCR
contact residues to mediate T cell activation. Such analog peptides,
termed altered peptide ligands, can be categorized as agonists,
weak agonists, or partial agonists according to their ability to stim-
ulate various hierarchical T cell responses (3). In addition, antag-
onist ligands, which induce no measurable effector responses on
their own, markedly inhibit T cell activation when presented con-
comitantly with agonist peptide (4).
Several reports have correlated peptide affinity for the TCR
and/or MHC with ligand potency (5–7). As a result, current models
have focused on the kinetics of TCR:ligand interactions as the
pivotal factor in T cell activation, as well as the role of endogenous
peptide:MHC (pMHC)3 in potentiating T cell activation (8, 9).
However, the relative contribution of TCR density to T cell re-
sponsiveness has received little attention (10–14), although recep-
tor density represents an important mechanism regulating the sen-
sitivity and rapidity of responses in other receptor-ligand systems.
Although T cells typically express tens of thousands TCRs, T cell
responses to agonist pMHC complexes require remarkably few
TCR molecules (15, 16). These results draw into question the role
of these excess Ag receptors. Our work has demonstrated that the
ability of CD4 T cells to respond to weak ligands is critically
dependent on high TCR expression (17, 18). Specifically, CD4 T
cells with as few as 1500 available TCRs were capable of respond-
ing to agonist peptides, whereas measurable responses to several
weak agonists required dramatically more TCRs (20,000) (17).
These data provided evidence supporting a spare receptor theory of
T cell activation. According to the spare receptor theory, agonist
ligands achieve maximal responses by engaging only a fraction of
available receptors while the excess receptors, termed “receptor
reserve”, are required for the induction of responses by less potent
ligands (19). The excess receptors provide a means for generating
responses to ligands encompassing a range of affinities and poten-
cies. In this study, we investigated the impact of TCR density on
the recognition of ligands of varying potency by CD8 T cells. We
demonstrate that the activation of CD8 T cells by weak agonist,
but not agonist peptides, requires the existence of a receptor re-
serve. One challenge to any model of T cell activation is to de-
scribe the action of antagonist pMHC complexes. As such, we
investigated whether the spare receptor theory of T cell activation
accurately describes the interactions of TCR molecules with an-
tagonist ligands. Our results demonstrate that high TCR density is
required for effective T cell antagonism, indicating that TCR-me-
diated responses function according to a spare receptor model.
Materials and Methods
Mice
OT-I transgenic mice (20) and P14 transgenic mice (21) were purchased
from The Jackson Laboratory. OT-I (V2V5) and P14 (V2V8) TCRs
were visualized with PE-conjugated mAbs to V5 (BD Pharmingen) and
V8 (BD Pharmingen), respectively (21, 22). OT-I and P14 mice were
bred to generate P14  OT-I dual transgenic mice bearing T cells express-
ing both TCRs. All mice were maintained according to federal guidelines
by the Emory University Department of Animal Resources (Atlanta, GA).
Cell culture and reagents
Cell culture medium consisted of RPMI medium 1640 (Mediatech) sup-
plemented with 10% FBS (Mediatech), 2 mM L-glutamine, 0.01 M HEPES
buffer, 100 g/ml gentamicin (Mediatech), and 2  105 M 2-ME (Sigma-
Aldrich). All peptides were synthesized using Fmoc chemistry on a Sym-
phony/Multiplex Peptide synthesizer (Rainin), purified by HPLC (purity 
90%) and analyzed by mass spectrometry at the Emory University Depart-
ment of Chemistry Core Facility (Atlanta, GA). The OT-I agonist
OVA257–264 (SIINFEKL) and antagonist E1 (EIINFEKL), as well as the
P14 agonist lymphocytic choriomeningitis virus (LCMV) gp33–41
(KAVYNFATM), antagonist 36S (KAVSNFATM), and weak agonist rat
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dopamine -mono-oxygenase (rDBM) (KALYNYAPI) have all been pre-
viously described (23–25). The mAbs used included PerCP-conjugated anti-
CD8 (BD Pharmingen), PE-conjugated anti-V5 (clone MR9-4) (Pharm-
ingen), PE-conjugated V8 (clone F23.1) (BD Pharmingen), biotinylated
and PE-conjugated anti-V2 (clone B20.1) (BD Pharmingen), and PE-
conjugated anti-IFN- (clone XMG1.2) (BD Pharmingen). LCMV gp33–
41:Db and OVA257–264:Kb monomers were assembled at the Emory Uni-
versity Tetramer Core Facility (Atlanta, GA) and multimerized with PE- or
allophycocyanin-conjugated streptavidin (Molecular Probes).
T cell proliferation assays
Proliferation of Ag-specific T cells was assessed by [3H]thymidine incor-
poration (26). Briefly, transgenic splenocytes were incubated with varying
concentrations of agonist peptides in HBSS for 2 h at 37°C. The cells were
then washed to remove free peptide, and the splenocytes were cultured at
3  105 cells/well in a flat-bottom, 96-well plate. For antagonism assays,
various concentrations of antagonist peptides were added to the appropriate
wells. After 48 h, the cells were pulsed with 0.4 Ci of [3H]thymidine for
18–24 h, at which time the cells were harvested and the cpm were counted
on a Matrix 96 direct -counter (Packard Instruments).
Intracellular cytokine production
Transgenic splenocytes were incubated with various peptides in HBSS for
2 h at 37°C, washed, resuspended in complete medium, and cultured in a
FIGURE 1. mAbs to V2 provide a range of densities of available
TCRs and effectively inhibit TCR:pMHC interaction. A, To establish the
relationship between Ab concentration and available TCR density, the
number of unbound TCRs on P14 or OT-I T cells at each corresponding Ab
concentration was determined by quantitative flow cytometry. -V2, An-
ti-V2. B, The concentrations of Abs used resulted in a range of TCR
densities, representing 5–100% of original levels. The data indicated that
the anti-V2 Abs were effective at masking both P14 (f) and OT-I (E)
TCRs. C, P14 and OT-I T cells that had been incubated with various con-
centrations of anti-V2 mAbs were stained with gp33–41:Db and SIIN
FEKL:Kb MHC tetramers, respectively. Results demonstrated an inverse
correlation between Ab concentration and tetramer binding, indicating that
anti-V2 mAbs effectively mask the pMHC binding site of the TCR.
FIGURE 2. mAbs to V2 inhibited the function of P14 weak agonist
and antagonist ligands but not agonist ligands. Naive P14 splenocytes were
stimulated with the indicated concentrations of gp33–41 in the presence of
anti-V2 mAbs. A, mAb treatment has no effect on agonist stimulation of
proliferation. B, The stimulatory capacity of the weak agonist, rDBM was
decreased by the addition of anti-V2 mAbs. C, The ability of the antag-
onist peptide (36S) to inhibit proliferation induced by stimulation with
agonist (1 nM gp33–41) was decreased in the presence of increasing con-
centrations of anti-V2 mAbs.
FIGURE 3. mAbs to V2 inhibited the function of an OT-I antagonist
but not that of the agonist ligand. A, Treatment with anti-V2 mAbs had no
effect on the agonist-induced stimulation of OT-I T cells as measured by
the proliferation of naive OT-I splenocytes in response to the indicated
concentrations of OVA257–264. B, The addition of anti-V2 mAbs de-
creased the effectiveness of the antagonist E1 at inhibiting agonist-induced
(1 nM OVA257–264) proliferation.
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24-well plate (3  106 cells/well) with 50 U/ml IL-2 (26). At day 4, the live
cells were collected by centrifugation over a Ficoll gradient (Mediatech).
EL-4 thymoma cells were incubated with various peptides in HBSS for 2 h
at 37°C, washed, resuspended in cell culture medium, and transferred to
flat-bottom, 96-well plates (2  105 cells/well). For antagonist assays, the
EL-4 APCs were incubated with continuous antagonist peptides before the
addition of T cells. T cells (2  105 cells/well) were added to each exper-
imental well with 50U/ml IL-2 and incubated for 6 h at 37°C. The cells
were then transferred to round-bottom, 96-well plates, fixed, and perme-
abilized (Caltag Laboratories). IFN- production was detected intracellu-
larly with PE-conjugated monoclonal rat anti-mouse IFN- Abs (BD
Pharmingen). In these experiments, CD8 was visualized with PerCP-con-
jugated monoclonal rat anti-mouse CD8 Abs (BD Pharmingen).
Determination of TCR level and tetramer staining
Quantitative analyses of TCR expression were achieved using Quantum
R-PE microbeads with 500–50,000 molecules of equivalent soluble fluo-
rochrome (MESF) (Bangs Laboratories) and PE-conjugated anti-V2 (27).
For tetramer staining, cells were incubated for 30 min on ice with 1 g of
tetramer per 1  106 cells. For Ab blockade of tetramer binding, cells were
preincubated with indicated concentrations of Abs for 1 h at 37°C and then
stained with tetramer as described. Flow cytometric data was collected on
a BD FACSCalibur (BD Biosciences) and analyzed using FlowJo software
(Tree Star).
Results
Manipulation of TCR density and effective blockade of the
pMHC binding site using mAbs to the TCR -chain
As an initial step in our investigation of the relationship between TCR
density and T cell responsiveness, the number of available TCRs in
the presence of various concentrations of mAbs to the TCR -chain
was determined by quantitative flow cytometry (Fig. 1) (27). P14 or
OT-I transgenic splenocytes were incubated with 2-fold dilutions of
anti-V2 (0.06–15 g/ml) (Fig. 1A). The unoccupied TCRs were
then visualized with R-PE-conjugated anti-V2 mAbs and quanti-
tated using Quantum R-PE microbeads. Quantitative analyses verified
that the doses of Abs chosen resulted in a range of TCR densities (Fig.
1B). To determine whether Abs to the TCR -chain successfully
inhibited the TCR:pMHC interaction, P14 and OT-I T cells were
incubated with gp33–41:Db and SIINFEKL/Kb tetramers, respec-
tively, in the presence of anti-V2 Abs. Importantly, anti-V2 Abs
FIGURE 4. Antagonist peptide efficacy correlated with TCR density at
all doses of antagonist ligand. The number of TCRs available at each dose
of anti-V2 mAb was plotted against the corresponding observed percent-
age inhibition of agonist-induced proliferation. Regression analysis was
conducted to determine the degree of correlation between TCR density and
antagonist efficacy (solid lines). Antagonism assays conducted in the pres-
ence of neutralizing Abs to V2 revealed that the ability of both P14 (A)
and OT-I (B) TCR antagonist to inhibit T cell activation correlated with
TCR density (r2  0.9–1.0). In addition, at a given TCR density the in-
hibition of both P14 (A) and OT-I (B) T cell proliferation was more effec-
tive at higher doses of antagonist peptide.
FIGURE 5. Anti-V2 Ab does not activate OT-I
cells. A, OT-I splenocytes were stimulated for 48 h with
5 g/ml anti-V2 Ab. Cells were stained for CD8, V2,
CD25, and CD44. Histograms were gated on CD8
cells. The shaded histogram represents Ab-treated cells
and the open histogram represents untreated cells. No
significant difference in CD25 or CD44 up-regulation
was detectable. B, Proliferation induced by the anti-V2
Ab was assessed by culturing cells for 48 h with the
indicated concentration of Ab. [3H]Thymidine was
added and cells were cultured for an additional 18 h.
Differences in proliferation were not statistically
significant.
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inhibited tetramer staining in a dose-dependent manner, demon-
strating that treatment of T cells with these Abs effectively masks
the pMHC binding site of the TCR (98% inhibition; Fig. 1C). In
addition, the minimal expression of TCR required for tetramer
staining of these two T cell lines was identified. These data indi-
cated that OT-I requires fewer TCR (1825), as compared with
the P14 T cell, which required 4000–7000 TCR for detectable
tetramer staining. Thus, inhibition of tetramer binding using anti-
V2 Abs demonstrated the effectiveness of Ab treatment for de-
creasing TCR density. These data also indicated differences in af-
finity of TCR for ligand, with the affinity of OT-I TCR for ligand
being greater than that of P14 TCR.
TCR expression level is a critical parameter governing T cell
responsiveness to suboptimal ligands
To assess whether agonist and weak agonist peptides exhibit differ-
ential requirements for TCR density, proliferation assays were con-
ducted in the presence of various concentrations of mAbs to V2
(Fig. 2). P14 T cells were stimulated with either the agonist peptide
gp33–41 (Fig. 2A) or the weak agonist peptide rDBM (Fig. 2B) in the
presence of the indicated concentrations of anti-V2 Abs, resulting in
a wide range of available TCR densities. Although the presence of
high concentrations of anti-V2 reduced the number of available
TCRs by 95%, this reduction in TCR density had little effect on
agonist-induced proliferation of P14 T cells (Fig. 2A). In contrast,
proliferation induced by the weak agonist rDBM was dramatically
inhibited at low densities of available TCRs (Fig. 2B). Of note, bio-
tinylated and R-PE-conjugated Abs proved the most effective at in-
hibiting T cell responses and tetramer staining, respectively, indicat-
ing a role for steric hindrance in their ability to inhibit pMHC binding.
We have previously demonstrated that higher concentrations of this
Ab (50 g/ml) completely abrogate the ability of both P14 and OT-I
T cells to bind to agonist pMHC (28). However, the concentrations
used in our experiments are sufficient to alter the functional response
to weak ligands.
Next, we used anti-V2 Abs to assess the role of TCR density
in determining antagonist peptide efficacy. The impact of mAbs to
V2 on the ability of 36S to antagonize the ex vivo proliferation
of P14 T cells following stimulation with gp33–41 is shown in
Fig. 2C. Decreasing the number of TCRs available for productive
interactions with pMHC ligands drastically reduced the ability of
36S to inhibit agonist-induced proliferation of P14 T cells. The
addition of 4.7 g/ml anti-V2 resulted in the complete abrogation
of TCR antagonism (Fig. 2C). Importantly, this observation was
not unique to the P14 TCR, as similar results were obtained using
OT-I (V2V5) T cells (Fig. 3, A and B). The presence of 15
g/ml anti-V2 resulted in the absolute loss of antagonist peptide
function while maintaining the response of OT-I T cells to the
FIGURE 6. P14  OT-I T cells expressed lower
V8 relative to cells from parental single transgenics,
but V5 levels were maintained at near parental levels.
A, Levels of V5 expression on P14  OT-I T cells
(solid line) was similar to those on cells from OT-I mice
(dotted line). P14 cells were included as a negative con-
trol (shaded). B, V8 expression is decreased on dual
receptor cells (solid line) relative to P14 single trans-
genic cells (dotted line). OT-I cells were included as a
negative control (shaded). C, P14 (left panel) and dual
TCR cells (right panel) exhibited similar proliferative
responses to agonist stimulation (), but responses to
the weak agonist rDBM (Œ) were abrogated in the
P14  OT-I cells.
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agonist peptide OVA257–264 (Fig. 3, B and A, respectively). In
conjunction with the results in Fig. 1, these data highlight the dis-
parate requirements for TCR density exhibited by agonist and an-
tagonist ligands. Specifically, the efficacy of antagonist ligands for
both the P14 and OT-I TCRs was negatively impacted by a 60%
reduction in TCR density, whereas the agonist-induced responses
remained intact with 5% of the TCRs remaining. Thus, reducing
the number of available TCRs selectively inhibits the function of
suboptimal ligands while leaving agonist-induced responses intact.
These results also indicate that antagonist ligands make use of the
receptor reserve to inhibit T cell activation.
The correlation between antagonist peptide efficacy and TCR
density is clearly illustrated in Fig. 4. Although the degree of max-
imal inhibition was dependent on the dose of the antagonist, the
ability of both 36S and E1 to inhibit agonist-induced responses
strongly correlated (r2  0.9–1.0) with the number of available
TCRs at all doses (Fig. 4, A and B, respectively). Strikingly, a
precipitous decline in antagonist efficacy was observed at TCR
densities below 5000 TCR/cell at all concentrations of antago-
nist peptide tested (Fig. 4, A and B).
Anti-V2 Ab does not activate OT-I or P14 T cells
We verified that the clone of the anti-V2 Ab used in these studies
(B20.1) was nonstimulatory by treating P14 or OT-I T cells with
up to 15 g/ml Ab. This concentration of Ab did not result in
up-regulation of CD25 or CD44 (Fig. 5A) proliferation (Fig. 5B) or
cytokine production (data not shown). Thus, we conclude that any
potential activating properties of this Ab would not be detectable
in our readouts of proliferation and cytokine production.
Differential expression of V5 and V8 on T cells isolated from
P14  OT-I dual transgenic mice results in limited responsiveness
Another means of reducing TCR expression is through the gener-
ation of T cells expressing two TCRs. This can be accomplished
through the breeding of two TCR transgenic mice to yield mice
bearing T cells that express both TCRs. As a result of the finite
number of TCRs that can be expressed on the T cell surface, both
TCRs cannot be present at parental levels. In this study, P14 TCR
transgenic mice were bred to OT-I TCR transgenic mice to gen-
erate F1 progeny bearing dual receptor T cells (Fig. 6). Flow cy-
tometric analyses indicated that while CD8 T cells from P14 
OT-I F1 mice expressed nearly equivalent levels of V5 as those
isolated from parental OT-I mice, the V8 TCR was expressed at
15% of parental P14 levels (Fig. 6, A, and B, respectively). This
data revealed that the OT-I and P14 receptors represented 85%
and 15% of the TCRs at the cell surface, respectively (Fig. 6).
Tetramer staining of the OT-I TCR was similar to that of the single
transgenic. However, tetramer staining of the P14 receptor was
undetectable, which is to be expected based on Fig. 1, as 15% of
the receptors would be 3000 P14 TCR. Thus, the conserved ex-
pression of the OT-I TCR and the reduced expression of the P14
TCR are significant features of this model.
Despite this skewing of receptor expression, CD8 T cells isolated
from P14  OT-I mice responded to both Ags in a dose-dependent
manner as determined by [3H]thymidine incorporation and intracel-
lular staining for IFN- production (Fig. 7 and data not shown). No-
tably, although expression of the P14 TCR on P14  OT-I T cells was
reduced by 85% relative to parental T cells, these cells remained
remarkably sensitive to stimulation with the agonist gp33–41 as dem-
onstrated by the similar dose-response curve exhibited by both single
and dual receptor T cells (Fig. 6C, left panel). However, no prolifer-
ative response was observed when P14  OT-I T cells were stimu-
lated with the weak agonist, rDBM (Fig. 6C, right panel). Strikingly,
these data indicate that while the response to agonist remains intact,
the reduced P14 TCR expression of P14  OT-I T cells renders these
cells at least 10,000-fold less sensitive than parental P14 T cells to
stimulation with the weak agonist.
Cross-talk antagonism of IFN- production by CD8 P14 
OT-I dual receptor T cells
Dual TCR models have been used by a number of groups in an
attempt to elucidate the mechanism of T cell antagonism. In such
models, the presence of two independent TCR species minimizes
or eliminates competition between agonist and antagonist pMHC
complexes for available TCRs. Therefore, the ability of antagonist
ligands for one TCR to inhibit the T cell responses induced via the
second TCR, termed “cross-talk antagonism,” would suggest that
antagonists function either through the sequestration of intracellu-
lar molecules or the production of a negative signal. In these ex-
periments, we examined whether antagonist peptides could inhibit
IFN- production through either conventional or cross-talk antag-
onism (Fig. 7). This assay allowed us to assess the inhibition of T
cell activation on a per cell basis. Antagonists for the P14 and OT-I
TCRs were tested for their ability to inhibit P14  OT-I T cell
responses induced by either the P14 agonist LCMV gp33–41 or
the OT-I agonist OVA257–264 (Fig. 7). The OT-I antagonist E1
potently reduced the number of cells producing IFN- in response
FIGURE 7. The OT-I antagonist (E1) but not the P14 antagonist (36S)
potently inhibited the production of IFN- by P14  OT-I dual receptor T
cells through either TCR. P14  OT-I T cells were cultured for 4 days with
gp33–41, restimulated with either 1 nM gp33–41 (A, left panel), or 1 nM
OVA257–264 (B, left panel) for 6 h and stained for the presence of intra-
cellular IFN-. The addition of 10 M E1 (A and B, center panels) but not
10 M 36S (A and B, right panels) dramatically inhibited the responses of
dual receptor T cells to either Ag. E1-mediated inhibition of both gp33–41
(C, left panel) and OVA257–264 (C, right panel) was dose dependent.
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to OVA257–264 (85%; Fig. 7B, compare left and center panels;
Fig. 7C, right panel). Furthermore, the antagonist for the OT-I
TCR (E1) reduced the response of P14  OT-I T cells to the P14
agonist (gp33–41) by 80% (Fig. A, compare left and center pan-
els; Fig. 7C, left panel). However, the P14 antagonist 36S was
unable to significantly inhibit the agonist-induced responses pro-
voked through either the P14 TCR or the dominantly expressed
OT-I TCR (Fig. 7C). Therefore, while the 36S antagonist for P14
potently inhibited both the proliferation (Figs. 2C and 4A) and the
production of IFN- (data not shown) by P14 single TCR-express-
ing T cells, minimal inhibition (20%) of agonist-induced re-
sponse in P14  OT-I dual receptor T cells was observed (Fig. 7C)
in concordance with the results from a previous study (29).
Discussion
According to the spare receptor theory, agonist ligands achieve
maximal responses by engaging far fewer receptors than are re-
quired for the induction of responses by less potent ligands (19).
Thus, receptor density represents an important mechanism for reg-
ulating cellular and, subsequently, tissue responsiveness. Our pre-
vious studies have shown that a spare receptor model accurately
describes the responses of CD4 T cells to weak agonist peptides
typified by altered peptide ligands or autoimmune Ags (17, 30). In
this study we extend our original observations and demonstrate
that this model also describes the responses of CD8 T cells to
agonist and weak agonist as well as antagonist ligands. For both
the P14 and OT-I systems, reducing the number of available TCRs
drastically diminished both weak agonist and antagonist peptide
potency while leaving responses to agonist ligands relatively un-
affected (Figs. 2 and 3). It is possible that the antagonist peptides
used in these experiments vary in potency. However, the data we
have presented demonstrate a similar ability of E1 and 36S to
antagonize their respective T cells (Figs. 2 and 3), allowing us to
compare these two transgenic systems. These results suggest that
high TCR density allows responsiveness to a wide variety of li-
gands. This ability to respond to suboptimal ligands has been shown
to play a critical role in thymic selection (31, 32), and antagonist
ligands have been shown to function as surrogate self-ligands in the
promotion of the survival of naive CD8 T cells (33). The finding that
T cell responses to weak ligands are absolutely dependent on TCR
density implies that the ability to perceive self-ligands and subse-
quently survive is also dependent on TCR density. This requirement
may represent an important selective pressure in the maintenance of
high TCR density. However, this ability to respond to a variety of
ligands due to the existence of a receptor reserve may also contribute
to T cell cross-reactivity (34).
The mechanism by which antagonist peptides inhibit T cell ac-
tivation remains incompletely understood, although commonly
proposed mechanisms include competition for available TCRs (4,
35, 36), the sequestration of intracellular signaling intermediates
(37), and the production of a qualitatively unique negative signal
by TCRs engaged by antagonist ligands (38, 39). Dual TCR mod-
els have been used by a number of groups in an attempt to eluci-
date the mechanism of T cell antagonism, as there is minimal
competition for TCRs in such dual receptor systems (26, 35, 36,
39). Initial studies using CD8 T cells failed to demonstrate cross-
talk antagonism (29, 36), but another study and the data presented
here report the opposite findings (29). In light of our current re-
sults, the establishment of TCR density as a critical parameter
governing the efficacy of antagonist ligands provides new insights
regarding the interpretation of these results from dual receptor
models. In the initial studies in CD8 dual TCR models where
cross-talk antagonism was not observed, the T cells displayed sim-
ilar albeit equally reduced TCR expression levels (36). Our current
data and our previous CD4 dual receptor model found substantial
skewing of TCR expression such that one receptor was represented
at near parental levels (26). Of interest, only antagonist ligands for
the dominantly expressed receptor were capable of inhibiting T
cell responses in trans (26).
The observation that the spare receptor theory accurately de-
scribes the action of TCR antagonists also provides correlative
evidence for their ability to signal. Proponents of the competition
model of TCR antagonism have suggested that, by virtue of their
rapid dissociation rates, antagonist peptides interact with a large
number of TCRs and thus merely prevent agonist complexes from
triggering the number of TCRs required for activation (40). As
such, the competition model predicts that as the number of avail-
able TCRs approaches the number required to support activation
(1500), antagonist pMHC complexes would need to sequester
fewer TCRs to inhibit activation. Thus, whether considering either
the total TCR population or the fraction of this population local-
ized to the T cell:APC contact zone, a strict competition model
predicts that antagonist peptides would be most effective at inhib-
iting the responses of Ag-specific T cells at low TCR density.
Therefore, our observation that antagonist peptide efficacy is di-
rectly proportional to TCR density is inconsistent with the com-
petition model of TCR antagonism. In contrast, if antagonist pep-
tides function through the activation of intracellular signaling
molecules, then the spare receptor theory predicts that sufficient
TCR density is critical for the ability of antagonist ligands to pro-
duce a negative signal. The mediation of antagonism by a negative
signal has been supported by the observation that the Src homol-
ogy domain containing protein tyrosine phosphatase (SHP-1) is
activated during T cell antagonism in CD4 T cells and is required
for effective inhibition of T cell activation by antagonist pMHC
ligands (41, 42).
Our data from both the single and dual TCR transgenic systems
highlight the significance of TCR number in governing the potency
of weak agonist and antagonist peptides. It is important that our
observations were consistent in both model systems, as this limits
the potential alternative explanations for our findings. The initial find-
ings were made using V-specific Abs as a means to limit TCR ac-
cess to pMHC Ag and were based on studies where mAbs have
proven to be potent and effective competitors for binding at the cel-
lular and purified protein levels (18, 43, 44). The high affinity inter-
action between TCR and Ab makes it unlikely that our data can be
explained by the inability of the weak agonist and antagonist pMHC
complexes to compete as effectively as agonist for TCR. The dual
TCR system also eliminates this possibility. Similarly, the Ab treat-
ment of the cells could alter the antagonists’ effects by altering signal
transduction pathways, TCR dimerization, or some other stereological
aspect of TCR:pMHC interaction. Again, these potentially confound-
ing effects were mitigated by using the dual TCR system. The dual
TCR system alone may allow for alternative interpretations in that the
presence of two different TCRs could affect engagement or clustering
in some manner. However, the consistent inhibition of responses to
weak ligands that we have observed in these complementary ap-
proaches suggests that the reduction of TCR and the spare receptor
model of T cell activation are the most likely explanations for the data
presented here.
Peptide:MHC tetramer staining was included to demonstrate
specificity of the anti-V2 Ab in altering TCR density, but it also
revealed several features related to Ag recognition by T cells. For
example, fewer TCRs were needed to detect functional T cell re-
sponses (800) as compared with tetramer staining (several thou-
sand; Fig. 1 as compared with Figs. 2 and 3). This would suggest
that although MHC tetramer staining is extremely valuable for
assessing levels of response, it may also identify fewer Ag reactive
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cells than are actually present if the T cells are of sufficiently low
affinity or express low numbers of Ag-reactive TCRs. We made
use of T cells with multiple TCRs to confirm the minimal TCR
density required for response to weak ligands, but dual receptor
cells can avoid allelic exclusion in the thymus and are normally
found in the periphery (45). Thus, T cells with low specific density
could contribute to a functional T cell response and yet be unde-
tectable by a specific peptide:MHC tetramer.
A recent study demonstrated that the proliferation, but not the
cytolytic function, of CD8 T cells is sensitive to cross-talk an-
tagonism (29). In this study, we report that antagonist ligands for
the OT-I TCR effectively inhibit IFN- production induced by the
P14 agonist in the P14  OT-I dual TCR model. Although Yang
et al. proposed that antagonist ligands may inhibit cytolysis
through a different mechanism than proliferation, another possible
explanation is that both proliferation and cytokine production re-
quire de novo mRNA and protein synthesis (46, 47) and, therefore,
the antagonist ligand may have a greater opportunity to interrupt
the signaling cascade. In contrast, cytolysis results from the release
of preformed granules (48), potentially rendering the process more
difficult to inhibit. Although the dependence of antagonist peptide
efficacy on TCR density supports the ability of antagonist ligands
to induce a negative signal, an answer to the question of whether
distinct mechanisms are active in the inhibition of different effector
functions will require further investigation.
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Introduction
According to the currently accepted model of T cell activation,
two signals are required to fully activate resting naı¨ve T
lymphocytes. The primary signal is provided by the clonotypic
T cell receptor (TCR) after recognition of antigen/MHC-
complexes on the surface of antigen presenting cells. However,
this signal by itself is not capable of fully activating T lymphocytes
but has to be complemented by secondary signals which emerge
from stimulation of so called co-stimulatory molecules [1,2]. In
mouse and human T cells the dimeric transmembrane glycopro-
tein CD28 represents the most important co-stimulatory molecule.
Under physiological conditions CD28-derived signals alone are
not capable of inducing T cell activation, whereas simultaneous
engagement of the TCR and CD28 (e.g. by its natural ligands
CD80 and CD86 which are expressed on mature antigen
presenting cells) leads to activation of resting T lymphocytes
(reviewed in [3,4]).
Monoclonal antibodies (mAbs) directed to the extracellular
domain of CD28 have been widely used during the last two
decades to analyze CD28-mediated signaling pathways and to
assess how CD28 facilitates activation and differentiation of
murine, rat, and human T lymphocytes. Most recently a particular
group of CD28 mAbs has been identified which is capable of
activating T cells without the need for additional engagement of
the TCR/CD3-complex [5–7]. These antibodies have collectively
been termed mitogenic CD28 antibodies or CD28 superagonists.
While conventional CD28 mAbs bind CD28 close to the binding
site of the natural CD28 ligands, CD80 and CD86, CD28
superagonists bind to a laterally exposed loop within the
extracellular domain of CD28 [8]. The particular binding
topology of superagonistic CD28 antibodies (CD28SAs) might
be responsible for their mitogenic potential.
A number of detailed biochemical studies in rat and mice
addressed the question how CD28SA-mediated signaling is
organized on the molecular level [5,6,8–13]. The emerged data
can be summarized as follows: (i) the signaling capacity of
CD28SAs depends on the expression of a functional TCR/CD3/
f-complex; (ii) CD28SA-stimulation does not lead to detectable
phosphorylation/activation of the TCRf chain or the proximal
TCR-effector molecules ZAP70 and LAT, but still induces
phosphorylation of the adapter protein SLP76 and the nucleotide
exchange factor Vav (likely via the Tec-family protein tyrosine
kinases Itk or Rlk); (iii) CD28SA-stimulation activates PLCc1
(phospholipase Cc1) and induces calcium flux, and (iv) CD28SA-
stimulation activates PKC h (protein kinase C h) as well as the
transcription factors NF-kB, NF-ATc1, and GATA-3.
Studies in rat and mice have also shown that CD28 super-
agonists preferentially induce the expansion of regulatory T cells
and therefore suggested that these antibodies can be used for the
treatment of autoimmune diseases such as experimental autoim-
mune encephalomyelitis [13–20]. Based on the promising data in
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rodents, it was hypothesized that CD28SAs might also be
applicable for the treatment of human autoimmune disorders.
However, when applied to healthy volunteers during a phase I
clinical trial performed on March 13th, 2006 in London, UK, the
humanized CD28 superagonist TGN1412 showed unexpected
serious adverse events. These were associated with the induction of
a cytokine storm, i.e. the release of high amounts of pro-
inflammatory cytokines, most notably TNF-a and IFN-c [21].
The molecular basis for the unexpected response upon
treatment with the CD28 superagonist TGN1412 is as yet unclear.
To shed light on this question, we here addressed membrane
proximal signaling events in human T cells upon stimulation with
two different CD28 superagonists. We show that, despite complete
conservation of the CD28 extracellular and cytoplasmic domains,
TGN1412 and a commercially available CD28SA, ANC28.1/
5D10, induced a delayed but extremely sustained calcium
response in human, but not in cynomolgus and rhesus monkey
T cells. Biochemical analyses further revealed that both CD28SAs
strongly activated a number of major T cell signaling pathways in
human T cells. Together these signals culminate in the in vitro
production of high amounts of IFN-c, TNF-a, and other pro-
inflammatory cytokines.
Our experiments contribute to the understanding of the
particular pharmacologic properties of human CD28 super-
agonists and further suggest that currently available animal models
do not necessarily correctly reproduce critical signaling mecha-
nisms of human T cells.
Results
Mitogenicity of anti-human CD28 superagonist ANC28.1
By definition, CD28 superagonists induce polyclonal T cell
activation in vitro without the need of concomitant stimulation of
the TCR/CD3 complex [5,7]. We assessed the mitogenicity of a
commercially available CD28 superagonist (ANC28.1). In contrast
to stimulation of human T cells with the conventional CD28
antibody 248.23.2 [22], ANC28.1 was able to induce T cell
proliferation without additional stimulation via CD3 (Fig. 1A),
thus fulfilling the criteria of a CD28 superagonist. Note that
ANC28.1 still exerted costimulatory properties as it strongly
augmented the proliferative response of T cells stimulated with
CD3 antibody (Fig. 1A).
Previously, several groups have assessed the signaling events
induced by anti-rat or anti-mouse CD28 superagonistic antibodies
[5,6,8,11–13]. In contrast, only few data are available regarding
the signaling properties of anti-human CD28 superagonists. To
explore the signaling properties of ANC28.1, phosphospecific
western blots were performed (Fig. 1B). The transmembrane
adapter protein LAT (Linker for Activation of T cells) represents a
35 kDa polypeptide that is essential for T cell activation [23,24].
Upon TCR-mediated phosphorylation of four critical tyrosine
residues, LAT assembles a multi-component signaling complex
consisting of the cytosolic adapter proteins Gads (Grb2-related
adaptor downstream of Shc) and SLP76 (SH2 domain containing
leucocyte specific phosphoprotein of 76 kDa), the Tec-family
protein tyrosine kinase Itk (Inducible T-cell kinase), and PLCc1
(Phospholipase Cc1; reviewed in [25]). This complex is responsible
for the rise in intracellular calcium upon stimulation of the TCR.
We first employed a phosphospecific antibody that detects one of
the major tyrosine phosphorylation sites within LAT, Y171. As
shown in Fig. 1B, upper panel, ANC28.1 induced a weak but
clearly detectable phosphorylation of Y171. Similar data were
obtained when the phosphorylation status of Y136, one of several
additional phosphorylation sites of LAT, was assessed (data not
shown). Hence, in contrast to rat T cells, anti-human CD28
superagonist ANC28.1 induced a weak but clearly detectable
phosphorylation of LAT. Interestingly and in line with previous
data obtained in human and rat T cells [8,12], ANC28.1
stimulation did not result in a detectable phosphorylation (a sign
for activation) of the protein tyrosine kinase ZAP70 which is
believed to be primarily responsible for LAT phosphorylation
upon TCR-stimulation (Fig. 1B, middle panel).
Upon engagement of the TCR/CD3-complex, phosphorylated
LAT facilitates the activation of PLCc1 which in turn generates
the second messenger molecules IP3 (Inositol-tris-phosphate) and
DAG (Diacyloglycerol; reviewed in [25]). To assess whether the
moderate phosphorylation of LAT induced by ANC28.1 was
sufficient to activate PLCc1, we investigated the phosphorylation
status of Y783 of PLCc1 which correlates with its enzymatic activity
[26]. The lower panel of Fig. 1B demonstrates that similar to rat T
Figure 1. The CD28 superagonist ANC28.1 induces polyclonal T
cell activation in vitro and leads to ZAP70 independent
phosphorylation of LAT and PLCc1. (A) 56104 freshly prepared
human T cells per well were seeded in 96-well plates and treated with
the indicated combinations of antibodies or were incubated in medium
as a control. 72 hours after stimulation, cultures were pulsed with 3H-
thymidine for 6 hours and harvested thereafter. Note that ANC28.1 only
induces polyclonal T cell proliferation when applied in soluble form (in
this case 10 mg/ml of soluble ANC28.1 were crosslinked in solution with
20 mg/ml of polyclonal goat-anti-mouse antiserum). All other stimula-
tions (including stimulation of T cells with CD3e mAb and ANC28.1; very
right bar in Fig. 1A) were performed in wells that were pre-coated with
polyclonal goat anti-mouse antiserum. Shown data are representative
for at least 6 independently performed experiments. (B) 16106 freshly
prepared human T cells/lane were stimulated in solution with 10 mg/ml
ANC28.1 followed by crosslinking with 20 mg/ml polyclonal goat anti-
mouse antiserum for the indicated periods of time. As a control, cells
were activated with a 1:50 v/v dilution of ascites fluid of CD3e mAb
MEM92 (IgM) or were left untreated. Cell lysates were processed for
western blotting using the indicated phosphospecific antibodies (Y319
of ZAP70, Y171 of LAT, and Y783 of PLCc1). Western blotting using an
anti-actin antibody was performed as loading control.
doi:10.1371/journal.pone.0001708.g001
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cells [11] ANC28.1 induced a weaker and delayed but clearly
sustained activation of PLCc1 when compared to stimulation of
human T cells with CD3 mAb. Thus, ANC28.1 induced a
phosphorylation pattern that was different from the one obtained
when human T cells were activated via CD3.
Sustained calcium flux upon T cell stimulation with
superagonistic ANC28.1
The different activation kinetics of PLCc1 produced by CD3 vs.
CD28 superagonist ANC28.1 were translated into corresponding
Ca++-responses (Fig. 2A). Thus, independently of the concentra-
tions used the CD3e mAbs MEM92 (Fig. 2A, upper panel and Fig.
S1) and OKT3 (Fig. S1 and [27]) induced a rapid, strong, and
transient rise in intracellular Ca++ whereas the CD28SA-mediated
Ca++-signal started delayed and was of lower intensity (Fig. 2A,
lower panel). Surprisingly, an extended analysis revealed that the
CD28SA-mediated Ca++-signal had an extremely sustained
kinetics (Fig. 2A–2F) that lasted for more than six hours without
significant decrease (Fig. S2).
The flow cytometric data obtained with Indo-1 labeled T cells
were confirmed by live time video microscopy of T cells loaded
with the calcium sensitive dye Fura2 (Movie S1 and Movie S2).
Note that stimulation of the same cells with two conventional
CD28 mAbs (CD28.2, Fig. 2A, middle panel and 248.23.2, data
not shown) did not induce any detectable Ca++-signal either with
or without crosslinking.
Downmodulation of the TCR by treatment of T cells with the
CD3e mAb 2AD2A2 [28] (Fig. 2B, TCRdull T cells) or pre-
treatment of T cells with the Src-kinase inhibitor PP2 (Fig. 2C,
lower panel) completely abrogated the ANC28.1-mediated
calcium response, whereas pharmacologic inhibition of PI3K by
Wortmannin had almost no effect (Fig. 2C, middle panel). Hence,
similar to the situation in rat T cells [11,12] expression of a
functional TCR and the activation of Src-kinases are required for
ANC28.1-mediated calcium flux, whereas activation of PI3K
appears to be dispensable. Further stimulation experiments in the
presence of the calcium-chelator EGTA revealed that the
ANC28.1-mediated Ca++-signal required the presence of extra-
cellular calcium ions (Fig. 2D).
Importantly, after inducing the expected peak (compare Fig. 2A,
upper panel), addition of a conventional CD3 mAb to CD28SA-
stimulated T cells abrogated the sustained Ca++-flux (Fig. 2E). This
might suggest that CD3 stimulation activates a negative feedback
loop that is otherwise not activated upon CD28SA-stimulation.
We next assessed which T cell population preferentially
responded to CD28SA stimulation. As expected from published
work [29,30] ANC28.1 induced a stronger Ca++-signal in CD4+ T
cells compared to CD8+ T cells (Fig. 2F, left panels) whereas
almost no differences were observed between CD4+/CD45RA+
naı¨ve vs. CD4+/CD45RO+ memory T lymphocytes (Fig. 2F, right
panels).
Induction of T cell proliferation and sustained calcium
flux by CD28 superagonist TGN1412
To exclude the possibility that the induction of a sustained
calcium signal was a particular property of ANC28.1, we repeated
the experiment shown in Fig. 2A using the superagonistic CD28-
specific antibody TGN1412. Fig. 3A depicts that TGN1412
generated a similarly shaped calcium signature as antibody
ANC28.1 although it induced a calcium response only upon
crosslinking. In addition, the magnitude of the calcium response
elicited by TGN1412 was generally lower than that of ANC28.1.
The weaker signaling properties of TGN1412 compared to the
ANC28.1 were also reflected by a generally lower mitogenic
potential of TGN1412 (Fig. 3B).
Intracellular signaling events induced by ANC28.1 and
TGN1412
Given the sustained calcium response induced by ANC28.1 and
TGN1412 we next investigated the consequences of CD28SA
stimulation on downstream signaling events using reporter
antibodies that monitor the activity of key signaling molecules
involved in T cell activation. The first and third panels of Fig. 3C
demonstrate that mAb ANC28.1 induced a delayed, strong, and
sustained activation of all signaling events we investigated (Erk1/2,
JNK, p38, AKT, GSK3b-1, NF-ATc1, and IkBa). Of note,
ANC28.1 induced an even stronger activation of JNK, p38, AKT,
and IkBa compared to CD3 mAb (second panel), whereas
activation of Erk1/2 and dephosphorylation of the transcription
factor NF-ATc1 were less pronounced. Similar results as for
ANC28.1 were obtained when cells were stimulated with
TGN1412 (Fig. 3C, right panel). However, in line with the lower
magnitude of Ca++-signaling and the weaker induction of a
proliferative response, the phosphorylation signals induced by
TGN1412 were generally less pronounced than those induced by
ANC28.1. In multiple experiments, both ANC28.1 and TGN1412
induced a sharp initial rise of p38 phosphorylation which
transiently dropped after 5 minutes of stimulation. The reason
for this particular phosphorylation signature is yet unknown. Note
that a conventional CD28 antibody only induced the known
activation of the AKT and the JNK pathways (data not shown and
[31]). In summary, both human CD28 superagonists not only
produced a sustained induction of Ca++-flux but also an activation
of multiple intracellular signaling pathways.
In vitro cytokine production upon conventional vs.
superagonistic human T cell stimulation
Within hours after administration of TGN1412 to six healthy
individuals, clinical symptoms became apparent that were
consistent with a massive cytokine storm mediated by the release
of TH1- and TH2-specific cytokines [21]. In line with previous
data obtained using TGN1412 [32] Fig. 4 shows that also in vitro
human T cells respond upon ANC28.1- or TGN1412-mediated
stimulation with a strong production of high amounts of the pro-
inflammatory cytokines IFN-c, TNF-a, IL-2, -4, -5, and anti-
inflammatory IL-10. In all experiments we observed that at the
chosen concentration, TGN1412 was a better inducer of IL-10
than ANC28.1. In contrast (and in agreement with the generally
stronger signals elicited by ANC28.1), the amounts of TNF-a,
IFN-c, IL-2, and IL-4 were higher upon stimulation with
ANC28.1. Nevertheless, at concentrations inducing similar levels
of proliferation, both CD28 superagonists induced the synthesis of
significantly higher levels of cytokines compared to conventional
CD3/CD28 co-stimulation. Hence, the activation of multiple
signaling pathways upon CD28SA-mediated T cell activation is
translated into a corresponding in vitro cytokine response.
Fig. 5A depicts that similar to the situation in vivo, IFN-c
secretion occurred very rapidly after CD28SA stimulation. This
allowed us to use pharmacological inhibitors to further dissect the
molecular requirements leading to CD28SA-mediated IFN-c
production. Fig. 5B shows that incubation of T cells with
cycloheximide, PP2, and Cyclosporin A (CSA) completely
abrogated ANC28.1-mediated IFN-c production. Hence, IFN-c
secretion upon CD28SA stimulation is due to de novo protein
synthesis. Further, it requires activity of Src-kinases and involves
the Calcineurin/NF-AT-mediated signaling pathway.
Anti-Human CD28 Superagonists
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Figure 2. Induction of sustained calcium flux by human CD28 superagonistic antibody ANC28.1. (A) 16106 freshly prepared Indo-1
loaded human T cells were stimulated with either a 1:50 v/v dilution of ascites fluid of CD3 mAb MEM92 (orange triangle), 10 mg/ml conventional
CD28 mAb (CD28.2; blue triangle) followed by crosslinking with 20 mg/ml polyclonal goat anti-mouse antiserum (black triangle) or 10 mg/ml ANC28.1
(red triangle) followed by crosslinking with 20 mg/ml polyclonal goat anti-mouse antiserum (black triangle). Induction of the Ca++-response was
monitored for approximately 75 minutes. Note that using another conventional anti-CD28 mAb (248.23.2; with or without crosslinking) no Ca++-flux
was induced as well (data not shown). (B) Untreated (untreated T cells) or 2AD2A2 pre-treated (TCRdull T cells) human T cells were stimulated with
ANC28.1 (red triangles) and subsequently crosslinked (black triangles) as described in (A) and induction of the Ca++-response was monitored for the
indicated periods of time. To confirm proper loading of the cells with Indo-1, the Ca++-ionophore Ionomycin (10 mg/ml) was added at the end of the
experiment (unfilled triangle). (C) Cells were treated with ANC28.1 (red triangles) followed by crosslinking (black triangles) as described in (A) in the
absence (no inhibitor) or presence of the PI3-kinase inhibitor Wortmannin (0.2 mM) or the Src-kinase inhibitor PP2 (10 mM). (D) CD3 (orange triangle)
or ANC28.1 (red triangle) stimulation plus crosslinking (black triangle) was performed as described in (A) in culture medium that was supplemented
with 1 mM EGTA to chelate extracellular Ca++ ions (solid arrow). At the indicated time points CaCl2 was added at a final concentration of 2 mM
(dashed arrow). (E) Cells were treated with ANC28.1 as described in Fig. 1A. Additionally, at about 1 h of Ca-flux, a 1:50 v/v dilution of ascites fluid of
CD3 mAb MEM92 (orange triangle) was added. (F) CD8+, CD4+, CD4+/CD45RA+ naı¨ve, and CD4+/CD45RO+ memory T lymphocytes were treated with
ANC28.1 as described in (A) and induction of the Ca++-response was monitored for approximately 150 minutes.
doi:10.1371/journal.pone.0001708.g002
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Similar to cycloheximide treatment, depletion of extracellular
calcium ions by EGTA completely abrogated IFN-c production
after ANC28.1 stimulation. This finding shows that transmem-
branous calcium flux is mandatory for CD28SA-mediated
induction of cytokine synthesis. Note that addition of extracellular
Ca++ ions to EGTA-treated cells completely restored the
CD28SA-induced IFN-c response (Fig. 5B), excluding toxic
EGTA effects.
Above we showed that the PI3K inhibitor Wortmannin did not
influence CD28SA-mediated calcium flux (Fig. 2C). Similarly,
neither Wortmannin nor a second PI3K inhibitor, LY294002,
influenced CD28SA-mediated phosphorylation of SLP76, Vav,
Erk, JNK, p38, the degradation of IKK or the dephosphorylation
of NF-ATc1 (Fig. 5C), whereas both inhibitors completely
abrogated CD28SA-mediated phosphorylation of AKT (upper
panel in Fig. 5C). These data corroborate a recent report showing
Figure 3. Sustained calcium flux, T cell proliferation, and T cell signaling upon TGN1412 treatment. (A) Freshly isolated human T cells
were treated as described in Fig. 2 using the superagonistic CD28 specific mAb TGN1412 (10 mg/ml; red triangle). For crosslinking, 20 mg/ml of
monoclonal mouse anti-human IgG4 was used (black triangle) and induction of the Ca
++-response was monitored. (B) 56104 freshly prepared human
T-cells/96-well were stimulated with the indicated concentrations of ANC28.1 or TGN1412 or were left untreated as a control. For crosslinking of
ANC28.1, a polyclonal goat anti-mouse antiserum was used and crosslinking of TGN1412 was performed as described in (A). Concentrations for
crosslinking were the following: 0.1–1.25 mg/ml primary Ab+2.5 mg/ml crosslinker; 2.5 mg/ml primary Ab+5 mg/ml crosslinker; 5 mg/ml primary
Ab+10 mg/ml crosslinker; 10 mg/ml primary Ab+20 mg/ml crosslinker. 72 hours after stimulation, cultures were pulsed with 3H-thymidine for 6 hours,
then harvested and proliferation analyzed by counts per minute [cpm]. (C) 16106 freshly prepared human T cells/lane were left untreated or were
stimulated with 10 mg/ml ANC28.1 (first and third panel) followed by crosslinking with 20 mg/ml polyclonal goat anti-mouse antiserum or with 10 mg/
ml TGN1412 (right panel) followed by crosslinking as described in (A) for the indicated periods of time. As a control, cells were activated with a 1:50
dilution of ascites fluid of CD3 mAb MEM92 (second panel). Postnuclear lysates were processed for western blotting using the indicated
phosphospecific antibodies. Western blotting using an anti-actin antibody was performed as loading control.
doi:10.1371/journal.pone.0001708.g003
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that CD28SAs still induce upregulation of CD69 in human T cells
pretreated with Wortmannin or Ly294002 [33]. Surprisingly, both
Wortmannin and Ly294002 induced an almost complete block of
IFN-c production after ANC28.1 stimulation (Fig. 5B). This
suggests that PI3K or its downstream effector AKT [34,35] is
mandatory (although not sufficient) for CD28SA-mediated IFN-c
production.
We next assessed the mechanisms underlying CD28SA-
mediated IL-2 induction. This was of particular interest because
a recent report suggested that in rat T cells CD28SA induced IL-2
production might not require PI3K activity [12]. Fig. 5D shows
that, similar to IFN-c production, CD28SA-mediated IL-2
synthesis by human T cells was sensitive to treatment with EGTA,
cycloheximide, CSA, and PP2. Furthermore, Wortmannin and
LY294002 abrogated CD28SA-mediated IL-2 synthesis. Hence, in
contrast to rat T cells, activation of PI3K was also mandatory for
CD28SA induced IL-2 production by human T lymphocytes.
We finally assessed whether the sustained Ca++ signaling that is
induced by ANC28.1 and TGN1412 (see Figs. 2 and 3) is required
for cytokine production upon CD28SA-stimulation. To achieve
Figure 4. Cytokine production upon conventional and superagonistic CD28 stimulation of human T cells. 56104 freshly prepared
human T-cells/96-well were stimulated with the indicated combination of antibodies as described in Fig. 1A or were left untreated as controls. At
48 hours 50 ml culture supernatant was removed from each well. Supernatants obtained from 3 wells were pooled and cytokine content was
determined using the Cytokine Bead Array from BD in signals per minute [spm] (black bars). Additionally, induction of T cell proliferation was
monitored upon treatment with the indicated antibody combinations (gray bars). 72 hours after stimulation, cultures were pulsed with 3H-thymidine
for 6 hours, then harvested and proliferation analyzed by counts per minute [cpm]. Data represent the mean of 5 individual experiments.
doi:10.1371/journal.pone.0001708.g004
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Figure 5. Analysis of the signaling pathways controlling CD28SA-mediated IFN-c and IL-2 production. (A) Short term IFN-c production
upon CD28SA stimulation of T cells. 16106 T cells/200 ml were activated by CD28SA ANC28.1 as described for Figs. 1–4. At the indicated time points
50 ml of the supernatants were removed, diluted 1:3 v/v, and the concentration of secreted IFN-c was determined using a commercially available
ELISA. (B) Molecular requirements determining CD28SA-mediated IFN-c production. T cells were pretreated for 30 minutes with the indicated
substances prior to stimulation with ANC28.1. EGTA was used at 1 mM, CaCl2 at 2 mM, cycloheximide at 50 mg/ml, CSA at 150 ng/ml, PP2 at 10 mM,
Wortmannin at 0.1 mM, and Ly294002 at 20 mM. At the indicated time points cytokine production was determined as described in (A). (C) 16106
freshly prepared human T cells/lane were stimulated with 10 mg/ml ANC28.1 followed by crosslinking with 20 mg/ml polyclonal goat anti-mouse
antiserum with or without Wortmannin treatment. Western blotting was conducted as described in Fig. 3. Note that identical results were obtained
when T cells were pretreated with LY294002 (data not shown). (D) Molecular requirements determining CD28SA-mediated IL-2 production. T cells
were pretreated for 30 minutes with the indicated substances prior to stimulation with ANC28.1 as described in (B). 4 h after stimulation 50 ml of the
supernatants were removed, diluted 1:3 v/v, and the concentration of IL-2 was analyzed in supernatants by an ELISA. (E) CD28SA-mediated IFN-c and
IL-2 production requires sustained Ca++-flux. T cells were stimulated with ANC28.1 as described above. At 159, 309, 1 h, 2 h, 3 h, 4 h, and 5 h Ca++-flux
was interrupted by addition of EGTA (1 mM) and the concentration of the cytokines in the supernatant was determined as described in (B) and (D).
The concentrations of IL-2 and IFN-c that were produced by ANC28.1-stimulated T cells following 6 hours of stimulation in the absence of EGTA were
set to 100%. All data shown in Fig. 5 are representative for three independently performed experiments.
doi:10.1371/journal.pone.0001708.g005
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this we inhibited transmembranous Ca++-flux at different time
points after stimulation with ANC28.1 by the addition of EGTA
and subsequently determined the concentration of IFN-c and IL-2
in the culture supernatants. Fig. 5E depicts that the amounts of
IFN-c and IL-2 secreted by CD28SA-stimulated T cells directly
correlated with the duration of CD28-mediated transmembranous
Ca++-flux. Thus, sustained calcium flux is important for the strong
production of IFN-c and IL-2 upon CD28SA stimulation.
Lack of a TGN1412-mediated calcium response in
monkey T cells
Before being used in the London phase I clinical trial,
TGN1412 had been applied to rhesus and cynomolgus monkeys
without showing obvious severe adverse effects [36]. Furthermore,
it was debated whether the extracellular domains of Macaca
fascicularis (cynomolgus), Macaca mulatta (rhesus), and Homo sapiens
CD28 show subtle differences on the protein level [37] [38]. To
clarify the latter question we sequenced CD28 cDNAs obtained
from 14 individual rhesus and 11 cynomolgus monkeys and
compared the deduced amino acid sequences with the protein
sequence of human CD28. Notably, this approach corroborated
that the CD28 extracellular domains (as well as the cytoplasmic
tails) are completely conserved between the three species (Fig. S3).
Interestingly, in all 25 monkeys investigated we observed three
non-conservative amino acid exchanges in the transmembrane
region (Fig. S3). Furthermore, one non-conservative amino acid
exchange was found within the leader sequence of the non-human
primates.
The complete conservation of the extracellular domains of
CD28 across the investigated species was further reflected by
similar TGN1412 binding of human CD3+ and non-human
primate CD3+ T cells. A 1:1 mixture of CD3+ human T cells
(stained with an anti-CD3-APC antibody) and CD3+ non-human
primate T cells (stained with an anti-CD3-PE antibody) derived
from cynomolgus (Fig. 6A, left panel) or rhesus (Fig. 6A, right
panel) monkeys, respectively, was incubated with Alexa 488
labeled TGN1412 at graded concentrations. Similar decoration of
T cells from both species with TGN1412 indicated similar binding
capacities of human and non-human primate CD28 to the
antibody. Moreover, FACS analyses revealed a similar ratio of
CD4+ vs. CD8+ T cells in blood samples of human and non-
human origin (Fig. 6B).
Interestingly, despite similar TGN1412 binding, identical
extracellular CD28 domains of all three species, and a similar
ratio of CD4+ vs. CD8+ T cells in blood samples of human and
non-human origin (Fig. 6 and Fig. S3), TGN1412 only induced a
very low calcium signal in rhesus or cynomolgus T cells (Fig. 6C).
Similar results were obtained with ANC28.1 (data not shown).
Note that the profound differences in the Ca++-response between
monkey and human T cells were also observed at higher
concentrations of both antibodies (up to 20 mg/ml; not shown).
Thus, despite comparable levels of CD28 expression and similar
reactivity with TGN1412 only human T cells are capable of
inducing a significant calcium response upon stimulation with
CD28 superagonists.
Discussion
The data shown in this report clearly demonstrate that two
superagonistic CD28 mAbs, TGN1412 and ANC28.1, generate a
remarkably sustained Ca++-response when applied to human T
cells in vitro (Fig. 2 and 3). The prolonged Ca++-signal is preceded
by a sustained activation of PLCc1 (Fig. 1) and is downstream
correlated with an activation of a number of different signaling
pathways (Fig. 3) that are involved in the activation and
differentiation of T lymphocytes. Together, these signals culminate
in the production of a variety of pro-inflammatory cytokines, most
notably IFN-c and TNF-a (Fig. 4).
The strong and sustained Ca++-response elicited by the
CD28SAs seems to be a particular property of the human system
and it appears as if human T cells react more sensitive to CD28SA
stimulation compared to rat and monkey T cells ([11] and Fig. 6).
A sustained Ca++-response following CD28SA-stimulation has
previously been described for rat T cells [11]. However, due to the
low on-rate or the weak accessibility of the CD28 epitope detected
by CD28SAs, the induction of Ca++-flux in rat T cells required
antibody pre-incubation for several hours [11]. Similarly, the
induction of proliferation by mitogenic rat CD28SA antibodies
needs extensive crosslinking and we also observed that the binding
of an anti-mouse CD28SA (D665) to the surface of murine T cells
occurred with an extremely slow kinetics and was strongest upon
overnight incubation on ice (data not shown).
In contrast, the binding of both TGN1412 and ANC28.1 to
human T cells occurs rapidly and is almost indistinguishable from
the binding of monoclonal antibodies directed to other cell surface
receptors (data not shown). Hence, the binding of CD28SAs to
human T cells occurs with much faster kinetics compared to
mouse and rat CD28SAs. A faster on-rate (presumably combined
with a slow off-rate) could explain why CD28SAs are capable of
inducing sustained signaling in human T lymphocytes.
A number of previous studies had assessed the capability of
conventional CD28 antibodies to induce Ca++-flux in Jurkat T
cells and primary human T cells. These studies suggested that
CD28-mediated Ca++-flux requires extracellular calcium ions and
hence, is EGTA-sensitive [30]. However, they also suggested that
CD28-mediated signals do not activate the PTK pathway [30],
occur in the absence of TCR signals [30], do not lead to
production of DAG [39], and also do not activate PKC. This
appears not to be the case for the anti-human CD28SAs for the
following reasons: (i) we show that (similar to rat T cells [12]) the
Ca++-signal produced by ANC28.1 required expression of a
functional TCR (Fig. 2B); (ii) anti-human CD28SA signaling was
Src protein tyrosine kinase dependent as it could be blocked by
PP2 (Fig. 2C); (iii) anti-human CD28SA-mediated signaling
induced the induction of the DAG-dependent Ras/Raf/Erk
pathway (Fig. 3C), and (iv) it led to activation of the IKK/NF-
kB pathway (Fig. 3C) which is dependent on activation of PKC.
Hence, despite some similarities, the signaling properties of
conventional anti-human CD28 antibodies fundamentally differ
from those of CD28 superagonists.
In agreement with data obtained in rat T cells [12], ANC28.1
stimulation did not result in a detectable tyrosine phosphorylation
of the protein tyrosine kinase ZAP70 (Fig. 1B, middle panel)
although ZAP70 is believed to be primarily responsible for LAT
phosphorylation upon TCR-stimulation. At present it is unclear
which protein kinase is responsible for LAT phosphorylation upon
CD28 superagonistic stimulation of human T cells. Attractive
candidates include the two Tec-family protein tyrosine kinases Itk
and Rlk [12].
An important question that needs to be addressed in the future
is why the calcium-signal induced by human superagonistic CD28
mAbs has such a dramatically prolonged kinetics. It is obvious
from our study that the potency of CD28SAs to activate PLCc1
and to induce Ca++-flux is lower than the potency of CD3 mAb.
Thus, it is possible that the amount of IP3 generated upon
triggering by CD28SAs suffices to activate membrane associated
Ca++-channels, but that the overall Ca++ influx is below the
threshold that is needed to close the channels. In line with this idea
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is our observation that the sustained calcium-response elicited by
the CD28SAs can be stopped by administration of a CD3 mAb
(Fig. 2E). However, further studies are required to elucidate the
question how transmembrane flux is induced and maintained
upon CD28SA-stimulation. Moreover, it will be important to
determine the functional roles of the recently identified ORAI1
and STIM proteins in CD28SA-induced transmembrane Ca++-
flux [40].
Our data show that CD28SA-stimulation leads to a strong and
very rapid production of cytokines in vitro (Figs. 4 and 5). Indeed,
IFN-c was detectable in the culture supernatant already 90–
120 minutes after CD28SA stimulation (Fig. 5A). Inhibition of
protein synthesis by cycloheximide completely abrogated IFN-c
secretion (Fig. 5B) which strongly suggests that this event is not due
to a release of the cytokine from intracellular stores but rather due
to de novo IFN-c synthesis. Furthermore, the production of IFN-c
was dependent on CD28SA-mediated Ca++-flux as pretreatment
of the cells with EGTA completely blocked the response. Perhaps
more importantly, our data show that the amounts of IFN-c and
IL-2 produced by CD28SA-treated cells directly depend on the
Figure 6. Despite similar TGN1412 binding, Macaca derived T cells show reduced calcium flux upon TGN1412 stimulation when
compared to human T cells. (A) MACS purified CD3+ human T cells (stained with an anti-CD3-APC antibody) and CD3+ monkey T cells (stained
with an anti-CD3-PE antibody) were mixed 1:1 and then incubated with graded concentrations of Alexa 488 labeled TGN1412. Binding of TGN1412-
Alexa 488 was monitored by FACS analysis. Numbers given indicate the mean fluorescence intensity of samples. (B) Ratio of CD4+ vs. CD8+ T cells
(gated on CD3+ cells) of human and monkey blood samples was analyzed by FACS analyses. (C) 16106 freshly isolated Indo-1 loaded M. fascicularis
and M. mulatta T cells were treated as described in Fig. 2 using the superagonistic CD28 specific mAb TGN1412 (10 mg/ml; red triangle). For
crosslinking, 20 mg/ml monoclonal mouse anti-human IgG4 was used (black triangle) and induction of the Ca
++-response was monitored. To confirm
viability of cells and proper loading with Indo-1, Ionomycin (10 mg/ml) was added at the end of the experiment (unfilled triangle).
doi:10.1371/journal.pone.0001708.g006
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duration of transmembranous Ca++-flux (Fig. 5E). Thus, it appears
as if the large amounts of cytokines produced upon anti-human
CD28SA-stimulation in vitro (and presumably also in vivo) are due
to the sustained Ca++-signal generated by the CD28 superagonistic
antibodies.
With regard to the induction of IL-2 synthesis the signaling
properties of CD28 superagonists again appear to differ from those
of conventional CD28 mAbs. Based on studies using cholera-toxin,
it was suggested that conventional CD28 antibodies activate two
functionally unrelated signaling pathways [22]. One of these
pathways was found to be cholera-toxin sensitive, initiated
transmembranous Ca++-flux, but did not influence IL-2 secretion
whereas the other one was cholera-toxin insensitive and
responsible for IL-2 production [22]. Both with regard to
production of IL-2 and IFN-c this mechanism does not hold true
for signaling induced by CD28SAs. Indeed, we show that both the
PTK/PLCc/Ca++-pathway and the PI3-kinase pathway must
operate simultaneously in order to allow IL-2 and IFN-c synthesis.
Whether this also applies for the production of other cytokines
upon CD28SA stimulation requires further analysis. Moreover,
despite costimulatory capacity, the same antibody that was used by
Nunes et al. to dissect signaling events upon CD28-stimulation in
Jurkat T cells (mAb 248.23.2 [22]) did not generate a detectable
Ca++ signal in primary human T cells (data not shown). These
differences might be due to the different cells that were
investigated or to different CD28 antibody preparations (ascites
fluid in [22] vs. cell culture supernatant in our study).
It is important to note that the signaling pathways induced by
CD28SAs also seem to differ between rat and human T cells. A
recent report suggested that IL-2 production upon CD28SA-
stimulation of rat T cells is primarily mediated via the SLP76/
Vav-module and does not require activation of PI3K [12]. The
latter assumption was based on the observation that anti-rat CD28
superagonists do not induce phosphorylation of AKT and that
mutation of the PI3K binding site within the cytoplasmic domain
of CD28 did not ablate CD28SA-mediated IL-2 production [12].
However, our data show that CD28-mediated IFN-c and IL-2
production required both transmembranous Ca++-flux and
activation of PI3K (Fig. 5). Indeed, inhibition of PI3K blocked
CD28SA-mediated IL-2 production in human T cells without
influencing transmembranous Ca++-flux, phosphorylation of
SLP76, Vav, Erk, JNK, p38 as well as the activation of the
transcription factors NF-AT and NF-kB. Together these data
suggest that anti-human CD28SA signaling involves at least
two major signaling modules, one that depends on activity of
PI3K and a second one that requires transmembranous Ca++-flux
(note that treatment of T cells with EGTA did not substan-
tially alter CD28SA-mediated activation of AKT (data not
shown)). However, we certainly cannot exclude the possibility
that CD28SA-stimulation activates a pool of PI3K that does
not associate with CD28 upon CD28SA stimulation. Further, it
will be important to investigate whether PI3K regulates the
production of IL-2 and IFN-c upon CD28SA stimulation in
human T lymphocytes via its proposed downstream effector AKT
[34,35].
Differences between human and rodent T cell activation are
also underlined by experiments analyzing Ca++-flux in CD4+ and
CD8+ T cell subpopulations. It was shown previously that in
mouse splenic T cells only CD4+ but not CD8+ T cells showed
Ca++-flux upon CD28 triggering [29] whereas within human
PBMCs also CD8+ cells were capable of Ca++-release upon CD28
stimulation [30]. In agreement with data shown in this study
(Fig. 2F) responses by CD8+ T cells were less pronounced than
those by CD4+ T cells [30].
It is still unclear how CD28SAs precisely activate the multiple
intracellular signaling pathways at the level of the plasma
membrane. Initially we thought that this might be due to
formation of large CD28 clusters on the T cell surface. However,
in line with a recent report [33] we did not see obvious differences
in CD28 cluster formation upon CD28SA vs. CD28 stimulation
by confocal laserscanning microscopy (data not shown). However,
we cannot exclude the possibility that the assembly or the
dynamics of the recently identified microclusters [41] differs
between CD28 vs. CD28SA stimulation. It will be important to
assess this possibility in the future.
Although we observed that CD28SA stimulation led to the
activation of many intracellular signaling pathways it is important
to note that CD28SAs do not fully activate human T cells. For
example, we did not observe an activation of b1- or b2-integrins
upon CD28SA stimulation and we also did not see formation of F-
actin or induction of cell migration by CD28SAs (data not shown).
Why these cellular events are not initiated upon CD28SA
stimulation is unclear at present. One reason might be that the
thresholds that are required to activate these pathways are higher
than those regulating cytokine production.
The amino acid sequence of the extracellular domains of rhesus
and cynomolgus CD28 are identical with the one of human CD28
(Fig. S3 and see genebank entries 111144662 and 112817616 for
Macaca mulatta and 110611295, 111144664, and 110611297 for
Macaca fascicularis as well as ref. [42]). This was also reflected by
similar decoration of CD28 on T cells of human, Macaca mulatta,
and Macaca fascicularis origin with Alexa 488 labeled TGN1412
(Fig. 6A). Intriguingly however, monkey T cells did not show
Ca++-response upon CD28SA stimulation (Fig. 6C) as it was
observed in human T cells. Unlike rodents, blood samples of non-
human primates and humans show approximately 70% T cells in
the lymphocyte gate and within the T cell population, non-human
primates and humans show a similar ratio of CD4+ vs. CD8+ T
cells (Fig. 6B and [43,44]). It is also important to note that the non-
human primates used in this study are not kept under specific
pathogen free (SPF) conditions although they are regularly
screened for infections with pathogens. Thus, the observation that
TGN1412 stimulation induced Ca++-flux only in human but not in
non-human primate T cells (Fig. 6C) can not be explained by
significantly decreased numbers of CD4+ T cells in non-human
primates or by a more naı¨ve activation state of the T cells due to
SPF housing conditions.
Importantly, a recent study showed that chimpanzee T cells are
also less responsive towards in vitro stimulation than human T
cells and it was suggested that this might be due to loss of Siglec
expression on human T cells [45]. Siglecs are inhibitory receptors
that are related to CD33 and it appears as if their expression is lost
on T cells during evolution from monkey to human [45]. Hence,
the lack of Siglec expression might explain why human T cells
react more sensitive upon CD28SA stimulation compared to
Macaca T cells.
Alternatively, the number/size and/or distribution of lipid rafts
might differ between monkey and human T lymphocytes. Finally,
three non-conservative amino acid exchanges are present within
the transmembrane regions of Macaca monkey and human CD28
which might influence the lateral interactions between CD28 and
other signaling molecules within the plasma membrane. Clearly,
these points need to be investigated in the future.
Collectively, our functional and biochemical data provide a first
explanation for the severe adverse effects induced upon TGN1412
administration to human beings. Further, they show that in spite of
absence of toxicity signals in the Macaca model that is broadly
considered as the golden standard for preclinical tests, a detailed in
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vitro analysis of human cells is still mandatory to reduce risks
inherently related with first-in-man studies.
Materials and Methods
Animals
Macaca mulatta (rhesus monkey) and Macaca fascicularis (cynomol-
gus monkey) were kept under conventional conditions at the
Central Animal Facility of the Paul-Ehrlich-Institut, Germany.
The animals are regularly screened for infections according the
recommendations of EUPRIM-Net including tuberculosis, alpha-
herpes virus, SIV, STLV, filovirus, and others. Experimental work
was carried out in compliance with regulations of German animal
welfare.
T cell purification
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll gradient (Biochrom) centrifugation of heparinized blood
collected from healthy volunteers. Human T cells were further
purified by non-T cell depletion using the Pan T cell isolation kit II
(Miltenyi Biotec). For monkey T cell enrichment, monkey blood
was Ficoll purified using individually adjusted Ficoll dilutions
(between 95 and 100%). Then T cells were MACS purified using
the Pan T cell isolation kit for non-human primates (Miltenyi
Biotec). Human CD8+, CD4+, CD4+/CD45RA+ naı¨ve, and
CD4+/CD45RO+ memory T lymphocytes were purified using
the CD4+/CD8+ T cell isolation kit and the CD4+ naı¨ve/memory
T cell isolation kit (Miltenyi Biotec).
Antibodies
For the different applications the following antibodies were
used: for cytokine release assays and proliferation assays the CD3e
monoclonal antibody OKT-3 (purchased from ATCC) was used
as hybridoma supernatant. Stimulations for western blotting
experiments and calcium release assays were performed using
the CD3e monoclonal antibody MEM92, kindly provided by Dr.
Vaclav Horejsi, Prague Academy of Sciences, Prague, Czech
Republic. For conventional co-stimulation, hybridoma superna-
tant of the CD28 monoclonal antibody 248.23.2 [22,46] or
commercially available CD28.2 (Biosciences) was used. The
superagonistic CD28 antibody ANC28.1/5D10 was obtained
from Ancell (referred to as ANC28.1 throughout the text) and
humanized superagonistic CD28 antibody TGN1412 was a gift
from Thomas Hanke.
In vitro proliferation assays
96-well round-bottomed tissue culture plates (Costar) were
coated with a 1:400 v/v dilution of polyclonal goat-anti-mouse
antiserum (specific for IgG and IgM, 50 ml/well). Plates were then
washed three times with phosphate buffered saline (Seromed) and
either 100 ml of CD3e mAb OKT-3 (1:2 v/v dilution of
hybridoma culture supernatant), 100 ml of conventional CD28
mAb 248.23.2 (1:2 v/v dilution of hybridoma culture supernatant)
or 100 ml of a 1:1 mixture of OKT-3 and 248.23.2 culture
supernatants were added. For CD3xANC28.1 induced prolifera-
tion 100 ml of a 1:2 v/v dilution of hybridoma culture supernatant
of CD3e mAb OKT-3 were supplemented with 10 mg/ml of
ANC28.1 were used. Alternatively, T cells were incubated with the
indicated concentrations of ANC28.1 or TGN1412 and cross-
linked with goat anti-mouse (IgG+IgM) polyclonal serum (Dia-
nova) or purified mouse anti-human IgG4 monoclonal antibody
(BD Pharmingen), respectively. For T cell proliferation experi-
ments, 56104 T cells/well were added in a final volume of 200 ml.
[3H]-thymidine (0.3 mCi/well; specific activity 50 Ci/mmol) was
added for the last 8–10 hours of the three day incubation and cells
were harvested using a PHD cell harvester. Thymidine incorpo-
ration was measured by liquid scintillation in counts per minute
[cpm].
In vitro cytokine production
Cells were stimulated in vitro in triplicates as described for T
cell proliferation. Approximately 48 hours after onset of the
stimulation 50 ml of culture supernatant was removed from each
well. Triplicate supernatants were pooled and 50 ml of each pool
was then used in the TH1/TH2/Inflammatory Cytometric Bead
Arrays (CBA) from Becton Dickenson according to the manufac-
turer’s recommendation. Cytokine expression is shown in signals
per minute [spm]. Data shown represent the mean of at least three
individual experiments.
To determine the concentration of IFN-c and IL-2 after short
term stimulation of T cells, the cell suspension was adjusted to
16105 T cells/200 ml. Cells were stimulated as described above
for the indicated periods of time. Subsequently, 50 ml culture
supernatant was removed and diluted 1:3 v/v in culture medium.
The concentrations of IFN-c and IL-2 were determined using the
Quantikine ELISA system from R&D Systems according to the
manufacturer’s recommendation. To assess the molecular require-
ments for CD28SA-mediated IFN-c and IL-2 production the
following inhibitors were used: EGTA (1 mM), CaCl2 (2 mM),
cycloheximide (50 mg/ml; Sigma), CSA (150 ng/ml; Calbiochem),
PP2 (10 mM; Calbiochem), Wortmannin (0.1 mM; Calbiochem),
and Ly294002 (20 mM; Calbiochem).
Western blotting
T cells were lysed in buffer containing 1% lauryl maltoside (N-
dodecyl b-maltoside), 1% NP-40, 1 mM Na3VO4, 1 mM PMSF,
10 mM NaF, 10 mM EDTA, 50 mM Tris pH 7.5, and 150 mM
NaCl. Postnuclear lysates were separated by SDS-PAGE and
transferred onto nitrocellulose membranes. Membranes were
probed with the indicated primary antibodies and the appropriate
HRP-conjugated secondary antibodies (Dianova) and developed
using the ECL detection system (Amersham Pharmacia). The
following antibodies were used for western blotting in this study:
anti-pErk1/2 (Thr202/Tyr234), anti-pZAP70 (Y319), anti-pLAT
(Y171), anti-pJNK (Thr183/185), anti-pp38 (Thr180/182), anti-IkBa,
anti-AKT, and anti-GSK3b-1 (all from Cell signaling), anti-
PLCc1 (Y783, Santa Cruz), anti-NF-ATc1 (Alexis/Axxora), anti-b-
actin (Sigma), anti-pVav (Y174 Santa Cruz), and anti-pSLP76 (BD
Biosciences).
Calcium measurements
Purified T cells (26107 cells/ml) in RPMI medium (phenol-red
free; Invitrogen) containing 10% FCS were loaded with 5 mg/ml
Indo-1-AM (Molecular Probes) at 37uC for 45 min. After washing,
cells were incubated in RPMI medium supplemented with 10%
FCS (phenol-red free) at 37uC for an additional 45 min. The
measurement was performed on a FACSortTM flow cytometer
(Becton Dickinson). The kinetics of the data was analyzed with
FlowJo software (TreeStar).
Sequencing
Blood was taken from 14 individuals Macaca mulatta (rhesus
monkey) and 11 individuals Macaca fascicularis (cynomolgus
monkey). The animals analyzed belong to different families and
were from different origins to avoid inbreeding effects. RNA from
blood cells was isolated using Paxgene RNA Blood Kit (Qiagen) in
combination with Paxgene Blood RNA tubes (Preanalytix). RNA
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was incubated with DNase I (Roche) for 15 min at 37uC and
cDNA was prepared by using SuperScript II (Invitrogen)
according to manufacturer’s instructions. RT-PCR with RNA as
template using GAPDH-specific primers confirmed the absence of
genomic DNA within all samples and controls with no template
confirmed specificity. Primers used for amplification were the
following (sequences listed in 59 to 39 orientation): GAPDH:
ACCACAGTCCATGCCATCAC and TCCACCACCCTGT-
TGCTGTA; CD28: CTCACACTTCGGGTTCCTCG and
GGTCATTTCCTATCCAGAGC. RT-PCR fragments were
sequenced both forward and reverse (MWG). Of note, there were
individual differences in the nucleotide sequences not resulting in
exchanged amino acids.
FACS Analysis
For FACS analysis TGN1412 was labeled using the Alexa
FlourH488 monoclonal labeling kit (Invitrogen/Molecular Probes)
according to the manufacturer’s instructions. Human and monkey
blood was stained with TGN1412-Alexa FlourH488 at the
indicated concentrations in a total volume of 50 ml. Human and
monkey cells were stained using the following antibodies: anti-
CD3-PE, -APC or -FITC, anti-CD4-PE, anti-CD8-FITC or -
PerCP (all from BD). After washing with FACS-buffer, samples
were incubated with blood lysing buffer (BD Pharm LyseTM) for
2–3 hours at 4uC and washed again. Cells were analyzed via Flow
cytometry (LSRTM II; BD) and evaluated with DIVAH software.
One representative experiment out of three comparable experi-
ments is shown.
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Naive B cells are ineffective antigen-
presenting cells and are considered un-
able to activate naive T cells. However,
antigen-specific contact of these cells
leads to stable cell pairs that remain
associated over hours in vivo. The physi-
ologic role of such pairs has not been
evaluated. We show here that antigen-
specific conjugates between naive
B cells and naive T cells display a
mature immunologic synapse in the con-
tact zone that is absent in T-cell–dendritic-
cell (DC) pairs. B cells induce substan-
tial proliferation but, contrary to DCs,
no loss of L-selectin in T cells. Surpris-
ingly, while DC-triggered T cells de-
velop into normal effector cells, B-cell
stimulation over 72 hours induces regu-
latory T cells inhibiting priming of fresh
T cells in a contact-dependent manner
in vitro. In vivo, the regulatory T cells
home to lymph nodes where they po-
tently suppress immune responses such
as in cutaneous hypersensitivity and
ectopic allogeneic heart transplant rejec-
tion. Our finding might help to explain
old observations on tolerance induction
by B cells, identify the mature immuno-
logic synapse as a central functional
module of this process, and suggest the
use of naive B-cell–primed regulatory
T cells, “bTregs,” as a useful approach
for therapeutic intervention in adverse
adaptive immune responses. (Blood.
2007;110:1519-1529)
© 2007 by The American Society of Hematology
Introduction
Naive B cells are poor antigen-presenting cells (APC) for naive
T cells. In many systems, they have been dispensable for CD4
T-cell priming.1,2 Yet antigen presentation by naive B cells is not an
immunologic null event. Animals can be rendered tolerant toward
antigens presented by naive B cells.3 Indeed, evidence suggests that
B cells can take part in antigen presentation via major histocompat-
ibility complex (MHC) II molecules4-7 and might even be required
to reach full T-cell effector potential.8
We have previously shown that naive B cells, despite low
efficiency on a per cell basis, when loaded with specific peptide
antigen can induce antigen-specific proliferation in naive T cells.9
However, the biophysics of the underlying T-B contact was very
different from bona fide T-cell activation by dendritic cells (DCs).10
While T-cell contacts to DCs were dynamic and sequential,
contacts to B cells were mostly very stable in vitro and in vivo.9,11
The functional significance of this discrepancy is not clear.
Information transfer between T cell and APC during cell-cell
interaction is characterized by the formation of a supramolecular
assembly of signaling and adhesion molecules termed immuno-
logic synapse (IS).12 Its exact function is still debated yet it is
generally accepted as a T-cell activating structure.13,14,14 A mature
IS presents with a distinguished central part of the supramolecular
activation cluster (c-SMAC) enriched in signaling molecules like
T-cell receptor (TCR) and MHC, and a peripheral part (p-SMAC)
enriched in adhesion molecules.15 The formation of a mature IS
takes between 30 to 60 minutes.12 Encounters between DCs and
T cells in early and late phases of immune responses, however, last
only for several minutes.16,17 This is too short to form a mature IS.
In contrast, antigen-specific contacts to naive B cells invariably last
several hours.9 It is unclear whether a mature synapse can form
under these circumstances.
Based on these arguments, we reasoned that the molecular
organization of the IS between T cells and naive B cells might be
different from the one found in T-DC pairs. We also wanted to
test the potential consequences for the resulting activated CD4
T cells. To further evaluate the outcome of antigen-specific
CD4 T-cell stimulation by naive B cells, we investigated the
molecular structure of the underlying IS and the phenotype of
CD4 T cells after in vitro contact with specific-antigen loaded
naive B cells or DCs.
We present evidence that stimulation of naive T cells by naive
B cells results in formation of a mature IS which is absent in
DC–T-cell pairs. In addition, while DC stimulation generates
classical effector T cells, naive B-cell–activated T cells show
regulatory capacity in vitro and in vivo.
Materials and methods
Mice
DO11.10 mice carrying a transgenic TCR that recognizes a peptide of
chicken ovalbumin (AA 323-339), pOVA, in context with I-Ad,18 and OT-II
mice carrying a TCR that recognizes the identical peptide in context with
I-Ab 19 were used as T-cell sources. C57BL/6 (H-2b) and Balb/c (H-2d) mice
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as sources of B cells and bone marrow DCs (bmDCs, DCs) were
purchased from Harlan Germany. IL-10 KO mice were a kind gift from
Werner Mu¨ller, Helmholtz Centre for Infection Research (HZI), Braun-
schweig, Germany. Animals were housed under specific pathogen-free
conditions and treated according to institutional guidelines. All animal
experiments were approved by the animal protection committee of the
regional board of Braunschweig, Germany.
Cell preparation
Naive CD4 T cells from spleens of DO11.10 or OT-II mice were enriched
by negative isolation via immunomagnetic depletion (Miltenyi, Bergisch-
Gladbach, Germany) to purities of more than 90% and 80%, respectively
(75%-85% TCR transgenic). Separation of naive splenic B cells from
Balb/c or C57BL/6 mice resulted in purities between 90% to 95%
B220/MHCII/cells. Pre-activated B cells were generated by coculture
of naive B cells with T cells in a 1:1 to 1:2 (T:B) ratio. After 72 hours,
pre-activated B cells were isolated as described above. BmDCs (DCs) were
generated in 8-day cultures as described20 and activated with 20ng/mL LPS
(E.coli 0111, B4; Sigma, Deisenhofen, Germany) during the final 2 days of
culture. Cell lines secreting murine granulocyte-macrophage colony-
stimulating factor or IL-4 were kindly provided by Thomas Blankenstein,
Max Delbru¨ck Center for Molecular Medicine (MDC), Berlin. pOVA
(10 g/mL; Peptide Core facility, HZI, Braunschweig, Germany) was
added to the cultures of B cells, and DCs overnight and for the final 4 hours,
respectively, before use.
In vitro T-cell activation assays
Primary T-cell activation. Naive T cells (105) were cocultured in 96-well
round bottom plates (Nunc, Roskilde, Denmark) with 104 mature, antigen-
loaded DCs or 105 antigen-loaded B cells unless noted otherwise. The liquid
medium used was RPMI-based and fetal calf serum (FCS) supplemented
(Gibco, Los Angeles, CA). For some experiments, 3-D collagen gels were
used.10 Gels were digested by type VII collagenase (30 U/100mL gel for
30 minutes at 37°C; Sigma). For estimation of T-cell proliferation, naive
T cells were stained with 5,6-carboxyfluorescein diacetate, succinimidyl
ester (CFSE, 0.5 M; Molecular Probes, Leiden, Netherlands). To obtain
B-cell– and DC-primed T cells, cocultures underwent immunomagnetic
depletion of non-CD4 cells after 72 hours. Naive T cells were CFSE-
labeled and cocultured with DCs as described in “Cell preparation.”
Varying numbers of B-cell– (TofB) or DC (TofDC)–primed T cells were
added to test their inhibitory effects on naive T cells, typically at a ratio of
1:1 (T primed: T naive). Readouts for proliferation or activation markers
were taken at 72 hours by flow cytometry.
Transwell experiments
Transwell experiments were done in 24-well plates (Nunc) using 106 naive,
CFSE-labeled CD4 T cells plus 105 antigen-loaded mature DCs. In
addition, 106 TofDCs, TofBs, or naive T cells were either directly added
or placed in transwell chambers (Millicell, 0.4 m; Millipore, Billerica,
MA) in the same well. Readouts for proliferation were taken at 72 hours
by flow cytometry.
Adoptive transfer and flow cytometric determination of in vivo
distribution of T cells
Primed T cells were dually stained with CFSE and with Cell Tracker
Orange (CTO), 5-(and-6)-(((4-chloromethyl)benzoyl)amino) tetramethyl-
rhodamine-mixed isomers (CMTMR; Molecular Probes), or carbocyanine
(DiD, Vybrant DiD; Molecular Probes). T cells, 5  106 per type, were
intravenously injected into tail veins. At indicated timepoints, mice were
anesthesized with Isoflurane (Deltaselect, Pfullingen, Germany), bled
by retroorbital venous puncture and killed to obtain spleen, Peyer
Patches, and mesenteric, inguinal, popliteal, axillar, and cervical lymph
nodes. Flow cytometric analysis of transferred cells was done based on
the dual dye labeling.
Flow cytometry of surface activation marker
and intracellular cytokines
The anti-CD11c was from Caltag (Burlingame, CA); antibodies against
other surface markers came from BD Pharmingen (San Jose, CA);
CCL19-huFc-Protein and anti-huFc were from eBioscience (San Diego, CA);
anti-IL-2, anti-IL-4, IL-10, and IFN were from Invitrogen (Karlsruhe, Ger-
many); the Fix&Perm Kits with Golgiplug from BD Pharmingen; anti-Foxp3
(FJK 16s) and staining kits were from eBioscience. Flow cytometry was
performed on a BD Pharmingen FacsCalibur. Mean fluorescence intensity
(MFI) was shown against the secondary antibody control.
ELISA
OptEIAkits (BD Pharmingen) were used for determining IL-2, IL-10, and IFN.
Immunohistology/confocal microscopy
Fixed cell pairs were generated by mixing DO11.10 T cells with pOVA
loaded naive Balb/c B cells in a ratio of 1:1, with pre-activated B cells 1:5,
and with mature DCs 1:5 (T cell: APC), in 96-well round bottom plates in
FCS-supplemented RPMI-based media for 2 hours. Cells were transferred
onto Poly-L-Lysine (Sigma)–coated cover slips, fixed with warm 4%
paraformaldehyde and permeabilized with 0.1% Triton X-100 (Sigma) in
PBS. Blocking with 5% horse serum in 1% bovine serum albumin (BSA,
Sigma). Staining in 1% BSA using 2 U/mL Alexa-488-Phalloidin (Molecu-
lar Probes), 5 g/mL biotinylated anti-DO11.10 TCR (KJ1.26, Caltag), and
5 g/mL Streptavidin-Cy3 (Dianova, Hamburg, Germany). Samples were
mounted in Mowiol (Calbiochem, Darmstadt, Germany) with 2.5 mg/mL
N-Propylgallate (Sigma) as antifading reagent. Analysis was done with an
Olympus FluoView1000 confocal microscope (Olympus, Hamburg, Ger-
many) performing 3-D-reconstructions of z-stacks (mean width 0.2 m/
slice), scanning with 40 s/Pixel using Kalman mode. Images were taken
with a PLAPO 100/TIRFM-SP, NA 1.45 oil immersion lens at room
temperature. Reconstructions were made with the Olympus FluoView
Software FV10-ASW, version 1.6 as well as with LSM Image Browser
version 4.0 (Zeiss, Jena, Germany).
2-photon-microscopy of explanted lymph nodes
Naive T cells, TofBs, and B cells were labeled with 1 M CFSE, CTO, or
7-amino-4-chloromethylcoumarin (CMAC, also called CTB, Cell Tracker
Blue, Molecular Probes). Inversion of colors had no effect on results. TofBs
(107) were injected intravenously into the tail veins of Balb/c mice 48 hours
before imaging; 2  107 naive T cells and 3  107 naive B cells were
applied 24 hours before imaging. Inguinal lymph nodes were removed and
immediately subjected to imaging in pH-stabilized culture media constantly
warmed to 37°C. Three-D 2-photon microscopy was performed with a
MaiTai laser (Spectra-Physics, Darmstadt, Germany) running at 800 nm, a
multibeam scanhead (LaVision Biotech, Bielefeld, Germany) and an
Olympus BX51WI stage equipped with a XLUMPL 20/0.95 NA water
dipping lens. Image detection was made with a cooled CCD-camera
(Imager Intense; LaVision, Goettingen, Germany). For estimation of TofB
distribution, RGB z-stacks of 200  200 m images were recorded in
48 steps of 3m. A total of 932 cells were quantified in 14 extended focus
projections within B follicles ( 90% B cells), in T-cell zones ( 80%
T cells), and in mixed T-B areas, respectively.
Contact hypersensitivity
Mice were sensitized by painting 100 L 2,4-dinitrofluorobenzene (DNFB)
solution (Sigma; 0.5% in acetone/olive oil 4:1) on the shaved backs on
day 0 as described.21 On day 5, the left ear was challenged by applying
12 L 0.3% DNFB, and the right ear was treated with acetone/olive oil
alone. Ear swelling was measured in a blinded fashion with a spring-
loaded micrometer (Mitutoyo, Hamburg, Germany) 48 hours after
challenge (day 7). Contact hypersensitivity was determined as amount
of swelling of the hapten-challenged ear compared with thickness of
vehicle-treated ear and was expressed in m (mean  standard devia-
tion [SD]). Mice that were ear-challenged without previous sensitization
1520 REICHARDT et al BLOOD, 1 SEPTEMBER 2007  VOLUME 110, NUMBER 5
served as negative controls. The immunoregulatory effect of adoptively
transferred primed T cells was tested by intravenously transferring 0.5 to
5  106 MACS-separated DC–primed or B-cell–primed T cells at day 1
(for inhibition of priming) or at day 4 (for inhibition of challenge), or at
d 10 (for inhibition of priming at later stage after transfer). In the latter
case, mice received an (un)specific antigen boost at day 1. Control mice
received media only. Each group consisted of 8 mice.
Allogeneic heart transplantation
Heterotopic vascularized heart transplantation was carried out according to
the method of Corry et al.22 Male C57BL/6 (H-2b) and female BALB/c
(H-2d) were used as donors and recipients, respectively. Briefly, animals
were anesthetized with isoflurane. The donor pulmonary artery was
anastomosed to the recipient inferior vena cava and the donor ascending
aorta was anastomosed to the recipient abdominal aorta. 2 experimental
groups of 6 animals each were evaluated: Recipients of the control group
were treated with saline and recipients of the TofB group received 5  106
cells via tail vein injection 24 hours prior to transplantation. No other
immunosuppressive treatment was administered. Graft function was as-
sessed by daily palpation. Rejection was defined as the lack of palpable
cardiac contraction.
Statistical analysis
Survival analysis was performed using a Kaplan-Meier estimator as part of
the statistical package in GraphPad Prism 4 (GraphPad Software, San
Diego, CA). For all other statistics, Student t test was applied. Significance
levels used are indicated in “Results.”
Results
Naive B cells signal to naive T cells via a mature
immunologic synapse
To study the molecular makeup of the interface between naive
T cells and different APC, we established pairs of chicken ovalbumin-
specific T cells18 interacting with either naive splenic B cells or
mature bmDCs, each loaded with specific peptide. Since the initial
description of the mature immunologic synapse,15 a large number
of molecules were found to be characteristically located at c- and
p-SMAC, respectively. The prototypic marker for c-SMAC is the
TCR complex.15 A more recent study shows that f-actin is highly
enriched in p-SMAC.23 Thus we chose to study the spatial
distribution of f-actin and the peptide-specific TCR. T cells (Figure
1A,E,I) and naive B cells (Figure 1A) recruited the majority of their
cortical actin cytoskeleton toward the contact zone, while DCs
(Figure 1I) showed a very prominent actin scaffold that was not
enhanced at the T-cell contact. While with T cells contacting naive
B cells (Figure 1A) almost the entire TCR was located at the B-cell
contact zone, surprisingly, the TCR in T cells contacting DCs
remained scattered over the entire T-cell surface (Figure 1I).
A three-dimensional reconstruction confirmed that in the contact
plane to DCs no c-SMAC enrichment of TCR or p-SMAC
enrichment of actin was detectable (Figure 1J,L). However, the
contact zone to B cells presented as a structure with highly
concentrated actin in the p-SMAC and the majority of TCR signal
in the c-SMAC (Figure 1B-D). This pattern was consistently found
in almost 90% of T naive B pairs, while more than 90% of the DC
contacts did not show a mature IS (Figure 1M). To assess the
impact of the activation state of the B cell, we also analyzed pairs of
preactivated B cells and T cells (Figure 1E-H). Preactivated B
cells showed an intermediate phenotype of IS formation with
heterogenous IS structures. In some cases this plasticity of IS
phenotype could even be found on a single preactivated B cell
contacting multiple naive T cells (Figure 1F-H and F’-H’).
Quantitatively, the majority (80%) of preactivated B cells did not
show a c-SMAC-(mature)–type of IS, while 20% did (Figure 1M).
As parameter for the activation level we measured expression of
the primary costimulatory molecules CD80 and CD86 and found
an increase in CD86 in preactivated B-cells and an increase of
Figure 1. Naive B cells naive T cells form a mature immuno-
logic synapse. Mature bmDC or naive or preactivated splenic
B cells were loaded with pOVA. Cells were mixed with naive
DO11.10 T cells and fixed after 120 minutes of interaction.
Immunohistologic staining was performed for actin (green) and
the clonotypic TCR (red). Individual pairs of T cells and naive
B cells (A-D), T cells and preactivated B cells (E-H’) or T cells and
DC (I-L), respectively, were analyzed by 2-color confocal micros-
copy making Z-stacks over the entire range of a cell pair. T cells in
contact with B cells have the entire TCR signal at the contact
plane (A), while T cells attached to DC show TCR staining
scattered over the body (I). T cells in contact with preactivated
B cells show both accumulation of TCR and distribution over the
whole T-cell surface (E). A three-dimensional reconstruction
showing the en face view of the contact plane reveals no
preferential accumulation of TCR in the contact with DC, see
Actin-stain (J), TCR-stain (K), and merged image (L). In contrast,
in T-cell–naive B-cell pairs the TCR signal is focused in the center
of contact (B-D). Interactions with preactivated B cells show
partially the formation of a mature IS (F-H’). Shown is a T-B
interface resembling a mature IS, yet with substantially scattered
TCR (T cell at 6 o’clock, F-H); and an interface between the same
preactivated B cells interacting with a second T cell, showing
almost no IS segregation (T cell at 2 o’clock, F’-H’). The scale bar
defines 5 m (A,E) and 10 m (I), respectively. (M) Quantitative
analysis of 300 random individual cell pairs for the distribution of
TCR in the contact plane. (N) Mean Fluorescence Intensity (MFI)
analysis of the expression of costimulatory molecules on APC.
While naive splenic B cells show only a sparse expression of
CD80 and CD86, CD86 is clearly up-regulated upon B-cell
activation. DCs exhibit a high amount of CD80 as well as CD86 on
their surface. (M,N) Bars represent mean plus or minus SD.
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CD80 and CD86 in DCs compared with naive B cells (Figure 1N).
IS formation in B-T pairs was antigen-specific as no IS formation
was seen when B cells were left unloaded (data not shown). Taken
together, naive B cells loaded with specific antigenic peptide
engage naive T cells under formation of a mature IS.
CD4 T-cell stimulation by specific antigen-loaded naive B cells
results in activated T cells with an unusual phenotype
We now asked whether the phenotype of activated CD4 T cells
based on such diverse IS structures would differ. We therefore
focused on naive B cells and mature DCs as these APC had shown
the most extreme forms of IS structure (Figure 1). We first looked at
the induction of T-cell proliferation and changes in characteristic
activation markers. After 72 hours of in vitro stimulation with
pOVA-loaded naive C57BL/6 B cells, TCR-transgenic OT-II
T cells showed clear induction of proliferation (Figure 1A). When
appropriate numbers of APC were used (B:T  1:1; DC:T  1:10),
equivalent proliferation levels were reached. In addition, efficient
and, within the type of APC, equivalent up-regulation of CD69 and
CD44 (not shown) as well as CD25 (Figure 2A top row) was
induced. Interestingly, under identical conditions, only DCs, but
not B cells, induced down-regulation of CD62L in T cells driven
into proliferation (Figure 2A bottom row). CD62L is a key
molecule mediating T-cell entry into lymph nodes; its down-
regulation is a hallmark for effective CD4 T-cell activation.24 This
effect was seen for all peptide concentrations tested, while DCs
showed a similar behavior only at very low antigen concentrations
in vitro (Figure 2B). Loading APCs with intact protein instead of
peptide led to similar results (data not shown). As it was possible
that the observed discrepancy between effective induction of prolifera-
tion and ineffective down-regulation of CD62L was an artifact of the
two-dimensional liquid culture system, we looked at T-cell priming in a
three-dimensional collagen matrix featuring a network of type I
collagen fibres, the major component of the extracellular matrix.
Cell behavior measured in this three-dimensional matrix closely
resemble values observed in vivo.9-11,25-27 Again, under conditions
where equivalent and effective T-cell activation (based on CD69
levels) could be observed, DCs effectively down-regulated CD62L
while B cells did not (Figure 2C). Next we wondered whether the
induced phenotype of B cells was dominant over simultaneous DC
stimulation. Thus, we looked at T-cell activation after contact with
a mixture of B cells and DCs. As seen in Figure 2D, in the presence
of 10% (compared with B cells) DCs, CD62L was down-regulated,
indicating the dominance of T-cell activation by DCs over the one
by B cells when both cell types were used as APC. This supremacy
could be detected even at DC numbers as low as 1% (data not
shown). The dominating role of DCs as APC in vivo has been
demonstrated extensively.28 In conclusion, exclusive stimulation of
T cells by naive B cells results in activated T cells that retain high
levels of CD62L.
In vivo, B-cell–stimulated T cells, TofBs, preferentially migrate
to lymph nodes
Our result that naive B-cell–activated T cells, TofBs, did not
down-regulate CD62L made us investigate possible implications of
this finding in vivo. As CD62L mediates the entry of T cells into
lymph nodes,29 we reasoned that TofBs would predominantly
migrate there. Indeed, when adoptively transferring intravenously
Figure 2. Antigen-specific T-cell activation by B cells leads to generation of T cells with aberrant phenotype. Naive splenic CD4 T cells were cocultured in vitro with
mature DC or B cells, both loaded with specific antigenic peptide. After 72 hours, proliferation and expression of surface markers were determined by fluorescence-assisted cell
sorting (FACS). (A) Specific antigenic peptide loaded B cells efficiently induce proliferation and up-regulation of CD25 in CD4 T cells. In contrast to DC, however, B cells fail to
down-regulate CD62L. (B) B cells remain unable to down-regulate CD62L even at high antigen doses. (C) The failure to downmodulate CD62L levels by B cells is not restricted
to a two-dimensional environment as it is also seen in a three-dimensional environment using a collagen matrix. (D) CD62L is down-regulated in cultures in which DC were
added (10% of corresponding B-cell number). The data shown are representative of 3 to 5 independent experiments.
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equal numbers (5  106) of dually stained TofBs or DC-primed
T cells (TofDCs), respectively, TofBs clearly outnumbered trans-
ferred TofDCs in peripheral lymph nodes. In contrast, both
populations were found at equal proportions in blood and spleen,
where CD62L is not involved in the entry of cells30 (Figure 3A-C).
We also measured expression of CCR7, another important homing
receptor for entry into lymph nodes. Using a monoclonal
antibody as well as a CCL19-Fc fusion protein we found that
TofBs retain CCR7 at levels similar to those in naive T cells (data
not shown). However, as TofDCs showed comparable CCR7
expression, this molecule is unlikely to account for the differences
in homing we observed.
To assess more precisely the localization of TofBs within the
lymph node we used two-photon microscopy imaging studies. We
found that adoptively transferred TofBs resided primarily in T-cell
zones and were basically excluded from B-cell follicles (Figure
3D,E). Thus, B-cell–primed T cells migrate preferentially to the
T-cell zones of peripheral lymph nodes where cell entry from the
circulation is known to be mediated by CD62L.
TofBs (but not TofDCs) regulate priming of naive T cells
The propensity of TofBs to home into lymph nodes might affect
their involvement in immune responses. Classical CD4 T-cell
activation results predominantly in short-lived effector cells that
home to peripheral sites of infection/inflammation.31-33 In addition,
a fraction of activated cells turns into effector memory (EM) and
central memory (CM) cells.34 While EM are long-lived in periph-
eral organs, CM remain localized in central lymphatic tissue, most
notably the spleen.34 TofBs share a CD4 CD62L phenotype with
CM, yet do not preferentially home to the spleen (Figure 3). We
also tested for a recently identified key memory T-cell marker,
CD127 (IL-7 receptor alpha chain), which is important for cells of
the CD835,36 and to some degree also of the CD4 lineage.37,38
TofBs showed very low levels of CD127 on days 3 and 7 of the
priming process (data not shown). Collectively, there was no
evidence that TofBs belong to the memory T-cell lineage. Interest-
ingly, there are reports that absence of expression of human CD127
correlates with a regulatory function.39 Such regulatory T cells of
natural occurrence (nTreg) are characterized by CD4, CD25 double
positivity.40 In addition, the subgroup of CD62Lhigh nTregs was
shown to have regulatory activity in autoimmune processes.41,42
Thus, we wanted to see whether the CD4/CD25/CD62Lhigh
TofBs also show regulatory capacity.
The key activity of Tregs is the (down)regulation of an immune
response, the inhibition of T-cell proliferation.43 We therefore
tested the effect of TofBs on fresh, naive T cells during priming by
specific-antigen-loaded DCs in vitro. Indeed, TofBs inhibited
almost completely the induced proliferation in naive T cells,
whereas TofDCs did not (Figure 4A). The effect could be titrated
and depended on the ratio of Treg versus T naive (Figure 4B). The
inhibitory effect was seen upon priming by peptide but not by
protein antigen (Figure 4C). The reason for the inability of protein
to induce Tregs is most likely the well-known inherent incapability
of B cells to take up and present complete protein. More than 100
times higher amounts of protein on a weight basis than peptide
were necessary to induce T-cell proliferation in our system (data
not shown). Thus, the great majority of T cells remain naive (based
on low expression of CD69, CD25, CD44, and absence of
CFSE-diluted proliferation, data not shown) after contact to B cells
loaded with protein and, therefore, do not show regulatory capacity.
We also included pre-activated B cells in our studies and
compared them with naive B cells and DCs in their capacity to
induce regulatory T cells. We found that T cells generated by
antigen-specific contact with pre-activated B cells (TofBpre)
inhibit the proliferation of naive T cells in vitro to some degree, yet
they do so clearly less than TofB(naive). In addition, TofBs retain
considerably less CD62L than TofB(naive) (data not shown). Taken
together and in accordance with our findings on IS formation
Figure 3. In vivo B-cell–primed T cells (TofB) preferentially migrate to lymph
nodes. T cells primed by peptide-loaded DC and B cells were differentially labeled
with live cell dyes. Equal numbers of TofDCs and TofBs were adoptively transferred
intravenously, and distribution of the cells was determined 24 hours after transfer by
organ removal and FACS analysis. (A) T cells for adoptive transfer were labeled with
CFSE; TofDCs were additionally labeled with CTO and TofBs with DiD. (B) Upon
organ analysis after transfer, equal numbers of TofDCs and TofBs as transferred can
be found in the spleen, whereas in lymph nodes TofBs clearly dominate. (C)
Distribution of the transferred T-cell populations in lymphatic organs 24 hours after
transfer. When analysis was performed at day 7 after transfer, a similar pattern was
observed (data not shown). The data shown are representative of at least 3
independent experiments. Within the lymph nodes, TofBs migrate to T-cell areas and
are excluded from B-cell follicles. A simplified drawing illustrates lymph node
architecture showing B-cell areas (blue), T-cell dominated areas [green], and the
imaged area shown above (red rectangle) at the transition of the 2 zones. (D) An
image stitched together of 6 individual extended focus projections of each 200  200 
144 m shows the transition from a B-cell follicle dominated by B cells (blue) to a
mixed T-B zone containing mostly naive T cells (green). Note that TofBs (red) are
found only in the T-cell area. Scale bar: 100 m. (E) A quantification of TofB
distribution analyzing 14 image stacks from within and outside B-cell follicles. TofBs
clearly show T-cell homing behavior and localize within T-cell–dominated areas but
are excluded from B-cell follicles. Bars represent mean plus or minus SD.
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(Figure 1), TofBpre show an intermediate phenotype with character-
istics between those found in TofB(naive) and TofDCs.
Taken together, we provide evidence that naive B-cell–primed
T cells, TofBs, can suppress the proliferation of naive T cells in vitro.
B cells substantially induce IL-2 and IFN in CD4 T cells
following antigen-specific contact. B cells are the source of
IL-10 found in T-B cocultures but the generation of regulatory
T cells is IL-10 independent
To explore the mechanism by which TofBs exert their regulatory
effect, we characterized the cytokine profile in T-APC-cocultures.
In T-DC– and T-B–cocultures, substantial and approximately
equivalent amounts of IL-2 and IFN were present (Figure 5A,B).
When identical numbers of B cells and DCs were used in their
respective cocultures, approximately half the amount (1415 pg/mL
vs 720 pg/mL) of IL-2 was induced after B-cell contact (Figure
5A). Interestingly, we found much higher levels of IL-10 in the
supernatants of T-B–cocultures than in supernatants of T-DC–
cocultures (Figure 5B). This appeared noteworthy at this point as
one regulatory T-cell subset (TR cells) is known to act via secretion
of IL-10.44,45 However, when tested at single cell level by
intracellular cytokine staining, B cells were revealed as the
source of IL-10 (Figure 5C,D). Previously, IL-10 produced by
APC was found to be involved in induction of a tolerogenic
T-cell phenotype.46-48 However, subsequent testing in our study
with B cells from IL-10 KO mice revealed that IL-10 was
Figure 4. TofBs show regulatory capacity and suppress the proliferation of
naive T-cells. Differentially primed T cells were added to in vitro cocultures of naive,
CFSE-labeled CD4 T cells and mature DCs loaded with antigenic pOVA. At 72
hours, proliferation of the naive T cells was determined by FACS. (A) Upon addition of
TofBs but not of TofDCs, proliferation of naive T cells determined by CFSE-dilution is
markedly inhibited. Equal numbers of cells (105) were used. No proliferation is
observed when naive T cells are cultured in the absence of DCs. (B) The regulatory
effect of TofBs can be titrated. When TofBs were added at a ratio of 3:1 to naive T
cells, the effect was more pronounced. At a ratio of 0.03:1, minor effects can be seen.
In contrast, TofDCs do not show inhibition even at a 3:1 ratio over naive T. (C) The
inhibitory effect can only be observed after B-cell loading with specific peptide (pOVA)
but not with complete protein (Ovalbumin). The data shown are representative of 2 (panel
B) to 5 (panelsA,C) independent experiments. Dots represent the mean plus or minus SD.
Figure 5. Cytokine profile during the activation of T cells by B cells shows
substantial amounts of Th1 cytokines but also high levels of B-cell–derived
IL-10. Supernatants were taken from DC–T-cell and from B-cell–T-cell cocultures and
analyzed for cytokines by ELISA. Cells were analyzed for intracellular cytokines by
FACS at 48 hours of culture. (A) B cells induce substantial amounts of IL-2 in
supernatants of B-cell–T-cell cocultures, but DCs are at least twice as powerful on a
per-cell basis. Bars represent mean plus or minus SD. (B) While equivalent amounts
of IFN can be observed in supernatants of DC–T-cell and B-cell–T-cell cocultures, a
marked increase in the amount of IL-10 is found in cultures containing B cells.
(C) Intracellular cytokine staining reveals that IL-10 is produced by the CD4 negative
population. The level of induced IL-4 is low for all cells. (D) Costaining with the
specific B-cell marker CD19 identifies B cells as the source of IL-10. The data shown
are representative of 3 independent experiments.
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dispensable for the generation of TofBs with regulatory pheno-
type (data not shown). Thus, B-cell priming leads to substantial
induction of Th1 cytokines in T cells. B cells are the source of
concomitantly found IL-10 but the mechanism of induction of
T cells with regulatory phenotype is IL-10 independent.
The mechanism of regulation by TofBs requires close cell-cell
proximity and is independent of Foxp3
Naturally occurring, “classic,” CD4 CD25 Tregs were shown to
mainly act independently of soluble mediators such as cytokines
and to depend on very close cell-cell interactions as recently
reviewed.49 It was possible that TofBs also required the proximity
of interacting cells for proliferation inhibition. We tested this
hypothesis by using a Transwell membrane assay. This assay tests
whether for a given effect cells need to be in close proximity, either
because direct cell-cell contact is necessary or because potentially
required soluble messengers are released in limited amounts and
work only at short distances. Indeed, regulation by TofBs requires
naive T cells to be in close proximity (Figure 6A). A molecular
marker for classical CD4 CD25 Tregs is the transcription factor
Foxp3.50 If TofBs use identical mechanisms as these Tregs, a great
part of TofBs in contrast to TofDCs should be Foxp3. We found,
however, that this was not the case. Only 5% of TofBs were
Foxp3, the same amount as within TofDCs (Figure 6B). This
proportion was also unchanged from naive T cells (not shown).
Foxp3 cells resided exclusively in the CD4 CD25 population
(Figure 6C) but no correlation was seen with expression of CD62L
(Figure 6D). Most of the Foxp3 Tregs were CD62L low. In conclusion,
B-cell priming of T cells does not lead to an increased frequency of
Foxp3 Tregs. Therefore, we believe that TofBs act via pathways
different from the ones of classical Tregs and do not require increased
expression of Foxp3 yet need close cell-cell proximity.
TofBs inhibit priming of T cells during immune responses
in vivo
Having demonstrated immunoinhibitory effects in vitro we then
tested the effects of TofBs in vivo. First, we used a hapten
hypersensitivity assay, where TofB were added to recipients at
different timepoints to dampen an immune response elicited by
priming and challenge with DNFB. The resulting inflammatory
response was significantly reduced when TofBs were added to
recipients shortly before priming (Figure 7B). In contrast, when
TofBs were added shortly before challenge, no effect was seen
(Figure 7A). This discrepancy complies with our finding that TofBs
migrate preferentially to lymph nodes where they are most
effective during priming. Thus, we could show that TofBs mediate
immunoregulation during the priming phase of immune responses
in vivo.
We then tested whether TofBs maintain their function over a
longer time span and whether function at later timepoints requires
specific antigen restimulation. To this end we extended the hapten
hypersensitivity assay, injecting TofBs 10 days before sensitiza-
tion. Without specific restimulation, TofBs were not able to
suppress priming at day 0. However, the cells were still present and
functional as application of specific antigen at day –1 re-activated
suppressor function (Figure 7C). Thus, TofBs are present at least
10 days after intravenous transfer but only regulate upon specific
antigenic restimulation.
Finally, we wanted to test TofBs in a model of ectopic
allogeneic heart transplantation. Based on our observation that
TofBs preferentially home to lymph nodes, we expected them to
work most efficiently when applied before initiation of immune
response, before an immune challenge occurs. Indeed, TofBs were
able to successfully suppress rejection and prolong functioning of
transplanted allogeneic hearts significantly (Figure 7D). Thus,
TofBs are able to suppress solid organ transplant rejection in vivo.
Discussion
The outcome of interactions between resting B lymphocytes and
naive T cells has always spurred a controversial discussion.51
Initially, contacts were believed to be nonproductive in vivo.1
Later, evidence accumulated that B cells can induce toler-
ance.3,52 Under some circumstances, B cells were even found to
be effective T-cell activators.53 It is known that naive B cells
show a lesser number of MHC-II and coactivation molecules on
their surface than DCs,54 and Figure 1N. In that sense, B cells
may be similar to immature DCs, which can also induce T-cell
tolerance.55-57 However, to our knowledge this is the first report
that tolerization after B-cell contact can be mediated, at least in
Figure 6. The generation of T cells with regulatory capacity requires immediate
vicinity of cells but is independent of Foxp3. (A) To in vitro cocultures of naive,
CFSE-labeled CD4 T cells and mature DC loaded with antigenic peptide (pOVA
323-339), TofDC or TofB were added directly and via a semipermeable transwell
membrane. At 72 hours, proliferation of the naive T cells was determined by FACS.
Close cell contact is needed for exertion of the regulatory effect of TofB, as separation
from naive T cells plus DC via a transwell membrane abrogates the effect. (B-D) The
level of the transcription factor Foxp3 was determined via intracellular staining and
FACS after 72 hours of cocultures of naive splenic CD4 T cells with peptide-loaded
mature DC or B cells, respectively. (B) Preferential induction of Foxp3 T cells could
not be observed after B-cell contact; equally low numbers were found in Tof B and
TofDC. (C) The Foxp3 T cells are also CD25. Depicted is the result for the CD4
TofB population only. (D) The positivity of Foxp3 is independent of the CD62L level.
Depicted is the result for the CD4 TofB population only. The data shown are
representative of at least 3 independent experiments.
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part, by the de novo generation of T cells with regulatory
phenotype. Such pathways have hitherto been discussed for
immature dendritic cells58,59 and recent reports have suggested a
similar mechanism for human macrophages.60
What triggers the differential response of T cells toward these
distinct APC? The result of T-cell priming is defined at the level of
earliest interactions.61,62 Thus, individual IS structures might be
decisive for this process. We demonstrate formation of a mature IS
between a naive B cell and an antigen-specific T cell and its
absence in T-DC pairs. This appears surprising at first glance as
naive B cells are very ineffective antigen presenters and synapses
are generally considered structures leading to effector T-cell
generation.63 However, many studies demonstrating presence of
mature IS actually used B cells as APC.15,64,65 In contrast, a
thorough analysis of singular T-DC interactions revealed the
predominance of multifocal structures without a typical p-SMAC–
c-SMAC appearance.66 The function of theses structures is usually
judged by the measurement of T-cell proliferation.12 Our data show
that T-cell proliferation alone is not sufficient to characterize the
phenotype of a T cell. Only analysis of proliferated T cells in
secondary coculture assay allowed us to identify a regulatory role
of these cells.
The function of the synapse, especially of the c-SMAC, is intensely
debated.67 As it was shown that phospho-tyrosine levels are low to
absent in c-SMAC,68 the current concept considers c-SMAC as an area
of TCR internalization and signal termination.14 Signaling in
p-SMAC is constantly maintained in microclusters that are then
transported to c-SMAC.69,70 Such microclusters might also be
present in T-B synapses because B cells can induce long-lasting Ca2
signaling in T cells.9 As shown here, this could be the basis for deviation
of T-cell effector function to a phenotype with regulatory properties.
Thus, synapses formed between naive B cells and naive T cells may be
the prototype of a novel type of IS, the regulatory synapse.
We show that inhibition of T-cell proliferation by TofBs is cell
contact–dependent or at least requires close cell-cell interactions.
In addition we show that most TofBs localize in T-cell zones of
lymph nodes. This suggests interactions between TofBs and T cells
or DCs in the T-cell zone being the mode of action in vivo. Contacts
of Tregs with T-DC clusters impacting on recruitment of signaling
molecules in involved naive T cells have been demonstrated
before.71 However, the intrinsic molecular mechanism of how
Tregs can mediate cell-contact inhibition is insufficiently defined.
Many independent pathways seem to exist, none of which can
alone account for all aspects of regulation. Signaling molecules like
CTLA-4 and Cbl-b as well as immunosuppressive cytokines such
as IL-10, TGF beta and more may have important roles (for recent
reviews see Miyara and Sakaguchi72 and Graca et al73). TGF beta
may be especially important during peripheral generation of Treg,
most notably CD4 CD25 Foxp3 T cells.74,75 The Forkhead box
transcription factor Foxp3 is considered to be the most specific
intracellular marker for naturally occurring (n)Tregs.76 Thus, it was
unexpected that TofBs did not show enhanced Foxp3 expression.
However, the group of Treg phenotypes is expanding.77 In fact, also
Foxp3 independent Tregs have been described.45,78
The most obvious molecular T-cell marker differentially regu-
lated by B cells and DCs, respectively, in this study, was CD62L,
L-Selectin. This molecule is down-regulated on lymphocytes
within 30 minutes after activation79 by cleavage near the cell
Figure 7. TofBs inhibit priming of T cells during immune responses in vivo. (A-C) In a hapten hypersensitivity assay, Balb/C mice were sensitized against DNFB by
epicutaneous application on the back. Ears were challenged with DNFB 5 days later and ear swelling was measured 48 hours after challenge. T cells primed by different APCs
loaded with T-cell antigen–specific, hapten-unrelated, peptide (pOVA) were intravenously applied at different time points to modulate ear swelling. Ear swelling response is
expressed as the difference (m, mean  SD) between the thickness of the challenged ear and the vehicle-treated ear. *, P less than.05; ***, P less than .005 versus positive
control. (A) Adoptive transfer of primed TofDCs, and TofBs at 24 hours before challenge. Transferred cells were unable to modulate the ear swelling induced by the challenge.
(B) In contrast, when T cells were transferred before priming (at d 	1), a specific inhibitory effect of TofBs could be seen. The transfer of TofBs but not of TofDCs resulted in a
decreased immune response post challenge. (C) TofBs are functioning at 10 days after transfer yet require specific antigen restimulation. The suppressive effect shown after
transfer at d 	1 (as in panel B) is lost when cells were transferred already at d 	10 before priming. However, when hapten priming and specific antigen restimulation (pOVA)
occurred together, TofBs were rescued to suppress. In contrast, the application of an unspecific control antigen (pHA; Hemagglutinin peptide) had no effect. (D) In ectopic
allogeneic heart transplantation in the mouse model, TofBs effectively inhibit organ rejection. At d 	1 before ectopic transplantation of C57BL/6 donor hearts, Balb/c recipients
of the treatment group were injected with TofBs, while the control group received only a saline injection. No other immunosuppressive treatment was administered. Graft
function was assessed by daily palpation. Rejection was defined as the lack of palpable cardiac contraction. **, P less than.01 vs. control group.
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surface by a member of the A Disintegrin and Metalloprotease
(ADAM) family ADAM-17.80 However, other sheddases or addi-
tional factors may be required.81 Whether B cells activate shed-
dases differently than DCs is not clear. Spatial distribution of Tregs
was shown to be of great importance for their role in immune
responses.82-84 Likewise, manipulation of molecules involved in
lymphocyte homing and trafficking greatly affects lymphocyte
function.83 In that respect, it is important that our data provide a
model correlating the level of CD62L and, thus, the entry into
peripheral lymphatic organs with the regulatory function in vivo.
Our demonstration that antigen presentation by naive B cells
induces Tregs might help to explain older findings on induction of
specific tolerance in vivo against antigens presented by naive
B cells.3,85 Our data might also shed light on results from a recent
study where prolonged subcutaneous infusion of low peptide doses
transformed mature T cells into CD4 25 suppressors.86 In
accordance with our data, this approach proved effective in
inducing tolerance prospectively (priming phase), but it was open
whether ongoing immune responses could be suppressed (chal-
lenge phase). Involvement of B-cell antigen presentation to gener-
ate Tregs in both systems seems to be an attractive model to explain
their mode of action. Indeed, Matzinger has suggested that B cells,
by virtue of their large quantities, may indeed participate in T-cell
priming in a tolerizing manner.85 In light of our data, this might be a
consequence of de novo generation of Tregs. Such processes may
play a role in vivo as B-cell–deficient individuals tend to develop
autoaggressive phenomena.87,88 Interestingly, T cells specifically
activated in vivo show substantial proliferation yet remain CD62L
high in up to 50% of the proliferating cells (unpublished observa-
tions). This could be interpreted as result of DC-triggering low
antigen doses or as B-cell participation in T-cell priming. It is
tempting to speculate that a fraction of these in vivo activated
T cells is regulatory as well.
More importantly, even if physiologic relevance of naive B-cell
triggered T-cell activation in vivo may be limited facing overwhelm-
ing competition by professional APC, the process described by us
can have important clinical implications. As we show, B cells with
their specific way of inducing T-cell activation may prove powerful
for cell-based immunosuppression. Currently, DCs are the main
focus of strategies against alloreactivity, transplant rejection,
autoimmune diseases and allergy.89-94 However, generation of DCs
for therapeutic applications requires sophisticated handling, is
expensive, time-consuming, and difficult to standardize.92 In that
respect, B cells may be a better option for obtaining defined APC.
Indeed, genetically modified B cells have been used to tolerize
animals against epitopes of pathophysiologic relevance.95 Our
model provides a more direct approach without the need for
transgenic manipulation. It can be envisioned that the use of B-cell
primed regulatory T cells, TofBs or “bTregs,” may be a new way of
significantly improving current cell-based therapies.
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Original article
Fatty acids in colostrum from mothers of children at high risk
of atopy in relation to clinical and laboratory signs of allergy
in the first year of life
The relationship between fatty aids (FA), in particular
long chain polyunsaturated fatty acids (long chain
PUFA, LCP) and atopy has been heavily investigated
since the first observation of increased levels of linoleic
acid (LA, 18:2n-6) and lower levels of its long chain
metabolites in the plasma of patients with eczema (1). A
number of LCP are involved in inflammatory responses,
where most member of the n-6 PUFA series such as AA
(20:4n-6) and its metabolites leukotriene B4 and prosta-
glandin E2 show proinflammatory capacity (2). In con-
trast, the n-3 series, e.g. eicosapentaenoic acid (EPA,
20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3), are
mostly referred to as suppressing the inflammatory
response (3). The parent PUFA, LA (18:2n-6) and
alpha-linolenic acid (LNA, 18:3n-3), respectively, com-
pete for the same enzyme systems, desaturases and
elongases. Linoleic acid and LNA are essential and have
to be provided with the diet. Thus, the nutritional intake
influences PUFA composition of the body, where small
changes between the n-3 and n-6 series can have import-
ant effects on physiological processes and may influence
the development of allergy (4).
The major nutritional source for newborns is breast
milk. It is still controversial whether the FA composition
of breast milk may relate to the development of atopy in
the child. Breast milk that was given to atopic children
has been reported to higher LA (5) or lower n-6 LCP (6)
than milk given to healthy children, but other studies
found instead decreased n-3 LCP (7, 8).
In our study, we investigated the FA composition of
colostrum in a population of 218 newborns at high risk of
atopy: (1) low birth weight (LBW) infants (<2500 g), (2)
newborns of atopic mothers, and (3) newborns with
elevated cord blood immunoglobulin (Ig)E (>0.9 IU/ml).
The main aim of this study was to investigate links
between the FA composition of colostrum and signs of
atopy in the child. We analyzed our data in association
with the development of clinical atopy and allergic
Background: It remains controversial whether fatty acid (FA) composition of
breast milk relates to development of atopy in the infant. This study evaluates
FA in colostrum from mothers of children at high risk of atopy in association
with atopy at the age of 1 year.
Methods: The FA of colostrum were analyzed for 218 children (60 with low birth
weight between 1500 and 2500 g, 84 with a history of maternal atopy, and 74
with an elevated cord blood immunoglobulin (Ig)E of >0.9 IU/ml). Total lipids
were extracted, methylated and separated by gas–liquid chromatography.
Laboratory screening for allergic sensitization and clinical examination took
place within the Leipzig Allergy Risk Children’s Study (LARS).
Results: Low birth weight was correlated with low percentage levels of 20:2n-6,
22:2n-6, and 22:3n-3 (r ¼ 0.14, P < 0.05; r ¼ 0.14, P < 0.05 and r ¼ 0.20,
P < 0.01, respectively) and low gestational age at birth was correlated with low
22:3n-3 (r ¼ 0.15, P < 0.05). There was no association between FA and atopic
eczema at the age of 1 year. However, high linoleic acid (LA, 18:2n-6) was linked
to high specific IgE against cow’s milk protein (P < 0.05), and low doc-
osapentaenoic acid (DPA, 22:5n-3) was associated with elevated total serum IgE
(P < 0.05) at the age of 1 year, respectively.
Conclusions: The polyunsaturated fatty acid composition of colostrum in a high
risk newborn population shows associations with atopic sensitization at the age
of 1 year and may be predictive for later atopic disease.
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sensitization in the first year of life, as followed-up within
the Leipzig Allergy Risk Children’s Study (LARS). By
choosing a high-risk population we aimed to increase
sensitivity of analysis because of an expected higher
percentage rate of atopic individuals. Additionally, we
wanted to see whether these risk factors would be
differentially reflected in the colostral FA composition.
Finally, by choosing colostrum for analysis we wanted to
explore, whether possible alterations in breast milk
composition might be visible at this early, well-defined
timepoint of lactation.
Material and methods
Patients and general experimental design
Between March 1995 and March 1996, 429 LBW neonates (birth
weight between 1500 and 2500 g and without neonatal intensive
care) and neonates with elevated cord blood IgE >0.9 kU/l or
double positive family atopy history were selected from a full 1 year
birth cohort (n ¼ 3540) within the LARS study. The response rate
was 47.9% (429 of 895 with these criteria). Two hundred and
eighteen of these 429 mothers additionally agreed on providing
breast milk samples for FA analysis. They also answered a nutri-
tional questionnaire to ensure comparable diet. Vegetarian mothers
were allowed to enter the study. Only three mothers declared to
have been on a vegetarian diet, and all of those reported to have
consumed cow’s milk products. No mother declared to be on a
predominantly fish diet or on other exotic diets, what would have
led to her exclusion from the study.
The corresponding 218 children were grouped into one of
three risk groups according to modified criteria from LARS, and
as such included in the study described here. Group 1 consisted
of 60 of these 218 children (27.5%) who had a LBW
(1500 < b.w. < 2500 g). Forty-one of these 60 LBW newborns
(68%) were also premature (<37 completed gestational weeks).
Group 2 was formed of 84 newborns (38.5%) with a history of
maternal atopy. Group 3 included 74 newborns (34%) showing an
elevated total IgE in cord blood (>0.9 kU/l; Pharmacia CAP
System, Pharmacia, Feucht, Germany). The mean birth weights
(±SD) for groups 1–3 were 2218 ± 247 g, 3483 ± 422 g, and
3452 ± 453 g, respectively. The mean gestational age at birth
(mean ± SD) for groups 1–3 were 36.1 ± 2.3, 39.3 ± 1.2, and
39.5 ± 1.1 weeks, respectively.
The grouping was performed hierarchically in the sequence given,
i.e. all LBW newborns were grouped into group 1 (irrespective of
additional risks such as maternal atopy or high IgE), then all non-
LBW with maternal atopy went into group 2 (irrespective of IgE-
level), followed by non-LBW, nonmaternal atopy newborns with
elevated IgE in group 3.
Clinical and laboratory evaluation of atopy
At the age of 6 weeks and at the age of 1 year, parents responded to
questionnaires on signs of allergy in the children, and infants
underwent a medical examination by an experienced pediatrician
(U.D.). A clinical endpoint under the pediatrician’s judgment was
atopic dermatitis diagnosed according to Sampson’s criteria (9).
Blood samples were taken at the age of 1 year in an outpatient
department of the children’s hospital specifically designed for the
follow-up of the study. Among other parameters tested, determin-
ation of total IgE, and specific IgE as well as radioallergosorbent
test (RAST) against a battery of antigens (milk protein, egg white,
egg yolk, grass, birch, aspergillus, candida, Dermatophagoides
pteronyssinus, D. farinae, cat) were performed as described previ-
ously (10). Total and specific IgE were measured from the same
blood sample and simultaneously, without prescreening for total
IgE. All antibodies and kits were provided by Pharmacia, Feucht,
Germany. Laboratory analyses were performed without knowledge
of the clinical evaluation of the patient. Signs of atopy were com-
pared with PUFA in colostrum of children with 5 months or more
of exclusive breast-feeding in order to ensure a possible maximal
effect of breast milk while still having enough children for statistical
valid analysis (analyses for 4 months, 3 months and irrespective of
duration of breast-feeding were also done, but did not reveal
additional statistical associations with FA, data not shown). The
5 months children group had been of special interest, as in a pre-
vious study of LARS investigating other aspects of this cohort, a
correlation between breast-feeding for at least 5 months and the
frequency of eczema at the age of 1 year had been found for chil-
dren with elevated cord blood IgE (11).
Breast milk sampling
Between day two and five after birth, 2–7 ml samples of midstream
colostrum were collected in duplicates into sterile plastic collecting
jars and stored at )20C until analysis. The mothers were instructed
to collect the milk in the early morning, at the first meal.
Preanalytical treatment of samples
The principles of analysis have been described previously (12) and
received modifications in incubation temperature and period for
best results with the given samples. Briefly, a 0.2 ml sample of milk
was mixed with 5 ml of methanol : acetyl chloride (50 : 1, v/v) and
incubated for 90 min at 70C. The process of ester formation was
stopped by adding sodium bicarbonate. After adding hexane and
vortexing, the upper phase, containing the FA methyl esters was
removed, purified by centrifugation and diluted with hexane before
analysis.
Analysis by gas chromatography
Fatty acid methyl esters were separated and quantitated using a
Hewlett Packard (HP) 5890 series II chromatograph (HP Co.,
Avondale, PA) with a HP INNO WAX (30 m · 0.32 mm · 25 lm)
column coated with cross-linked polyethylenglycole and quantitated
by a 3396A HP integrator with a split ratio of 1 : 32. Helium
gas was used as carrier gas (5.7 ml/min). Identification of FA of
carbon chain length C10–24 occurred by comparison with com-
mercially available standards (Supelco Inc. and Sigma Chemical
Co., St Louis, MO). The level of each FA was expressed as weight
percent of total lipid.
Statistical analysis
Data were analyzed with the statistical package1 SPSS 9.0 (Chicago,
IL). Nonparametric analyses were performed as FA had been
recorded as weight percentages of total weight. Nonparametric
anova (Kruskal–Wallis H-test) was performed in the three group
comparison of the risk population (The Kruskal–Wallis anova by
Ranks test assumes that the variable under consideration is con-
tinuous and that it was measured on at least an ordinal (rank
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order) scale. The test assesses the hypothesis that the different
samples in the comparison were drawn from the same distribution
of from distributions with the same median. Thus, the interpret-
ation of the Kruskal–Wallis test is basically identical to that of the
parametric one-way anova, except that it is based on ranks rather
than on means. Mann–Whitney’s U test (a nonparametric rank
sum test) was performed for pairwise comparisons between FA
and with clinical and laboratory expression of allergy. Spearman’s
Rank correlation was employed for comparison of FA with birth
weight and gestational age at births. Individual Spearman’s
correlation coefficients r are listed. Differences were considered
statistically significant if P < 0.05.
Ethical considerations
Participation in the study was voluntary. Informed consent was
obtained from the parents of all children. The study was approved
by the Ethics Committee of the University of Leipzig.
Results
Table 1 compares the FA composition of colostrum in
218 mothers of children at high risk of atopic disease.
Table 1. Fatty acid composition (% wt/wt; median, interquartile range IR) of colostrum in mothers of children at high risk of atopic disease
Fatty acid
All risk groups (n ¼ 218)
Low birth weight
(1550–2500 g) (n ¼ 60) Atopic mother (n ¼ 84)
Elevated cord blood
immunoglobulin E
(>0.9 IU/l) (n ¼ 74)
Median IR Median IR Median IR Median IR
10:0 0.17 0.15 0.18 0.28 0.18 0.15 0.16 0.14
12:0 1.55 1.01 1.70 1.54 1.51 1.01 1.49 0.89
14:0 4.14 1.76 4.22 2.12 4.13 1.94 3.99 1.46
14:1n-5 0.14 0.06 0.13 0.08 0.14 0.06 0.14 0.05
15:0 0.34 0.12 0.33 0.15 0.35 0.12 0.33 0.12
16:0 22.72 2.49 22.59 3.08 22.75 2.72 22.75 2.61
16:1n-7 2.30 0.67 2.29 0.69 2.24 0.64 2.34 0.75
18:0 8.34 1.59 8.20 1.70 8.37 1.94 8.29 1.41
18:1n-9c 38.38 3.78 38.62 4.52 38.39 3.93 37.97 3.38
18:1n-9t 1.70 0.44 1.68 0.54 1.70 0.41 1.71 0.40
18:2n-6 9.34 2.86 9.31 2.79 9.15 3.41 9.68 2.44
18:3n-9 0.11 0.06 0.10 0.06 0.10 0.06 0.12 0.08
18:3n-6 0.05 0.07 0.05 0.09 0.05 0.07 0.04 0.06
18:3n-3 0.80 0.25 0.78 0.29 0.79 0.21 0.81 0.23
18:4n-3 0.41 0.14 0.42 0.14 0.41 0.13 0.41 0.21
20:0 0.31 0.09 0.31 0.10 0.30 0.10 0.30 0.08
20:1n-9 1.16 0.29 1.12 0.38 1.18 0.29 1.15 0.28
20:2n-6 0.67 0.26 0.61 0.28 0.72 0.23 0.69 0.33
20:3n-6 0.63 0.24 0.65 0.26 0.61 0.22 0.62 0.26
20:4n-6 0.83 0.24 0.82 0.28 0.84 0.21 0.85 0.20
20:3n-3 0.12 0.04 0.12 0.03 0.12 0.04 0.13 0.04
20:5n-3 0.11 0.05 0.11 0.05 0.11 0.05 0.10 0.05
22:0 0.18 0.12 0.17 0.12 0.19 0.12 0.18 0.12
22:1n-9 0.24 0.07 0.24 0.08 0.25 0.08 0.24 0.09
22:2n-6 0.12 0.06 0.11 0.07 0.13 0.06 0.12 0.07
22:4n-6 0.36 0.19 0.34 0.19 0.36 0.18 0.36 0.21
22:3n-3 0.10 0.05 0.08 0.04 0.10 0.04 0.10 0.06
22:5n-3 0.34 0.14 0.31 0.14 0.33 0.14 0.34 0.15
22:6n-3 0.75 0.26 0.71 0.28 0.76 0.26 0.76 0.20
24:1n-9 0.26 0.17 0.24 0.15 0.28 0.16 0.26 0.18
Total n-6 12.05 3.00 11.87 2.78 11.87 3.25 12.24 3.03
LCP n-6 2.63 0.72 2.54 0.64 2.67 0.67 2.68 0.86
LA/n-6 LCP 3.53 1.40 3.45 1.37 3.49 1.62 3.65 1.23
Total n-3 2.69 0.49 2.70 0.51 2.70 0.52 2.66 0.59
LCP n-3 1.41 0.48 1.40 0.48 1.41 0.54 1.42 0.42
LNA/n-3LCP 0.57 0.25 0.56 0.29 0.57 0.30 0.60 0.22
SAFA 38.07 5.41 38.12 6.70 38.59 5.33 37.77 4.62
MUFA 44.28 4.00 44.43 5.30 44.11 4.02 44.14 3.50
PUFA 14.88 3.17 14.72 3.14 14.79 3.44 15.10 3.32
P/S-ratio 0.39 0.13 0.38 0.14 0.39 0.12 0.41 0.13
n-6/n-3 4.54 1.34 4.46 1.26 4.58 1.47 4.60 1.08
n-6 LCP/n-3 LCP 1.85 0.44 1.87 0.52 1.84 0.40 1.85 0.38
wt, weight; SAFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, Polyunsaturated fatty acids; P/S, PUFA/SAFA; LCP, long chain PUFA.
No statistical differences (nonparamatic ANOVA of Kruskal–Wallis).
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When the three risk groups, each defined by a single risk
factor, were compared, no differences were seen. Neither
the saturated FA, nor monounsaturates or n-6 series or
n-3 series of polyunsaturates in each group showed
statistically significant deviations. Furthermore, when a
group was formed of all atopic mothers (group 2+atopic
mothers in group 1) and compared against the remaining
(all nonatopic) mothers, also no associations with the FA
status of colostrums were detected.
While the group comparisons did not reveal differ-
ences, correlation analyses with birth weight (irrespective
of the arbitrary threshold of 2500 g defining LBW) and
gestational age at birth did. Low birth weight was shown
to be correlated with low 20:2n-6, 22:2n-6, and 22:3n-3
(r ¼ 0.142, P < 0.05; r ¼ 0.136, P < 0.05; and
r ¼ 0.196, P < 0.01, respectively). Low gestational age
at birth (which as expected correlated by itself with LBW,
r ¼ 0.558, P < 0.001) correlated with low 22:3n-3
(r ¼ 0.147, P < 0.05).
We also compared the breast milk of the three mothers
who declared to have been on a vegetarian diet with that
of their nonvegetarian counterparts. The breast milk did
not differ significantly within the respective groups and in
the total risk population, respectively.
Table 2 shows the results of the comparison of FA with
clinical expression of allergy (atopic eczema) at the age of
1 year. Of the initial 218 children 164 were seen at the age
of 1 year. Results are demonstrated for the 78 children
exclusively breast-fed for at least the first 5 months. These
78 children consisted of 11 children (14%) of group 1, 36
children (46%) of group 2, and 31 children (40%) of
group 3. The data demonstrate that there were no
differences between the weight percentages of PUFA in
colostrum of children expressing atopic eczema or
obstructive bronchitis compared with clinically healthy
infants at the age of 1 year.
Table 3 comparatively lists the colostral PUFA for the
children with and without allergic sensitization at the age
of 1 year. Statistically significant differences between the
groups are marked. Here, the parent FA of the n-6 series
of polyunsaturates, LA, was higher among mothers with
children bearing specific IgE against cow’s milk
(P < 0.05). This effect also leads to a higher amount of
total n-6 series of PUFA (P < 0.01), an elevated ratio of
LA to LNA (P < 0.05), and an elevated ratio of n-6/n-3
PUFA (P < 0.05). No changes were seen among the long
chain derivatives of LA, AA and dihomo-gamma-linoleic
acid (DHGLA, 20:3n-6) in relation to specific IgE. In
contrast, DPA (22:5n-3) was found to be decreased
(P < 0.05) in the breast milk of mothers of children with
elevated total IgE in serum at the age of 1 year. Other
members of the n-3 series including EPA and DHA were
found unchanged. Data are presented for children with
5 months or more of exclusive breast-feeding for possible
maximal effect of breast milk. Analyses of 4 months,
3 months, and irrespective of duration disclosed no
additional statistical differences.
Analyses of other specific IgE tested showed no
associations between FA and sensitization. Fourteen
children (of the 78 children exclusively breast-fed for at
least 5 months) were tested CAP positive against egg
white, and seven against egg yolk. Sensitization against
respiratory allergens was considerably lower as expected:
grass (two children), birch (two), cat (one), aspergillus
(one), candida (one), D. pteronyssinus (1), D. farinae
(none). For all of these antigens, analyses of breast-
feeding periods of 4 months, 3 months, and irrespective
of duration showed no statistical association with the FA
investigated (data not shown).
Discussion
Our data demonstrate an association between the PUFA
composition of colostrum of mothers of children at high
risk of atopy and an increased rate of atopic sensitization
in the child. High percentage levels of LA (18:2n-6), and
resulting higher LA/LNA ratio and higher total n-6/n-3
ratio were correlated with high specific IgE against cow’s
milk protein, and low levels of 22:5n-3 and low total n-3
were associated with elevated serum total IgE at the age
of 1 year.
Table 2. Parent fatty acids and polyunsaturated fatty acids (% wt/wt; median,
interquartile range IR) in colostrum of children at high risk of allergy and expression
of atopic eczema at the age of 1 year. Results are shown for children exclusively
breast-fed for at least the first 5 months
Atopic eczema at the age of 1 year
Yes (n ¼ 17) No (n ¼ 60)
Median IR Median IR
Omega (n)-6
18:2n-6 8.81 3.16 9.10 2.78
20:2n-6 0.63 0.29 0.63 0.24
20:3n-6 0.56 0.20 0.63 0.22
20:4n-6 0.81 0.21 0.84 0.19
22:2n-6 0.12 0.04 0.12 0.06
22:4n-6 0.38 0.18 0.36 0.19
Total n-6 11.26 4.18 12.02 2.93
n-6 LCP 2.69 0.62 2.61 0.78
18:2n-6/n-6 LCP 3.35 1.63 3.43 1.26
Omega (n)-3
18:3n-3 0.74 0.35 0.80 0.22
20:3n-3 0.13 0.04 0.12 0.04
20:5n-3 0.11 0.06 0.10 0.04
22:3n-3 0.10 0.05 0.10 0.06
22:5n-3 0.34 0.16 0.34 0.16
22:6n-3 0.72 0.27 0.79 0.31
Total n-3 2.77 0.36 2.73 0.45
n-3 LCP 1.42 0.63 1.41 0.55
18:3n-3/n-3 LCP 0.45 0.40 0.57 0.24
18:2n-6/18:3n-3 11.02 5.19 11.46 2.46
Total n-6/total n-3 4.12 1.55 4.53 1.29
wt, weight; LCP, long chain polyunsaturated fatty acids.
No statistical differences (Mann–Whitney's U-test).
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Our observation resembles data from previous studies
of breast milk, where high LA and low n-3 LCP (6), low
n-3 LCP plus low total n-3 (7), and low total n-3 and high
n-6/n-3 ratio (because of both higher n-6 and lower n-3)
(8) were linked to atopic development in children. Studies
in serum phospholipids also found higher LA (13–15),
lower n-3 LCP (33) or both (8, 16) in atopic compared
with healthy individuals. Many of these studies also
Table 3. Parent fatty acids and polyunsaturated fatty acids (% wt/wt; median, interquartile range IR) in colostrum of children at high risk of allergy and signs of allergic
sensitization at the age of 1 year. Results are shown for children exclusively breast-fed for at least the first 5 months
Elevated total IgE in serum (>34 IU/ml) Specific IgE against cow's milk in serum (CAP > 0)
Yes (n ¼ 31) No (n ¼ 32) Yes (n ¼ 8) No (n ¼ 54)
Median IR Median IR Median IR Median IR
Omega (n)-6
C 18:2n-6 9.12 3.49 9.28 2.79 11.11* 8.73 8.07* 2.64
C20:2n-6 0.62 0.24 0.66 0.26 0.73 0.37 0.62 0.21
C 20:3n-6 0.60 0.20 0.67 0.21 0.75 0.22 0.61 0.22
C 20:4n-6 0.82 0.18 0.86 0.18 0.84 0.26 0.83 0.16
C22:2n-6 0.12 0.06 0.13 0.05 0.14 0.08 0.12 0.06
C22:4n-6 0.35 0.16 0.36 0.19 0.36 0.12 0.35 0.18
Total n-6 11.64 2.41 12.21 2.89 13.57** 9.19 11.55** 2.56
n-6 LCP 2.51 0.78 2.65 0.73 2.93 0.90 2.60 0.60
C 18:2n-6/n-6 LCP 3.82 1.46 3.38 1.17 4.32 2.49 3.41 1.14
Omega (n)-3
C 18:3n-3 0.75 0.28 0.81 0.26 0.91 0.49 0.78 0.27
C 20:3n-3 0.12 0.04 0.12 0.04 0.11 0.09 0.12 0.04
C 20:5n-3 0.10 0.04 0.11 0.04 0.10 0.04 0.11 0.05
C 22:3n-3 0.10 0.0 0.10 0.06 0.10 0.06 0.10 0.06
C 22:5n-3 0.31* 0.11 0.38* 0.18 0.32 0.11 0.35 0.14
C 22:6n-3 0.74 0.26 0.86 0.36 0.74 0.35 0.77 0.28
Total n-3 2.66* 0.42 2.88* 0.41 2.75 0.45 2.75 0.46
n-3 LCP 1.29 0.56 1.60 0.61 1.33 0.58 1.46 0.54
C 18:3n-3/n-3 LCP 0.62 0.30 0.48 0.22 0.61 0.29 0.56 0.26
C 18:2n-6/C 18:3n-3 11.77 4.62 11.27 2.46 14.54* 4.27 11.12* 2.48
Total n-6/total n-3 4.62 1.51 4.21 1.15 5.63* 2.06 4.16* 1.20
* P < 0.05; ** P < 0.01 (Mann–Whitney's U-test).
LCP, long chain polyunsaturated fatty acids; IgE, immunoglobulin E.
Figure 1. Percentages of characteristic polyunsaturated fatty acids (PUFA) and PUFA ratios as determined in our study compared to
results from studies of colostrum of healthy Caucasian women in developed (Western) central European countries on a normal,
nonmediterranean diet.
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found decreased n-6 LCP. In fact, for many years
research was more focused on disturbances in the n-6
series. The concomitant increase of LA and decrease of
n-6 LCP gave rise to the idea of an abnormal metabolism
in atopic individuals, namely of an impaired conversion
of the C18 precursors into their LCP products because of
enzymatic deficiencies (16, 17). However, this hypothesis
is not unquestioned (14). Recently, the importance of
disturbances in the n-3 series for the development of
atopy has been stressed (7, 8). In one report, only the
composition of n-3 LCP was related to atopic develop-
ment in children (18). 22:5n-3, which we found connected
to elevated serum IgE is the metabolic linker between
20:3n-5 (EPA) and 22:6n-3 (DHA) both of which have
reportedly anti-inflammatory capacity (3).
The varying results in previous studies regarding
PUFA in breast milk in relation to atopy may have one
reason in the fact that the percentage of LCP in breast
milk varies substantially throughout lactation. The
PUFA metabolites were found to be highest in colostrum
and to decrease later (12, 19). Thereby, the decline of
n-3-PUFA during lactation occurs more rapidly than of
n-6-PUFA (17), what has to be considered in analysis. In
our study, we chose colostrum for several reasons. First,
sampling breast milk at one convenient and well-defined
timepoint minimizes errors because of varying composi-
tion of breast milk during the time course of lactation.
Secondly, some studies investigating breast milk in the
context of atopy were able to observe differences at earlier
timepoints, which disappeared later through lactation
(7, 17). Thirdly, because of the higher percentual contents
of PUFA metabolites in colostrum, possible differences
can be more apparent and increase the reliability of
detection. This can be of importance, as many of the
characteristic PUFA are available in only low quantities.
Our observation of associations between PUFA in
colostrum and atopic sensitization but not clinical atopy
at the age of 1 year can likely be explained by the early
timepoint of clinical analysis. While clinical symptoms for
atopy, e.g. atopic dermatitis, start often before the age of
1 year (9), many and more specific symptoms will become
apparent only later. However, there is evidence that
exposure to environmental antigens, modulated by gen-
etic susceptibility, can result in allergic sensitization very
early (22). As sensitization generally preceeds manifesta-
tion of atopy, our finding of associations with atopic
sensitization may point to a possible development of
allergy later in life. It would therefore be of interest to
follow-up the children included for a longer time. In this
regard, is it somewhat disappointing that there was no
association between FA and IgE specific to hen’s egg
protein, as the presence of such antibodies in the first year
of life is reportedly predictive for allergic sensitization
against other antigens later in life (23). However, we
observed sensitization against cow’s milk protein, which
can also be associated with a higher incidence of asthma
later in childhood (24).
A secondary result of our study was that the FA
composition of colostrum did not differ between the
three individual risk groups when compared with each
other. In fact, the composition seemed to closely match
values obtained in studies of colostrum of healthy
Caucasian women in developed (Western) central Euro-
pean countries on a normal, nonmediterranean diet (see
Fig. 1). Maternal nutrition is a key influence factor for
the composition of breast milk is (20). We had all
women included in our study fill in a nutritional
questionnaire to exclude exotic diets. Breast milk of
the three vegetarians in our study was not statistically
different from nonvegetarians. It is known that vegetar-
ian diet can lead to increased levels of LA, and LNA as
well as to reduced levels of DHA (21). While we have no
solid explanation for the lack of difference in our study,
it is possible that the low number of participating
vegetarians and the fact that all three reported to have
consumed cow’s milk products may have masked some
differences.
Our data suggest that the risk factors elevated cord
blood IgE in the child and atopic mother were not
reflected in the colostral FA composition. A number of
studies observed lower LA in the milk of atopic mothers
(7, 25), but others did not (8, 26). It is possible that some
deviations will only reveal in mature milk, while being
masked in colostrum or early transitional milk (7, 18).
Our data correlating birth weight and gestational age at
birth with LCP levels in breast milk confirm previous
reports (19, 27). However, other studies were unable to
find differences when preterm and term breast milk was
compared (28, 29). The selection of an appropriate time
point of investigation may again be of importance for the
results.
In conclusion, our data show that links between the FA
status of breast milk and atopic sensitization in children
can be observed as early as during the first few days of
lactation, in colostrum. Apart from the advantage of
using a well-defined and convenient timepoint, it seems
worthwhile to speculate on the future importance of
detecting FA deficiencies early after birth. Future studies
will need to further our understanding of defects in
metabolic pathways of FA related to atopic disease. They
also might reveal specific deficiencies in subgroups of
individuals/families at high risk of atopy. It is possible to
envision that some of these patients might profit from an
early individual supplementation of nutrition by specific
LCP, an approach currently recommended only for
nutritional purposes for very LBW infants (30).
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ABSTRACT: Formation of in vitro adducts between different classes of xenobiotics and the lysine-containing
peptide Lys-Tyr was monitored by high-performance liquid chromatography and electrospray ionization mass
spectrometry. The molecular structures of the main resulting products could be sensitively analyzed by mass
spectrometry (flow injection analysis), enabling the detection of characteristic binding formations. Aldehydes
such as formaldehyde, acetaldehyde, and benzaldehyde were shown to form stable linkages to lysine amino
groups via Schiff bases. Other electrophilic substances (e.g., toluene-2,4-diisocyanate, 2,4-dinitro-1-fluoro-
benzene, 2,4,6-trinitrobenzene sulfonic acid, dansyl chloride, and phthalic acid anhydride) also formed cova-
lent adducts with lysine residues. The reactivity of the compounds was quantified by measuring the amount
of peptide that remained unchanged after incubation for a certain period with the xenobiotic. Although
reactivity levels within this group of aldehydes varied only to a small extent, as would be expected, extreme
differences were seen among the structurally heterogeneous group of nonaldehyde xenobiotics. These results
support the hypothesis that simple chemical reactions may lead to the adduction of nucleophilic macromol-
ecules such as peptides or proteins. Such reactions, in particular, Schiff base formation of aldehydes, have
previously been shown to be capable of specifically interfering with costimulatory signaling on T cells. Our
results suggest that electrophilic xenobiotics of other classes may also inherit the capacity to exert similar
effects. Forming covalent linkage to peptides may represent a possible molecular mechanism of electrophilic
xenobiotics in vivo, yielding immunotoxic effects. The model utilized in this study is appropriate for monitoring
the adduction of xenobiotics to basic peptides and for analyzing the resulting molecular structures. © 2003
Wiley Periodicals, Inc. Environ Toxicol 18: 29–36, 2003.
Keywords: xenobiotics; peptides; proteins; lysine; adducts; mass spectrometry; immunotoxic effects
INTRODUCTION
Environmental pollutants are increasingly made responsible
for the rise in immunologically determined diseases such as
allergies and autoimmunities (Peterson and Saxon, 1996;
Davies et al., 1998). Electrophilic xenobiotics are an impor-
tant group of pollutants. The in vivo adduction of nucleo-
philic macromolecules such as DNA, proteins, and peptides
can be one of several molecular mechanisms for such in-
fluences on the immune system (Luster et al., 1987; Hess
and Rieder, 1997). In proteins, the main nucleophilic reac-
tion partners involved are mercapto and basic amino groups.
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The -amino group of the lysine residue belongs to the most
commonly involved and characteristic groups for protein–
xenobiotic interaction in vivo because of its high basicity
and degree of ionization (Braun et al., 1995; Hazen et al.,
1997). Mass spectrometry was used in a recent study to
reveal the amino groups of peptides that frequently interact
via Schiff bases with adduct partners (Boutaud et al., 1999).
The existence of Schiff base–forming ligands seems to be a
universal principle of molecular interaction between pro-
teins and an essential part of antigen presentation on (mu-
rine) T cells (Gao and Rhodes, 1990). Aldehydes, which
form Schiff bases with amino groups of lysine residues,
have been shown to specifically interact with the immune
system, binding to the T-cell surface and interfering with
clofilium-sensitive sodium and potassium channels also in-
volved in costimulatory signaling (Rhodes, 1989). Hence,
aldehydes may provide a costimulatory signal to the cell,
thus favoring an immune response and directing it toward a
Th1 answer (Shearer, 1995; Rhodes et al., 1995). Much less
has been learned about the reactions of other electrophilic
xenobiotics with proteins under physiological conditions. In
this article we report on a study that demonstrated that
xenobiotics of different chemical classes may bind effec-
tively and stably to lysine-containing peptides upon in vitro
incubation under physiological conditions. Characterization
of a selection of main adducts by mass spectrometry is
presented, as well as an approach for quantifying the impact
on the molecular structure of the peptide.
MATERIALS AND METHODS
Peptide and Xenobiotics
The peptide used, HOlysine-tyrosineOOH, salt, with a
molecular weight of 369.4 was supplied by Bachem (Hei-
delberg, Germany). The xenobiotic acetonitrile (ACN),
C2H3N, 75-05-8, came from Merck (Darmstadt, Germany)
and the xenobiotic dansyl chloride (DC), C12H12ClNO2S,
605-65-2, from Molecular Probes (Eugene, OR). Sigma
(Deisenhofen, Germany) was the supplier for the following
xenobiotics: acetaldehyde (AA), C2H4O, CAS (Chemical
Abstract Service) 75-07-0; benzaldehyde (BA), C7H6O,
100-52-7; 2,4-dinitro-1-fluorobenzene (DNFB), C6H3FN2O4,
70-34-8; formaldehyde (FO), CH2O, 50-00-0; glutaraldehyde
(GA), pentane-1,5-dial, C5H8O2, 111-30-8; phthalic acid an-
hydride (PA), C8H4O3, 85-44-9; toluene-2,4-diisocyanate
(TDI), 4-methyl-m-phenylene diisocyanate, C9H6N2O2, 584-
84-9; trifluoroacetic anhydride (TFAA), C4F603, 407-25-0;
and 2,4,6-trinitrobenzene sulfonic acid (TNBS), C6H3N3O9S,
2508-19-29.
Instrumentation
High-performance liquid chromatography (HPLC) was per-
formed using a Bischoff (Leonberg, Germany) HPLC sys-
tem consisting of two compact pumps (19-95) and a Knauer
dynamic mixer (19-93), in combination with reversed-phase
columns [Nucleosil 5 C18 (Grom Analytic, Herrenberg-
Kayh, Germany); 5 C18, 5 C18 PAH, C18 MPN (Mach-
erey-Nagel, Dueren, Germany); Adsorbosphere C18 3, C18
5 (Alltech, San Jose, CA); Nucleosil 300-5 C 8, 300-7
C6H5, 300-5 C 4 (Macherey-Nagel, Dueren, Germany)];
mixed-mode columns [C18 Anion 100 A 5U, 150  4.6
(Alltech, San Jose, CA)]; and gel permeation columns [125
Bio-Sil (Biorad, Hercules, CA), Macrosphere GPC 100,
Macrosphere GPC 60 (Alltech, San Jose, CA)]. The eluent
(flow rate of 1 mL/min) was 0.1% TFA in water with a
linear gradient to 0.1% TFA in CH3CN/H2O (various ra-
tios), sodium phosphate buffer in water with a linear gradi-
ent to sodium phosphate buffer in methanol/H2O (various
ratios), and sulfonic acid buffer in water with a linear
gradient to methanol/H2O (various ratios), respectively. The
eluate was monitored at 220 and 280 nm with a Bio-
Dimension UV-vis monitor (Bio-Rad, Hercules, CA) and at
250/350, 325/392, and 335/515 nm (excitation/emission)
with an 8450 fluorescence HPLC monitor (Bischoff, Leon-
berg, Germany). Flow injection analysis–mass spectrometry
(FIA-MS) was performed on an API mass spectrometer
[Applied Biosystems/MDS Sciex API 100 LC-MS System
(Concord, Ontario, Canada)]. Samples were applied through
a Rheodyne 7125 injection valve equipped with a 20-L
sample loop. Conditions for mass spectrometry are given in
the relevant entries. Reaction vials (1.8 mL) and corre-
sponding microvials were obtained from CRS (Fairbanks,
AL) and Bischoff (Leonberg, Germany).
Incubation of Lys-Tyr with Xenobiotics
For subsequent MS analysis, to 20 L of a 100 mM peptide
solution (0.1M phosphate buffer, pH 7.4) were added 5 L
of a solution of a 1M xenobiotic in H2O (glutaraldehyde)
and CH3CN (all other xenobiotics), respectively. After in-
cubation for varying time spans according to the protocol
(15 min standardized for concentration dependency and 15
min up to 4 days for kinetic studies) at 37°C in the dark, 75
L of 0.1M phosphate buffer (pH 7.4) was added to the
reaction solution. The mixture was then centrifuged, imme-
diately after which MS analysis was done. For subsequent
HPLC analysis incubation was performed as described
above except that the initial concentration of xenobiotics
varied from 10 M to 1 M. After incubation and centrifu-
gation, samples were placed in a cooled (4°C) autosampling
chamber to do immediate HPLC analysis.
FIA-MS Analysis of Adducts
The peptide and possible adducts were analyzed by FIA-MS
on an API mass spectrometer. The native peptide Lys-Tyr
was detected by collision-induced dissociation (CID) of a
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[M  H] ion at m/z 310. For adduct formation with the
intact peptide, in our experiments the resulting adducts
could be detected at higher mass-to-charge ratios (m/z),
ranging from 336 to 793. The operating conditions of the
mass spectrometer were: scan range, m/z 100–500 (for
fragmentation) and m/z 300–800; scan time, 2 s; cone
voltage, 30 V: injection volume, 20 L (2 L of sample 
18 L of eluent [CH3CN, 2 mM of ammonium acetate in
H2O; 3:1 (v/v)]; flow rate of injection, 0.4 mL/min).
HPLC Analysis and Quantification of Peptide
Adduct Formation
To do this analysis, 20 L of the sample solution (50 L
for gel permeation columns) was injected and eluted with
one of the elution systems described above. Retention
times and peak areas of native and added peptides were
determined by UV- and fluorescence monitoring as de-
scribed above.
Mathematical Description of Total Peptide
Turnover after Incubation with Xenobiotic
To assess the total changes that occurred in the molecular
structure of the peptide after incubation with the xenobiotic,
we introduced the factor of reactivity (FR), defined as the
amount of xenobiotic necessary to allow a reaction with
50% of the peptide in a given solution. The peptide was
deemed unchanged when its retention time in HPLC did not
change (1%) and/or its mass-to-charge ratio remained the
same as before incubation. FR summarizes the effects of
specific adduct formation, changes in tertiary structure, ion-
ization, degradation, and other factors associated with the
xenobiotic. It provides a simple tool for estimating how
much the molecular structure of the peptide is affected by
the reactive agent. For FR the concentration of a xenobiotic
at which the amount of unchanged peptide is 50% is termed
the concentration (x) of this xenobiotic [eq. (1)], making FR
defined as the quotient of the concentration of the peptide in
the solution and concentration (x) [eq. (2)]. Thus, FR is
calculated as the inverse of the relative amount of xenobi-
otic necessary to transform 50% of the peptide into an
adduct (mM/mM).
mPeptide
Xeno(x)
mPeptide
Xeno0  50% (1)
FR50 
Peptide
Xenox (2)
RESULTS
Identification of Specific Xenobiotic Peptide
Adducts
The structures identified in our experiments confirmed the
results of previous studies on in vitro and in vivo adduct
formation of xenobiotics as, for example, AA, BA, FO, and
DNFB. In addition, new insights were gained about the
reactions of a number of other substances, such as DC, PA,
TDI, TFAA, and TNBS. In general, most xenobiotics were
shown to react via covalent linkage to the -amino group of
the lysine residue. The specific adducts that resulted were
predominantly in a ratio of 1:1. For AA and PA, 2:1 ad-
ducts, in which two xenobiotic molecules were bound to one
peptide molecule, using both - and -amino groups of
lysine, also could be demonstrated. We first directed our
attention toward identification of the adducts of a number of
aldehydes to Lys-Tyr. In a first attempt, AA was incubated
with the peptide. Two genuine adducts could be shown,
representing a 1:1 adduct and a 2:1 adduct, resulting from
Schiff base formation between the hydroxyl group of AA
and the amino group or groups of the lysine residue (Fig. 1).
To sustain the hypothesis that binding occurs mainly via the
-amino group of lysine, we investigated which amino acid
of Lys-Tyr AA actually binds to upon adduct formation.
After the peptide was incubated with AA, cone voltage was
raised to 70 V during MS analysis, resulting in partial
fragmentation of the peptide. Subsequently, we analyzed
adduct formation of other aldehydes. It was found that BA
and FO also form Schiff bases when binding to Lys-Tyr (not
shown). However, although a 1:1 adduct occurred in quan-
tities similar to that with AA, a 2:1 adduct could not be
detected in significant amounts (data not shown).
We then turned our attention to the analysis of adducts
with protein reactive xenobiotics of other classes. DNFB
(Fig. 2), PA (Fig. 3), and TDI (Fig. 4) also form CON
bindings with the -amino group. Of note is that PA also
Fig. 1. Mass spectrum of molecular ion [M  H] of Lys-Tyr
after incubation with acetaldehyde. A spectrum of new prod-
ucts is shown. Two genuine adducts can be observed: the
1:1 adduct at 336 (blue) and the 2:1 adduct at 362 (red). All
other peaks are formed by sodium and potassium clusters of
the former adducts. [Color figure can be viewed in the online
issue, which is available at www.interscience.wiley.com.]
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leads to a 2:1 adduct and that TDI reacts in an even more
complicated manner, including the formation of a 1:2 ad-
duct (1 TDI  2 Lys-Tyr). The common principle of TDI
reactions is the derivatization of isocyanate groups into urea
derivatives on reaction with the -amino group of lysine
residues (Fig. 4). DC reacts with the amino group differ-
ently, forming a sulfonamide bond (Fig. 5). TNBS forms a
number of different adducts with the amino group, some of
which can be explained by trinitrophenylation of amino
groups and conjugation of the complete molecules of the
partners (not shown). In contrast to all the other xenobiotics
investigated, TFAA did not lead to any observable specific
adducts when the peptide was incubated with it (not shown).
Localization of Adduction of Acetaldehyde to
Lys-Tyr at the Single Amino Acid Level by
Adduct Fragmentation
To investigate whether the adduction of xenobiotics, which
was suspected to occur by binding to Lys-Tyr via the
formation of Schiff bases, indeed occurs at the amino acid
lysine and not tyrosine, we changed the parameters of the
mass spectrometry such that the adduct formed was dis-
rupted so that fragments could be analyzed. The results
confirmed our hypothesis that adduction was to the amino
acid lysine under release of H2O, whereas no binding to
tyrosine could be observed (not shown).
Quantification of Adduct Formation by HPLC
and Mass Spectrometry
After the detection of specific adduct formation, the turn-
over of the peptide in association with the incubation with
xenobiotics was quantified using the factor of reactivity
(FR). FR values for all chemicals investigated were calcu-
lated. The results are presented in Table I.
Fig. 2. Mass spectrum of molecular ion [M  H] after
incubation of Lys-Tyr with 2,4-dinitro-1-fluorobenzene
(DNFB). One genuine adduct appears at 476.
Fig. 3. Mass spectrum of molecular ion [M  H] after
incubation of Lys-Tyr with phthalic anhydride (PA). A spec-
trum of new products is shown. The adduct at 458 results
from a decomposing of the furan ring. It is followed by the
adduct’s sodium clusters (480, 502, 524). Adduction of an-
other molecule PA results in the 2:1 adduct (606), again
followed by its sodium clusters (628, 650, 672). Phthalimide
(440) and a corresponding product (750) are only marginally
available (see text).
Fig. 4. Mass spectrum of molecular ion [M  H] after
incubation of Lys-Tyr with toluene-2,4-diisocyanate (TDI).
The adduct at 458 is the result of adduction of the -amino
group of Lys-Tyr, possibly to the sterically favored p-isocya-
nate group of TDI. When the second isocyanate group also
reacts with a peptide molecule, the toluyl-diurea bipeptide
results (793). The peak at 397 may be interpreted as the
double-charged toluyl-di-urea bipeptide (1:2 adduct) and
the peak at 408 as its sodium cluster. The product at 336
possibly results from the adduction of an intermittently
formed carboxy amino acid to an amino group of Lys-Tyr.
The identity of the peak at m/z 639 could not be unraveled.
Fig. 5. Mass spectrum of molecular ion [M  H] of Lys-Tyr
after incubation with dansyl chloride (DC). One genuine ad-
duct results at 543 from the binding of the sulfur atom to the
-amino acid of the peptide.
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DISCUSSION
To develop sensitive methods for the detection and quan-
tification of protein–xenobiotic adducts formed under
near-physiological in vitro conditions, we initiated a
study of a range of protein reactive and immunotoxic
compounds binding to a model peptide containing one of
the most characteristic groups for protein–xenobiotic in-
teraction, the -amino group of the lysine residue. Reac-
tions of electrophilic xenobiotics with the -amino group
of the lysine residue are especially favored in vivo be-
cause of the high basicity of this group. By binding to
lysine residues, electrophilic organic compounds such as
products of lipid peroxidation (alkenals) have been
shown to change the molecular structure of proteins and
to alter their function (Baker et al., 1999). In addition,
E-amino groups have been shown to be involved in a
number of immunological signaling processes (Chen et
al., 1997). We chose a dipeptide to minimize the steric
hindrances and dipole effects that are known to influence
the binding characteristics of proteins (Chen et al., 1999).
Tyrosine was used as the second amino acid, as its
aromatic ring is easily detectable in UV light. Because of
its much lower reactivity, it would be expected that
reactions would mainly occur at the lysine residue, a
hypothesis that was confirmed in our experiments.
Among the xenobiotics investigated, Schiff base–forming
aldehydes represented a main group, as Schiff bases have
been detected to play an important role in immunological
signal cascade in T cells (Rhodes, 1989; Rhodes et al.,
1995). Compared with various aldehydes, where xenobi-
otics of other classes are known to be protein reactive and
to have immunotoxic capacity. As we hypothesized, all
xenobiotics investigated in the in vitro system, except for
TFAA, were shown to undergo simple chemical reactions
with the amino group of the peptide, mainly forming 1:1
adducts. The structural analyses that were done in our
experiments enabled some new insights into possible
reactions occurring under physiological conditions and
confirmed the available reports on reaction mechanisms.
In detail, AA is well known to react with amino-contain-
ing compounds in an aqueous environment, forming
Schiff bases (Braun et al., 1995, 1997). Basically, the
same is true for the other aldehydes investigated. BA may
cause costimulation (Chen and Rhodes, 1996), FO–albu-
minadducts may result in production of specific anti-
adduct IgG (Kim et al., 1999), and GA may cause allergic
sensitization (Dearman et al., 1999). For all aldehydes
investigated, our results confirmed the formation of
Schiff bases with the -amino group of lysine, mainly
leading to 1:1 adducts under the chosen conditions. In
contrast to nonaldehydes, reactivities differed only little
within the aldehyde group. This might be because of an
identical binding type. Among the nonaldehydes, DNFB,
which is used as a model hapten for contact sensitization
(Manetz and Meade, 1999), reacts with amino groups of
peptides, forming highly immunogenic dinitrophenylpep-
tides. Our experiments confirmed the formation of ad-
ducts via dinitrophenylation of amino groups. For PA,
which can cause sensitization in vivo (Yokota et al.,
1998), we observed adduct formation via decomposing of
the furan ring. Under the conditions chosen, this phenom-
enon has not yet been described to our knowledge. Of
further interest was the marginal availability of phtha-
limide (m/z 440), an intermediate product of this reaction
frequently formed in conditions used in technical chem-
istry. It is possible that its formation, which occurs under
release of H2O, is only a minor reaction path under
physiological conditions. This possibility is supported by
the probable product of a reaction of phthalimide itself,
an adduct formed after reaction of the second carboxyl
group of phthalic acid with a second molecule of the
peptide, also being hardly detectable (m/z 750). TDI, one
of the major causes of occupational asthma (Aul et al.,
1999), is known to convert in aqueous solutions into urea
and aromatic diamines (Seel et al., 1999). In our system,
along with direct adduct formation with the peptide, TDI
also underwent changes in which the peptide was only
secondarily involved. Isocyanates react in water solutions
immediately to carboxy amino acids (carbamino acids).
These unstable compounds dissolve into primary amine
and CO2 or may further react to become stable final
products. Such a reaction could explain the product at
336, which possibly was formed after the adduction of a
carboxy amino acid to an amino group of Lys-Tyr. The
identity of the peak at m/z 639 could not be unraveled.
When investigating TFAA, surprisingly, there were no
specific adducts to be observed. TFAA was investigated
as being a very reactive trifluoroacetylating substance.
Microsomal peptides trifluoroacetylated by metabolites
of halothane, a volatile anesthetic, trigger halothane hep-
atitis (Clarke et al., 1995). A possible explanation for the
TABLE I. Factors of reactivity (FR) in in vitro adduct
formation between selected xenobiotics and the
peptide lysine-tyrosine
Xenobiotics
Factor of Reactivity (FR)
[mM/mM]
Acetonitrile (ACN) 4.22*105  0.91*105
Acetaldehyde (AA) 0.164  0.037
Benzaldehyde (BA) 0.406  0.084
Formaldehyde (FO) 0.509  0.032
Glutaraldehyde (GA) 0.575  0.046
Trifluoroacetic anhydride (TFAA) 0.019  0.001
Trinitrobenzene sulfonic acid (TNBS) 0.030  0.06
2,4-Dinitro-1-fluorobenzene (DNFB) 0.077  0.041
Dansyl chloride (DC) 0.713  0.348
Phthalic acid anhydride (PA) 1.061  0.057
Toluene-2,4-diisocyanate (TDI) 2.620  0.663
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apparently low peptide reactivity is the sufficient nucleo-
philic capacity of the surrounding H2O to react with
TFAA because of the extremely high reactivity of the
molecule. Thus, TFAA was turned completely into a
poorly reactive trifluoroacetic acid, leaving the peptide
unchanged. This shows that high structural activity may
not necessarily be connected with a high rate of adduct
formation under physiological conditions. It has been
found that in a group of electrophilic xenobiotics those
with medium chemical reactivity showed the highest
mutagenicity (Eder and Kutt, 1989). The molecular basis
of adduct formation by TNBS, a model hapten for hap-
ten-associated colitis (Neurath et al., 1996), is trinitro-
phenylation of the -amino groups of lysine (von Bonin
et al., 1992), a process, that we also observed in our
reaction system. In addition, we found adducts whose
structures could not be elucidated. The main product at
338 and smaller products possibly represent fragments of
TNBS, resulting from hydrolytic processes, and conju-
gates of these fragments.
The quantification of peptide reactivity of xenobiotics by
determination of the amount of specific adducts did not
seem very promising, as adducts may be unstable, frag-
mented, or clustered with a number of ions, thus making
quantification of specific adducts difficult. Therefore, we
instead determined the amount of peptide with apparently
unchanged molecular structure remaining after a specific
duration of incubation. For this purpose, we introduced a
factor of reactivity (FR). The advantage of this mathemat-
ical approach is enabling the recording of the summarized
effect of all factors that lead to a structural change in the
peptide recognizable in HPLC or MS. Thus, exact knowl-
edge about the kinetics of major and minor reaction path-
ways that may occur in parallel and are mostly unknown is
not necessary.
The quantification of reactivity using the FR showed
that peptide conversion occurred with a reaction kinetic
higher than first grade. This would be expected, as,
according to the concentrations used in our system, the
velocity of adduct formation depended on the concentra-
tion of both the peptide and the xenobiotic. When com-
paring the FRs of the substances, it was evident that
among aldehydes reactivities varied only to a small de-
gree. GA, the most reactive compound in this group, was
only 3.5 times more reactive than AA, the least reactive
aldehyde. In contrast, extreme differences were seen in
the group of nonaldehydes. ACN, the organic solvent
used for all lipophilic compounds, was, as expected, by
far the least reactive chemical. TFAA, the second least
reactive xenobiotic, was both 1000 times more reactive
than ACN and 100 times less reactive than the xenobiotic
with the highest factor of reactivity, TDI. These enor-
mous differences may be linked to the structural hetero-
geneity within this group. However, when substances
were compared according to their principle of binding, no
substantial differences were noted. Schiff base–forming
xenobiotics (AA, BA, FO, GA) in general were equally
potent whether they were substances forming similar
CON bindings (PA, TDI, TFAA) or substances using
other binding forms (DC, DNFB, TNBS). As it is known
that Schiff base–forming aldehydes may help provide
costimulatory signals and that the type of costimulatory
signal may influence functional priming of T lympho-
cytes (Rhodes, 1989; Rhodes et al., 1995; Shanafelt et al.,
1995), it seemed interesting to look at whether substances
known to lead to a predominantly Th1-driven immune
response in vivo (AA, BA, FO, DNFB, TNBS; Dearman
et al., 1996) would show a generally different reactivity
from those inducing a Th2 response (PA, TDI; Kapsen-
berg, 1996). In our experiments, we did not observe such
differences. We speculate that although specific reactiv-
ity toward amino groups is necessary for initiating po-
tentially costimulatory signals, the grade of this reactivity
may not be reflected in the functional quality of the signal
(Th1 vs. Th2). It is obvious that our in vitro results carry
a number of limitations and only incompletely reflect the
in vivo protein reactivity of a substance. In particular in
vivo groups other than -amino groups may also become
targets of an electrophilic attack of xenobiotics, and some
highly reactive chemicals may only arise as a result of
metabolizing processes. In addition, the covalent protein
binding of xenobiotics in vivo frequently shows a sub-
stance-specific affinity for certain tissue- or organ-spe-
cific proteins, and regional specificity for binding xeno-
biotics may occur within macromolecules (Brunmark et
al., 1997). Thus, quantification of binding to such specific
proteins in some cases may correlate better with toxicity
than the total protein-binding capacity (Cohen et al.,
1997).
Our results demonstrate that simple chemical reactions
may lead to the adduction of peptides, proteins, or other
macromolecules by protein-reactive xenobiotics. Such reac-
tions may represent a possible molecular effector mecha-
nism of protein-reactive xenobiotics in vivo. Thus, they may
influence the immunotoxic properties of chemical agents.
We believe that knowledge of the molecular structures of
adduct formation between protein-reactive xenobiotics and
macromolecules may contribute substantially to the risk
assessment of potentially hazardous and immunotoxic xe-
nobiotics and may enhance understanding of influencing
receptor systems, translator proteins, and DNA enhancer
sequences. We therefore suggest the inclusion of appropri-
ate methods into a careful evaluation of the (immuno)toxic
properties of a substance that will cover not only reactivity
to DNA but also to other macromolecules. Although deter-
mination of the adducts to structural proteins for dosimetry
and risk assessment is well established (Bartsch, 2000),
relatively few attempts have been made to measure protein
reactivity and adduct formation (Wass and Belin, 1990). In
our opinion, the model utilized in our study may be appro-
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priate for monitoring certain aspects of in vitro adduction of
xenobiotics to basic peptides and for investigating the re-
sulting molecular structures.
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Analysis of T-Cell Receptor V-Beta 2 in Peripheral
Blood Lymphocytes as a Diagnostic Marker for
Kawasaki Disease
P. Reichardt, I. Lehmann, G. Sierig, M. Borte
Abstract
Background: Kawasaki disease (KD) is the most frequent
cause of acquired heart disease in children, yet there are no
specific diagnostic markers for it. There is controversy
whether and by what mechanism selective expansion of 
T-cell subsets occurs and whether this phenomenon might be
helpful for early diagnosis. 
Patients and Methods: To obtain age-related normal values
of V-beta 2+ T-lymphocytes in healthy children and to
investigate expansion in KD, we measured expression in 228
children. Peripheral CD3+ cells were stained with monoclonal
antibodies to V-beta 2.1 and the percentage of V-beta 2+ T-
cells was analyzed using flow cytometry. 
Results: In a control group of 184 healthy subjects (0 to 17
years; median age 6.0 years) we found age-related changes.
Levels were highest from 0–2 years (9.02 ± 2.80%) and
declined towards adolescence (7.56 ± 2.42% in 11–15 year
olds) (p < 0.001). Results were compared with 24 patients
with acute febrile diseases of origin other than KD and with
20 patients with presumed diagnosis KD at admission.
Interestingly, while all seven patients whose clinical picture
retrospectively confirmed KD showed elevated levels, none
of the other children, including none of the patients with
initially suspected but not clinically confirmed KD, had
levels higher than normal, with the exception of two
teenage girls with toxic shock syndrome, a classical
superantigen-mediated disease. 
Conclusion: When compared with appropriate age-matched
controls, estimation of V-beta 2+ T-cells might be a valuable
tool when making diagnostic decisions suspecting KD.
Infection 2002; 30: 360–364
DOI 10.1007/s15010-002-3063-4
Introduction
Kawasaki disease (KD) is an acute systemic vasculitis of in-
fancy and early childhood characterized by prolonged fever,
conjunctivitis, inflammation of the oropharynx, rash, erythe-
matous induration of the distal extremities and cervical lym-
phadenopathy [1, 2]. When untreated, coronary artery ab-
normalities can develop in up to 25% of patients [3,4].High-
dose iv immunglobulins (IVIG) are the single therapeutic
option shown to significantly reduce this risk to less than 5%
[5–7], but administration must occur within the first 10 days
after onset of fever for efficacy [8]. Thus, early recognition
and prompt treatment is critical for successful outcome.
Diagnosis mainly relies on clinical signs and symptoms
[9], as there is so far no specific and reliable diagnostic test
for KD. Unfortunately, the initial clinical picture resembles
a variety of other illnesses and can be incomplete, making
early detection of disease difficult.
While there is increasing evidence for an infectious eti-
ology of KD, the responsible agents and pathomechanisms
leading to KD remain unknown.The intense search for a spe-
cific laboratory parameter allowing early diagnosis of KD
has not yet been very successful. A variety of immunologic
abnormalities demonstrating an inflammatory response have
been observed in patients with KD, including increased
serum levels of cytokines, such as IL-1, IL-2, IL-6, tumor
necrosis factor-alpha, interferon-gamma and soluble IL-2 re-
ceptors [10–14]. However, these changes are of low speci-
ficity.A number of reports observed a selective expansion of
specific V-beta chain bearing subsets of T-cells in KD and this
has widely been interpreted as being suggestive for the in-
volvement of superantigens (SAs) in the pathogenesis of the
disease [15–20]. T-cells are a major target of SAs, which can
polyclonally activate up to 20% of T-cells [21].They thereby
generate a severe immune response with liberation of large
amounts of cytokines and activation of effector cells that is
thought to be the main cause for tissue destruction in SA-
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mediated diseases [22].SAs omit binding to the antigen-spe-
cific binding site at the T-cell receptor (TCR) but interact di-
rectly with specific variable V-beta chains of TCR [23].There
is evidence that this might lead to selective proliferation of
particular V-beta fractions of T-cells such as V-beta 2 [24,25],
V-beta 3 [26], V-beta 6 [27], V-beta 7 [28] and V-beta 8 [26,
29] and V-beta 11 [26].
For KD, V-beta 2+ T-cells are of special importance, as
different bacterial toxins reported to be involved in the
pathogenesis of KD are potent activators of this subset.
Toxins found in KD are predominantly toxic shock syn-
drome (TSS) toxin-1 (TSST-1) of Staphylococcus aureus
and to a lesser extent a number of exotoxins produced from
Group A streptococci, all believed to predominantly stim-
ulate V-beta 2+ T-cells [24, 30, 31]. Indeed, in all studies ob-
serving selective expansion of T-cells in KD, V-beta 2 was
involved with some studies also showing elevation of other
subsets [15–20, 32, 33]. However, changes were generally
only minor, and a number of studies failed to see any spe-
cific elevation in KD [34–36]. While each of these studies
had its own control group, one problem in making a gen-
eral evaluation of the parameter might be the lack of ap-
propriate age-matched healthy controls in children.
The purpose of our study was to obtain age-related nor-
mal values in healthy children and to further investigate the
existence of selective expansion of V-beta 2+ T-lymphocytes
in KD in order to examine if the determination of the level
of TCR V-beta 2+ T-cells in peripheral blood can be a help-
ful tool for early detection of patients with KD.
Patients and Methods
Patients and General Experimental Design
All patients enrolled in this study were admitted to the Children’s
Hospital of the University of Leipzig. The control group for age-
and sex-matched normal values in healthy children consisted of
184 children between 0 and 17 years (median age 6.0 years; 94 male
and 90 female subjects) undergoing corrective surgery or medical
checkup. Patients qualified for this group, when free of febrile dis-
eases for at least 4 weeks before examination and not under the
influence of any treatment.
A second group of patients served as a disease control group.
It included 24 patients (median age 7.5 years; 11 male and 13 fe-
male patients) with febrile illness of known origin other than KD.
The diagnoses were anaphylactoid purpura in six, rotavirus en-
teritis in five, febrile seizure in one, paravertebral abscess in one,
burn injuries in two, febrile complications after abdominal surgery
in seven and TSS in two patients (isolation of S. aureus in both pa-
tients, diagnostic criteria according to [37]).
In a third group, patients with presumed diagnosis of KD at
admission were included in a prospective manner.The group con-
sisted of 20 patients (median age 2.5 years; 12 male and eight fe-
male patients).The diagnosis KD was finally made when the clin-
ical criteria in accordance with the international consensus state-
ment [9] were fulfilled. In detail, prolonged fever of unknown ori-
gin (temperature of more than 38.5 °C for more than 5 days) had
to be present together with four of the following criteria: bilateral
nonpurulent conjunctivitis, mucosal inflammation of the orophar-
ynx, erythematous induration of the peripheral extremities, poly-
morphous rash, and nonsuppurative cervical lymphadenopathy. In
addition, the diagnosis KD required that the illness could not be
explained by other diseases known to mimic KD.
The study was approved by the Research Ethics Committee
of the University of Leipzig. Written informed consent was ob-
tained from the parents of all patients before entry into the study.
Collection of EDTA Blood Samples
Peripheral blood (0.5 ml in EDTA) was obtained by peripheral
venipuncture and was stored at room temperature for a maximum
of 12 h until staining and analysis by fluorescent-activated cell
sorter (FACS).
Two-Color Staining of T-Cells from Peripheral Blood
V-beta 2+ T-cells were determined using fluorescence-conjugated
monoclonal antibody (mAb).The whole blood samples of each pa-
tient were divided into two aliquots of 100 µl for staining. To one
aliquot of 100 µl whole blood, 10 µl anti-TCR V-beta 2.1 (FITC,
Clone E22E7, COULTER-Immunotech) and 10 µl of anti-CD3
(PE, Clone UCHT; COULTER-Immunotech) were added.To the
other aliquot of the pair, 10 µl anti-CD3 alone was added as con-
trol. Incubation proceeded for 20 min at room temperature. Cells
were fixed in PBS/1% formaldehyde and erythrocytes were lysed
using FACS lysing solution (Becton Dickinson) for 10 min at room
temperature. Cells were washed twice, resuspended in 250 µl
PBS/1% formaldehyde and immediately analyzed by FACS.
Determination of TCR V-Beta 2+ Expression of T-Cells
by Flow Cytometry
Samples were examined on an FACScan cytometer (Becton Dick-
inson) using CellQuest software; 10,000 events were collected. For-
ward and sideward scatter were used to gate on lymphocytes.The
percentage of T-cells bearing the TCR V-beta 2 was expressed as
the percentage of total T(CD3+)-cells.
Statistics
Means and variances were calculated for each measured patient
as well as for the different patient groups and age-groups, respec-
Figure 1. Correlation between age and TCR V-beta 2.1 expression of
peripheral T-cells in healthy or clinically inconspicuous children. The
amount of TCR V-beta 2.1+ T-lymphocytes was determined by flow cy-
tometry and expressed as a percentage of total T(CD3+)-cells.
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tively. Statistical comparisons were made based on a 95% overall
CI. Data were analyzed and plotted with the statistical package
SPSS 9.0, using the Mann-Whitney rank sum test. Z scores (stan-
dard scores) of V-beta 2 values comparing data to the corre-
sponding age-groups in the normal child population were calcu-
lated for all KD patients.
Results
In the control group of 184 healthy subjects (0 to 17 years;
median age 6.0 years) we obtained a wide range for normal
V-beta 2.1 expression on peripheral T-cells. Levels were
found to be highest in newborns and toddlers while declin-
ing towards adolescence (Figure 1). When being divided
into four age-groups, ranges for TCR V-beta 2 expression
were significantly higher in the younger age-groups. In the
group of children ranging from 0–2 years and in the group
of 3–6 years levels were higher than in every older age-
group, respectively (Table 1). No differences between fe-
males and males were found (data not shown); accordingly,
the data are presented as pooled values.
In the disease control group of 24 patients with febrile
diseases other than (suspected) KD, the rates of TCR V-
beta 2+ T-cells were not higher than predicted from our data
from age-matched controls in the healthy child population
(Figure 2), with the exception of two teenage girls with TSS
who showed elevated levels (19.0%, and 21.9%, respec-
tively).
In the group of 20 patients initially suspected to have
KD, retrospectively only seven fulfilled the diagnostic cri-
teria of KD, while in the 13 others the diagnosis had to be
dropped. In seven of the 13, an infection of the upper res-
piratory tract was diagnosed. Fever in these patients
dropped after less than 5 days (without administration of
IVIG) and not more than three KD criteria were fulfilled.
In particular, none of these children showed a polymor-
phous rash, while all showed some of the oropharyngeal or
cervical affections. Two children suffered pneumonia, as
proved by X-ray. In one of them, high levels of antibodies
to influenza A virus were detected, suggesting influenza
pneumonia. One child was diagnosed as having an intraab-
dominal infection after Salmonella spp. was isolated. One
child had a multisystemic vasculitis. He showed sustained
fever and rash, but lacked conjunctivitis, mucosal inflam-
mation of oropharynx and cervical lymphadenopathy. One
patient showed fever and a suspicious rash, the latter being
later recognized as severe contact dermatitis possibly ac-
companied by an infection of the upper respiratory tract at
that time. One patient turned out to have erythema ex-
sudativum multiforme. Strikingly, while none of the 13 pa-
tients in whom the presumed diagnosis KD had to be
dropped showed elevated levels of TCR V-beta 2+ T-cells
compared to the healthy child population, all seven patients
with clinically proven KD had levels which were higher
than the expected age-related normal range (12.9% 
[z-score 2.77], 12.9% [4.21], 13.0% [2.84], 13.8% [3.41],
14.1% [5.29], 14.3% [3.77] and 33.5% [17.49], respectively)
(Figure 2). Samples were taken on the day of admission,
corresponding to day 3 (two patients), day 4 (two patients),
day 5 (two patients) and day 6 (one patient) after onset of
fever, respectively. There was no correlation between lev-
els of V-beta 2 expression and day after onset of fever (data
not shown). In all seven patients and in the two patients
with TSS, levels later declined and
were found to be normal at follow-
up less than 4 weeks after onset of
disease (data not shown).
Discussion
Our results provide data about nor-
mal values of V-beta 2+ T-cells in
the healthy child population. We
were able to show that the level of
V-beta 2 expression significantly
differs with the age of the subject
during childhood and adolescence.
Age Age- No. Median Statistical significance of 
(years) group of patients ± 2 SD differences between age-groups
0–2 1 78 9.02 ± 2.80 p < 0.001 1 vs 3; 1 vs. 4, p < 0.01 1 vs 2
3–6 2 19 8.18 ± 2.24 p < 0.01 2 vs 1; 2 vs. 3, p < 0.05 2 vs 4
7–10 3 47 7.23 ± 2.86 p < 0.001 3 vs 1, p < 0.01 3 vs 2
11–15 4 38 7.56 ± 2.42 p < 0.001 4 vs 1, p < 0.05 4 vs 2
Table 1
Ranges of a normal child population of TCR V-beta 2+ T-cell expression (% of total T-cells) in
diverse age-groups (median ± 2 SD).
Figure 2. TCR V-beta 2.1 expression in patients with suspected KD and
in children with other acute febrile diseases. While all patients with
clinically proven KD showed elevated V-beta 2+ levels (black dots), pa-
tients who did not fulfill criteria for KD in the course of disease
showed normal values (white dots). Also, no patient with other
febrile diseases suspected at admission showed elevated levels
(white triangles), with the exception of the two patients diagnosed
with toxic shock syndrome (asterix).
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Such age-related differences can be crucial for correct in-
terpretation of data, as differences between V-beta 2 ex-
pression in patients and controls seem to be narrow in most
cases. Furthermore, when comparing our data with those
from children with infectious diseases, among them KD, we
observed elevated V-beta 2+ T-cells in all of our patients
with KD and in two patients with TSS, but not in patients
with other febrile diseases. Our data suggest elevated lev-
els of V-beta 2+ T-cells in SA-driven diseases such as KD
and TSS.
Conflicting data have been reported regarding ex-
panded T-cell populations in KD. Elevated levels of V-beta
2+ and to a lesser extent V-beta 6+ and V-beta 8.1+ T-cells
were shown in a number of reports in the peripheral blood
during the acute phase of KD compared with age-matched
normal children and patients with other febrile illnesses
[15–17, 20]. The observed elevated levels returned to nor-
mal in convalescence. The pathogenetical impact of ele-
vated T-cell fractions, however, is not fully understood.
Some reports describe V-beta 2 changes but suggest no in-
volvement of these cells in disease pathogenesis [15]. In
contrast, other authors were not able to confirm abnormal
usage of any V-beta family neither acutely nor during con-
valescence [34–36]. One reason for the failure of detection
of selective enhancement of T-cell populations in KD might
be the dynamic nature of the disease process. Specific T-
cells may already have been transferred into inflamed tis-
sue when analysis in blood samples is performed [19, 33].
In our study, in all KD patients V-beta 2 was determined
relatively early, between day 3 and 6 after onset of disease.
In addition, the fate of the stimulated T-cells varies de-
pending on a number of factors and can range from sus-
tained expansion to apoptosis and clonal deletion [24]. Fi-
nally, studies in mice indicate that SAs also use major his-
tocompatitbility complex (MHC)-independent pathways
which may lead to different immune responses [38]. Be-
sides, the participation of conventional infectious antigens
in KD, which might even be responsible for the observed
clonal expansions of T-cells in the acute phase of KD, is still
discussed [30, 39]. In our study, apart from the KD patients,
two patients with TSS showed elevated V-beta 2 levels.TSS
is considered a classical SA-mediated disease, which shows
great clinical similarity to KD. TSST-1, the leading SA as-
sociated with KD, is also responsible for the majority of
cases of TSS [40].TSS may even belong to the same patho-
physiological entity as KD [41]. Thus, while elevation of V-
beta 2 may not be specific for KD, it may well point to the
existence of a potentially lethal SA-triggered immune re-
sponse such as KD and TSS. Furthermore, given the char-
acteristic age range of KD, we believe that determination
of V-beta 2 can provide valuable help to the clinician sus-
pecting KD.
We conclude that the analysis of TCR V-beta 2+ T-cells
in peripheral blood may be a useful laboratory tool for early
diagnosis of KD when carefully compared to appropriate
age-matched control values.
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Abstract In an 11-year old boy with Crohn disease,
long-term therapy with prednisolone was decided to be
augmented by infliximab, a monoclonal antibody to
tumour necrosis factor alpha. The patient, who was in a
stable clinical condition with low signs of inflammation
at that time, deteriorated 3 days after the first dose of
200 mg infliximab with fever, nausea, myalgia and signs
of cardiac failure. Echocardiography demonstrated de-
struction of the aortic valve with third grade insuffi-
ciency. In the blood culture, a susceptible strain of
Staphylococcus aureus was isolated. Antibiotic therapy
resulted in rapid improvement, but the aortic valve had
to be replaced by a homograft due to massive insuffi-
ciency. At surgery, there were no signs of endocarditic
vegetations, the aortic ring and the right coronary aortic
cusp had been destroyed by a massive intramyocardial
abscess, leading from close beneath the aortic ring in the
direction of the right atrium. The size of the process
suggested chronic infection or reinfection after several
weeks. As clinical and laboratory signs as well as echo-
cardiographic changes pointed to a dramatic flare-up
shortly after the administration of infliximab, we suggest
that this chronic inflammatory process was activated by
infliximab. Conclusion: when using infliximab, special
awareness of potential risks is necessary in patients with
chronic infections or in a state of immunodeficiency.
Keywords Anti-tumour necrosis factor alpha Æ
Crohn disease Æ Infection Æ Myocard
Abbreviation TNF tumour necrosis factor
Introduction
Infliximab, a monoclonal antibody to tumour necrosis
factor (TNF) alpha, is a new immunosuppressive drug.
Showing remarkable effectiveness, the drug is increas-
ingly being used in refractory cases of rheumatoid ar-
thritis [8,14] and Crohn disease [3, 4, 7, 11, 16]. While
side-effects consist mainly of local and systemic hyper-
sensitivity reactions, an increased susceptibility to in-
fections is also known. Invasive fungal infections
associated with infliximab therapy have been reported
[17] and there is evidence suggesting increased suscepti-
bility to certain severe bacterial infections [9].
We report on an 11-year-old boy with Crohn disease,
who 3 days after the first administration of infliximab,
developed fever, signs of cardiac failure and a Staphy-
lococcus aureus sepsis. Upon surgery, an intramyocar-
dial para-aortic abscess was found suggesting a chronic
infection, possibly activated by infliximab. The aim of
this case report is to highlight the potential risks asso-
ciated with the use of this powerful immunomodulating
drug.
Case report
In an 11-year-old boy treated for 1 year with azathioprine and
prednisolone for Crohn disease, therapy was intensified with inf-
liximab. At that time, the patient was in good clinical condition.
Laboratory studies showed good control of inflammatory activity
with leucocytes falling, bands, CRP and body temperature all re-
turning to normal values before administration of infliximab. Three
days after the first dose of infliximab (200 mg, concomitantly
azathioprine 1·50 mg and prednisolone 3·20 mg at 32 kg body
weight) the patient deteriorated with high fever, signs of heart
failure, and erythematous lesions on the fingers and toes resembling
Osler nodules (Fig. 1). Laboratory studies revealed a sharp rise in
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activity of systemic inflammation (Fig. 2). Echocardiography sug-
gested endocarditis, a therapy with ceftazidime and gentamicin was
started and the patient was transferred to our cardiology unit.
Echocardiography showed a third degree aortic insufficiency
(ejection fraction 0.37, fractional shortening 0.18) and a destruction
of the aortic valve with the right coronary cusp being totally dis-
rupted and floating in the bloodstream (Fig. 3). Haematological
data were as follows: leucocytes 24,800/ll, haematocrit 0.47,
thrombocytes 313,000/ll, IgG 6.89 g/l, IgA 2.46 g/l, IgM 3.21 g/l,
creatinine 44 lmol/l, BUN 3.0 mmol/l. In two blood cultures a
highly susceptible S. aureus strain was isolated. After 21 days of
antibiotic treatment with cefuroxime and gentamicin, replacement
of the highly insufficient aortic valve was performed. Upon surgery,
a large para-aortic intramyocardial abscess was detected, reaching
from close beneath the destroyed right aortic cusp in the direction
of the right atrium. The abscess cavity was drained and primarily
closed and the aortic root including the valve was replaced by an
aortic homograft. Histologically, the myocard showed an increased
amount of lymphocytes and macrophages, probably reflecting the
inflammatory process. Post-operatively, the homograft appeared
competent and laboratory signs of inflammation completely nor-
malised within a week. The patient is currently in good clinical
condition with a competent aortic valve and stable Crohn disease.
Discussion
Our patient presented with Crohn disease, S.aureus
sepsis and a large intramyocardial para-aortic abscess
which led to the destruction of the aortic valve. Due to
the close time lag between the administration of inflix-
imab and the deterioration of the patient we believe that
the activation of the inflammatory process had been
favoured by the drug.
Experience with infliximab is still limited, especially
in patients with immunosuppression and chronic in-
fections [1]. Concerns have been raised about the safety
of the drug because of its immunomodulating potential
[14]. Patients with Crohn disease do carry additional
risks as they are more susceptible to bacterial infections
possibly due to their disturbed mucosal barrier and to
concomitant immunosuppressive therapy [6, 18]. In
addition, Crohn disease itself may lead to vasculitic
changes of the aorta [5, 10, 15], which might have
further favoured the development of the intramyocar-
dial abscess in our patient. The size of the abscess
suggested its persistence for several weeks, however, it
gained only destructive activity shortly after infliximab
was given. The lesions detected on echocardiography
had not been present at routine echocardiography the
previous week, with exception of a first degree aortic
insufficiency. Furthermore, according to laboratory
studies, inflammatory activity in our patient was low
before administration of infliximab. What may have
further contributed to the precipitation of the systemic
Fig. 1. Painful pin-point sized erythematous lesions with haemor-
rhagic periphery resembling Osler nodules on the toes (and fingers)
of a patient with Crohn disease and intramyocardial para-aortic
abscess due to S. aureus infection
Fig. 2. Course of systemic inflammation after administration of
infliximab in a patient with intramyocardial para-aortic abscess
and Crohn disease
Fig. 3. Echocardiography of a patient with intramyocardial para-
aortic abscess and Crohn disease. The arrow shows the disrupted
right coronary aortic cusp appearing as filamentous structure
floating in the bloodstream. The left ventricle shows enlargment
(left ventricular enddiastolic diameter 62 mm), possibly secondary
to the severely insufficient aortic valve. The left ventricular function
was heavily diminished (fractional shortening 0,18; ejection
fraction 0.37)
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infection with S. aureus is the fact that 3 days before
administration of infliximab, the dosage of predniso-
lone had been increased (from 1·10 mg to 3·20 mg)
and that the patient received a total of 6.25 mg inf-
liximab per kg body weight. While most studies sug-
gest an initial dose of 5 mg/kg, safety in doses up to
20 mg/kg body weight has been demonstrated [12,13].
However, adverse events may be elevated when higher
doses are administered [2]. As others [9,17], we express
our concern that infliximab may bear the potential for
serious side-effects such as invasive infections. In order
to minimise the chance of such complications, we
suggest that upon the use of infliximab, possible
co-infections must be carefully excluded. In children
with Crohn disease, we suggest that an initial dose of
5 mg/kg should not be surpassed and that, if possible,
doses of concomitant immunosuppressive drugs should
not be simultaneously increased. When using inflix-
imab, extreme care should be taken in patients in
whom additional risks such as immunodeficiency or
chronic infections may exist.
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Recurrent Polytopic Chromaffin Paragangliomas in a
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Abstract: Pheochromocytomas are frequently associated with in-
herited cancer syndromes such as von Hippel–Lindau disease
(VHL). Retinal angioma and hemangioblastomas of the central
nervous system are hallmarks of VHL, but its clinical variety is
remarkably broad. Pheochromocytomas as the sole or first mani-
festation of VHL are rare but have been observed. In this case
report, the authors describe an unusual case of initial collapse,
seizures, and hypertensive crisis in a child who later was found to
have multiple extraadrenal pheochromocytomas. Molecular diag-
nostics revealed a novel point mutation in the VHL gene (VHL nt.
406 T→G). Only 7 months after the first lesions had been re-
moved, a new paraganglioma developed in the contralateral peri-
adrenal region. When encountering pheochromocytomas in chil-
dren, the clinician should be aware that an associated tumor
syndrome might be present, and appropriate molecular screening
should be initiated. Molecular genetics aid in the clinical decision-
making and clinical management of individual patients with pheo-
chromocytoma.
Key Words: von Hippel–Lindau disease—VHL gene—
Pheochromocytoma—Paraganglioma.
Pheochromocytomas are catecholamine-secreting neuro-endocrine tumors arising from chromaffin cells in the
adrenal medulla (1). Extraadrenal forms associated with
ganglia of the autonomic nervous system are called para-
gangliomas. Excessive secretion of epinephrine and norepi-
nephrine can lead to severe hypertensive crisis and heart
failure. Pheochromocytomas can be part of three inherited
tumor syndromes: multiple endocrine neoplasia II, neurofi-
bromatosis type 1, and von Hippel–Lindau disease (VHL)
(2). Pheochromocytomas, even when apparently sporadic,
are in 10% to 20% part of VHL (3,4). Bilateral adrenal and
extraadrenal forms, which tend to be more frequent in chil-
dren than in adults (5), have an even higher risk of being
associated with an hereditary syndrome (6).
von Hippel–Lindau disease is rare, with an estimated
incidence of 1 in 40,000 (7,8). The clinical variety of VHL
is remarkably broad. Retinal angiomas and cerebellar he-
mangioblastomas, renal cell carcinomas, pancreatic cysts,
and pheochromocytomas are predominantly observed; cyst-
adenomas of the epididymis, islet cell tumors, and tumors of
the inner ear are found more rarely (9). Pheochromocytomas
or paragangliomas as single manifestations of VHL are un-
common, but familial pheochromocytomas caused by VHL
mutations have been described (10,11).
von Hippel–Lindau disease is an autosomal, dominant,
inherited disease. The VHL susceptibility gene, a tumor sup-
pressor gene, is located on chromosome 3p and has been
identified and characterized (12). The VHL protein is fairly
ubiquitously expressed (13). As part of a protein complex
with elongin C and elongin B (14), the VHL protein is
involved in angiogenesis, formation of extracellular matrix,
regulation of cell cycles, and ubiquitin-mediated proteolysis
(15). Nearly 300 mutations in the VHL gene are known, a
large proportion of which interfere with the elongin-binding
site (16). Loss of elongin-binding capacity of the VHL pro-
tein may lead to substrate accumulation and up-regulation
of hypoxia-inducible factors such as vascular endothelial
growth factor (17).
In this case report, we describe an unusual case of severe
hypertensive crisis in a child in whom consecutively devel-
oping adrenal and thoracic paragangliomas were found. On
molecular analysis, a novel mutation in the VHL gene was
found. The aim of this case report is to stress the importance
of screening for inherited diseases in patients with pheo-
chromocytomas and to increase awareness of the presence
of VHL in children.
CASE REPORT
A 9-year-old boy was admitted to the hospital with gen-
eralized seizures necessitating mechanical ventilation and
with marked hypertension (maximum systolic blood pres-
sure 190 mmHg). Heart rate was 110 bpm, respiratory rate
was 20, and body temperature was 37.5°C. Physical exami-
nation revealed no other internal and no focal neurologic
abnormalities. No café-au-lait-spots were present. Echocar-
diography showed muscular hypertrophy of the left ven-
Submitted for publication July 19, 2002; accepted January 1, 2001.
From the Intensive Care Unit (P.R.) and the Department of Hematology
and Oncology (M.D., U.B., W.K.), Children’s Hospital of the University of
Leipzig, Leipzig, Germany; Department of Internal Medicine IV (T.W.A.,
H.B.H.N.), Hospital of the Albert Ludwigs University, Freiburg, Germany;
Department of Pediatric Surgery (R.-B.T.), University of Leipzig, Leipzig,
Germany; and Department of Pediatric Hematology (I.K.), Children’s Hos-
pital of the Klinikum Chemnitz, Chemnitz, Germany.
Address correspondence and reprint requests to Peter Reichardt, M.D.,
Intensive Care Unit, Children’s Hospital of the University of Leipzig,
Oststr. 21–25, 04317 Leipzig, Germany. E-mail: reichp@medizin.uni-
leipzig.de.
Journal of Pediatric Hematology/Oncology, Vol. 24, No. 2, February 2002 © 2002 Lippincott Williams & Wilkins, Inc.
145
tricle. A radiograph of the thorax revealed a round parame-
diastinal mass at the left side at the level of the fourth
thoracic vertebra. The patient, whose condition had quickly
stabilized with an intravenous nifedipine infusion, was
transferred to the oncology department, with a presumed
diagnosis of neuroblastoma, for further evaluation. Mag-
netic resonance imaging confirmed a thoracic structure of
2 × 2 × 3 cm (Fig. 1). A second tumor was seen in the
abdomen, a structure of 2 × 3 × 5 cm in the right suprarenal
region (Fig. 2). No structural changes in other abdominal
organs were noted. Magnetic resonance imaging of the head
showed no cerebral lesions. On metaiodobenzylguanidine
scintigraphy, the suprarenal tumor showed selective en-
hancement, whereas the intrathoracic tumor remained silent.
Technetium Tc 99 scintigraphy of the skeleton revealed no
osseous metastasis. Bone marrow aspiration proved to be
cytomorphologically negative for tumor cell metastasis. On
ophthalmologic examination, a beginning fundus hypertoni-
cus was found, but no angiomatosis of the retina was pres-
ent. Laboratory investigations showed increased levels of
neuron-specific enolase and chromogranin A (15 ng/mL and
153 g/L, respectively). A diagnostic clue for a catechol-
amine-secreting tumor was the determination of catechol-
amines and metabolites measured in plasma and urine. Nor-
epinephrine was markedly increased in plasma at 3390 ng/L
(normal 0–600). Both norepinephrine and vanillylmandelic
acid were increased in urine at 1,156 g/24 hours (0–105)
and 17 mg/24 hours (0–8.0), respectively.
Because the laboratory parameters and clinical course
made the lesions highly suspicious for pheochromocytomas,
they were excised. The abdominal lesion was removed first.
It presented as two separate tumors apart from the adrenal
gland. The tumors were completely excised, sparing the
adrenal gland. Four weeks later, the thoracic tumor was
removed. All three tumors were classified histologically as
pigmented paragangliomas showing positivity for neuron-
specific enolase, chromogranin A, and synaptophysin.
To exclude multiple endocrine neoplasia II, DNA of pe-
ripheral blood cells was tested. There was no amplification
of N-myc and there was no amplification or mutation in the
RET-protooncogene on chromosome 10. Analyzed were
exon 10 (for codon 609, 611, 618, 620), exon 11 (for codon
630, 634), exon 13 (for codon 768, 790, 791), exon 14 (for
codon 803), exon 15 (for codon 883, 891), and exon 16 (for
codon 918). Molecular DNA analysis of the VHL gene was
performed as previously described (6). For sequence analy-
sis, aberrant DNA bands from the single-strand conforma-
tion polymorphism were cut out of the gel and reamplified,
and the double strand was sequenced. Aberrant bands were
confirmed by a second DNA sample extracted from newly
drawn blood. This procedure revealed a novel point muta-
tion in exon 1. At position 406, thymine was replaced by
guanine (406 T→G), which resulted in codon 65 in a change
of the amino acid serine to alanine (Fig. 3). This mutation
was absent in the mother. Paternal DNA was not available
for study.
The patient’s blood pressure returned to normal and an-
tihypertensive therapy could be stopped 9 days after sur-
gery. Catecholamine and metabolite levels decreased into
normal ranges. Postoperative imaging excluded residual tu-
FIG. 1. Magnetic resonance imaging of a patient with a thoracic
paraganglioma (arrow) in the left paravertebral region at the level of
the fourth thoracic vertebra.
FIG. 2. Magnetic resonance imaging of a patient with an abdominal
pheochromocytoma in the right periadrenal region. Arrow 1 indicates
the pheochromocytoma; arrow 2 shows a normal paraadrenal gland
left with no signs of the later-developing tumor.
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mor or new tumor manifestations. The patient was released
from hospital in good condition but was soon lost to follow-
up as a result of poor compliance. Seven months later, he
returned with tachycardia, vomiting, and hypertension. Nor-
epinephrine was again increased at 2,025 ng/L in serum and
525 g/24 hours in urine. Scintigraphy with metaiodoben-
zylguanidine and magnetic resonance imaging showed a
new tumor of 2 × 2 × 2 cm in the left periadrenal region.
Detailed imaging excluded other tumor manifestations.
During surgery, three distinct paragangliomas were found
localized in the proximity of the adrenal gland. The tumors
were removed, again sparing the adrenal gland. Levels of
catecholamines were normal on day 10 after surgery.
As of this writing, 16 months after his first admission to
the hospital, the patient is in good health. Improved com-
pliance seems to ensure regular follow-up. Visits every 4 to
6 weeks with 24-hour ambulatory blood pressure recording
will ensure close contact with the family. In addition, every
3 months, catecholamine metabolites are measured in urine
and sonography of the abdomen is performed. Radiologic
imaging of the thorax and abdomen and ophthalmologic
controls are performed once per year.
DISCUSSION
Our patient had multiple extraadrenal pheochromocyto-
mas as result of a novel germline mutation in the VHL gene.
Of further interest is the rapid occurrence of a third tumor,
which was not detectable at excision of the first two lesions
7 months before.
The diagnosis of paragangliomas in our patient was
based on radiologic imaging, metaiodobenzylguanidine
scintigraphy, measurement of catecholamine metabolites,
and histologic examination of the excised tumors. Whereas
pheochromocytomas usually appear alone in or close to the
adrenal medulla, they are bilateral in 5% to 10% of patients
and occur extraadrenally in 15% to 20% of the cells asso-
ciated with the ganglia of the autonomic nervous system (5).
Only 5% of reported pheochromocytomas occur in children,
but extraadrenal forms seem to be more frequent, appearing
in up to 30%. In particular, a thoracic location of pheochro-
mocytomas producing catecholamines, so-called function-
ing paragangliomas, is suspicious for the presence of un-
derlying VHL (6).
von Hippel–Lindau disease was diagnosed by detection
of a previously unknown germline mutation in the VHL
gene (VHL nt. 406 T→G). Apart from the paragangliomas,
no other tumor manifestations were found. Whereas classic
VHL manifests with retinal angiomas and hemangioblasto-
mas of the central nervous system, the affected organs and
the age of onset vary greatly. Some patients show only mild
anomalies; others suffer from a severe disease. Pheochro-
mocytomas as part of VHL are so well recognized that they
are used to subclassify the disease. von Hippel–Lindau dis-
ease without pheochromocytoma is classified as type 1 (7).
Manifestations with pheochromocytoma are further divided
into 2A (without renal cell carcinoma) and 2B (with pheo-
chromocytoma and renal cell carcinoma). Some authors ad-
ditionally suggest classifying cases of pheochromocytoma
as the sole manifestation of VHL as separate subtype (2C
disease) (18).
There is a noticeable genotype–phenotype correlation in
VHL. Patients with pheochromocytomas show almost ex-
clusively missense mutations in the VHL gene. Patients
without pheochromocytomas mainly show deletions, splice-
site mutations, or nonsense mutations in the VHL gene (19).
Indeed, the mutation we describe is a missense mutation.
Although the mutation is unique in the literature, germline
mutations of neighboring codons have been associated with
primary pheochromocytomas (4). The inheritance of VHL
is autosomal dominant, but spontaneous de novo mutations
are also possible. Our patient is living with his mother, who
was proven to have no germline mutation in the VHL gene.
There is no contact with the father. The patient has 10
siblings, but all from a different father. In none of the sib-
lings was a tumor or other severe disease known, and none
was willing to be analyzed for the given mutation. We there-
fore cannot definitely differentiate between an inherited or a
de novo mutation in our patient. Screening for germline
mutation of the VHL gene should be performed in any pa-
tient with pheochromocytoma in childhood, even when only
a single tumor is present because more than 20% of patients
with apparently sporadic pheochromocytomas may be car-
riers of familial disorders (3). Gene testing for VHL has
FIG. 3. Automated sequence analysis of exon 1 of the VHL gene of
a patient with mutation in the VHL gene (A) and his mother (B): The
aberrant DNA band found in the SSCP (single-strand conformation
polymorphism) of the patient shows the mutation with a G at nucleo-
tide position 406 (A), whereas the band of the patient’s mother
shows the wildtype (wt) sequence (B). Note that the minor T peak in
A results from a little amount of the patient wt allel in the sequencing
probe preparation.
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been performed successfully in families at risk and persons
with symptoms suspicious for the disease (20,21). In famil-
ial forms, with the recent use of more powerful diagnostic
methods, germline mutations in up to 100% of affected
families can be detected (22).
When a mutation is found in a patient, genetic screening
of the family and genetic counseling are indicated. Patients
and family members showing a mutation must be included
in a clinical screening program, with radiologic imaging of
the head and spinal cord and eye examinations. Regular and
prolonged follow-up is essential. Tumors at other locations
may become apparent after years. Successful treatment re-
quires timely detection, often before symptoms occur, es-
pecially in the case of eye lesions and renal carcinoma.
Follow-up procedures must be designed individually ac-
cording to the associated clinical picture. In our opinion, a
complete follow-up program for VHL in childhood should
include the measurement of blood pressure at least every 3
months, measurement of catecholamines and metabolites in
urine every 6 months, and ophthalmologic examinations
and magnetic resonance imaging studies less than 6 months
after surgery and afterward once per year.
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Leukocytopenia, Thrombocytopenia and Fever
Related to Piperacillin/Tazobactam Treatment –
A Retrospective Analysis in 38 Children 
with Cystic Fibrosis
P. Reichardt,W.Handrick, A. Linke, R. Schille,W. Kiess
Summary
Bone marrow suppression is an important adverse
reaction to most betalactam antibiotics. Recently it was
suggested that piperacillin/tazobactam (PT) also may
cause bone marrow toxicity.We retrospectively analyzed
100 IV antibiotic treatment courses (mean duration 12.5
days) in 38 patients (median age 14 years) with cystic
fibrosis (CF) who were treated in our hospital. Of the
patients receiving PT (84%), 6 patients (18.75% of PT-
treated patients, 10.3% of PT treatment courses)
developed fever,malaise and headache during treatment
without signs of acute infection. In one patient definite
thrombocytopenia and neutropenia, in two others a
milder decrease in leukocyte and thrombocyte counts
was observed after the onset of fever. The events were
time- and dose-dependent occurring between day 11 and
15 of treatment. Treatment courses lasted longer (14.2 vs
11.3 days; p < 0.05) and patients had received a higher
cumulative dose of PT (4919 ± 1975 mg/kg b.w. vs
3161 ± 1635 mg/kg; p < 0.02, Student’s t-test) in the
affected group than in the unaffected group. After
discontinuation of PT, fever subsided within 24 h and
blood cell counts normalized.We hypothesize that these
fever episodes and changes of blood parameters are
related to PT therapy.
Key Words
Betalactams · Penicillins · Piperacillin/tazobactam ·
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Introduction
Betalactam antibiotics can cause neutropenia and throm-
bocytopenia as a result of bone marrow suppression. Hema-
tologic complications during treatment with betalactams
have been first described in 1946 [1]. Lately, neutropenia
has also been observed in association with betalactam/be-
talactamase inhibitors, which may cause dose-dependent,
reversible maturation arrest of bone marrow precursor
cells. Neutropenia occurs in 1–4% of patients treated with
betalactam antibiotics [2, 3].With longer durations of treat-
ment and higher doses, this rate may rise to 27.5% [2, 4].
Relatively little is known about hematological adverse
events associated with the use of piperacillin/tazobactam
(PT). One study did not show any clinically significant
hematological adverse effects of PT [5]. However, PT was
only given for short time periods in these studies. In con-
trast, more recent reports demonstrated substantial hema-
tological adverse events associated with PT when treatment
lasted more than 10 days [6, 7].
Over the course of several years, we observed the de-
velopment of fever without signs of acute infection in a
number of cystic fibrosis (CF) patients who were treated
with intravenous antibiotics. We therefore hypothesized
that these febrile episodes might have been at least in part
drug induced.
Patients and Methods
We retrospectively analyzed the data of all 38 patients with cystic
fibrosis who were treated with intravenous antibiotics between
December 1996 and June 1998. Patients were between 2 and 22
years old (median age 14 years). All had chronic pulmonary in-
fection with P. aeruginosa, 31 simultaneously with S. aureus. Drug-
related fever was suspected when febrile patients did not show any
other clinical signs of acute systemic or local infection, and labo-
ratory parameters including blood cultures did not indicate the
presence of infection or inflammation. The diagnosis of drug-re-
lated fever was further supported by the observation of sponta-
neous normalization of the temperature within 24 h after discon-
tinuation of the drug. Onset and duration of fever (rectal temper-
ature of ≥ 38.5 °C) was recorded as were the results of hemato-
logical and chemical blood tests as well as type, dose and duration
of antibiotic treatment and other therapeutic measures.
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Results
During the study period, 38 CF patients received a total of
100 treatment courses of parenteral antibiotics (mean du-
ration 12.5 days). Ten different antibiotics were used in 11
combinations. PT was the most frequently used antibiotic,
representing 57 treatment courses in 32 patients (84%). In
40 courses it was combined with gentamicin, in 17 with
amikacin.The occurrence of fever was only observed in the
PT group. It affected 6 patients (18.75% of PT patients,
10.3% of PT treatment courses) and included 4 patients also
receiving gentamicin or amikacin (2 patients each). In some
patients malaise and/or headache were additional symp-
toms. Fever was neither observed in patients treated with
aminoglycosides, which were given in combination with
drugs other than PT, nor with any other antibiotic or con-
comitant drug. This was also the case for 33 treatment
episodes with ceftazidime, the second most frequently used
antibiotic.
Onset of fever occurred between day 11 and 15 of treat-
ment (mean 13.3 days). Two patients were switched to cef-
tazidime or meropenem, in the 4 remaining patients antibi-
otic therapy was stopped. Fever subsided in all cases within
24 h after discontinuation of PT. In 3 of the 6 febrile patients,
a complete blood count was done after onset of fever.These
patients showed a decrease in leukocyte and thrombocyte
counts. One of them developed definite thrombocytopenia
(< 150,000) and neutropenia (< 1000). Recovery of blood
cells was recorded as early as 4 days after discontinuation of
PT in one patient. At follow-up (2–18 weeks after onset),
complete remission was observed in all cases. Anemia did
not occur in any of these cases, nor was any significant
change in liver enzymes noted. Patients received between
191 and 672 mg PT per kg daily (mean 288 ± 91 mg/kg/day).
The induction of fever and hematological changes appeared
to be dose dependent. While no significant difference was
seen between the daily dose per kg (355 ± 164 in febrile pa-
tients vs 281 ± 77 mg/kg in patients without fever; p = 0.059),
all patients developing fever received at least 240 mg
PT/kg/day, treatment courses lasted longer (mean 14.2 vs
11.3 days; p < 0.05), and patients received a higher cumula-
tive PT dose during the course (mean 4919 ± 1975 mg/kg vs
3161 ± 1635 mg/kg; p < 0.02, Student’s t-test).
Discussion
Hematological side effects of PT have been reported to be
rare (< 1%) and are mostly mild [8]. However, life-threat-
ening neutropenia due to PT may occur [6]. Fever due to
PT was seen in 5–24% of CF patients [7, 9]. Whether the
rate of adverse events in CF patients is generally higher
than in other patients is unclear [10], as is the question
whether penicillin-induced neutropenia is more frequent in
children than in adults [11].
Six of our 32 PT-treated patients (18.75% of PT-treated
patients and 10.3% of PT treatment courses) developed an
episode of fever.We conclude that PT may be associated with
febrile reactions at a rate comparable to that seen with
piperacillin alone.No other antibiotic used in our CF patients
during the study period was associated with similar reactions.
Blood cell counts were done in 3 of the 6 affected patients
after onset of fever.All showed a decrease in leukocyte and
thrombocyte counts during the febrile episode. Hematolog-
ical changes were completely reversible. This is consistent
with other reports [2, 6, 8]. Fever occurred between the 11th
and 15th day of treatment. This corresponds to the finding
that hematological adverse reactions involving PT occur
rarely before day 10 of treatment [8]. The dose dependency
of hematological complications, which are usually mediated
through reversible maturation arrest of precursor cells in the
bone marrow, has been demonstrated before [8]. However,
sudden falls of cell counts as seen in one of our patients can
only partially be explained by cumulative toxicity. Immuno-
logically mediated processes may play an additional role.
Such processes may be responsible for the development of
thrombocytopenia following treatment with betalactams [12,
13]. No difference in sex, age or body weight was seen be-
tween patients with fever and those without. However, mar-
row suppression in underweight adults receiving the unad-
justed adult dose has been observed [8]. In conclusion, in CF
patients treated with PT, particular attention should be paid
to the potential for hematologic side effects.
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